data_2dhg_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2dhg _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 67.3 m-85 . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.872 0.367 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.8 m -97.91 161.68 13.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.876 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.436 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . 26.0 mt -125.78 143.57 51.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.899 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -93.47 115.78 28.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.462 HG22 ' CD1' ' A' ' 103' ' ' LEU . 5.3 m -108.09 148.48 12.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.143 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.7 -177.41 15.14 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.505 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . 0.42 ' N ' ' O ' ' A' ' 138' ' ' GLY . 24.8 m-20 50.87 51.81 16.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.868 0.366 . . . . 0.0 110.887 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.462 ' CD1' HG22 ' A' ' 100' ' ' VAL . 31.1 mt -98.27 102.58 14.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.897 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 72.9 p -47.57 149.85 1.94 Allowed Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.583 0.706 . . . . 0.0 111.116 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 2.99 3.07 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.675 2.25 . . . . 0.0 112.327 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -98.32 -16.47 19.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.905 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . 0.417 ' HA ' ' CE ' ' A' ' 111' ' ' MET . 51.1 t -93.39 145.56 7.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.161 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -129.78 -179.72 5.36 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.862 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -57.77 -51.12 70.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -39.85 -36.18 0.75 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' MET . . . . . 0.418 ' O ' ' C ' ' A' ' 112' ' ' LEU . 18.5 mtm -82.79 -59.26 2.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.795 0.331 . . . . 0.0 110.916 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.418 ' C ' ' O ' ' A' ' 111' ' ' MET . 25.2 tp -36.05 -44.02 0.36 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.88 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.401 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 16.1 t80 -63.6 -61.16 2.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.907 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.45 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 18.3 mt-10 -54.17 -55.68 25.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.862 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . 0.567 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 71.3 t80 -41.13 -32.29 0.25 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.873 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.48 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.5 m-85 -95.25 -68.16 0.82 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.841 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.45 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.7 -30.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.148 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.48 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.5 ttpt -68.78 -53.96 18.69 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.888 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.566 HG22 ' CE2' ' A' ' 120' ' ' TYR . 2.6 p -70.73 -31.47 45.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.109 179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.566 ' CE2' HG22 ' A' ' 119' ' ' VAL . 94.2 m-85 -135.84 114.47 11.04 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.679 0.752 . . . . 0.0 110.913 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.82 0.53 5.55 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.658 2.239 . . . . 0.0 112.361 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 26.0 m -98.2 21.01 11.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.885 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 7.7 t -84.72 134.78 34.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.888 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 9.0 mmt85 -91.87 -38.94 12.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.836 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.401 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.96 152.27 7.13 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.536 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -101.66 143.01 15.9 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.488 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 21.7 tptm -132.78 127.38 34.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 110.865 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.5 p -116.8 127.18 74.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.145 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.566 HG11 ' CE1' ' A' ' 139' ' ' TYR . 20.3 m -73.91 143.65 13.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.127 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 25.5 mt -130.57 163.82 26.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.927 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 134' ' ' GLY . 23.8 t70 -94.68 176.17 6.38 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -44.34 -40.38 5.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.894 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 18.1 p -72.37 -28.58 63.11 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.179 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 104.98 20.36 9.92 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.487 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 26.1 m -99.64 134.75 37.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.831 0.348 . . . . 0.0 111.15 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.0 t -48.62 112.92 0.67 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.813 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.3 mtmt -58.69 -28.56 65.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.954 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 122.83 15.25 3.97 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.441 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.566 ' CE1' HG11 ' A' ' 129' ' ' VAL . 29.8 p90 -161.88 167.99 23.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.896 0.379 . . . . 0.0 110.912 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.64 -160.02 16.85 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.467 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -153.7 148.64 26.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.9 0.381 . . . . 0.0 110.874 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.436 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 28.5 m -123.3 170.6 13.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.077 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 25.3 mttt -129.67 156.06 44.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -143.09 171.56 13.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.9 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 1.7 p -108.3 -28.79 9.23 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -113.1 128.4 56.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.881 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 12.9 tm-20 -69.37 -38.37 78.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.87 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 26.9 mt -51.0 -44.82 60.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -73.16 -42.88 62.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.852 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 19.8 tt0 -38.74 -57.94 1.14 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.928 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 9.2 mmmm -63.21 -49.32 74.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.91 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 34.4 mtt-85 -43.43 -41.06 4.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.832 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.98 -44.3 76.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.098 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.444 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 24.2 mt -48.46 -40.63 26.98 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.906 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.1 t -91.36 -34.7 14.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 17.4 mm-40 -79.58 -65.1 1.04 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.876 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.494 ' N ' ' O ' ' A' ' 153' ' ' ALA . 11.2 m -65.14 -8.74 18.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.877 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . 0.444 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.5 tp-100 -35.6 137.9 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.923 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.48 42.81 2.72 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.521 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -57.75 110.9 0.98 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.803 0.335 . . . . 0.0 111.068 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.403 ' O ' ' C ' ' A' ' 162' ' ' GLY . 20.1 t -82.72 -41.76 17.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.135 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -37.87 -34.84 0.2 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.459 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.567 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 26.5 tp -90.23 115.77 27.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.811 0.339 . . . . 0.0 110.938 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.415 ' O ' ' C ' ' A' ' 165' ' ' SER . . . 62.52 137.85 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.481 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' SER . . . . . 0.415 ' C ' ' O ' ' A' ' 164' ' ' GLY . 1.2 t -37.4 -32.87 0.05 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.916 0.389 . . . . 0.0 110.866 -179.782 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 164' ' ' GLY . 58.0 mttt -100.46 153.6 37.65 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.519 0.676 . . . . 0.0 110.913 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -179.19 2.77 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.67 2.247 . . . . 0.0 112.311 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 13.8 m -130.59 129.68 64.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.1 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.6 ttt-85 -89.27 110.58 21.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.883 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.453 HD11 ' CB ' ' A' ' 157' ' ' CYS . 12.5 mt -87.24 144.59 26.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.927 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.2 m -160.89 175.06 12.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 2.6 t -102.66 104.43 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.136 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.074 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . 0.414 ' CD1' ' HG3' ' A' ' 147' ' ' GLU . 9.4 m-85 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.867 0.365 . . . . 0.0 110.98 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 51.6 m -124.92 154.12 41.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.872 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 96.1 mt -126.65 143.44 51.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.9 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.445 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 11.4 t80 -92.51 142.13 27.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.863 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 21.6 m -132.02 150.86 34.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.109 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.15 -174.32 13.27 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.489 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 46.55 54.74 8.37 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.797 0.332 . . . . 0.0 110.852 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.409 HD11 ' C ' ' A' ' 139' ' ' TYR . 29.6 mt -101.84 112.09 24.57 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.895 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 73.3 p -53.59 148.98 16.67 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.61 0.719 . . . . 0.0 111.126 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 2.14 3.78 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.71 2.273 . . . . 0.0 112.35 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -97.98 -17.52 19.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.868 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 14.7 t -87.58 143.77 10.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.102 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -131.65 172.2 12.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.855 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -49.59 -46.31 48.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -49.25 -28.91 9.27 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.461 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' MET . . . . . 0.452 ' O ' ' N ' ' A' ' 113' ' ' TYR . 14.1 mtp -86.4 -66.54 0.89 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.814 0.34 . . . . 0.0 110.866 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.423 ' C ' ' O ' ' A' ' 111' ' ' MET . 24.6 tp -35.75 -32.88 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.887 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.452 ' N ' ' O ' ' A' ' 111' ' ' MET . 12.0 t80 -68.84 -65.01 0.76 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.927 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.451 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 18.4 mt-10 -55.59 -39.57 70.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . 0.563 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 58.0 t80 -54.55 -33.88 60.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.886 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.46 ' O ' ' N ' ' A' ' 118' ' ' LYS . 10.0 m-85 -95.27 -64.92 1.01 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.818 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.451 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.78 -30.92 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.076 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.46 ' N ' ' O ' ' A' ' 116' ' ' PHE . 5.3 ttpm? -65.45 -58.79 4.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.874 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.421 HG12 ' N ' ' A' ' 120' ' ' TYR . 3.5 p -64.56 -33.78 65.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.172 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.421 ' N ' HG12 ' A' ' 119' ' ' VAL . 91.0 m-85 -135.44 116.53 11.97 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.664 0.745 . . . . 0.0 110.965 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 1.94 3.97 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.671 2.247 . . . . 0.0 112.365 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 86.4 p -87.85 -23.27 24.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.835 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 7.7 t -47.19 137.04 8.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.885 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 51.7 mtm180 -99.3 -36.53 9.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.874 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.417 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.53 143.2 3.65 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.493 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -87.16 145.24 19.69 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.492 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 21.5 tptm -131.49 110.65 11.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.855 0.359 . . . . 0.0 110.86 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.7 p -102.48 139.85 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.109 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.404 HG22 ' CD1' ' A' ' 139' ' ' TYR . 25.0 m -86.32 158.34 3.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 24.2 mt -137.38 167.78 20.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.878 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.443 ' O ' ' N ' ' A' ' 134' ' ' GLY . 17.7 t0 -102.18 175.06 5.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.83 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -42.03 -42.07 2.75 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.948 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 65.2 p -72.82 -31.83 65.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.097 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 108.88 19.79 8.41 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.487 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 24.9 m -99.7 127.76 52.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.353 . . . . 0.0 111.114 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 3.0 t -40.21 106.76 0.06 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.831 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.547 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.7 mtmt -50.38 -37.16 35.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.944 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 128.81 18.7 1.71 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.459 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.547 ' CE2' ' HE3' ' A' ' 137' ' ' LYS . 16.3 p90 -160.81 173.41 15.41 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.953 0.406 . . . . 0.0 110.935 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -177.26 -163.85 29.95 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.484 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.445 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 2.5 m-85 -152.83 150.44 29.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.888 0.375 . . . . 0.0 110.9 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.513 HG21 ' CE1' ' A' ' 144' ' ' PHE . 28.1 m -123.83 174.54 7.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.174 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . 0.447 ' N ' ' HD3' ' A' ' 143' ' ' LYS . 0.5 OUTLIER -134.77 158.43 44.18 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 179.872 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.513 ' CE1' HG21 ' A' ' 142' ' ' VAL . 75.1 m-85 -143.03 160.98 39.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.89 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 75.3 p -95.38 -14.81 23.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.177 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -128.16 123.66 34.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.898 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.414 ' HG3' ' CD1' ' A' ' 96' ' ' TYR . 15.3 tt0 -64.45 -39.23 93.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.911 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 95.3 mt -47.7 -46.96 30.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.941 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 55.8 mm-40 -74.53 -33.46 62.77 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.847 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 33.0 tt0 -46.73 -40.93 14.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.919 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.0 mmtp -81.59 -46.83 13.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 46.0 mtt180 -44.27 -41.36 5.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.85 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.474 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.95 -42.97 80.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.476 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 29.9 mt -51.99 -38.14 55.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.44 HG22 ' N ' ' A' ' 156' ' ' GLU . 14.3 t -92.35 -33.53 14.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.166 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.44 ' N ' HG22 ' A' ' 155' ' ' THR . 45.8 mm-40 -83.49 -66.07 0.94 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.474 ' N ' ' O ' ' A' ' 153' ' ' ALA . 87.7 m -59.66 -13.26 9.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.93 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . 0.476 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.3 tp-100 -39.0 140.33 0.39 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.893 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 50.43 36.42 30.46 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.497 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . 0.462 ' HB1' ' CG2' ' A' ' 168' ' ' VAL . . . -67.55 110.94 3.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.863 0.364 . . . . 0.0 111.073 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.433 ' O ' ' C ' ' A' ' 162' ' ' GLY . 25.2 t -92.68 -35.91 7.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.132 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -35.12 -35.85 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.482 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.563 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 38.1 tp -86.21 117.45 25.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.843 0.354 . . . . 0.0 110.911 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 66.46 170.46 3.81 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.499 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' SER . . . . . 0.493 ' O ' ' CG ' ' A' ' 166' ' ' LYS . 35.9 m -82.09 40.35 0.62 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.891 0.377 . . . . 0.0 110.873 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . 0.493 ' CG ' ' O ' ' A' ' 165' ' ' SER . 36.0 mttt -169.23 157.22 6.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.527 0.679 . . . . 0.0 110.912 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 172.37 12.77 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.677 2.251 . . . . 0.0 112.317 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.462 ' CG2' ' HB1' ' A' ' 160' ' ' ALA . 32.2 m -135.69 126.9 44.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.136 179.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 44.7 ttt180 -89.95 117.51 28.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.866 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.468 ' CB ' HD22 ' A' ' 154' ' ' LEU . 17.1 mt -93.35 145.19 24.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.97 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 9.9 m -158.16 174.25 15.48 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 39.4 t -98.69 102.08 12.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.082 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.152 179.811 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.894 0.378 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.9 m -121.15 154.87 35.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.407 HD13 ' CE1' ' A' ' 144' ' ' PHE . 83.2 mt -124.06 145.82 48.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -95.4 124.11 39.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.414 HG23 ' C ' ' A' ' 140' ' ' GLY . 33.0 m -115.25 148.41 18.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.131 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -136.19 -177.86 15.32 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.47 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 49.77 54.09 11.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.873 0.368 . . . . 0.0 110.88 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 30.1 mt -100.51 102.56 13.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.936 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.8 p -47.52 151.26 1.47 Allowed Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.591 0.71 . . . . 0.0 111.136 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.79 -1.38 8.4 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.689 2.259 . . . . 0.0 112.343 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -102.04 25.52 8.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.857 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . 0.444 ' CG1' ' HE1' ' A' ' 111' ' ' MET . 22.2 t -134.62 138.73 49.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.148 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 45.0 m-20 -123.22 169.35 11.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.875 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.405 ' N ' HG13 ' A' ' 128' ' ' VAL . 0.5 OUTLIER -46.77 -46.23 20.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 -179.958 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -41.8 -44.47 4.45 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.508 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' MET . . . . . 0.444 ' HE1' ' CG1' ' A' ' 107' ' ' VAL . 32.3 mtm -77.97 -41.37 36.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.785 0.326 . . . . 0.0 110.887 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 16.8 tp -57.05 -25.13 58.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.974 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.487 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 8.5 t80 -84.23 -63.03 1.42 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.905 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.45 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 23.9 mt-10 -55.39 -43.24 75.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . 0.455 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 85.2 t80 -51.14 -33.02 24.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.845 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.492 ' O ' ' N ' ' A' ' 118' ' ' LYS . 7.9 m-85 -95.25 -65.78 0.95 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.45 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -37.16 -28.42 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.106 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.492 ' N ' ' O ' ' A' ' 116' ' ' PHE . 3.1 tptm -65.6 -53.73 37.62 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.937 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.452 HG21 ' CE2' ' A' ' 120' ' ' TYR . 4.1 p -71.16 -38.25 70.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 179.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.452 ' CE2' HG21 ' A' ' 119' ' ' VAL . 93.1 m-85 -127.17 116.19 21.75 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.629 0.728 . . . . 0.0 110.934 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 2.94 3.06 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.668 2.246 . . . . 0.0 112.365 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 18.5 p -89.96 -26.47 20.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . 0.548 ' HA ' ' CD2' ' A' ' 144' ' ' PHE . 9.5 t -45.25 128.39 7.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.936 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -90.08 -34.88 15.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.869 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.487 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 172.14 166.2 30.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.443 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -115.66 144.22 18.36 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.462 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 18.1 tptt -136.01 128.89 31.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.792 0.329 . . . . 0.0 110.916 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.405 HG13 ' N ' ' A' ' 109' ' ' ASP . 6.5 p -119.02 127.32 75.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.165 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.458 HG23 ' CE1' ' A' ' 139' ' ' TYR . 10.3 m -74.58 153.51 6.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.139 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 13.4 mt -130.52 176.82 7.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 134' ' ' GLY . 18.3 t70 -108.23 174.41 5.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.875 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -40.98 -45.06 2.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.879 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 20.8 p -71.57 -34.26 69.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.111 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 113.53 20.92 5.98 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.485 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 136' ' ' SER . 27.3 m -100.44 122.85 52.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.855 0.36 . . . . 0.0 111.138 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 135' ' ' VAL . 7.3 t -34.57 106.83 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.87 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.49 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 26.8 mtmt -50.45 -34.51 25.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.869 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.2 18.64 2.27 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.518 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.49 ' CE2' ' HE3' ' A' ' 137' ' ' LYS . 19.1 p90 -163.08 165.89 24.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.966 0.412 . . . . 0.0 110.883 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.414 ' C ' HG23 ' A' ' 100' ' ' VAL . . . -166.67 -161.35 15.59 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.512 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -154.03 145.51 23.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.915 0.388 . . . . 0.0 110.861 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.511 HG21 ' CE1' ' A' ' 144' ' ' PHE . 24.4 m -117.31 -176.09 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.133 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 20.2 mtmm -143.57 160.76 40.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.864 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.548 ' CD2' ' HA ' ' A' ' 123' ' ' CYS . 65.5 m-85 -149.85 179.32 8.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -125.08 -16.62 5.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.16 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -122.17 97.33 5.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.876 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.6 tt0 -44.83 -48.95 11.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.917 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 63.5 mt -44.85 -33.0 1.77 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.926 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -89.79 -36.69 14.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.834 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 13.6 tt0 -52.4 -47.53 66.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 61.9 mttt -69.99 -41.9 73.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.907 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 69.8 mtt180 -49.7 -34.3 18.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.869 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.452 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -73.3 -45.63 54.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.103 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . . . . . . . . . 26.6 mt -48.4 -36.49 14.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 9.4 t -91.35 -40.61 11.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 56.7 mm-40 -77.56 -66.45 0.83 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.863 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.47 ' CB ' HD12 ' A' ' 170' ' ' LEU . 63.3 m -60.59 -11.6 7.64 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.855 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 157' ' ' CYS . 2.8 tp-100 -34.99 139.86 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.892 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 43.5 35.8 3.01 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.519 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . 0.447 ' HB2' ' CG2' ' A' ' 168' ' ' VAL . . . -55.71 120.14 6.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.82 0.343 . . . . 0.0 111.146 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.8 t -95.1 -33.26 4.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.101 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -41.47 -36.53 1.54 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.53 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.455 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 22.6 tp -89.06 116.48 27.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.895 0.378 . . . . 0.0 110.875 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 68.77 157.89 1.31 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.505 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 49.9 m -62.34 -11.47 15.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.961 0.41 . . . . 0.0 110.839 -179.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 51.1 mttt -120.02 156.79 54.19 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.59 0.71 . . . . 0.0 110.895 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 177.36 5.68 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.65 2.233 . . . . 0.0 112.382 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.447 ' CG2' ' HB2' ' A' ' 160' ' ' ALA . 15.7 m -131.96 125.13 54.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.144 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 21.4 ttm180 -86.82 102.31 14.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.854 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.47 HD12 ' CB ' ' A' ' 157' ' ' CYS . 12.8 mt -81.55 140.67 34.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 19.9 m -156.46 178.03 10.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.839 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 3.3 t -99.95 99.69 8.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.081 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.144 179.826 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 13.4 m-85 . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.908 0.385 . . . . 0.0 110.921 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.1 m -138.91 148.27 43.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.861 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 82.9 mt -117.41 151.63 36.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.915 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -98.31 123.29 42.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.907 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 29.8 m -117.45 144.09 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.125 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.11 178.5 18.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.483 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . 0.45 ' N ' ' O ' ' A' ' 138' ' ' GLY . 1.2 m-20 57.73 53.88 6.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.82 0.343 . . . . 0.0 110.859 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 23.0 mt -100.8 103.34 14.55 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.896 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 39.9 p -48.31 150.1 2.41 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.578 0.704 . . . . 0.0 111.146 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -1.56 8.69 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.678 2.252 . . . . 0.0 112.352 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -99.33 12.08 37.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.858 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . 0.44 ' CG1' ' HE3' ' A' ' 111' ' ' MET . 62.1 t -123.32 139.92 48.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.096 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -122.08 171.59 8.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.878 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -52.63 -43.91 65.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.893 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -43.87 -37.3 4.04 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.507 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' MET . . . . . 0.44 ' HE3' ' CG1' ' A' ' 107' ' ' VAL . 28.2 mtm -81.45 -44.72 17.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.833 0.349 . . . . 0.0 110.889 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.458 HD13 ' CD2' ' A' ' 163' ' ' LEU . 22.1 tp -53.92 -28.52 37.37 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.873 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.555 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 13.9 t80 -76.36 -65.36 0.93 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.908 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.471 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 17.0 mt-10 -55.23 -48.25 74.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.918 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . . . . . . . . . 69.0 t80 -46.31 -33.82 4.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.938 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.492 ' O ' ' N ' ' A' ' 118' ' ' LYS . 6.9 m-85 -95.3 -67.09 0.87 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.847 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.471 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.8 p -36.51 -29.41 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.079 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.492 ' N ' ' O ' ' A' ' 116' ' ' PHE . 18.8 ttpp -67.47 -55.56 13.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.914 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.564 HG22 ' CE2' ' A' ' 120' ' ' TYR . 2.3 p -70.98 -30.72 42.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.123 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.576 ' CE1' ' HB3' ' A' ' 152' ' ' ARG . 97.6 m-85 -132.26 112.36 14.32 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.602 0.715 . . . . 0.0 110.955 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.75 2.39 3.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.671 2.247 . . . . 0.0 112.338 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 6.3 p -92.87 -20.27 20.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.862 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.0 t -50.05 134.28 22.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.883 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -94.85 -35.7 11.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.555 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 167.1 143.91 3.93 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.492 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -97.34 136.58 12.83 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.473 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 19.3 tttp -124.83 139.2 54.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.77 0.319 . . . . 0.0 110.925 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.3 p -123.17 139.62 49.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.149 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.535 HG22 ' CE1' ' A' ' 139' ' ' TYR . 6.3 m -89.91 152.71 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 7.9 mt -128.68 160.92 30.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -87.59 172.72 9.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.848 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.56 -19.99 0.39 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 58.1 p -89.45 -29.76 18.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.131 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 111.8 10.77 18.19 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.489 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 33.8 m -98.92 136.49 29.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.79 0.329 . . . . 0.0 111.159 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.6 t -43.23 105.78 0.06 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.88 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.505 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 26.0 mtmt -50.58 -32.98 20.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.918 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 123.58 19.9 2.72 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.548 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.535 ' CE1' HG22 ' A' ' 129' ' ' VAL . 13.9 p90 -163.83 168.77 19.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.952 0.406 . . . . 0.0 110.914 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.53 -160.88 18.8 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.522 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.4 m-85 -153.97 144.16 22.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.848 0.356 . . . . 0.0 110.918 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 20.6 m -120.97 174.02 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.144 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -132.93 163.75 28.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.869 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -149.79 159.78 44.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.923 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 14.0 p -90.34 -39.37 12.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -109.23 132.04 54.49 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.87 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -72.27 -38.3 68.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.923 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 30.2 mt -48.78 -34.06 11.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.923 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -87.83 -37.27 16.69 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.905 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 22.4 tt0 -41.61 -48.39 4.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.947 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 47.2 mttt -71.7 -32.22 67.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.864 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.576 ' HB3' ' CE1' ' A' ' 120' ' ' TYR . 0.6 OUTLIER -52.67 -39.45 61.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.841 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.499 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.86 -46.57 71.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.129 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . . . . . . . . . 17.0 mt -40.36 -43.68 1.81 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.47 HG21 ' N ' ' A' ' 156' ' ' GLU . 14.6 t -92.7 -50.63 5.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.124 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.47 ' N ' HG21 ' A' ' 155' ' ' THR . 76.9 mm-40 -62.51 -57.63 10.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.914 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.499 ' N ' ' O ' ' A' ' 153' ' ' ALA . 24.7 m -83.2 20.53 1.25 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.824 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . 0.419 ' OE1' ' N ' ' A' ' 159' ' ' GLY . 2.0 tp-100 -64.71 131.89 48.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.9 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . 0.419 ' N ' ' OE1' ' A' ' 158' ' ' GLN . . . 47.09 29.69 4.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.479 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -50.12 119.23 3.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.827 0.346 . . . . 0.0 111.112 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.427 ' O ' ' C ' ' A' ' 162' ' ' GLY . 37.5 t -88.12 -36.75 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.134 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -35.97 -38.59 0.23 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.492 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.458 ' CD2' HD13 ' A' ' 112' ' ' LEU . 20.0 tp -89.08 118.84 29.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.866 0.365 . . . . 0.0 110.918 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 64.91 153.49 0.11 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.487 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 16.7 t -55.66 -23.8 30.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.962 0.41 . . . . 0.0 110.839 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 58.8 mttt -109.24 154.95 41.84 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.572 0.701 . . . . 0.0 110.908 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 171.23 14.89 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.7 2.267 . . . . 0.0 112.34 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 16.4 m -121.18 125.84 74.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.085 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 35.1 ttt-85 -88.71 103.27 15.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.411 HD12 ' C ' ' A' ' 157' ' ' CYS . 11.7 mt -80.64 148.61 30.17 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.857 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 3.2 m -160.75 177.61 10.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.917 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 21.2 t -99.36 96.83 5.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.116 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.082 179.89 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . 0.529 ' CD1' ' HG3' ' A' ' 147' ' ' GLU . 63.5 m-85 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.903 0.383 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 66.3 p -112.81 154.58 26.04 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.855 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 33.5 mt -124.79 142.4 51.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.907 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -91.25 132.88 35.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.899 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 18.9 m -126.02 151.82 32.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.128 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -141.72 -179.62 18.97 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.5 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 57.76 38.84 27.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.841 0.353 . . . . 0.0 110.905 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.412 HD11 ' C ' ' A' ' 139' ' ' TYR . 31.2 mt -86.51 108.83 18.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 81.9 p -53.82 150.25 14.62 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.612 0.72 . . . . 0.0 111.144 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 2.21 3.74 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.706 2.271 . . . . 0.0 112.337 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 19.0 t0 -102.02 -3.17 28.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . 0.422 ' CG1' ' HE1' ' A' ' 111' ' ' MET . 41.3 t -103.68 145.08 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.141 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -129.18 179.68 5.63 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -60.34 -37.86 81.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.881 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.43 -33.23 39.51 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.47 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' MET . . . . . 0.422 ' HE1' ' CG1' ' A' ' 107' ' ' VAL . 27.3 mtm -86.85 -46.91 9.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.842 0.353 . . . . 0.0 110.886 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.439 HD23 ' N ' ' A' ' 127' ' ' LYS . 18.1 tp -53.34 -23.03 8.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.929 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.491 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 13.0 t80 -82.63 -61.75 1.8 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.926 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.458 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 22.4 mt-10 -57.23 -46.58 82.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.867 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . 0.477 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 75.6 t80 -47.68 -33.23 6.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.463 ' O ' ' N ' ' A' ' 118' ' ' LYS . 7.6 m-85 -95.28 -66.98 0.88 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.861 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.458 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.73 -30.97 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.132 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.463 ' N ' ' O ' ' A' ' 116' ' ' PHE . 59.2 tttt -67.31 -60.61 2.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.903 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -64.65 -27.15 41.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.114 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -137.94 115.89 9.57 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.7 0.762 . . . . 0.0 110.906 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -2.77 10.7 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.751 2.301 . . . . 0.0 112.336 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 73.2 m -99.25 32.28 2.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.854 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . 0.43 ' CB ' ' HA ' ' A' ' 117' ' ' VAL . 19.6 t -94.51 135.2 36.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.881 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 16.8 mtp180 -93.17 -39.0 11.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.867 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.491 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 163.56 149.43 5.73 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -102.9 134.27 11.75 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.518 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.439 ' N ' HD23 ' A' ' 112' ' ' LEU . 4.3 tppp? -123.21 137.56 54.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.806 0.336 . . . . 0.0 110.925 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.4 p -124.69 129.4 73.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.126 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.562 HG22 ' CD1' ' A' ' 139' ' ' TYR . 22.5 m -75.18 150.49 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.085 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 14.9 mt -127.03 174.91 8.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.925 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -103.18 178.27 4.6 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.846 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 25.3 tt0 -45.28 -43.08 10.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.905 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 27.8 p -74.68 -25.04 58.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.167 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 107.88 17.67 10.8 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.475 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 28.8 m -95.9 134.31 33.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.872 0.368 . . . . 0.0 111.126 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.8 t -44.18 107.2 0.08 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.863 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.497 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.7 mtmt -52.75 -32.36 42.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.902 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.7 18.74 2.63 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.482 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.562 ' CD1' HG22 ' A' ' 129' ' ' VAL . 23.4 p90 -163.14 168.25 21.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.981 0.42 . . . . 0.0 110.9 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -170.74 -165.18 27.68 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.478 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -150.88 146.99 26.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.869 0.366 . . . . 0.0 110.893 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.483 HG21 ' CE2' ' A' ' 144' ' ' PHE . 17.8 m -119.2 179.32 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.113 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 31.3 mttt -138.53 160.35 39.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.899 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.483 ' CE2' HG21 ' A' ' 142' ' ' VAL . 96.2 m-85 -148.34 161.99 40.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.855 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 44.0 p -101.88 -12.34 18.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.099 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.443 ' CG ' ' OE1' ' A' ' 149' ' ' GLU . 14.3 t0 -129.61 130.04 45.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.857 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.529 ' HG3' ' CD1' ' A' ' 96' ' ' TYR . 20.0 tt0 -71.83 -43.23 65.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 37.2 mt -45.23 -49.21 12.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.954 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.443 ' OE1' ' CG ' ' A' ' 146' ' ' ASP . 3.6 mp0 -72.8 -44.05 61.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.855 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 149' ' ' GLU . 17.4 tt0 -36.97 -55.28 0.93 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.932 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 13.7 mttm -64.48 -52.59 57.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 28.4 mtt180 -39.41 -33.29 0.15 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.853 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.448 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -73.98 -49.93 22.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.133 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . . . . . . . . . 33.9 mt -43.34 -38.36 2.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.912 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.467 HG22 ' N ' ' A' ' 156' ' ' GLU . 9.8 t -91.03 -48.3 7.06 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.167 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.467 ' N ' HG22 ' A' ' 155' ' ' THR . 53.1 mt-10 -69.56 -64.58 0.85 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.9 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.448 ' N ' ' O ' ' A' ' 153' ' ' ALA . 54.1 m -62.82 -8.3 6.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.905 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -40.5 140.95 0.59 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 37.66 45.6 1.48 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.465 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.18 115.09 4.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.802 0.334 . . . . 0.0 111.129 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.0 t -84.88 -35.57 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.143 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -43.06 -34.44 2.06 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.453 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.477 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 19.2 tp -91.81 115.82 28.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.866 0.365 . . . . 0.0 110.922 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 166' ' ' LYS . . . 64.55 138.48 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.497 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 t -41.05 -27.92 0.07 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.944 0.402 . . . . 0.0 110.838 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . 0.401 ' N ' ' O ' ' A' ' 164' ' ' GLY . 57.5 mttt -103.78 154.67 37.83 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.526 0.679 . . . . 0.0 110.924 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.69 173.15 11.33 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.7 2.266 . . . . 0.0 112.413 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 21.1 m -124.45 131.27 73.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.127 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 43.4 ttt180 -94.84 105.01 16.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.92 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.44 HD12 ' CB ' ' A' ' 157' ' ' CYS . 13.3 mt -82.66 148.87 27.69 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.933 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.0 m -158.72 -177.87 6.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.9 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 4.4 t -108.83 102.15 13.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.145 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.07 179.895 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.896 0.379 . . . . 0.0 110.934 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.0 p -117.13 146.26 43.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.859 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 46.3 mt -110.43 150.4 28.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.906 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -96.34 127.23 42.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.852 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.8 m -119.42 146.05 24.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.15 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.84 -177.99 15.9 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.463 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 52.85 51.57 15.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.88 0.371 . . . . 0.0 110.877 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 30.1 mt -98.04 118.52 34.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.936 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p -61.97 151.54 79.9 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.587 0.708 . . . . 0.0 111.094 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -0.02 6.29 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.718 2.278 . . . . 0.0 112.333 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -99.46 -0.24 41.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . 0.46 ' HA ' ' CE ' ' A' ' 111' ' ' MET . 26.5 t -111.09 147.68 14.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.096 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -131.83 -178.81 5.05 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.885 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.64 -37.78 85.28 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.78 -26.93 26.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.52 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' MET . . . . . 0.46 ' CE ' ' HA ' ' A' ' 107' ' ' VAL . 34.3 mtm -93.8 -39.29 10.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 0.0 110.919 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.464 HD23 ' N ' ' A' ' 127' ' ' LYS . 49.3 tp -55.86 -30.41 61.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.938 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.496 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 22.5 t80 -78.8 -63.86 1.31 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.947 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.449 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 17.0 mt-10 -53.54 -36.31 61.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.886 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . . . . . . . . . 67.6 t80 -58.09 -34.2 69.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.88 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.501 ' O ' ' N ' ' A' ' 118' ' ' LYS . 10.2 m-85 -95.25 -62.74 1.25 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.875 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.449 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -38.44 -26.39 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.115 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.501 ' N ' ' O ' ' A' ' 116' ' ' PHE . 18.2 tttm -71.05 -60.73 2.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.911 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.561 HG22 ' CE2' ' A' ' 120' ' ' TYR . 3.7 p -67.62 -25.79 33.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.165 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.561 ' CE2' HG22 ' A' ' 119' ' ' VAL . 92.2 m-85 -136.09 112.26 10.31 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.633 0.73 . . . . 0.0 110.95 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 2.81 3.18 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.672 2.248 . . . . 0.0 112.343 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 32.0 m -105.44 27.9 7.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.853 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 36.8 t -89.0 124.73 34.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.857 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.467 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 14.0 mtp180 -79.21 -42.8 25.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.862 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.496 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 168.52 159.56 14.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.507 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -114.7 134.87 11.95 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.497 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.464 ' N ' HD23 ' A' ' 112' ' ' LEU . 3.5 tppp? -130.13 132.69 46.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.838 0.352 . . . . 0.0 110.878 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.2 p -118.1 129.7 74.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.558 HG12 ' CE1' ' A' ' 139' ' ' TYR . 23.8 m -73.76 144.98 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.083 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.417 ' HB3' ' C ' ' A' ' 134' ' ' GLY . 46.4 mt -123.9 162.3 23.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.903 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.424 ' CG ' ' HG2' ' A' ' 137' ' ' LYS . 3.0 m-20 -93.33 -178.25 4.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -40.75 -59.05 1.49 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.955 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.36 -30.83 71.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.417 ' C ' ' HB3' ' A' ' 130' ' ' LEU . . . 116.65 0.54 20.01 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.498 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 3.5 m -73.43 141.12 16.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.787 0.327 . . . . 0.0 111.126 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.2 t -50.27 113.83 0.97 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.457 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 22.1 mtmt -58.76 -30.72 67.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.916 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 120.13 17.26 4.56 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.512 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.558 ' CE1' HG12 ' A' ' 129' ' ' VAL . 19.0 p90 -163.29 167.96 21.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.985 0.422 . . . . 0.0 110.864 -179.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -171.56 -162.48 23.91 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.51 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -153.3 139.9 18.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.893 0.378 . . . . 0.0 110.88 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.4 m -110.75 176.85 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . 0.467 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 47.8 mttt -133.35 156.72 47.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.878 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -148.57 152.57 37.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 25.3 p -96.0 -24.96 16.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.147 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -115.06 103.55 11.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.837 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 15.2 tm-20 -48.51 -47.23 39.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.914 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 65.6 mt -39.68 -44.35 1.51 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.935 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -72.48 -40.65 66.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.918 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 24.9 tt0 -40.36 -60.6 1.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 14.4 mttm -62.51 -44.78 95.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 57.6 mtt180 -48.0 -42.64 28.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.904 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.459 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -69.15 -45.19 70.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . . . . . . . . . 13.8 mt -43.52 -41.38 4.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.952 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.444 HG22 ' N ' ' A' ' 156' ' ' GLU . 6.0 t -92.46 -41.64 10.18 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.444 ' N ' HG22 ' A' ' 155' ' ' THR . 21.6 mm-40 -70.04 -63.59 1.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.868 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.459 ' N ' ' O ' ' A' ' 153' ' ' ALA . 20.9 m -70.82 -0.32 8.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . 0.438 ' N ' HD13 ' A' ' 170' ' ' LEU . 2.6 tp-100 -43.69 129.79 5.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 55.45 33.78 59.1 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.495 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . 0.402 ' CB ' ' CG2' ' A' ' 168' ' ' VAL . . . -48.64 116.58 1.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.799 0.333 . . . . 0.0 111.062 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.7 t -93.85 -31.39 4.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.138 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -46.29 -31.64 4.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.517 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 20.4 tp -91.37 115.7 28.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.851 0.358 . . . . 0.0 110.923 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.0 159.92 0.97 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.493 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 m -61.95 -19.68 63.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.959 0.409 . . . . 0.0 110.883 -179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 35.0 mttm -111.13 153.53 43.9 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.559 0.695 . . . . 0.0 110.89 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 171.79 13.85 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.659 2.239 . . . . 0.0 112.371 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.402 ' CG2' ' CB ' ' A' ' 160' ' ' ALA . 22.2 m -127.22 125.06 65.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.119 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.5 ttt180 -86.42 111.68 20.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.851 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.438 HD13 ' N ' ' A' ' 158' ' ' GLN . 14.7 mt -87.16 139.95 30.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.2 m -152.74 178.17 9.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.823 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 2.8 t -100.73 96.15 4.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.128 179.863 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . 0.441 ' CD1' ' HG3' ' A' ' 147' ' ' GLU . 32.4 m-85 . . . . . 0 N--CA 1.457 -0.084 0 CA-C-O 120.897 0.38 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 52.6 p -138.52 159.66 41.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.9 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.451 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . 79.5 mt -124.84 147.73 48.61 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -94.03 120.6 34.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.902 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 31.2 m -114.04 145.41 19.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -133.67 -174.02 13.41 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.494 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 46.91 50.88 13.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.841 0.353 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 20.4 mt -96.05 99.07 10.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.954 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 23.9 p -48.79 151.57 2.08 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.597 0.713 . . . . 0.0 111.122 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 1.56 4.32 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.694 2.262 . . . . 0.0 112.326 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -100.99 10.38 41.17 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.851 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . 0.403 ' HA ' ' CE ' ' A' ' 111' ' ' MET . 3.9 t -121.57 147.03 25.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.1 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -132.77 178.52 6.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.873 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -56.18 -40.07 73.39 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -49.28 -40.18 29.41 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' MET . . . . . 0.403 ' CE ' ' HA ' ' A' ' 107' ' ' VAL . 36.1 mtm -82.57 -39.73 21.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.835 0.35 . . . . 0.0 110.876 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.46 HD21 ' N ' ' A' ' 127' ' ' LYS . 28.3 tp -57.71 -28.11 63.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.414 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.2 t80 -81.77 -60.02 2.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.92 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.45 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 20.7 mt-10 -56.13 -47.43 78.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . 0.425 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 62.8 t80 -48.79 -33.64 10.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.917 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.484 ' CE2' HG12 ' A' ' 142' ' ' VAL . 7.5 m-85 -94.41 -66.12 0.94 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.873 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.45 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.71 -30.43 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.15 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.472 ' N ' ' O ' ' A' ' 116' ' ' PHE . 20.2 ttpp -65.84 -59.37 3.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.941 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.405 HG12 ' N ' ' A' ' 120' ' ' TYR . 3.6 p -67.13 -34.21 68.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.172 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.42 ' CE2' ' HB1' ' A' ' 153' ' ' ALA . 92.8 m-85 -130.06 112.01 17.1 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.662 0.744 . . . . 0.0 110.96 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 1.39 4.46 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.679 2.252 . . . . 0.0 112.352 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -99.05 19.9 14.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.828 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 38.8 t -82.01 132.8 35.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.875 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.461 ' NE ' HG21 ' A' ' 145' ' ' THR . 46.1 mtt-85 -89.52 -41.92 11.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.868 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.414 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 168.94 150.35 6.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.468 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -103.18 142.34 15.48 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.517 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.46 ' N ' HD21 ' A' ' 112' ' ' LEU . 12.1 tptm -136.95 132.71 34.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.869 0.366 . . . . 0.0 110.868 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 3.0 p -120.72 129.26 75.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.454 HG23 ' CE1' ' A' ' 139' ' ' TYR . 23.5 m -72.41 142.88 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.107 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 11.5 mt -127.7 163.97 23.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.936 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.444 ' OD1' ' C ' ' A' ' 131' ' ' ASP . 0.6 OUTLIER -97.89 -175.08 3.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.839 179.865 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 44.5 tt0 -49.09 -48.67 44.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 21.5 p -65.91 -23.2 66.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.147 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.46 22.57 18.72 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 30.1 m -102.93 131.27 51.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.8 0.334 . . . . 0.0 111.138 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.4 t -39.45 116.83 0.65 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.864 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.1 mtmt -63.17 -28.17 69.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.914 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 123.98 14.34 3.8 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.506 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.454 ' CE1' HG23 ' A' ' 129' ' ' VAL . 17.9 p90 -162.2 170.82 18.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.939 0.399 . . . . 0.0 110.921 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -172.71 -160.79 21.98 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.507 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -153.85 143.72 21.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.867 0.365 . . . . 0.0 110.861 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.484 HG12 ' CE2' ' A' ' 116' ' ' PHE . 14.7 m -115.39 -176.68 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.123 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 13.8 mttp -141.55 153.02 44.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -146.48 128.82 15.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.88 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' THR . . . . . 0.461 HG21 ' NE ' ' A' ' 124' ' ' ARG . 36.7 p -66.5 -12.7 58.8 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.162 -179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -126.54 135.21 51.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.868 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.441 ' HG3' ' CD1' ' A' ' 96' ' ' TYR . 29.7 tt0 -79.08 -34.17 43.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.887 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 38.9 mt -53.98 -60.2 3.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.911 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -65.09 -38.45 90.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.446 ' NE2' HD22 ' A' ' 98' ' ' LEU . 1.4 tm0? -48.06 -42.55 28.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.888 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 34.7 mmtm -77.85 -26.94 49.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 27.1 mtt180 -65.09 -37.48 87.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.855 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.454 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -66.12 -36.04 82.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.104 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.466 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 28.1 mt -52.49 -41.49 63.43 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.934 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.469 HG23 ' N ' ' A' ' 156' ' ' GLU . 8.8 t -91.86 -36.42 13.51 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.176 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.469 ' N ' HG23 ' A' ' 155' ' ' THR . 16.0 mm-40 -76.24 -62.54 1.58 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.877 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.454 ' N ' ' O ' ' A' ' 153' ' ' ALA . 10.5 m -71.79 0.54 8.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . 0.466 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.0 tp-100 -43.17 136.14 3.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.9 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 45.93 30.16 3.59 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.475 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . 0.416 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -49.79 112.31 0.64 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.828 0.347 . . . . 0.0 111.115 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 18.8 t -87.18 -33.84 7.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.84 -31.13 1.09 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.463 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.425 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 28.4 tp -90.17 109.43 20.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.882 0.372 . . . . 0.0 110.919 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 71.53 168.05 9.02 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.471 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 39.5 m -66.24 -23.1 66.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.918 0.39 . . . . 0.0 110.863 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 58.9 mttm -110.29 155.81 41.29 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.632 0.73 . . . . 0.0 110.873 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.85 -176.85 1.65 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.676 2.25 . . . . 0.0 112.325 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.416 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 28.6 m -135.04 128.28 49.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.131 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 12.5 ttp180 -91.99 94.16 9.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.835 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.417 HD13 ' N ' ' A' ' 158' ' ' GLN . 10.6 mt -72.14 152.64 42.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' SER . . . . . 0.418 ' N ' ' CD2' ' A' ' 154' ' ' LEU . 0.9 OUTLIER -167.01 178.32 5.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.891 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 45.5 t -103.79 99.45 8.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.086 179.893 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 19.5 m-85 . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.851 0.358 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 45.9 m -118.69 146.55 44.62 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.86 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 68.3 mt -113.53 153.36 28.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.921 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -100.77 123.05 44.41 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.848 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 23.1 m -114.38 145.8 19.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.114 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.11 -176.75 14.51 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.513 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 48.78 52.06 14.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.827 0.346 . . . . 0.0 110.879 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 28.7 mt -98.24 105.89 18.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.879 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 25.1 p -50.6 150.63 4.73 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.582 0.705 . . . . 0.0 111.158 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 3.16 2.95 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.665 2.243 . . . . 0.0 112.316 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -98.38 -13.33 20.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.881 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 41.4 t -98.21 134.46 36.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.151 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.25 175.88 5.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.828 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -53.37 -44.79 68.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.858 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.96 -29.07 7.98 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.499 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' MET . . . . . . . . . . . . . 22.3 mtp -86.88 -59.47 2.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.788 0.328 . . . . 0.0 110.873 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 15.8 tp -40.18 -41.06 1.22 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.898 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.421 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 12.9 t80 -62.65 -67.17 0.44 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.966 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.455 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 30.3 mt-10 -52.52 -55.52 21.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.927 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . 0.42 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 57.2 t80 -41.49 -32.28 0.33 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.896 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.498 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.0 m-85 -95.14 -67.53 0.85 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.883 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.455 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -37.65 -27.58 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.103 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.498 ' N ' ' O ' ' A' ' 116' ' ' PHE . 20.1 tptt -67.57 -57.87 5.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.885 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.3 p -71.56 -32.73 46.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.175 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.555 ' CE2' ' HB2' ' A' ' 153' ' ' ALA . 97.0 m-85 -126.3 108.04 24.09 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.622 0.725 . . . . 0.0 110.954 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 2.44 3.53 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.667 2.245 . . . . 0.0 112.339 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 47.6 p -95.0 -10.33 31.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 10.0 t -57.09 142.65 41.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.887 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 61.7 mtp180 -104.46 -34.1 8.36 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.88 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.421 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 166.72 145.99 4.68 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.453 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -96.35 139.25 14.39 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.477 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 46.6 tptt -125.28 127.73 47.15 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.87 0.366 . . . . 0.0 110.866 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.1 p -117.72 141.28 37.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.555 HG23 ' CD1' ' A' ' 139' ' ' TYR . 33.2 m -92.73 145.33 7.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.096 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 23.4 mt -123.8 179.09 4.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.888 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 11.1 t0 -108.96 -178.96 3.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.875 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -53.57 -18.9 3.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.917 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 43.6 p -93.61 -27.27 16.69 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.163 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 107.52 17.29 11.47 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.476 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 19.1 m -100.05 139.27 21.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 0.0 111.112 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.5 t -49.76 100.34 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.506 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.4 mtmt -42.97 -36.09 1.44 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.877 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 128.35 16.97 2.03 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.548 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.555 ' CD1' HG23 ' A' ' 129' ' ' VAL . 28.1 p90 -161.07 172.07 17.47 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.901 0.381 . . . . 0.0 110.96 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -174.94 -163.23 27.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.475 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -153.76 145.58 23.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.861 0.363 . . . . 0.0 110.863 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.427 HG12 ' CE2' ' A' ' 116' ' ' PHE . 29.3 m -119.6 -177.74 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.087 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 32.8 mttm -142.16 156.73 45.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -145.87 163.43 35.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 29.2 p -101.1 -19.88 15.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.129 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -117.02 120.47 38.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.825 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -65.45 -33.55 76.21 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.948 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 44.6 mt -57.71 -40.57 79.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.931 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.462 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 38.6 mt-10 -76.28 -38.53 56.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.829 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 22.0 tt0 -44.95 -48.43 11.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.869 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 5.1 mmmm -73.57 -37.37 65.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.407 ' O ' ' CG ' ' A' ' 156' ' ' GLU . 9.1 mtt-85 -56.25 -34.23 66.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.892 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.555 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -72.0 -46.2 58.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.487 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 48.6 mt -44.36 -40.98 5.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 14.9 t -92.33 -42.54 9.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.165 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.407 ' CG ' ' O ' ' A' ' 152' ' ' ARG . 25.6 mm-40 -68.96 -64.87 0.79 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.433 ' CB ' HD12 ' A' ' 170' ' ' LEU . 10.4 m -70.11 -1.68 10.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.893 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . 0.487 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.8 tp-100 -42.48 141.95 0.9 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.891 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 158' ' ' GLN . . . 35.51 34.29 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.502 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . 0.428 ' N ' ' O ' ' A' ' 158' ' ' GLN . . . -58.49 110.65 1.02 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.769 0.319 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.41 ' O ' ' C ' ' A' ' 162' ' ' GLY . 22.9 t -79.27 -34.27 16.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.121 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.65 -36.23 0.15 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.464 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.42 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 25.2 tp -92.72 115.17 27.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.85 0.357 . . . . 0.0 110.885 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.77 146.85 0.13 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.495 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 m -50.81 -21.09 1.5 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.966 0.413 . . . . 0.0 110.855 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 36.5 mttm -109.08 156.05 39.86 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.595 0.712 . . . . 0.0 110.903 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 171.84 13.74 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.699 2.266 . . . . 0.0 112.295 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 35.4 m -125.34 127.6 72.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.185 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 17.7 ttt180 -91.54 107.82 19.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.433 HD12 ' CB ' ' A' ' 157' ' ' CYS . 14.4 mt -84.4 143.39 29.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.932 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 15.2 m -154.6 171.41 19.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.881 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 3.0 t -101.0 100.6 10.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.112 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.136 179.838 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.918 0.39 . . . . 0.0 110.934 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.8 m -112.33 147.19 36.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.839 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.518 HD11 ' CE1' ' A' ' 144' ' ' PHE . 92.2 mt -115.75 155.99 26.79 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.412 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 8.6 t80 -104.6 127.49 52.35 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.856 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.4 m -116.55 155.28 18.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -142.59 178.12 21.26 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.485 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 52.87 50.28 18.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.874 0.369 . . . . 0.0 110.898 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 29.1 mt -96.9 103.44 15.37 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.899 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 17.4 p -47.94 150.16 2.1 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 121.617 0.723 . . . . 0.0 111.152 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 2.98 3.03 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.623 2.215 . . . . 0.0 112.375 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.34 16.34 26.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . 0.456 ' HA ' ' CE ' ' A' ' 111' ' ' MET . 59.5 t -129.62 142.17 44.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.109 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -128.95 -177.6 4.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.817 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -58.18 -47.98 81.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.848 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -42.26 -35.1 1.72 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.48 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' MET . . . . . 0.456 ' CE ' ' HA ' ' A' ' 107' ' ' VAL . 26.0 mtm -86.03 -45.72 11.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.823 0.344 . . . . 0.0 110.884 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.455 HD22 ' N ' ' A' ' 127' ' ' LYS . 16.0 tp -53.5 -33.45 54.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.496 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 9.8 t80 -68.71 -61.62 1.74 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.45 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 22.2 mt-10 -57.76 -51.78 68.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.901 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . 0.536 ' CE1' ' HB2' ' A' ' 163' ' ' LEU . 66.5 t80 -44.1 -32.34 1.17 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.876 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.483 ' O ' ' N ' ' A' ' 118' ' ' LYS . 7.7 m-85 -95.25 -67.52 0.85 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.45 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.83 -29.35 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.158 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.483 ' N ' ' O ' ' A' ' 116' ' ' PHE . 22.9 ttpp -66.31 -58.31 5.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.901 179.883 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.411 HG11 ' N ' ' A' ' 120' ' ' TYR . 3.6 p -67.41 -33.0 59.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.124 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.482 ' CD1' ' HB3' ' A' ' 149' ' ' GLU . 89.4 m-85 -129.12 113.31 18.5 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.683 0.754 . . . . 0.0 110.944 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -0.05 6.35 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.722 2.281 . . . . 0.0 112.353 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 69.0 m -105.22 35.41 2.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.864 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 3.0 t -98.09 138.59 35.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.907 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 44.8 mtp85 -93.6 -38.06 11.55 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.857 -179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.496 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 159.22 141.72 3.21 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.491 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.455 ' CA ' HD22 ' A' ' 112' ' ' LEU . . . -90.41 138.04 14.25 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.44 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.455 ' N ' HD22 ' A' ' 112' ' ' LEU . 20.2 tptm -122.05 128.28 51.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.81 0.338 . . . . 0.0 110.9 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.9 p -114.86 135.64 54.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.508 HG22 ' CD1' ' A' ' 139' ' ' TYR . 32.9 m -84.71 145.98 7.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.092 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.413 ' HB3' ' C ' ' A' ' 134' ' ' GLY . 31.1 mt -126.69 -179.66 4.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.849 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.48 ' O ' ' N ' ' A' ' 134' ' ' GLY . 2.2 t70 -118.69 -176.0 3.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.891 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -38.35 -61.38 0.69 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.887 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.92 -24.84 66.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.148 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.48 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 105.16 4.45 41.27 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.502 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 5.3 m -77.24 145.2 10.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.811 0.339 . . . . 0.0 111.168 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.1 t -56.93 113.9 1.87 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.501 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 30.0 mtmt -56.73 -31.65 64.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.885 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.21 17.71 2.95 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.484 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.508 ' CD1' HG22 ' A' ' 129' ' ' VAL . 28.0 p90 -162.55 174.8 12.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.964 0.412 . . . . 0.0 110.889 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -178.29 -162.42 28.01 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.485 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.412 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 4.5 m-85 -153.98 146.18 23.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.953 0.406 . . . . 0.0 110.858 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.483 HG12 ' CE2' ' A' ' 116' ' ' PHE . 17.8 m -116.87 -176.51 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.139 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 25.7 mttm -143.75 157.83 44.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.891 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.518 ' CE1' HD11 ' A' ' 98' ' ' LEU . 50.0 m-85 -146.79 161.85 39.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.884 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 69.9 p -95.76 -29.73 14.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.152 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -112.9 133.9 54.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.799 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -74.64 -34.47 62.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.867 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 64.6 mt -53.39 -40.45 65.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.927 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.482 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 4.3 mm-40 -80.66 -40.53 25.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.877 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 13.4 tt0 -41.6 -48.08 3.97 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.9 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 154' ' ' LEU . 40.4 mttp -71.67 -57.2 4.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.902 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.4 ' C ' ' O ' ' A' ' 151' ' ' LYS . 21.0 mtt-85 -38.18 -33.55 0.1 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.897 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.426 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -74.66 -43.49 55.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.117 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.47 ' N ' ' O ' ' A' ' 151' ' ' LYS . 14.7 mt -48.32 -38.2 18.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.463 HG22 ' N ' ' A' ' 156' ' ' GLU . 10.1 t -92.14 -45.76 8.11 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.136 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.463 ' N ' HG22 ' A' ' 155' ' ' THR . 16.8 mm-40 -67.99 -62.35 1.44 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.851 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.463 ' CB ' HD12 ' A' ' 170' ' ' LEU . 33.0 m -68.24 -3.25 10.12 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.897 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 5.1 tp-100 -45.36 139.58 3.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.916 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 44.2 34.35 3.23 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.505 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . 0.447 ' HB2' ' CG2' ' A' ' 168' ' ' VAL . . . -55.33 113.0 1.23 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.814 0.34 . . . . 0.0 111.077 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.8 t -88.02 -32.31 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.151 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.53 -37.0 2.46 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.482 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.536 ' HB2' ' CE1' ' A' ' 115' ' ' PHE . 26.4 tp -89.65 117.19 28.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.901 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 68.19 154.22 0.55 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.528 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 19.3 m -55.98 -25.4 43.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.953 0.406 . . . . 0.0 110.871 -179.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 59.8 mttt -108.0 154.71 40.97 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.615 0.721 . . . . 0.0 110.871 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 173.39 11.07 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.696 2.264 . . . . 0.0 112.304 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.447 ' CG2' ' HB2' ' A' ' 160' ' ' ALA . 33.0 m -126.33 127.02 70.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.153 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 34.6 ttt85 -92.77 102.44 14.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.856 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.463 HD12 ' CB ' ' A' ' 157' ' ' CYS . 11.2 mt -76.88 149.84 36.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.919 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.7 m -158.58 175.57 13.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.871 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 11.3 t -105.78 101.62 12.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.141 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.119 179.852 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . 0.498 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 5.0 m-85 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.904 0.383 . . . . 0.0 110.923 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 58.2 p -116.22 142.52 46.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.849 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 37.3 mt -115.79 147.89 40.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.917 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -93.88 135.68 34.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.5 m -128.6 139.56 51.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.158 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -132.39 171.23 21.6 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.508 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . 0.403 ' N ' ' O ' ' A' ' 138' ' ' GLY . 29.4 m-20 61.74 51.72 3.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.864 0.364 . . . . 0.0 110.928 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 25.6 mt -99.29 103.31 15.13 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.94 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 16.9 p -48.4 150.19 2.43 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.609 0.718 . . . . 0.0 111.111 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 -0.27 6.73 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.668 2.246 . . . . 0.0 112.333 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -99.73 10.19 41.77 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . 0.454 ' HA ' ' CE ' ' A' ' 111' ' ' MET . 21.7 t -123.76 133.9 67.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.101 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -118.9 176.3 5.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.879 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.5 p-10 -52.22 -50.55 61.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -39.41 -39.12 1.07 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.468 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' MET . . . . . 0.454 ' CE ' ' HA ' ' A' ' 107' ' ' VAL . 29.7 mtm -82.77 -41.33 19.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.743 0.306 . . . . 0.0 110.876 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.6 tp -58.8 -24.39 61.81 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.927 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.415 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 16.7 t80 -84.45 -62.37 1.57 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.884 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.454 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 17.0 mt-10 -57.76 -34.74 69.87 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.931 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . 0.485 ' CZ ' ' HB2' ' A' ' 163' ' ' LEU . 84.7 t80 -59.85 -34.03 72.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.462 ' O ' ' N ' ' A' ' 118' ' ' LYS . 9.5 m-85 -95.03 -62.13 1.36 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.863 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.454 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.3 p -39.03 -27.16 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.131 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.462 ' N ' ' O ' ' A' ' 116' ' ' PHE . 19.5 tptt -68.96 -60.52 2.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.898 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.553 HG22 ' CE2' ' A' ' 120' ' ' TYR . 4.2 p -67.58 -28.86 43.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.146 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.553 ' CE2' HG22 ' A' ' 119' ' ' VAL . 95.1 m-85 -132.72 110.55 13.38 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.667 0.746 . . . . 0.0 110.894 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.1 Cg_endo -69.8 -2.47 10.25 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.701 2.267 . . . . 0.0 112.294 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 23.4 p -90.3 -4.04 57.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.855 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . 0.471 ' HA ' ' CD1' ' A' ' 144' ' ' PHE . 14.1 t -57.35 146.46 28.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.931 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.424 ' NH1' ' HB3' ' A' ' 124' ' ' ARG . 1.6 mmm180 -109.01 -36.45 6.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.901 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.415 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.29 149.24 5.78 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.48 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -100.11 135.82 12.36 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.472 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -127.91 110.9 13.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.848 0.356 . . . . 0.0 110.883 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 14.2 p -103.25 119.91 52.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.128 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.544 HG11 ' CE1' ' A' ' 139' ' ' TYR . 18.2 m -66.36 143.33 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.113 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 43.5 mt -121.49 -176.6 3.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.911 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -113.77 -175.72 2.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . 0.442 ' CD ' HG23 ' A' ' 133' ' ' THR . 0.0 OUTLIER -48.39 -35.18 12.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.912 -179.928 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' THR . . . . . 0.442 HG23 ' CD ' ' A' ' 132' ' ' GLN . 9.6 p -86.65 -23.16 25.76 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.145 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.54 23.36 8.93 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.503 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 30.6 m -99.12 128.56 50.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.836 0.351 . . . . 0.0 111.12 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.6 t -39.37 109.75 0.12 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.861 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.3 mtmt -58.53 -28.45 65.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.403 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 123.74 16.07 3.44 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.479 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.544 ' CE1' HG11 ' A' ' 129' ' ' VAL . 16.2 p90 -162.76 173.19 14.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.941 0.4 . . . . 0.0 110.929 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -176.73 -163.7 29.44 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.525 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -151.23 148.12 27.82 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.878 0.37 . . . . 0.0 110.934 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 15.4 m -120.85 176.06 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . 0.418 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -133.69 161.86 33.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 179.939 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.471 ' CD1' ' HA ' ' A' ' 123' ' ' CYS . 96.9 m-85 -149.61 167.88 25.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 25.8 p -108.79 -8.13 15.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.142 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -132.51 124.44 28.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.856 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.498 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 16.3 tt0 -69.88 -30.92 68.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.889 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 48.6 mt -58.16 -54.61 44.98 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.928 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 54.4 mt-10 -67.57 -39.54 84.91 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -44.01 -45.57 7.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.905 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 74.1 mttt -73.11 -29.89 63.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.942 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 47.3 mtp180 -63.57 -39.84 95.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.873 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.55 ' HB1' ' CE2' ' A' ' 120' ' ' TYR . . . -68.52 -42.87 77.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.138 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.427 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 29.3 mt -45.85 -43.1 13.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.933 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.418 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.4 t -91.1 -46.66 7.99 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.168 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.418 ' N ' HG23 ' A' ' 155' ' ' THR . 47.4 mm-40 -63.32 -63.58 1.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.877 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.425 ' CB ' HD13 ' A' ' 170' ' ' LEU . 34.0 m -67.7 -9.43 43.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.917 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . 0.427 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.6 tp-100 -37.93 145.22 0.07 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.969 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.07 33.71 0.5 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.514 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . 0.457 ' HB1' ' CG2' ' A' ' 168' ' ' VAL . . . -58.71 115.86 3.34 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.826 0.346 . . . . 0.0 111.054 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 23.1 t -90.77 -35.33 7.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.136 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.12 -33.28 0.16 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.498 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.485 ' HB2' ' CZ ' ' A' ' 115' ' ' PHE . 25.7 tp -93.69 115.98 28.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.868 0.366 . . . . 0.0 110.871 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 69.1 156.69 1.15 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.475 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 65.8 m -59.83 -19.97 54.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.995 0.426 . . . . 0.0 110.878 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 49.2 mttt -111.83 156.67 41.28 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.527 0.68 . . . . 0.0 110.93 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 177.62 5.38 Favored 'Trans proline' 0 N--CA 1.465 -0.153 0 C-N-CA 122.681 2.254 . . . . 0.0 112.376 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.457 ' CG2' ' HB1' ' A' ' 160' ' ' ALA . 31.4 m -131.33 125.98 57.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.138 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 30.3 ttm180 -91.65 99.76 12.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.856 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.425 HD13 ' CB ' ' A' ' 157' ' ' CYS . 13.4 mt -77.73 151.5 34.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.916 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' SER . . . . . 0.416 ' C ' HD23 ' A' ' 154' ' ' LEU . 1.7 m -162.83 171.47 16.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.86 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 2.8 t -97.93 105.02 16.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.145 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.092 179.883 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.915 0.388 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.7 p -133.3 149.13 51.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.887 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.405 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . 23.6 mt -118.86 149.62 41.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.934 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 8.9 t80 -96.1 131.37 42.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.906 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.407 HG23 ' N ' ' A' ' 140' ' ' GLY . 17.1 m -122.25 138.3 52.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -130.47 179.77 16.66 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.514 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 51.32 54.03 11.84 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.8 0.334 . . . . 0.0 110.865 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 31.0 mt -101.95 103.24 13.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 52.3 p -49.37 150.53 3.18 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.561 0.696 . . . . 0.0 111.145 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 3.0 3.02 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.748 2.299 . . . . 0.0 112.381 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -99.21 -4.32 32.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . 0.443 ' HA ' ' CE ' ' A' ' 111' ' ' MET . 93.1 t -109.1 144.39 17.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.151 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -129.8 179.75 5.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.86 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.7 -35.27 74.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.862 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -53.5 -32.46 45.74 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.465 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' MET . . . . . 0.443 ' CE ' ' HA ' ' A' ' 107' ' ' VAL . 32.9 mtm -89.03 -42.64 11.63 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.855 0.359 . . . . 0.0 110.892 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.42 HD21 ' CA ' ' A' ' 126' ' ' GLY . 17.0 tp -56.91 -28.84 62.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.912 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.466 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 9.5 t80 -74.96 -62.87 1.4 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.452 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 19.4 mt-10 -61.65 -26.77 68.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.89 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . 0.503 ' CE1' ' HB2' ' A' ' 163' ' ' LEU . 84.2 t80 -65.85 -34.62 78.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.893 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -94.63 -58.37 2.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.888 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.452 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.2 p -43.21 -25.55 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.147 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 5.1 ttpm? -69.5 -60.65 2.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.892 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.52 HG23 ' CE2' ' A' ' 120' ' ' TYR . 3.2 p -65.46 -27.67 42.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.52 ' CE2' HG23 ' A' ' 119' ' ' VAL . 97.1 m-85 -137.79 113.18 9.13 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.666 0.746 . . . . 0.0 110.94 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 0.05 6.18 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.68 2.253 . . . . 0.0 112.344 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 16.1 m -99.72 24.89 7.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.864 -179.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 14.9 t -85.87 140.51 30.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.879 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.457 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 7.9 mmt85 -95.82 -32.5 12.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.857 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.466 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 151.84 140.78 3.2 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.42 ' CA ' HD21 ' A' ' 112' ' ' LEU . . . -90.22 137.24 13.89 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.479 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.415 ' N ' HD21 ' A' ' 112' ' ' LEU . 1.6 tppp? -125.96 129.72 49.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 110.898 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.11 128.28 73.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.096 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.557 HG23 ' CE1' ' A' ' 139' ' ' TYR . 22.3 m -74.31 147.21 9.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.13 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 11.6 mt -129.01 173.32 10.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.928 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -105.55 -179.15 3.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.883 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 32.9 tt0 -46.24 -39.79 10.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 52.2 p -74.84 -34.07 62.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.131 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.02 23.35 6.17 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.505 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 18.8 m -103.37 132.63 49.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.842 0.353 . . . . 0.0 111.083 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.0 t -42.12 114.06 0.51 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.849 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.433 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.1 mtmt -61.3 -24.7 66.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.831 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 119.71 15.96 5.16 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.484 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.557 ' CE1' HG23 ' A' ' 129' ' ' VAL . 25.1 p90 -162.13 177.81 9.35 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.933 0.397 . . . . 0.0 110.913 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.407 ' N ' HG23 ' A' ' 100' ' ' VAL . . . -179.63 -163.45 30.4 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.492 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -153.01 147.97 26.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.857 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.405 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 14.7 m -120.94 -178.61 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.139 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . 0.457 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 21.9 mtmm -141.04 159.18 42.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.826 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -147.32 171.21 15.8 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.857 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 75.4 p -110.48 -25.61 9.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.152 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -111.7 117.25 32.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.829 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -68.01 -23.74 65.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.879 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 67.7 mt -64.34 -35.85 82.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.931 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.488 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 20.8 mt-10 -88.94 -35.89 16.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 22.4 tt0 -42.99 -45.14 4.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.928 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 36.6 mttp -77.41 -35.16 54.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.444 ' O ' ' CG ' ' A' ' 156' ' ' GLU . 21.3 mtp85 -55.69 -34.0 64.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.842 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.414 ' HB1' ' CE2' ' A' ' 120' ' ' TYR . . . -74.19 -40.74 62.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.107 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.457 ' CD2' ' HB3' ' A' ' 170' ' ' LEU . 19.1 mt -47.5 -41.76 21.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.931 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 11.9 t -92.51 -42.4 9.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.173 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.444 ' CG ' ' O ' ' A' ' 152' ' ' ARG . 46.5 mm-40 -67.33 -66.32 0.57 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.909 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.454 ' CB ' HD11 ' A' ' 170' ' ' LEU . 3.7 m -64.26 -13.08 47.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.862 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . 0.411 ' C ' ' O ' ' A' ' 157' ' ' CYS . 3.3 tp-100 -35.6 129.62 0.57 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.926 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 59.0 33.25 73.28 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.525 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -56.1 112.95 1.34 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 111.102 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.2 t -91.6 -32.95 5.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.153 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -43.52 -31.38 1.63 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.509 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.503 ' HB2' ' CE1' ' A' ' 115' ' ' PHE . 26.7 tp -94.97 112.85 24.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.842 0.353 . . . . 0.0 110.886 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 70.82 148.45 0.49 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.498 179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 49.0 m -50.92 -31.61 18.15 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.939 0.399 . . . . 0.0 110.841 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -99.92 155.52 36.36 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.534 0.683 . . . . 0.0 110.904 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.84 174.48 9.51 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.703 2.269 . . . . 0.0 112.302 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 30.7 m -130.32 135.42 60.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.165 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 5.7 ptm180 -95.93 128.04 42.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.862 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.457 ' HB3' ' CD2' ' A' ' 154' ' ' LEU . 31.9 mt -102.06 136.75 41.35 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.951 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.3 m -151.78 -176.9 5.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 10.7 t -107.48 94.3 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.158 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.08 179.917 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . 0.515 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 7.3 m-85 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.888 0.375 . . . . 0.0 110.909 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.1 p -126.23 155.09 42.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 85.7 mt -126.15 144.05 50.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.918 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.48 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 11.6 t80 -94.47 131.24 40.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 34.8 m -120.03 147.52 23.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.125 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -134.9 -177.9 15.28 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.482 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 50.24 48.39 22.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.803 0.335 . . . . 0.0 110.882 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.412 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.2 mt -93.86 103.09 15.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.889 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 71.1 p -48.2 149.49 2.59 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.588 0.709 . . . . 0.0 111.153 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 2.61 3.34 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.707 2.271 . . . . 0.0 112.38 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -99.11 -9.83 23.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.852 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 15.7 t -98.12 144.05 11.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.134 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -130.24 174.46 9.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.844 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -51.66 -50.74 59.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.875 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -45.54 -33.99 4.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.506 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' MET . . . . . . . . . . . . . 50.4 mtp -80.92 -61.5 1.94 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.781 0.324 . . . . 0.0 110.855 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.3 tp -41.23 -40.2 1.54 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.919 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.493 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 17.6 t80 -63.01 -68.12 0.37 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.903 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.451 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 26.7 mt-10 -48.74 -55.51 11.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.88 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -42.75 -32.1 0.56 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.885 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.467 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.1 m-85 -95.0 -67.23 0.86 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.873 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.451 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.81 -30.31 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.14 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.2 tttp -65.41 -58.5 5.7 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.929 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.526 HG22 ' CE2' ' A' ' 120' ' ' TYR . 3.3 p -67.27 -29.81 47.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.132 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.526 ' CE2' HG22 ' A' ' 119' ' ' VAL . 96.3 m-85 -137.06 109.49 9.05 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.685 0.755 . . . . 0.0 110.924 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 2.43 3.53 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.671 2.247 . . . . 0.0 112.318 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 1.3 p -95.49 -0.18 52.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.833 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 19.1 t -66.4 138.07 57.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.931 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -91.59 -38.61 12.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.493 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 164.37 150.42 6.13 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.476 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -94.21 137.52 13.57 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.447 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 19.7 tptm -125.27 118.72 26.61 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.838 0.351 . . . . 0.0 110.903 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.7 p -112.45 115.57 50.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.109 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.46 HG21 ' CE2' ' A' ' 139' ' ' TYR . 32.6 m -61.66 151.27 7.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.161 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 49.0 mt -133.16 164.48 26.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.924 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.452 ' O ' ' N ' ' A' ' 134' ' ' GLY . 13.7 t70 -96.96 175.84 6.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.866 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 2.0 tp-100 -42.66 -44.25 4.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.905 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 44.0 p -70.0 -28.51 65.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.118 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 103.81 23.73 8.1 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.505 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 136' ' ' SER . 28.4 m -105.12 131.43 54.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-O 120.824 0.345 . . . . 0.0 111.122 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' SER . . . . . 0.405 ' C ' ' O ' ' A' ' 135' ' ' VAL . 5.8 t -37.89 114.16 0.33 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.425 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.7 mtmt -62.66 -25.89 68.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.907 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 119.41 17.18 4.9 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.5 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.46 ' CE2' HG21 ' A' ' 129' ' ' VAL . 20.3 p90 -163.54 172.05 14.96 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.916 0.389 . . . . 0.0 110.984 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -176.22 -164.11 29.84 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.501 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . 0.48 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 3.7 m-85 -152.05 149.15 28.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.906 0.384 . . . . 0.0 110.845 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.451 HG21 ' CZ ' ' A' ' 144' ' ' PHE . 16.1 m -123.0 161.05 25.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.131 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -119.05 158.41 25.89 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.872 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.451 ' CZ ' HG21 ' A' ' 142' ' ' VAL . 84.4 m-85 -145.6 169.36 18.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 43.3 p -115.0 -24.79 8.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.123 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -112.99 99.82 8.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.515 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 16.7 tt0 -46.94 -45.26 20.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.884 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 33.6 mt -48.1 -40.57 23.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.927 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.466 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 4.4 mm-40 -80.98 -33.98 33.41 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.825 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -49.79 -63.89 0.97 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.944 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -57.92 -47.62 82.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.923 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 47.0 mtt180 -43.97 -30.89 0.78 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.855 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -73.76 -39.1 64.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.064 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.46 ' CD2' ' HB3' ' A' ' 170' ' ' LEU . 12.2 mt -51.01 -38.14 49.46 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.886 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.44 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.8 t -92.46 -46.35 7.69 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.44 ' N ' HG23 ' A' ' 155' ' ' THR . 10.7 mt-10 -68.45 -63.1 1.13 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.828 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.46 ' CB ' HD12 ' A' ' 170' ' ' LEU . 40.3 m -68.64 -2.61 9.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.873 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -43.5 136.69 3.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.876 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 42.61 43.85 5.15 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.45 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -61.33 110.89 1.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.784 0.326 . . . . 0.0 111.134 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.7 -35.95 10.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.137 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -40.68 -34.48 0.74 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.501 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 16.1 tp -91.07 118.77 30.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.835 0.35 . . . . 0.0 110.946 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 165' ' ' SER . . . 61.22 135.07 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.465 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' SER . . . . . 0.411 ' C ' ' O ' ' A' ' 164' ' ' GLY . 58.8 m -37.58 -33.58 0.08 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.924 0.392 . . . . 0.0 110.844 -179.692 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 31.7 mttp -95.61 153.5 39.43 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.574 0.702 . . . . 0.0 110.876 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -176.27 1.44 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.677 2.252 . . . . 0.0 112.313 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 33.2 m -140.84 126.59 19.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 18.3 mtt180 -90.26 116.68 28.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.847 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.46 HD12 ' CB ' ' A' ' 157' ' ' CYS . 17.4 mt -89.9 137.48 32.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.903 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 13.2 m -149.52 179.72 7.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.89 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 5.0 t -103.99 98.1 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.087 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.069 179.886 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . 0.513 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 33.1 m-85 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.924 0.392 . . . . 0.0 110.895 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 64.6 m -105.18 156.38 18.15 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.892 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.457 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . 21.8 mt -122.23 143.01 49.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.949 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -93.11 126.87 38.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.912 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.41 HG23 ' C ' ' A' ' 140' ' ' GLY . 30.2 m -119.17 148.6 22.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.142 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.61 176.33 20.9 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.522 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . 0.468 ' N ' ' O ' ' A' ' 138' ' ' GLY . 22.7 m-20 56.57 50.74 12.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.837 0.351 . . . . 0.0 110.878 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 25.9 mt -98.6 100.34 11.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 75.0 p -42.69 149.38 0.48 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.602 0.715 . . . . 0.0 111.128 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 3.13 2.93 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.711 2.274 . . . . 0.0 112.368 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 65.5 m-20 -104.22 11.93 34.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.903 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . 0.451 HG23 ' CE ' ' A' ' 111' ' ' MET . 75.3 t -128.42 134.98 63.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.125 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -120.69 -175.99 3.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.869 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.433 ' N ' HG11 ' A' ' 128' ' ' VAL . 1.7 p30 -57.88 -37.01 73.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -46.59 -41.51 12.82 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.443 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' MET . . . . . 0.451 ' CE ' HG23 ' A' ' 107' ' ' VAL . 27.9 mtm -83.82 -44.8 13.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.787 0.327 . . . . 0.0 110.863 -179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.46 HD11 ' CD2' ' A' ' 163' ' ' LEU . 21.2 tp -51.74 -22.82 3.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.901 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.409 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 14.8 t80 -83.74 -64.69 1.12 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.863 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.454 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 27.1 mt-10 -57.2 -26.45 60.68 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.889 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . . . . . . . . . 60.5 t80 -66.7 -34.83 78.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.907 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 11.5 m-85 -95.22 -57.72 2.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.839 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.454 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -43.23 -28.69 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.119 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 3.6 tptm -68.9 -59.61 2.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.856 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.415 HG21 ' CE2' ' A' ' 120' ' ' TYR . 3.3 p -65.29 -28.75 45.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.137 179.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.415 ' CE2' HG21 ' A' ' 119' ' ' VAL . 91.5 m-85 -138.17 114.43 9.08 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.695 0.759 . . . . 0.0 110.922 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.67 -0.2 6.49 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.717 2.278 . . . . 0.0 112.335 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 17.2 p -88.85 -17.73 29.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.816 -179.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . 0.43 ' HA ' ' CD1' ' A' ' 144' ' ' PHE . 7.7 t -48.08 139.36 8.25 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.895 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.442 ' CG ' HG21 ' A' ' 145' ' ' THR . 25.2 mtp180 -100.71 -34.96 9.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.862 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.409 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 164.02 145.56 4.42 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.521 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -98.39 133.82 11.47 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.485 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 13.4 tptt -124.79 128.94 49.5 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.834 0.349 . . . . 0.0 110.867 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.433 HG11 ' N ' ' A' ' 109' ' ' ASP . 7.1 p -114.43 138.05 45.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.176 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.566 HG11 ' CE1' ' A' ' 139' ' ' TYR . 24.4 m -83.76 143.25 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.12 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 17.1 mt -122.7 171.73 8.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.904 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -105.55 -179.88 4.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.815 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 15.8 pt20 -45.6 -39.86 8.19 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.925 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 44.2 p -74.88 -33.79 62.11 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.136 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 111.79 21.28 6.47 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.526 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 27.3 m -100.66 143.45 14.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.812 0.339 . . . . 0.0 111.16 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 3.7 t -54.55 107.26 0.27 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.859 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.488 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.5 mtmt -52.47 -29.95 27.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.885 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.468 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 122.53 19.23 3.16 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.49 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.566 ' CE1' HG11 ' A' ' 129' ' ' VAL . 27.3 p90 -163.8 167.77 20.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.921 0.391 . . . . 0.0 110.909 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.41 ' C ' HG23 ' A' ' 100' ' ' VAL . . . -171.11 -159.91 18.34 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.498 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -153.58 151.52 29.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.9 0.381 . . . . 0.0 110.877 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.457 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 18.4 m -124.1 176.36 5.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.16 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 33.8 mtmt -136.83 158.23 44.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.43 ' CD1' ' HA ' ' A' ' 123' ' ' CYS . 91.5 m-85 -145.38 167.05 23.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.905 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' THR . . . . . 0.442 HG21 ' CG ' ' A' ' 124' ' ' ARG . 27.7 p -105.48 -25.41 12.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.147 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -119.5 111.15 17.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.513 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 2.9 tm-20 -51.43 -45.75 62.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.874 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 24.0 mt -42.0 -42.2 2.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.915 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 57.0 mm-40 -76.23 -41.77 48.17 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 17.7 tt0 -40.84 -57.79 1.85 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.924 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 32.9 mmtm -62.53 -51.53 67.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.925 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 36.8 mtp180 -41.81 -40.97 2.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.43 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.88 -48.22 66.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.043 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.493 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 15.3 mt -42.61 -42.46 3.42 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.913 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.463 HG22 ' N ' ' A' ' 156' ' ' GLU . 9.2 t -89.12 -48.13 7.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.13 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.463 ' N ' HG22 ' A' ' 155' ' ' THR . 18.2 mm-40 -63.56 -64.35 0.92 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.43 ' N ' ' O ' ' A' ' 153' ' ' ALA . 2.5 m -68.25 -8.09 36.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.926 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . 0.493 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 3.5 tp-100 -36.14 134.38 0.41 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 -179.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 46.57 41.32 12.52 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.474 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . 0.415 ' HB2' ' CG2' ' A' ' 168' ' ' VAL . . . -57.39 117.44 4.12 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.848 0.356 . . . . 0.0 111.084 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.6 t -92.9 -33.5 5.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.163 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.94 -36.33 2.55 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.443 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.46 ' CD2' HD11 ' A' ' 112' ' ' LEU . 18.2 tp -87.94 114.83 24.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.829 0.347 . . . . 0.0 110.868 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 70.8 161.27 3.88 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.4 p -66.97 -3.83 8.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.946 0.403 . . . . 0.0 110.85 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -128.37 154.78 79.17 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.547 0.689 . . . . 0.0 110.917 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 171.6 14.16 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.696 2.264 . . . . 0.0 112.337 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.415 ' CG2' ' HB2' ' A' ' 160' ' ' ALA . 32.8 m -128.97 126.29 64.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.137 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -87.99 112.6 22.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.886 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.431 ' HB3' ' CD2' ' A' ' 154' ' ' LEU . 13.9 mt -85.94 146.07 26.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.913 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.2 m -157.57 169.04 25.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 40.9 t -94.45 102.41 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.121 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.094 179.86 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 10.0 m-85 . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.92 0.39 . . . . 0.0 110.946 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 29.0 m -145.14 162.9 35.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.839 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.437 HD23 ' CD2' ' A' ' 154' ' ' LEU . 91.8 mt -131.35 135.39 47.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.933 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.6 t80 -86.83 131.43 34.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.896 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.422 ' CG2' HD12 ' A' ' 103' ' ' LEU . 30.8 m -127.09 150.57 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.176 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.43 -170.99 12.26 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.476 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 45.41 51.47 9.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.828 0.347 . . . . 0.0 110.861 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.422 HD12 ' CG2' ' A' ' 100' ' ' VAL . 31.0 mt -96.93 102.46 14.24 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 37.1 p -48.74 151.37 2.13 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.617 0.722 . . . . 0.0 111.125 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 2.95 3.09 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.699 2.266 . . . . 0.0 112.351 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -103.85 17.8 23.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 2.8 t -125.57 134.34 66.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.167 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -124.04 170.79 10.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.849 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.46 ' CG ' ' N ' ' A' ' 110' ' ' GLY . 0.3 OUTLIER -47.06 -49.97 20.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.912 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.46 ' N ' ' CG ' ' A' ' 109' ' ' ASP . . . -47.61 -26.46 3.85 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.454 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' MET . . . . . . . . . . . . . 27.2 mtp -89.23 -57.6 2.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.766 0.317 . . . . 0.0 110.874 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 15.3 tp -46.86 -28.43 1.57 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.977 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.406 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.3 t80 -76.5 -66.64 0.78 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.93 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.456 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 17.9 mt-10 -54.96 -25.98 33.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.891 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . 0.433 ' CE1' ' N ' ' A' ' 163' ' ' LEU . 72.2 t80 -68.27 -35.73 78.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.862 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.551 ' CD2' HG13 ' A' ' 142' ' ' VAL . 12.1 m-85 -95.09 -56.97 2.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.456 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -42.41 -27.89 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.16 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 15.2 ttmm -66.88 -60.71 2.42 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.946 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.0 p -63.32 -32.91 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.112 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.436 ' CD1' ' HB3' ' A' ' 149' ' ' GLU . 93.6 m-85 -134.75 115.41 12.32 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.749 0.785 . . . . 0.0 110.905 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -1.8 9.13 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.672 2.248 . . . . 0.0 112.321 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 3.1 m -86.41 -12.64 48.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.806 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . 0.436 ' CB ' ' HA ' ' A' ' 117' ' ' VAL . 13.5 t -50.27 135.19 21.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.462 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 93.9 mtt180 -96.99 -37.67 10.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.406 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 166.54 143.44 3.75 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.472 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -96.9 134.54 11.81 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.516 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 10.1 tptm -125.78 123.86 39.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.81 0.338 . . . . 0.0 110.886 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -113.5 123.35 69.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.083 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.526 HG21 ' CD1' ' A' ' 139' ' ' TYR . 25.0 m -68.81 149.22 11.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.097 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 40.9 mt -127.34 -177.02 3.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.482 ' O ' ' N ' ' A' ' 134' ' ' GLY . 13.2 t0 -116.94 176.09 5.28 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.799 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -39.86 -39.84 0.89 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.913 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -82.29 -29.57 31.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.14 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 112.41 0.99 26.38 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.506 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . 0.436 ' O ' ' CG2' ' A' ' 135' ' ' VAL . 9.6 m -76.21 118.99 23.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 111.155 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 135' ' ' VAL . 6.9 t -35.01 108.27 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.473 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.4 mtmt -50.39 -35.63 29.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.883 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.62 19.07 2.11 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.473 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.526 ' CD1' HG21 ' A' ' 129' ' ' VAL . 22.1 p90 -163.32 168.61 20.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.918 0.39 . . . . 0.0 110.911 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -173.65 -163.56 27.4 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.43 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -152.89 147.6 26.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.92 0.39 . . . . 0.0 110.87 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.551 HG13 ' CD2' ' A' ' 116' ' ' PHE . 16.4 m -119.08 171.08 7.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.145 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . 0.462 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 34.3 mtpt -127.63 161.76 28.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -149.75 160.91 43.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.867 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' THR . . . . . 0.44 HG21 ' CG ' ' A' ' 124' ' ' ARG . 76.7 p -99.73 -20.03 16.46 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.169 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -119.09 126.32 51.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.843 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 14.5 tt0 -71.71 -25.98 62.31 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.919 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 23.9 mt -65.85 -47.95 73.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.436 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 24.4 mt-10 -73.56 -39.29 64.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.862 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.418 ' C ' ' OE1' ' A' ' 150' ' ' GLN . 1.4 tm0? -46.09 -39.13 8.93 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.907 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 27.8 mmtp -79.99 -43.94 21.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.896 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 3.0 mtt-85 -48.04 -28.47 2.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.426 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -78.64 -34.51 46.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.08 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.437 ' CD2' HD23 ' A' ' 98' ' ' LEU . 22.9 mt -55.87 -36.94 68.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.3 t -92.28 -35.71 13.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.131 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -81.8 -66.88 0.83 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.873 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.404 ' N ' ' O ' ' A' ' 153' ' ' ALA . 99.7 m -60.92 -10.26 5.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.861 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . 0.429 ' N ' HD13 ' A' ' 170' ' ' LEU . 3.0 tp-100 -36.34 132.05 0.59 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.937 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 52.54 38.49 51.78 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.479 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . 0.415 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -54.02 115.04 1.82 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.851 0.357 . . . . 0.0 111.086 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 40.2 t -93.98 -36.27 7.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.11 -35.51 1.73 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.545 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.433 ' N ' ' CE1' ' A' ' 115' ' ' PHE . 27.6 tp -83.9 109.58 17.7 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.853 0.358 . . . . 0.0 110.915 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 74.91 174.71 34.16 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.501 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 38.4 m -84.56 28.09 0.68 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.897 0.379 . . . . 0.0 110.837 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 29.5 mttm -159.55 156.59 25.35 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.561 0.695 . . . . 0.0 110.909 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 170.19 17.15 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.685 2.257 . . . . 0.0 112.314 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.415 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 31.1 m -131.09 128.57 62.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.098 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 36.7 ttt180 -86.54 109.6 19.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.826 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.429 HD13 ' N ' ' A' ' 158' ' ' GLN . 12.6 mt -85.42 145.9 27.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.94 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.9 m -162.16 177.76 9.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.827 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 8.8 t -100.68 103.22 14.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.163 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.07 179.905 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . 0.501 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 2.1 m-85 . . . . . 0 C--O 1.231 0.079 0 CA-C-O 120.916 0.389 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.7 m -135.56 139.42 43.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.88 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.458 HD23 ' CG ' ' A' ' 150' ' ' GLN . 98.4 mt -108.69 151.93 25.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.891 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -99.63 121.29 41.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.903 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.416 HG22 ' C ' ' A' ' 140' ' ' GLY . 23.6 m -110.0 137.12 43.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.121 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -126.91 176.58 17.67 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.472 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 53.37 52.45 13.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.826 0.346 . . . . 0.0 110.87 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . 0.407 HD11 ' C ' ' A' ' 139' ' ' TYR . 24.8 mt -97.92 98.49 9.84 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.926 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.2 p -45.99 151.54 0.88 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.599 0.714 . . . . 0.0 111.162 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 0.0 6.32 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.665 2.243 . . . . 0.0 112.309 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -101.23 16.58 25.03 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.831 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 61.5 t -129.41 131.93 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.095 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -118.69 171.54 8.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.869 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.4 ' CG ' ' N ' ' A' ' 110' ' ' GLY . 2.3 p30 -48.62 -49.48 36.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.799 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . 0.4 ' N ' ' CG ' ' A' ' 109' ' ' ASP . . . -38.36 -37.2 0.47 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.469 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' MET . . . . . . . . . . . . . 27.6 mtm -86.43 -45.46 11.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.779 0.323 . . . . 0.0 110.848 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 13.9 tp -54.12 -20.36 6.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.905 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.499 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 15.0 t80 -86.19 -60.67 1.94 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.925 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.465 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 33.7 mt-10 -59.38 -46.73 87.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.879 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . 0.46 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 69.5 t80 -48.03 -33.81 8.51 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.896 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.474 ' O ' ' N ' ' A' ' 118' ' ' LYS . 7.2 m-85 -95.02 -66.61 0.9 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.881 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.465 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.59 -30.0 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.091 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.474 ' N ' ' O ' ' A' ' 116' ' ' PHE . 0.0 OUTLIER -65.08 -57.29 9.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.915 179.922 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.571 HG21 ' CE2' ' A' ' 120' ' ' TYR . 2.6 p -66.4 -34.8 72.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.144 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.571 ' CE2' HG21 ' A' ' 119' ' ' VAL . 91.8 m-85 -135.22 115.67 11.93 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-O 121.701 0.762 . . . . 0.0 110.954 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 2.9 3.14 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.69 2.26 . . . . 0.0 112.321 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.0 p -86.06 -18.94 31.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 29.2 t -53.06 135.96 36.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.882 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 18.3 mtt180 -98.88 -30.86 12.15 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.877 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.499 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 161.62 147.73 5.07 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.484 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -91.35 141.67 15.77 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.533 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.85 105.29 7.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.756 0.312 . . . . 0.0 110.874 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.447 HG23 ' N ' ' A' ' 129' ' ' VAL . 7.5 p -98.23 149.14 5.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.155 179.825 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.509 ' CG2' ' CE1' ' A' ' 139' ' ' TYR . 19.5 m -95.86 142.57 13.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.102 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.405 ' O ' ' NZ ' ' A' ' 137' ' ' LYS . 13.9 mt -130.0 173.4 10.76 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.898 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.421 ' O ' ' N ' ' A' ' 134' ' ' GLY . 26.3 t0 -107.34 171.97 7.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.865 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -44.54 -26.0 0.32 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.92 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 49.2 p -86.42 -33.94 20.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.124 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 109.14 20.62 7.81 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.502 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 25.0 m -100.19 115.71 41.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.881 0.372 . . . . 0.0 111.101 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.4 t -37.65 103.64 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.837 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.405 ' NZ ' ' O ' ' A' ' 130' ' ' LEU . 16.8 mttm -43.59 -37.49 2.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.891 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 129.43 20.46 1.4 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.464 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.509 ' CE1' ' CG2' ' A' ' 129' ' ' VAL . 28.0 p90 -161.39 -179.31 7.27 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.922 0.391 . . . . 0.0 110.923 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . 0.416 ' C ' HG22 ' A' ' 100' ' ' VAL . . . 177.17 -166.33 36.86 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.472 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 3.6 m-85 -153.37 139.37 18.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.86 0.362 . . . . 0.0 110.935 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.565 HG21 ' CE2' ' A' ' 144' ' ' PHE . 27.8 m -112.93 -178.23 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -140.36 163.8 31.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.923 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.565 ' CE2' HG21 ' A' ' 142' ' ' VAL . 93.8 m-85 -149.83 167.12 27.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.89 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 58.6 p -102.33 -12.07 18.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.118 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -137.04 122.33 19.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.895 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.501 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 4.6 tt0 -60.11 -37.5 80.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.905 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 34.9 mt -52.39 -49.97 63.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.935 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -70.04 -33.29 71.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.878 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.458 ' CG ' HD23 ' A' ' 98' ' ' LEU . 28.6 tt0 -58.44 -57.05 14.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.957 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 30.2 mmtm -59.11 -42.28 90.16 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.899 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 40.6 mtt-85 -54.69 -30.62 56.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.902 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.487 ' O ' ' CD1' ' A' ' 170' ' ' LEU . . . -73.36 -34.53 65.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.06 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.477 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 43.9 mt -56.51 -40.36 74.9 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.905 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 15.1 t -92.43 -34.3 14.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.128 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 39.0 mm-40 -78.55 -58.3 3.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.864 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.467 ' N ' ' O ' ' A' ' 153' ' ' ALA . 36.0 m -79.96 11.77 3.15 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . 0.477 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 3.5 tp-100 -52.92 137.81 31.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.955 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.62 33.46 0.59 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.469 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . 0.467 ' HB1' ' CG2' ' A' ' 168' ' ' VAL . . . -53.17 116.73 2.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.815 0.34 . . . . 0.0 111.1 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' A' ' 162' ' ' GLY . 24.1 t -86.91 -35.41 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.137 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.18 -38.6 0.26 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.535 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.46 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 18.9 tp -87.42 115.36 24.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.871 0.367 . . . . 0.0 110.864 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.42 159.19 1.03 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.511 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 71.1 m -62.47 -16.62 56.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.936 0.398 . . . . 0.0 110.869 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 28.3 mttp -113.33 155.79 44.09 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.584 0.707 . . . . 0.0 110.905 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 173.51 10.86 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.757 2.304 . . . . 0.0 112.336 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.467 ' CG2' ' HB1' ' A' ' 160' ' ' ALA . 27.1 m -128.51 125.93 64.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.091 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 11.3 ttm180 -88.44 108.61 19.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.889 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.487 ' CD1' ' O ' ' A' ' 153' ' ' ALA . 17.1 mt -84.23 147.27 27.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 4.5 m -163.95 177.42 8.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 39.7 t -103.55 101.7 12.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.116 179.875 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 13.1 m-85 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.851 0.358 . . . . 0.0 110.934 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.7 p -110.07 138.01 47.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.83 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 97.5 mt -111.25 146.77 36.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.933 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -93.09 130.73 38.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.907 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 17.9 m -123.55 149.27 27.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.15 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.99 -167.63 11.0 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 41.44 52.57 3.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.828 0.347 . . . . 0.0 110.861 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 26.4 mt -101.04 101.63 12.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 75.9 p -47.01 150.2 1.41 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.556 0.693 . . . . 0.0 111.17 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 3.12 2.96 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.69 2.26 . . . . 0.0 112.359 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 -100.57 -0.74 37.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . 0.447 ' CG1' ' HE3' ' A' ' 111' ' ' MET . 20.9 t -108.01 136.52 43.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.168 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -118.92 175.77 5.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.868 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -58.29 -36.2 72.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -53.65 -33.92 49.25 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.542 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' MET . . . . . 0.447 ' HE3' ' CG1' ' A' ' 107' ' ' VAL . 23.7 mtm -83.69 -55.01 4.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.806 0.336 . . . . 0.0 110.921 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 29.4 tp -41.02 -37.37 0.81 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.943 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.43 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 17.6 t80 -70.19 -65.92 0.66 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.942 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.452 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 19.1 mt-10 -49.42 -53.19 24.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.897 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . 0.476 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 58.2 t80 -44.58 -33.29 1.72 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.934 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.566 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.6 m-85 -93.99 -66.7 0.9 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.888 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.452 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.88 -31.09 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.108 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.456 ' N ' ' O ' ' A' ' 116' ' ' PHE . 0.5 OUTLIER -65.31 -61.28 2.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.949 179.884 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.564 HG22 ' CD2' ' A' ' 120' ' ' TYR . 1.6 p -64.65 -32.56 58.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.157 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.57 ' CE1' ' HB3' ' A' ' 152' ' ' ARG . 97.8 m-85 -131.23 113.82 15.94 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.657 0.741 . . . . 0.0 110.933 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 1.09 4.76 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.67 2.247 . . . . 0.0 112.331 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 1.4 p -104.14 31.95 4.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.804 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 41.9 t -91.12 124.9 35.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.455 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 22.5 mtp180 -79.18 -39.54 33.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.873 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.43 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 159.74 154.18 7.18 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.524 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -97.29 147.0 18.51 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.514 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 2.7 tmtp? -137.66 112.58 9.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.839 0.352 . . . . 0.0 110.887 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 12.8 p -106.76 119.43 56.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.127 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.547 HG13 ' CE1' ' A' ' 139' ' ' TYR . 20.1 m -63.75 155.5 5.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 20.8 mt -134.81 167.66 20.46 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.426 ' O ' ' N ' ' A' ' 134' ' ' GLY . 20.6 t70 -99.65 175.4 5.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . 0.437 ' HG3' ' N ' ' A' ' 133' ' ' THR . 20.2 pt20 -43.38 -43.33 5.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' THR . . . . . 0.437 ' N ' ' HG3' ' A' ' 132' ' ' GLN . 34.3 p -72.65 -28.47 62.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.166 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 106.48 24.59 6.69 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.523 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 31.3 m -103.45 137.18 32.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.821 0.344 . . . . 0.0 111.1 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 1.6 t -48.95 110.46 0.36 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.835 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.46 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.1 mtmt -57.16 -33.86 67.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.882 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 127.31 17.54 2.17 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.537 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.547 ' CE1' HG13 ' A' ' 129' ' ' VAL . 24.7 p90 -162.2 174.16 13.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.943 0.402 . . . . 0.0 110.949 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -177.94 -161.29 25.86 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.471 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -153.09 148.19 26.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.85 0.357 . . . . 0.0 110.897 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.566 HG11 ' CD2' ' A' ' 116' ' ' PHE . 16.9 m -118.63 -177.16 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.175 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . 0.455 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 40.5 mtmt -144.17 157.21 44.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.878 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -146.93 160.72 41.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 32.8 p -102.01 -16.08 16.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.191 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -120.28 110.72 16.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.836 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 11.9 tt0 -57.91 -41.59 82.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.887 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 75.4 mt -48.16 -47.96 34.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.935 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.557 ' N ' ' CD ' ' A' ' 149' ' ' GLU . 0.0 OUTLIER -72.22 -44.6 62.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.887 179.899 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.437 ' C ' ' O ' ' A' ' 149' ' ' GLU . 20.2 tt0 -34.84 -58.59 0.51 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.93 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 12.6 mmtp -63.49 -34.35 77.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.912 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . 0.57 ' HB3' ' CE1' ' A' ' 120' ' ' TYR . 4.0 tpt180 -51.61 -41.03 60.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.849 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -71.77 -44.77 63.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.091 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . . . . . . . . . 29.7 mt -50.47 -38.34 43.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 14.6 t -92.57 -37.08 12.66 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.402 ' CG ' ' O ' ' A' ' 152' ' ' ARG . 6.7 mm-40 -83.05 -65.02 1.06 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.897 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.494 ' N ' ' O ' ' A' ' 153' ' ' ALA . 76.2 m -62.8 -8.22 6.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.921 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -37.71 128.96 1.14 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.858 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 50.36 38.89 34.99 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.464 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . 0.465 ' HB2' ' CG2' ' A' ' 168' ' ' VAL . . . -60.0 116.35 4.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.813 0.34 . . . . 0.0 111.141 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.42 ' O ' ' C ' ' A' ' 162' ' ' GLY . 23.9 t -85.28 -37.85 12.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.144 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.75 -37.2 0.21 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.514 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.476 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 17.0 tp -86.38 114.52 23.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.848 0.356 . . . . 0.0 110.926 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 64.54 151.78 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.487 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 9.4 t -51.3 -25.28 5.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.948 0.404 . . . . 0.0 110.835 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 53.5 mttt -106.45 156.18 37.46 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.568 0.699 . . . . 0.0 110.892 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -175.42 1.15 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.682 2.255 . . . . 0.0 112.323 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.465 ' CG2' ' HB2' ' A' ' 160' ' ' ALA . 12.6 m -137.84 128.63 37.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.139 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 7.8 mtp85 -88.51 111.89 22.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.846 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 15.3 mt -91.83 140.47 29.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.918 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 13.9 m -155.83 -177.61 6.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.833 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 4.7 t -102.69 100.13 9.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.149 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.119 179.892 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . 0.489 ' CE2' ' HB2' ' A' ' 147' ' ' GLU . 47.5 m-85 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.855 0.36 . . . . 0.0 110.944 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 11.1 m -120.65 154.79 35.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.849 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 22.4 mt -120.37 144.48 47.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.927 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -94.96 123.06 38.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.9 m -114.88 149.05 17.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.44 -175.1 13.65 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.509 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 50.83 50.01 19.89 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.806 0.336 . . . . 0.0 110.897 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 30.9 mt -98.94 104.34 16.38 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.924 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 14.9 p -49.08 150.16 3.01 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.583 0.706 . . . . 0.0 111.112 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 2.95 3.08 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.651 2.234 . . . . 0.0 112.342 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -99.69 -13.4 19.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.865 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . 0.452 ' HA ' ' CE ' ' A' ' 111' ' ' MET . 73.1 t -96.2 138.95 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.153 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.94 -176.11 3.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.849 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -65.4 -41.74 93.33 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.88 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.47 -34.47 13.78 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.475 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' MET . . . . . 0.452 ' CE ' ' HA ' ' A' ' 107' ' ' VAL . 25.5 mtm -81.71 -49.61 10.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.816 0.341 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.464 HD12 ' CD2' ' A' ' 163' ' ' LEU . 18.9 tp -50.86 -34.42 27.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.925 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . . . . . . . . . 12.9 t80 -68.8 -61.45 1.8 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.946 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.458 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 17.1 mt-10 -57.28 -53.86 53.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.847 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -42.3 -32.46 0.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.489 ' O ' ' N ' ' A' ' 118' ' ' LYS . 7.6 m-85 -95.17 -67.97 0.83 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.458 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.7 -29.37 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.489 ' N ' ' O ' ' A' ' 116' ' ' PHE . 19.1 tptt -67.46 -60.67 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.1 p -65.18 -31.91 55.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.133 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -134.11 114.3 12.7 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.647 0.737 . . . . 0.0 110.965 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.31 8.25 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.678 2.252 . . . . 0.0 112.377 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 87.2 p -85.9 -16.45 38.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.834 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.4 t -52.22 139.7 23.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.839 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.426 ' CG ' HG23 ' A' ' 145' ' ' THR . 42.0 mtm180 -105.0 -33.57 8.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.875 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 166.66 145.62 4.54 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.451 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -95.25 137.54 13.49 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.475 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -125.87 122.43 36.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.783 0.325 . . . . 0.0 110.914 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.407 HG23 ' N ' ' A' ' 129' ' ' VAL . 6.0 p -113.62 138.14 44.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.137 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.537 HG22 ' CD1' ' A' ' 139' ' ' TYR . 33.7 m -86.17 152.08 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.131 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . 0.402 HD23 ' N ' ' A' ' 136' ' ' SER . 17.8 mt -130.84 176.37 8.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.486 ' O ' ' N ' ' A' ' 134' ' ' GLY . 25.6 t0 -107.52 174.27 5.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -39.6 -40.27 0.86 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.909 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 30.4 p -74.83 -33.75 62.22 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.158 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 112.83 17.78 7.75 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.498 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 34.0 m -97.88 133.47 39.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.872 0.368 . . . . 0.0 111.105 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' SER . . . . . 0.402 ' N ' HD23 ' A' ' 130' ' ' LEU . 2.6 t -43.2 105.68 0.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.889 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.498 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 27.1 mtmt -50.64 -35.82 32.39 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.897 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 129.27 20.22 1.45 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.483 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.537 ' CD1' HG22 ' A' ' 129' ' ' VAL . 27.4 p90 -163.81 169.06 18.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.909 0.385 . . . . 0.0 110.95 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -171.87 -163.29 25.54 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.446 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -153.58 148.67 26.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.89 0.376 . . . . 0.0 110.898 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.564 HG23 ' CE2' ' A' ' 144' ' ' PHE . 27.8 m -124.6 168.49 17.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . 0.448 ' N ' ' HD3' ' A' ' 143' ' ' LYS . 0.0 OUTLIER -125.97 159.19 33.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.936 179.896 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.564 ' CE2' HG23 ' A' ' 142' ' ' VAL . 95.2 m-85 -145.37 157.5 44.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.915 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' THR . . . . . 0.426 HG23 ' CG ' ' A' ' 124' ' ' ARG . 76.4 p -96.73 -19.22 19.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.169 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -120.64 120.58 36.14 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.863 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.489 ' HB2' ' CE2' ' A' ' 96' ' ' TYR . 0.1 OUTLIER -67.31 -39.19 85.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 39.3 mt -52.62 -34.44 51.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.911 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -85.06 -37.07 20.76 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.876 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 -43.84 -57.28 3.35 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 73.2 mttt -65.07 -27.53 68.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 15.1 ttt180 -59.94 -40.88 90.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.849 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.488 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -69.33 -46.12 67.85 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.136 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.43 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 29.7 mt -43.62 -40.82 4.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.906 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.433 HG22 ' N ' ' A' ' 156' ' ' GLU . 10.9 t -92.52 -45.32 8.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.119 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.433 ' N ' HG22 ' A' ' 155' ' ' THR . 12.2 mm-40 -67.38 -60.08 2.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.894 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.488 ' N ' ' O ' ' A' ' 153' ' ' ALA . 4.8 m -78.21 9.59 3.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . 0.43 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.8 tp-100 -51.85 128.73 24.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.894 -179.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 51.37 35.23 35.25 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . 0.405 ' N ' HG23 ' A' ' 168' ' ' VAL . . . -57.94 121.94 11.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.794 0.33 . . . . 0.0 111.122 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 25.6 t -93.38 -34.72 6.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.65 -34.12 0.24 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.501 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.464 ' CD2' HD12 ' A' ' 112' ' ' LEU . 29.1 tp -91.57 115.69 28.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.822 0.344 . . . . 0.0 110.895 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 65.17 146.14 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.531 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 6.2 t -48.97 -20.45 0.52 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.912 0.387 . . . . 0.0 110.86 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 16.2 mtmt -108.48 155.29 40.69 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.586 0.708 . . . . 0.0 110.916 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 -173.07 0.65 Allowed 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.672 2.248 . . . . 0.0 112.38 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.405 HG23 ' N ' ' A' ' 160' ' ' ALA . 34.6 m -139.62 124.53 20.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.075 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 39.8 ttm-85 -91.4 99.99 12.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.868 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.406 HD11 ' CB ' ' A' ' 157' ' ' CYS . 14.0 mt -76.36 145.73 39.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.905 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' SER . . . . . 0.421 ' N ' ' CD2' ' A' ' 154' ' ' LEU . 4.3 m -160.74 178.32 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.847 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 36.9 t -105.61 104.17 16.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.143 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.115 179.904 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . 0.499 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 21.1 m-85 . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.934 0.397 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 12.3 p -137.48 145.45 43.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.864 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 47.1 mt -120.99 139.17 53.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.945 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -90.22 131.07 36.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.899 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 25.2 m -121.99 155.77 26.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.142 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -142.92 178.17 21.4 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.449 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 52.93 53.87 11.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.817 0.341 . . . . 0.0 110.831 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 24.6 mt -100.35 100.17 10.92 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.905 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 58.5 p -46.71 150.0 1.35 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.552 0.691 . . . . 0.0 111.172 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 2.75 3.25 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -102.43 6.81 40.34 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.835 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 12.9 t -119.6 129.93 74.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.124 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -116.95 177.03 4.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.86 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -51.05 -53.75 30.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.836 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -38.74 -35.61 0.37 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.44 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' MET . . . . . . . . . . . . . 48.7 mtp -81.93 -59.43 2.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.807 0.336 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.462 HD13 ' CD2' ' A' ' 163' ' ' LEU . 22.5 tp -42.08 -31.43 0.36 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.914 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.53 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 10.9 t80 -72.24 -66.59 0.63 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.942 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.451 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 46.8 mt-10 -52.43 -47.39 66.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.873 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . 0.492 ' CZ ' ' HB2' ' A' ' 163' ' ' LEU . 60.4 t80 -48.11 -33.08 7.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.896 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.451 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.1 m-85 -94.99 -66.23 0.93 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.904 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.451 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.74 -31.45 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.122 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.451 ' N ' ' O ' ' A' ' 116' ' ' PHE . 30.3 tttp -64.66 -58.16 7.06 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.878 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.571 HG22 ' CE2' ' A' ' 120' ' ' TYR . 2.8 p -66.7 -33.97 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.148 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.571 ' CE2' HG22 ' A' ' 119' ' ' VAL . 90.2 m-85 -129.55 115.09 18.21 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.714 0.768 . . . . 0.0 110.935 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -2.72 10.67 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.678 2.252 . . . . 0.0 112.361 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 56.4 m -104.85 39.87 1.61 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 49.6 t -98.17 132.43 43.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.89 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.435 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 19.7 mmt180 -83.26 -35.26 25.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 -179.847 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.53 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 148.34 139.99 3.26 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.464 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -82.88 148.61 25.97 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.509 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . 0.413 ' N ' HD23 ' A' ' 112' ' ' LEU . 12.5 tptp -139.47 117.25 11.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.84 0.352 . . . . 0.0 110.881 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . 0.417 HG23 ' N ' ' A' ' 129' ' ' VAL . 7.6 p -106.04 146.76 12.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.145 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.421 HG21 ' CE2' ' A' ' 139' ' ' TYR . 30.1 m -93.66 150.93 3.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.08 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 15.5 mt -129.57 165.43 21.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.864 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -95.7 -177.2 3.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.848 179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -50.08 -37.6 34.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.941 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 41.0 p -75.16 -33.67 61.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.172 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 114.64 18.46 6.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.472 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 34.9 m -98.06 144.57 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.844 0.354 . . . . 0.0 111.114 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.9 t -56.79 105.06 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.476 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.1 mtmt -47.84 -29.18 3.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.89 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 121.0 18.37 3.88 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.542 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.476 ' CE2' ' HE3' ' A' ' 137' ' ' LYS . 9.9 p90 -161.8 175.89 11.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.926 0.393 . . . . 0.0 110.926 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -178.88 -162.23 27.94 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.44 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -153.64 146.32 24.24 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.896 0.379 . . . . 0.0 110.895 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 15.8 m -121.2 -176.61 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . 0.435 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 39.8 mtmt -144.56 162.78 35.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.886 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -149.78 159.04 44.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' THR . . . . . 0.423 HG21 ' NE ' ' A' ' 124' ' ' ARG . 69.8 p -93.92 -33.27 13.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.129 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 21.2 t0 -108.53 115.89 30.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.871 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.499 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 7.6 tt0 -59.62 -36.25 75.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.924 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 62.9 mt -53.31 -40.11 64.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.91 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.555 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 61.7 mt-10 -85.79 -22.48 27.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.856 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 18.3 tt0 -57.73 -53.67 55.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.91 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 3.2 mtpm? -69.24 -43.62 73.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.935 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 53.1 mtt-85 -45.54 -35.96 4.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.844 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.502 ' HB1' ' CE2' ' A' ' 120' ' ' TYR . . . -72.2 -43.43 64.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . . . . . . . . . 17.6 mt -46.1 -41.79 12.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.455 HG21 ' N ' ' A' ' 156' ' ' GLU . 12.3 t -91.37 -48.96 6.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.455 ' N ' HG21 ' A' ' 155' ' ' THR . 43.2 mm-40 -62.07 -66.5 0.53 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . . . . . . . . . 66.4 m -62.83 -13.01 28.47 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.89 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . 0.466 ' N ' HD12 ' A' ' 170' ' ' LEU . 4.2 tp-100 -37.68 131.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.926 -179.847 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 59.9 30.24 69.35 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.485 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -52.94 111.35 0.65 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.834 0.35 . . . . 0.0 111.083 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.4 t -89.35 -38.82 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.141 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -41.1 -32.35 0.6 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.451 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.492 ' HB2' ' CZ ' ' A' ' 115' ' ' PHE . 24.1 tp -90.84 116.27 28.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.857 0.36 . . . . 0.0 110.95 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 62.08 143.03 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.45 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 50.2 m -42.08 -32.16 0.43 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.934 0.397 . . . . 0.0 110.868 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 24.5 mttm -100.76 154.38 37.2 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.535 0.684 . . . . 0.0 110.888 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -178.99 2.6 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.697 2.264 . . . . 0.0 112.368 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 34.1 m -131.48 125.35 56.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.099 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 35.0 ttm180 -88.57 104.96 17.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.868 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.466 HD12 ' N ' ' A' ' 158' ' ' GLN . 9.1 mt -84.18 145.86 28.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.938 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 5.1 m -159.24 173.72 15.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.855 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 5.4 t -95.25 90.79 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.163 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.095 179.934 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.918 0.389 . . . . 0.0 110.917 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 77.3 p -129.53 157.36 42.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.867 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.468 HD22 ' CD2' ' A' ' 154' ' ' LEU . 87.1 mt -127.47 148.65 50.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.904 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -95.78 130.49 42.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.882 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -122.72 139.35 49.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.147 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -126.9 178.98 16.57 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.484 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 53.34 51.47 15.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.85 0.357 . . . . 0.0 110.903 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 21.3 mt -95.48 101.05 12.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 63.3 p -48.49 150.11 2.54 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.588 0.709 . . . . 0.0 111.133 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 2.96 3.04 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.679 2.253 . . . . 0.0 112.334 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -102.75 2.5 35.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.843 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 5.7 t -108.49 136.64 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.116 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -124.66 168.43 13.17 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.906 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -46.29 -45.9 17.62 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.833 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.97 -36.45 20.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.512 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' MET . . . . . . . . . . . . . 19.2 mtp -78.56 -58.4 3.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.772 0.32 . . . . 0.0 110.846 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . 0.459 HD11 ' CD2' ' A' ' 163' ' ' LEU . 19.4 tp -45.32 -36.27 4.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.935 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.522 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 7.4 t80 -67.24 -61.11 2.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.901 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.451 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 44.6 mt-10 -57.17 -54.58 45.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.872 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . 0.49 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 69.5 t80 -42.08 -32.19 0.44 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.855 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.496 ' O ' ' N ' ' A' ' 118' ' ' LYS . 7.8 m-85 -95.19 -67.54 0.85 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.892 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.451 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.69 -29.17 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.081 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.496 ' N ' ' O ' ' A' ' 116' ' ' PHE . 46.3 tttp -67.88 -57.19 6.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.907 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.538 HG21 ' CE2' ' A' ' 120' ' ' TYR . 3.8 p -71.15 -25.1 24.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.114 179.856 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.538 ' CE2' HG21 ' A' ' 119' ' ' VAL . 95.9 m-85 -135.26 109.17 10.44 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.702 0.763 . . . . 0.0 110.926 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 2.96 3.09 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.716 2.278 . . . . 0.0 112.357 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 15.0 m -109.97 30.83 6.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.834 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 42.6 t -92.83 132.12 37.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.903 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.445 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 42.2 mtp180 -83.31 -29.13 28.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.909 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.522 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 147.0 139.24 3.25 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.488 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -93.24 135.9 12.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.512 -179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -121.4 143.71 49.07 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.784 0.326 . . . . 0.0 110.95 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.97 127.16 72.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.13 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.57 HG22 ' CE1' ' A' ' 139' ' ' TYR . 7.0 m -76.32 138.19 21.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.149 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 26.1 mt -116.28 160.68 20.12 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -87.88 -176.58 5.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -52.85 -37.24 60.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.921 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 27.6 p -75.76 -21.81 57.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.091 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.99 22.36 10.12 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.456 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 24.0 m -106.3 140.83 23.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.797 0.332 . . . . 0.0 111.159 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.7 t -47.06 108.63 0.15 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.867 -179.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.465 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 30.4 mtmt -54.64 -32.26 58.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.912 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.24 17.44 2.44 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.491 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.57 ' CE1' HG22 ' A' ' 129' ' ' VAL . 17.2 p90 -163.76 171.27 15.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.913 0.387 . . . . 0.0 110.937 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -172.75 -162.59 25.13 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.447 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -154.0 142.4 20.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.878 0.37 . . . . 0.0 110.896 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.472 HG12 ' CE2' ' A' ' 116' ' ' PHE . 29.0 m -117.24 170.9 6.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.126 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . 0.445 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -131.05 160.54 34.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.948 179.849 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -148.81 162.53 39.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.903 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 33.7 p -98.41 -26.6 14.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.154 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . 0.431 ' CG ' ' OE1' ' A' ' 149' ' ' GLU . 4.9 t70 -112.1 119.73 39.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.864 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -67.29 -31.65 72.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.908 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 21.7 mt -56.81 -54.01 51.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.893 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 150' ' ' GLN . 1.9 mp0 -64.81 -45.87 84.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.905 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.449 ' C ' ' O ' ' A' ' 149' ' ' GLU . 21.7 tt0 -33.46 -46.86 0.2 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.949 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . 0.434 ' O ' ' N ' ' A' ' 154' ' ' LEU . 13.8 mmtp -66.98 -55.76 13.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -38.69 -35.12 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.481 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -72.72 -44.89 61.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.468 ' CD2' HD22 ' A' ' 98' ' ' LEU . 16.1 mt -47.16 -38.95 12.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.925 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.46 HG22 ' N ' ' A' ' 156' ' ' GLU . 12.1 t -92.47 -51.12 5.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.145 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.46 ' N ' HG22 ' A' ' 155' ' ' THR . 79.1 mm-40 -64.35 -57.79 8.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.462 ' N ' ' O ' ' A' ' 153' ' ' ALA . 53.3 m -75.18 5.33 5.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.871 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 3.3 tp-100 -53.1 137.45 33.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.903 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 45.48 37.24 6.39 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.468 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . 0.403 ' CB ' ' CG2' ' A' ' 168' ' ' VAL . . . -54.89 116.19 2.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.894 0.378 . . . . 0.0 111.104 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 32.7 t -94.74 -33.45 4.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.16 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -45.04 -33.55 3.77 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.51 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.49 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 56.4 tp -85.63 115.24 23.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.866 0.365 . . . . 0.0 110.915 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 69.88 175.21 14.81 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.51 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 11.7 m -84.19 25.87 0.81 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.92 0.391 . . . . 0.0 110.825 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 19.7 mttp -157.24 157.05 30.16 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.585 0.707 . . . . 0.0 110.909 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 170.24 17.02 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.654 2.236 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . 0.403 ' CG2' ' CB ' ' A' ' 160' ' ' ALA . 30.1 m -132.37 125.98 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.129 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 36.3 ttt85 -88.89 117.12 27.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.46 HD13 ' CB ' ' A' ' 157' ' ' CYS . 11.7 mt -93.24 139.37 30.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.894 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 15.9 m -156.55 173.0 17.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.836 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 15.6 t -93.79 99.21 9.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.134 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.06 179.891 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' TYR . . . . . 0.466 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 4.3 m-85 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.89 0.376 . . . . 0.0 110.946 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 35.4 p -126.72 155.02 43.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.836 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' LEU . . . . . 0.512 HD12 ' CE1' ' A' ' 144' ' ' PHE . 85.9 mt -124.87 139.57 53.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -90.27 125.97 35.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.9 m -120.8 141.43 41.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.131 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -129.78 -175.87 14.21 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.431 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 51.13 52.65 14.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.839 0.352 . . . . 0.0 110.88 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 22.3 mt -98.49 112.67 24.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.978 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 10.2 p -58.55 150.82 54.29 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.591 0.71 . . . . 0.0 111.115 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 2.42 3.55 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.689 2.259 . . . . 0.0 112.342 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -99.42 -5.67 29.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.822 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 31.6 t -102.08 143.49 14.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.162 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -127.93 173.87 9.65 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -54.0 -45.25 71.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.862 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.99 -26.28 26.6 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.488 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' MET . . . . . . . . . . . . . 35.0 mtp -85.36 -58.52 2.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.825 0.345 . . . . 0.0 110.885 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 40.5 tp -42.86 -36.7 1.58 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.919 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' TYR . . . . . 0.448 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.6 t80 -66.3 -68.33 0.38 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.88 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.452 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 23.8 mt-10 -48.9 -41.72 34.48 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.91 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' PHE . . . . . 0.465 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 53.8 t80 -54.29 -34.1 60.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.849 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' PHE . . . . . 0.464 ' O ' ' N ' ' A' ' 118' ' ' LYS . 9.1 m-85 -95.19 -64.36 1.07 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.895 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' VAL . . . . . 0.452 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.7 -30.91 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.105 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' LYS . . . . . 0.464 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.1 ttpt -65.01 -61.17 2.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.916 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.503 HG22 ' CE2' ' A' ' 120' ' ' TYR . 2.5 p -66.78 -34.35 69.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.097 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' TYR . . . . . 0.503 ' CE2' HG22 ' A' ' 119' ' ' VAL . 90.7 m-85 -126.05 109.02 24.65 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.673 0.749 . . . . 0.0 110.946 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 2.13 3.8 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.69 2.26 . . . . 0.0 112.328 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 10.6 m -108.32 34.4 3.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.2 t -90.32 135.43 33.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.855 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.442 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 63.1 mtt180 -85.14 -36.39 21.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.448 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 154.48 143.04 3.58 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.484 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -91.52 138.68 14.4 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.488 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.71 131.96 45.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.79 0.328 . . . . 0.0 110.914 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 8.7 p -117.3 137.19 52.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.143 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' VAL . . . . . 0.569 HG21 ' CD1' ' A' ' 139' ' ' TYR . 18.7 m -81.03 148.44 5.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.118 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 16.3 mt -133.09 169.8 16.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.88 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -104.22 177.32 4.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -46.36 -36.47 6.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 41.5 p -77.75 -33.27 52.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.49 17.04 9.57 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.49 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 20.3 m -96.42 127.63 48.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.342 . . . . 0.0 111.104 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 9.3 t -43.79 108.86 0.12 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.869 -179.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' LYS . . . . . 0.51 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.5 mtmt -52.51 -31.36 34.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.932 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.36 19.77 2.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.524 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' TYR . . . . . 0.569 ' CD1' HG21 ' A' ' 129' ' ' VAL . 26.5 p90 -163.62 169.67 18.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.389 . . . . 0.0 110.915 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.14 -163.86 23.87 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.446 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -153.86 148.91 26.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.917 0.389 . . . . 0.0 110.871 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . 0.46 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 16.6 m -124.33 179.29 2.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.091 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' LYS . . . . . 0.442 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 22.9 mtpt -142.57 161.52 37.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.929 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.512 ' CE1' HD12 ' A' ' 98' ' ' LEU . 37.7 m-85 -149.9 153.66 37.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.877 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 51.5 p -91.5 -19.14 23.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -113.92 110.29 19.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.863 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' GLU . . . . . 0.466 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 16.0 tt0 -60.29 -35.75 76.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 93.6 mt -57.88 -45.01 87.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.946 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -74.56 -43.57 55.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.864 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' GLN . . . . . 0.426 ' C ' ' OE1' ' A' ' 150' ' ' GLN . 1.6 tm0? -44.18 -38.91 4.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.976 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 24.7 mmtt -76.51 -40.3 50.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.921 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 54.9 mtt85 -53.84 -31.58 49.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.906 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' ALA . . . . . 0.482 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -69.1 -54.06 17.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.101 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.423 HD21 ' CB ' ' A' ' 170' ' ' LEU . 21.8 mt -40.27 -36.33 0.51 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.907 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' THR . . . . . 0.451 HG21 ' N ' ' A' ' 156' ' ' GLU . 7.7 t -92.4 -42.36 9.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.122 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' GLU . . . . . 0.451 ' N ' HG21 ' A' ' 155' ' ' THR . 24.0 mm-40 -75.68 -62.93 1.42 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.903 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' CYS . . . . . 0.482 ' N ' ' O ' ' A' ' 153' ' ' ALA . 53.7 m -67.13 -3.82 8.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.7 tp-100 -41.8 131.11 3.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.91 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 47.4 41.18 16.7 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.539 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -60.22 111.05 1.38 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.788 0.328 . . . . 0.0 111.109 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.7 t -84.97 -35.66 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.132 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.5 -35.53 0.33 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.473 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' LEU . . . . . 0.465 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 29.7 tp -88.7 122.12 31.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.861 0.362 . . . . 0.0 110.921 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 61.94 157.62 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.486 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 72.0 m -60.62 -12.51 10.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.923 0.392 . . . . 0.0 110.864 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 61.8 mttt -118.44 156.8 50.74 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.571 0.701 . . . . 0.0 110.88 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -177.26 1.8 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.651 2.234 . . . . 0.0 112.374 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 29.8 m -138.73 124.76 24.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.154 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 34.6 ttt180 -87.84 107.0 18.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' LEU . . . . . 0.442 HD12 ' CB ' ' A' ' 157' ' ' CYS . 10.3 mt -81.98 146.84 29.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.908 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 8.0 m -163.33 179.73 7.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.839 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 13.4 t -102.66 101.75 12.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.128 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.117 179.88 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 79.8 p -89.19 42.0 1.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.911 0.386 . . . . 0.0 110.852 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 88.1 p -58.41 123.47 16.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.856 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 149.17 49.14 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.486 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.9 m -155.26 111.02 3.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.866 0.365 . . . . 0.0 110.853 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 27.4 t -86.31 82.02 8.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.887 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.09 69.1 1.42 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.529 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -173.27 0.68 Allowed 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.695 2.263 . . . . 0.0 112.372 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -126.07 143.69 51.01 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.9 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 67.3 m-85 -128.08 86.79 2.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.924 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.8 m -97.91 161.68 13.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.876 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.436 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . 26.0 mt -125.78 143.57 51.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.899 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -93.47 115.78 28.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.462 HG22 ' CD1' ' A' ' 103' ' ' LEU . 5.3 m -108.09 148.48 12.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.143 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.7 -177.41 15.14 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.505 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . 0.42 ' N ' ' O ' ' A' ' 138' ' ' GLY . 24.8 m-20 50.87 51.81 16.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.868 0.366 . . . . 0.0 110.887 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.462 ' CD1' HG22 ' A' ' 100' ' ' VAL . 31.1 mt -98.27 102.58 14.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.897 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 72.9 p -47.57 149.85 1.94 Allowed Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.583 0.706 . . . . 0.0 111.116 179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 2.99 3.07 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.675 2.25 . . . . 0.0 112.327 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -98.32 -16.47 19.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.905 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . 0.417 ' HA ' ' CE ' ' A' ' 111' ' ' MET . 51.1 t -93.39 145.56 7.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.161 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -129.78 -179.72 5.36 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.862 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -57.77 -51.12 70.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -39.85 -36.18 0.75 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' MET . . . . . 0.418 ' O ' ' C ' ' A' ' 112' ' ' LEU . 18.5 mtm -82.79 -59.26 2.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.795 0.331 . . . . 0.0 110.916 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.418 ' C ' ' O ' ' A' ' 111' ' ' MET . 25.2 tp -36.05 -44.02 0.36 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.88 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.401 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 16.1 t80 -63.6 -61.16 2.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.907 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.45 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 18.3 mt-10 -54.17 -55.68 25.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.862 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . 0.567 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 71.3 t80 -41.13 -32.29 0.25 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.873 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.48 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.5 m-85 -95.25 -68.16 0.82 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.841 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.45 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.7 -30.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.148 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.48 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.5 ttpt -68.78 -53.96 18.69 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.888 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.566 HG22 ' CE2' ' A' ' 120' ' ' TYR . 2.6 p -70.73 -31.47 45.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.109 179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.566 ' CE2' HG22 ' A' ' 119' ' ' VAL . 94.2 m-85 -135.84 114.47 11.04 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.679 0.752 . . . . 0.0 110.913 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.82 0.53 5.55 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.658 2.239 . . . . 0.0 112.361 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 26.0 m -98.2 21.01 11.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.885 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 7.7 t -84.72 134.78 34.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.888 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 9.0 mmt85 -91.87 -38.94 12.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.836 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.401 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.96 152.27 7.13 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.536 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -101.66 143.01 15.9 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.488 -179.905 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 21.7 tptm -132.78 127.38 34.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 110.865 -179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.5 p -116.8 127.18 74.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.145 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.566 HG11 ' CE1' ' A' ' 139' ' ' TYR . 20.3 m -73.91 143.65 13.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.127 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 25.5 mt -130.57 163.82 26.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.927 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 134' ' ' GLY . 23.8 t70 -94.68 176.17 6.38 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -44.34 -40.38 5.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.894 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 18.1 p -72.37 -28.58 63.11 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.179 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 104.98 20.36 9.92 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.487 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 26.1 m -99.64 134.75 37.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.831 0.348 . . . . 0.0 111.15 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 6.0 t -48.62 112.92 0.67 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.813 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.3 mtmt -58.69 -28.56 65.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.954 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 122.83 15.25 3.97 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.441 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.566 ' CE1' HG11 ' A' ' 129' ' ' VAL . 29.8 p90 -161.88 167.99 23.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.896 0.379 . . . . 0.0 110.912 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.64 -160.02 16.85 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.467 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -153.7 148.64 26.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.9 0.381 . . . . 0.0 110.874 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.436 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 28.5 m -123.3 170.6 13.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.077 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 25.3 mttt -129.67 156.06 44.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -143.09 171.56 13.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.9 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 1.7 p -108.3 -28.79 9.23 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -113.1 128.4 56.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.881 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 12.9 tm-20 -69.37 -38.37 78.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.87 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 26.9 mt -51.0 -44.82 60.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -73.16 -42.88 62.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.852 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 19.8 tt0 -38.74 -57.94 1.14 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.928 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 9.2 mmmm -63.21 -49.32 74.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.91 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 34.4 mtt-85 -43.43 -41.06 4.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.832 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.98 -44.3 76.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.098 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.444 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 24.2 mt -48.46 -40.63 26.98 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.906 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.1 t -91.36 -34.7 14.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 17.4 mm-40 -79.58 -65.1 1.04 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.876 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.494 ' N ' ' O ' ' A' ' 153' ' ' ALA . 11.2 m -65.14 -8.74 18.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.877 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . 0.444 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.5 tp-100 -35.6 137.9 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.923 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.48 42.81 2.72 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.521 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -57.75 110.9 0.98 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.803 0.335 . . . . 0.0 111.068 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.403 ' O ' ' C ' ' A' ' 162' ' ' GLY . 20.1 t -82.72 -41.76 17.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.135 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -37.87 -34.84 0.2 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.459 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.567 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 26.5 tp -90.23 115.77 27.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.811 0.339 . . . . 0.0 110.938 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.415 ' O ' ' C ' ' A' ' 165' ' ' SER . . . 62.52 137.85 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.481 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' SER . . . . . 0.415 ' C ' ' O ' ' A' ' 164' ' ' GLY . 1.2 t -37.4 -32.87 0.05 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.916 0.389 . . . . 0.0 110.866 -179.782 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 164' ' ' GLY . 58.0 mttt -100.46 153.6 37.65 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.519 0.676 . . . . 0.0 110.913 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -179.19 2.77 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.67 2.247 . . . . 0.0 112.311 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 13.8 m -130.59 129.68 64.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.1 179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.6 ttt-85 -89.27 110.58 21.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.883 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.453 HD11 ' CB ' ' A' ' 157' ' ' CYS . 12.5 mt -87.24 144.59 26.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.927 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.2 m -160.89 175.06 12.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 2.6 t -102.66 104.43 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.136 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -85.81 161.81 18.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.074 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . 0.431 ' CG2' ' HD2' ' A' ' 175' ' ' PRO . 85.5 mt -131.74 137.46 30.37 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.635 0.731 . . . . 0.0 111.14 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.431 ' HD2' ' CG2' ' A' ' 174' ' ' ILE . 53.7 Cg_endo -69.76 -173.91 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.668 2.245 . . . . 0.0 112.359 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 18.7 ttpp -54.81 94.61 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.873 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -107.33 76.29 1.07 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.038 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 1.6 t -174.99 174.05 2.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.809 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 15.1 mmm180 -120.1 110.72 16.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.872 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 28.7 m -73.6 135.69 27.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.21 141.72 42.91 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.543 0.687 . . . . 0.0 110.892 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 139.67 40.62 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.723 2.282 . . . . 0.0 112.334 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 31.3 m -108.8 162.36 6.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.14 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -160.17 149.83 17.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.877 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.4 m -145.28 144.72 30.93 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.865 -179.79 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 168.35 69.59 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.48 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 175.31 8.3 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.66 2.24 . . . . 0.0 112.324 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 36.0 p -165.48 145.87 6.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.886 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 1.2 t -126.83 156.62 41.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.831 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.486 -180.0 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 36.1 m -157.46 168.51 27.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.86 0.362 . . . . 0.0 110.853 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.2 t -105.56 80.28 1.55 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.874 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 140.44 176.16 15.0 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.48 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.0 m -90.51 -50.87 5.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.858 0.361 . . . . 0.0 110.857 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 79.0 p -68.61 -50.69 49.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.843 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 109.22 83.44 1.48 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.521 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 163.06 39.64 Favored 'Trans proline' 0 C--O 1.231 0.155 0 C-N-CA 122.701 2.267 . . . . 0.0 112.334 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 34.9 mp0 -73.23 178.0 4.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.855 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . 0.414 ' CD1' ' HG3' ' A' ' 147' ' ' GLU . 9.4 m-85 -132.45 103.76 6.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.98 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 51.6 m -124.92 154.12 41.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.872 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 96.1 mt -126.65 143.44 51.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.9 -179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.445 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 11.4 t80 -92.51 142.13 27.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.863 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 21.6 m -132.02 150.86 34.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.109 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.15 -174.32 13.27 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.489 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 46.55 54.74 8.37 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.797 0.332 . . . . 0.0 110.852 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.409 HD11 ' C ' ' A' ' 139' ' ' TYR . 29.6 mt -101.84 112.09 24.57 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.895 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 73.3 p -53.59 148.98 16.67 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.61 0.719 . . . . 0.0 111.126 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 2.14 3.78 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.71 2.273 . . . . 0.0 112.35 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -97.98 -17.52 19.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.868 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 14.7 t -87.58 143.77 10.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.102 -179.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -131.65 172.2 12.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.855 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -49.59 -46.31 48.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -49.25 -28.91 9.27 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.461 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' MET . . . . . 0.452 ' O ' ' N ' ' A' ' 113' ' ' TYR . 14.1 mtp -86.4 -66.54 0.89 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.814 0.34 . . . . 0.0 110.866 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.423 ' C ' ' O ' ' A' ' 111' ' ' MET . 24.6 tp -35.75 -32.88 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.887 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.452 ' N ' ' O ' ' A' ' 111' ' ' MET . 12.0 t80 -68.84 -65.01 0.76 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.927 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.451 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 18.4 mt-10 -55.59 -39.57 70.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . 0.563 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 58.0 t80 -54.55 -33.88 60.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.886 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.46 ' O ' ' N ' ' A' ' 118' ' ' LYS . 10.0 m-85 -95.27 -64.92 1.01 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.818 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.451 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.78 -30.92 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.076 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.46 ' N ' ' O ' ' A' ' 116' ' ' PHE . 5.3 ttpm? -65.45 -58.79 4.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.874 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.421 HG12 ' N ' ' A' ' 120' ' ' TYR . 3.5 p -64.56 -33.78 65.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.172 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.421 ' N ' HG12 ' A' ' 119' ' ' VAL . 91.0 m-85 -135.44 116.53 11.97 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.664 0.745 . . . . 0.0 110.965 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 1.94 3.97 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.671 2.247 . . . . 0.0 112.365 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 86.4 p -87.85 -23.27 24.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.835 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 7.7 t -47.19 137.04 8.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.885 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 51.7 mtm180 -99.3 -36.53 9.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.874 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.417 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.53 143.2 3.65 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.493 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -87.16 145.24 19.69 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.492 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 21.5 tptm -131.49 110.65 11.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.855 0.359 . . . . 0.0 110.86 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.7 p -102.48 139.85 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.109 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.404 HG22 ' CD1' ' A' ' 139' ' ' TYR . 25.0 m -86.32 158.34 3.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 24.2 mt -137.38 167.78 20.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.878 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.443 ' O ' ' N ' ' A' ' 134' ' ' GLY . 17.7 t0 -102.18 175.06 5.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.83 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -42.03 -42.07 2.75 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.948 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 65.2 p -72.82 -31.83 65.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.097 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 108.88 19.79 8.41 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.487 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 24.9 m -99.7 127.76 52.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.353 . . . . 0.0 111.114 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 3.0 t -40.21 106.76 0.06 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.831 -179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.547 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.7 mtmt -50.38 -37.16 35.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.944 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 128.81 18.7 1.71 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.459 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.547 ' CE2' ' HE3' ' A' ' 137' ' ' LYS . 16.3 p90 -160.81 173.41 15.41 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.953 0.406 . . . . 0.0 110.935 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -177.26 -163.85 29.95 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.484 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.445 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 2.5 m-85 -152.83 150.44 29.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.888 0.375 . . . . 0.0 110.9 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.513 HG21 ' CE1' ' A' ' 144' ' ' PHE . 28.1 m -123.83 174.54 7.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.174 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . 0.447 ' N ' ' HD3' ' A' ' 143' ' ' LYS . 0.5 OUTLIER -134.77 158.43 44.18 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 179.872 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.513 ' CE1' HG21 ' A' ' 142' ' ' VAL . 75.1 m-85 -143.03 160.98 39.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.89 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 75.3 p -95.38 -14.81 23.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.177 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -128.16 123.66 34.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.898 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.414 ' HG3' ' CD1' ' A' ' 96' ' ' TYR . 15.3 tt0 -64.45 -39.23 93.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.911 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 95.3 mt -47.7 -46.96 30.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.941 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 55.8 mm-40 -74.53 -33.46 62.77 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.847 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 33.0 tt0 -46.73 -40.93 14.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.919 -179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.0 mmtp -81.59 -46.83 13.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 46.0 mtt180 -44.27 -41.36 5.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.85 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.474 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.95 -42.97 80.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.476 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 29.9 mt -51.99 -38.14 55.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.44 HG22 ' N ' ' A' ' 156' ' ' GLU . 14.3 t -92.35 -33.53 14.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.166 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.44 ' N ' HG22 ' A' ' 155' ' ' THR . 45.8 mm-40 -83.49 -66.07 0.94 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.898 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.474 ' N ' ' O ' ' A' ' 153' ' ' ALA . 87.7 m -59.66 -13.26 9.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.93 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . 0.476 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.3 tp-100 -39.0 140.33 0.39 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.893 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 50.43 36.42 30.46 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.497 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.462 ' HB1' ' CG2' ' A' ' 168' ' ' VAL . . . -67.55 110.94 3.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.863 0.364 . . . . 0.0 111.073 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.433 ' O ' ' C ' ' A' ' 162' ' ' GLY . 25.2 t -92.68 -35.91 7.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.132 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -35.12 -35.85 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.482 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.563 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 38.1 tp -86.21 117.45 25.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.843 0.354 . . . . 0.0 110.911 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 66.46 170.46 3.81 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.499 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' SER . . . . . 0.493 ' O ' ' CG ' ' A' ' 166' ' ' LYS . 35.9 m -82.09 40.35 0.62 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.891 0.377 . . . . 0.0 110.873 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . 0.493 ' CG ' ' O ' ' A' ' 165' ' ' SER . 36.0 mttt -169.23 157.22 6.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.527 0.679 . . . . 0.0 110.912 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 172.37 12.77 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.677 2.251 . . . . 0.0 112.317 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.462 ' CG2' ' HB1' ' A' ' 160' ' ' ALA . 32.2 m -135.69 126.9 44.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.136 179.874 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 44.7 ttt180 -89.95 117.51 28.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.866 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.468 ' CB ' HD22 ' A' ' 154' ' ' LEU . 17.1 mt -93.35 145.19 24.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.97 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 9.9 m -158.16 174.25 15.48 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 39.4 t -98.69 102.08 12.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.082 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -93.17 131.28 38.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.152 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 53.6 mt -69.0 130.25 91.62 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.565 0.698 . . . . 0.0 111.165 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -42.25 3.56 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.648 2.232 . . . . 0.0 112.37 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 49.1 tttt -129.39 110.16 11.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.891 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -133.97 169.16 17.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.074 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 73.6 m 42.58 38.62 1.32 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.888 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . 0.491 ' H ' ' NE ' ' A' ' 179' ' ' ARG . 0.0 OUTLIER -77.5 164.11 25.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.885 -179.938 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 91.1 t -115.36 138.68 44.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.162 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -99.82 143.92 27.37 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.567 0.698 . . . . 0.0 110.861 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 105.84 1.57 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.626 2.217 . . . . 0.0 112.357 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 25.8 m -117.4 127.23 74.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.134 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.6 tm-20 -119.41 136.54 54.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.896 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 75.0 p -83.46 110.59 18.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.867 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -71.7 -157.92 3.18 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.468 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 96.61 0.6 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.666 2.244 . . . . 0.0 112.346 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 31.1 t -79.06 149.08 32.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.891 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 58.9 m -80.1 172.14 14.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.836 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.53 -179.968 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.436 -0.266 . . . . 0.0 112.436 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.8 m -51.06 175.97 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.87 0.367 . . . . 0.0 110.888 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 30.1 t -82.61 114.48 21.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.877 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -111.49 79.03 0.25 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.467 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 10.3 t 56.2 42.63 27.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.927 0.394 . . . . 0.0 110.898 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.0 t -57.86 -61.13 2.76 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.845 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.85 83.88 0.31 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.49 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 120.47 7.25 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.713 2.275 . . . . 0.0 112.32 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 2.0 pp20? -117.16 151.8 36.11 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.846 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -134.92 102.95 5.41 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.935 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.9 m -121.15 154.87 35.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.407 HD13 ' CE1' ' A' ' 144' ' ' PHE . 83.2 mt -124.06 145.82 48.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -95.4 124.11 39.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.414 HG23 ' C ' ' A' ' 140' ' ' GLY . 33.0 m -115.25 148.41 18.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.131 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -136.19 -177.86 15.32 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.47 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 49.77 54.09 11.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.873 0.368 . . . . 0.0 110.88 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 30.1 mt -100.51 102.56 13.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.936 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.8 p -47.52 151.26 1.47 Allowed Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.591 0.71 . . . . 0.0 111.136 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.79 -1.38 8.4 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.689 2.259 . . . . 0.0 112.343 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -102.04 25.52 8.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.857 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . 0.444 ' CG1' ' HE1' ' A' ' 111' ' ' MET . 22.2 t -134.62 138.73 49.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.148 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 45.0 m-20 -123.22 169.35 11.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.875 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.405 ' N ' HG13 ' A' ' 128' ' ' VAL . 0.5 OUTLIER -46.77 -46.23 20.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 -179.958 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -41.8 -44.47 4.45 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.508 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' MET . . . . . 0.444 ' HE1' ' CG1' ' A' ' 107' ' ' VAL . 32.3 mtm -77.97 -41.37 36.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.785 0.326 . . . . 0.0 110.887 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 16.8 tp -57.05 -25.13 58.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.974 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.487 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 8.5 t80 -84.23 -63.03 1.42 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.905 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.45 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 23.9 mt-10 -55.39 -43.24 75.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . 0.455 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 85.2 t80 -51.14 -33.02 24.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.845 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.492 ' O ' ' N ' ' A' ' 118' ' ' LYS . 7.9 m-85 -95.25 -65.78 0.95 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.45 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -37.16 -28.42 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.106 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.492 ' N ' ' O ' ' A' ' 116' ' ' PHE . 3.1 tptm -65.6 -53.73 37.62 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.937 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.452 HG21 ' CE2' ' A' ' 120' ' ' TYR . 4.1 p -71.16 -38.25 70.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 179.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.452 ' CE2' HG21 ' A' ' 119' ' ' VAL . 93.1 m-85 -127.17 116.19 21.75 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.629 0.728 . . . . 0.0 110.934 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 2.94 3.06 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.668 2.246 . . . . 0.0 112.365 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 18.5 p -89.96 -26.47 20.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . 0.548 ' HA ' ' CD2' ' A' ' 144' ' ' PHE . 9.5 t -45.25 128.39 7.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.936 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -90.08 -34.88 15.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.869 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.487 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 172.14 166.2 30.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.443 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -115.66 144.22 18.36 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.462 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 18.1 tptt -136.01 128.89 31.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.792 0.329 . . . . 0.0 110.916 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.405 HG13 ' N ' ' A' ' 109' ' ' ASP . 6.5 p -119.02 127.32 75.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.165 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.458 HG23 ' CE1' ' A' ' 139' ' ' TYR . 10.3 m -74.58 153.51 6.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.139 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 13.4 mt -130.52 176.82 7.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 -179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 134' ' ' GLY . 18.3 t70 -108.23 174.41 5.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.875 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -40.98 -45.06 2.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.879 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 20.8 p -71.57 -34.26 69.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.111 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 113.53 20.92 5.98 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.485 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 136' ' ' SER . 27.3 m -100.44 122.85 52.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.855 0.36 . . . . 0.0 111.138 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.444 ' C ' ' O ' ' A' ' 135' ' ' VAL . 7.3 t -34.57 106.83 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.87 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.49 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 26.8 mtmt -50.45 -34.51 25.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.869 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.2 18.64 2.27 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.518 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.49 ' CE2' ' HE3' ' A' ' 137' ' ' LYS . 19.1 p90 -163.08 165.89 24.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.966 0.412 . . . . 0.0 110.883 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.414 ' C ' HG23 ' A' ' 100' ' ' VAL . . . -166.67 -161.35 15.59 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.512 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -154.03 145.51 23.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.915 0.388 . . . . 0.0 110.861 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.511 HG21 ' CE1' ' A' ' 144' ' ' PHE . 24.4 m -117.31 -176.09 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.133 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 20.2 mtmm -143.57 160.76 40.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.864 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.548 ' CD2' ' HA ' ' A' ' 123' ' ' CYS . 65.5 m-85 -149.85 179.32 8.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -125.08 -16.62 5.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.16 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -122.17 97.33 5.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.876 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.6 tt0 -44.83 -48.95 11.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.917 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 63.5 mt -44.85 -33.0 1.77 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.926 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -89.79 -36.69 14.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.834 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 13.6 tt0 -52.4 -47.53 66.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 -179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 61.9 mttt -69.99 -41.9 73.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.907 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 69.8 mtt180 -49.7 -34.3 18.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.869 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.452 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -73.3 -45.63 54.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.103 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . . . . . . . . . 26.6 mt -48.4 -36.49 14.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 9.4 t -91.35 -40.61 11.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 56.7 mm-40 -77.56 -66.45 0.83 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.863 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.47 ' CB ' HD12 ' A' ' 170' ' ' LEU . 63.3 m -60.59 -11.6 7.64 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.855 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 157' ' ' CYS . 2.8 tp-100 -34.99 139.86 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.892 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 43.5 35.8 3.01 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.519 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.447 ' HB2' ' CG2' ' A' ' 168' ' ' VAL . . . -55.71 120.14 6.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.82 0.343 . . . . 0.0 111.146 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.8 t -95.1 -33.26 4.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.101 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -41.47 -36.53 1.54 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.53 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.455 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 22.6 tp -89.06 116.48 27.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.895 0.378 . . . . 0.0 110.875 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 68.77 157.89 1.31 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.505 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 49.9 m -62.34 -11.47 15.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.961 0.41 . . . . 0.0 110.839 -179.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 51.1 mttt -120.02 156.79 54.19 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.59 0.71 . . . . 0.0 110.895 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 177.36 5.68 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.65 2.233 . . . . 0.0 112.382 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.447 ' CG2' ' HB2' ' A' ' 160' ' ' ALA . 15.7 m -131.96 125.13 54.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.144 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 21.4 ttm180 -86.82 102.31 14.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.854 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.47 HD12 ' CB ' ' A' ' 157' ' ' CYS . 12.8 mt -81.55 140.67 34.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 19.9 m -156.46 178.03 10.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.839 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 3.3 t -99.95 99.69 8.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.081 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -71.53 162.04 30.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.144 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 70.9 mt -118.83 125.07 27.94 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.669 0.747 . . . . 0.0 111.105 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -49.45 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.644 2.229 . . . . 0.0 112.357 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . 0.442 ' HD3' ' NE ' ' A' ' 179' ' ' ARG . 3.1 ttmm -141.11 108.33 5.5 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.908 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -61.21 -72.54 0.11 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.074 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 5.7 t -146.09 158.17 43.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.868 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . 0.442 ' NE ' ' HD3' ' A' ' 176' ' ' LYS . 24.5 mmt180 -95.31 149.08 21.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.917 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 9.0 p -114.16 138.71 43.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.138 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 11.5 mtpp -151.36 146.58 19.13 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.593 0.711 . . . . 0.0 110.868 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 128.35 15.9 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.66 2.24 . . . . 0.0 112.366 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 82.4 t -91.49 95.78 5.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.137 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -85.92 165.48 16.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.875 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -137.47 124.27 21.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.882 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -139.94 72.89 0.41 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.505 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 112.46 3.09 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.693 2.262 . . . . 0.0 112.339 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 25.9 p -95.99 83.44 3.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.861 -179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 68.7 m 40.79 41.99 1.32 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.895 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.524 -179.949 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 1.9 m -113.44 -44.95 3.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.874 0.368 . . . . 0.0 110.808 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 77.5 p -89.36 134.14 34.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.886 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 150.82 -91.81 0.14 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.454 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 14.0 t -69.02 137.69 53.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 110.808 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 89.2 p -71.35 88.65 0.88 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.823 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -48.24 150.34 3.23 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.472 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . 0.553 ' O ' ' CE1' ' A' ' 96' ' ' TYR . 53.8 Cg_endo -69.75 158.4 57.09 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.675 2.25 . . . . 0.0 112.362 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -50.98 174.94 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.884 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . 0.553 ' CE1' ' O ' ' A' ' 94' ' ' PRO . 13.4 m-85 -143.62 119.3 10.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.921 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.1 m -138.91 148.27 43.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.861 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 82.9 mt -117.41 151.63 36.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.915 179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 7.6 t80 -98.31 123.29 42.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.907 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 29.8 m -117.45 144.09 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.125 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.11 178.5 18.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.483 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . 0.45 ' N ' ' O ' ' A' ' 138' ' ' GLY . 1.2 m-20 57.73 53.88 6.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.82 0.343 . . . . 0.0 110.859 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 23.0 mt -100.8 103.34 14.55 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.896 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 39.9 p -48.31 150.1 2.41 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.578 0.704 . . . . 0.0 111.146 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -1.56 8.69 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.678 2.252 . . . . 0.0 112.352 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -99.33 12.08 37.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.858 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . 0.44 ' CG1' ' HE3' ' A' ' 111' ' ' MET . 62.1 t -123.32 139.92 48.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.096 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -122.08 171.59 8.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.878 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.5 p30 -52.63 -43.91 65.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.893 179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -43.87 -37.3 4.04 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.507 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' MET . . . . . 0.44 ' HE3' ' CG1' ' A' ' 107' ' ' VAL . 28.2 mtm -81.45 -44.72 17.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.833 0.349 . . . . 0.0 110.889 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.458 HD13 ' CD2' ' A' ' 163' ' ' LEU . 22.1 tp -53.92 -28.52 37.37 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.873 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.555 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 13.9 t80 -76.36 -65.36 0.93 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.908 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.471 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 17.0 mt-10 -55.23 -48.25 74.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.918 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . . . . . . . . . 69.0 t80 -46.31 -33.82 4.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.938 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.492 ' O ' ' N ' ' A' ' 118' ' ' LYS . 6.9 m-85 -95.3 -67.09 0.87 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.847 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.471 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.8 p -36.51 -29.41 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.079 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.492 ' N ' ' O ' ' A' ' 116' ' ' PHE . 18.8 ttpp -67.47 -55.56 13.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.914 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.564 HG22 ' CE2' ' A' ' 120' ' ' TYR . 2.3 p -70.98 -30.72 42.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.123 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.576 ' CE1' ' HB3' ' A' ' 152' ' ' ARG . 97.6 m-85 -132.26 112.36 14.32 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.602 0.715 . . . . 0.0 110.955 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.75 2.39 3.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.671 2.247 . . . . 0.0 112.338 179.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 6.3 p -92.87 -20.27 20.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.862 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.0 t -50.05 134.28 22.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.883 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -94.85 -35.7 11.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.555 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 167.1 143.91 3.93 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.492 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -97.34 136.58 12.83 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.473 -179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 19.3 tttp -124.83 139.2 54.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.77 0.319 . . . . 0.0 110.925 179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.3 p -123.17 139.62 49.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.149 179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.535 HG22 ' CE1' ' A' ' 139' ' ' TYR . 6.3 m -89.91 152.71 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 7.9 mt -128.68 160.92 30.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -87.59 172.72 9.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.848 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.56 -19.99 0.39 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 58.1 p -89.45 -29.76 18.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.131 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 111.8 10.77 18.19 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.489 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 33.8 m -98.92 136.49 29.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.79 0.329 . . . . 0.0 111.159 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.6 t -43.23 105.78 0.06 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.88 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.505 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 26.0 mtmt -50.58 -32.98 20.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.918 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 123.58 19.9 2.72 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.548 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.535 ' CE1' HG22 ' A' ' 129' ' ' VAL . 13.9 p90 -163.83 168.77 19.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.952 0.406 . . . . 0.0 110.914 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.53 -160.88 18.8 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.522 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.4 m-85 -153.97 144.16 22.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.848 0.356 . . . . 0.0 110.918 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 20.6 m -120.97 174.02 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.144 179.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -132.93 163.75 28.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.869 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -149.79 159.78 44.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.923 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 14.0 p -90.34 -39.37 12.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -109.23 132.04 54.49 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.87 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -72.27 -38.3 68.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.923 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 30.2 mt -48.78 -34.06 11.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.923 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -87.83 -37.27 16.69 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.905 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 22.4 tt0 -41.61 -48.39 4.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.947 -179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 47.2 mttt -71.7 -32.22 67.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.864 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.576 ' HB3' ' CE1' ' A' ' 120' ' ' TYR . 0.6 OUTLIER -52.67 -39.45 61.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.841 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.499 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.86 -46.57 71.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.129 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . . . . . . . . . 17.0 mt -40.36 -43.68 1.81 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 -179.991 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.47 HG21 ' N ' ' A' ' 156' ' ' GLU . 14.6 t -92.7 -50.63 5.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.124 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.47 ' N ' HG21 ' A' ' 155' ' ' THR . 76.9 mm-40 -62.51 -57.63 10.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.914 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.499 ' N ' ' O ' ' A' ' 153' ' ' ALA . 24.7 m -83.2 20.53 1.25 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.824 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . 0.419 ' OE1' ' N ' ' A' ' 159' ' ' GLY . 2.0 tp-100 -64.71 131.89 48.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.9 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . 0.419 ' N ' ' OE1' ' A' ' 158' ' ' GLN . . . 47.09 29.69 4.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.479 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -50.12 119.23 3.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.827 0.346 . . . . 0.0 111.112 179.989 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.427 ' O ' ' C ' ' A' ' 162' ' ' GLY . 37.5 t -88.12 -36.75 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.134 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -35.97 -38.59 0.23 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.492 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.458 ' CD2' HD13 ' A' ' 112' ' ' LEU . 20.0 tp -89.08 118.84 29.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.866 0.365 . . . . 0.0 110.918 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 64.91 153.49 0.11 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.487 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 16.7 t -55.66 -23.8 30.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.962 0.41 . . . . 0.0 110.839 -179.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 58.8 mttt -109.24 154.95 41.84 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.572 0.701 . . . . 0.0 110.908 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 171.23 14.89 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.7 2.267 . . . . 0.0 112.34 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 16.4 m -121.18 125.84 74.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.085 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 35.1 ttt-85 -88.71 103.27 15.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.411 HD12 ' C ' ' A' ' 157' ' ' CYS . 11.7 mt -80.64 148.61 30.17 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.857 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 3.2 m -160.75 177.61 10.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.917 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 21.2 t -99.36 96.83 5.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.116 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -93.09 172.47 8.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.082 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . 0.426 ' CG2' ' HD2' ' A' ' 175' ' ' PRO . 83.4 mt -125.68 137.71 30.51 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.604 0.716 . . . . 0.0 111.135 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.426 ' HD2' ' CG2' ' A' ' 174' ' ' ILE . 54.0 Cg_endo -69.7 174.86 8.83 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.665 2.243 . . . . 0.0 112.377 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 38.9 tptt -45.82 118.54 1.87 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.868 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -68.56 145.98 53.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.077 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 50.6 m -105.68 -50.32 3.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.864 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 6.6 tpm_? 40.78 50.26 2.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.884 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 7.2 p -117.22 155.19 18.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.122 179.997 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 9.1 tppt? -143.08 134.65 12.88 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.623 0.725 . . . . 0.0 110.843 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 85.56 0.61 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.684 2.256 . . . . 0.0 112.325 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 67.1 t -134.14 107.89 10.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.094 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 6.6 tp10 -130.68 133.9 46.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.927 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.6 m -115.74 157.84 23.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.84 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 120.96 86.64 0.91 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.503 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 138.29 37.5 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.643 2.229 . . . . 0.0 112.363 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 31.1 t -95.64 -49.4 5.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.864 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 44.7 t -98.54 150.68 21.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.88 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.527 -179.96 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 47.9 t -123.54 103.07 8.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.93 0.395 . . . . 0.0 110.884 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.4 t -166.43 146.01 5.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.889 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -90.06 113.33 4.19 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.512 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 47.4 p -170.37 141.34 1.98 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.886 0.374 . . . . 0.0 110.88 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 70.1 p -135.59 118.47 16.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.84 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -118.57 -161.31 11.77 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.517 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 125.21 11.89 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.722 2.282 . . . . 0.0 112.36 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 25.0 pm0 -65.28 154.28 38.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.853 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . 0.529 ' CD1' ' HG3' ' A' ' 147' ' ' GLU . 63.5 m-85 -127.76 104.04 7.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.924 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 66.3 p -112.81 154.58 26.04 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.855 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 33.5 mt -124.79 142.4 51.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.907 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -91.25 132.88 35.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.899 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 18.9 m -126.02 151.82 32.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.128 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -141.72 -179.62 18.97 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.5 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 57.76 38.84 27.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.841 0.353 . . . . 0.0 110.905 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.412 HD11 ' C ' ' A' ' 139' ' ' TYR . 31.2 mt -86.51 108.83 18.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 81.9 p -53.82 150.25 14.62 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.612 0.72 . . . . 0.0 111.144 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 2.21 3.74 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.706 2.271 . . . . 0.0 112.337 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 19.0 t0 -102.02 -3.17 28.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . 0.422 ' CG1' ' HE1' ' A' ' 111' ' ' MET . 41.3 t -103.68 145.08 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.141 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -129.18 179.68 5.63 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -60.34 -37.86 81.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.881 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.43 -33.23 39.51 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.47 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' MET . . . . . 0.422 ' HE1' ' CG1' ' A' ' 107' ' ' VAL . 27.3 mtm -86.85 -46.91 9.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.842 0.353 . . . . 0.0 110.886 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.439 HD23 ' N ' ' A' ' 127' ' ' LYS . 18.1 tp -53.34 -23.03 8.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.929 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.491 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 13.0 t80 -82.63 -61.75 1.8 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.926 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.458 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 22.4 mt-10 -57.23 -46.58 82.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.867 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . 0.477 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 75.6 t80 -47.68 -33.23 6.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.463 ' O ' ' N ' ' A' ' 118' ' ' LYS . 7.6 m-85 -95.28 -66.98 0.88 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.861 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.458 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.73 -30.97 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.132 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.463 ' N ' ' O ' ' A' ' 116' ' ' PHE . 59.2 tttt -67.31 -60.61 2.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.903 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.7 p -64.65 -27.15 41.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.114 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 92.6 m-85 -137.94 115.89 9.57 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.7 0.762 . . . . 0.0 110.906 -179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -2.77 10.7 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.751 2.301 . . . . 0.0 112.336 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 73.2 m -99.25 32.28 2.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.854 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . 0.43 ' CB ' ' HA ' ' A' ' 117' ' ' VAL . 19.6 t -94.51 135.2 36.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.881 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 16.8 mtp180 -93.17 -39.0 11.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.867 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.491 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 163.56 149.43 5.73 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -102.9 134.27 11.75 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.518 -179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.439 ' N ' HD23 ' A' ' 112' ' ' LEU . 4.3 tppp? -123.21 137.56 54.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.806 0.336 . . . . 0.0 110.925 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.4 p -124.69 129.4 73.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.126 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.562 HG22 ' CD1' ' A' ' 139' ' ' TYR . 22.5 m -75.18 150.49 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.085 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 14.9 mt -127.03 174.91 8.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.925 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -103.18 178.27 4.6 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.846 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 25.3 tt0 -45.28 -43.08 10.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.905 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 27.8 p -74.68 -25.04 58.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.167 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 107.88 17.67 10.8 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.475 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 28.8 m -95.9 134.31 33.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.872 0.368 . . . . 0.0 111.126 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.8 t -44.18 107.2 0.08 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.863 -179.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.497 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.7 mtmt -52.75 -32.36 42.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.902 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.7 18.74 2.63 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.482 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.562 ' CD1' HG22 ' A' ' 129' ' ' VAL . 23.4 p90 -163.14 168.25 21.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.981 0.42 . . . . 0.0 110.9 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -170.74 -165.18 27.68 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.478 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -150.88 146.99 26.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.869 0.366 . . . . 0.0 110.893 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.483 HG21 ' CE2' ' A' ' 144' ' ' PHE . 17.8 m -119.2 179.32 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.113 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 31.3 mttt -138.53 160.35 39.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.899 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.483 ' CE2' HG21 ' A' ' 142' ' ' VAL . 96.2 m-85 -148.34 161.99 40.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.855 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 44.0 p -101.88 -12.34 18.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.099 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.443 ' CG ' ' OE1' ' A' ' 149' ' ' GLU . 14.3 t0 -129.61 130.04 45.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.857 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.529 ' HG3' ' CD1' ' A' ' 96' ' ' TYR . 20.0 tt0 -71.83 -43.23 65.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 37.2 mt -45.23 -49.21 12.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.954 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.443 ' OE1' ' CG ' ' A' ' 146' ' ' ASP . 3.6 mp0 -72.8 -44.05 61.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.855 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 149' ' ' GLU . 17.4 tt0 -36.97 -55.28 0.93 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.932 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 13.7 mttm -64.48 -52.59 57.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 28.4 mtt180 -39.41 -33.29 0.15 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.853 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.448 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -73.98 -49.93 22.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.133 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . . . . . . . . . 33.9 mt -43.34 -38.36 2.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.912 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.467 HG22 ' N ' ' A' ' 156' ' ' GLU . 9.8 t -91.03 -48.3 7.06 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.167 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.467 ' N ' HG22 ' A' ' 155' ' ' THR . 53.1 mt-10 -69.56 -64.58 0.85 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.9 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.448 ' N ' ' O ' ' A' ' 153' ' ' ALA . 54.1 m -62.82 -8.3 6.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.905 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -40.5 140.95 0.59 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 37.66 45.6 1.48 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.465 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -64.18 115.09 4.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.802 0.334 . . . . 0.0 111.129 179.928 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.0 t -84.88 -35.57 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.143 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -43.06 -34.44 2.06 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.453 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.477 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 19.2 tp -91.81 115.82 28.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.866 0.365 . . . . 0.0 110.922 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 166' ' ' LYS . . . 64.55 138.48 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.497 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 t -41.05 -27.92 0.07 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.944 0.402 . . . . 0.0 110.838 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . 0.401 ' N ' ' O ' ' A' ' 164' ' ' GLY . 57.5 mttt -103.78 154.67 37.83 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.526 0.679 . . . . 0.0 110.924 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.69 173.15 11.33 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.7 2.266 . . . . 0.0 112.413 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 21.1 m -124.45 131.27 73.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.127 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 43.4 ttt180 -94.84 105.01 16.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.92 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.44 HD12 ' CB ' ' A' ' 157' ' ' CYS . 13.3 mt -82.66 148.87 27.69 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.933 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.0 m -158.72 -177.87 6.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.9 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 4.4 t -108.83 102.15 13.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.145 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -86.55 138.34 31.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.07 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 74.6 mt -88.11 122.96 69.58 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.597 0.713 . . . . 0.0 111.131 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -34.67 14.06 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.648 2.232 . . . . 0.0 112.341 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 10.6 tmtt? -123.68 109.55 13.85 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.894 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -124.94 127.08 46.49 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.105 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 4.2 t -78.96 83.57 5.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.84 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . 0.495 ' CD ' ' O ' ' A' ' 179' ' ' ARG . 0.0 OUTLIER -66.66 114.64 5.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.882 -179.965 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 81.3 t -132.07 135.27 58.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.132 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.4 ' C ' ' HD3' ' A' ' 181' ' ' LYS . 0.0 OUTLIER -116.83 142.86 30.42 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.542 0.687 . . . . 0.0 110.904 179.916 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 144.48 54.17 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.662 2.241 . . . . 0.0 112.369 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 97.0 t -117.63 135.92 56.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.116 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -150.25 121.98 8.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.882 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 2.8 m -149.19 161.92 41.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -176.61 69.27 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.47 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -24.25 29.75 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.641 2.227 . . . . 0.0 112.307 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 89.2 p -53.12 146.54 11.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.797 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.9 m -165.03 152.85 11.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.842 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.49 -179.956 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.515 -0.234 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 4.8 t 67.76 42.05 2.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.868 0.366 . . . . 0.0 110.87 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 57.1 m -81.55 -60.63 2.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.837 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 95.11 54.55 1.47 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.488 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 91.1 p -38.76 129.23 1.52 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.937 0.399 . . . . 0.0 110.814 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 36.4 p -123.38 163.2 21.26 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.867 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -132.0 -77.98 0.15 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.471 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 157.88 58.86 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.685 2.257 . . . . 0.0 112.363 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -84.57 161.99 19.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.884 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -127.93 99.73 5.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.934 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.0 p -117.13 146.26 43.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.859 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 46.3 mt -110.43 150.4 28.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.906 -179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 4.9 t80 -96.34 127.23 42.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.852 179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.8 m -119.42 146.05 24.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.15 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.84 -177.99 15.9 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.463 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 52.85 51.57 15.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.88 0.371 . . . . 0.0 110.877 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 30.1 mt -98.04 118.52 34.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.936 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p -61.97 151.54 79.9 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.587 0.708 . . . . 0.0 111.094 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -0.02 6.29 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.718 2.278 . . . . 0.0 112.333 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -99.46 -0.24 41.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . 0.46 ' HA ' ' CE ' ' A' ' 111' ' ' MET . 26.5 t -111.09 147.68 14.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.096 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -131.83 -178.81 5.05 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.885 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.64 -37.78 85.28 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.78 -26.93 26.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.52 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' MET . . . . . 0.46 ' CE ' ' HA ' ' A' ' 107' ' ' VAL . 34.3 mtm -93.8 -39.29 10.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 0.0 110.919 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.464 HD23 ' N ' ' A' ' 127' ' ' LYS . 49.3 tp -55.86 -30.41 61.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.938 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.496 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 22.5 t80 -78.8 -63.86 1.31 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.947 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.449 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 17.0 mt-10 -53.54 -36.31 61.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.886 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . . . . . . . . . 67.6 t80 -58.09 -34.2 69.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.88 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.501 ' O ' ' N ' ' A' ' 118' ' ' LYS . 10.2 m-85 -95.25 -62.74 1.25 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.875 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.449 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -38.44 -26.39 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.115 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.501 ' N ' ' O ' ' A' ' 116' ' ' PHE . 18.2 tttm -71.05 -60.73 2.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.911 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.561 HG22 ' CE2' ' A' ' 120' ' ' TYR . 3.7 p -67.62 -25.79 33.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.165 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.561 ' CE2' HG22 ' A' ' 119' ' ' VAL . 92.2 m-85 -136.09 112.26 10.31 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.633 0.73 . . . . 0.0 110.95 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 2.81 3.18 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.672 2.248 . . . . 0.0 112.343 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 32.0 m -105.44 27.9 7.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.853 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 36.8 t -89.0 124.73 34.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.857 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.467 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 14.0 mtp180 -79.21 -42.8 25.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.862 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.496 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 168.52 159.56 14.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.507 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -114.7 134.87 11.95 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.497 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.464 ' N ' HD23 ' A' ' 112' ' ' LEU . 3.5 tppp? -130.13 132.69 46.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.838 0.352 . . . . 0.0 110.878 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.2 p -118.1 129.7 74.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.558 HG12 ' CE1' ' A' ' 139' ' ' TYR . 23.8 m -73.76 144.98 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.083 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.417 ' HB3' ' C ' ' A' ' 134' ' ' GLY . 46.4 mt -123.9 162.3 23.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.903 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.424 ' CG ' ' HG2' ' A' ' 137' ' ' LYS . 3.0 m-20 -93.33 -178.25 4.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -40.75 -59.05 1.49 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.955 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -62.36 -30.83 71.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 -179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.417 ' C ' ' HB3' ' A' ' 130' ' ' LEU . . . 116.65 0.54 20.01 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.498 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 3.5 m -73.43 141.12 16.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.787 0.327 . . . . 0.0 111.126 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.2 t -50.27 113.83 0.97 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 -179.889 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.457 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 22.1 mtmt -58.76 -30.72 67.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.916 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 120.13 17.26 4.56 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.512 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.558 ' CE1' HG12 ' A' ' 129' ' ' VAL . 19.0 p90 -163.29 167.96 21.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.985 0.422 . . . . 0.0 110.864 -179.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -171.56 -162.48 23.91 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.51 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -153.3 139.9 18.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.893 0.378 . . . . 0.0 110.88 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.4 m -110.75 176.85 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . 0.467 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 47.8 mttt -133.35 156.72 47.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.878 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -148.57 152.57 37.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 25.3 p -96.0 -24.96 16.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.147 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -115.06 103.55 11.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.837 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 15.2 tm-20 -48.51 -47.23 39.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.914 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 65.6 mt -39.68 -44.35 1.51 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.935 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -72.48 -40.65 66.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.918 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 24.9 tt0 -40.36 -60.6 1.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 14.4 mttm -62.51 -44.78 95.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 57.6 mtt180 -48.0 -42.64 28.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.904 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.459 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -69.15 -45.19 70.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . . . . . . . . . 13.8 mt -43.52 -41.38 4.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.952 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.444 HG22 ' N ' ' A' ' 156' ' ' GLU . 6.0 t -92.46 -41.64 10.18 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.444 ' N ' HG22 ' A' ' 155' ' ' THR . 21.6 mm-40 -70.04 -63.59 1.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.868 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.459 ' N ' ' O ' ' A' ' 153' ' ' ALA . 20.9 m -70.82 -0.32 8.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . 0.438 ' N ' HD13 ' A' ' 170' ' ' LEU . 2.6 tp-100 -43.69 129.79 5.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 55.45 33.78 59.1 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.495 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.402 ' CB ' ' CG2' ' A' ' 168' ' ' VAL . . . -48.64 116.58 1.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.799 0.333 . . . . 0.0 111.062 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.7 t -93.85 -31.39 4.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.138 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -46.29 -31.64 4.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.517 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 20.4 tp -91.37 115.7 28.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.851 0.358 . . . . 0.0 110.923 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.0 159.92 0.97 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.493 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 m -61.95 -19.68 63.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.959 0.409 . . . . 0.0 110.883 -179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 35.0 mttm -111.13 153.53 43.9 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.559 0.695 . . . . 0.0 110.89 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 171.79 13.85 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.659 2.239 . . . . 0.0 112.371 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.402 ' CG2' ' CB ' ' A' ' 160' ' ' ALA . 22.2 m -127.22 125.06 65.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.119 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.5 ttt180 -86.42 111.68 20.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.851 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.438 HD13 ' N ' ' A' ' 158' ' ' GLN . 14.7 mt -87.16 139.95 30.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.2 m -152.74 178.17 9.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.823 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 2.8 t -100.73 96.15 4.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -80.66 168.98 18.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.128 179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 58.0 mt -143.14 120.86 7.0 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.582 0.706 . . . . 0.0 111.106 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -41.02 4.63 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.687 2.258 . . . . 0.0 112.348 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 26.7 mmtm -109.36 71.29 0.76 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -76.47 -33.98 58.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.092 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 83.1 p -98.4 56.64 1.16 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.853 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 8.2 ttp85 -95.96 75.17 3.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.893 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 86.8 t -115.94 108.18 24.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.088 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 4.2 mmpt? -134.46 153.02 78.95 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.605 0.717 . . . . 0.0 110.905 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 134.99 29.28 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.697 2.265 . . . . 0.0 112.358 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 98.5 t -69.38 87.68 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.125 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . 0.461 ' C ' ' CD ' ' A' ' 184' ' ' GLU . 0.6 OUTLIER -85.36 153.73 22.35 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.924 -179.993 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 76.3 p -147.31 164.46 33.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.85 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -97.75 146.05 18.07 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.525 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 139.68 40.55 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.714 2.276 . . . . 0.0 112.316 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 1.4 t -140.6 154.52 46.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.849 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.0 m -81.07 144.46 31.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.828 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.529 179.953 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.4 t -66.83 128.39 36.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.877 0.37 . . . . 0.0 110.864 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 72.9 m -131.59 133.89 45.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.874 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -171.04 81.37 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.497 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 83.7 p -97.55 91.86 5.64 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.857 0.36 . . . . 0.0 110.853 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.8 m -158.74 142.54 15.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.886 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -117.82 72.67 0.29 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.485 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 150.87 68.73 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.654 2.236 . . . . 0.0 112.319 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -72.16 154.24 41.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.876 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . 0.441 ' CD1' ' HG3' ' A' ' 147' ' ' GLU . 32.4 m-85 -130.29 124.06 31.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.932 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 52.6 p -138.52 159.66 41.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.9 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.451 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . 79.5 mt -124.84 147.73 48.61 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -94.03 120.6 34.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.902 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 31.2 m -114.04 145.41 19.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -133.67 -174.02 13.41 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.494 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 46.91 50.88 13.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.841 0.353 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 20.4 mt -96.05 99.07 10.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.954 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 23.9 p -48.79 151.57 2.08 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.597 0.713 . . . . 0.0 111.122 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 1.56 4.32 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.694 2.262 . . . . 0.0 112.326 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -100.99 10.38 41.17 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.851 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . 0.403 ' HA ' ' CE ' ' A' ' 111' ' ' MET . 3.9 t -121.57 147.03 25.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.1 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -132.77 178.52 6.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.873 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -56.18 -40.07 73.39 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -49.28 -40.18 29.41 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' MET . . . . . 0.403 ' CE ' ' HA ' ' A' ' 107' ' ' VAL . 36.1 mtm -82.57 -39.73 21.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.835 0.35 . . . . 0.0 110.876 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.46 HD21 ' N ' ' A' ' 127' ' ' LYS . 28.3 tp -57.71 -28.11 63.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.414 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.2 t80 -81.77 -60.02 2.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.92 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.45 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 20.7 mt-10 -56.13 -47.43 78.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . 0.425 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 62.8 t80 -48.79 -33.64 10.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.917 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.484 ' CE2' HG12 ' A' ' 142' ' ' VAL . 7.5 m-85 -94.41 -66.12 0.94 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.873 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.45 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.71 -30.43 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.15 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.472 ' N ' ' O ' ' A' ' 116' ' ' PHE . 20.2 ttpp -65.84 -59.37 3.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.941 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.405 HG12 ' N ' ' A' ' 120' ' ' TYR . 3.6 p -67.13 -34.21 68.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.172 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.42 ' CE2' ' HB1' ' A' ' 153' ' ' ALA . 92.8 m-85 -130.06 112.01 17.1 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.662 0.744 . . . . 0.0 110.96 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 1.39 4.46 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.679 2.252 . . . . 0.0 112.352 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -99.05 19.9 14.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.828 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 38.8 t -82.01 132.8 35.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.875 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.461 ' NE ' HG21 ' A' ' 145' ' ' THR . 46.1 mtt-85 -89.52 -41.92 11.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.868 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.414 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 168.94 150.35 6.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.468 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -103.18 142.34 15.48 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.517 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.46 ' N ' HD21 ' A' ' 112' ' ' LEU . 12.1 tptm -136.95 132.71 34.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.869 0.366 . . . . 0.0 110.868 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 3.0 p -120.72 129.26 75.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.454 HG23 ' CE1' ' A' ' 139' ' ' TYR . 23.5 m -72.41 142.88 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.107 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 11.5 mt -127.7 163.97 23.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.936 -179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.444 ' OD1' ' C ' ' A' ' 131' ' ' ASP . 0.6 OUTLIER -97.89 -175.08 3.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.839 179.865 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 44.5 tt0 -49.09 -48.67 44.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 21.5 p -65.91 -23.2 66.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.147 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.46 22.57 18.72 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 30.1 m -102.93 131.27 51.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.8 0.334 . . . . 0.0 111.138 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.4 t -39.45 116.83 0.65 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.864 -179.813 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.1 mtmt -63.17 -28.17 69.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.914 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 123.98 14.34 3.8 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.506 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.454 ' CE1' HG23 ' A' ' 129' ' ' VAL . 17.9 p90 -162.2 170.82 18.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.939 0.399 . . . . 0.0 110.921 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -172.71 -160.79 21.98 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.507 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -153.85 143.72 21.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.867 0.365 . . . . 0.0 110.861 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.484 HG12 ' CE2' ' A' ' 116' ' ' PHE . 14.7 m -115.39 -176.68 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.123 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 13.8 mttp -141.55 153.02 44.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 88.7 m-85 -146.48 128.82 15.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.88 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' THR . . . . . 0.461 HG21 ' NE ' ' A' ' 124' ' ' ARG . 36.7 p -66.5 -12.7 58.8 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.162 -179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -126.54 135.21 51.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.868 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.441 ' HG3' ' CD1' ' A' ' 96' ' ' TYR . 29.7 tt0 -79.08 -34.17 43.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.887 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 38.9 mt -53.98 -60.2 3.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.911 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -65.09 -38.45 90.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.446 ' NE2' HD22 ' A' ' 98' ' ' LEU . 1.4 tm0? -48.06 -42.55 28.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.888 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 34.7 mmtm -77.85 -26.94 49.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 27.1 mtt180 -65.09 -37.48 87.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.855 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.454 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -66.12 -36.04 82.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.104 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.466 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 28.1 mt -52.49 -41.49 63.43 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.934 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.469 HG23 ' N ' ' A' ' 156' ' ' GLU . 8.8 t -91.86 -36.42 13.51 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.176 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.469 ' N ' HG23 ' A' ' 155' ' ' THR . 16.0 mm-40 -76.24 -62.54 1.58 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.877 179.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.454 ' N ' ' O ' ' A' ' 153' ' ' ALA . 10.5 m -71.79 0.54 8.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . 0.466 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.0 tp-100 -43.17 136.14 3.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.9 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 45.93 30.16 3.59 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.475 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.416 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -49.79 112.31 0.64 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.828 0.347 . . . . 0.0 111.115 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 18.8 t -87.18 -33.84 7.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.84 -31.13 1.09 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.463 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.425 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 28.4 tp -90.17 109.43 20.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.882 0.372 . . . . 0.0 110.919 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 71.53 168.05 9.02 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.471 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 39.5 m -66.24 -23.1 66.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.918 0.39 . . . . 0.0 110.863 -179.722 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 58.9 mttm -110.29 155.81 41.29 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.632 0.73 . . . . 0.0 110.873 179.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.85 -176.85 1.65 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.676 2.25 . . . . 0.0 112.325 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.416 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 28.6 m -135.04 128.28 49.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.131 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 12.5 ttp180 -91.99 94.16 9.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.835 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.417 HD13 ' N ' ' A' ' 158' ' ' GLN . 10.6 mt -72.14 152.64 42.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.418 ' N ' ' CD2' ' A' ' 154' ' ' LEU . 0.9 OUTLIER -167.01 178.32 5.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.891 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 45.5 t -103.79 99.45 8.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -78.74 137.92 37.99 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.086 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 72.4 mt -142.93 124.98 8.68 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.611 0.72 . . . . 0.0 111.12 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 -166.56 0.19 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.667 2.245 . . . . 0.0 112.37 179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . 0.439 ' CD ' ' O ' ' A' ' 176' ' ' LYS . 0.4 OUTLIER -53.15 120.77 6.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.909 179.893 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -103.47 -45.71 4.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.124 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 87.9 p -154.8 166.19 34.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.864 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 17.8 mmm180 45.53 39.4 4.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.894 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 12.7 p -49.89 -22.72 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.101 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.415 ' C ' ' HD2' ' A' ' 181' ' ' LYS . 0.7 OUTLIER -173.13 143.87 1.12 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.566 0.698 . . . . 0.0 110.89 179.953 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 140.54 42.69 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.659 2.24 . . . . 0.0 112.341 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 7.5 p -148.16 109.28 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.138 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -134.82 122.05 21.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.895 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 67.1 m -133.64 132.35 40.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.889 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 118.81 151.55 9.03 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.527 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 139.88 41.59 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.672 2.248 . . . . 0.0 112.373 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 188' ' ' SER . . . . . 0.434 ' O ' ' C ' ' A' ' 189' ' ' SER . 6.9 t -75.11 -47.49 28.39 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.842 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 189' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 188' ' ' SER . 17.4 p 35.41 44.82 0.19 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.841 -179.877 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.286 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.513 -179.96 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.456 -0.257 . . . . 0.0 112.456 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 72.8 p -114.01 41.52 2.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.85 0.357 . . . . 0.0 110.844 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 77.7 p 40.21 41.61 1.02 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.846 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -84.28 -51.45 3.93 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.494 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 4.4 m -101.32 102.79 13.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.905 0.383 . . . . 0.0 110.821 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 22.7 t -49.87 162.23 0.2 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.83 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -123.18 -156.62 9.62 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.522 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 157.86 58.87 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.638 2.225 . . . . 0.0 112.366 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -65.61 166.32 10.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.93 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 19.5 m-85 -124.72 100.37 6.59 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.928 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 45.9 m -118.69 146.55 44.62 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.86 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 68.3 mt -113.53 153.36 28.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.921 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -100.77 123.05 44.41 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.848 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 23.1 m -114.38 145.8 19.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.114 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.11 -176.75 14.51 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.513 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 48.78 52.06 14.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.827 0.346 . . . . 0.0 110.879 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 28.7 mt -98.24 105.89 18.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.879 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 25.1 p -50.6 150.63 4.73 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.582 0.705 . . . . 0.0 111.158 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 3.16 2.95 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.665 2.243 . . . . 0.0 112.316 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -98.38 -13.33 20.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.881 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 41.4 t -98.21 134.46 36.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.151 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.25 175.88 5.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.828 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -53.37 -44.79 68.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.858 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.96 -29.07 7.98 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.499 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' MET . . . . . . . . . . . . . 22.3 mtp -86.88 -59.47 2.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.788 0.328 . . . . 0.0 110.873 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 15.8 tp -40.18 -41.06 1.22 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.898 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.421 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 12.9 t80 -62.65 -67.17 0.44 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.966 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.455 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 30.3 mt-10 -52.52 -55.52 21.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.927 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . 0.42 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 57.2 t80 -41.49 -32.28 0.33 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.896 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.498 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.0 m-85 -95.14 -67.53 0.85 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.883 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.455 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -37.65 -27.58 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.103 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.498 ' N ' ' O ' ' A' ' 116' ' ' PHE . 20.1 tptt -67.57 -57.87 5.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.885 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.3 p -71.56 -32.73 46.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.175 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.555 ' CE2' ' HB2' ' A' ' 153' ' ' ALA . 97.0 m-85 -126.3 108.04 24.09 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.622 0.725 . . . . 0.0 110.954 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 2.44 3.53 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.667 2.245 . . . . 0.0 112.339 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 47.6 p -95.0 -10.33 31.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 10.0 t -57.09 142.65 41.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.887 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 61.7 mtp180 -104.46 -34.1 8.36 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.88 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.421 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 166.72 145.99 4.68 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.453 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -96.35 139.25 14.39 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.477 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 46.6 tptt -125.28 127.73 47.15 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.87 0.366 . . . . 0.0 110.866 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.1 p -117.72 141.28 37.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.555 HG23 ' CD1' ' A' ' 139' ' ' TYR . 33.2 m -92.73 145.33 7.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.096 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 23.4 mt -123.8 179.09 4.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.888 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 11.1 t0 -108.96 -178.96 3.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.875 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -53.57 -18.9 3.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.917 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 43.6 p -93.61 -27.27 16.69 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.163 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 107.52 17.29 11.47 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.476 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 19.1 m -100.05 139.27 21.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 0.0 111.112 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.5 t -49.76 100.34 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.506 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.4 mtmt -42.97 -36.09 1.44 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.877 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 128.35 16.97 2.03 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.548 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.555 ' CD1' HG23 ' A' ' 129' ' ' VAL . 28.1 p90 -161.07 172.07 17.47 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.901 0.381 . . . . 0.0 110.96 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -174.94 -163.23 27.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.475 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -153.76 145.58 23.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.861 0.363 . . . . 0.0 110.863 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.427 HG12 ' CE2' ' A' ' 116' ' ' PHE . 29.3 m -119.6 -177.74 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.087 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 32.8 mttm -142.16 156.73 45.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -145.87 163.43 35.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 29.2 p -101.1 -19.88 15.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.129 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -117.02 120.47 38.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.825 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -65.45 -33.55 76.21 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.948 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 44.6 mt -57.71 -40.57 79.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.931 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.462 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 38.6 mt-10 -76.28 -38.53 56.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.829 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 22.0 tt0 -44.95 -48.43 11.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.869 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 5.1 mmmm -73.57 -37.37 65.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.407 ' O ' ' CG ' ' A' ' 156' ' ' GLU . 9.1 mtt-85 -56.25 -34.23 66.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.892 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.555 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -72.0 -46.2 58.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.487 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 48.6 mt -44.36 -40.98 5.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 14.9 t -92.33 -42.54 9.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.165 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.407 ' CG ' ' O ' ' A' ' 152' ' ' ARG . 25.6 mm-40 -68.96 -64.87 0.79 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.433 ' CB ' HD12 ' A' ' 170' ' ' LEU . 10.4 m -70.11 -1.68 10.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.893 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . 0.487 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.8 tp-100 -42.48 141.95 0.9 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.891 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 158' ' ' GLN . . . 35.51 34.29 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.502 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.428 ' N ' ' O ' ' A' ' 158' ' ' GLN . . . -58.49 110.65 1.02 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.769 0.319 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.41 ' O ' ' C ' ' A' ' 162' ' ' GLY . 22.9 t -79.27 -34.27 16.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.121 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.65 -36.23 0.15 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.464 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.42 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 25.2 tp -92.72 115.17 27.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.85 0.357 . . . . 0.0 110.885 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.77 146.85 0.13 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.495 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 m -50.81 -21.09 1.5 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.966 0.413 . . . . 0.0 110.855 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 36.5 mttm -109.08 156.05 39.86 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.595 0.712 . . . . 0.0 110.903 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 171.84 13.74 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.699 2.266 . . . . 0.0 112.295 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 35.4 m -125.34 127.6 72.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.185 179.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 17.7 ttt180 -91.54 107.82 19.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.433 HD12 ' CB ' ' A' ' 157' ' ' CYS . 14.4 mt -84.4 143.39 29.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.932 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 15.2 m -154.6 171.41 19.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.881 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 3.0 t -101.0 100.6 10.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.112 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -82.37 140.12 33.68 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.136 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 41.5 mt -119.18 120.98 30.62 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.668 0.747 . . . . 0.0 111.131 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 1.4 4.5 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.704 2.269 . . . . 0.0 112.312 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 17.7 mmmt -102.83 -42.09 5.97 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.883 179.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -47.31 134.24 11.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.117 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 68.7 m -96.26 90.5 5.49 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.884 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 3.5 tmm_? -95.42 74.44 3.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.852 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 71.4 t -115.39 107.09 21.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.119 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 34.9 mmtt -66.11 142.25 97.84 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.561 0.696 . . . . 0.0 110.93 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 162.64 41.29 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.678 2.252 . . . . 0.0 112.395 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 92.9 t -134.95 109.99 12.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.142 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -136.73 120.34 17.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 11.6 m -58.49 -54.26 49.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.849 -179.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 49.92 73.01 0.4 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.478 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 117.85 5.33 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.682 2.255 . . . . 0.0 112.329 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 5.2 m -90.34 169.79 10.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.831 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 36.4 m -156.49 152.83 27.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.889 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.482 -179.954 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.2 t -116.62 140.16 49.71 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.842 0.353 . . . . 0.0 110.903 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 57.8 m -98.4 -49.38 4.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.851 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 148.2 -93.11 0.15 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.474 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 20.3 t -115.1 86.06 2.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.857 0.36 . . . . 0.0 110.876 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 33.3 p -172.37 136.61 0.81 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.847 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 147.68 168.0 13.77 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.469 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 147.81 63.68 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.68 2.254 . . . . 0.0 112.333 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 26.3 mp0 -83.41 162.11 21.12 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.9 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -131.79 93.74 3.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.934 -179.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.8 m -112.33 147.19 36.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.839 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.518 HD11 ' CE1' ' A' ' 144' ' ' PHE . 92.2 mt -115.75 155.99 26.79 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.412 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 8.6 t80 -104.6 127.49 52.35 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.856 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.4 m -116.55 155.28 18.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -142.59 178.12 21.26 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.485 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 52.87 50.28 18.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.874 0.369 . . . . 0.0 110.898 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 29.1 mt -96.9 103.44 15.37 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.899 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 17.4 p -47.94 150.16 2.1 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 121.617 0.723 . . . . 0.0 111.152 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 2.98 3.03 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.623 2.215 . . . . 0.0 112.375 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.34 16.34 26.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . 0.456 ' HA ' ' CE ' ' A' ' 111' ' ' MET . 59.5 t -129.62 142.17 44.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.109 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -128.95 -177.6 4.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.817 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -58.18 -47.98 81.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.848 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -42.26 -35.1 1.72 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.48 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' MET . . . . . 0.456 ' CE ' ' HA ' ' A' ' 107' ' ' VAL . 26.0 mtm -86.03 -45.72 11.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.823 0.344 . . . . 0.0 110.884 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.455 HD22 ' N ' ' A' ' 127' ' ' LYS . 16.0 tp -53.5 -33.45 54.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.496 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 9.8 t80 -68.71 -61.62 1.74 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.45 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 22.2 mt-10 -57.76 -51.78 68.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.901 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . 0.536 ' CE1' ' HB2' ' A' ' 163' ' ' LEU . 66.5 t80 -44.1 -32.34 1.17 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.876 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.483 ' O ' ' N ' ' A' ' 118' ' ' LYS . 7.7 m-85 -95.25 -67.52 0.85 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.45 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.83 -29.35 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.158 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.483 ' N ' ' O ' ' A' ' 116' ' ' PHE . 22.9 ttpp -66.31 -58.31 5.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.901 179.883 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.411 HG11 ' N ' ' A' ' 120' ' ' TYR . 3.6 p -67.41 -33.0 59.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.124 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.482 ' CD1' ' HB3' ' A' ' 149' ' ' GLU . 89.4 m-85 -129.12 113.31 18.5 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.683 0.754 . . . . 0.0 110.944 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -0.05 6.35 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.722 2.281 . . . . 0.0 112.353 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 69.0 m -105.22 35.41 2.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.864 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 3.0 t -98.09 138.59 35.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.907 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 44.8 mtp85 -93.6 -38.06 11.55 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.857 -179.839 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.496 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 159.22 141.72 3.21 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.491 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.455 ' CA ' HD22 ' A' ' 112' ' ' LEU . . . -90.41 138.04 14.25 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.44 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.455 ' N ' HD22 ' A' ' 112' ' ' LEU . 20.2 tptm -122.05 128.28 51.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.81 0.338 . . . . 0.0 110.9 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.9 p -114.86 135.64 54.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.508 HG22 ' CD1' ' A' ' 139' ' ' TYR . 32.9 m -84.71 145.98 7.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.092 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.413 ' HB3' ' C ' ' A' ' 134' ' ' GLY . 31.1 mt -126.69 -179.66 4.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.849 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.48 ' O ' ' N ' ' A' ' 134' ' ' GLY . 2.2 t70 -118.69 -176.0 3.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.891 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -38.35 -61.38 0.69 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.887 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -60.92 -24.84 66.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.148 -179.898 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.48 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 105.16 4.45 41.27 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.502 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 5.3 m -77.24 145.2 10.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.811 0.339 . . . . 0.0 111.168 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.1 t -56.93 113.9 1.87 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.501 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 30.0 mtmt -56.73 -31.65 64.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.885 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.21 17.71 2.95 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.484 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.508 ' CD1' HG22 ' A' ' 129' ' ' VAL . 28.0 p90 -162.55 174.8 12.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.964 0.412 . . . . 0.0 110.889 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -178.29 -162.42 28.01 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.485 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.412 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 4.5 m-85 -153.98 146.18 23.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.953 0.406 . . . . 0.0 110.858 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.483 HG12 ' CE2' ' A' ' 116' ' ' PHE . 17.8 m -116.87 -176.51 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.139 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 25.7 mttm -143.75 157.83 44.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.891 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.518 ' CE1' HD11 ' A' ' 98' ' ' LEU . 50.0 m-85 -146.79 161.85 39.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.884 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 69.9 p -95.76 -29.73 14.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.152 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -112.9 133.9 54.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.799 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -74.64 -34.47 62.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.867 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 64.6 mt -53.39 -40.45 65.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.927 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.482 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 4.3 mm-40 -80.66 -40.53 25.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.877 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 13.4 tt0 -41.6 -48.08 3.97 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.9 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 154' ' ' LEU . 40.4 mttp -71.67 -57.2 4.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.902 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.4 ' C ' ' O ' ' A' ' 151' ' ' LYS . 21.0 mtt-85 -38.18 -33.55 0.1 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.897 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.426 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -74.66 -43.49 55.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.117 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.47 ' N ' ' O ' ' A' ' 151' ' ' LYS . 14.7 mt -48.32 -38.2 18.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.463 HG22 ' N ' ' A' ' 156' ' ' GLU . 10.1 t -92.14 -45.76 8.11 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.136 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.463 ' N ' HG22 ' A' ' 155' ' ' THR . 16.8 mm-40 -67.99 -62.35 1.44 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.851 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.463 ' CB ' HD12 ' A' ' 170' ' ' LEU . 33.0 m -68.24 -3.25 10.12 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.897 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 5.1 tp-100 -45.36 139.58 3.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.916 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 44.2 34.35 3.23 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.505 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.447 ' HB2' ' CG2' ' A' ' 168' ' ' VAL . . . -55.33 113.0 1.23 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.814 0.34 . . . . 0.0 111.077 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.8 t -88.02 -32.31 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.151 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.53 -37.0 2.46 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.482 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.536 ' HB2' ' CE1' ' A' ' 115' ' ' PHE . 26.4 tp -89.65 117.19 28.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.901 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 68.19 154.22 0.55 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.528 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 19.3 m -55.98 -25.4 43.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.953 0.406 . . . . 0.0 110.871 -179.757 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 59.8 mttt -108.0 154.71 40.97 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.615 0.721 . . . . 0.0 110.871 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 173.39 11.07 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.696 2.264 . . . . 0.0 112.304 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.447 ' CG2' ' HB2' ' A' ' 160' ' ' ALA . 33.0 m -126.33 127.02 70.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.153 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 34.6 ttt85 -92.77 102.44 14.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.856 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.463 HD12 ' CB ' ' A' ' 157' ' ' CYS . 11.2 mt -76.88 149.84 36.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.919 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.7 m -158.58 175.57 13.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.871 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 11.3 t -105.78 101.62 12.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.141 179.949 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -75.97 171.58 14.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.119 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . 0.46 ' CG2' ' HB3' ' A' ' 177' ' ' ALA . 65.3 mt -133.76 123.13 17.02 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.639 0.733 . . . . 0.0 111.086 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.453 ' O ' ' C ' ' A' ' 176' ' ' LYS . 53.0 Cg_endo -69.79 79.93 0.92 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.663 2.242 . . . . 0.0 112.321 179.883 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . 0.453 ' C ' ' O ' ' A' ' 175' ' ' PRO . 45.2 mttm 33.56 37.05 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.912 179.906 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . 0.46 ' HB3' ' CG2' ' A' ' 174' ' ' ILE . . . -56.5 -59.83 4.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.087 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 63.6 p -82.66 123.17 29.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.869 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 45.3 mtm180 -95.99 155.8 16.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.873 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 7.2 p -123.57 144.38 33.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.126 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -122.1 87.58 47.67 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.587 0.708 . . . . 0.0 110.901 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 111.39 2.79 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.698 2.265 . . . . 0.0 112.368 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 91.4 t -60.83 104.27 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.107 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -75.06 143.02 43.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.9 p -140.54 155.36 46.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 169.75 146.29 5.02 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.461 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 126.26 13.1 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.646 2.23 . . . . 0.0 112.361 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 188' ' ' SER . . . . . 0.412 ' O ' ' C ' ' A' ' 189' ' ' SER . 31.7 t -151.03 124.03 8.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.864 -179.857 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 189' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 188' ' ' SER . 3.1 t -36.49 -43.3 0.39 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.852 -179.808 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.308 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.471 179.995 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.445 -0.262 . . . . 0.0 112.445 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 30.8 t -75.5 134.98 40.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.869 0.366 . . . . 0.0 110.872 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 33.6 m -67.15 -53.55 29.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.829 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 89.22 -119.85 5.57 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.496 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 35.8 m -74.8 -47.85 28.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.878 0.371 . . . . 0.0 110.852 -179.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 47.4 t -64.04 120.39 11.94 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.882 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -48.51 146.29 5.74 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.491 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 108.96 2.2 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.694 2.263 . . . . 0.0 112.339 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -144.98 144.48 31.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.895 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . 0.498 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 5.0 m-85 -140.39 107.02 5.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.923 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 58.2 p -116.22 142.52 46.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.849 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 37.3 mt -115.79 147.89 40.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.917 179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -93.88 135.68 34.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.5 m -128.6 139.56 51.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.158 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -132.39 171.23 21.6 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.508 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . 0.403 ' N ' ' O ' ' A' ' 138' ' ' GLY . 29.4 m-20 61.74 51.72 3.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.864 0.364 . . . . 0.0 110.928 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 25.6 mt -99.29 103.31 15.13 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.94 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 16.9 p -48.4 150.19 2.43 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.609 0.718 . . . . 0.0 111.111 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 -0.27 6.73 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.668 2.246 . . . . 0.0 112.333 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -99.73 10.19 41.77 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . 0.454 ' HA ' ' CE ' ' A' ' 111' ' ' MET . 21.7 t -123.76 133.9 67.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.101 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -118.9 176.3 5.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.879 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.5 p-10 -52.22 -50.55 61.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -39.41 -39.12 1.07 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.468 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' MET . . . . . 0.454 ' CE ' ' HA ' ' A' ' 107' ' ' VAL . 29.7 mtm -82.77 -41.33 19.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.743 0.306 . . . . 0.0 110.876 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.6 tp -58.8 -24.39 61.81 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.927 179.98 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.415 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 16.7 t80 -84.45 -62.37 1.57 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.884 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.454 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 17.0 mt-10 -57.76 -34.74 69.87 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.931 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . 0.485 ' CZ ' ' HB2' ' A' ' 163' ' ' LEU . 84.7 t80 -59.85 -34.03 72.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.462 ' O ' ' N ' ' A' ' 118' ' ' LYS . 9.5 m-85 -95.03 -62.13 1.36 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.863 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.454 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.3 p -39.03 -27.16 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.131 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.462 ' N ' ' O ' ' A' ' 116' ' ' PHE . 19.5 tptt -68.96 -60.52 2.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.898 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.553 HG22 ' CE2' ' A' ' 120' ' ' TYR . 4.2 p -67.58 -28.86 43.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.146 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.553 ' CE2' HG22 ' A' ' 119' ' ' VAL . 95.1 m-85 -132.72 110.55 13.38 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.667 0.746 . . . . 0.0 110.894 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . 0.402 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.1 Cg_endo -69.8 -2.47 10.25 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.701 2.267 . . . . 0.0 112.294 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 23.4 p -90.3 -4.04 57.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.855 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . 0.471 ' HA ' ' CD1' ' A' ' 144' ' ' PHE . 14.1 t -57.35 146.46 28.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.931 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.424 ' NH1' ' HB3' ' A' ' 124' ' ' ARG . 1.6 mmm180 -109.01 -36.45 6.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.901 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.415 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.29 149.24 5.78 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.48 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -100.11 135.82 12.36 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.472 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -127.91 110.9 13.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.848 0.356 . . . . 0.0 110.883 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 14.2 p -103.25 119.91 52.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.128 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.544 HG11 ' CE1' ' A' ' 139' ' ' TYR . 18.2 m -66.36 143.33 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.113 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 43.5 mt -121.49 -176.6 3.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.911 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -113.77 -175.72 2.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . 0.442 ' CD ' HG23 ' A' ' 133' ' ' THR . 0.0 OUTLIER -48.39 -35.18 12.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.912 -179.928 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.442 HG23 ' CD ' ' A' ' 132' ' ' GLN . 9.6 p -86.65 -23.16 25.76 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.145 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.54 23.36 8.93 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.503 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 30.6 m -99.12 128.56 50.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.836 0.351 . . . . 0.0 111.12 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.6 t -39.37 109.75 0.12 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.861 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.3 mtmt -58.53 -28.45 65.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.403 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 123.74 16.07 3.44 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.479 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.544 ' CE1' HG11 ' A' ' 129' ' ' VAL . 16.2 p90 -162.76 173.19 14.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.941 0.4 . . . . 0.0 110.929 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -176.73 -163.7 29.44 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.525 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -151.23 148.12 27.82 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.878 0.37 . . . . 0.0 110.934 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 15.4 m -120.85 176.06 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . 0.418 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -133.69 161.86 33.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 179.939 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.471 ' CD1' ' HA ' ' A' ' 123' ' ' CYS . 96.9 m-85 -149.61 167.88 25.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 25.8 p -108.79 -8.13 15.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.142 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -132.51 124.44 28.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.856 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.498 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 16.3 tt0 -69.88 -30.92 68.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.889 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 48.6 mt -58.16 -54.61 44.98 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.928 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 54.4 mt-10 -67.57 -39.54 84.91 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 17.6 tt0 -44.01 -45.57 7.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.905 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 74.1 mttt -73.11 -29.89 63.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.942 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 47.3 mtp180 -63.57 -39.84 95.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.873 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.55 ' HB1' ' CE2' ' A' ' 120' ' ' TYR . . . -68.52 -42.87 77.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.138 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.427 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 29.3 mt -45.85 -43.1 13.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.933 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.418 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.4 t -91.1 -46.66 7.99 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.168 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.418 ' N ' HG23 ' A' ' 155' ' ' THR . 47.4 mm-40 -63.32 -63.58 1.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.877 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.425 ' CB ' HD13 ' A' ' 170' ' ' LEU . 34.0 m -67.7 -9.43 43.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.917 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . 0.427 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.6 tp-100 -37.93 145.22 0.07 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.969 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.07 33.71 0.5 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.514 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.457 ' HB1' ' CG2' ' A' ' 168' ' ' VAL . . . -58.71 115.86 3.34 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.826 0.346 . . . . 0.0 111.054 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 23.1 t -90.77 -35.33 7.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.136 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.12 -33.28 0.16 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.498 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.485 ' HB2' ' CZ ' ' A' ' 115' ' ' PHE . 25.7 tp -93.69 115.98 28.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.868 0.366 . . . . 0.0 110.871 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 69.1 156.69 1.15 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.475 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 65.8 m -59.83 -19.97 54.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.995 0.426 . . . . 0.0 110.878 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 49.2 mttt -111.83 156.67 41.28 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.527 0.68 . . . . 0.0 110.93 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 177.62 5.38 Favored 'Trans proline' 0 N--CA 1.465 -0.153 0 C-N-CA 122.681 2.254 . . . . 0.0 112.376 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.457 ' CG2' ' HB1' ' A' ' 160' ' ' ALA . 31.4 m -131.33 125.98 57.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.138 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 30.3 ttm180 -91.65 99.76 12.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.856 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.425 HD13 ' CB ' ' A' ' 157' ' ' CYS . 13.4 mt -77.73 151.5 34.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.916 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.416 ' C ' HD23 ' A' ' 154' ' ' LEU . 1.7 m -162.83 171.47 16.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.86 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 2.8 t -97.93 105.02 16.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.145 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -102.85 170.2 8.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.092 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . 0.471 ' CG2' ' HD2' ' A' ' 175' ' ' PRO . 77.2 mt -123.54 138.2 29.83 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.622 0.725 . . . . 0.0 111.131 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.471 ' HD2' ' CG2' ' A' ' 174' ' ' ILE . 53.8 Cg_endo -69.77 -49.87 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.68 2.254 . . . . 0.0 112.351 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 25.8 ttpp -132.69 139.0 47.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.92 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -153.26 134.6 14.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.08 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 58.0 p -121.57 103.62 9.05 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.839 -179.787 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 60.4 mtm180 -74.92 166.03 24.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.875 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . 0.402 ' C ' ' HD2' ' A' ' 181' ' ' LYS . 8.2 p -119.01 157.11 20.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.16 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.402 ' HD2' ' C ' ' A' ' 180' ' ' VAL . 0.0 OUTLIER -141.2 140.9 21.82 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.605 0.716 . . . . 0.0 110.933 179.883 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.75 115.98 4.35 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.707 2.271 . . . . 0.0 112.347 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 84.7 t -90.01 108.43 19.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -112.86 139.27 48.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.911 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 59.6 p -127.12 169.64 13.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.855 -179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 169.69 157.83 12.68 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.493 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 139.17 39.57 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.694 2.263 . . . . 0.0 112.379 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 49.7 m -73.57 -51.64 16.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.848 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 2.5 t -140.33 166.07 25.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.847 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.367 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.52 179.998 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 27.1 t -146.92 154.45 41.31 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.904 0.383 . . . . 0.0 110.853 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 67.1 m -116.23 46.67 1.53 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.871 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 87.07 161.87 36.94 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.5 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 47.5 t -165.65 150.65 8.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.902 0.382 . . . . 0.0 110.844 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 15.3 m -152.55 123.84 7.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.846 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 66.51 87.61 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.482 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 81.82 0.8 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.704 2.27 . . . . 0.0 112.357 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . 0.467 ' O ' ' CD1' ' A' ' 96' ' ' TYR . 34.1 tt0 -162.78 136.16 5.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.858 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . 0.467 ' CD1' ' O ' ' A' ' 95' ' ' GLU . 4.4 m-85 -147.23 119.8 8.52 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.88 -179.824 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.7 p -133.3 149.13 51.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.887 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.405 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . 23.6 mt -118.86 149.62 41.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.934 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 8.9 t80 -96.1 131.37 42.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.906 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.407 HG23 ' N ' ' A' ' 140' ' ' GLY . 17.1 m -122.25 138.3 52.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -130.47 179.77 16.66 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.514 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 51.32 54.03 11.84 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.8 0.334 . . . . 0.0 110.865 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 31.0 mt -101.95 103.24 13.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 -179.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 52.3 p -49.37 150.53 3.18 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.561 0.696 . . . . 0.0 111.145 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 3.0 3.02 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.748 2.299 . . . . 0.0 112.381 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -99.21 -4.32 32.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . 0.443 ' HA ' ' CE ' ' A' ' 111' ' ' MET . 93.1 t -109.1 144.39 17.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.151 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -129.8 179.75 5.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.86 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.7 -35.27 74.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.862 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -53.5 -32.46 45.74 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.465 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' MET . . . . . 0.443 ' CE ' ' HA ' ' A' ' 107' ' ' VAL . 32.9 mtm -89.03 -42.64 11.63 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.855 0.359 . . . . 0.0 110.892 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.42 HD21 ' CA ' ' A' ' 126' ' ' GLY . 17.0 tp -56.91 -28.84 62.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.912 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.466 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 9.5 t80 -74.96 -62.87 1.4 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.452 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 19.4 mt-10 -61.65 -26.77 68.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.89 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . 0.503 ' CE1' ' HB2' ' A' ' 163' ' ' LEU . 84.2 t80 -65.85 -34.62 78.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.893 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -94.63 -58.37 2.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.888 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.452 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.2 p -43.21 -25.55 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.147 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 5.1 ttpm? -69.5 -60.65 2.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.892 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.52 HG23 ' CE2' ' A' ' 120' ' ' TYR . 3.2 p -65.46 -27.67 42.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.52 ' CE2' HG23 ' A' ' 119' ' ' VAL . 97.1 m-85 -137.79 113.18 9.13 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.666 0.746 . . . . 0.0 110.94 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 0.05 6.18 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.68 2.253 . . . . 0.0 112.344 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 16.1 m -99.72 24.89 7.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.864 -179.818 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 14.9 t -85.87 140.51 30.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.879 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.457 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 7.9 mmt85 -95.82 -32.5 12.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.857 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.466 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 151.84 140.78 3.2 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.42 ' CA ' HD21 ' A' ' 112' ' ' LEU . . . -90.22 137.24 13.89 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.479 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.415 ' N ' HD21 ' A' ' 112' ' ' LEU . 1.6 tppp? -125.96 129.72 49.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 110.898 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.11 128.28 73.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.096 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.557 HG23 ' CE1' ' A' ' 139' ' ' TYR . 22.3 m -74.31 147.21 9.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.13 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 11.6 mt -129.01 173.32 10.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.928 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -105.55 -179.15 3.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.883 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 32.9 tt0 -46.24 -39.79 10.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 52.2 p -74.84 -34.07 62.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.131 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.02 23.35 6.17 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.505 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 18.8 m -103.37 132.63 49.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.842 0.353 . . . . 0.0 111.083 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.0 t -42.12 114.06 0.51 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.849 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.433 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.1 mtmt -61.3 -24.7 66.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.831 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 119.71 15.96 5.16 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.484 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.557 ' CE1' HG23 ' A' ' 129' ' ' VAL . 25.1 p90 -162.13 177.81 9.35 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.933 0.397 . . . . 0.0 110.913 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.407 ' N ' HG23 ' A' ' 100' ' ' VAL . . . -179.63 -163.45 30.4 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.492 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -153.01 147.97 26.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.857 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.405 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 14.7 m -120.94 -178.61 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.139 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . 0.457 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 21.9 mtmm -141.04 159.18 42.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.826 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -147.32 171.21 15.8 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.857 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 75.4 p -110.48 -25.61 9.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.152 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -111.7 117.25 32.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.829 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -68.01 -23.74 65.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.879 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 67.7 mt -64.34 -35.85 82.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.931 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.488 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 20.8 mt-10 -88.94 -35.89 16.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 22.4 tt0 -42.99 -45.14 4.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.928 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 36.6 mttp -77.41 -35.16 54.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.444 ' O ' ' CG ' ' A' ' 156' ' ' GLU . 21.3 mtp85 -55.69 -34.0 64.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.842 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.414 ' HB1' ' CE2' ' A' ' 120' ' ' TYR . . . -74.19 -40.74 62.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.107 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.457 ' CD2' ' HB3' ' A' ' 170' ' ' LEU . 19.1 mt -47.5 -41.76 21.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.931 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 11.9 t -92.51 -42.4 9.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.173 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.444 ' CG ' ' O ' ' A' ' 152' ' ' ARG . 46.5 mm-40 -67.33 -66.32 0.57 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.909 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.454 ' CB ' HD11 ' A' ' 170' ' ' LEU . 3.7 m -64.26 -13.08 47.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.862 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . 0.411 ' C ' ' O ' ' A' ' 157' ' ' CYS . 3.3 tp-100 -35.6 129.62 0.57 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.926 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 59.0 33.25 73.28 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.525 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -56.1 112.95 1.34 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 111.102 -179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.2 t -91.6 -32.95 5.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.153 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -43.52 -31.38 1.63 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.509 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.503 ' HB2' ' CE1' ' A' ' 115' ' ' PHE . 26.7 tp -94.97 112.85 24.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.842 0.353 . . . . 0.0 110.886 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 70.82 148.45 0.49 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.498 179.886 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 49.0 m -50.92 -31.61 18.15 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.939 0.399 . . . . 0.0 110.841 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -99.92 155.52 36.36 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.534 0.683 . . . . 0.0 110.904 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.84 174.48 9.51 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.703 2.269 . . . . 0.0 112.302 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 30.7 m -130.32 135.42 60.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.165 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 5.7 ptm180 -95.93 128.04 42.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.862 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.457 ' HB3' ' CD2' ' A' ' 154' ' ' LEU . 31.9 mt -102.06 136.75 41.35 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.951 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.3 m -151.78 -176.9 5.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 10.7 t -107.48 94.3 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.158 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -70.98 160.38 33.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.08 179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 83.7 mt -124.14 122.79 26.1 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.64 0.734 . . . . 0.0 111.12 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.488 ' O ' ' N ' ' A' ' 177' ' ' ALA . 53.8 Cg_endo -69.75 -176.65 1.55 Allowed 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.676 2.251 . . . . 0.0 112.376 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . 0.415 ' CA ' ' HE3' ' A' ' 176' ' ' LYS . 0.1 OUTLIER -46.93 89.52 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.867 179.941 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . 0.488 ' N ' ' O ' ' A' ' 175' ' ' PRO . . . -104.36 76.42 1.32 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.107 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 58.2 m -132.4 175.54 9.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.842 -179.736 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 2.6 ttt85 -124.1 126.04 45.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.838 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 13.4 p -64.26 136.04 27.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.166 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.474 ' CG ' ' HD2' ' A' ' 182' ' ' PRO . 41.5 tttt -162.42 139.62 6.23 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.581 0.705 . . . . 0.0 110.921 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.474 ' HD2' ' CG ' ' A' ' 181' ' ' LYS . 53.8 Cg_endo -69.83 95.99 0.58 Allowed 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.658 2.239 . . . . 0.0 112.368 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 68.2 t -98.38 88.46 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.107 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -174.83 133.7 0.35 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.888 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 43.5 m -107.84 140.57 40.74 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.837 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -82.41 -94.04 0.55 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.514 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 148.43 64.92 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.727 2.285 . . . . 0.0 112.299 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 36.1 p -90.99 -57.9 2.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.862 -179.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 53.8 p -158.03 139.85 13.93 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.806 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.47 179.982 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 68.8 m -53.3 147.5 10.18 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.864 0.364 . . . . 0.0 110.863 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 t -123.97 41.64 3.44 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.811 -179.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 68.65 -179.63 21.53 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.471 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 25.4 m -117.57 118.6 32.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.827 0.346 . . . . 0.0 110.858 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 93.3 p -135.7 106.43 6.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.887 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 147.49 -83.83 0.18 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.508 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 148.98 66.15 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.684 2.256 . . . . 0.0 112.337 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -151.03 151.93 32.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . 0.515 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 7.3 m-85 -123.18 105.47 9.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.909 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.1 p -126.23 155.09 42.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 85.7 mt -126.15 144.05 50.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.918 -179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.48 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 11.6 t80 -94.47 131.24 40.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 34.8 m -120.03 147.52 23.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.125 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -134.9 -177.9 15.28 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.482 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 50.24 48.39 22.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.803 0.335 . . . . 0.0 110.882 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.412 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.2 mt -93.86 103.09 15.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.889 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 71.1 p -48.2 149.49 2.59 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.588 0.709 . . . . 0.0 111.153 179.9 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 2.61 3.34 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.707 2.271 . . . . 0.0 112.38 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -99.11 -9.83 23.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.852 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 15.7 t -98.12 144.05 11.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.134 -179.985 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -130.24 174.46 9.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.844 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -51.66 -50.74 59.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.875 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -45.54 -33.99 4.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.506 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' MET . . . . . . . . . . . . . 50.4 mtp -80.92 -61.5 1.94 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.781 0.324 . . . . 0.0 110.855 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.3 tp -41.23 -40.2 1.54 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.919 -179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.493 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 17.6 t80 -63.01 -68.12 0.37 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.903 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.451 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 26.7 mt-10 -48.74 -55.51 11.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.88 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . . . . . . . . . 76.4 t80 -42.75 -32.1 0.56 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.885 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.467 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.1 m-85 -95.0 -67.23 0.86 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.873 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.451 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.81 -30.31 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.14 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.2 tttp -65.41 -58.5 5.7 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.929 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.526 HG22 ' CE2' ' A' ' 120' ' ' TYR . 3.3 p -67.27 -29.81 47.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.132 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.526 ' CE2' HG22 ' A' ' 119' ' ' VAL . 96.3 m-85 -137.06 109.49 9.05 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.685 0.755 . . . . 0.0 110.924 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 2.43 3.53 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.671 2.247 . . . . 0.0 112.318 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 1.3 p -95.49 -0.18 52.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.833 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 19.1 t -66.4 138.07 57.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.931 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -91.59 -38.61 12.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.493 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 164.37 150.42 6.13 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.476 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -94.21 137.52 13.57 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.447 -179.887 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 19.7 tptm -125.27 118.72 26.61 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.838 0.351 . . . . 0.0 110.903 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.7 p -112.45 115.57 50.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.109 179.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.46 HG21 ' CE2' ' A' ' 139' ' ' TYR . 32.6 m -61.66 151.27 7.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.161 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 49.0 mt -133.16 164.48 26.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.924 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.452 ' O ' ' N ' ' A' ' 134' ' ' GLY . 13.7 t70 -96.96 175.84 6.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.866 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 2.0 tp-100 -42.66 -44.25 4.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.905 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 44.0 p -70.0 -28.51 65.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.118 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 103.81 23.73 8.1 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.505 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 136' ' ' SER . 28.4 m -105.12 131.43 54.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-O 120.824 0.345 . . . . 0.0 111.122 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.405 ' C ' ' O ' ' A' ' 135' ' ' VAL . 5.8 t -37.89 114.16 0.33 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.425 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.7 mtmt -62.66 -25.89 68.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.907 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 119.41 17.18 4.9 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.5 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.46 ' CE2' HG21 ' A' ' 129' ' ' VAL . 20.3 p90 -163.54 172.05 14.96 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.916 0.389 . . . . 0.0 110.984 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -176.22 -164.11 29.84 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.501 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . 0.48 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 3.7 m-85 -152.05 149.15 28.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.906 0.384 . . . . 0.0 110.845 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.451 HG21 ' CZ ' ' A' ' 144' ' ' PHE . 16.1 m -123.0 161.05 25.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.131 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -119.05 158.41 25.89 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.872 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.451 ' CZ ' HG21 ' A' ' 142' ' ' VAL . 84.4 m-85 -145.6 169.36 18.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 43.3 p -115.0 -24.79 8.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.123 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -112.99 99.82 8.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.515 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 16.7 tt0 -46.94 -45.26 20.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.884 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 33.6 mt -48.1 -40.57 23.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.927 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.466 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 4.4 mm-40 -80.98 -33.98 33.41 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.825 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 15.4 tt0 -49.79 -63.89 0.97 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.944 -179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -57.92 -47.62 82.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.923 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 47.0 mtt180 -43.97 -30.89 0.78 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.855 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -73.76 -39.1 64.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.064 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.46 ' CD2' ' HB3' ' A' ' 170' ' ' LEU . 12.2 mt -51.01 -38.14 49.46 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.886 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.44 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.8 t -92.46 -46.35 7.69 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.44 ' N ' HG23 ' A' ' 155' ' ' THR . 10.7 mt-10 -68.45 -63.1 1.13 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.828 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.46 ' CB ' HD12 ' A' ' 170' ' ' LEU . 40.3 m -68.64 -2.61 9.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.873 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -43.5 136.69 3.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.876 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 42.61 43.85 5.15 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.45 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -61.33 110.89 1.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.784 0.326 . . . . 0.0 111.134 179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.7 -35.95 10.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.137 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -40.68 -34.48 0.74 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.501 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 16.1 tp -91.07 118.77 30.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.835 0.35 . . . . 0.0 110.946 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 165' ' ' SER . . . 61.22 135.07 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.465 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' SER . . . . . 0.411 ' C ' ' O ' ' A' ' 164' ' ' GLY . 58.8 m -37.58 -33.58 0.08 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.924 0.392 . . . . 0.0 110.844 -179.692 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 31.7 mttp -95.61 153.5 39.43 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.574 0.702 . . . . 0.0 110.876 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -176.27 1.44 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.677 2.252 . . . . 0.0 112.313 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 33.2 m -140.84 126.59 19.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 18.3 mtt180 -90.26 116.68 28.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.847 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.46 HD12 ' CB ' ' A' ' 157' ' ' CYS . 17.4 mt -89.9 137.48 32.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.903 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 13.2 m -149.52 179.72 7.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.89 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 5.0 t -103.99 98.1 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.087 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -69.73 146.36 51.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.069 179.886 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 59.8 mt -102.21 120.63 52.97 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.602 0.715 . . . . 0.0 111.134 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 -49.46 0.55 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.665 2.243 . . . . 0.0 112.35 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 19.6 tptm -78.06 65.32 3.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.87 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -80.54 -62.22 1.74 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.088 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 26.9 t -72.01 109.86 6.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.862 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 53.5 mtt180 -100.91 119.26 38.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.889 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 33.7 m -105.61 145.03 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.128 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 32.7 tttp -116.73 136.7 23.26 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.576 0.703 . . . . 0.0 110.889 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.71 107.04 1.76 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.718 2.279 . . . . 0.0 112.311 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 35.5 m -82.18 155.03 4.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.118 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -121.34 112.1 18.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.891 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 58.5 p -151.07 138.57 19.55 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.821 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 125.6 157.92 9.79 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.493 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 127.92 15.26 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.708 2.272 . . . . 0.0 112.363 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 52.3 p -156.93 167.44 30.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.82 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 85.5 p -67.87 169.83 9.13 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.832 -179.776 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.52 -179.975 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.501 -0.239 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 23.9 m -105.55 94.57 5.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.858 0.361 . . . . 0.0 110.878 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 m -91.25 -60.39 1.91 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.891 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -137.23 -139.32 3.88 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.466 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 63.2 p -126.32 134.22 51.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.875 0.369 . . . . 0.0 110.836 -179.691 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 28.8 t -101.27 -38.36 8.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.856 -179.814 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -168.24 95.3 0.11 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.481 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 101.22 0.88 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.742 2.294 . . . . 0.0 112.325 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -168.54 117.78 0.72 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . 0.513 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 33.1 m-85 -114.88 87.69 2.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.895 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 64.6 m -105.18 156.38 18.15 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.892 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.457 ' HB2' ' CG2' ' A' ' 142' ' ' VAL . 21.8 mt -122.23 143.01 49.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.949 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 8.5 t80 -93.11 126.87 38.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.912 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.41 HG23 ' C ' ' A' ' 140' ' ' GLY . 30.2 m -119.17 148.6 22.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.142 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.61 176.33 20.9 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.522 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . 0.468 ' N ' ' O ' ' A' ' 138' ' ' GLY . 22.7 m-20 56.57 50.74 12.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.837 0.351 . . . . 0.0 110.878 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 25.9 mt -98.6 100.34 11.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 75.0 p -42.69 149.38 0.48 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.602 0.715 . . . . 0.0 111.128 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 3.13 2.93 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.711 2.274 . . . . 0.0 112.368 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 65.5 m-20 -104.22 11.93 34.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.903 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . 0.451 HG23 ' CE ' ' A' ' 111' ' ' MET . 75.3 t -128.42 134.98 63.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.125 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -120.69 -175.99 3.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.869 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.433 ' N ' HG11 ' A' ' 128' ' ' VAL . 1.7 p30 -57.88 -37.01 73.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.969 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -46.59 -41.51 12.82 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.443 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' MET . . . . . 0.451 ' CE ' HG23 ' A' ' 107' ' ' VAL . 27.9 mtm -83.82 -44.8 13.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.787 0.327 . . . . 0.0 110.863 -179.952 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.46 HD11 ' CD2' ' A' ' 163' ' ' LEU . 21.2 tp -51.74 -22.82 3.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.901 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.409 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 14.8 t80 -83.74 -64.69 1.12 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.863 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.454 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 27.1 mt-10 -57.2 -26.45 60.68 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.889 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . . . . . . . . . 60.5 t80 -66.7 -34.83 78.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.907 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 11.5 m-85 -95.22 -57.72 2.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.839 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.454 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -43.23 -28.69 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.119 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 3.6 tptm -68.9 -59.61 2.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.856 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.415 HG21 ' CE2' ' A' ' 120' ' ' TYR . 3.3 p -65.29 -28.75 45.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.137 179.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.415 ' CE2' HG21 ' A' ' 119' ' ' VAL . 91.5 m-85 -138.17 114.43 9.08 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.695 0.759 . . . . 0.0 110.922 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.67 -0.2 6.49 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.717 2.278 . . . . 0.0 112.335 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 17.2 p -88.85 -17.73 29.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.816 -179.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . 0.43 ' HA ' ' CD1' ' A' ' 144' ' ' PHE . 7.7 t -48.08 139.36 8.25 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.895 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.442 ' CG ' HG21 ' A' ' 145' ' ' THR . 25.2 mtp180 -100.71 -34.96 9.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.862 -179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.409 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 164.02 145.56 4.42 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.521 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -98.39 133.82 11.47 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.485 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 13.4 tptt -124.79 128.94 49.5 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.834 0.349 . . . . 0.0 110.867 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.433 HG11 ' N ' ' A' ' 109' ' ' ASP . 7.1 p -114.43 138.05 45.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.176 179.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.566 HG11 ' CE1' ' A' ' 139' ' ' TYR . 24.4 m -83.76 143.25 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.12 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 17.1 mt -122.7 171.73 8.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.904 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -105.55 -179.88 4.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.815 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 15.8 pt20 -45.6 -39.86 8.19 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.925 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 44.2 p -74.88 -33.79 62.11 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.136 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 111.79 21.28 6.47 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.526 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 27.3 m -100.66 143.45 14.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.812 0.339 . . . . 0.0 111.16 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 3.7 t -54.55 107.26 0.27 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.859 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.488 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.5 mtmt -52.47 -29.95 27.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.885 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.468 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 122.53 19.23 3.16 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.49 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.566 ' CE1' HG11 ' A' ' 129' ' ' VAL . 27.3 p90 -163.8 167.77 20.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.921 0.391 . . . . 0.0 110.909 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.41 ' C ' HG23 ' A' ' 100' ' ' VAL . . . -171.11 -159.91 18.34 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.498 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -153.58 151.52 29.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.9 0.381 . . . . 0.0 110.877 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.457 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 18.4 m -124.1 176.36 5.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.16 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 33.8 mtmt -136.83 158.23 44.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.43 ' CD1' ' HA ' ' A' ' 123' ' ' CYS . 91.5 m-85 -145.38 167.05 23.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.905 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' THR . . . . . 0.442 HG21 ' CG ' ' A' ' 124' ' ' ARG . 27.7 p -105.48 -25.41 12.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.147 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -119.5 111.15 17.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.513 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 2.9 tm-20 -51.43 -45.75 62.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.874 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 24.0 mt -42.0 -42.2 2.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.915 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 57.0 mm-40 -76.23 -41.77 48.17 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 17.7 tt0 -40.84 -57.79 1.85 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.924 -179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 32.9 mmtm -62.53 -51.53 67.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.925 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 36.8 mtp180 -41.81 -40.97 2.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.43 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.88 -48.22 66.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.043 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.493 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 15.3 mt -42.61 -42.46 3.42 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.913 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.463 HG22 ' N ' ' A' ' 156' ' ' GLU . 9.2 t -89.12 -48.13 7.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.13 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.463 ' N ' HG22 ' A' ' 155' ' ' THR . 18.2 mm-40 -63.56 -64.35 0.92 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.43 ' N ' ' O ' ' A' ' 153' ' ' ALA . 2.5 m -68.25 -8.09 36.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.926 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . 0.493 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 3.5 tp-100 -36.14 134.38 0.41 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 -179.871 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 46.57 41.32 12.52 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.474 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.415 ' HB2' ' CG2' ' A' ' 168' ' ' VAL . . . -57.39 117.44 4.12 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.848 0.356 . . . . 0.0 111.084 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.6 t -92.9 -33.5 5.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.163 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.94 -36.33 2.55 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.443 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.46 ' CD2' HD11 ' A' ' 112' ' ' LEU . 18.2 tp -87.94 114.83 24.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.829 0.347 . . . . 0.0 110.868 -179.891 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 70.8 161.27 3.88 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.4 p -66.97 -3.83 8.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.946 0.403 . . . . 0.0 110.85 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -128.37 154.78 79.17 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.547 0.689 . . . . 0.0 110.917 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 171.6 14.16 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.696 2.264 . . . . 0.0 112.337 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.415 ' CG2' ' HB2' ' A' ' 160' ' ' ALA . 32.8 m -128.97 126.29 64.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.137 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -87.99 112.6 22.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.886 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.431 ' HB3' ' CD2' ' A' ' 154' ' ' LEU . 13.9 mt -85.94 146.07 26.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.913 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.2 m -157.57 169.04 25.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 40.9 t -94.45 102.41 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.121 179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -95.69 117.56 30.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.094 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 48.1 mt -54.17 133.2 60.23 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.565 0.697 . . . . 0.0 111.142 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -41.37 4.32 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.665 2.243 . . . . 0.0 112.344 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 3.1 mmmp? -148.74 132.13 16.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.909 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -130.6 36.91 3.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.12 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 11.5 t 41.97 44.24 2.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.833 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -96.08 100.53 12.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.869 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 3.1 p -137.23 132.16 46.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.161 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 8.1 ptmm? -116.75 77.99 8.76 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.6 0.714 . . . . 0.0 110.872 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 80.23 0.89 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.664 2.242 . . . . 0.0 112.342 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 87.3 t -138.41 127.56 31.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.146 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -87.34 146.74 25.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.893 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.5 m -134.62 168.07 19.66 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.859 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -136.22 144.73 16.57 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.493 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.67 153.12 69.72 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.71 2.273 . . . . 0.0 112.344 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 73.5 p -145.41 158.1 43.9 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.885 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 66.4 m -102.64 156.53 17.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.854 -179.816 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.451 179.951 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.451 -0.26 . . . . 0.0 112.451 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 79.7 p -61.29 127.03 29.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.861 0.362 . . . . 0.0 110.875 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 41.5 p -148.67 132.82 17.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.853 -179.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -120.5 173.97 15.54 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.44 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.4 t -117.89 -54.36 2.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.926 0.393 . . . . 0.0 110.839 -179.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 1.1 t -158.56 153.77 25.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.868 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 51.67 79.01 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.503 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 104.24 1.29 Allowed 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.65 2.233 . . . . 0.0 112.342 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -123.39 142.64 50.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.886 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 10.0 m-85 -134.38 131.85 38.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.946 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 29.0 m -145.14 162.9 35.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.839 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.437 HD23 ' CD2' ' A' ' 154' ' ' LEU . 91.8 mt -131.35 135.39 47.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.933 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.6 t80 -86.83 131.43 34.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.896 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.422 ' CG2' HD12 ' A' ' 103' ' ' LEU . 30.8 m -127.09 150.57 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.176 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.43 -170.99 12.26 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.476 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 45.41 51.47 9.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.828 0.347 . . . . 0.0 110.861 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.422 HD12 ' CG2' ' A' ' 100' ' ' VAL . 31.0 mt -96.93 102.46 14.24 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 37.1 p -48.74 151.37 2.13 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.617 0.722 . . . . 0.0 111.125 179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 2.95 3.09 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.699 2.266 . . . . 0.0 112.351 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -103.85 17.8 23.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 2.8 t -125.57 134.34 66.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.167 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -124.04 170.79 10.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.849 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.46 ' CG ' ' N ' ' A' ' 110' ' ' GLY . 0.3 OUTLIER -47.06 -49.97 20.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.912 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.46 ' N ' ' CG ' ' A' ' 109' ' ' ASP . . . -47.61 -26.46 3.85 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.454 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' MET . . . . . . . . . . . . . 27.2 mtp -89.23 -57.6 2.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.766 0.317 . . . . 0.0 110.874 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 15.3 tp -46.86 -28.43 1.57 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.977 179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.406 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.3 t80 -76.5 -66.64 0.78 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.93 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.456 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 17.9 mt-10 -54.96 -25.98 33.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.891 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . 0.433 ' CE1' ' N ' ' A' ' 163' ' ' LEU . 72.2 t80 -68.27 -35.73 78.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.862 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.551 ' CD2' HG13 ' A' ' 142' ' ' VAL . 12.1 m-85 -95.09 -56.97 2.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.456 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -42.41 -27.89 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.16 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 15.2 ttmm -66.88 -60.71 2.42 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.946 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.0 p -63.32 -32.91 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.112 179.849 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.436 ' CD1' ' HB3' ' A' ' 149' ' ' GLU . 93.6 m-85 -134.75 115.41 12.32 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.749 0.785 . . . . 0.0 110.905 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -1.8 9.13 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.672 2.248 . . . . 0.0 112.321 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 3.1 m -86.41 -12.64 48.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.806 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . 0.436 ' CB ' ' HA ' ' A' ' 117' ' ' VAL . 13.5 t -50.27 135.19 21.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.462 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 93.9 mtt180 -96.99 -37.67 10.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.406 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 166.54 143.44 3.75 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.472 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -96.9 134.54 11.81 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.516 -179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 10.1 tptm -125.78 123.86 39.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.81 0.338 . . . . 0.0 110.886 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -113.5 123.35 69.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.083 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.526 HG21 ' CD1' ' A' ' 139' ' ' TYR . 25.0 m -68.81 149.22 11.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.097 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 40.9 mt -127.34 -177.02 3.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.482 ' O ' ' N ' ' A' ' 134' ' ' GLY . 13.2 t0 -116.94 176.09 5.28 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.799 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -39.86 -39.84 0.89 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.913 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -82.29 -29.57 31.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.14 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 112.41 0.99 26.38 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.506 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . 0.436 ' O ' ' CG2' ' A' ' 135' ' ' VAL . 9.6 m -76.21 118.99 23.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 111.155 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.43 ' C ' ' O ' ' A' ' 135' ' ' VAL . 6.9 t -35.01 108.27 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.473 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.4 mtmt -50.39 -35.63 29.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.883 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.62 19.07 2.11 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.473 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.526 ' CD1' HG21 ' A' ' 129' ' ' VAL . 22.1 p90 -163.32 168.61 20.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.918 0.39 . . . . 0.0 110.911 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -173.65 -163.56 27.4 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.43 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -152.89 147.6 26.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.92 0.39 . . . . 0.0 110.87 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.551 HG13 ' CD2' ' A' ' 116' ' ' PHE . 16.4 m -119.08 171.08 7.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.145 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . 0.462 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 34.3 mtpt -127.63 161.76 28.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -149.75 160.91 43.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.867 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' THR . . . . . 0.44 HG21 ' CG ' ' A' ' 124' ' ' ARG . 76.7 p -99.73 -20.03 16.46 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.169 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -119.09 126.32 51.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.843 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 14.5 tt0 -71.71 -25.98 62.31 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.919 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 23.9 mt -65.85 -47.95 73.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.436 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 24.4 mt-10 -73.56 -39.29 64.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.862 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.418 ' C ' ' OE1' ' A' ' 150' ' ' GLN . 1.4 tm0? -46.09 -39.13 8.93 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.907 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 27.8 mmtp -79.99 -43.94 21.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.896 179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 3.0 mtt-85 -48.04 -28.47 2.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.426 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -78.64 -34.51 46.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.08 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.437 ' CD2' HD23 ' A' ' 98' ' ' LEU . 22.9 mt -55.87 -36.94 68.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.3 t -92.28 -35.71 13.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.131 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -81.8 -66.88 0.83 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.873 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.404 ' N ' ' O ' ' A' ' 153' ' ' ALA . 99.7 m -60.92 -10.26 5.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.861 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . 0.429 ' N ' HD13 ' A' ' 170' ' ' LEU . 3.0 tp-100 -36.34 132.05 0.59 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.937 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 52.54 38.49 51.78 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.479 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.415 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -54.02 115.04 1.82 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.851 0.357 . . . . 0.0 111.086 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 40.2 t -93.98 -36.27 7.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.11 -35.51 1.73 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.545 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.433 ' N ' ' CE1' ' A' ' 115' ' ' PHE . 27.6 tp -83.9 109.58 17.7 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.853 0.358 . . . . 0.0 110.915 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 74.91 174.71 34.16 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.501 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 38.4 m -84.56 28.09 0.68 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.897 0.379 . . . . 0.0 110.837 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 29.5 mttm -159.55 156.59 25.35 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.561 0.695 . . . . 0.0 110.909 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 170.19 17.15 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.685 2.257 . . . . 0.0 112.314 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.415 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 31.1 m -131.09 128.57 62.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.098 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 36.7 ttt180 -86.54 109.6 19.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.826 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.429 HD13 ' N ' ' A' ' 158' ' ' GLN . 12.6 mt -85.42 145.9 27.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.94 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.9 m -162.16 177.76 9.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.827 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 8.8 t -100.68 103.22 14.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.163 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -77.86 157.95 29.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.07 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 57.7 mt -129.35 119.23 19.42 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.646 0.736 . . . . 0.0 111.121 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -41.75 3.93 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.685 2.257 . . . . 0.0 112.343 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 1.1 tppp? -113.88 97.83 6.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.878 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -39.61 -67.81 0.2 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.112 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 38.5 m -147.6 116.25 6.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.868 -179.801 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 8.3 tpt180 -67.05 82.99 0.12 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.886 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 82.0 t -128.36 125.34 63.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.117 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 17.9 mmtt -113.19 143.06 28.49 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.575 0.702 . . . . 0.0 110.884 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 156.99 61.91 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.68 2.253 . . . . 0.0 112.377 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 34.4 m -140.29 164.16 22.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.121 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -127.83 162.27 27.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.905 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 93.1 p -168.41 176.69 5.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.826 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 178.42 82.61 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.453 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 175.85 7.52 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.676 2.251 . . . . 0.0 112.385 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 1.8 m -145.34 172.72 12.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.847 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 59.8 p -109.7 170.14 8.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.908 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.482 -179.987 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.506 -0.237 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 1.8 t -81.48 107.61 14.38 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.841 0.353 . . . . 0.0 110.891 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 86.6 p -86.96 -44.54 11.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.841 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -118.17 -134.17 5.01 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.522 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 90.0 p -98.01 146.62 25.33 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.867 0.365 . . . . 0.0 110.87 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 33.5 t -109.96 36.17 3.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.852 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -50.65 149.46 6.63 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.459 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 82.0 0.77 Allowed 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.678 2.252 . . . . 0.0 112.308 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -151.34 114.67 4.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.93 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . 0.501 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 2.1 m-85 -135.35 118.69 16.72 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.889 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.7 m -135.56 139.42 43.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.88 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.458 HD23 ' CG ' ' A' ' 150' ' ' GLN . 98.4 mt -108.69 151.93 25.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.891 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -99.63 121.29 41.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.903 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.416 HG22 ' C ' ' A' ' 140' ' ' GLY . 23.6 m -110.0 137.12 43.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.121 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -126.91 176.58 17.67 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.472 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 53.37 52.45 13.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.826 0.346 . . . . 0.0 110.87 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . 0.407 HD11 ' C ' ' A' ' 139' ' ' TYR . 24.8 mt -97.92 98.49 9.84 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.926 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.2 p -45.99 151.54 0.88 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.599 0.714 . . . . 0.0 111.162 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 0.0 6.32 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.665 2.243 . . . . 0.0 112.309 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -101.23 16.58 25.03 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.831 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 61.5 t -129.41 131.93 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.095 180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -118.69 171.54 8.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.869 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.4 ' CG ' ' N ' ' A' ' 110' ' ' GLY . 2.3 p30 -48.62 -49.48 36.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.799 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . 0.4 ' N ' ' CG ' ' A' ' 109' ' ' ASP . . . -38.36 -37.2 0.47 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.469 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' MET . . . . . . . . . . . . . 27.6 mtm -86.43 -45.46 11.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.779 0.323 . . . . 0.0 110.848 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 13.9 tp -54.12 -20.36 6.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.905 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.499 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 15.0 t80 -86.19 -60.67 1.94 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.925 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.465 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 33.7 mt-10 -59.38 -46.73 87.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.879 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . 0.46 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 69.5 t80 -48.03 -33.81 8.51 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.896 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.474 ' O ' ' N ' ' A' ' 118' ' ' LYS . 7.2 m-85 -95.02 -66.61 0.9 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.881 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.465 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.59 -30.0 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.091 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.474 ' N ' ' O ' ' A' ' 116' ' ' PHE . 0.0 OUTLIER -65.08 -57.29 9.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.915 179.922 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.571 HG21 ' CE2' ' A' ' 120' ' ' TYR . 2.6 p -66.4 -34.8 72.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.144 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.571 ' CE2' HG21 ' A' ' 119' ' ' VAL . 91.8 m-85 -135.22 115.67 11.93 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-O 121.701 0.762 . . . . 0.0 110.954 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 2.9 3.14 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.69 2.26 . . . . 0.0 112.321 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.0 p -86.06 -18.94 31.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 29.2 t -53.06 135.96 36.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.882 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 18.3 mtt180 -98.88 -30.86 12.15 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.877 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.499 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 161.62 147.73 5.07 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.484 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -91.35 141.67 15.77 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.533 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.85 105.29 7.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.756 0.312 . . . . 0.0 110.874 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.447 HG23 ' N ' ' A' ' 129' ' ' VAL . 7.5 p -98.23 149.14 5.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.155 179.825 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.509 ' CG2' ' CE1' ' A' ' 139' ' ' TYR . 19.5 m -95.86 142.57 13.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.102 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.405 ' O ' ' NZ ' ' A' ' 137' ' ' LYS . 13.9 mt -130.0 173.4 10.76 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.898 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.421 ' O ' ' N ' ' A' ' 134' ' ' GLY . 26.3 t0 -107.34 171.97 7.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.865 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -44.54 -26.0 0.32 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.92 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 49.2 p -86.42 -33.94 20.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.124 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 109.14 20.62 7.81 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.502 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 25.0 m -100.19 115.71 41.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.881 0.372 . . . . 0.0 111.101 -179.947 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.4 t -37.65 103.64 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.837 -179.845 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.405 ' NZ ' ' O ' ' A' ' 130' ' ' LEU . 16.8 mttm -43.59 -37.49 2.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.891 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 129.43 20.46 1.4 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.464 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.509 ' CE1' ' CG2' ' A' ' 129' ' ' VAL . 28.0 p90 -161.39 -179.31 7.27 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.922 0.391 . . . . 0.0 110.923 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . 0.416 ' C ' HG22 ' A' ' 100' ' ' VAL . . . 177.17 -166.33 36.86 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.472 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 3.6 m-85 -153.37 139.37 18.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.86 0.362 . . . . 0.0 110.935 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.565 HG21 ' CE2' ' A' ' 144' ' ' PHE . 27.8 m -112.93 -178.23 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -140.36 163.8 31.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.923 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.565 ' CE2' HG21 ' A' ' 142' ' ' VAL . 93.8 m-85 -149.83 167.12 27.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.89 179.936 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 58.6 p -102.33 -12.07 18.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.118 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -137.04 122.33 19.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.895 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.501 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 4.6 tt0 -60.11 -37.5 80.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.905 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 34.9 mt -52.39 -49.97 63.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.935 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -70.04 -33.29 71.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.878 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.458 ' CG ' HD23 ' A' ' 98' ' ' LEU . 28.6 tt0 -58.44 -57.05 14.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.957 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 30.2 mmtm -59.11 -42.28 90.16 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.899 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 40.6 mtt-85 -54.69 -30.62 56.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.902 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.487 ' O ' ' CD1' ' A' ' 170' ' ' LEU . . . -73.36 -34.53 65.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.06 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.477 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 43.9 mt -56.51 -40.36 74.9 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.905 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 15.1 t -92.43 -34.3 14.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.128 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 39.0 mm-40 -78.55 -58.3 3.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.864 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.467 ' N ' ' O ' ' A' ' 153' ' ' ALA . 36.0 m -79.96 11.77 3.15 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . 0.477 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 3.5 tp-100 -52.92 137.81 31.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.955 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.62 33.46 0.59 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.469 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.467 ' HB1' ' CG2' ' A' ' 168' ' ' VAL . . . -53.17 116.73 2.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.815 0.34 . . . . 0.0 111.1 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' A' ' 162' ' ' GLY . 24.1 t -86.91 -35.41 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.137 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.18 -38.6 0.26 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.535 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.46 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 18.9 tp -87.42 115.36 24.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.871 0.367 . . . . 0.0 110.864 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.42 159.19 1.03 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.511 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 71.1 m -62.47 -16.62 56.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.936 0.398 . . . . 0.0 110.869 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 28.3 mttp -113.33 155.79 44.09 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.584 0.707 . . . . 0.0 110.905 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 173.51 10.86 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.757 2.304 . . . . 0.0 112.336 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.467 ' CG2' ' HB1' ' A' ' 160' ' ' ALA . 27.1 m -128.51 125.93 64.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.091 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 11.3 ttm180 -88.44 108.61 19.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.889 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.487 ' CD1' ' O ' ' A' ' 153' ' ' ALA . 17.1 mt -84.23 147.27 27.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 4.5 m -163.95 177.42 8.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 39.7 t -103.55 101.7 12.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -93.33 147.84 22.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.116 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 57.7 mt -128.64 130.88 23.49 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.623 0.725 . . . . 0.0 111.148 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -39.22 6.76 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.645 2.23 . . . . 0.0 112.397 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 22.7 mmtt -110.02 78.38 1.12 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.908 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -134.85 -55.31 0.82 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.109 179.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 28.9 t -170.72 116.32 0.47 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.888 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . 0.468 ' HD3' ' N ' ' A' ' 180' ' ' VAL . 0.0 OUTLIER -44.82 144.53 1.14 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.863 -179.948 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . 0.468 ' N ' ' HD3' ' A' ' 179' ' ' ARG . 32.9 m -46.79 -20.0 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.15 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.405 ' HD3' ' C ' ' A' ' 181' ' ' LYS . 0.0 OUTLIER -170.6 131.15 0.88 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.566 0.698 . . . . 0.0 110.867 179.943 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.73 156.82 62.42 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.726 2.284 . . . . 0.0 112.333 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 35.1 m -58.88 118.02 2.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.132 179.879 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -147.99 161.71 40.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.919 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 2.0 t -139.34 144.14 38.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.85 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 126.72 84.29 0.5 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . 0.446 ' O ' ' C ' ' A' ' 188' ' ' SER . 53.8 Cg_endo -69.74 -32.87 17.79 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.73 2.287 . . . . 0.0 112.315 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 188' ' ' SER . . . . . 0.446 ' C ' ' O ' ' A' ' 187' ' ' PRO . 47.9 m 34.36 46.34 0.17 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.89 -179.784 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 2.8 m -149.34 161.61 41.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.854 -179.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.515 -179.983 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.433 -0.267 . . . . 0.0 112.433 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 74.4 m -62.49 109.77 1.48 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 0.0 110.845 -179.744 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 78.4 p -112.68 134.2 54.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.854 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -167.72 75.37 0.13 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.513 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 18.3 m -131.74 135.62 46.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.887 0.375 . . . . 0.0 110.847 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 31.2 t -58.06 141.44 50.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.852 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 75.24 87.81 0.26 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.497 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 98.01 0.66 Allowed 'Trans proline' 0 C--N 1.34 0.129 0 C-N-CA 122.679 2.253 . . . . 0.0 112.387 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -134.22 158.78 42.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.882 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 13.1 m-85 -125.61 89.18 2.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.934 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.7 p -110.07 138.01 47.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.83 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 97.5 mt -111.25 146.77 36.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.933 -179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -93.09 130.73 38.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.907 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 17.9 m -123.55 149.27 27.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.15 179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.99 -167.63 11.0 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 41.44 52.57 3.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.828 0.347 . . . . 0.0 110.861 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 26.4 mt -101.04 101.63 12.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 75.9 p -47.01 150.2 1.41 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.556 0.693 . . . . 0.0 111.17 179.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 3.12 2.96 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.69 2.26 . . . . 0.0 112.359 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 -100.57 -0.74 37.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . 0.447 ' CG1' ' HE3' ' A' ' 111' ' ' MET . 20.9 t -108.01 136.52 43.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.168 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -118.92 175.77 5.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.868 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -58.29 -36.2 72.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -53.65 -33.92 49.25 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.542 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' MET . . . . . 0.447 ' HE3' ' CG1' ' A' ' 107' ' ' VAL . 23.7 mtm -83.69 -55.01 4.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.806 0.336 . . . . 0.0 110.921 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 29.4 tp -41.02 -37.37 0.81 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.943 -179.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.43 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 17.6 t80 -70.19 -65.92 0.66 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.942 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.452 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 19.1 mt-10 -49.42 -53.19 24.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.897 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . 0.476 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 58.2 t80 -44.58 -33.29 1.72 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.934 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.566 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.6 m-85 -93.99 -66.7 0.9 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.888 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.452 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.88 -31.09 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.108 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.456 ' N ' ' O ' ' A' ' 116' ' ' PHE . 0.5 OUTLIER -65.31 -61.28 2.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.949 179.884 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.564 HG22 ' CD2' ' A' ' 120' ' ' TYR . 1.6 p -64.65 -32.56 58.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.157 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.57 ' CE1' ' HB3' ' A' ' 152' ' ' ARG . 97.8 m-85 -131.23 113.82 15.94 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.657 0.741 . . . . 0.0 110.933 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 1.09 4.76 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.67 2.247 . . . . 0.0 112.331 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 1.4 p -104.14 31.95 4.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.804 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 41.9 t -91.12 124.9 35.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.455 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 22.5 mtp180 -79.18 -39.54 33.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.873 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.43 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 159.74 154.18 7.18 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.524 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -97.29 147.0 18.51 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.514 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 2.7 tmtp? -137.66 112.58 9.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.839 0.352 . . . . 0.0 110.887 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 12.8 p -106.76 119.43 56.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.127 179.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.547 HG13 ' CE1' ' A' ' 139' ' ' TYR . 20.1 m -63.75 155.5 5.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 20.8 mt -134.81 167.66 20.46 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.426 ' O ' ' N ' ' A' ' 134' ' ' GLY . 20.6 t70 -99.65 175.4 5.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . 0.437 ' HG3' ' N ' ' A' ' 133' ' ' THR . 20.2 pt20 -43.38 -43.33 5.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' THR . . . . . 0.437 ' N ' ' HG3' ' A' ' 132' ' ' GLN . 34.3 p -72.65 -28.47 62.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.166 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 106.48 24.59 6.69 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.523 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 31.3 m -103.45 137.18 32.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.821 0.344 . . . . 0.0 111.1 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 1.6 t -48.95 110.46 0.36 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.835 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.46 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.1 mtmt -57.16 -33.86 67.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.882 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 127.31 17.54 2.17 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.537 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.547 ' CE1' HG13 ' A' ' 129' ' ' VAL . 24.7 p90 -162.2 174.16 13.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.943 0.402 . . . . 0.0 110.949 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -177.94 -161.29 25.86 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.471 179.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -153.09 148.19 26.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.85 0.357 . . . . 0.0 110.897 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.566 HG11 ' CD2' ' A' ' 116' ' ' PHE . 16.9 m -118.63 -177.16 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.175 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . 0.455 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 40.5 mtmt -144.17 157.21 44.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.878 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 76.3 m-85 -146.93 160.72 41.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 32.8 p -102.01 -16.08 16.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.191 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -120.28 110.72 16.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.836 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 11.9 tt0 -57.91 -41.59 82.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.887 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 75.4 mt -48.16 -47.96 34.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.935 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.557 ' N ' ' CD ' ' A' ' 149' ' ' GLU . 0.0 OUTLIER -72.22 -44.6 62.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.887 179.899 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.437 ' C ' ' O ' ' A' ' 149' ' ' GLU . 20.2 tt0 -34.84 -58.59 0.51 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.93 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 12.6 mmtp -63.49 -34.35 77.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.912 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . 0.57 ' HB3' ' CE1' ' A' ' 120' ' ' TYR . 4.0 tpt180 -51.61 -41.03 60.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.849 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -71.77 -44.77 63.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.091 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . . . . . . . . . 29.7 mt -50.47 -38.34 43.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 14.6 t -92.57 -37.08 12.66 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.402 ' CG ' ' O ' ' A' ' 152' ' ' ARG . 6.7 mm-40 -83.05 -65.02 1.06 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.897 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.494 ' N ' ' O ' ' A' ' 153' ' ' ALA . 76.2 m -62.8 -8.22 6.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.921 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -37.71 128.96 1.14 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.858 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 50.36 38.89 34.99 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.464 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.465 ' HB2' ' CG2' ' A' ' 168' ' ' VAL . . . -60.0 116.35 4.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.813 0.34 . . . . 0.0 111.141 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.42 ' O ' ' C ' ' A' ' 162' ' ' GLY . 23.9 t -85.28 -37.85 12.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.144 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.75 -37.2 0.21 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.514 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.476 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 17.0 tp -86.38 114.52 23.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.848 0.356 . . . . 0.0 110.926 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 64.54 151.78 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.487 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 9.4 t -51.3 -25.28 5.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.948 0.404 . . . . 0.0 110.835 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 53.5 mttt -106.45 156.18 37.46 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.568 0.699 . . . . 0.0 110.892 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -175.42 1.15 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.682 2.255 . . . . 0.0 112.323 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.465 ' CG2' ' HB2' ' A' ' 160' ' ' ALA . 12.6 m -137.84 128.63 37.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.139 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 7.8 mtp85 -88.51 111.89 22.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.846 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . . . . . . . . . 15.3 mt -91.83 140.47 29.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.918 -179.967 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 13.9 m -155.83 -177.61 6.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.833 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 4.7 t -102.69 100.13 9.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.149 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -78.39 172.56 13.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.119 179.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 10.8 mt -141.35 129.13 12.01 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.594 0.711 . . . . 0.0 111.136 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.69 4.32 2.23 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.71 2.274 . . . . 0.0 112.304 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 20.9 ttmt -119.98 -56.97 1.98 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.92 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . 37.75 38.83 0.18 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.143 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 92.9 p -171.4 143.68 1.85 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.85 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 17.2 tpp85 -112.03 80.93 1.38 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.859 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 84.1 t -88.7 148.41 4.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.114 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 59.2 tttp -149.04 136.53 11.08 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.607 0.717 . . . . 0.0 110.897 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 102.11 0.98 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.685 2.257 . . . . 0.0 112.345 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 89.8 t -53.81 117.62 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.123 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -106.47 136.14 46.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.887 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 5.9 m -137.51 112.31 8.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -118.58 74.22 0.3 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.446 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 171.95 13.58 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.678 2.252 . . . . 0.0 112.315 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 6.3 t -140.41 111.2 6.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.896 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 50.0 p -169.49 169.64 8.73 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.864 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.272 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.486 -179.972 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.447 -0.261 . . . . 0.0 112.447 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 1.1 t -140.17 147.72 40.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.88 0.371 . . . . 0.0 110.892 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.1 t -104.57 89.36 3.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . 0.446 ' O ' ' C ' ' A' ' 91' ' ' SER . . . 76.08 99.06 0.14 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.503 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' SER . . . . . 0.446 ' C ' ' O ' ' A' ' 90' ' ' GLY . 11.4 t -34.98 135.5 0.2 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.875 0.369 . . . . 0.0 110.843 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 60.7 m -117.1 -56.22 2.27 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.855 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -178.41 107.85 0.24 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.469 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 84.07 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.624 2.216 . . . . 0.0 112.322 -179.949 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -146.04 133.37 20.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.869 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . 0.489 ' CE2' ' HB2' ' A' ' 147' ' ' GLU . 47.5 m-85 -131.15 106.41 8.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.944 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 11.1 m -120.65 154.79 35.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.849 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 22.4 mt -120.37 144.48 47.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.927 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -94.96 123.06 38.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.9 m -114.88 149.05 17.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.44 -175.1 13.65 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.509 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 50.83 50.01 19.89 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.806 0.336 . . . . 0.0 110.897 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 30.9 mt -98.94 104.34 16.38 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.924 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 14.9 p -49.08 150.16 3.01 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.583 0.706 . . . . 0.0 111.112 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 2.95 3.08 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.651 2.234 . . . . 0.0 112.342 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -99.69 -13.4 19.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.865 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . 0.452 ' HA ' ' CE ' ' A' ' 111' ' ' MET . 73.1 t -96.2 138.95 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.153 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.94 -176.11 3.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.849 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -65.4 -41.74 93.33 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.88 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.47 -34.47 13.78 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.475 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' MET . . . . . 0.452 ' CE ' ' HA ' ' A' ' 107' ' ' VAL . 25.5 mtm -81.71 -49.61 10.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.816 0.341 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.464 HD12 ' CD2' ' A' ' 163' ' ' LEU . 18.9 tp -50.86 -34.42 27.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.925 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . . . . . . . . . 12.9 t80 -68.8 -61.45 1.8 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.946 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.458 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 17.1 mt-10 -57.28 -53.86 53.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.847 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -42.3 -32.46 0.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.489 ' O ' ' N ' ' A' ' 118' ' ' LYS . 7.6 m-85 -95.17 -67.97 0.83 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.458 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.7 -29.37 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.489 ' N ' ' O ' ' A' ' 116' ' ' PHE . 19.1 tptt -67.46 -60.67 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 3.1 p -65.18 -31.91 55.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.133 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -134.11 114.3 12.7 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.647 0.737 . . . . 0.0 110.965 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.31 8.25 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.678 2.252 . . . . 0.0 112.377 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 87.2 p -85.9 -16.45 38.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.834 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.4 t -52.22 139.7 23.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.839 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.426 ' CG ' HG23 ' A' ' 145' ' ' THR . 42.0 mtm180 -105.0 -33.57 8.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.875 -179.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 166.66 145.62 4.54 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.451 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -95.25 137.54 13.49 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.475 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -125.87 122.43 36.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.783 0.325 . . . . 0.0 110.914 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.407 HG23 ' N ' ' A' ' 129' ' ' VAL . 6.0 p -113.62 138.14 44.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.137 179.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.537 HG22 ' CD1' ' A' ' 139' ' ' TYR . 33.7 m -86.17 152.08 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.131 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . 0.402 HD23 ' N ' ' A' ' 136' ' ' SER . 17.8 mt -130.84 176.37 8.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.486 ' O ' ' N ' ' A' ' 134' ' ' GLY . 25.6 t0 -107.52 174.27 5.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -39.6 -40.27 0.86 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.909 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 30.4 p -74.83 -33.75 62.22 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.158 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 112.83 17.78 7.75 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.498 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 34.0 m -97.88 133.47 39.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.872 0.368 . . . . 0.0 111.105 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' SER . . . . . 0.402 ' N ' HD23 ' A' ' 130' ' ' LEU . 2.6 t -43.2 105.68 0.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.889 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.498 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 27.1 mtmt -50.64 -35.82 32.39 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.897 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 129.27 20.22 1.45 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.483 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.537 ' CD1' HG22 ' A' ' 129' ' ' VAL . 27.4 p90 -163.81 169.06 18.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.909 0.385 . . . . 0.0 110.95 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -171.87 -163.29 25.54 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.446 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -153.58 148.67 26.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.89 0.376 . . . . 0.0 110.898 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.564 HG23 ' CE2' ' A' ' 144' ' ' PHE . 27.8 m -124.6 168.49 17.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . 0.448 ' N ' ' HD3' ' A' ' 143' ' ' LYS . 0.0 OUTLIER -125.97 159.19 33.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.936 179.896 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.564 ' CE2' HG23 ' A' ' 142' ' ' VAL . 95.2 m-85 -145.37 157.5 44.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.915 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' THR . . . . . 0.426 HG23 ' CG ' ' A' ' 124' ' ' ARG . 76.4 p -96.73 -19.22 19.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.169 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -120.64 120.58 36.14 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.863 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.489 ' HB2' ' CE2' ' A' ' 96' ' ' TYR . 0.1 OUTLIER -67.31 -39.19 85.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 39.3 mt -52.62 -34.44 51.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.911 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -85.06 -37.07 20.76 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.876 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 -43.84 -57.28 3.35 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 73.2 mttt -65.07 -27.53 68.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 15.1 ttt180 -59.94 -40.88 90.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.849 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.488 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -69.33 -46.12 67.85 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.136 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.43 ' O ' ' NE2' ' A' ' 158' ' ' GLN . 29.7 mt -43.62 -40.82 4.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.906 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.433 HG22 ' N ' ' A' ' 156' ' ' GLU . 10.9 t -92.52 -45.32 8.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.119 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.433 ' N ' HG22 ' A' ' 155' ' ' THR . 12.2 mm-40 -67.38 -60.08 2.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.894 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.488 ' N ' ' O ' ' A' ' 153' ' ' ALA . 4.8 m -78.21 9.59 3.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . 0.43 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.8 tp-100 -51.85 128.73 24.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.894 -179.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 51.37 35.23 35.25 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.405 ' N ' HG23 ' A' ' 168' ' ' VAL . . . -57.94 121.94 11.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.794 0.33 . . . . 0.0 111.122 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 25.6 t -93.38 -34.72 6.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.65 -34.12 0.24 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.501 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.464 ' CD2' HD12 ' A' ' 112' ' ' LEU . 29.1 tp -91.57 115.69 28.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.822 0.344 . . . . 0.0 110.895 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 65.17 146.14 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.531 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 6.2 t -48.97 -20.45 0.52 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.912 0.387 . . . . 0.0 110.86 -179.753 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 16.2 mtmt -108.48 155.29 40.69 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.586 0.708 . . . . 0.0 110.916 179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 -173.07 0.65 Allowed 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.672 2.248 . . . . 0.0 112.38 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.405 HG23 ' N ' ' A' ' 160' ' ' ALA . 34.6 m -139.62 124.53 20.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.075 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 39.8 ttm-85 -91.4 99.99 12.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.868 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.406 HD11 ' CB ' ' A' ' 157' ' ' CYS . 14.0 mt -76.36 145.73 39.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.905 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.421 ' N ' ' CD2' ' A' ' 154' ' ' LEU . 4.3 m -160.74 178.32 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.847 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 36.9 t -105.61 104.17 16.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.143 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -93.37 131.05 38.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.115 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . 0.474 ' CG2' ' HD2' ' A' ' 175' ' ' PRO . 84.7 mt -128.36 138.52 33.21 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.59 0.709 . . . . 0.0 111.144 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.474 ' HD2' ' CG2' ' A' ' 174' ' ' ILE . 53.8 Cg_endo -69.75 152.29 69.35 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.699 2.266 . . . . 0.0 112.355 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 17.9 ttpt -41.91 108.85 0.1 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.907 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -40.45 -59.06 1.41 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.097 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 3.4 m -155.33 178.26 10.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.859 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 69.6 ttt180 -90.3 134.23 34.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.929 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 78.2 t -109.74 132.98 56.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.157 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -136.02 144.96 50.48 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.569 0.699 . . . . 0.0 110.898 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.84 101.29 0.9 Allowed 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.627 2.218 . . . . 0.0 112.33 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 79.7 t -101.21 111.23 30.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.147 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.9 tt0 -104.39 129.39 52.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.911 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 79.6 p -162.44 147.9 12.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.842 -179.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -163.52 146.25 11.41 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.498 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 172.13 13.18 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.698 2.265 . . . . 0.0 112.334 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 67.9 p -171.25 164.68 7.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.845 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 36.0 t -163.9 159.1 20.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.853 -179.784 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.497 179.995 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.288 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 79.5 p -58.76 155.01 13.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.884 0.374 . . . . 0.0 110.865 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 19.5 m -71.36 89.1 0.9 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.849 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -145.99 -119.9 1.25 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.506 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 30.0 t -55.05 150.3 10.65 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.928 0.395 . . . . 0.0 110.839 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 46.3 m -118.09 55.64 0.88 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.849 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 39.03 73.45 0.16 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.496 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.84 173.56 10.86 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.668 2.245 . . . . 0.0 112.312 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -85.76 143.27 28.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.876 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . 0.499 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 21.1 m-85 -124.22 127.49 47.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.902 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 12.3 p -137.48 145.45 43.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.864 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 47.1 mt -120.99 139.17 53.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.945 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 12.3 t80 -90.22 131.07 36.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.899 179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 25.2 m -121.99 155.77 26.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.142 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -142.92 178.17 21.4 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.449 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 52.93 53.87 11.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.817 0.341 . . . . 0.0 110.831 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 24.6 mt -100.35 100.17 10.92 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.905 -179.988 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 58.5 p -46.71 150.0 1.35 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.552 0.691 . . . . 0.0 111.172 179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 2.75 3.25 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -102.43 6.81 40.34 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.835 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 12.9 t -119.6 129.93 74.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.124 179.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -116.95 177.03 4.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.86 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -51.05 -53.75 30.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.836 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -38.74 -35.61 0.37 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.44 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' MET . . . . . . . . . . . . . 48.7 mtp -81.93 -59.43 2.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.807 0.336 . . . . 0.0 110.901 -179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.462 HD13 ' CD2' ' A' ' 163' ' ' LEU . 22.5 tp -42.08 -31.43 0.36 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.914 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.53 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 10.9 t80 -72.24 -66.59 0.63 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.942 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.451 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 46.8 mt-10 -52.43 -47.39 66.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.873 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . 0.492 ' CZ ' ' HB2' ' A' ' 163' ' ' LEU . 60.4 t80 -48.11 -33.08 7.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.896 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.451 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.1 m-85 -94.99 -66.23 0.93 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.904 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.451 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.74 -31.45 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.122 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.451 ' N ' ' O ' ' A' ' 116' ' ' PHE . 30.3 tttp -64.66 -58.16 7.06 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.878 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.571 HG22 ' CE2' ' A' ' 120' ' ' TYR . 2.8 p -66.7 -33.97 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.148 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.571 ' CE2' HG22 ' A' ' 119' ' ' VAL . 90.2 m-85 -129.55 115.09 18.21 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.714 0.768 . . . . 0.0 110.935 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -2.72 10.67 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.678 2.252 . . . . 0.0 112.361 179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 56.4 m -104.85 39.87 1.61 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 49.6 t -98.17 132.43 43.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.89 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.435 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 19.7 mmt180 -83.26 -35.26 25.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 -179.847 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.53 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 148.34 139.99 3.26 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.464 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -82.88 148.61 25.97 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.509 -179.892 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . 0.413 ' N ' HD23 ' A' ' 112' ' ' LEU . 12.5 tptp -139.47 117.25 11.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.84 0.352 . . . . 0.0 110.881 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . 0.417 HG23 ' N ' ' A' ' 129' ' ' VAL . 7.6 p -106.04 146.76 12.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.145 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.421 HG21 ' CE2' ' A' ' 139' ' ' TYR . 30.1 m -93.66 150.93 3.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.08 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 15.5 mt -129.57 165.43 21.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.864 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -95.7 -177.2 3.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.848 179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -50.08 -37.6 34.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.941 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 41.0 p -75.16 -33.67 61.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.172 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 114.64 18.46 6.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.472 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 34.9 m -98.06 144.57 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.844 0.354 . . . . 0.0 111.114 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.9 t -56.79 105.06 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.476 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.1 mtmt -47.84 -29.18 3.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.89 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 121.0 18.37 3.88 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.542 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.476 ' CE2' ' HE3' ' A' ' 137' ' ' LYS . 9.9 p90 -161.8 175.89 11.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.926 0.393 . . . . 0.0 110.926 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -178.88 -162.23 27.94 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.44 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -153.64 146.32 24.24 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.896 0.379 . . . . 0.0 110.895 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 15.8 m -121.2 -176.61 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.136 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . 0.435 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 39.8 mtmt -144.56 162.78 35.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.886 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -149.78 159.04 44.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' THR . . . . . 0.423 HG21 ' NE ' ' A' ' 124' ' ' ARG . 69.8 p -93.92 -33.27 13.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.129 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 21.2 t0 -108.53 115.89 30.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.871 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.499 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 7.6 tt0 -59.62 -36.25 75.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.924 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 62.9 mt -53.31 -40.11 64.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.91 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.555 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 61.7 mt-10 -85.79 -22.48 27.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.856 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 18.3 tt0 -57.73 -53.67 55.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.91 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 3.2 mtpm? -69.24 -43.62 73.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.935 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 53.1 mtt-85 -45.54 -35.96 4.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.844 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.502 ' HB1' ' CE2' ' A' ' 120' ' ' TYR . . . -72.2 -43.43 64.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . . . . . . . . . 17.6 mt -46.1 -41.79 12.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.455 HG21 ' N ' ' A' ' 156' ' ' GLU . 12.3 t -91.37 -48.96 6.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.455 ' N ' HG21 ' A' ' 155' ' ' THR . 43.2 mm-40 -62.07 -66.5 0.53 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . . . . . . . . . 66.4 m -62.83 -13.01 28.47 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.89 -179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . 0.466 ' N ' HD12 ' A' ' 170' ' ' LEU . 4.2 tp-100 -37.68 131.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.926 -179.847 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 59.9 30.24 69.35 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.485 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -52.94 111.35 0.65 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.834 0.35 . . . . 0.0 111.083 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.4 t -89.35 -38.82 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.141 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -41.1 -32.35 0.6 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.451 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.492 ' HB2' ' CZ ' ' A' ' 115' ' ' PHE . 24.1 tp -90.84 116.27 28.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.857 0.36 . . . . 0.0 110.95 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 62.08 143.03 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.45 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 50.2 m -42.08 -32.16 0.43 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.934 0.397 . . . . 0.0 110.868 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 24.5 mttm -100.76 154.38 37.2 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.535 0.684 . . . . 0.0 110.888 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -178.99 2.6 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.697 2.264 . . . . 0.0 112.368 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 34.1 m -131.48 125.35 56.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.099 179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 35.0 ttm180 -88.57 104.96 17.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.868 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.466 HD12 ' N ' ' A' ' 158' ' ' GLN . 9.1 mt -84.18 145.86 28.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.938 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 5.1 m -159.24 173.72 15.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.855 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 5.4 t -95.25 90.79 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.163 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -78.77 167.01 21.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.095 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 63.2 mt -124.23 123.08 26.01 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.64 0.733 . . . . 0.0 111.126 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.4 ' O ' ' C ' ' A' ' 176' ' ' LYS . 53.9 Cg_endo -69.83 -179.92 3.28 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.682 2.254 . . . . 0.0 112.326 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . 0.4 ' C ' ' O ' ' A' ' 175' ' ' PRO . 45.3 mtpt -37.37 114.62 0.34 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.906 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -122.9 103.78 8.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.096 179.814 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 28.5 t -64.89 140.45 58.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.876 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 21.0 ttt-85 -112.85 151.24 30.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.851 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 28.3 m -99.14 126.79 52.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.103 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 11.5 tptt -86.78 131.85 44.03 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.518 0.675 . . . . 0.0 110.906 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 161.99 43.8 Favored 'Trans proline' 0 N--CA 1.465 -0.149 0 C-N-CA 122.713 2.275 . . . . 0.0 112.344 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 35.6 m -109.05 129.97 62.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.077 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -120.52 151.56 39.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 3.3 t -160.96 113.62 1.94 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.871 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -60.02 145.02 46.47 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.453 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 149.63 67.03 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.684 2.256 . . . . 0.0 112.333 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 4.0 t -126.22 126.24 43.72 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.854 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 32.7 t -83.23 -48.24 10.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.835 -179.814 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 -179.975 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 89.2 p -136.28 155.16 50.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.859 0.362 . . . . 0.0 110.859 -179.721 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 82.0 p 42.53 41.95 2.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.854 -179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -67.25 -54.89 18.09 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.465 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 73.1 m -103.08 151.34 22.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.866 0.365 . . . . 0.0 110.894 -179.755 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 95.3 p -70.35 174.42 5.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.83 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 112.0 72.14 0.62 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.496 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 91.62 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.684 2.256 . . . . 0.0 112.394 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -154.87 135.41 13.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.89 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 -142.92 114.21 7.84 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.917 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 77.3 p -129.53 157.36 42.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.867 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.468 HD22 ' CD2' ' A' ' 154' ' ' LEU . 87.1 mt -127.47 148.65 50.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.904 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -95.78 130.49 42.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.882 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -122.72 139.35 49.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.147 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -126.9 178.98 16.57 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.484 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 53.34 51.47 15.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.85 0.357 . . . . 0.0 110.903 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 21.3 mt -95.48 101.05 12.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 63.3 p -48.49 150.11 2.54 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.588 0.709 . . . . 0.0 111.133 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 2.96 3.04 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.679 2.253 . . . . 0.0 112.334 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -102.75 2.5 35.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.843 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 5.7 t -108.49 136.64 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.116 -179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -124.66 168.43 13.17 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.906 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -46.29 -45.9 17.62 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.833 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.97 -36.45 20.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.512 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' MET . . . . . . . . . . . . . 19.2 mtp -78.56 -58.4 3.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.772 0.32 . . . . 0.0 110.846 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . 0.459 HD11 ' CD2' ' A' ' 163' ' ' LEU . 19.4 tp -45.32 -36.27 4.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.935 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.522 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 7.4 t80 -67.24 -61.11 2.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.901 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.451 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 44.6 mt-10 -57.17 -54.58 45.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.872 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . 0.49 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 69.5 t80 -42.08 -32.19 0.44 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.855 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.496 ' O ' ' N ' ' A' ' 118' ' ' LYS . 7.8 m-85 -95.19 -67.54 0.85 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.892 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.451 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.69 -29.17 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.081 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.496 ' N ' ' O ' ' A' ' 116' ' ' PHE . 46.3 tttp -67.88 -57.19 6.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.907 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.538 HG21 ' CE2' ' A' ' 120' ' ' TYR . 3.8 p -71.15 -25.1 24.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.114 179.856 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.538 ' CE2' HG21 ' A' ' 119' ' ' VAL . 95.9 m-85 -135.26 109.17 10.44 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.702 0.763 . . . . 0.0 110.926 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 2.96 3.09 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.716 2.278 . . . . 0.0 112.357 179.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 15.0 m -109.97 30.83 6.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.834 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 42.6 t -92.83 132.12 37.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.903 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.445 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 42.2 mtp180 -83.31 -29.13 28.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.909 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.522 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 147.0 139.24 3.25 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.488 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -93.24 135.9 12.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.512 -179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -121.4 143.71 49.07 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.784 0.326 . . . . 0.0 110.95 -179.988 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.97 127.16 72.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.13 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.57 HG22 ' CE1' ' A' ' 139' ' ' TYR . 7.0 m -76.32 138.19 21.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.149 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 26.1 mt -116.28 160.68 20.12 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -87.88 -176.58 5.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -52.85 -37.24 60.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.921 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 27.6 p -75.76 -21.81 57.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.091 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.99 22.36 10.12 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.456 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 24.0 m -106.3 140.83 23.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.797 0.332 . . . . 0.0 111.159 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 2.7 t -47.06 108.63 0.15 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.867 -179.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.465 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 30.4 mtmt -54.64 -32.26 58.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.912 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.24 17.44 2.44 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.491 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.57 ' CE1' HG22 ' A' ' 129' ' ' VAL . 17.2 p90 -163.76 171.27 15.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.913 0.387 . . . . 0.0 110.937 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -172.75 -162.59 25.13 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.447 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -154.0 142.4 20.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.878 0.37 . . . . 0.0 110.896 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.472 HG12 ' CE2' ' A' ' 116' ' ' PHE . 29.0 m -117.24 170.9 6.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.126 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . 0.445 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -131.05 160.54 34.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.948 179.849 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -148.81 162.53 39.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.903 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 33.7 p -98.41 -26.6 14.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.154 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . 0.431 ' CG ' ' OE1' ' A' ' 149' ' ' GLU . 4.9 t70 -112.1 119.73 39.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.864 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -67.29 -31.65 72.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.908 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 21.7 mt -56.81 -54.01 51.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.893 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 150' ' ' GLN . 1.9 mp0 -64.81 -45.87 84.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.905 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.449 ' C ' ' O ' ' A' ' 149' ' ' GLU . 21.7 tt0 -33.46 -46.86 0.2 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.949 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . 0.434 ' O ' ' N ' ' A' ' 154' ' ' LEU . 13.8 mmtp -66.98 -55.76 13.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -38.69 -35.12 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.481 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -72.72 -44.89 61.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.468 ' CD2' HD22 ' A' ' 98' ' ' LEU . 16.1 mt -47.16 -38.95 12.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.925 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.46 HG22 ' N ' ' A' ' 156' ' ' GLU . 12.1 t -92.47 -51.12 5.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.145 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.46 ' N ' HG22 ' A' ' 155' ' ' THR . 79.1 mm-40 -64.35 -57.79 8.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.462 ' N ' ' O ' ' A' ' 153' ' ' ALA . 53.3 m -75.18 5.33 5.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.871 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 3.3 tp-100 -53.1 137.45 33.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.903 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 45.48 37.24 6.39 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.468 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . 0.403 ' CB ' ' CG2' ' A' ' 168' ' ' VAL . . . -54.89 116.19 2.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.894 0.378 . . . . 0.0 111.104 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 32.7 t -94.74 -33.45 4.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.16 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -45.04 -33.55 3.77 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.51 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.49 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 56.4 tp -85.63 115.24 23.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.866 0.365 . . . . 0.0 110.915 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 69.88 175.21 14.81 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.51 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 11.7 m -84.19 25.87 0.81 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.92 0.391 . . . . 0.0 110.825 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 19.7 mttp -157.24 157.05 30.16 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.585 0.707 . . . . 0.0 110.909 179.924 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 170.24 17.02 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.654 2.236 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . 0.403 ' CG2' ' CB ' ' A' ' 160' ' ' ALA . 30.1 m -132.37 125.98 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.129 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 36.3 ttt85 -88.89 117.12 27.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.46 HD13 ' CB ' ' A' ' 157' ' ' CYS . 11.7 mt -93.24 139.37 30.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.894 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 15.9 m -156.55 173.0 17.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.836 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 15.6 t -93.79 99.21 9.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.134 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -82.23 128.36 34.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.06 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 25.8 mt -79.1 126.88 81.05 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.599 0.714 . . . . 0.0 111.136 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 4.63 2.09 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.723 2.282 . . . . 0.0 112.348 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . 0.421 ' HG2' ' N ' ' A' ' 177' ' ' ALA . 34.4 tttt -144.03 148.83 35.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.944 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . 0.421 ' N ' ' HG2' ' A' ' 176' ' ' LYS . . . -166.14 151.41 8.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.069 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 95.5 p -135.38 130.74 35.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.907 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 15.7 ttt180 -150.56 123.14 8.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.898 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 94.2 t -111.51 88.31 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.158 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . 0.427 ' CG ' ' HD2' ' A' ' 182' ' ' PRO . 45.3 tttp -81.31 138.63 48.46 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.609 0.719 . . . . 0.0 110.862 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . 0.427 ' HD2' ' CG ' ' A' ' 181' ' ' LYS . 53.5 Cg_endo -69.82 178.83 4.2 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.662 2.242 . . . . 0.0 112.357 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 9.8 p -109.22 131.58 59.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.104 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.1 mp0 -80.62 128.97 34.22 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.919 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 78.4 p -128.96 107.87 9.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.872 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 174.86 143.62 4.55 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.488 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 -179.25 2.77 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.672 2.248 . . . . 0.0 112.33 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 17.4 m -145.53 157.54 43.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.836 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.9 t -51.14 156.05 1.17 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.828 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.479 179.983 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 55.7 p -146.05 142.03 28.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.826 0.346 . . . . 0.0 110.881 -179.731 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 32.3 m -74.89 -46.0 39.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.813 -179.772 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.68 89.81 2.01 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.504 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 76.8 p -131.91 139.21 48.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.891 0.377 . . . . 0.0 110.879 -179.768 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 3.5 t -59.08 153.98 16.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.818 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -83.75 149.09 25.31 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.501 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 150.67 68.48 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.667 2.245 . . . . 0.0 112.335 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -83.29 160.17 21.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' TYR . . . . . 0.466 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 4.3 m-85 -120.03 104.74 10.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.946 -179.881 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 35.4 p -126.72 155.02 43.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.836 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . 0.512 HD12 ' CE1' ' A' ' 144' ' ' PHE . 85.9 mt -124.87 139.57 53.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -90.27 125.97 35.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.9 m -120.8 141.43 41.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.131 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -129.78 -175.87 14.21 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.431 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 51.13 52.65 14.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.839 0.352 . . . . 0.0 110.88 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 22.3 mt -98.49 112.67 24.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.978 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 10.2 p -58.55 150.82 54.29 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.591 0.71 . . . . 0.0 111.115 -179.982 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 2.42 3.55 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.689 2.259 . . . . 0.0 112.342 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -99.42 -5.67 29.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.822 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' VAL . . . . . . . . . . . . . 31.6 t -102.08 143.49 14.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.162 -179.976 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -127.93 173.87 9.65 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -54.0 -45.25 71.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.862 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.99 -26.28 26.6 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.488 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' MET . . . . . . . . . . . . . 35.0 mtp -85.36 -58.52 2.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.825 0.345 . . . . 0.0 110.885 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 40.5 tp -42.86 -36.7 1.58 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.919 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' TYR . . . . . 0.448 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.6 t80 -66.3 -68.33 0.38 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.88 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.452 ' HA ' ' CG1' ' A' ' 117' ' ' VAL . 23.8 mt-10 -48.9 -41.72 34.48 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.91 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' PHE . . . . . 0.465 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 53.8 t80 -54.29 -34.1 60.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.849 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' PHE . . . . . 0.464 ' O ' ' N ' ' A' ' 118' ' ' LYS . 9.1 m-85 -95.19 -64.36 1.07 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.895 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.452 ' CG1' ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.7 -30.91 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.105 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' LYS . . . . . 0.464 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.1 ttpt -65.01 -61.17 2.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.916 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.503 HG22 ' CE2' ' A' ' 120' ' ' TYR . 2.5 p -66.78 -34.35 69.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.097 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' TYR . . . . . 0.503 ' CE2' HG22 ' A' ' 119' ' ' VAL . 90.7 m-85 -126.05 109.02 24.65 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.673 0.749 . . . . 0.0 110.946 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 2.13 3.8 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.69 2.26 . . . . 0.0 112.328 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 10.6 m -108.32 34.4 3.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.2 t -90.32 135.43 33.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.855 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.442 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 63.1 mtt180 -85.14 -36.39 21.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.448 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 154.48 143.04 3.58 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.484 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -91.52 138.68 14.4 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.488 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.71 131.96 45.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.79 0.328 . . . . 0.0 110.914 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 8.7 p -117.3 137.19 52.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.143 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' VAL . . . . . 0.569 HG21 ' CD1' ' A' ' 139' ' ' TYR . 18.7 m -81.03 148.44 5.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.118 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 16.3 mt -133.09 169.8 16.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.88 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -104.22 177.32 4.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -46.36 -36.47 6.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 41.5 p -77.75 -33.27 52.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.49 17.04 9.57 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.49 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 20.3 m -96.42 127.63 48.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.342 . . . . 0.0 111.104 -179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 9.3 t -43.79 108.86 0.12 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.869 -179.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' LYS . . . . . 0.51 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.5 mtmt -52.51 -31.36 34.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.932 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.36 19.77 2.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.524 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' TYR . . . . . 0.569 ' CD1' HG21 ' A' ' 129' ' ' VAL . 26.5 p90 -163.62 169.67 18.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.389 . . . . 0.0 110.915 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.14 -163.86 23.87 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.446 179.973 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -153.86 148.91 26.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.917 0.389 . . . . 0.0 110.871 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . 0.46 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 16.6 m -124.33 179.29 2.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.091 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' LYS . . . . . 0.442 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 22.9 mtpt -142.57 161.52 37.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.929 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.512 ' CE1' HD12 ' A' ' 98' ' ' LEU . 37.7 m-85 -149.9 153.66 37.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.877 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 51.5 p -91.5 -19.14 23.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -113.92 110.29 19.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.863 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' GLU . . . . . 0.466 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 16.0 tt0 -60.29 -35.75 76.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 93.6 mt -57.88 -45.01 87.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.946 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -74.56 -43.57 55.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.864 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' GLN . . . . . 0.426 ' C ' ' OE1' ' A' ' 150' ' ' GLN . 1.6 tm0? -44.18 -38.91 4.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.976 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 24.7 mmtt -76.51 -40.3 50.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.921 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 54.9 mtt85 -53.84 -31.58 49.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.906 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' ALA . . . . . 0.482 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -69.1 -54.06 17.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.101 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.423 HD21 ' CB ' ' A' ' 170' ' ' LEU . 21.8 mt -40.27 -36.33 0.51 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.907 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' THR . . . . . 0.451 HG21 ' N ' ' A' ' 156' ' ' GLU . 7.7 t -92.4 -42.36 9.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.122 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' GLU . . . . . 0.451 ' N ' HG21 ' A' ' 155' ' ' THR . 24.0 mm-40 -75.68 -62.93 1.42 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.903 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' CYS . . . . . 0.482 ' N ' ' O ' ' A' ' 153' ' ' ALA . 53.7 m -67.13 -3.82 8.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.7 tp-100 -41.8 131.11 3.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.91 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 47.4 41.18 16.7 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.539 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' ALA . . . . . . . . . . . . . . . -60.22 111.05 1.38 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.788 0.328 . . . . 0.0 111.109 -179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.7 t -84.97 -35.66 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.132 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.5 -35.53 0.33 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.473 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' LEU . . . . . 0.465 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 29.7 tp -88.7 122.12 31.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.861 0.362 . . . . 0.0 110.921 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 61.94 157.62 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.486 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 72.0 m -60.62 -12.51 10.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.923 0.392 . . . . 0.0 110.864 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 61.8 mttt -118.44 156.8 50.74 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.571 0.701 . . . . 0.0 110.88 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -177.26 1.8 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.651 2.234 . . . . 0.0 112.374 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' VAL . . . . . . . . . . . . . 29.8 m -138.73 124.76 24.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.154 179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 34.6 ttt180 -87.84 107.0 18.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' LEU . . . . . 0.442 HD12 ' CB ' ' A' ' 157' ' ' CYS . 10.3 mt -81.98 146.84 29.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.908 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 8.0 m -163.33 179.73 7.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.839 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 13.4 t -102.66 101.75 12.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.128 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -76.89 167.33 22.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.117 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 86.9 mt -113.24 124.03 32.26 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.633 0.73 . . . . 0.0 111.121 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -49.47 0.55 Allowed 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.636 2.224 . . . . 0.0 112.329 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 29.9 mtmt -147.08 123.49 10.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.891 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -93.29 -54.14 3.81 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.111 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 33.4 t -171.51 133.01 0.78 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.896 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 21.4 tpt180 -44.93 130.26 7.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.891 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 95.5 t -94.0 111.69 25.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.125 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 1.4 ttmp? -115.8 93.5 37.85 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.649 0.738 . . . . 0.0 110.88 179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.75 101.5 0.92 Allowed 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.666 2.244 . . . . 0.0 112.339 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 26.8 m -63.59 141.9 17.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.111 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -70.54 151.38 45.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.937 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 40.2 p -77.75 -48.34 16.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.866 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 83.87 143.18 5.47 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.452 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -178.22 2.23 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.693 2.262 . . . . 0.0 112.383 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 68.2 p -156.21 156.57 34.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.856 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 58.7 m -123.82 -49.76 1.85 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.845 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.467 -179.999 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 96' ' ' TYR . . . . . 0.523 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 67.3 m-85 . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.872 0.367 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.8 m -97.91 161.68 13.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.876 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.884 HD22 HD21 ' A' ' 154' ' ' LEU . 26.0 mt -125.78 143.57 51.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.899 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -93.47 115.78 28.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.523 HG22 ' C ' ' A' ' 140' ' ' GLY . 5.3 m -108.09 148.48 12.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.143 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.7 -177.41 15.14 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.505 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ASP . . . . . 0.42 ' N ' ' O ' ' A' ' 138' ' ' GLY . 24.8 m-20 50.87 51.81 16.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.868 0.366 . . . . 0.0 110.887 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.412 HD11 ' CG2' ' A' ' 100' ' ' VAL . 31.1 mt -98.27 102.58 14.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.897 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.501 ' OG1' HG23 ' A' ' 107' ' ' VAL . 72.9 p -47.57 149.85 1.94 Allowed Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.583 0.706 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 2.99 3.07 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.675 2.25 . . . . 0.0 112.327 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -98.32 -16.47 19.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.905 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.596 HG22 ' HE3' ' A' ' 111' ' ' MET . 51.1 t -93.39 145.56 7.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.161 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -129.78 -179.72 5.36 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.862 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -57.77 -51.12 70.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -39.85 -36.18 0.75 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.596 ' HE3' HG22 ' A' ' 107' ' ' VAL . 18.5 mtm -82.79 -59.26 2.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.795 0.331 . . . . 0.0 110.916 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.436 HD23 ' N ' ' A' ' 127' ' ' LYS . 25.2 tp -36.05 -44.02 0.36 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.88 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.406 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 16.1 t80 -63.6 -61.16 2.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.907 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.755 ' HA ' HG12 ' A' ' 117' ' ' VAL . 18.3 mt-10 -54.17 -55.68 25.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.862 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.828 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 71.3 t80 -41.13 -32.29 0.25 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.873 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.48 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.5 m-85 -95.25 -68.16 0.82 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.841 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.755 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.7 -30.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.148 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.48 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.5 ttpt -68.78 -53.96 18.69 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.888 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.574 HG13 ' CD2' ' A' ' 120' ' ' TYR . 2.6 p -70.73 -31.47 45.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.109 179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.574 ' CD2' HG13 ' A' ' 119' ' ' VAL . 94.2 m-85 -135.84 114.47 11.04 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.679 0.752 . . . . 0.0 110.913 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.82 0.53 5.55 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.658 2.239 . . . . 0.0 112.361 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 26.0 m -98.2 21.01 11.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.885 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 7.7 t -84.72 134.78 34.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.888 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 9.0 mmt85 -91.87 -38.94 12.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.836 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.406 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.96 152.27 7.13 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.536 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.406 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -101.66 143.01 15.9 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.488 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.436 ' N ' HD23 ' A' ' 112' ' ' LEU . 21.7 tptm -132.78 127.38 34.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 110.865 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.5 p -116.8 127.18 74.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.145 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.959 HG22 ' O ' ' A' ' 139' ' ' TYR . 20.3 m -73.91 143.65 13.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.127 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.627 HD23 ' HA ' ' A' ' 136' ' ' SER . 25.5 mt -130.57 163.82 26.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.927 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 134' ' ' GLY . 23.8 t70 -94.68 176.17 6.38 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -44.34 -40.38 5.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.894 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 18.1 p -72.37 -28.58 63.11 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.179 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 104.98 20.36 9.92 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.487 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 26.1 m -99.64 134.75 37.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.831 0.348 . . . . 0.0 111.15 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.627 ' HA ' HD23 ' A' ' 130' ' ' LEU . 6.0 t -48.62 112.92 0.67 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.813 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.3 mtmt -58.69 -28.56 65.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.954 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 122.83 15.25 3.97 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.441 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.959 ' O ' HG22 ' A' ' 129' ' ' VAL . 29.8 p90 -161.88 167.99 23.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.896 0.379 . . . . 0.0 110.912 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.523 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -169.64 -160.02 16.85 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.467 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -153.7 148.64 26.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.9 0.381 . . . . 0.0 110.874 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.446 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 28.5 m -123.3 170.6 13.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.077 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 25.3 mttt -129.67 156.06 44.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -143.09 171.56 13.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.9 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 1.7 p -108.3 -28.79 9.23 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -113.1 128.4 56.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.881 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.523 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 12.9 tm-20 -69.37 -38.37 78.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.87 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 26.9 mt -51.0 -44.82 60.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -73.16 -42.88 62.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.852 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 19.8 tt0 -38.74 -57.94 1.14 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.928 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 9.2 mmmm -63.21 -49.32 74.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.91 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 34.4 mtt-85 -43.43 -41.06 4.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.832 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.98 -44.3 76.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.098 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.884 HD21 HD22 ' A' ' 98' ' ' LEU . 24.2 mt -48.46 -40.63 26.98 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.906 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.1 t -91.36 -34.7 14.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 17.4 mm-40 -79.58 -65.1 1.04 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.876 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.549 ' C ' HD11 ' A' ' 170' ' ' LEU . 11.2 m -65.14 -8.74 18.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.877 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 158' ' ' GLN . . . . . 0.444 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.5 tp-100 -35.6 137.9 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.923 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.48 42.81 2.72 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.521 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.828 ' HB1' ' CZ ' ' A' ' 115' ' ' PHE . . . -57.75 110.9 0.98 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.803 0.335 . . . . 0.0 111.068 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.403 ' O ' ' C ' ' A' ' 162' ' ' GLY . 20.1 t -82.72 -41.76 17.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.135 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 162' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -37.87 -34.84 0.2 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.459 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.572 HD13 ' HB2' ' A' ' 115' ' ' PHE . 26.5 tp -90.23 115.77 27.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.811 0.339 . . . . 0.0 110.938 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.415 ' O ' ' C ' ' A' ' 165' ' ' SER . . . 62.52 137.85 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.481 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 165' ' ' SER . . . . . 0.415 ' C ' ' O ' ' A' ' 164' ' ' GLY . 1.2 t -37.4 -32.87 0.05 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.916 0.389 . . . . 0.0 110.866 -179.782 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 166' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 164' ' ' GLY . 58.0 mttt -100.46 153.6 37.65 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.519 0.676 . . . . 0.0 110.913 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -179.19 2.77 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.67 2.247 . . . . 0.0 112.311 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.787 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 13.8 m -130.59 129.68 64.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.1 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.6 ttt-85 -89.27 110.58 21.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.883 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.825 ' HB3' HD23 ' A' ' 154' ' ' LEU . 12.5 mt -87.24 144.59 26.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.927 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.2 m -160.89 175.06 12.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 2.6 t -102.66 104.43 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.136 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.074 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 96' ' ' TYR . . . . . 0.405 ' CD1' ' HG3' ' A' ' 147' ' ' GLU . 9.4 m-85 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.867 0.365 . . . . 0.0 110.98 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 51.6 m -124.92 154.12 41.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.872 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.72 HD21 ' HG2' ' A' ' 150' ' ' GLN . 96.1 mt -126.65 143.44 51.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.9 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.445 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 11.4 t80 -92.51 142.13 27.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.863 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 21.6 m -132.02 150.86 34.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.109 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.15 -174.32 13.27 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.489 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 46.55 54.74 8.37 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.797 0.332 . . . . 0.0 110.852 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.421 HD12 ' C ' ' A' ' 139' ' ' TYR . 29.6 mt -101.84 112.09 24.57 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.895 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.74 ' OG1' HG23 ' A' ' 107' ' ' VAL . 73.3 p -53.59 148.98 16.67 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.61 0.719 . . . . 0.0 111.126 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 2.14 3.78 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.71 2.273 . . . . 0.0 112.35 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -97.98 -17.52 19.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.868 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.74 HG23 ' OG1' ' A' ' 104' ' ' THR . 14.7 t -87.58 143.77 10.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.102 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -131.65 172.2 12.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.855 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -49.59 -46.31 48.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -49.25 -28.91 9.27 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.461 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.452 ' O ' ' N ' ' A' ' 113' ' ' TYR . 14.1 mtp -86.4 -66.54 0.89 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.814 0.34 . . . . 0.0 110.866 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.423 ' C ' ' O ' ' A' ' 111' ' ' MET . 24.6 tp -35.75 -32.88 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.887 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.452 ' N ' ' O ' ' A' ' 111' ' ' MET . 12.0 t80 -68.84 -65.01 0.76 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.927 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.725 ' HA ' HG12 ' A' ' 117' ' ' VAL . 18.4 mt-10 -55.59 -39.57 70.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.559 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 58.0 t80 -54.55 -33.88 60.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.886 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.46 ' O ' ' N ' ' A' ' 118' ' ' LYS . 10.0 m-85 -95.27 -64.92 1.01 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.818 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.725 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.78 -30.92 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.076 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.46 ' N ' ' O ' ' A' ' 116' ' ' PHE . 5.3 ttpm? -65.45 -58.79 4.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.874 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.612 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.5 p -64.56 -33.78 65.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.172 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.612 ' CD2' HG13 ' A' ' 119' ' ' VAL . 91.0 m-85 -135.44 116.53 11.97 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.664 0.745 . . . . 0.0 110.965 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 1.94 3.97 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.671 2.247 . . . . 0.0 112.365 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 86.4 p -87.85 -23.27 24.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.835 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 7.7 t -47.19 137.04 8.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.885 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 51.7 mtm180 -99.3 -36.53 9.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.874 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.42 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.53 143.2 3.65 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.493 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.512 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -87.16 145.24 19.69 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.492 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 21.5 tptm -131.49 110.65 11.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.855 0.359 . . . . 0.0 110.86 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.7 p -102.48 139.85 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.109 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.776 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 25.0 m -86.32 158.34 3.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.566 HD23 ' HA ' ' A' ' 136' ' ' SER . 24.2 mt -137.38 167.78 20.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.878 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.443 ' O ' ' N ' ' A' ' 134' ' ' GLY . 17.7 t0 -102.18 175.06 5.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.83 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -42.03 -42.07 2.75 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.948 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 65.2 p -72.82 -31.83 65.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.097 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 108.88 19.79 8.41 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.487 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 24.9 m -99.7 127.76 52.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.353 . . . . 0.0 111.114 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.566 ' HA ' HD23 ' A' ' 130' ' ' LEU . 3.0 t -40.21 106.76 0.06 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.831 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.551 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.7 mtmt -50.38 -37.16 35.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.944 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 128.81 18.7 1.71 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.459 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.776 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 16.3 p90 -160.81 173.41 15.41 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.953 0.406 . . . . 0.0 110.935 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -177.26 -163.85 29.95 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.484 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.445 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 2.5 m-85 -152.83 150.44 29.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.888 0.375 . . . . 0.0 110.9 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.512 HG12 ' HA2' ' A' ' 126' ' ' GLY . 28.1 m -123.83 174.54 7.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.174 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' LYS . . . . . 0.445 ' N ' ' HD3' ' A' ' 143' ' ' LYS . 0.5 OUTLIER -134.77 158.43 44.18 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 179.872 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.479 ' CE1' HD12 ' A' ' 98' ' ' LEU . 75.1 m-85 -143.03 160.98 39.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.89 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 75.3 p -95.38 -14.81 23.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.177 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -128.16 123.66 34.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.898 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.405 ' HG3' ' CD1' ' A' ' 96' ' ' TYR . 15.3 tt0 -64.45 -39.23 93.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.911 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 95.3 mt -47.7 -46.96 30.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.941 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 55.8 mm-40 -74.53 -33.46 62.77 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.847 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.72 ' HG2' HD21 ' A' ' 98' ' ' LEU . 33.0 tt0 -46.73 -40.93 14.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.919 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.0 mmtp -81.59 -46.83 13.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 46.0 mtt180 -44.27 -41.36 5.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.85 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.474 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.95 -42.97 80.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.848 HD23 ' HB3' ' A' ' 170' ' ' LEU . 29.9 mt -51.99 -38.14 55.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 14.3 t -92.35 -33.53 14.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.166 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 45.8 mm-40 -83.49 -66.07 0.94 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.898 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.623 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 87.7 m -59.66 -13.26 9.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.93 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 158' ' ' GLN . . . . . 0.476 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.3 tp-100 -39.0 140.33 0.39 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.893 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 50.43 36.42 30.46 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.497 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.7 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -67.55 110.94 3.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.863 0.364 . . . . 0.0 111.073 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.433 ' O ' ' C ' ' A' ' 162' ' ' GLY . 25.2 t -92.68 -35.91 7.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.132 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 162' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -35.12 -35.85 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.482 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.559 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 38.1 tp -86.21 117.45 25.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.843 0.354 . . . . 0.0 110.911 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 66.46 170.46 3.81 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.499 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' SER . . . . . 0.58 ' H ' HG21 ' A' ' 104' ' ' THR . 35.9 m -82.09 40.35 0.62 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.891 0.377 . . . . 0.0 110.873 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 166' ' ' LYS . . . . . 0.493 ' CG ' ' O ' ' A' ' 165' ' ' SER . 36.0 mttt -169.23 157.22 6.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.527 0.679 . . . . 0.0 110.912 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 172.37 12.77 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.677 2.251 . . . . 0.0 112.317 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.7 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 32.2 m -135.69 126.9 44.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.136 179.874 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 44.7 ttt180 -89.95 117.51 28.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.866 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.848 ' HB3' HD23 ' A' ' 154' ' ' LEU . 17.1 mt -93.35 145.19 24.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.97 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 9.9 m -158.16 174.25 15.48 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 39.4 t -98.69 102.08 12.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.082 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.152 179.811 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.894 0.378 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.9 m -121.15 154.87 35.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.604 HD21 ' HG2' ' A' ' 150' ' ' GLN . 83.2 mt -124.06 145.82 48.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -95.4 124.11 39.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.431 HG22 ' C ' ' A' ' 140' ' ' GLY . 33.0 m -115.25 148.41 18.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.131 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -136.19 -177.86 15.32 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.47 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 49.77 54.09 11.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.873 0.368 . . . . 0.0 110.88 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.421 HD12 ' C ' ' A' ' 139' ' ' TYR . 30.1 mt -100.51 102.56 13.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.936 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.419 HG21 ' HB2' ' A' ' 165' ' ' SER . 2.8 p -47.52 151.26 1.47 Allowed Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.591 0.71 . . . . 0.0 111.136 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.79 -1.38 8.4 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.689 2.259 . . . . 0.0 112.343 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -102.04 25.52 8.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.857 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.47 HG22 ' HE3' ' A' ' 111' ' ' MET . 22.2 t -134.62 138.73 49.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.148 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 45.0 m-20 -123.22 169.35 11.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.875 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.493 ' CG ' HG12 ' A' ' 128' ' ' VAL . 0.5 OUTLIER -46.77 -46.23 20.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 -179.958 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -41.8 -44.47 4.45 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.508 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.47 ' HE3' HG22 ' A' ' 107' ' ' VAL . 32.3 mtm -77.97 -41.37 36.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.785 0.326 . . . . 0.0 110.887 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 16.8 tp -57.05 -25.13 58.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.974 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.49 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 8.5 t80 -84.23 -63.03 1.42 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.905 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.726 ' HA ' HG12 ' A' ' 117' ' ' VAL . 23.9 mt-10 -55.39 -43.24 75.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.579 ' HB2' HD13 ' A' ' 163' ' ' LEU . 85.2 t80 -51.14 -33.02 24.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.845 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.557 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.9 m-85 -95.25 -65.78 0.95 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.726 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -37.16 -28.42 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.106 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.492 ' N ' ' O ' ' A' ' 116' ' ' PHE . 3.1 tptm -65.6 -53.73 37.62 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.937 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.551 HG13 ' CD2' ' A' ' 120' ' ' TYR . 4.1 p -71.16 -38.25 70.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 179.85 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.599 ' CE2' ' HB2' ' A' ' 153' ' ' ALA . 93.1 m-85 -127.17 116.19 21.75 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.629 0.728 . . . . 0.0 110.934 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 2.94 3.06 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.668 2.246 . . . . 0.0 112.365 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' SER . . . . . 0.684 ' O ' HG22 ' A' ' 145' ' ' THR . 18.5 p -89.96 -26.47 20.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.818 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' CYS . . . . . 0.549 ' HA ' ' CD2' ' A' ' 144' ' ' PHE . 9.5 t -45.25 128.39 7.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.936 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -90.08 -34.88 15.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.869 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.49 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 172.14 166.2 30.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.443 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -115.66 144.22 18.36 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.462 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 18.1 tptt -136.01 128.89 31.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.792 0.329 . . . . 0.0 110.916 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.493 HG12 ' CG ' ' A' ' 109' ' ' ASP . 6.5 p -119.02 127.32 75.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.165 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.885 HG22 ' O ' ' A' ' 139' ' ' TYR . 10.3 m -74.58 153.51 6.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.139 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.489 HD23 ' HA ' ' A' ' 136' ' ' SER . 13.4 mt -130.52 176.82 7.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 134' ' ' GLY . 18.3 t70 -108.23 174.41 5.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.875 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -40.98 -45.06 2.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.879 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 20.8 p -71.57 -34.26 69.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.111 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 113.53 20.92 5.98 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.485 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 136' ' ' SER . 27.3 m -100.44 122.85 52.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.855 0.36 . . . . 0.0 111.138 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.489 ' HA ' HD23 ' A' ' 130' ' ' LEU . 7.3 t -34.57 106.83 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.87 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.496 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 26.8 mtmt -50.45 -34.51 25.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.869 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.2 18.64 2.27 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.518 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.885 ' O ' HG22 ' A' ' 129' ' ' VAL . 19.1 p90 -163.08 165.89 24.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.966 0.412 . . . . 0.0 110.883 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.431 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -166.67 -161.35 15.59 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.512 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -154.03 145.51 23.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.915 0.388 . . . . 0.0 110.861 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.557 HG11 ' CD2' ' A' ' 116' ' ' PHE . 24.4 m -117.31 -176.09 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.133 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 20.2 mtmm -143.57 160.76 40.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.864 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.549 ' CD2' ' HA ' ' A' ' 123' ' ' CYS . 65.5 m-85 -149.85 179.32 8.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' THR . . . . . 0.684 HG22 ' O ' ' A' ' 122' ' ' SER . 0.1 OUTLIER -125.08 -16.62 5.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.16 -179.983 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -122.17 97.33 5.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.876 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.6 tt0 -44.83 -48.95 11.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.917 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 63.5 mt -44.85 -33.0 1.77 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.926 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -89.79 -36.69 14.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.834 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.604 ' HG2' HD21 ' A' ' 98' ' ' LEU . 13.6 tt0 -52.4 -47.53 66.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 61.9 mttt -69.99 -41.9 73.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.907 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 69.8 mtt180 -49.7 -34.3 18.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.869 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.599 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -73.3 -45.63 54.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.103 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.708 HD23 ' HB3' ' A' ' 170' ' ' LEU . 26.6 mt -48.4 -36.49 14.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.411 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.4 t -91.35 -40.61 11.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.411 ' N ' HG23 ' A' ' 155' ' ' THR . 56.7 mm-40 -77.56 -66.45 0.83 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.863 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.605 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 63.3 m -60.59 -11.6 7.64 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.855 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 158' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 157' ' ' CYS . 2.8 tp-100 -34.99 139.86 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.892 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 43.5 35.8 3.01 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.519 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.792 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -55.71 120.14 6.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.82 0.343 . . . . 0.0 111.146 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.8 t -95.1 -33.26 4.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.101 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -41.47 -36.53 1.54 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.53 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.579 HD13 ' HB2' ' A' ' 115' ' ' PHE . 22.6 tp -89.06 116.48 27.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.895 0.378 . . . . 0.0 110.875 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 68.77 157.89 1.31 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.505 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 165' ' ' SER . . . . . 0.419 ' HB2' HG21 ' A' ' 104' ' ' THR . 49.9 m -62.34 -11.47 15.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.961 0.41 . . . . 0.0 110.839 -179.682 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 51.1 mttt -120.02 156.79 54.19 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.59 0.71 . . . . 0.0 110.895 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 177.36 5.68 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.65 2.233 . . . . 0.0 112.382 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.792 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 15.7 m -131.96 125.13 54.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.144 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 21.4 ttm180 -86.82 102.31 14.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.854 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.708 ' HB3' HD23 ' A' ' 154' ' ' LEU . 12.8 mt -81.55 140.67 34.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 19.9 m -156.46 178.03 10.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.839 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 3.3 t -99.95 99.69 8.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.081 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.144 179.826 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 13.4 m-85 . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.908 0.385 . . . . 0.0 110.921 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.1 m -138.91 148.27 43.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.861 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.668 HD12 ' CE2' ' A' ' 144' ' ' PHE . 82.9 mt -117.41 151.63 36.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.915 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.69 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 7.6 t80 -98.31 123.29 42.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.907 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 29.8 m -117.45 144.09 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.125 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.11 178.5 18.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.483 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ASP . . . . . 0.45 ' N ' ' O ' ' A' ' 138' ' ' GLY . 1.2 m-20 57.73 53.88 6.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.82 0.343 . . . . 0.0 110.859 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.417 HD23 ' HA ' ' A' ' 103' ' ' LEU . 23.0 mt -100.8 103.34 14.55 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.896 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.488 HG21 ' HB3' ' A' ' 165' ' ' SER . 39.9 p -48.31 150.1 2.41 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.578 0.704 . . . . 0.0 111.146 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -1.56 8.69 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.678 2.252 . . . . 0.0 112.352 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -99.33 12.08 37.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.858 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.614 HG22 ' HE3' ' A' ' 111' ' ' MET . 62.1 t -123.32 139.92 48.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.096 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -122.08 171.59 8.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.878 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.411 ' HB3' HG12 ' A' ' 128' ' ' VAL . 3.5 p30 -52.63 -43.91 65.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.893 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -43.87 -37.3 4.04 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.507 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.614 ' HE3' HG22 ' A' ' 107' ' ' VAL . 28.2 mtm -81.45 -44.72 17.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.833 0.349 . . . . 0.0 110.889 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.488 HD23 ' N ' ' A' ' 127' ' ' LYS . 22.1 tp -53.92 -28.52 37.37 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.873 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.56 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 13.9 t80 -76.36 -65.36 0.93 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.908 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.776 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.0 mt-10 -55.23 -48.25 74.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.918 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.406 ' CB ' HD13 ' A' ' 163' ' ' LEU . 69.0 t80 -46.31 -33.82 4.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.938 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.492 ' O ' ' N ' ' A' ' 118' ' ' LYS . 6.9 m-85 -95.3 -67.09 0.87 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.847 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.776 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.8 p -36.51 -29.41 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.079 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.492 ' N ' ' O ' ' A' ' 116' ' ' PHE . 18.8 ttpp -67.47 -55.56 13.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.914 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.507 HG13 ' HD2' ' A' ' 120' ' ' TYR . 2.3 p -70.98 -30.72 42.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.123 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.582 ' CE1' ' HB3' ' A' ' 152' ' ' ARG . 97.6 m-85 -132.26 112.36 14.32 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.602 0.715 . . . . 0.0 110.955 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.3 Cg_endo -69.75 2.39 3.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.671 2.247 . . . . 0.0 112.338 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 6.3 p -92.87 -20.27 20.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.862 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.0 t -50.05 134.28 22.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.883 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -94.85 -35.7 11.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.56 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 167.1 143.91 3.93 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.492 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.54 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -97.34 136.58 12.83 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.473 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.488 ' N ' HD23 ' A' ' 112' ' ' LEU . 19.3 tttp -124.83 139.2 54.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.77 0.319 . . . . 0.0 110.925 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.411 HG12 ' HB3' ' A' ' 109' ' ' ASP . 6.3 p -123.17 139.62 49.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.149 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.812 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 6.3 m -89.91 152.71 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 7.9 mt -128.68 160.92 30.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -87.59 172.72 9.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.848 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.56 -19.99 0.39 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 58.1 p -89.45 -29.76 18.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.131 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 111.8 10.77 18.19 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.489 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 33.8 m -98.92 136.49 29.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.79 0.329 . . . . 0.0 111.159 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.6 t -43.23 105.78 0.06 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.88 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.512 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 26.0 mtmt -50.58 -32.98 20.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.918 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 123.58 19.9 2.72 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.548 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.812 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 13.9 p90 -163.83 168.77 19.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.952 0.406 . . . . 0.0 110.914 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.53 -160.88 18.8 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.522 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.4 m-85 -153.97 144.16 22.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.848 0.356 . . . . 0.0 110.918 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.54 HG12 ' HA2' ' A' ' 126' ' ' GLY . 20.6 m -120.97 174.02 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.144 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -132.93 163.75 28.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.869 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.668 ' CE2' HD12 ' A' ' 98' ' ' LEU . 75.3 m-85 -149.79 159.78 44.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.923 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 14.0 p -90.34 -39.37 12.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -109.23 132.04 54.49 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.87 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -72.27 -38.3 68.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.923 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 30.2 mt -48.78 -34.06 11.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.923 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -87.83 -37.27 16.69 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.905 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.473 ' O ' HD11 ' A' ' 98' ' ' LEU . 22.4 tt0 -41.61 -48.39 4.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.947 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 47.2 mttt -71.7 -32.22 67.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.864 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.582 ' HB3' ' CE1' ' A' ' 120' ' ' TYR . 0.6 OUTLIER -52.67 -39.45 61.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.841 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.499 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.86 -46.57 71.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.129 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.601 HD23 ' HB3' ' A' ' 170' ' ' LEU . 17.0 mt -40.36 -43.68 1.81 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.614 HG23 ' N ' ' A' ' 156' ' ' GLU . 14.6 t -92.7 -50.63 5.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.124 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.614 ' N ' HG23 ' A' ' 155' ' ' THR . 76.9 mm-40 -62.51 -57.63 10.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.914 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.683 ' O ' HD11 ' A' ' 170' ' ' LEU . 24.7 m -83.2 20.53 1.25 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.824 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 158' ' ' GLN . . . . . 0.419 ' OE1' ' N ' ' A' ' 159' ' ' GLY . 2.0 tp-100 -64.71 131.89 48.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.9 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.419 ' N ' ' OE1' ' A' ' 158' ' ' GLN . . . 47.09 29.69 4.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.479 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.438 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -50.12 119.23 3.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.827 0.346 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.427 ' O ' ' C ' ' A' ' 162' ' ' GLY . 37.5 t -88.12 -36.75 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.134 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 162' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -35.97 -38.59 0.23 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.492 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.406 HD13 ' CB ' ' A' ' 115' ' ' PHE . 20.0 tp -89.08 118.84 29.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.866 0.365 . . . . 0.0 110.918 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.454 ' CA ' HG21 ' A' ' 107' ' ' VAL . . . 64.91 153.49 0.11 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.487 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 165' ' ' SER . . . . . 0.488 ' HB3' HG21 ' A' ' 104' ' ' THR . 16.7 t -55.66 -23.8 30.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.962 0.41 . . . . 0.0 110.839 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 58.8 mttt -109.24 154.95 41.84 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.572 0.701 . . . . 0.0 110.908 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 171.23 14.89 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.7 2.267 . . . . 0.0 112.34 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.438 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 16.4 m -121.18 125.84 74.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.085 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 35.1 ttt-85 -88.71 103.27 15.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.683 HD11 ' O ' ' A' ' 157' ' ' CYS . 11.7 mt -80.64 148.61 30.17 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.857 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 3.2 m -160.75 177.61 10.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.917 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.49 HG22 HD11 ' A' ' 154' ' ' LEU . 21.2 t -99.36 96.83 5.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.116 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.69 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.082 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' TYR . . . . . 0.528 ' CD1' ' HG3' ' A' ' 147' ' ' GLU . 63.5 m-85 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.903 0.383 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 66.3 p -112.81 154.58 26.04 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.855 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 33.5 mt -124.79 142.4 51.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.907 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -91.25 132.88 35.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.899 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 18.9 m -126.02 151.82 32.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.128 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -141.72 -179.62 18.97 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.5 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 57.76 38.84 27.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.841 0.353 . . . . 0.0 110.905 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.484 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.2 mt -86.51 108.83 18.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.672 ' OG1' HG23 ' A' ' 107' ' ' VAL . 81.9 p -53.82 150.25 14.62 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.612 0.72 . . . . 0.0 111.144 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 2.21 3.74 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.706 2.271 . . . . 0.0 112.337 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 19.0 t0 -102.02 -3.17 28.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.672 HG23 ' OG1' ' A' ' 104' ' ' THR . 41.3 t -103.68 145.08 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.141 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -129.18 179.68 5.63 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -60.34 -37.86 81.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.881 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.43 -33.23 39.51 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.47 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.528 ' HE3' HG22 ' A' ' 107' ' ' VAL . 27.3 mtm -86.85 -46.91 9.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.842 0.353 . . . . 0.0 110.886 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.463 HD23 ' N ' ' A' ' 127' ' ' LYS . 18.1 tp -53.34 -23.03 8.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.929 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.496 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 13.0 t80 -82.63 -61.75 1.8 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.926 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.758 ' HA ' HG12 ' A' ' 117' ' ' VAL . 22.4 mt-10 -57.23 -46.58 82.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.867 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.683 ' HZ ' ' HB1' ' A' ' 160' ' ' ALA . 75.6 t80 -47.68 -33.23 6.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.499 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.6 m-85 -95.28 -66.98 0.88 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.861 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.758 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.73 -30.97 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.132 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.463 ' N ' ' O ' ' A' ' 116' ' ' PHE . 59.2 tttt -67.31 -60.61 2.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.903 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.603 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.7 p -64.65 -27.15 41.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.114 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.603 ' CD2' HG13 ' A' ' 119' ' ' VAL . 92.6 m-85 -137.94 115.89 9.57 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.7 0.762 . . . . 0.0 110.906 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -2.77 10.7 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.751 2.301 . . . . 0.0 112.336 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 73.2 m -99.25 32.28 2.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.854 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' CYS . . . . . 0.461 ' HB3' HG23 ' A' ' 117' ' ' VAL . 19.6 t -94.51 135.2 36.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.881 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 16.8 mtp180 -93.17 -39.0 11.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.867 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.496 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 163.56 149.43 5.73 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.582 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -102.9 134.27 11.75 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.518 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.463 ' N ' HD23 ' A' ' 112' ' ' LEU . 4.3 tppp? -123.21 137.56 54.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.806 0.336 . . . . 0.0 110.925 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.4 p -124.69 129.4 73.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.126 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.97 HG22 ' O ' ' A' ' 139' ' ' TYR . 22.5 m -75.18 150.49 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.085 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.429 HD23 ' HA ' ' A' ' 136' ' ' SER . 14.9 mt -127.03 174.91 8.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.925 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -103.18 178.27 4.6 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.846 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 25.3 tt0 -45.28 -43.08 10.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.905 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 27.8 p -74.68 -25.04 58.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.167 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 107.88 17.67 10.8 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.475 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 28.8 m -95.9 134.31 33.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.872 0.368 . . . . 0.0 111.126 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.429 ' HA ' HD23 ' A' ' 130' ' ' LEU . 4.8 t -44.18 107.2 0.08 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.863 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.5 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.7 mtmt -52.75 -32.36 42.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.902 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.7 18.74 2.63 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.482 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.97 ' O ' HG22 ' A' ' 129' ' ' VAL . 23.4 p90 -163.14 168.25 21.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.981 0.42 . . . . 0.0 110.9 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -170.74 -165.18 27.68 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.478 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -150.88 146.99 26.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.869 0.366 . . . . 0.0 110.893 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.582 HG12 ' HA2' ' A' ' 126' ' ' GLY . 17.8 m -119.2 179.32 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.113 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 31.3 mttt -138.53 160.35 39.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.899 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -148.34 161.99 40.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.855 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 44.0 p -101.88 -12.34 18.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.099 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.443 ' CG ' ' OE1' ' A' ' 149' ' ' GLU . 14.3 t0 -129.61 130.04 45.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.857 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.528 ' HG3' ' CD1' ' A' ' 96' ' ' TYR . 20.0 tt0 -71.83 -43.23 65.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 37.2 mt -45.23 -49.21 12.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.954 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.443 ' OE1' ' CG ' ' A' ' 146' ' ' ASP . 3.6 mp0 -72.8 -44.05 61.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.855 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 149' ' ' GLU . 17.4 tt0 -36.97 -55.28 0.93 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.932 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 13.7 mttm -64.48 -52.59 57.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 28.4 mtt180 -39.41 -33.29 0.15 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.853 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.448 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -73.98 -49.93 22.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.133 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.756 HD23 ' HB3' ' A' ' 170' ' ' LEU . 33.9 mt -43.34 -38.36 2.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.912 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.539 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.8 t -91.03 -48.3 7.06 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.167 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.539 ' N ' HG23 ' A' ' 155' ' ' THR . 53.1 mt-10 -69.56 -64.58 0.85 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.9 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.546 ' CB ' HD11 ' A' ' 170' ' ' LEU . 54.1 m -62.82 -8.3 6.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.905 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -40.5 140.95 0.59 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 37.66 45.6 1.48 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.465 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.683 ' HB1' ' HZ ' ' A' ' 115' ' ' PHE . . . -64.18 115.09 4.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.802 0.334 . . . . 0.0 111.129 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.0 t -84.88 -35.57 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.143 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -43.06 -34.44 2.06 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.453 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.618 HD13 ' CB ' ' A' ' 115' ' ' PHE . 19.2 tp -91.81 115.82 28.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.866 0.365 . . . . 0.0 110.922 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 166' ' ' LYS . . . 64.55 138.48 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.497 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 t -41.05 -27.92 0.07 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.944 0.402 . . . . 0.0 110.838 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 166' ' ' LYS . . . . . 0.401 ' N ' ' O ' ' A' ' 164' ' ' GLY . 57.5 mttt -103.78 154.67 37.83 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.526 0.679 . . . . 0.0 110.924 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.69 173.15 11.33 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.7 2.266 . . . . 0.0 112.413 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.672 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 21.1 m -124.45 131.27 73.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.127 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 43.4 ttt180 -94.84 105.01 16.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.92 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.756 ' HB3' HD23 ' A' ' 154' ' ' LEU . 13.3 mt -82.66 148.87 27.69 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.933 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.535 ' O ' HD21 ' A' ' 154' ' ' LEU . 2.0 m -158.72 -177.87 6.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.9 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 4.4 t -108.83 102.15 13.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.145 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.07 179.895 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.896 0.379 . . . . 0.0 110.934 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.0 p -117.13 146.26 43.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.859 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.88 HD21 ' HG2' ' A' ' 150' ' ' GLN . 46.3 mt -110.43 150.4 28.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.906 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.661 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 4.9 t80 -96.34 127.23 42.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.852 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.8 m -119.42 146.05 24.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.15 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.84 -177.99 15.9 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.463 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 52.85 51.57 15.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.88 0.371 . . . . 0.0 110.877 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 30.1 mt -98.04 118.52 34.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.936 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p -61.97 151.54 79.9 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.587 0.708 . . . . 0.0 111.094 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -0.02 6.29 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.718 2.278 . . . . 0.0 112.333 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -99.46 -0.24 41.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.484 HG22 ' HE3' ' A' ' 111' ' ' MET . 26.5 t -111.09 147.68 14.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.096 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -131.83 -178.81 5.05 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.885 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.64 -37.78 85.28 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.78 -26.93 26.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.52 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.484 ' HE3' HG22 ' A' ' 107' ' ' VAL . 34.3 mtm -93.8 -39.29 10.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 0.0 110.919 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.403 HD23 ' N ' ' A' ' 127' ' ' LYS . 49.3 tp -55.86 -30.41 61.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.938 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.501 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 22.5 t80 -78.8 -63.86 1.31 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.947 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.704 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.0 mt-10 -53.54 -36.31 61.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.886 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.488 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 67.6 t80 -58.09 -34.2 69.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.88 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.501 ' O ' ' N ' ' A' ' 118' ' ' LYS . 10.2 m-85 -95.25 -62.74 1.25 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.875 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.704 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -38.44 -26.39 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.115 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.501 ' N ' ' O ' ' A' ' 116' ' ' PHE . 18.2 tttm -71.05 -60.73 2.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.911 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.659 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.7 p -67.62 -25.79 33.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.165 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.659 ' CD2' HG13 ' A' ' 119' ' ' VAL . 92.2 m-85 -136.09 112.26 10.31 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.633 0.73 . . . . 0.0 110.95 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 54.0 Cg_endo -69.73 2.81 3.18 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.672 2.248 . . . . 0.0 112.343 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 32.0 m -105.44 27.9 7.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.853 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 36.8 t -89.0 124.73 34.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.857 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.488 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 14.0 mtp180 -79.21 -42.8 25.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.862 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.501 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 168.52 159.56 14.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.507 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -114.7 134.87 11.95 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.497 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.403 ' N ' HD23 ' A' ' 112' ' ' LEU . 3.5 tppp? -130.13 132.69 46.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.838 0.352 . . . . 0.0 110.878 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.2 p -118.1 129.7 74.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.911 HG22 ' O ' ' A' ' 139' ' ' TYR . 23.8 m -73.76 144.98 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.083 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.616 HD22 ' O ' ' A' ' 134' ' ' GLY . 46.4 mt -123.9 162.3 23.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.903 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.42 ' CG ' ' HG2' ' A' ' 137' ' ' LYS . 3.0 m-20 -93.33 -178.25 4.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -40.75 -59.05 1.49 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.955 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.411 ' H ' HG22 ' A' ' 133' ' ' THR . 0.0 OUTLIER -62.36 -30.83 71.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.616 ' O ' HD22 ' A' ' 130' ' ' LEU . . . 116.65 0.54 20.01 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.498 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.406 HG13 HG23 ' A' ' 133' ' ' THR . 3.5 m -73.43 141.12 16.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.787 0.327 . . . . 0.0 111.126 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.435 ' HA ' HD23 ' A' ' 130' ' ' LEU . 8.2 t -50.27 113.83 0.97 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.487 ' HB2' HG23 ' A' ' 129' ' ' VAL . 22.1 mtmt -58.76 -30.72 67.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.916 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 120.13 17.26 4.56 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.512 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.911 ' O ' HG22 ' A' ' 129' ' ' VAL . 19.0 p90 -163.29 167.96 21.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.985 0.422 . . . . 0.0 110.864 -179.797 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -171.56 -162.48 23.91 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.51 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -153.3 139.9 18.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.893 0.378 . . . . 0.0 110.88 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.4 m -110.75 176.85 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' LYS . . . . . 0.488 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 47.8 mttt -133.35 156.72 47.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.878 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -148.57 152.57 37.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' THR . . . . . 0.428 HG23 ' CG ' ' A' ' 124' ' ' ARG . 25.3 p -96.0 -24.96 16.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.147 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -115.06 103.55 11.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.837 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 15.2 tm-20 -48.51 -47.23 39.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.914 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 65.6 mt -39.68 -44.35 1.51 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.935 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -72.48 -40.65 66.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.918 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.88 ' HG2' HD21 ' A' ' 98' ' ' LEU . 24.9 tt0 -40.36 -60.6 1.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.897 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 14.4 mttm -62.51 -44.78 95.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 57.6 mtt180 -48.0 -42.64 28.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.904 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.459 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -69.15 -45.19 70.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.814 HD21 HD22 ' A' ' 98' ' ' LEU . 13.8 mt -43.52 -41.38 4.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.952 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.431 HG23 ' N ' ' A' ' 156' ' ' GLU . 6.0 t -92.46 -41.64 10.18 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.431 ' N ' HG23 ' A' ' 155' ' ' THR . 21.6 mm-40 -70.04 -63.59 1.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.868 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.484 ' CB ' HD11 ' A' ' 170' ' ' LEU . 20.9 m -70.82 -0.32 8.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -43.69 129.79 5.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 55.45 33.78 59.1 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.495 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.887 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -48.64 116.58 1.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.799 0.333 . . . . 0.0 111.062 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.7 t -93.85 -31.39 4.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.138 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -46.29 -31.64 4.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.517 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.407 HD13 ' HB2' ' A' ' 115' ' ' PHE . 20.4 tp -91.37 115.7 28.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.851 0.358 . . . . 0.0 110.923 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.0 159.92 0.97 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.493 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 m -61.95 -19.68 63.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.959 0.409 . . . . 0.0 110.883 -179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 35.0 mttm -111.13 153.53 43.9 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.559 0.695 . . . . 0.0 110.89 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 171.79 13.85 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.659 2.239 . . . . 0.0 112.371 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.887 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 22.2 m -127.22 125.06 65.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.119 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.5 ttt180 -86.42 111.68 20.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.851 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.566 ' HB3' HD23 ' A' ' 154' ' ' LEU . 14.7 mt -87.16 139.95 30.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.2 m -152.74 178.17 9.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.823 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.431 HG22 HD11 ' A' ' 154' ' ' LEU . 2.8 t -100.73 96.15 4.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.661 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.128 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' TYR . . . . . 0.437 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 32.4 m-85 . . . . . 0 N--CA 1.457 -0.084 0 CA-C-O 120.897 0.38 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 52.6 p -138.52 159.66 41.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.9 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.58 HD21 ' CD ' ' A' ' 150' ' ' GLN . 79.5 mt -124.84 147.73 48.61 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -94.03 120.6 34.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.902 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.42 HG22 ' C ' ' A' ' 140' ' ' GLY . 31.2 m -114.04 145.41 19.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -133.67 -174.02 13.41 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.494 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 46.91 50.88 13.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.841 0.353 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 103' ' ' LEU . 20.4 mt -96.05 99.07 10.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.954 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.466 HG23 ' HB2' ' A' ' 166' ' ' LYS . 23.9 p -48.79 151.57 2.08 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.597 0.713 . . . . 0.0 111.122 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 1.56 4.32 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.694 2.262 . . . . 0.0 112.326 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -100.99 10.38 41.17 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.851 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.521 HG13 ' CE ' ' A' ' 111' ' ' MET . 3.9 t -121.57 147.03 25.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.1 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -132.77 178.52 6.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.873 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -56.18 -40.07 73.39 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -49.28 -40.18 29.41 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.521 ' CE ' HG13 ' A' ' 107' ' ' VAL . 36.1 mtm -82.57 -39.73 21.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.835 0.35 . . . . 0.0 110.876 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.635 HD23 ' N ' ' A' ' 127' ' ' LYS . 28.3 tp -57.71 -28.11 63.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.417 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.2 t80 -81.77 -60.02 2.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.92 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.727 ' HA ' HG12 ' A' ' 117' ' ' VAL . 20.7 mt-10 -56.13 -47.43 78.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.445 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 62.8 t80 -48.79 -33.64 10.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.917 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.561 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.5 m-85 -94.41 -66.12 0.94 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.873 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.727 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.71 -30.43 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.15 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.472 ' N ' ' O ' ' A' ' 116' ' ' PHE . 20.2 ttpp -65.84 -59.37 3.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.941 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.604 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.6 p -67.13 -34.21 68.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.172 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.604 ' CD2' HG13 ' A' ' 119' ' ' VAL . 92.8 m-85 -130.06 112.01 17.1 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.662 0.744 . . . . 0.0 110.96 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 1.39 4.46 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.679 2.252 . . . . 0.0 112.352 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -99.05 19.9 14.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.828 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 38.8 t -82.01 132.8 35.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.875 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.693 ' HG3' HG23 ' A' ' 145' ' ' THR . 46.1 mtt-85 -89.52 -41.92 11.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.868 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.417 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 168.94 150.35 6.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.468 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -103.18 142.34 15.48 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.517 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.635 ' N ' HD23 ' A' ' 112' ' ' LEU . 12.1 tptm -136.95 132.71 34.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.869 0.366 . . . . 0.0 110.868 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 3.0 p -120.72 129.26 75.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.849 HG22 ' O ' ' A' ' 139' ' ' TYR . 23.5 m -72.41 142.88 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.107 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.49 HD23 ' HA ' ' A' ' 136' ' ' SER . 11.5 mt -127.7 163.97 23.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.936 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.444 ' OD1' ' C ' ' A' ' 131' ' ' ASP . 0.6 OUTLIER -97.89 -175.08 3.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.839 179.865 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 44.5 tt0 -49.09 -48.67 44.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 21.5 p -65.91 -23.2 66.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.147 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.46 22.57 18.72 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 30.1 m -102.93 131.27 51.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.8 0.334 . . . . 0.0 111.138 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.49 ' HA ' HD23 ' A' ' 130' ' ' LEU . 5.4 t -39.45 116.83 0.65 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.864 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.1 mtmt -63.17 -28.17 69.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.914 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 123.98 14.34 3.8 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.506 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.849 ' O ' HG22 ' A' ' 129' ' ' VAL . 17.9 p90 -162.2 170.82 18.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.939 0.399 . . . . 0.0 110.921 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.42 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -172.71 -160.79 21.98 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.507 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -153.85 143.72 21.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.867 0.365 . . . . 0.0 110.861 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.561 HG11 ' CD2' ' A' ' 116' ' ' PHE . 14.7 m -115.39 -176.68 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.123 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 13.8 mttp -141.55 153.02 44.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.418 ' CE2' HD12 ' A' ' 98' ' ' LEU . 88.7 m-85 -146.48 128.82 15.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.88 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' THR . . . . . 0.693 HG23 ' HG3' ' A' ' 124' ' ' ARG . 36.7 p -66.5 -12.7 58.8 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.162 -179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -126.54 135.21 51.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.868 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.437 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 29.7 tt0 -79.08 -34.17 43.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.887 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 38.9 mt -53.98 -60.2 3.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.911 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -65.09 -38.45 90.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.58 ' CD ' HD21 ' A' ' 98' ' ' LEU . 1.4 tm0? -48.06 -42.55 28.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.888 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.573 ' HA ' HD12 ' A' ' 154' ' ' LEU . 34.7 mmtm -77.85 -26.94 49.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 27.1 mtt180 -65.09 -37.48 87.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.855 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.454 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -66.12 -36.04 82.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.104 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.573 HD12 ' HA ' ' A' ' 151' ' ' LYS . 28.1 mt -52.49 -41.49 63.43 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.934 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 8.8 t -91.86 -36.42 13.51 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.176 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 16.0 mm-40 -76.24 -62.54 1.58 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.877 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.574 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 10.5 m -71.79 0.54 8.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 158' ' ' GLN . . . . . 0.466 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.0 tp-100 -43.17 136.14 3.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.9 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 45.93 30.16 3.59 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.475 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.574 ' HB2' ' O ' ' A' ' 157' ' ' CYS . . . -49.79 112.31 0.64 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.828 0.347 . . . . 0.0 111.115 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 18.8 t -87.18 -33.84 7.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.84 -31.13 1.09 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.463 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.445 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 28.4 tp -90.17 109.43 20.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.882 0.372 . . . . 0.0 110.919 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 71.53 168.05 9.02 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.471 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 165' ' ' SER . . . . . 0.44 ' HB2' HG21 ' A' ' 104' ' ' THR . 39.5 m -66.24 -23.1 66.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.918 0.39 . . . . 0.0 110.863 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 166' ' ' LYS . . . . . 0.466 ' HB2' HG23 ' A' ' 104' ' ' THR . 58.9 mttm -110.29 155.81 41.29 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.632 0.73 . . . . 0.0 110.873 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.85 -176.85 1.65 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.676 2.25 . . . . 0.0 112.325 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.543 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 28.6 m -135.04 128.28 49.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.131 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 12.5 ttp180 -91.99 94.16 9.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.835 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.541 ' HB3' HD23 ' A' ' 154' ' ' LEU . 10.6 mt -72.14 152.64 42.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.484 ' O ' HD21 ' A' ' 154' ' ' LEU . 0.9 OUTLIER -167.01 178.32 5.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.891 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 45.5 t -103.79 99.45 8.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.086 179.893 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 19.5 m-85 . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.851 0.358 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 45.9 m -118.69 146.55 44.62 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.86 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.717 HD22 HD21 ' A' ' 154' ' ' LEU . 68.3 mt -113.53 153.36 28.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.921 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -100.77 123.05 44.41 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.848 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 23.1 m -114.38 145.8 19.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.114 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.11 -176.75 14.51 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.513 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 48.78 52.06 14.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.827 0.346 . . . . 0.0 110.879 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.424 HD12 ' C ' ' A' ' 139' ' ' TYR . 28.7 mt -98.24 105.89 18.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.879 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.459 HG23 ' HB2' ' A' ' 166' ' ' LYS . 25.1 p -50.6 150.63 4.73 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.582 0.705 . . . . 0.0 111.158 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 3.16 2.95 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.665 2.243 . . . . 0.0 112.316 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -98.38 -13.33 20.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.881 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.471 HG13 ' HE2' ' A' ' 111' ' ' MET . 41.4 t -98.21 134.46 36.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.151 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.25 175.88 5.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.828 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -53.37 -44.79 68.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.858 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.96 -29.07 7.98 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.499 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.471 ' HE2' HG13 ' A' ' 107' ' ' VAL . 22.3 mtp -86.88 -59.47 2.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.788 0.328 . . . . 0.0 110.873 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 15.8 tp -40.18 -41.06 1.22 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.898 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.423 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 12.9 t80 -62.65 -67.17 0.44 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.966 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.77 ' HA ' HG12 ' A' ' 117' ' ' VAL . 30.3 mt-10 -52.52 -55.52 21.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.927 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 57.2 t80 -41.49 -32.28 0.33 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.896 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.498 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.0 m-85 -95.14 -67.53 0.85 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.883 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.77 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -37.65 -27.58 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.103 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.498 ' N ' ' O ' ' A' ' 116' ' ' PHE . 20.1 tptt -67.57 -57.87 5.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.885 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.655 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.3 p -71.56 -32.73 46.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.175 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.655 ' CD2' HG13 ' A' ' 119' ' ' VAL . 97.0 m-85 -126.3 108.04 24.09 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.622 0.725 . . . . 0.0 110.954 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.8 Cg_endo -69.76 2.44 3.53 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.667 2.245 . . . . 0.0 112.339 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 47.6 p -95.0 -10.33 31.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 10.0 t -57.09 142.65 41.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.887 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 61.7 mtp180 -104.46 -34.1 8.36 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.88 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.423 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 166.72 145.99 4.68 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.453 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.43 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -96.35 139.25 14.39 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.477 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 46.6 tptt -125.28 127.73 47.15 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.87 0.366 . . . . 0.0 110.866 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.1 p -117.72 141.28 37.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.958 HG22 ' O ' ' A' ' 139' ' ' TYR . 33.2 m -92.73 145.33 7.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.096 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.582 HD23 ' HA ' ' A' ' 136' ' ' SER . 23.4 mt -123.8 179.09 4.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.888 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 11.1 t0 -108.96 -178.96 3.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.875 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -53.57 -18.9 3.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.917 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 43.6 p -93.61 -27.27 16.69 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.163 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 107.52 17.29 11.47 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.476 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 19.1 m -100.05 139.27 21.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 0.0 111.112 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.582 ' HA ' HD23 ' A' ' 130' ' ' LEU . 7.5 t -49.76 100.34 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.507 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.4 mtmt -42.97 -36.09 1.44 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.877 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 128.35 16.97 2.03 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.548 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.958 ' O ' HG22 ' A' ' 129' ' ' VAL . 28.1 p90 -161.07 172.07 17.47 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.901 0.381 . . . . 0.0 110.96 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -174.94 -163.23 27.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.475 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -153.76 145.58 23.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.861 0.363 . . . . 0.0 110.863 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.487 HG11 ' CD2' ' A' ' 116' ' ' PHE . 29.3 m -119.6 -177.74 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.087 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 32.8 mttm -142.16 156.73 45.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -145.87 163.43 35.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 29.2 p -101.1 -19.88 15.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.129 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -117.02 120.47 38.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.825 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -65.45 -33.55 76.21 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.948 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 44.6 mt -57.71 -40.57 79.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.931 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.464 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 38.6 mt-10 -76.28 -38.53 56.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.829 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.684 ' HG2' HD21 ' A' ' 98' ' ' LEU . 22.0 tt0 -44.95 -48.43 11.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.869 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 5.1 mmmm -73.57 -37.37 65.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.407 ' O ' ' CG ' ' A' ' 156' ' ' GLU . 9.1 mtt-85 -56.25 -34.23 66.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.892 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.439 ' O ' HD12 ' A' ' 170' ' ' LEU . . . -72.0 -46.2 58.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.784 HD23 ' HB3' ' A' ' 170' ' ' LEU . 48.6 mt -44.36 -40.98 5.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.47 HG23 ' N ' ' A' ' 156' ' ' GLU . 14.9 t -92.33 -42.54 9.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.165 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.47 ' N ' HG23 ' A' ' 155' ' ' THR . 25.6 mm-40 -68.96 -64.87 0.79 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.611 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 10.4 m -70.11 -1.68 10.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.893 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 158' ' ' GLN . . . . . 0.487 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.8 tp-100 -42.48 141.95 0.9 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.891 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 158' ' ' GLN . . . 35.51 34.29 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.502 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.611 ' HB2' ' O ' ' A' ' 157' ' ' CYS . . . -58.49 110.65 1.02 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.769 0.319 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.41 ' O ' ' C ' ' A' ' 162' ' ' GLY . 22.9 t -79.27 -34.27 16.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.121 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 162' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.65 -36.23 0.15 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.464 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.441 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 25.2 tp -92.72 115.17 27.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.85 0.357 . . . . 0.0 110.885 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.77 146.85 0.13 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.495 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 m -50.81 -21.09 1.5 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.966 0.413 . . . . 0.0 110.855 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' LYS . . . . . 0.459 ' HB2' HG23 ' A' ' 104' ' ' THR . 36.5 mttm -109.08 156.05 39.86 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.595 0.712 . . . . 0.0 110.903 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 171.84 13.74 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.699 2.266 . . . . 0.0 112.295 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 168' ' ' VAL . 35.4 m -125.34 127.6 72.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.185 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 17.7 ttt180 -91.54 107.82 19.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.784 ' HB3' HD23 ' A' ' 154' ' ' LEU . 14.4 mt -84.4 143.39 29.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.932 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 15.2 m -154.6 171.41 19.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.881 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.673 HG22 HD11 ' A' ' 154' ' ' LEU . 3.0 t -101.0 100.6 10.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.112 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.136 179.838 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.918 0.39 . . . . 0.0 110.934 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.8 m -112.33 147.19 36.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.839 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.817 HD22 HD21 ' A' ' 154' ' ' LEU . 92.2 mt -115.75 155.99 26.79 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.412 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 8.6 t80 -104.6 127.49 52.35 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.856 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.438 HG22 ' C ' ' A' ' 140' ' ' GLY . 28.4 m -116.55 155.28 18.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -142.59 178.12 21.26 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.485 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 52.87 50.28 18.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.874 0.369 . . . . 0.0 110.898 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 29.1 mt -96.9 103.44 15.37 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.899 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.426 HG21 ' HB2' ' A' ' 165' ' ' SER . 17.4 p -47.94 150.16 2.1 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 121.617 0.723 . . . . 0.0 111.152 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 2.98 3.03 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.623 2.215 . . . . 0.0 112.375 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.34 16.34 26.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.721 HG22 ' HE3' ' A' ' 111' ' ' MET . 59.5 t -129.62 142.17 44.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.109 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -128.95 -177.6 4.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.817 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -58.18 -47.98 81.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.848 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -42.26 -35.1 1.72 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.48 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.721 ' HE3' HG22 ' A' ' 107' ' ' VAL . 26.0 mtm -86.03 -45.72 11.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.823 0.344 . . . . 0.0 110.884 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.532 HD23 ' N ' ' A' ' 127' ' ' LYS . 16.0 tp -53.5 -33.45 54.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.503 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 9.8 t80 -68.71 -61.62 1.74 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.755 ' HA ' HG12 ' A' ' 117' ' ' VAL . 22.2 mt-10 -57.76 -51.78 68.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.901 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.545 ' CE1' ' HB2' ' A' ' 163' ' ' LEU . 66.5 t80 -44.1 -32.34 1.17 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.876 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.619 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.7 m-85 -95.25 -67.52 0.85 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.755 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.83 -29.35 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.158 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.483 ' N ' ' O ' ' A' ' 116' ' ' PHE . 22.9 ttpp -66.31 -58.31 5.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.901 179.883 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.529 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.6 p -67.41 -33.0 59.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.124 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.686 ' CE2' ' HB2' ' A' ' 153' ' ' ALA . 89.4 m-85 -129.12 113.31 18.5 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.683 0.754 . . . . 0.0 110.944 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.8 Cg_endo -69.77 -0.05 6.35 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.722 2.281 . . . . 0.0 112.353 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 69.0 m -105.22 35.41 2.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.864 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 3.0 t -98.09 138.59 35.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.907 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.571 HH11 HG22 ' A' ' 145' ' ' THR . 44.8 mtp85 -93.6 -38.06 11.55 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.857 -179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.503 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 159.22 141.72 3.21 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.491 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.645 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -90.41 138.04 14.25 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.44 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.532 ' N ' HD23 ' A' ' 112' ' ' LEU . 20.2 tptm -122.05 128.28 51.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.81 0.338 . . . . 0.0 110.9 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.9 p -114.86 135.64 54.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.948 HG22 ' O ' ' A' ' 139' ' ' TYR . 32.9 m -84.71 145.98 7.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.092 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.562 HD23 ' HA ' ' A' ' 136' ' ' SER . 31.1 mt -126.69 -179.66 4.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.849 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.479 ' O ' ' N ' ' A' ' 134' ' ' GLY . 2.2 t70 -118.69 -176.0 3.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.891 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -38.35 -61.38 0.69 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.887 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.402 ' H ' HG22 ' A' ' 133' ' ' THR . 0.0 OUTLIER -60.92 -24.84 66.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.148 -179.898 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.485 ' O ' HD22 ' A' ' 130' ' ' LEU . . . 105.16 4.45 41.27 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.502 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 5.3 m -77.24 145.2 10.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.811 0.339 . . . . 0.0 111.168 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.562 ' HA ' HD23 ' A' ' 130' ' ' LEU . 5.1 t -56.93 113.9 1.87 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.502 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 30.0 mtmt -56.73 -31.65 64.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.885 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.21 17.71 2.95 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.484 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.948 ' O ' HG22 ' A' ' 129' ' ' VAL . 28.0 p90 -162.55 174.8 12.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.964 0.412 . . . . 0.0 110.889 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.438 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -178.29 -162.42 28.01 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.485 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.412 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 4.5 m-85 -153.98 146.18 23.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.953 0.406 . . . . 0.0 110.858 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.645 HG12 ' HA2' ' A' ' 126' ' ' GLY . 17.8 m -116.87 -176.51 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.139 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 25.7 mttm -143.75 157.83 44.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.891 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.421 ' CE1' HG23 ' A' ' 142' ' ' VAL . 50.0 m-85 -146.79 161.85 39.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.884 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' THR . . . . . 0.571 HG22 HH11 ' A' ' 124' ' ' ARG . 69.9 p -95.76 -29.73 14.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.152 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -112.9 133.9 54.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.799 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -74.64 -34.47 62.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.867 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 64.6 mt -53.39 -40.45 65.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.927 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.484 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 4.3 mm-40 -80.66 -40.53 25.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.877 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.591 ' HG2' HD21 ' A' ' 98' ' ' LEU . 13.4 tt0 -41.6 -48.08 3.97 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.9 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 154' ' ' LEU . 40.4 mttp -71.67 -57.2 4.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.902 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.4 ' C ' ' O ' ' A' ' 151' ' ' LYS . 21.0 mtt-85 -38.18 -33.55 0.1 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.897 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.686 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -74.66 -43.49 55.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.117 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.817 HD21 HD22 ' A' ' 98' ' ' LEU . 14.7 mt -48.32 -38.2 18.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.499 HG23 ' N ' ' A' ' 156' ' ' GLU . 10.1 t -92.14 -45.76 8.11 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.136 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.499 ' N ' HG23 ' A' ' 155' ' ' THR . 16.8 mm-40 -67.99 -62.35 1.44 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.851 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.544 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 33.0 m -68.24 -3.25 10.12 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.897 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 5.1 tp-100 -45.36 139.58 3.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.916 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 44.2 34.35 3.23 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.505 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.629 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -55.33 113.0 1.23 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.814 0.34 . . . . 0.0 111.077 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.8 t -88.02 -32.31 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.151 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.53 -37.0 2.46 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.482 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.545 ' HB2' ' CE1' ' A' ' 115' ' ' PHE . 26.4 tp -89.65 117.19 28.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.901 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 68.19 154.22 0.55 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.528 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 165' ' ' SER . . . . . 0.426 ' HB2' HG21 ' A' ' 104' ' ' THR . 19.3 m -55.98 -25.4 43.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.953 0.406 . . . . 0.0 110.871 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 59.8 mttt -108.0 154.71 40.97 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.615 0.721 . . . . 0.0 110.871 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 173.39 11.07 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.696 2.264 . . . . 0.0 112.304 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.629 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 33.0 m -126.33 127.02 70.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.153 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 34.6 ttt85 -92.77 102.44 14.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.856 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.58 ' HB3' HD23 ' A' ' 154' ' ' LEU . 11.2 mt -76.88 149.84 36.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.919 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.7 m -158.58 175.57 13.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.871 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.624 HG22 HD11 ' A' ' 154' ' ' LEU . 11.3 t -105.78 101.62 12.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.141 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.119 179.852 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 96' ' ' TYR . . . . . 0.493 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 5.0 m-85 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.904 0.383 . . . . 0.0 110.923 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 58.2 p -116.22 142.52 46.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.849 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.791 HD22 HD21 ' A' ' 154' ' ' LEU . 37.3 mt -115.79 147.89 40.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.917 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -93.88 135.68 34.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 140' ' ' GLY . 15.5 m -128.6 139.56 51.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.158 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -132.39 171.23 21.6 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.508 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ASP . . . . . 0.403 ' N ' ' O ' ' A' ' 138' ' ' GLY . 29.4 m-20 61.74 51.72 3.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.864 0.364 . . . . 0.0 110.928 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 25.6 mt -99.29 103.31 15.13 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.94 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.558 HG23 ' HB2' ' A' ' 166' ' ' LYS . 16.9 p -48.4 150.19 2.43 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.609 0.718 . . . . 0.0 111.111 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 -0.27 6.73 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.668 2.246 . . . . 0.0 112.333 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -99.73 10.19 41.77 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.479 ' HA ' ' HE2' ' A' ' 111' ' ' MET . 21.7 t -123.76 133.9 67.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.101 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -118.9 176.3 5.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.879 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.5 p-10 -52.22 -50.55 61.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -39.41 -39.12 1.07 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.468 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.479 ' HE2' ' HA ' ' A' ' 107' ' ' VAL . 29.7 mtm -82.77 -41.33 19.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.743 0.306 . . . . 0.0 110.876 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.412 HD23 ' N ' ' A' ' 127' ' ' LYS . 18.6 tp -58.8 -24.39 61.81 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.927 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.418 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 16.7 t80 -84.45 -62.37 1.57 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.884 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.7 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.0 mt-10 -57.76 -34.74 69.87 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.931 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.504 ' CZ ' ' HB2' ' A' ' 163' ' ' LEU . 84.7 t80 -59.85 -34.03 72.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.51 ' CD2' HG11 ' A' ' 142' ' ' VAL . 9.5 m-85 -95.03 -62.13 1.36 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.863 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.7 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.3 p -39.03 -27.16 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.131 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.462 ' N ' ' O ' ' A' ' 116' ' ' PHE . 19.5 tptt -68.96 -60.52 2.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.898 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.668 HG13 ' CD2' ' A' ' 120' ' ' TYR . 4.2 p -67.58 -28.86 43.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.146 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.668 ' CD2' HG13 ' A' ' 119' ' ' VAL . 95.1 m-85 -132.72 110.55 13.38 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.667 0.746 . . . . 0.0 110.894 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.1 Cg_endo -69.8 -2.47 10.25 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.701 2.267 . . . . 0.0 112.294 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 23.4 p -90.3 -4.04 57.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.855 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' CYS . . . . . 0.475 ' HA ' ' CD1' ' A' ' 144' ' ' PHE . 14.1 t -57.35 146.46 28.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.931 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.439 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 1.6 mmm180 -109.01 -36.45 6.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.901 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.418 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.29 149.24 5.78 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.48 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.442 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -100.11 135.82 12.36 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.472 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.412 ' N ' HD23 ' A' ' 112' ' ' LEU . 1.7 tmtp? -127.91 110.9 13.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.848 0.356 . . . . 0.0 110.883 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.527 ' O ' HG13 ' A' ' 128' ' ' VAL . 14.2 p -103.25 119.91 52.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.128 179.856 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.847 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 18.2 m -66.36 143.33 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.113 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 43.5 mt -121.49 -176.6 3.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.911 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -113.77 -175.72 2.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' GLN . . . . . 0.751 ' OE1' HG22 ' A' ' 133' ' ' THR . 0.0 OUTLIER -48.39 -35.18 12.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.912 -179.928 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.751 HG22 ' OE1' ' A' ' 132' ' ' GLN . 9.6 p -86.65 -23.16 25.76 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.145 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.54 23.36 8.93 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.503 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 30.6 m -99.12 128.56 50.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.836 0.351 . . . . 0.0 111.12 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.6 t -39.37 109.75 0.12 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.861 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.3 mtmt -58.53 -28.45 65.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.403 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 123.74 16.07 3.44 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.479 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.847 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 16.2 p90 -162.76 173.19 14.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.941 0.4 . . . . 0.0 110.929 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.421 ' O ' HG22 ' A' ' 100' ' ' VAL . . . -176.73 -163.7 29.44 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.525 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -151.23 148.12 27.82 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.878 0.37 . . . . 0.0 110.934 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.51 HG11 ' CD2' ' A' ' 116' ' ' PHE . 15.4 m -120.85 176.06 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 143' ' ' LYS . . . . . 0.439 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -133.69 161.86 33.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 179.939 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.475 ' CD1' ' HA ' ' A' ' 123' ' ' CYS . 96.9 m-85 -149.61 167.88 25.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 25.8 p -108.79 -8.13 15.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.142 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -132.51 124.44 28.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.856 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.493 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 16.3 tt0 -69.88 -30.92 68.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.889 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 48.6 mt -58.16 -54.61 44.98 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.928 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 54.4 mt-10 -67.57 -39.54 84.91 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.526 ' HG2' HD21 ' A' ' 98' ' ' LEU . 17.6 tt0 -44.01 -45.57 7.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.905 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 74.1 mttt -73.11 -29.89 63.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.942 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 47.3 mtp180 -63.57 -39.84 95.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.873 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.635 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -68.52 -42.87 77.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.138 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.791 HD21 HD22 ' A' ' 98' ' ' LEU . 29.3 mt -45.85 -43.1 13.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.933 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.51 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.4 t -91.1 -46.66 7.99 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.168 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.51 ' N ' HG23 ' A' ' 155' ' ' THR . 47.4 mm-40 -63.32 -63.58 1.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.877 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.731 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 34.0 m -67.7 -9.43 43.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.917 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 158' ' ' GLN . . . . . 0.427 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.6 tp-100 -37.93 145.22 0.07 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.969 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.07 33.71 0.5 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.514 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.731 ' HB2' ' O ' ' A' ' 157' ' ' CYS . . . -58.71 115.86 3.34 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.826 0.346 . . . . 0.0 111.054 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 23.1 t -90.77 -35.33 7.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.136 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.12 -33.28 0.16 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.498 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.504 ' HB2' ' CZ ' ' A' ' 115' ' ' PHE . 25.7 tp -93.69 115.98 28.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.868 0.366 . . . . 0.0 110.871 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 69.1 156.69 1.15 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.475 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 65.8 m -59.83 -19.97 54.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.995 0.426 . . . . 0.0 110.878 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 166' ' ' LYS . . . . . 0.558 ' HB2' HG23 ' A' ' 104' ' ' THR . 49.2 mttt -111.83 156.67 41.28 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.527 0.68 . . . . 0.0 110.93 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 177.62 5.38 Favored 'Trans proline' 0 N--CA 1.465 -0.153 0 C-N-CA 122.681 2.254 . . . . 0.0 112.376 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.652 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 31.4 m -131.33 125.98 57.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.138 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 30.3 ttm180 -91.65 99.76 12.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.856 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.559 ' HB3' HD23 ' A' ' 154' ' ' LEU . 13.4 mt -77.73 151.5 34.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.916 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.7 m -162.83 171.47 16.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.86 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.571 HG22 ' CD1' ' A' ' 154' ' ' LEU . 2.8 t -97.93 105.02 16.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.145 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.092 179.883 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.915 0.388 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.7 p -133.3 149.13 51.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.887 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.83 HD22 HD21 ' A' ' 154' ' ' LEU . 23.6 mt -118.86 149.62 41.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.934 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.483 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 8.9 t80 -96.1 131.37 42.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.906 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.475 HG22 ' C ' ' A' ' 140' ' ' GLY . 17.1 m -122.25 138.3 52.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -130.47 179.77 16.66 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.514 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 51.32 54.03 11.84 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.8 0.334 . . . . 0.0 110.865 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.404 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.0 mt -101.95 103.24 13.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 52.3 p -49.37 150.53 3.18 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.561 0.696 . . . . 0.0 111.145 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 3.0 3.02 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.748 2.299 . . . . 0.0 112.381 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -99.21 -4.32 32.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.662 HG22 ' HE3' ' A' ' 111' ' ' MET . 93.1 t -109.1 144.39 17.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.151 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -129.8 179.75 5.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.86 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.7 -35.27 74.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.862 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -53.5 -32.46 45.74 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.465 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.662 ' HE3' HG22 ' A' ' 107' ' ' VAL . 32.9 mtm -89.03 -42.64 11.63 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.855 0.359 . . . . 0.0 110.892 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.531 HD23 ' N ' ' A' ' 127' ' ' LYS . 17.0 tp -56.91 -28.84 62.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.912 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.474 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 9.5 t80 -74.96 -62.87 1.4 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.709 ' HA ' HG12 ' A' ' 117' ' ' VAL . 19.4 mt-10 -61.65 -26.77 68.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.89 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.64 ' HZ ' ' HB1' ' A' ' 160' ' ' ALA . 84.2 t80 -65.85 -34.62 78.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.893 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -94.63 -58.37 2.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.888 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.709 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.2 p -43.21 -25.55 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.147 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 5.1 ttpm? -69.5 -60.65 2.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.892 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.624 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.2 p -65.46 -27.67 42.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.624 ' CD2' HG13 ' A' ' 119' ' ' VAL . 97.1 m-85 -137.79 113.18 9.13 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.666 0.746 . . . . 0.0 110.94 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 0.05 6.18 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.68 2.253 . . . . 0.0 112.344 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 16.1 m -99.72 24.89 7.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.864 -179.818 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 14.9 t -85.87 140.51 30.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.879 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.588 ' HE ' HG22 ' A' ' 145' ' ' THR . 7.9 mmt85 -95.82 -32.5 12.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.857 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.474 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 151.84 140.78 3.2 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.785 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -90.22 137.24 13.89 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.479 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.531 ' N ' HD23 ' A' ' 112' ' ' LEU . 1.6 tppp? -125.96 129.72 49.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 110.898 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.11 128.28 73.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.096 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.926 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 22.3 m -74.31 147.21 9.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.13 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 11.6 mt -129.01 173.32 10.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.928 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -105.55 -179.15 3.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.883 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 32.9 tt0 -46.24 -39.79 10.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 52.2 p -74.84 -34.07 62.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.131 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.02 23.35 6.17 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.505 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 18.8 m -103.37 132.63 49.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.842 0.353 . . . . 0.0 111.083 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.0 t -42.12 114.06 0.51 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.849 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.438 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.1 mtmt -61.3 -24.7 66.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.831 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 119.71 15.96 5.16 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.484 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.926 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 25.1 p90 -162.13 177.81 9.35 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.933 0.397 . . . . 0.0 110.913 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.475 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -179.63 -163.45 30.4 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.492 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -153.01 147.97 26.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.857 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.785 HG12 ' HA2' ' A' ' 126' ' ' GLY . 14.7 m -120.94 -178.61 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.139 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' LYS . . . . . 0.47 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 21.9 mtmm -141.04 159.18 42.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.826 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -147.32 171.21 15.8 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.857 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' THR . . . . . 0.588 HG22 ' HE ' ' A' ' 124' ' ' ARG . 75.4 p -110.48 -25.61 9.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.152 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -111.7 117.25 32.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.829 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -68.01 -23.74 65.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.879 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 67.7 mt -64.34 -35.85 82.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.931 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.497 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 20.8 mt-10 -88.94 -35.89 16.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.444 ' O ' HD11 ' A' ' 98' ' ' LEU . 22.4 tt0 -42.99 -45.14 4.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.928 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 36.6 mttp -77.41 -35.16 54.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.444 ' O ' ' CG ' ' A' ' 156' ' ' GLU . 21.3 mtp85 -55.69 -34.0 64.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.842 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -74.19 -40.74 62.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.107 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.83 HD21 HD22 ' A' ' 98' ' ' LEU . 19.1 mt -47.5 -41.76 21.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.931 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.456 HG23 ' N ' ' A' ' 156' ' ' GLU . 11.9 t -92.51 -42.4 9.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.173 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.456 ' N ' HG23 ' A' ' 155' ' ' THR . 46.5 mm-40 -67.33 -66.32 0.57 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.909 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.477 ' CB ' HD11 ' A' ' 170' ' ' LEU . 3.7 m -64.26 -13.08 47.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.862 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 158' ' ' GLN . . . . . 0.411 ' C ' ' O ' ' A' ' 157' ' ' CYS . 3.3 tp-100 -35.6 129.62 0.57 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.926 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 59.0 33.25 73.28 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.525 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.829 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -56.1 112.95 1.34 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 111.102 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.2 t -91.6 -32.95 5.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.153 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -43.52 -31.38 1.63 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.509 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.51 ' HB2' ' CE1' ' A' ' 115' ' ' PHE . 26.7 tp -94.97 112.85 24.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.842 0.353 . . . . 0.0 110.886 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.421 ' CA ' HG21 ' A' ' 107' ' ' VAL . . . 70.82 148.45 0.49 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.498 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 49.0 m -50.92 -31.61 18.15 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.939 0.399 . . . . 0.0 110.841 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -99.92 155.52 36.36 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.534 0.683 . . . . 0.0 110.904 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.84 174.48 9.51 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.703 2.269 . . . . 0.0 112.302 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.829 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 30.7 m -130.32 135.42 60.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.165 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 169' ' ' ARG . . . . . 0.405 ' O ' ' HG2' ' A' ' 169' ' ' ARG . 5.7 ptm180 -95.93 128.04 42.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.862 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.762 ' HB3' HD23 ' A' ' 154' ' ' LEU . 31.9 mt -102.06 136.75 41.35 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.951 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.3 m -151.78 -176.9 5.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 10.7 t -107.48 94.3 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.158 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.483 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.08 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' TYR . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 7.3 m-85 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.888 0.375 . . . . 0.0 110.909 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.1 p -126.23 155.09 42.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.784 HD22 HD21 ' A' ' 154' ' ' LEU . 85.7 mt -126.15 144.05 50.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.918 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.48 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 11.6 t80 -94.47 131.24 40.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.436 ' CG2' HD11 ' A' ' 103' ' ' LEU . 34.8 m -120.03 147.52 23.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.125 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -134.9 -177.9 15.28 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.482 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 50.24 48.39 22.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.803 0.335 . . . . 0.0 110.882 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.446 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.2 mt -93.86 103.09 15.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.889 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.666 ' OG1' HG23 ' A' ' 107' ' ' VAL . 71.1 p -48.2 149.49 2.59 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.588 0.709 . . . . 0.0 111.153 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 2.61 3.34 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.707 2.271 . . . . 0.0 112.38 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -99.11 -9.83 23.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.852 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.666 HG23 ' OG1' ' A' ' 104' ' ' THR . 15.7 t -98.12 144.05 11.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.134 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -130.24 174.46 9.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.844 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -51.66 -50.74 59.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.875 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -45.54 -33.99 4.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.506 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.432 ' HE2' HG13 ' A' ' 107' ' ' VAL . 50.4 mtp -80.92 -61.5 1.94 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.781 0.324 . . . . 0.0 110.855 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.452 HD12 ' CD2' ' A' ' 163' ' ' LEU . 18.3 tp -41.23 -40.2 1.54 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.919 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.497 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 17.6 t80 -63.01 -68.12 0.37 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.903 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.749 ' HA ' HG12 ' A' ' 117' ' ' VAL . 26.7 mt-10 -48.74 -55.51 11.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.88 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.55 ' CB ' HD13 ' A' ' 163' ' ' LEU . 76.4 t80 -42.75 -32.1 0.56 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.885 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.467 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.1 m-85 -95.0 -67.23 0.86 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.873 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.749 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.81 -30.31 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.14 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.2 tttp -65.41 -58.5 5.7 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.929 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.58 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.3 p -67.27 -29.81 47.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.132 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.58 ' CD2' HG13 ' A' ' 119' ' ' VAL . 96.3 m-85 -137.06 109.49 9.05 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.685 0.755 . . . . 0.0 110.924 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 2.43 3.53 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.671 2.247 . . . . 0.0 112.318 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 1.3 p -95.49 -0.18 52.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.833 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 19.1 t -66.4 138.07 57.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.931 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -91.59 -38.61 12.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.497 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 164.37 150.42 6.13 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.476 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.631 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -94.21 137.52 13.57 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.447 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 19.7 tptm -125.27 118.72 26.61 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.838 0.351 . . . . 0.0 110.903 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.518 ' O ' HG13 ' A' ' 128' ' ' VAL . 7.7 p -112.45 115.57 50.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.109 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.913 HG22 ' O ' ' A' ' 139' ' ' TYR . 32.6 m -61.66 151.27 7.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.161 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.583 HD23 ' HA ' ' A' ' 136' ' ' SER . 49.0 mt -133.16 164.48 26.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.924 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.452 ' O ' ' N ' ' A' ' 134' ' ' GLY . 13.7 t70 -96.96 175.84 6.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.866 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 2.0 tp-100 -42.66 -44.25 4.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.905 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 44.0 p -70.0 -28.51 65.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.118 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 103.81 23.73 8.1 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.505 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 136' ' ' SER . 28.4 m -105.12 131.43 54.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-O 120.824 0.345 . . . . 0.0 111.122 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.583 ' HA ' HD23 ' A' ' 130' ' ' LEU . 5.8 t -37.89 114.16 0.33 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.426 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.7 mtmt -62.66 -25.89 68.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.907 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 119.41 17.18 4.9 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.5 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.913 ' O ' HG22 ' A' ' 129' ' ' VAL . 20.3 p90 -163.54 172.05 14.96 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.916 0.389 . . . . 0.0 110.984 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -176.22 -164.11 29.84 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.501 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' PHE . . . . . 0.48 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 3.7 m-85 -152.05 149.15 28.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.906 0.384 . . . . 0.0 110.845 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.631 HG12 ' HA2' ' A' ' 126' ' ' GLY . 16.1 m -123.0 161.05 25.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.131 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -119.05 158.41 25.89 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.872 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.524 ' CE1' HG23 ' A' ' 142' ' ' VAL . 84.4 m-85 -145.6 169.36 18.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 43.3 p -115.0 -24.79 8.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.123 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -112.99 99.82 8.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 16.7 tt0 -46.94 -45.26 20.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.884 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 33.6 mt -48.1 -40.57 23.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.927 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.474 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 4.4 mm-40 -80.98 -33.98 33.41 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.825 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.48 ' HG2' HD21 ' A' ' 98' ' ' LEU . 15.4 tt0 -49.79 -63.89 0.97 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.944 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -57.92 -47.62 82.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.923 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 47.0 mtt180 -43.97 -30.89 0.78 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.855 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -73.76 -39.1 64.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.064 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.784 HD21 HD22 ' A' ' 98' ' ' LEU . 12.2 mt -51.01 -38.14 49.46 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.886 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.508 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.8 t -92.46 -46.35 7.69 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.508 ' N ' HG23 ' A' ' 155' ' ' THR . 10.7 mt-10 -68.45 -63.1 1.13 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.828 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.48 ' CB ' HD11 ' A' ' 170' ' ' LEU . 40.3 m -68.64 -2.61 9.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.873 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -43.5 136.69 3.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.876 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 42.61 43.85 5.15 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.45 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.571 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -61.33 110.89 1.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.784 0.326 . . . . 0.0 111.134 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.7 -35.95 10.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.137 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -40.68 -34.48 0.74 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.501 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.55 HD13 ' CB ' ' A' ' 115' ' ' PHE . 16.1 tp -91.07 118.77 30.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.835 0.35 . . . . 0.0 110.946 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 165' ' ' SER . . . 61.22 135.07 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.465 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 165' ' ' SER . . . . . 0.411 ' C ' ' O ' ' A' ' 164' ' ' GLY . 58.8 m -37.58 -33.58 0.08 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.924 0.392 . . . . 0.0 110.844 -179.692 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 31.7 mttp -95.61 153.5 39.43 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.574 0.702 . . . . 0.0 110.876 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -176.27 1.44 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.677 2.252 . . . . 0.0 112.313 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.571 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 33.2 m -140.84 126.59 19.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 18.3 mtt180 -90.26 116.68 28.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.847 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.562 ' HB3' HD23 ' A' ' 154' ' ' LEU . 17.4 mt -89.9 137.48 32.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.903 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 13.2 m -149.52 179.72 7.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.89 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 5.0 t -103.99 98.1 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.087 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.46 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.069 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' TYR . . . . . 0.509 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 33.1 m-85 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.924 0.392 . . . . 0.0 110.895 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 64.6 m -105.18 156.38 18.15 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.892 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.959 HD22 HD21 ' A' ' 154' ' ' LEU . 21.8 mt -122.23 143.01 49.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.949 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.439 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 8.5 t80 -93.11 126.87 38.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.912 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.438 HG22 ' C ' ' A' ' 140' ' ' GLY . 30.2 m -119.17 148.6 22.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.142 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.61 176.33 20.9 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.522 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ASP . . . . . 0.468 ' N ' ' O ' ' A' ' 138' ' ' GLY . 22.7 m-20 56.57 50.74 12.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.837 0.351 . . . . 0.0 110.878 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.406 ' H ' ' C ' ' A' ' 138' ' ' GLY . 25.9 mt -98.6 100.34 11.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 75.0 p -42.69 149.38 0.48 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.602 0.715 . . . . 0.0 111.128 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 3.13 2.93 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.711 2.274 . . . . 0.0 112.368 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 65.5 m-20 -104.22 11.93 34.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.903 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 1.02 HG22 ' HE3' ' A' ' 111' ' ' MET . 75.3 t -128.42 134.98 63.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.125 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -120.69 -175.99 3.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.869 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -57.88 -37.01 73.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -46.59 -41.51 12.82 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.443 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' MET . . . . . 1.02 ' HE3' HG22 ' A' ' 107' ' ' VAL . 27.9 mtm -83.82 -44.8 13.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.787 0.327 . . . . 0.0 110.863 -179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 21.2 tp -51.74 -22.82 3.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.901 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.414 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 14.8 t80 -83.74 -64.69 1.12 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.863 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.712 ' HA ' HG12 ' A' ' 117' ' ' VAL . 27.1 mt-10 -57.2 -26.45 60.68 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.889 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.561 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 60.5 t80 -66.7 -34.83 78.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.907 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 11.5 m-85 -95.22 -57.72 2.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.839 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.712 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -43.23 -28.69 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.119 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 3.6 tptm -68.9 -59.61 2.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.856 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.631 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.3 p -65.29 -28.75 45.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.137 179.841 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.631 ' CD2' HG13 ' A' ' 119' ' ' VAL . 91.5 m-85 -138.17 114.43 9.08 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.695 0.759 . . . . 0.0 110.922 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.67 -0.2 6.49 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.717 2.278 . . . . 0.0 112.335 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' SER . . . . . 0.474 ' O ' HG23 ' A' ' 145' ' ' THR . 17.2 p -88.85 -17.73 29.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.816 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' CYS . . . . . 0.433 ' HA ' ' CD1' ' A' ' 144' ' ' PHE . 7.7 t -48.08 139.36 8.25 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.895 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 25.2 mtp180 -100.71 -34.96 9.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.862 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.414 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 164.02 145.56 4.42 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.521 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.435 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -98.39 133.82 11.47 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.485 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 13.4 tptt -124.79 128.94 49.5 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.834 0.349 . . . . 0.0 110.867 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.1 p -114.43 138.05 45.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.176 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.873 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 24.4 m -83.76 143.25 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.12 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 17.1 mt -122.7 171.73 8.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.904 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -105.55 -179.88 4.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.815 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 15.8 pt20 -45.6 -39.86 8.19 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.925 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 44.2 p -74.88 -33.79 62.11 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.136 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 111.79 21.28 6.47 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.526 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 27.3 m -100.66 143.45 14.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.812 0.339 . . . . 0.0 111.16 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 3.7 t -54.55 107.26 0.27 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.859 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.49 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.5 mtmt -52.47 -29.95 27.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.885 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.468 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 122.53 19.23 3.16 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.49 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.873 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 27.3 p90 -163.8 167.77 20.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.921 0.391 . . . . 0.0 110.909 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.438 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -171.11 -159.91 18.34 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.498 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -153.58 151.52 29.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.9 0.381 . . . . 0.0 110.877 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.465 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 18.4 m -124.1 176.36 5.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.16 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 33.8 mtmt -136.83 158.23 44.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.433 ' CD1' ' HA ' ' A' ' 123' ' ' CYS . 91.5 m-85 -145.38 167.05 23.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.905 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' THR . . . . . 0.474 HG23 ' O ' ' A' ' 122' ' ' SER . 27.7 p -105.48 -25.41 12.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.147 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.413 ' OD2' HD12 ' A' ' 148' ' ' LEU . 6.4 t70 -119.5 111.15 17.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.509 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 2.9 tm-20 -51.43 -45.75 62.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.874 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 148' ' ' LEU . . . . . 0.413 HD12 ' OD2' ' A' ' 146' ' ' ASP . 24.0 mt -42.0 -42.2 2.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.915 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 57.0 mm-40 -76.23 -41.77 48.17 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.424 ' HG2' HD21 ' A' ' 98' ' ' LEU . 17.7 tt0 -40.84 -57.79 1.85 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.924 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 32.9 mmtm -62.53 -51.53 67.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.925 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 36.8 mtp180 -41.81 -40.97 2.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.452 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -67.88 -48.22 66.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.043 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.959 HD21 HD22 ' A' ' 98' ' ' LEU . 15.3 mt -42.61 -42.46 3.42 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.913 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.534 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.2 t -89.12 -48.13 7.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.13 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.534 ' N ' HG23 ' A' ' 155' ' ' THR . 18.2 mm-40 -63.56 -64.35 0.92 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.437 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 2.5 m -68.25 -8.09 36.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.926 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 158' ' ' GLN . . . . . 0.493 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 3.5 tp-100 -36.14 134.38 0.41 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 -179.871 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 46.57 41.32 12.52 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.474 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.683 ' HB3' HG22 ' A' ' 168' ' ' VAL . . . -57.39 117.44 4.12 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.848 0.356 . . . . 0.0 111.084 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.6 t -92.9 -33.5 5.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.163 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.94 -36.33 2.55 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.443 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 18.2 tp -87.94 114.83 24.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.829 0.347 . . . . 0.0 110.868 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 70.8 161.27 3.88 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.4 p -66.97 -3.83 8.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.946 0.403 . . . . 0.0 110.85 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -128.37 154.78 79.17 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.547 0.689 . . . . 0.0 110.917 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 171.6 14.16 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.696 2.264 . . . . 0.0 112.337 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.683 HG22 ' HB3' ' A' ' 160' ' ' ALA . 32.8 m -128.97 126.29 64.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.137 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -87.99 112.6 22.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.886 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.687 ' HB3' HD23 ' A' ' 154' ' ' LEU . 13.9 mt -85.94 146.07 26.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.913 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.2 m -157.57 169.04 25.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.43 HG22 HD11 ' A' ' 154' ' ' LEU . 40.9 t -94.45 102.41 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.121 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.439 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.094 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 10.0 m-85 . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.92 0.39 . . . . 0.0 110.946 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 29.0 m -145.14 162.9 35.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.839 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.78 HD22 HD21 ' A' ' 154' ' ' LEU . 91.8 mt -131.35 135.39 47.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.933 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.6 t80 -86.83 131.43 34.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.896 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 30.8 m -127.09 150.57 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.176 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.43 -170.99 12.26 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.476 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 45.41 51.47 9.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.828 0.347 . . . . 0.0 110.861 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.487 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.0 mt -96.93 102.46 14.24 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.465 HG23 ' HB2' ' A' ' 166' ' ' LYS . 37.1 p -48.74 151.37 2.13 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.617 0.722 . . . . 0.0 111.125 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 2.95 3.09 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.699 2.266 . . . . 0.0 112.351 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -103.85 17.8 23.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.432 HG13 ' CE ' ' A' ' 111' ' ' MET . 2.8 t -125.57 134.34 66.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.167 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -124.04 170.79 10.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.849 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.46 ' CG ' ' N ' ' A' ' 110' ' ' GLY . 0.3 OUTLIER -47.06 -49.97 20.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.912 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.46 ' N ' ' CG ' ' A' ' 109' ' ' ASP . . . -47.61 -26.46 3.85 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.454 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.432 ' CE ' HG13 ' A' ' 107' ' ' VAL . 27.2 mtp -89.23 -57.6 2.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.766 0.317 . . . . 0.0 110.874 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.501 HD23 ' N ' ' A' ' 127' ' ' LYS . 15.3 tp -46.86 -28.43 1.57 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.977 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.408 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.3 t80 -76.5 -66.64 0.78 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.93 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.679 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.9 mt-10 -54.96 -25.98 33.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.891 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.455 ' CB ' HD13 ' A' ' 163' ' ' LEU . 72.2 t80 -68.27 -35.73 78.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.862 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.594 ' CD2' HG11 ' A' ' 142' ' ' VAL . 12.1 m-85 -95.09 -56.97 2.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.679 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -42.41 -27.89 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.16 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 15.2 ttmm -66.88 -60.71 2.42 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.946 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.573 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.0 p -63.32 -32.91 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.112 179.849 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.573 ' CD2' HG13 ' A' ' 119' ' ' VAL . 93.6 m-85 -134.75 115.41 12.32 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.749 0.785 . . . . 0.0 110.905 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -1.8 9.13 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.672 2.248 . . . . 0.0 112.321 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 3.1 m -86.41 -12.64 48.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.806 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' CYS . . . . . 0.448 ' CB ' ' HA ' ' A' ' 117' ' ' VAL . 13.5 t -50.27 135.19 21.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.587 ' HE ' HG22 ' A' ' 145' ' ' THR . 93.9 mtt180 -96.99 -37.67 10.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.408 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 166.54 143.44 3.75 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.472 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.42 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -96.9 134.54 11.81 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.516 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.501 ' N ' HD23 ' A' ' 112' ' ' LEU . 10.1 tptm -125.78 123.86 39.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.81 0.338 . . . . 0.0 110.886 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -113.5 123.35 69.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.083 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.98 HG22 ' O ' ' A' ' 139' ' ' TYR . 25.0 m -68.81 149.22 11.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.097 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.628 HD22 ' O ' ' A' ' 134' ' ' GLY . 40.9 mt -127.34 -177.02 3.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.482 ' O ' ' N ' ' A' ' 134' ' ' GLY . 13.2 t0 -116.94 176.09 5.28 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.799 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -39.86 -39.84 0.89 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.913 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -82.29 -29.57 31.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.14 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.628 ' O ' HD22 ' A' ' 130' ' ' LEU . . . 112.41 0.99 26.38 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.506 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.59 ' O ' HG23 ' A' ' 135' ' ' VAL . 9.6 m -76.21 118.99 23.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 111.155 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.507 ' HA ' HD23 ' A' ' 130' ' ' LEU . 6.9 t -35.01 108.27 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.473 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.4 mtmt -50.39 -35.63 29.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.883 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.62 19.07 2.11 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.473 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.98 ' O ' HG22 ' A' ' 129' ' ' VAL . 22.1 p90 -163.32 168.61 20.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.918 0.39 . . . . 0.0 110.911 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -173.65 -163.56 27.4 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.43 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -152.89 147.6 26.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.92 0.39 . . . . 0.0 110.87 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.594 HG11 ' CD2' ' A' ' 116' ' ' PHE . 16.4 m -119.08 171.08 7.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.145 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' LYS . . . . . 0.475 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 34.3 mtpt -127.63 161.76 28.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.555 ' CE2' HD12 ' A' ' 98' ' ' LEU . 93.8 m-85 -149.75 160.91 43.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.867 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' THR . . . . . 0.587 HG22 ' HE ' ' A' ' 124' ' ' ARG . 76.7 p -99.73 -20.03 16.46 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.169 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -119.09 126.32 51.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.843 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 14.5 tt0 -71.71 -25.98 62.31 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.919 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 23.9 mt -65.85 -47.95 73.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.437 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 24.4 mt-10 -73.56 -39.29 64.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.862 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.551 ' CD ' HD21 ' A' ' 98' ' ' LEU . 1.4 tm0? -46.09 -39.13 8.93 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.907 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.433 ' HD3' HD12 ' A' ' 154' ' ' LEU . 27.8 mmtp -79.99 -43.94 21.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.896 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 3.0 mtt-85 -48.04 -28.47 2.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.552 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -78.64 -34.51 46.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.08 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.78 HD21 HD22 ' A' ' 98' ' ' LEU . 22.9 mt -55.87 -36.94 68.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.3 t -92.28 -35.71 13.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.131 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -81.8 -66.88 0.83 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.873 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.467 ' C ' HD11 ' A' ' 170' ' ' LEU . 99.7 m -60.92 -10.26 5.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.861 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 158' ' ' GLN . . . . . 0.404 ' C ' ' O ' ' A' ' 157' ' ' CYS . 3.0 tp-100 -36.34 132.05 0.59 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.937 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 52.54 38.49 51.78 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.479 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.756 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -54.02 115.04 1.82 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.851 0.357 . . . . 0.0 111.086 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 40.2 t -93.98 -36.27 7.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.11 -35.51 1.73 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.545 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.474 ' CD2' HD12 ' A' ' 112' ' ' LEU . 27.6 tp -83.9 109.58 17.7 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.853 0.358 . . . . 0.0 110.915 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 74.91 174.71 34.16 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.501 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 38.4 m -84.56 28.09 0.68 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.897 0.379 . . . . 0.0 110.837 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 166' ' ' LYS . . . . . 0.465 ' HB2' HG23 ' A' ' 104' ' ' THR . 29.5 mttm -159.55 156.59 25.35 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.561 0.695 . . . . 0.0 110.909 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 170.19 17.15 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.685 2.257 . . . . 0.0 112.314 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.756 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 31.1 m -131.09 128.57 62.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.098 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 36.7 ttt180 -86.54 109.6 19.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.826 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.575 ' HB3' HD23 ' A' ' 154' ' ' LEU . 12.6 mt -85.42 145.9 27.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.94 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.9 m -162.16 177.76 9.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.827 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 8.8 t -100.68 103.22 14.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.163 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.07 179.905 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 96' ' ' TYR . . . . . 0.501 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 2.1 m-85 . . . . . 0 C--O 1.231 0.079 0 CA-C-O 120.916 0.389 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.7 m -135.56 139.42 43.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.88 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.593 HD21 ' CG ' ' A' ' 150' ' ' GLN . 98.4 mt -108.69 151.93 25.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.891 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.571 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 5.7 t80 -99.63 121.29 41.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.903 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.443 HG22 ' C ' ' A' ' 140' ' ' GLY . 23.6 m -110.0 137.12 43.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.121 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -126.91 176.58 17.67 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.472 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 53.37 52.45 13.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.826 0.346 . . . . 0.0 110.87 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.453 HD12 ' C ' ' A' ' 139' ' ' TYR . 24.8 mt -97.92 98.49 9.84 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.926 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.451 HG23 ' HB2' ' A' ' 166' ' ' LYS . 2.2 p -45.99 151.54 0.88 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.599 0.714 . . . . 0.0 111.162 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 0.0 6.32 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.665 2.243 . . . . 0.0 112.309 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -101.23 16.58 25.03 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.831 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.536 HG22 ' HE3' ' A' ' 111' ' ' MET . 61.5 t -129.41 131.93 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.095 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -118.69 171.54 8.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.869 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.4 ' CG ' ' N ' ' A' ' 110' ' ' GLY . 2.3 p30 -48.62 -49.48 36.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.799 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' GLY . . . . . 0.4 ' N ' ' CG ' ' A' ' 109' ' ' ASP . . . -38.36 -37.2 0.47 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.469 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.536 ' HE3' HG22 ' A' ' 107' ' ' VAL . 27.6 mtm -86.43 -45.46 11.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.779 0.323 . . . . 0.0 110.848 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 13.9 tp -54.12 -20.36 6.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.905 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.504 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 15.0 t80 -86.19 -60.67 1.94 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.925 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.76 ' HA ' HG12 ' A' ' 117' ' ' VAL . 33.7 mt-10 -59.38 -46.73 87.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.879 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.495 ' CG ' HD13 ' A' ' 163' ' ' LEU . 69.5 t80 -48.03 -33.81 8.51 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.896 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.495 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.2 m-85 -95.02 -66.61 0.9 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.881 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.76 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.59 -30.0 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.091 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.474 ' N ' ' O ' ' A' ' 116' ' ' PHE . 0.0 OUTLIER -65.08 -57.29 9.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.915 179.922 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.551 HG22 ' CE2' ' A' ' 120' ' ' TYR . 2.6 p -66.4 -34.8 72.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.144 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.551 ' CE2' HG22 ' A' ' 119' ' ' VAL . 91.8 m-85 -135.22 115.67 11.93 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-O 121.701 0.762 . . . . 0.0 110.954 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 2.9 3.14 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.69 2.26 . . . . 0.0 112.321 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.0 p -86.06 -18.94 31.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 29.2 t -53.06 135.96 36.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.882 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 18.3 mtt180 -98.88 -30.86 12.15 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.877 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.504 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 161.62 147.73 5.07 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.484 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -91.35 141.67 15.77 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.533 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.85 105.29 7.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.756 0.312 . . . . 0.0 110.874 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -98.23 149.14 5.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.155 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.992 HG21 ' CE1' ' A' ' 139' ' ' TYR . 19.5 m -95.86 142.57 13.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.102 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.639 HD23 ' HA ' ' A' ' 136' ' ' SER . 13.9 mt -130.0 173.4 10.76 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.898 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.421 ' O ' ' N ' ' A' ' 134' ' ' GLY . 26.3 t0 -107.34 171.97 7.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.865 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -44.54 -26.0 0.32 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.92 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 49.2 p -86.42 -33.94 20.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.124 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 109.14 20.62 7.81 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.502 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.582 ' O ' HG23 ' A' ' 135' ' ' VAL . 25.0 m -100.19 115.71 41.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.881 0.372 . . . . 0.0 111.101 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.639 ' HA ' HD23 ' A' ' 130' ' ' LEU . 8.4 t -37.65 103.64 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.837 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.8 mttm -43.59 -37.49 2.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.891 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 129.43 20.46 1.4 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.464 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.992 ' CE1' HG21 ' A' ' 129' ' ' VAL . 28.0 p90 -161.39 -179.31 7.27 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.922 0.391 . . . . 0.0 110.923 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.443 ' C ' HG22 ' A' ' 100' ' ' VAL . . . 177.17 -166.33 36.86 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.472 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 3.6 m-85 -153.37 139.37 18.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.86 0.362 . . . . 0.0 110.935 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.495 HG11 ' CD2' ' A' ' 116' ' ' PHE . 27.8 m -112.93 -178.23 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -140.36 163.8 31.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.923 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -149.83 167.12 27.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.89 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 58.6 p -102.33 -12.07 18.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.118 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -137.04 122.33 19.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.895 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.501 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 4.6 tt0 -60.11 -37.5 80.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.905 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 34.9 mt -52.39 -49.97 63.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.935 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -70.04 -33.29 71.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.878 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.593 ' CG ' HD21 ' A' ' 98' ' ' LEU . 28.6 tt0 -58.44 -57.05 14.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.957 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.572 ' HD3' HD12 ' A' ' 154' ' ' LEU . 30.2 mmtm -59.11 -42.28 90.16 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.899 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 40.6 mtt-85 -54.69 -30.62 56.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.902 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.487 ' O ' ' CD1' ' A' ' 170' ' ' LEU . . . -73.36 -34.53 65.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.06 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.796 HD23 ' HB3' ' A' ' 170' ' ' LEU . 43.9 mt -56.51 -40.36 74.9 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.905 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 15.1 t -92.43 -34.3 14.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.128 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 39.0 mm-40 -78.55 -58.3 3.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.864 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.587 ' C ' HD11 ' A' ' 170' ' ' LEU . 36.0 m -79.96 11.77 3.15 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 158' ' ' GLN . . . . . 0.477 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 3.5 tp-100 -52.92 137.81 31.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.955 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.62 33.46 0.59 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.469 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.472 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -53.17 116.73 2.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.815 0.34 . . . . 0.0 111.1 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' A' ' 162' ' ' GLY . 24.1 t -86.91 -35.41 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.137 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 162' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.18 -38.6 0.26 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.535 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.495 HD13 ' CG ' ' A' ' 115' ' ' PHE . 18.9 tp -87.42 115.36 24.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.871 0.367 . . . . 0.0 110.864 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.42 159.19 1.03 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.511 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 71.1 m -62.47 -16.62 56.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.936 0.398 . . . . 0.0 110.869 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 166' ' ' LYS . . . . . 0.451 ' HB2' HG23 ' A' ' 104' ' ' THR . 28.3 mttp -113.33 155.79 44.09 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.584 0.707 . . . . 0.0 110.905 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 173.51 10.86 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.757 2.304 . . . . 0.0 112.336 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.472 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 27.1 m -128.51 125.93 64.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.091 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 11.3 ttm180 -88.44 108.61 19.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.889 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.796 ' HB3' HD23 ' A' ' 154' ' ' LEU . 17.1 mt -84.23 147.27 27.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 4.5 m -163.95 177.42 8.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 39.7 t -103.55 101.7 12.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.571 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.116 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 13.1 m-85 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.851 0.358 . . . . 0.0 110.934 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.7 p -110.07 138.01 47.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.83 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.65 HD12 ' CE2' ' A' ' 144' ' ' PHE . 97.5 mt -111.25 146.77 36.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.933 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -93.09 130.73 38.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.907 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.495 HG22 ' C ' ' A' ' 140' ' ' GLY . 17.9 m -123.55 149.27 27.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.15 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.99 -167.63 11.0 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 41.44 52.57 3.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.828 0.347 . . . . 0.0 110.861 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.416 HD12 ' C ' ' A' ' 139' ' ' TYR . 26.4 mt -101.04 101.63 12.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.561 ' OG1' HG23 ' A' ' 107' ' ' VAL . 75.9 p -47.01 150.2 1.41 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.556 0.693 . . . . 0.0 111.17 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 3.12 2.96 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.69 2.26 . . . . 0.0 112.359 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 -100.57 -0.74 37.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.561 HG23 ' OG1' ' A' ' 104' ' ' THR . 20.9 t -108.01 136.52 43.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.168 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -118.92 175.77 5.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.868 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -58.29 -36.2 72.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -53.65 -33.92 49.25 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.542 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.455 ' CE ' HG13 ' A' ' 107' ' ' VAL . 23.7 mtm -83.69 -55.01 4.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.806 0.336 . . . . 0.0 110.921 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.409 HD23 ' N ' ' A' ' 127' ' ' LYS . 29.4 tp -41.02 -37.37 0.81 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.943 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.435 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 17.6 t80 -70.19 -65.92 0.66 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.942 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.737 ' HA ' HG12 ' A' ' 117' ' ' VAL . 19.1 mt-10 -49.42 -53.19 24.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.897 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.602 ' CB ' HD13 ' A' ' 163' ' ' LEU . 58.2 t80 -44.58 -33.29 1.72 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.934 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.565 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.6 m-85 -93.99 -66.7 0.9 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.888 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.737 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.88 -31.09 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.108 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.456 ' N ' ' O ' ' A' ' 116' ' ' PHE . 0.5 OUTLIER -65.31 -61.28 2.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.949 179.884 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.631 HG22 ' CD2' ' A' ' 120' ' ' TYR . 1.6 p -64.65 -32.56 58.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.157 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.631 ' CD2' HG22 ' A' ' 119' ' ' VAL . 97.8 m-85 -131.23 113.82 15.94 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.657 0.741 . . . . 0.0 110.933 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 1.09 4.76 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.67 2.247 . . . . 0.0 112.331 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 1.4 p -104.14 31.95 4.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.804 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 41.9 t -91.12 124.9 35.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.472 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 22.5 mtp180 -79.18 -39.54 33.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.873 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.435 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 159.74 154.18 7.18 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.524 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -97.29 147.0 18.51 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.514 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.409 ' N ' HD23 ' A' ' 112' ' ' LEU . 2.7 tmtp? -137.66 112.58 9.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.839 0.352 . . . . 0.0 110.887 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' VAL . . . . . 0.526 ' O ' HG13 ' A' ' 128' ' ' VAL . 12.8 p -106.76 119.43 56.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.127 179.899 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.746 HG22 ' O ' ' A' ' 139' ' ' TYR . 20.1 m -63.75 155.5 5.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 20.8 mt -134.81 167.66 20.46 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.426 ' O ' ' N ' ' A' ' 134' ' ' GLY . 20.6 t70 -99.65 175.4 5.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' GLN . . . . . 0.452 ' HG3' ' N ' ' A' ' 133' ' ' THR . 20.2 pt20 -43.38 -43.33 5.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' THR . . . . . 0.452 ' N ' ' HG3' ' A' ' 132' ' ' GLN . 34.3 p -72.65 -28.47 62.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.166 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 106.48 24.59 6.69 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.523 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 31.3 m -103.45 137.18 32.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.821 0.344 . . . . 0.0 111.1 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 1.6 t -48.95 110.46 0.36 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.835 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.461 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.1 mtmt -57.16 -33.86 67.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.882 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 127.31 17.54 2.17 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.537 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.746 ' O ' HG22 ' A' ' 129' ' ' VAL . 24.7 p90 -162.2 174.16 13.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.943 0.402 . . . . 0.0 110.949 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.495 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -177.94 -161.29 25.86 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.471 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -153.09 148.19 26.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.85 0.357 . . . . 0.0 110.897 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.565 HG11 ' CD2' ' A' ' 116' ' ' PHE . 16.9 m -118.63 -177.16 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.175 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' LYS . . . . . 0.472 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 40.5 mtmt -144.17 157.21 44.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.878 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.65 ' CE2' HD12 ' A' ' 98' ' ' LEU . 76.3 m-85 -146.93 160.72 41.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 32.8 p -102.01 -16.08 16.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.191 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -120.28 110.72 16.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.836 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 11.9 tt0 -57.91 -41.59 82.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.887 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 75.4 mt -48.16 -47.96 34.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.935 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.557 ' N ' ' CD ' ' A' ' 149' ' ' GLU . 0.0 OUTLIER -72.22 -44.6 62.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.887 179.899 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.437 ' C ' ' O ' ' A' ' 149' ' ' GLU . 20.2 tt0 -34.84 -58.59 0.51 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.93 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 12.6 mmtp -63.49 -34.35 77.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.912 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 152' ' ' ARG . . . . . 0.577 ' HB3' ' CE1' ' A' ' 120' ' ' TYR . 4.0 tpt180 -51.61 -41.03 60.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.849 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -71.77 -44.77 63.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.091 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.764 HD23 ' HB3' ' A' ' 170' ' ' LEU . 29.7 mt -50.47 -38.34 43.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.472 HG23 ' HG2' ' A' ' 156' ' ' GLU . 14.6 t -92.57 -37.08 12.66 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.472 ' HG2' HG23 ' A' ' 155' ' ' THR . 6.7 mm-40 -83.05 -65.02 1.06 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.897 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.494 ' N ' ' O ' ' A' ' 153' ' ' ALA . 76.2 m -62.8 -8.22 6.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.921 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -37.71 128.96 1.14 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.858 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 50.36 38.89 34.99 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.464 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.517 ' O ' HG22 ' A' ' 168' ' ' VAL . . . -60.0 116.35 4.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.813 0.34 . . . . 0.0 111.141 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.42 ' O ' ' C ' ' A' ' 162' ' ' GLY . 23.9 t -85.28 -37.85 12.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.144 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 162' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.75 -37.2 0.21 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.514 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.602 HD13 ' CB ' ' A' ' 115' ' ' PHE . 17.0 tp -86.38 114.52 23.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.848 0.356 . . . . 0.0 110.926 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 64.54 151.78 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.487 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 9.4 t -51.3 -25.28 5.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.948 0.404 . . . . 0.0 110.835 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 166' ' ' LYS . . . . . 0.402 ' HB2' HG23 ' A' ' 104' ' ' THR . 53.5 mttt -106.45 156.18 37.46 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.568 0.699 . . . . 0.0 110.892 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -175.42 1.15 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.682 2.255 . . . . 0.0 112.323 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.517 HG22 ' O ' ' A' ' 160' ' ' ALA . 12.6 m -137.84 128.63 37.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.139 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 7.8 mtp85 -88.51 111.89 22.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.846 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.764 ' HB3' HD23 ' A' ' 154' ' ' LEU . 15.3 mt -91.83 140.47 29.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 13.9 m -155.83 -177.61 6.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.833 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 4.7 t -102.69 100.13 9.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.149 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.119 179.892 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 96' ' ' TYR . . . . . 0.495 ' CE2' ' HB2' ' A' ' 147' ' ' GLU . 47.5 m-85 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.855 0.36 . . . . 0.0 110.944 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 11.1 m -120.65 154.79 35.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.849 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.531 HD22 HD21 ' A' ' 154' ' ' LEU . 22.4 mt -120.37 144.48 47.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.927 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -94.96 123.06 38.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.9 m -114.88 149.05 17.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.44 -175.1 13.65 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.509 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 50.83 50.01 19.89 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.806 0.336 . . . . 0.0 110.897 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 30.9 mt -98.94 104.34 16.38 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.924 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.631 HG23 ' HB2' ' A' ' 166' ' ' LYS . 14.9 p -49.08 150.16 3.01 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.583 0.706 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 2.95 3.08 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.651 2.234 . . . . 0.0 112.342 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -99.69 -13.4 19.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.865 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.724 HG22 ' HE3' ' A' ' 111' ' ' MET . 73.1 t -96.2 138.95 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.153 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.94 -176.11 3.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.849 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -65.4 -41.74 93.33 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.88 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.47 -34.47 13.78 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.475 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.724 ' HE3' HG22 ' A' ' 107' ' ' VAL . 25.5 mtm -81.71 -49.61 10.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.816 0.341 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.9 tp -50.86 -34.42 27.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.925 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' TYR . . . . . . . . . . . . . 12.9 t80 -68.8 -61.45 1.8 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.946 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.769 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.1 mt-10 -57.28 -53.86 53.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.847 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.426 ' HB2' HD13 ' A' ' 163' ' ' LEU . 69.2 t80 -42.3 -32.46 0.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.526 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.6 m-85 -95.17 -67.97 0.83 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.769 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.7 -29.37 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.489 ' N ' ' O ' ' A' ' 116' ' ' PHE . 19.1 tptt -67.46 -60.67 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.68 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.1 p -65.18 -31.91 55.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.133 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.68 ' CD2' HG13 ' A' ' 119' ' ' VAL . 97.3 m-85 -134.11 114.3 12.7 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.647 0.737 . . . . 0.0 110.965 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.31 8.25 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.678 2.252 . . . . 0.0 112.377 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 87.2 p -85.9 -16.45 38.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.834 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.4 t -52.22 139.7 23.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.839 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 42.0 mtm180 -105.0 -33.57 8.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.875 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 166.66 145.62 4.54 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.451 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.454 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -95.25 137.54 13.49 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.475 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -125.87 122.43 36.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.783 0.325 . . . . 0.0 110.914 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.0 p -113.62 138.14 44.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.137 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.976 HG22 ' O ' ' A' ' 139' ' ' TYR . 33.7 m -86.17 152.08 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.131 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.572 HD23 ' HA ' ' A' ' 136' ' ' SER . 17.8 mt -130.84 176.37 8.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.486 ' O ' ' N ' ' A' ' 134' ' ' GLY . 25.6 t0 -107.52 174.27 5.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -39.6 -40.27 0.86 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.909 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 30.4 p -74.83 -33.75 62.22 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.158 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 112.83 17.78 7.75 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.498 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 34.0 m -97.88 133.47 39.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.872 0.368 . . . . 0.0 111.105 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.572 ' HA ' HD23 ' A' ' 130' ' ' LEU . 2.6 t -43.2 105.68 0.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.889 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.499 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 27.1 mtmt -50.64 -35.82 32.39 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.897 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 129.27 20.22 1.45 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.483 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.976 ' O ' HG22 ' A' ' 129' ' ' VAL . 27.4 p90 -163.81 169.06 18.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.909 0.385 . . . . 0.0 110.95 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -171.87 -163.29 25.54 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.446 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -153.58 148.67 26.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.89 0.376 . . . . 0.0 110.898 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.526 HG11 ' CD2' ' A' ' 116' ' ' PHE . 27.8 m -124.6 168.49 17.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 143' ' ' LYS . . . . . 0.448 ' N ' ' HD3' ' A' ' 143' ' ' LYS . 0.0 OUTLIER -125.97 159.19 33.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.936 179.896 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -145.37 157.5 44.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.915 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 76.4 p -96.73 -19.22 19.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.169 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -120.64 120.58 36.14 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.863 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.495 ' HB2' ' CE2' ' A' ' 96' ' ' TYR . 0.1 OUTLIER -67.31 -39.19 85.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 39.3 mt -52.62 -34.44 51.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.911 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -85.06 -37.07 20.76 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.876 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 -43.84 -57.28 3.35 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.537 ' HA ' HD12 ' A' ' 154' ' ' LEU . 73.2 mttt -65.07 -27.53 68.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 15.1 ttt180 -59.94 -40.88 90.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.849 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.464 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -69.33 -46.12 67.85 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.136 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.76 HD23 ' HB3' ' A' ' 170' ' ' LEU . 29.7 mt -43.62 -40.82 4.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.906 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.505 HG23 ' N ' ' A' ' 156' ' ' GLU . 10.9 t -92.52 -45.32 8.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.119 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.505 ' N ' HG23 ' A' ' 155' ' ' THR . 12.2 mm-40 -67.38 -60.08 2.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.894 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.464 ' N ' ' O ' ' A' ' 153' ' ' ALA . 4.8 m -78.21 9.59 3.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 158' ' ' GLN . . . . . 0.43 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.8 tp-100 -51.85 128.73 24.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.894 -179.871 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 51.37 35.23 35.25 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.491 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -57.94 121.94 11.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.794 0.33 . . . . 0.0 111.122 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 25.6 t -93.38 -34.72 6.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.65 -34.12 0.24 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.501 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.426 HD13 ' HB2' ' A' ' 115' ' ' PHE . 29.1 tp -91.57 115.69 28.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.822 0.344 . . . . 0.0 110.895 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 164' ' ' GLY . . . . . 0.449 ' HA3' HG21 ' A' ' 107' ' ' VAL . . . 65.17 146.14 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.531 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 165' ' ' SER . . . . . 0.445 ' HB3' HG21 ' A' ' 104' ' ' THR . 6.2 t -48.97 -20.45 0.52 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.912 0.387 . . . . 0.0 110.86 -179.753 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 166' ' ' LYS . . . . . 0.631 ' HB2' HG23 ' A' ' 104' ' ' THR . 16.2 mtmt -108.48 155.29 40.69 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.586 0.708 . . . . 0.0 110.916 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 -173.07 0.65 Allowed 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.672 2.248 . . . . 0.0 112.38 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.491 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 34.6 m -139.62 124.53 20.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.075 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 39.8 ttm-85 -91.4 99.99 12.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.868 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.76 ' HB3' HD23 ' A' ' 154' ' ' LEU . 14.0 mt -76.36 145.73 39.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.905 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.421 ' N ' ' CD2' ' A' ' 154' ' ' LEU . 4.3 m -160.74 178.32 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.847 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 36.9 t -105.61 104.17 16.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.143 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.115 179.904 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 96' ' ' TYR . . . . . 0.5 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 21.1 m-85 . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.934 0.397 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 12.3 p -137.48 145.45 43.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.864 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.753 HD22 HD21 ' A' ' 154' ' ' LEU . 47.1 mt -120.99 139.17 53.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.945 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.907 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 12.3 t80 -90.22 131.07 36.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.899 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.521 HG22 ' C ' ' A' ' 140' ' ' GLY . 25.2 m -121.99 155.77 26.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.142 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -142.92 178.17 21.4 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.449 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 52.93 53.87 11.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.817 0.341 . . . . 0.0 110.831 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.406 HD23 ' HA ' ' A' ' 103' ' ' LEU . 24.6 mt -100.35 100.17 10.92 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.905 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.532 ' OG1' HG23 ' A' ' 107' ' ' VAL . 58.5 p -46.71 150.0 1.35 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.552 0.691 . . . . 0.0 111.172 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 2.75 3.25 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -102.43 6.81 40.34 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.835 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 1.086 HG13 ' HE2' ' A' ' 111' ' ' MET . 12.9 t -119.6 129.93 74.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.124 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -116.95 177.03 4.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.86 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -51.05 -53.75 30.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.836 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -38.74 -35.61 0.37 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.44 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' MET . . . . . 1.086 ' HE2' HG13 ' A' ' 107' ' ' VAL . 48.7 mtp -81.93 -59.43 2.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.807 0.336 . . . . 0.0 110.901 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.486 HD23 ' N ' ' A' ' 127' ' ' LYS . 22.5 tp -42.08 -31.43 0.36 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.914 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.541 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 10.9 t80 -72.24 -66.59 0.63 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.942 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.738 ' HA ' HG12 ' A' ' 117' ' ' VAL . 46.8 mt-10 -52.43 -47.39 66.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.873 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.508 ' CZ ' ' HB2' ' A' ' 163' ' ' LEU . 60.4 t80 -48.11 -33.08 7.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.896 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.492 ' CD2' HG11 ' A' ' 142' ' ' VAL . 8.1 m-85 -94.99 -66.23 0.93 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.904 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.738 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.74 -31.45 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.122 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.451 ' N ' ' O ' ' A' ' 116' ' ' PHE . 30.3 tttp -64.66 -58.16 7.06 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.878 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.454 HG13 ' CD2' ' A' ' 120' ' ' TYR . 2.8 p -66.7 -33.97 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.148 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.559 ' CD1' ' HB3' ' A' ' 149' ' ' GLU . 90.2 m-85 -129.55 115.09 18.21 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.714 0.768 . . . . 0.0 110.935 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.7 Cg_endo -69.79 -2.72 10.67 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.678 2.252 . . . . 0.0 112.361 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 56.4 m -104.85 39.87 1.61 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 49.6 t -98.17 132.43 43.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.89 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.448 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 19.7 mmt180 -83.26 -35.26 25.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 -179.847 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.541 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 148.34 139.99 3.26 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.464 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.768 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -82.88 148.61 25.97 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.509 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.486 ' N ' HD23 ' A' ' 112' ' ' LEU . 12.5 tptp -139.47 117.25 11.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.84 0.352 . . . . 0.0 110.881 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -106.04 146.76 12.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.145 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.81 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 30.1 m -93.66 150.93 3.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.08 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 15.5 mt -129.57 165.43 21.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.864 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -95.7 -177.2 3.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.848 179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -50.08 -37.6 34.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.941 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 41.0 p -75.16 -33.67 61.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.172 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 114.64 18.46 6.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.472 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 34.9 m -98.06 144.57 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.844 0.354 . . . . 0.0 111.114 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.9 t -56.79 105.06 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.48 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.1 mtmt -47.84 -29.18 3.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.89 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 121.0 18.37 3.88 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.542 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.81 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 9.9 p90 -161.8 175.89 11.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.926 0.393 . . . . 0.0 110.926 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.521 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -178.88 -162.23 27.94 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.44 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -153.64 146.32 24.24 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.896 0.379 . . . . 0.0 110.895 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.768 HG12 ' HA2' ' A' ' 126' ' ' GLY . 15.8 m -121.2 -176.61 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 143' ' ' LYS . . . . . 0.448 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 39.8 mtmt -144.56 162.78 35.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.886 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -149.78 159.04 44.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 69.8 p -93.92 -33.27 13.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.129 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 21.2 t0 -108.53 115.89 30.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.871 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.5 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 7.6 tt0 -59.62 -36.25 75.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.924 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 62.9 mt -53.31 -40.11 64.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.91 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.559 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 61.7 mt-10 -85.79 -22.48 27.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.856 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.517 ' O ' HD11 ' A' ' 98' ' ' LEU . 18.3 tt0 -57.73 -53.67 55.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.91 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 3.2 mtpm? -69.24 -43.62 73.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.935 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 53.1 mtt-85 -45.54 -35.96 4.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.844 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.405 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -72.2 -43.43 64.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.753 HD21 HD22 ' A' ' 98' ' ' LEU . 17.6 mt -46.1 -41.79 12.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 156' ' ' GLU . 12.3 t -91.37 -48.96 6.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.572 ' N ' HG23 ' A' ' 155' ' ' THR . 43.2 mm-40 -62.07 -66.5 0.53 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.479 ' CB ' HD11 ' A' ' 170' ' ' LEU . 66.4 m -62.83 -13.01 28.47 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.89 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 4.2 tp-100 -37.68 131.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.926 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 59.9 30.24 69.35 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.485 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.838 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -52.94 111.35 0.65 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.834 0.35 . . . . 0.0 111.083 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.4 t -89.35 -38.82 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.141 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -41.1 -32.35 0.6 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.451 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.508 ' HB2' ' CZ ' ' A' ' 115' ' ' PHE . 24.1 tp -90.84 116.27 28.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.857 0.36 . . . . 0.0 110.95 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 62.08 143.03 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.45 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 50.2 m -42.08 -32.16 0.43 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.934 0.397 . . . . 0.0 110.868 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 24.5 mttm -100.76 154.38 37.2 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.535 0.684 . . . . 0.0 110.888 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -178.99 2.6 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.697 2.264 . . . . 0.0 112.368 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.838 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 34.1 m -131.48 125.35 56.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.099 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 35.0 ttm180 -88.57 104.96 17.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.868 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.522 ' HB3' HD23 ' A' ' 154' ' ' LEU . 9.1 mt -84.18 145.86 28.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.938 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 5.1 m -159.24 173.72 15.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.855 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 172' ' ' VAL . . . . . 0.404 HG22 ' CD1' ' A' ' 154' ' ' LEU . 5.4 t -95.25 90.79 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.163 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.907 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.095 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.918 0.389 . . . . 0.0 110.917 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 77.3 p -129.53 157.36 42.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.867 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.855 HD22 HD21 ' A' ' 154' ' ' LEU . 87.1 mt -127.47 148.65 50.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.904 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.433 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 8.4 t80 -95.78 130.49 42.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.882 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -122.72 139.35 49.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.147 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -126.9 178.98 16.57 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.484 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 53.34 51.47 15.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.85 0.357 . . . . 0.0 110.903 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' LEU . . . . . 0.501 HD12 ' C ' ' A' ' 139' ' ' TYR . 21.3 mt -95.48 101.05 12.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.694 ' OG1' HG23 ' A' ' 107' ' ' VAL . 63.3 p -48.49 150.11 2.54 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.588 0.709 . . . . 0.0 111.133 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 2.96 3.04 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.679 2.253 . . . . 0.0 112.334 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -102.75 2.5 35.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.843 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.694 HG23 ' OG1' ' A' ' 104' ' ' THR . 5.7 t -108.49 136.64 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.116 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -124.66 168.43 13.17 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.906 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -46.29 -45.9 17.62 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.833 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.97 -36.45 20.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.512 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.434 ' HE2' HG13 ' A' ' 107' ' ' VAL . 19.2 mtp -78.56 -58.4 3.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.772 0.32 . . . . 0.0 110.846 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.594 HD23 ' N ' ' A' ' 127' ' ' LYS . 19.4 tp -45.32 -36.27 4.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.935 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.529 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 7.4 t80 -67.24 -61.11 2.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.901 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.751 ' HA ' HG12 ' A' ' 117' ' ' VAL . 44.6 mt-10 -57.17 -54.58 45.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.872 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.489 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 69.5 t80 -42.08 -32.19 0.44 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.855 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.586 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.8 m-85 -95.19 -67.54 0.85 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.892 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.751 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.69 -29.17 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.081 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.496 ' N ' ' O ' ' A' ' 116' ' ' PHE . 46.3 tttp -67.88 -57.19 6.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.907 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.677 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.8 p -71.15 -25.1 24.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.114 179.856 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.677 ' CD2' HG13 ' A' ' 119' ' ' VAL . 95.9 m-85 -135.26 109.17 10.44 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.702 0.763 . . . . 0.0 110.926 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' PRO . . . . . 0.426 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.4 Cg_endo -69.81 2.96 3.09 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.716 2.278 . . . . 0.0 112.357 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 15.0 m -109.97 30.83 6.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.834 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 42.6 t -92.83 132.12 37.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.903 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.46 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 42.2 mtp180 -83.31 -29.13 28.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.909 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.529 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 147.0 139.24 3.25 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.488 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.68 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -93.24 135.9 12.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.512 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' LYS . . . . . 0.594 ' N ' HD23 ' A' ' 112' ' ' LEU . 0.1 OUTLIER -121.4 143.71 49.07 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.784 0.326 . . . . 0.0 110.95 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.97 127.16 72.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.13 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.816 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 7.0 m -76.32 138.19 21.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.149 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 136' ' ' SER . 26.1 mt -116.28 160.68 20.12 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -87.88 -176.58 5.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -52.85 -37.24 60.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.921 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 27.6 p -75.76 -21.81 57.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.091 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.99 22.36 10.12 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.456 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 24.0 m -106.3 140.83 23.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.797 0.332 . . . . 0.0 111.159 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' SER . . . . . 0.438 ' HA ' HD23 ' A' ' 130' ' ' LEU . 2.7 t -47.06 108.63 0.15 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.867 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.473 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 30.4 mtmt -54.64 -32.26 58.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.912 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.24 17.44 2.44 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.491 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.816 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 17.2 p90 -163.76 171.27 15.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.913 0.387 . . . . 0.0 110.937 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -172.75 -162.59 25.13 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.447 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -154.0 142.4 20.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.878 0.37 . . . . 0.0 110.896 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.68 HG12 ' HA2' ' A' ' 126' ' ' GLY . 29.0 m -117.24 170.9 6.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.126 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 143' ' ' LYS . . . . . 0.46 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -131.05 160.54 34.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.948 179.849 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.41 ' CE2' HG23 ' A' ' 142' ' ' VAL . 86.2 m-85 -148.81 162.53 39.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.903 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 33.7 p -98.41 -26.6 14.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.154 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' ASP . . . . . 0.431 ' CG ' ' OE1' ' A' ' 149' ' ' GLU . 4.9 t70 -112.1 119.73 39.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.864 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -67.29 -31.65 72.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.908 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 21.7 mt -56.81 -54.01 51.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.893 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 149' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 150' ' ' GLN . 1.9 mp0 -64.81 -45.87 84.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.905 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.449 ' C ' ' O ' ' A' ' 149' ' ' GLU . 21.7 tt0 -33.46 -46.86 0.2 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.949 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 151' ' ' LYS . . . . . 0.434 ' O ' ' N ' ' A' ' 154' ' ' LEU . 13.8 mmtp -66.98 -55.76 13.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -38.69 -35.12 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.599 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -72.72 -44.89 61.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.855 HD21 HD22 ' A' ' 98' ' ' LEU . 16.1 mt -47.16 -38.95 12.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.925 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.616 HG23 ' N ' ' A' ' 156' ' ' GLU . 12.1 t -92.47 -51.12 5.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.145 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.616 ' N ' HG23 ' A' ' 155' ' ' THR . 79.1 mm-40 -64.35 -57.79 8.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.632 ' C ' HD11 ' A' ' 170' ' ' LEU . 53.3 m -75.18 5.33 5.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.871 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 3.3 tp-100 -53.1 137.45 33.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.903 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 45.48 37.24 6.39 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.468 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.862 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -54.89 116.19 2.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.894 0.378 . . . . 0.0 111.104 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 32.7 t -94.74 -33.45 4.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.16 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -45.04 -33.55 3.77 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.51 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.489 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 56.4 tp -85.63 115.24 23.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.866 0.365 . . . . 0.0 110.915 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 69.88 175.21 14.81 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.51 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 11.7 m -84.19 25.87 0.81 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.92 0.391 . . . . 0.0 110.825 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 166' ' ' LYS . . . . . 0.468 ' HB2' HG23 ' A' ' 104' ' ' THR . 19.7 mttp -157.24 157.05 30.16 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.585 0.707 . . . . 0.0 110.909 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 170.24 17.02 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.654 2.236 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.862 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 30.1 m -132.37 125.98 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.129 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 36.3 ttt85 -88.89 117.12 27.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.665 ' HB3' HD23 ' A' ' 154' ' ' LEU . 11.7 mt -93.24 139.37 30.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.894 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 15.9 m -156.55 173.0 17.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.836 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 15.6 t -93.79 99.21 9.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.134 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 173' ' ' ALA . . . . . 0.433 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.06 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' TYR . . . . . 0.466 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 4.3 m-85 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.89 0.376 . . . . 0.0 110.946 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 35.4 p -126.72 155.02 43.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.836 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' LEU . . . . . 0.611 HD21 ' CD ' ' A' ' 150' ' ' GLN . 85.9 mt -124.87 139.57 53.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -90.27 125.97 35.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.415 HG22 ' C ' ' A' ' 140' ' ' GLY . 15.9 m -120.8 141.43 41.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.131 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -129.78 -175.87 14.21 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.431 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 51.13 52.65 14.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.839 0.352 . . . . 0.0 110.88 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 22.3 mt -98.49 112.67 24.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.978 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.419 HG21 ' HB2' ' A' ' 165' ' ' SER . 10.2 p -58.55 150.82 54.29 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.591 0.71 . . . . 0.0 111.115 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 2.42 3.55 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.689 2.259 . . . . 0.0 112.342 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -99.42 -5.67 29.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.822 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 107' ' ' VAL . . . . . 0.486 HG13 ' HE2' ' A' ' 111' ' ' MET . 31.6 t -102.08 143.49 14.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.162 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -127.93 173.87 9.65 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -54.0 -45.25 71.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.862 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.99 -26.28 26.6 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.488 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' MET . . . . . 0.486 ' HE2' HG13 ' A' ' 107' ' ' VAL . 35.0 mtp -85.36 -58.52 2.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.825 0.345 . . . . 0.0 110.885 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 40.5 tp -42.86 -36.7 1.58 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.919 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' TYR . . . . . 0.455 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.6 t80 -66.3 -68.33 0.38 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.88 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.715 ' HA ' HG12 ' A' ' 117' ' ' VAL . 23.8 mt-10 -48.9 -41.72 34.48 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.91 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 115' ' ' PHE . . . . . 0.519 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 53.8 t80 -54.29 -34.1 60.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.849 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' PHE . . . . . 0.464 ' O ' ' N ' ' A' ' 118' ' ' LYS . 9.1 m-85 -95.19 -64.36 1.07 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.895 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' VAL . . . . . 0.715 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.7 -30.91 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.105 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 118' ' ' LYS . . . . . 0.464 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.1 ttpt -65.01 -61.17 2.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.916 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.455 HG13 ' CD2' ' A' ' 120' ' ' TYR . 2.5 p -66.78 -34.35 69.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.097 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' TYR . . . . . 0.509 ' CE2' ' HB2' ' A' ' 153' ' ' ALA . 90.7 m-85 -126.05 109.02 24.65 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.673 0.749 . . . . 0.0 110.946 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 2.13 3.8 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.69 2.26 . . . . 0.0 112.328 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 10.6 m -108.32 34.4 3.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.2 t -90.32 135.43 33.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.855 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.46 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 63.1 mtt180 -85.14 -36.39 21.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.455 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 154.48 143.04 3.58 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.484 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.67 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -91.52 138.68 14.4 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.488 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.71 131.96 45.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.79 0.328 . . . . 0.0 110.914 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 8.7 p -117.3 137.19 52.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.143 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' VAL . . . . . 0.873 HG22 ' O ' ' A' ' 139' ' ' TYR . 18.7 m -81.03 148.44 5.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.118 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 16.3 mt -133.09 169.8 16.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.88 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -104.22 177.32 4.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -46.36 -36.47 6.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 41.5 p -77.75 -33.27 52.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.49 17.04 9.57 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.49 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 135' ' ' VAL . . . . . 0.442 ' O ' HG23 ' A' ' 135' ' ' VAL . 20.3 m -96.42 127.63 48.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.342 . . . . 0.0 111.104 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 9.3 t -43.79 108.86 0.12 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.869 -179.846 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' LYS . . . . . 0.511 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.5 mtmt -52.51 -31.36 34.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.932 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.36 19.77 2.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.524 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' TYR . . . . . 0.873 ' O ' HG22 ' A' ' 129' ' ' VAL . 26.5 p90 -163.62 169.67 18.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.389 . . . . 0.0 110.915 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 140' ' ' GLY . . . . . 0.415 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -169.14 -163.86 23.87 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.446 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -153.86 148.91 26.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.917 0.389 . . . . 0.0 110.871 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.67 HG12 ' HA2' ' A' ' 126' ' ' GLY . 16.6 m -124.33 179.29 2.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.091 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' LYS . . . . . 0.46 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 22.9 mtpt -142.57 161.52 37.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.929 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.403 ' HE1' HG23 ' A' ' 142' ' ' VAL . 37.7 m-85 -149.9 153.66 37.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.877 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 51.5 p -91.5 -19.14 23.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -113.92 110.29 19.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.863 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 147' ' ' GLU . . . . . 0.466 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 16.0 tt0 -60.29 -35.75 76.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 93.6 mt -57.88 -45.01 87.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.946 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -74.56 -43.57 55.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.864 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' GLN . . . . . 0.611 ' CD ' HD21 ' A' ' 98' ' ' LEU . 1.6 tm0? -44.18 -38.91 4.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.976 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 24.7 mmtt -76.51 -40.3 50.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.921 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 54.9 mtt85 -53.84 -31.58 49.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.906 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' ALA . . . . . 0.509 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -69.1 -54.06 17.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.101 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.576 HD23 ' CB ' ' A' ' 170' ' ' LEU . 21.8 mt -40.27 -36.33 0.51 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.907 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 155' ' ' THR . . . . . 0.422 HG23 ' N ' ' A' ' 156' ' ' GLU . 7.7 t -92.4 -42.36 9.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.122 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 156' ' ' GLU . . . . . 0.422 ' N ' HG23 ' A' ' 155' ' ' THR . 24.0 mm-40 -75.68 -62.93 1.42 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.903 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 157' ' ' CYS . . . . . 0.574 ' CB ' HD11 ' A' ' 170' ' ' LEU . 53.7 m -67.13 -3.82 8.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.7 tp-100 -41.8 131.11 3.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.91 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 47.4 41.18 16.7 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.539 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 160' ' ' ALA . . . . . 0.564 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -60.22 111.05 1.38 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.788 0.328 . . . . 0.0 111.109 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.7 t -84.97 -35.66 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.132 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.5 -35.53 0.33 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.473 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 163' ' ' LEU . . . . . 0.463 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 29.7 tp -88.7 122.12 31.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.861 0.362 . . . . 0.0 110.921 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 61.94 157.62 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.486 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 165' ' ' SER . . . . . 0.419 ' HB2' HG21 ' A' ' 104' ' ' THR . 72.0 m -60.62 -12.51 10.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.923 0.392 . . . . 0.0 110.864 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 61.8 mttt -118.44 156.8 50.74 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.571 0.701 . . . . 0.0 110.88 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -177.26 1.8 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.651 2.234 . . . . 0.0 112.374 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 168' ' ' VAL . . . . . 0.564 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 29.8 m -138.73 124.76 24.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.154 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 34.6 ttt180 -87.84 107.0 18.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 170' ' ' LEU . . . . . 0.576 ' CB ' HD23 ' A' ' 154' ' ' LEU . 10.3 mt -81.98 146.84 29.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.908 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 8.0 m -163.33 179.73 7.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.839 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 13.4 t -102.66 101.75 12.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.128 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.117 179.88 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 79.8 p -89.19 42.0 1.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.911 0.386 . . . . 0.0 110.852 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 88.1 p -58.41 123.47 16.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.856 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 149.17 49.14 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.486 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.9 m -155.26 111.02 3.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.866 0.365 . . . . 0.0 110.853 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 27.4 t -86.31 82.02 8.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.887 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.09 69.1 1.42 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.529 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -173.27 0.68 Allowed 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.695 2.263 . . . . 0.0 112.372 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -126.07 143.69 51.01 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.9 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' TYR . . . . . 0.523 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 67.3 m-85 -128.08 86.79 2.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.924 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.8 m -97.91 161.68 13.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.876 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.884 HD22 HD21 ' A' ' 154' ' ' LEU . 26.0 mt -125.78 143.57 51.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.899 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -93.47 115.78 28.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.523 HG22 ' C ' ' A' ' 140' ' ' GLY . 5.3 m -108.09 148.48 12.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.143 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.7 -177.41 15.14 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.505 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ASP . . . . . 0.42 ' N ' ' O ' ' A' ' 138' ' ' GLY . 24.8 m-20 50.87 51.81 16.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.868 0.366 . . . . 0.0 110.887 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.412 HD11 ' CG2' ' A' ' 100' ' ' VAL . 31.1 mt -98.27 102.58 14.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.897 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.501 ' OG1' HG23 ' A' ' 107' ' ' VAL . 72.9 p -47.57 149.85 1.94 Allowed Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.583 0.706 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 2.99 3.07 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.675 2.25 . . . . 0.0 112.327 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -98.32 -16.47 19.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.905 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.596 HG22 ' HE3' ' A' ' 111' ' ' MET . 51.1 t -93.39 145.56 7.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.161 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -129.78 -179.72 5.36 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.862 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -57.77 -51.12 70.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -39.85 -36.18 0.75 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.596 ' HE3' HG22 ' A' ' 107' ' ' VAL . 18.5 mtm -82.79 -59.26 2.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.795 0.331 . . . . 0.0 110.916 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.436 HD23 ' N ' ' A' ' 127' ' ' LYS . 25.2 tp -36.05 -44.02 0.36 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.88 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.406 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 16.1 t80 -63.6 -61.16 2.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.907 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.755 ' HA ' HG12 ' A' ' 117' ' ' VAL . 18.3 mt-10 -54.17 -55.68 25.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.862 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.828 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 71.3 t80 -41.13 -32.29 0.25 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.873 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.48 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.5 m-85 -95.25 -68.16 0.82 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.841 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.755 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.7 -30.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.148 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.48 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.5 ttpt -68.78 -53.96 18.69 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.888 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.574 HG13 ' CD2' ' A' ' 120' ' ' TYR . 2.6 p -70.73 -31.47 45.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.109 179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.574 ' CD2' HG13 ' A' ' 119' ' ' VAL . 94.2 m-85 -135.84 114.47 11.04 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.679 0.752 . . . . 0.0 110.913 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.82 0.53 5.55 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.658 2.239 . . . . 0.0 112.361 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 26.0 m -98.2 21.01 11.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.885 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 7.7 t -84.72 134.78 34.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.888 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 9.0 mmt85 -91.87 -38.94 12.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.836 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.406 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.96 152.27 7.13 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.536 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.406 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -101.66 143.01 15.9 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.488 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.436 ' N ' HD23 ' A' ' 112' ' ' LEU . 21.7 tptm -132.78 127.38 34.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 110.865 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.5 p -116.8 127.18 74.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.145 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.959 HG22 ' O ' ' A' ' 139' ' ' TYR . 20.3 m -73.91 143.65 13.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.127 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.627 HD23 ' HA ' ' A' ' 136' ' ' SER . 25.5 mt -130.57 163.82 26.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.927 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 134' ' ' GLY . 23.8 t70 -94.68 176.17 6.38 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -44.34 -40.38 5.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.894 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 18.1 p -72.37 -28.58 63.11 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.179 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 104.98 20.36 9.92 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.487 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 26.1 m -99.64 134.75 37.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.831 0.348 . . . . 0.0 111.15 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.627 ' HA ' HD23 ' A' ' 130' ' ' LEU . 6.0 t -48.62 112.92 0.67 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.813 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.3 mtmt -58.69 -28.56 65.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.954 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 122.83 15.25 3.97 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.441 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.959 ' O ' HG22 ' A' ' 129' ' ' VAL . 29.8 p90 -161.88 167.99 23.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.896 0.379 . . . . 0.0 110.912 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.523 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -169.64 -160.02 16.85 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.467 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -153.7 148.64 26.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.9 0.381 . . . . 0.0 110.874 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.446 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 28.5 m -123.3 170.6 13.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.077 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 25.3 mttt -129.67 156.06 44.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -143.09 171.56 13.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.9 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 1.7 p -108.3 -28.79 9.23 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -113.1 128.4 56.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.881 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.523 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 12.9 tm-20 -69.37 -38.37 78.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.87 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 26.9 mt -51.0 -44.82 60.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -73.16 -42.88 62.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.852 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 19.8 tt0 -38.74 -57.94 1.14 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.928 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 9.2 mmmm -63.21 -49.32 74.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.91 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 34.4 mtt-85 -43.43 -41.06 4.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.832 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.98 -44.3 76.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.098 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.884 HD21 HD22 ' A' ' 98' ' ' LEU . 24.2 mt -48.46 -40.63 26.98 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.906 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.1 t -91.36 -34.7 14.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 17.4 mm-40 -79.58 -65.1 1.04 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.876 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.549 ' C ' HD11 ' A' ' 170' ' ' LEU . 11.2 m -65.14 -8.74 18.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.877 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' GLN . . . . . 0.444 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.5 tp-100 -35.6 137.9 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.923 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.48 42.81 2.72 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.521 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.828 ' HB1' ' CZ ' ' A' ' 115' ' ' PHE . . . -57.75 110.9 0.98 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.803 0.335 . . . . 0.0 111.068 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.403 ' O ' ' C ' ' A' ' 162' ' ' GLY . 20.1 t -82.72 -41.76 17.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.135 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 162' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -37.87 -34.84 0.2 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.459 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.572 HD13 ' HB2' ' A' ' 115' ' ' PHE . 26.5 tp -90.23 115.77 27.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.811 0.339 . . . . 0.0 110.938 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.415 ' O ' ' C ' ' A' ' 165' ' ' SER . . . 62.52 137.85 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.481 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' SER . . . . . 0.415 ' C ' ' O ' ' A' ' 164' ' ' GLY . 1.2 t -37.4 -32.87 0.05 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.916 0.389 . . . . 0.0 110.866 -179.782 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 164' ' ' GLY . 58.0 mttt -100.46 153.6 37.65 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.519 0.676 . . . . 0.0 110.913 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -179.19 2.77 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.67 2.247 . . . . 0.0 112.311 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.787 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 13.8 m -130.59 129.68 64.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.1 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.6 ttt-85 -89.27 110.58 21.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.883 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.825 ' HB3' HD23 ' A' ' 154' ' ' LEU . 12.5 mt -87.24 144.59 26.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.927 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.2 m -160.89 175.06 12.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 2.6 t -102.66 104.43 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.136 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -85.81 161.81 18.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.074 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' ILE . . . . . 0.614 HG23 ' HD2' ' A' ' 175' ' ' PRO . 85.5 mt -131.74 137.46 30.37 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.635 0.731 . . . . 0.0 111.14 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.614 ' HD2' HG23 ' A' ' 174' ' ' ILE . 53.7 Cg_endo -69.76 -173.91 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.668 2.245 . . . . 0.0 112.359 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 18.7 ttpp -54.81 94.61 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.873 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -107.33 76.29 1.07 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.038 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 1.6 t -174.99 174.05 2.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.809 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 15.1 mmm180 -120.1 110.72 16.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.872 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 28.7 m -73.6 135.69 27.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.21 141.72 42.91 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.543 0.687 . . . . 0.0 110.892 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 139.67 40.62 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.723 2.282 . . . . 0.0 112.334 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 31.3 m -108.8 162.36 6.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.14 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -160.17 149.83 17.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.877 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.4 m -145.28 144.72 30.93 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.865 -179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 168.35 69.59 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.48 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 175.31 8.3 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.66 2.24 . . . . 0.0 112.324 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 36.0 p -165.48 145.87 6.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.886 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 1.2 t -126.83 156.62 41.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.831 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.486 -180.0 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 36.1 m -157.46 168.51 27.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.86 0.362 . . . . 0.0 110.853 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.2 t -105.56 80.28 1.55 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.874 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 140.44 176.16 15.0 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.48 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.0 m -90.51 -50.87 5.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.858 0.361 . . . . 0.0 110.857 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 79.0 p -68.61 -50.69 49.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.843 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 109.22 83.44 1.48 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.521 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 163.06 39.64 Favored 'Trans proline' 0 C--O 1.231 0.155 0 C-N-CA 122.701 2.267 . . . . 0.0 112.334 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 34.9 mp0 -73.23 178.0 4.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.855 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' TYR . . . . . 0.405 ' CD1' ' HG3' ' A' ' 147' ' ' GLU . 9.4 m-85 -132.45 103.76 6.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.98 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 51.6 m -124.92 154.12 41.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.872 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.72 HD21 ' HG2' ' A' ' 150' ' ' GLN . 96.1 mt -126.65 143.44 51.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.9 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.445 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 11.4 t80 -92.51 142.13 27.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.863 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 21.6 m -132.02 150.86 34.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.109 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.15 -174.32 13.27 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.489 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 46.55 54.74 8.37 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.797 0.332 . . . . 0.0 110.852 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.421 HD12 ' C ' ' A' ' 139' ' ' TYR . 29.6 mt -101.84 112.09 24.57 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.895 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.74 ' OG1' HG23 ' A' ' 107' ' ' VAL . 73.3 p -53.59 148.98 16.67 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.61 0.719 . . . . 0.0 111.126 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 2.14 3.78 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.71 2.273 . . . . 0.0 112.35 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -97.98 -17.52 19.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.868 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.74 HG23 ' OG1' ' A' ' 104' ' ' THR . 14.7 t -87.58 143.77 10.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.102 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -131.65 172.2 12.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.855 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -49.59 -46.31 48.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -49.25 -28.91 9.27 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.461 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.452 ' O ' ' N ' ' A' ' 113' ' ' TYR . 14.1 mtp -86.4 -66.54 0.89 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.814 0.34 . . . . 0.0 110.866 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.423 ' C ' ' O ' ' A' ' 111' ' ' MET . 24.6 tp -35.75 -32.88 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.887 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.452 ' N ' ' O ' ' A' ' 111' ' ' MET . 12.0 t80 -68.84 -65.01 0.76 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.927 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.725 ' HA ' HG12 ' A' ' 117' ' ' VAL . 18.4 mt-10 -55.59 -39.57 70.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.559 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 58.0 t80 -54.55 -33.88 60.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.886 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.46 ' O ' ' N ' ' A' ' 118' ' ' LYS . 10.0 m-85 -95.27 -64.92 1.01 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.818 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.725 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.78 -30.92 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.076 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.46 ' N ' ' O ' ' A' ' 116' ' ' PHE . 5.3 ttpm? -65.45 -58.79 4.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.874 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.612 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.5 p -64.56 -33.78 65.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.172 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.612 ' CD2' HG13 ' A' ' 119' ' ' VAL . 91.0 m-85 -135.44 116.53 11.97 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.664 0.745 . . . . 0.0 110.965 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 1.94 3.97 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.671 2.247 . . . . 0.0 112.365 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 86.4 p -87.85 -23.27 24.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.835 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 7.7 t -47.19 137.04 8.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.885 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 51.7 mtm180 -99.3 -36.53 9.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.874 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.42 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.53 143.2 3.65 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.493 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.512 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -87.16 145.24 19.69 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.492 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 21.5 tptm -131.49 110.65 11.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.855 0.359 . . . . 0.0 110.86 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.7 p -102.48 139.85 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.109 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.776 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 25.0 m -86.32 158.34 3.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.566 HD23 ' HA ' ' A' ' 136' ' ' SER . 24.2 mt -137.38 167.78 20.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.878 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.443 ' O ' ' N ' ' A' ' 134' ' ' GLY . 17.7 t0 -102.18 175.06 5.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.83 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -42.03 -42.07 2.75 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.948 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 65.2 p -72.82 -31.83 65.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.097 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 108.88 19.79 8.41 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.487 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 24.9 m -99.7 127.76 52.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.353 . . . . 0.0 111.114 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.566 ' HA ' HD23 ' A' ' 130' ' ' LEU . 3.0 t -40.21 106.76 0.06 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.831 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.551 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.7 mtmt -50.38 -37.16 35.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.944 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 128.81 18.7 1.71 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.459 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.776 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 16.3 p90 -160.81 173.41 15.41 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.953 0.406 . . . . 0.0 110.935 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -177.26 -163.85 29.95 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.484 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.445 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 2.5 m-85 -152.83 150.44 29.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.888 0.375 . . . . 0.0 110.9 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.512 HG12 ' HA2' ' A' ' 126' ' ' GLY . 28.1 m -123.83 174.54 7.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.174 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' LYS . . . . . 0.445 ' N ' ' HD3' ' A' ' 143' ' ' LYS . 0.5 OUTLIER -134.77 158.43 44.18 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 179.872 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.479 ' CE1' HD12 ' A' ' 98' ' ' LEU . 75.1 m-85 -143.03 160.98 39.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.89 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 75.3 p -95.38 -14.81 23.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.177 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -128.16 123.66 34.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.898 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.405 ' HG3' ' CD1' ' A' ' 96' ' ' TYR . 15.3 tt0 -64.45 -39.23 93.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.911 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 95.3 mt -47.7 -46.96 30.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.941 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 55.8 mm-40 -74.53 -33.46 62.77 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.847 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.72 ' HG2' HD21 ' A' ' 98' ' ' LEU . 33.0 tt0 -46.73 -40.93 14.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.919 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.0 mmtp -81.59 -46.83 13.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 46.0 mtt180 -44.27 -41.36 5.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.85 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.474 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.95 -42.97 80.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.848 HD23 ' HB3' ' A' ' 170' ' ' LEU . 29.9 mt -51.99 -38.14 55.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 14.3 t -92.35 -33.53 14.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.166 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 45.8 mm-40 -83.49 -66.07 0.94 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.898 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.623 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 87.7 m -59.66 -13.26 9.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.93 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' GLN . . . . . 0.476 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.3 tp-100 -39.0 140.33 0.39 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.893 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 50.43 36.42 30.46 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.497 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.7 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -67.55 110.94 3.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.863 0.364 . . . . 0.0 111.073 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.433 ' O ' ' C ' ' A' ' 162' ' ' GLY . 25.2 t -92.68 -35.91 7.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.132 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 162' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -35.12 -35.85 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.482 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.559 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 38.1 tp -86.21 117.45 25.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.843 0.354 . . . . 0.0 110.911 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 66.46 170.46 3.81 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.499 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' SER . . . . . 0.58 ' H ' HG21 ' A' ' 104' ' ' THR . 35.9 m -82.09 40.35 0.62 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.891 0.377 . . . . 0.0 110.873 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 166' ' ' LYS . . . . . 0.493 ' CG ' ' O ' ' A' ' 165' ' ' SER . 36.0 mttt -169.23 157.22 6.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.527 0.679 . . . . 0.0 110.912 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 172.37 12.77 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.677 2.251 . . . . 0.0 112.317 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.7 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 32.2 m -135.69 126.9 44.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.136 179.874 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 44.7 ttt180 -89.95 117.51 28.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.866 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.848 ' HB3' HD23 ' A' ' 154' ' ' LEU . 17.1 mt -93.35 145.19 24.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.97 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 9.9 m -158.16 174.25 15.48 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 39.4 t -98.69 102.08 12.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.082 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -93.17 131.28 38.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.152 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 53.6 mt -69.0 130.25 91.62 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.565 0.698 . . . . 0.0 111.165 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -42.25 3.56 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.648 2.232 . . . . 0.0 112.37 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 49.1 tttt -129.39 110.16 11.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.891 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -133.97 169.16 17.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.074 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 73.6 m 42.58 38.62 1.32 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.888 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 179' ' ' ARG . . . . . 0.547 ' H ' ' NE ' ' A' ' 179' ' ' ARG . 0.0 OUTLIER -77.5 164.11 25.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.885 -179.938 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 91.1 t -115.36 138.68 44.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.162 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -99.82 143.92 27.37 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.567 0.698 . . . . 0.0 110.861 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 105.84 1.57 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.626 2.217 . . . . 0.0 112.357 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 25.8 m -117.4 127.23 74.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.134 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.6 tm-20 -119.41 136.54 54.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.896 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 75.0 p -83.46 110.59 18.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.867 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -71.7 -157.92 3.18 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.468 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 96.61 0.6 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.666 2.244 . . . . 0.0 112.346 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 31.1 t -79.06 149.08 32.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.891 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 58.9 m -80.1 172.14 14.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.836 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.53 -179.968 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.436 -0.266 . . . . 0.0 112.436 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.8 m -51.06 175.97 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.87 0.367 . . . . 0.0 110.888 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 30.1 t -82.61 114.48 21.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.877 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -111.49 79.03 0.25 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.467 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 10.3 t 56.2 42.63 27.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.927 0.394 . . . . 0.0 110.898 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.0 t -57.86 -61.13 2.76 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.845 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.85 83.88 0.31 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.49 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 120.47 7.25 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.713 2.275 . . . . 0.0 112.32 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 2.0 pp20? -117.16 151.8 36.11 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.846 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -134.92 102.95 5.41 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.935 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.9 m -121.15 154.87 35.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.604 HD21 ' HG2' ' A' ' 150' ' ' GLN . 83.2 mt -124.06 145.82 48.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -95.4 124.11 39.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.431 HG22 ' C ' ' A' ' 140' ' ' GLY . 33.0 m -115.25 148.41 18.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.131 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -136.19 -177.86 15.32 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.47 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 49.77 54.09 11.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.873 0.368 . . . . 0.0 110.88 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.421 HD12 ' C ' ' A' ' 139' ' ' TYR . 30.1 mt -100.51 102.56 13.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.936 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.419 HG21 ' HB2' ' A' ' 165' ' ' SER . 2.8 p -47.52 151.26 1.47 Allowed Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.591 0.71 . . . . 0.0 111.136 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.79 -1.38 8.4 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.689 2.259 . . . . 0.0 112.343 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -102.04 25.52 8.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.857 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.47 HG22 ' HE3' ' A' ' 111' ' ' MET . 22.2 t -134.62 138.73 49.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.148 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 45.0 m-20 -123.22 169.35 11.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.875 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.493 ' CG ' HG12 ' A' ' 128' ' ' VAL . 0.5 OUTLIER -46.77 -46.23 20.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 -179.958 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -41.8 -44.47 4.45 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.508 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.47 ' HE3' HG22 ' A' ' 107' ' ' VAL . 32.3 mtm -77.97 -41.37 36.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.785 0.326 . . . . 0.0 110.887 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 16.8 tp -57.05 -25.13 58.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.974 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.49 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 8.5 t80 -84.23 -63.03 1.42 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.905 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.726 ' HA ' HG12 ' A' ' 117' ' ' VAL . 23.9 mt-10 -55.39 -43.24 75.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.579 ' HB2' HD13 ' A' ' 163' ' ' LEU . 85.2 t80 -51.14 -33.02 24.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.845 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.557 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.9 m-85 -95.25 -65.78 0.95 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.726 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -37.16 -28.42 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.106 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.492 ' N ' ' O ' ' A' ' 116' ' ' PHE . 3.1 tptm -65.6 -53.73 37.62 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.937 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.551 HG13 ' CD2' ' A' ' 120' ' ' TYR . 4.1 p -71.16 -38.25 70.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 179.85 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.599 ' CE2' ' HB2' ' A' ' 153' ' ' ALA . 93.1 m-85 -127.17 116.19 21.75 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.629 0.728 . . . . 0.0 110.934 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 2.94 3.06 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.668 2.246 . . . . 0.0 112.365 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' SER . . . . . 0.684 ' O ' HG22 ' A' ' 145' ' ' THR . 18.5 p -89.96 -26.47 20.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.818 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' CYS . . . . . 0.549 ' HA ' ' CD2' ' A' ' 144' ' ' PHE . 9.5 t -45.25 128.39 7.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.936 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -90.08 -34.88 15.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.869 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.49 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 172.14 166.2 30.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.443 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -115.66 144.22 18.36 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.462 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 18.1 tptt -136.01 128.89 31.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.792 0.329 . . . . 0.0 110.916 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.493 HG12 ' CG ' ' A' ' 109' ' ' ASP . 6.5 p -119.02 127.32 75.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.165 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.885 HG22 ' O ' ' A' ' 139' ' ' TYR . 10.3 m -74.58 153.51 6.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.139 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.489 HD23 ' HA ' ' A' ' 136' ' ' SER . 13.4 mt -130.52 176.82 7.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 134' ' ' GLY . 18.3 t70 -108.23 174.41 5.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.875 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -40.98 -45.06 2.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.879 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 20.8 p -71.57 -34.26 69.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.111 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 113.53 20.92 5.98 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.485 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 136' ' ' SER . 27.3 m -100.44 122.85 52.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.855 0.36 . . . . 0.0 111.138 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.489 ' HA ' HD23 ' A' ' 130' ' ' LEU . 7.3 t -34.57 106.83 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.87 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.496 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 26.8 mtmt -50.45 -34.51 25.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.869 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.2 18.64 2.27 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.518 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.885 ' O ' HG22 ' A' ' 129' ' ' VAL . 19.1 p90 -163.08 165.89 24.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.966 0.412 . . . . 0.0 110.883 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.431 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -166.67 -161.35 15.59 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.512 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -154.03 145.51 23.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.915 0.388 . . . . 0.0 110.861 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.557 HG11 ' CD2' ' A' ' 116' ' ' PHE . 24.4 m -117.31 -176.09 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.133 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 20.2 mtmm -143.57 160.76 40.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.864 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.549 ' CD2' ' HA ' ' A' ' 123' ' ' CYS . 65.5 m-85 -149.85 179.32 8.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' THR . . . . . 0.684 HG22 ' O ' ' A' ' 122' ' ' SER . 0.1 OUTLIER -125.08 -16.62 5.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.16 -179.983 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -122.17 97.33 5.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.876 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.6 tt0 -44.83 -48.95 11.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.917 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 63.5 mt -44.85 -33.0 1.77 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.926 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -89.79 -36.69 14.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.834 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.604 ' HG2' HD21 ' A' ' 98' ' ' LEU . 13.6 tt0 -52.4 -47.53 66.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 61.9 mttt -69.99 -41.9 73.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.907 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 69.8 mtt180 -49.7 -34.3 18.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.869 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.599 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -73.3 -45.63 54.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.103 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.708 HD23 ' HB3' ' A' ' 170' ' ' LEU . 26.6 mt -48.4 -36.49 14.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.411 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.4 t -91.35 -40.61 11.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.411 ' N ' HG23 ' A' ' 155' ' ' THR . 56.7 mm-40 -77.56 -66.45 0.83 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.863 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.605 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 63.3 m -60.59 -11.6 7.64 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.855 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 157' ' ' CYS . 2.8 tp-100 -34.99 139.86 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.892 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 43.5 35.8 3.01 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.519 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.792 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -55.71 120.14 6.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.82 0.343 . . . . 0.0 111.146 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.8 t -95.1 -33.26 4.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.101 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -41.47 -36.53 1.54 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.53 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.579 HD13 ' HB2' ' A' ' 115' ' ' PHE . 22.6 tp -89.06 116.48 27.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.895 0.378 . . . . 0.0 110.875 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 68.77 157.89 1.31 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.505 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 165' ' ' SER . . . . . 0.419 ' HB2' HG21 ' A' ' 104' ' ' THR . 49.9 m -62.34 -11.47 15.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.961 0.41 . . . . 0.0 110.839 -179.682 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 51.1 mttt -120.02 156.79 54.19 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.59 0.71 . . . . 0.0 110.895 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 177.36 5.68 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.65 2.233 . . . . 0.0 112.382 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.792 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 15.7 m -131.96 125.13 54.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.144 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 21.4 ttm180 -86.82 102.31 14.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.854 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.708 ' HB3' HD23 ' A' ' 154' ' ' LEU . 12.8 mt -81.55 140.67 34.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 19.9 m -156.46 178.03 10.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.839 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 3.3 t -99.95 99.69 8.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.081 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -71.53 162.04 30.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.144 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 70.9 mt -118.83 125.07 27.94 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.669 0.747 . . . . 0.0 111.105 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -49.45 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.644 2.229 . . . . 0.0 112.357 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.461 ' HD3' ' NE ' ' A' ' 179' ' ' ARG . 3.1 ttmm -141.11 108.33 5.5 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.908 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -61.21 -72.54 0.11 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.074 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 5.7 t -146.09 158.17 43.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.868 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' ARG . . . . . 0.461 ' NE ' ' HD3' ' A' ' 176' ' ' LYS . 24.5 mmt180 -95.31 149.08 21.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.917 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 9.0 p -114.16 138.71 43.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.138 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 11.5 mtpp -151.36 146.58 19.13 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.593 0.711 . . . . 0.0 110.868 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 128.35 15.9 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.66 2.24 . . . . 0.0 112.366 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 82.4 t -91.49 95.78 5.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.137 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -85.92 165.48 16.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.875 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -137.47 124.27 21.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.882 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -139.94 72.89 0.41 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.505 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 112.46 3.09 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.693 2.262 . . . . 0.0 112.339 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 25.9 p -95.99 83.44 3.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.861 -179.849 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 68.7 m 40.79 41.99 1.32 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.895 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.524 -179.949 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 1.9 m -113.44 -44.95 3.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.874 0.368 . . . . 0.0 110.808 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 77.5 p -89.36 134.14 34.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.886 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 150.82 -91.81 0.14 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.454 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 14.0 t -69.02 137.69 53.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 110.808 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 89.2 p -71.35 88.65 0.88 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.823 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -48.24 150.34 3.23 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.472 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.553 ' O ' ' CE1' ' A' ' 96' ' ' TYR . 53.8 Cg_endo -69.75 158.4 57.09 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.675 2.25 . . . . 0.0 112.362 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -50.98 174.94 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.884 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' TYR . . . . . 0.553 ' CE1' ' O ' ' A' ' 94' ' ' PRO . 13.4 m-85 -143.62 119.3 10.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.921 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.1 m -138.91 148.27 43.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.861 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.668 HD12 ' CE2' ' A' ' 144' ' ' PHE . 82.9 mt -117.41 151.63 36.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.915 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.69 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 7.6 t80 -98.31 123.29 42.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.907 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 29.8 m -117.45 144.09 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.125 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.11 178.5 18.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.483 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ASP . . . . . 0.45 ' N ' ' O ' ' A' ' 138' ' ' GLY . 1.2 m-20 57.73 53.88 6.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.82 0.343 . . . . 0.0 110.859 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.417 HD23 ' HA ' ' A' ' 103' ' ' LEU . 23.0 mt -100.8 103.34 14.55 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.896 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.488 HG21 ' HB3' ' A' ' 165' ' ' SER . 39.9 p -48.31 150.1 2.41 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.578 0.704 . . . . 0.0 111.146 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -1.56 8.69 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.678 2.252 . . . . 0.0 112.352 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -99.33 12.08 37.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.858 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.614 HG22 ' HE3' ' A' ' 111' ' ' MET . 62.1 t -123.32 139.92 48.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.096 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -122.08 171.59 8.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.878 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.411 ' HB3' HG12 ' A' ' 128' ' ' VAL . 3.5 p30 -52.63 -43.91 65.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.893 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -43.87 -37.3 4.04 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.507 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.614 ' HE3' HG22 ' A' ' 107' ' ' VAL . 28.2 mtm -81.45 -44.72 17.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.833 0.349 . . . . 0.0 110.889 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.488 HD23 ' N ' ' A' ' 127' ' ' LYS . 22.1 tp -53.92 -28.52 37.37 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.873 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.56 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 13.9 t80 -76.36 -65.36 0.93 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.908 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.776 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.0 mt-10 -55.23 -48.25 74.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.918 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.406 ' CB ' HD13 ' A' ' 163' ' ' LEU . 69.0 t80 -46.31 -33.82 4.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.938 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.492 ' O ' ' N ' ' A' ' 118' ' ' LYS . 6.9 m-85 -95.3 -67.09 0.87 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.847 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.776 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.8 p -36.51 -29.41 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.079 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.492 ' N ' ' O ' ' A' ' 116' ' ' PHE . 18.8 ttpp -67.47 -55.56 13.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.914 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.507 HG13 ' HD2' ' A' ' 120' ' ' TYR . 2.3 p -70.98 -30.72 42.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.123 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.582 ' CE1' ' HB3' ' A' ' 152' ' ' ARG . 97.6 m-85 -132.26 112.36 14.32 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.602 0.715 . . . . 0.0 110.955 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.3 Cg_endo -69.75 2.39 3.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.671 2.247 . . . . 0.0 112.338 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 6.3 p -92.87 -20.27 20.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.862 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.0 t -50.05 134.28 22.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.883 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -94.85 -35.7 11.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.56 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 167.1 143.91 3.93 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.492 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.54 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -97.34 136.58 12.83 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.473 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.488 ' N ' HD23 ' A' ' 112' ' ' LEU . 19.3 tttp -124.83 139.2 54.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.77 0.319 . . . . 0.0 110.925 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.411 HG12 ' HB3' ' A' ' 109' ' ' ASP . 6.3 p -123.17 139.62 49.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.149 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.812 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 6.3 m -89.91 152.71 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 7.9 mt -128.68 160.92 30.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -87.59 172.72 9.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.848 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.56 -19.99 0.39 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 58.1 p -89.45 -29.76 18.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.131 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 111.8 10.77 18.19 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.489 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 33.8 m -98.92 136.49 29.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.79 0.329 . . . . 0.0 111.159 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.6 t -43.23 105.78 0.06 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.88 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.512 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 26.0 mtmt -50.58 -32.98 20.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.918 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 123.58 19.9 2.72 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.548 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.812 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 13.9 p90 -163.83 168.77 19.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.952 0.406 . . . . 0.0 110.914 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.53 -160.88 18.8 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.522 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.4 m-85 -153.97 144.16 22.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.848 0.356 . . . . 0.0 110.918 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.54 HG12 ' HA2' ' A' ' 126' ' ' GLY . 20.6 m -120.97 174.02 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.144 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -132.93 163.75 28.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.869 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.668 ' CE2' HD12 ' A' ' 98' ' ' LEU . 75.3 m-85 -149.79 159.78 44.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.923 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 14.0 p -90.34 -39.37 12.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -109.23 132.04 54.49 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.87 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -72.27 -38.3 68.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.923 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 30.2 mt -48.78 -34.06 11.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.923 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -87.83 -37.27 16.69 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.905 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.473 ' O ' HD11 ' A' ' 98' ' ' LEU . 22.4 tt0 -41.61 -48.39 4.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.947 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 47.2 mttt -71.7 -32.22 67.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.864 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.582 ' HB3' ' CE1' ' A' ' 120' ' ' TYR . 0.6 OUTLIER -52.67 -39.45 61.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.841 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.499 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.86 -46.57 71.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.129 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.601 HD23 ' HB3' ' A' ' 170' ' ' LEU . 17.0 mt -40.36 -43.68 1.81 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.614 HG23 ' N ' ' A' ' 156' ' ' GLU . 14.6 t -92.7 -50.63 5.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.124 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.614 ' N ' HG23 ' A' ' 155' ' ' THR . 76.9 mm-40 -62.51 -57.63 10.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.914 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.683 ' O ' HD11 ' A' ' 170' ' ' LEU . 24.7 m -83.2 20.53 1.25 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.824 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 158' ' ' GLN . . . . . 0.419 ' OE1' ' N ' ' A' ' 159' ' ' GLY . 2.0 tp-100 -64.71 131.89 48.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.9 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.419 ' N ' ' OE1' ' A' ' 158' ' ' GLN . . . 47.09 29.69 4.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.479 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.438 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -50.12 119.23 3.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.827 0.346 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.427 ' O ' ' C ' ' A' ' 162' ' ' GLY . 37.5 t -88.12 -36.75 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.134 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 162' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -35.97 -38.59 0.23 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.492 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.406 HD13 ' CB ' ' A' ' 115' ' ' PHE . 20.0 tp -89.08 118.84 29.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.866 0.365 . . . . 0.0 110.918 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.454 ' CA ' HG21 ' A' ' 107' ' ' VAL . . . 64.91 153.49 0.11 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.487 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 165' ' ' SER . . . . . 0.488 ' HB3' HG21 ' A' ' 104' ' ' THR . 16.7 t -55.66 -23.8 30.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.962 0.41 . . . . 0.0 110.839 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 58.8 mttt -109.24 154.95 41.84 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.572 0.701 . . . . 0.0 110.908 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 171.23 14.89 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.7 2.267 . . . . 0.0 112.34 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.438 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 16.4 m -121.18 125.84 74.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.085 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 35.1 ttt-85 -88.71 103.27 15.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.683 HD11 ' O ' ' A' ' 157' ' ' CYS . 11.7 mt -80.64 148.61 30.17 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.857 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 3.2 m -160.75 177.61 10.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.917 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.49 HG22 HD11 ' A' ' 154' ' ' LEU . 21.2 t -99.36 96.83 5.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.116 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.69 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -93.09 172.47 8.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.082 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 174' ' ' ILE . . . . . 0.645 HG23 ' HD2' ' A' ' 175' ' ' PRO . 83.4 mt -125.68 137.71 30.51 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.604 0.716 . . . . 0.0 111.135 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.645 ' HD2' HG23 ' A' ' 174' ' ' ILE . 54.0 Cg_endo -69.7 174.86 8.83 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.665 2.243 . . . . 0.0 112.377 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 38.9 tptt -45.82 118.54 1.87 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.868 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -68.56 145.98 53.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.077 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 50.6 m -105.68 -50.32 3.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.864 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 6.6 tpm_? 40.78 50.26 2.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.884 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 180' ' ' VAL . . . . . 0.461 HG22 ' N ' ' A' ' 181' ' ' LYS . 7.2 p -117.22 155.19 18.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.122 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.461 ' N ' HG22 ' A' ' 180' ' ' VAL . 9.1 tppt? -143.08 134.65 12.88 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.623 0.725 . . . . 0.0 110.843 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 85.56 0.61 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.684 2.256 . . . . 0.0 112.325 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 67.1 t -134.14 107.89 10.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.094 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 6.6 tp10 -130.68 133.9 46.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.927 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.6 m -115.74 157.84 23.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.84 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 120.96 86.64 0.91 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.503 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 138.29 37.5 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.643 2.229 . . . . 0.0 112.363 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 31.1 t -95.64 -49.4 5.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.864 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 44.7 t -98.54 150.68 21.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.88 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.527 -179.96 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 47.9 t -123.54 103.07 8.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.93 0.395 . . . . 0.0 110.884 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.4 t -166.43 146.01 5.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.889 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -90.06 113.33 4.19 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.512 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 47.4 p -170.37 141.34 1.98 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.886 0.374 . . . . 0.0 110.88 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 70.1 p -135.59 118.47 16.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.84 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -118.57 -161.31 11.77 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.517 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 125.21 11.89 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.722 2.282 . . . . 0.0 112.36 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 25.0 pm0 -65.28 154.28 38.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.853 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' TYR . . . . . 0.528 ' CD1' ' HG3' ' A' ' 147' ' ' GLU . 63.5 m-85 -127.76 104.04 7.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.924 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 66.3 p -112.81 154.58 26.04 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.855 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 33.5 mt -124.79 142.4 51.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.907 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -91.25 132.88 35.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.899 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 18.9 m -126.02 151.82 32.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.128 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -141.72 -179.62 18.97 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.5 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 57.76 38.84 27.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.841 0.353 . . . . 0.0 110.905 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.484 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.2 mt -86.51 108.83 18.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.672 ' OG1' HG23 ' A' ' 107' ' ' VAL . 81.9 p -53.82 150.25 14.62 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.612 0.72 . . . . 0.0 111.144 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 2.21 3.74 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.706 2.271 . . . . 0.0 112.337 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 19.0 t0 -102.02 -3.17 28.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.672 HG23 ' OG1' ' A' ' 104' ' ' THR . 41.3 t -103.68 145.08 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.141 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -129.18 179.68 5.63 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -60.34 -37.86 81.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.881 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.43 -33.23 39.51 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.47 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.528 ' HE3' HG22 ' A' ' 107' ' ' VAL . 27.3 mtm -86.85 -46.91 9.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.842 0.353 . . . . 0.0 110.886 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.463 HD23 ' N ' ' A' ' 127' ' ' LYS . 18.1 tp -53.34 -23.03 8.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.929 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.496 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 13.0 t80 -82.63 -61.75 1.8 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.926 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.758 ' HA ' HG12 ' A' ' 117' ' ' VAL . 22.4 mt-10 -57.23 -46.58 82.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.867 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.683 ' HZ ' ' HB1' ' A' ' 160' ' ' ALA . 75.6 t80 -47.68 -33.23 6.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.499 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.6 m-85 -95.28 -66.98 0.88 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.861 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.758 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.73 -30.97 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.132 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.463 ' N ' ' O ' ' A' ' 116' ' ' PHE . 59.2 tttt -67.31 -60.61 2.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.903 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.603 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.7 p -64.65 -27.15 41.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.114 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.603 ' CD2' HG13 ' A' ' 119' ' ' VAL . 92.6 m-85 -137.94 115.89 9.57 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.7 0.762 . . . . 0.0 110.906 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -2.77 10.7 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.751 2.301 . . . . 0.0 112.336 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 73.2 m -99.25 32.28 2.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.854 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' CYS . . . . . 0.461 ' HB3' HG23 ' A' ' 117' ' ' VAL . 19.6 t -94.51 135.2 36.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.881 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 16.8 mtp180 -93.17 -39.0 11.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.867 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.496 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 163.56 149.43 5.73 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.582 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -102.9 134.27 11.75 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.518 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.463 ' N ' HD23 ' A' ' 112' ' ' LEU . 4.3 tppp? -123.21 137.56 54.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.806 0.336 . . . . 0.0 110.925 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.4 p -124.69 129.4 73.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.126 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.97 HG22 ' O ' ' A' ' 139' ' ' TYR . 22.5 m -75.18 150.49 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.085 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.429 HD23 ' HA ' ' A' ' 136' ' ' SER . 14.9 mt -127.03 174.91 8.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.925 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -103.18 178.27 4.6 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.846 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 25.3 tt0 -45.28 -43.08 10.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.905 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 27.8 p -74.68 -25.04 58.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.167 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 107.88 17.67 10.8 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.475 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 28.8 m -95.9 134.31 33.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.872 0.368 . . . . 0.0 111.126 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.429 ' HA ' HD23 ' A' ' 130' ' ' LEU . 4.8 t -44.18 107.2 0.08 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.863 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.5 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.7 mtmt -52.75 -32.36 42.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.902 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.7 18.74 2.63 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.482 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.97 ' O ' HG22 ' A' ' 129' ' ' VAL . 23.4 p90 -163.14 168.25 21.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.981 0.42 . . . . 0.0 110.9 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -170.74 -165.18 27.68 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.478 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -150.88 146.99 26.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.869 0.366 . . . . 0.0 110.893 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.582 HG12 ' HA2' ' A' ' 126' ' ' GLY . 17.8 m -119.2 179.32 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.113 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 31.3 mttt -138.53 160.35 39.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.899 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -148.34 161.99 40.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.855 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 44.0 p -101.88 -12.34 18.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.099 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.443 ' CG ' ' OE1' ' A' ' 149' ' ' GLU . 14.3 t0 -129.61 130.04 45.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.857 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.528 ' HG3' ' CD1' ' A' ' 96' ' ' TYR . 20.0 tt0 -71.83 -43.23 65.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 37.2 mt -45.23 -49.21 12.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.954 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.443 ' OE1' ' CG ' ' A' ' 146' ' ' ASP . 3.6 mp0 -72.8 -44.05 61.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.855 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 149' ' ' GLU . 17.4 tt0 -36.97 -55.28 0.93 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.932 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 13.7 mttm -64.48 -52.59 57.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 28.4 mtt180 -39.41 -33.29 0.15 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.853 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.448 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -73.98 -49.93 22.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.133 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.756 HD23 ' HB3' ' A' ' 170' ' ' LEU . 33.9 mt -43.34 -38.36 2.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.912 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.539 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.8 t -91.03 -48.3 7.06 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.167 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.539 ' N ' HG23 ' A' ' 155' ' ' THR . 53.1 mt-10 -69.56 -64.58 0.85 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.9 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.546 ' CB ' HD11 ' A' ' 170' ' ' LEU . 54.1 m -62.82 -8.3 6.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.905 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -40.5 140.95 0.59 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 37.66 45.6 1.48 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.465 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.683 ' HB1' ' HZ ' ' A' ' 115' ' ' PHE . . . -64.18 115.09 4.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.802 0.334 . . . . 0.0 111.129 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.0 t -84.88 -35.57 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.143 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -43.06 -34.44 2.06 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.453 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.618 HD13 ' CB ' ' A' ' 115' ' ' PHE . 19.2 tp -91.81 115.82 28.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.866 0.365 . . . . 0.0 110.922 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 166' ' ' LYS . . . 64.55 138.48 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.497 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 t -41.05 -27.92 0.07 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.944 0.402 . . . . 0.0 110.838 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 166' ' ' LYS . . . . . 0.401 ' N ' ' O ' ' A' ' 164' ' ' GLY . 57.5 mttt -103.78 154.67 37.83 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.526 0.679 . . . . 0.0 110.924 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.69 173.15 11.33 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.7 2.266 . . . . 0.0 112.413 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.672 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 21.1 m -124.45 131.27 73.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.127 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 43.4 ttt180 -94.84 105.01 16.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.92 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.756 ' HB3' HD23 ' A' ' 154' ' ' LEU . 13.3 mt -82.66 148.87 27.69 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.933 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.535 ' O ' HD21 ' A' ' 154' ' ' LEU . 2.0 m -158.72 -177.87 6.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.9 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 4.4 t -108.83 102.15 13.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.145 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -86.55 138.34 31.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.07 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 74.6 mt -88.11 122.96 69.58 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.597 0.713 . . . . 0.0 111.131 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -34.67 14.06 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.648 2.232 . . . . 0.0 112.341 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 10.6 tmtt? -123.68 109.55 13.85 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.894 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -124.94 127.08 46.49 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.105 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 4.2 t -78.96 83.57 5.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.84 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 179' ' ' ARG . . . . . 0.495 ' CD ' ' O ' ' A' ' 179' ' ' ARG . 0.0 OUTLIER -66.66 114.64 5.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.882 -179.965 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 81.3 t -132.07 135.27 58.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.132 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.403 ' C ' ' HD3' ' A' ' 181' ' ' LYS . 0.0 OUTLIER -116.83 142.86 30.42 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.542 0.687 . . . . 0.0 110.904 179.916 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 144.48 54.17 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.662 2.241 . . . . 0.0 112.369 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 97.0 t -117.63 135.92 56.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.116 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -150.25 121.98 8.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.882 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 2.8 m -149.19 161.92 41.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -176.61 69.27 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.47 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -24.25 29.75 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.641 2.227 . . . . 0.0 112.307 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 89.2 p -53.12 146.54 11.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.797 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.9 m -165.03 152.85 11.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.842 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.49 -179.956 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.515 -0.234 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 4.8 t 67.76 42.05 2.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.868 0.366 . . . . 0.0 110.87 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 57.1 m -81.55 -60.63 2.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.837 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 95.11 54.55 1.47 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.488 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 91.1 p -38.76 129.23 1.52 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.937 0.399 . . . . 0.0 110.814 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 36.4 p -123.38 163.2 21.26 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.867 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -132.0 -77.98 0.15 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.471 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 157.88 58.86 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.685 2.257 . . . . 0.0 112.363 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -84.57 161.99 19.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.884 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -127.93 99.73 5.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.934 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.0 p -117.13 146.26 43.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.859 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.88 HD21 ' HG2' ' A' ' 150' ' ' GLN . 46.3 mt -110.43 150.4 28.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.906 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.661 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 4.9 t80 -96.34 127.23 42.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.852 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.8 m -119.42 146.05 24.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.15 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.84 -177.99 15.9 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.463 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 52.85 51.57 15.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.88 0.371 . . . . 0.0 110.877 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 30.1 mt -98.04 118.52 34.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.936 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p -61.97 151.54 79.9 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.587 0.708 . . . . 0.0 111.094 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -0.02 6.29 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.718 2.278 . . . . 0.0 112.333 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -99.46 -0.24 41.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.484 HG22 ' HE3' ' A' ' 111' ' ' MET . 26.5 t -111.09 147.68 14.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.096 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -131.83 -178.81 5.05 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.885 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.64 -37.78 85.28 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.78 -26.93 26.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.52 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.484 ' HE3' HG22 ' A' ' 107' ' ' VAL . 34.3 mtm -93.8 -39.29 10.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 0.0 110.919 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.403 HD23 ' N ' ' A' ' 127' ' ' LYS . 49.3 tp -55.86 -30.41 61.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.938 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.501 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 22.5 t80 -78.8 -63.86 1.31 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.947 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.704 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.0 mt-10 -53.54 -36.31 61.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.886 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.488 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 67.6 t80 -58.09 -34.2 69.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.88 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.501 ' O ' ' N ' ' A' ' 118' ' ' LYS . 10.2 m-85 -95.25 -62.74 1.25 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.875 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.704 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -38.44 -26.39 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.115 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.501 ' N ' ' O ' ' A' ' 116' ' ' PHE . 18.2 tttm -71.05 -60.73 2.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.911 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.659 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.7 p -67.62 -25.79 33.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.165 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.659 ' CD2' HG13 ' A' ' 119' ' ' VAL . 92.2 m-85 -136.09 112.26 10.31 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.633 0.73 . . . . 0.0 110.95 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 54.0 Cg_endo -69.73 2.81 3.18 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.672 2.248 . . . . 0.0 112.343 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 32.0 m -105.44 27.9 7.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.853 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 36.8 t -89.0 124.73 34.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.857 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.488 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 14.0 mtp180 -79.21 -42.8 25.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.862 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.501 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 168.52 159.56 14.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.507 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -114.7 134.87 11.95 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.497 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.403 ' N ' HD23 ' A' ' 112' ' ' LEU . 3.5 tppp? -130.13 132.69 46.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.838 0.352 . . . . 0.0 110.878 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.2 p -118.1 129.7 74.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.911 HG22 ' O ' ' A' ' 139' ' ' TYR . 23.8 m -73.76 144.98 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.083 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.616 HD22 ' O ' ' A' ' 134' ' ' GLY . 46.4 mt -123.9 162.3 23.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.903 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.42 ' CG ' ' HG2' ' A' ' 137' ' ' LYS . 3.0 m-20 -93.33 -178.25 4.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -40.75 -59.05 1.49 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.955 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.411 ' H ' HG22 ' A' ' 133' ' ' THR . 0.0 OUTLIER -62.36 -30.83 71.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.616 ' O ' HD22 ' A' ' 130' ' ' LEU . . . 116.65 0.54 20.01 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.498 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.406 HG13 HG23 ' A' ' 133' ' ' THR . 3.5 m -73.43 141.12 16.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.787 0.327 . . . . 0.0 111.126 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.435 ' HA ' HD23 ' A' ' 130' ' ' LEU . 8.2 t -50.27 113.83 0.97 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.487 ' HB2' HG23 ' A' ' 129' ' ' VAL . 22.1 mtmt -58.76 -30.72 67.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.916 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 120.13 17.26 4.56 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.512 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.911 ' O ' HG22 ' A' ' 129' ' ' VAL . 19.0 p90 -163.29 167.96 21.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.985 0.422 . . . . 0.0 110.864 -179.797 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -171.56 -162.48 23.91 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.51 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -153.3 139.9 18.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.893 0.378 . . . . 0.0 110.88 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.4 m -110.75 176.85 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' LYS . . . . . 0.488 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 47.8 mttt -133.35 156.72 47.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.878 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -148.57 152.57 37.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' THR . . . . . 0.428 HG23 ' CG ' ' A' ' 124' ' ' ARG . 25.3 p -96.0 -24.96 16.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.147 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -115.06 103.55 11.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.837 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 15.2 tm-20 -48.51 -47.23 39.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.914 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 65.6 mt -39.68 -44.35 1.51 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.935 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -72.48 -40.65 66.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.918 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.88 ' HG2' HD21 ' A' ' 98' ' ' LEU . 24.9 tt0 -40.36 -60.6 1.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.897 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 14.4 mttm -62.51 -44.78 95.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 57.6 mtt180 -48.0 -42.64 28.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.904 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.459 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -69.15 -45.19 70.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.814 HD21 HD22 ' A' ' 98' ' ' LEU . 13.8 mt -43.52 -41.38 4.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.952 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.431 HG23 ' N ' ' A' ' 156' ' ' GLU . 6.0 t -92.46 -41.64 10.18 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.431 ' N ' HG23 ' A' ' 155' ' ' THR . 21.6 mm-40 -70.04 -63.59 1.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.868 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.484 ' CB ' HD11 ' A' ' 170' ' ' LEU . 20.9 m -70.82 -0.32 8.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -43.69 129.79 5.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 55.45 33.78 59.1 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.495 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.887 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -48.64 116.58 1.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.799 0.333 . . . . 0.0 111.062 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.7 t -93.85 -31.39 4.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.138 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -46.29 -31.64 4.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.517 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.407 HD13 ' HB2' ' A' ' 115' ' ' PHE . 20.4 tp -91.37 115.7 28.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.851 0.358 . . . . 0.0 110.923 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.0 159.92 0.97 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.493 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 m -61.95 -19.68 63.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.959 0.409 . . . . 0.0 110.883 -179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 35.0 mttm -111.13 153.53 43.9 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.559 0.695 . . . . 0.0 110.89 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 171.79 13.85 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.659 2.239 . . . . 0.0 112.371 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.887 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 22.2 m -127.22 125.06 65.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.119 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.5 ttt180 -86.42 111.68 20.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.851 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.566 ' HB3' HD23 ' A' ' 154' ' ' LEU . 14.7 mt -87.16 139.95 30.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.2 m -152.74 178.17 9.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.823 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.431 HG22 HD11 ' A' ' 154' ' ' LEU . 2.8 t -100.73 96.15 4.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.661 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -80.66 168.98 18.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.128 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 58.0 mt -143.14 120.86 7.0 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.582 0.706 . . . . 0.0 111.106 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -41.02 4.63 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.687 2.258 . . . . 0.0 112.348 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 26.7 mmtm -109.36 71.29 0.76 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -76.47 -33.98 58.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.092 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 83.1 p -98.4 56.64 1.16 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.853 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 8.2 ttp85 -95.96 75.17 3.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.893 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 86.8 t -115.94 108.18 24.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.088 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 4.2 mmpt? -134.46 153.02 78.95 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.605 0.717 . . . . 0.0 110.905 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 134.99 29.28 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.697 2.265 . . . . 0.0 112.358 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 98.5 t -69.38 87.68 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.125 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 184' ' ' GLU . . . . . 0.461 ' C ' ' CD ' ' A' ' 184' ' ' GLU . 0.6 OUTLIER -85.36 153.73 22.35 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.924 -179.993 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 76.3 p -147.31 164.46 33.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.85 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -97.75 146.05 18.07 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.525 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 139.68 40.55 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.714 2.276 . . . . 0.0 112.316 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 1.4 t -140.6 154.52 46.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.849 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.0 m -81.07 144.46 31.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.828 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.529 179.953 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.4 t -66.83 128.39 36.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.877 0.37 . . . . 0.0 110.864 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 72.9 m -131.59 133.89 45.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.874 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -171.04 81.37 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.497 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 83.7 p -97.55 91.86 5.64 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.857 0.36 . . . . 0.0 110.853 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.8 m -158.74 142.54 15.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.886 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -117.82 72.67 0.29 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.485 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 150.87 68.73 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.654 2.236 . . . . 0.0 112.319 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -72.16 154.24 41.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.876 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' TYR . . . . . 0.437 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 32.4 m-85 -130.29 124.06 31.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.932 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 52.6 p -138.52 159.66 41.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.9 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.58 HD21 ' CD ' ' A' ' 150' ' ' GLN . 79.5 mt -124.84 147.73 48.61 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -94.03 120.6 34.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.902 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.42 HG22 ' C ' ' A' ' 140' ' ' GLY . 31.2 m -114.04 145.41 19.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -133.67 -174.02 13.41 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.494 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 46.91 50.88 13.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.841 0.353 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 103' ' ' LEU . 20.4 mt -96.05 99.07 10.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.954 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.466 HG23 ' HB2' ' A' ' 166' ' ' LYS . 23.9 p -48.79 151.57 2.08 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.597 0.713 . . . . 0.0 111.122 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 1.56 4.32 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.694 2.262 . . . . 0.0 112.326 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -100.99 10.38 41.17 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.851 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.521 HG13 ' CE ' ' A' ' 111' ' ' MET . 3.9 t -121.57 147.03 25.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.1 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -132.77 178.52 6.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.873 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -56.18 -40.07 73.39 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -49.28 -40.18 29.41 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.521 ' CE ' HG13 ' A' ' 107' ' ' VAL . 36.1 mtm -82.57 -39.73 21.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.835 0.35 . . . . 0.0 110.876 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.635 HD23 ' N ' ' A' ' 127' ' ' LYS . 28.3 tp -57.71 -28.11 63.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.417 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.2 t80 -81.77 -60.02 2.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.92 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.727 ' HA ' HG12 ' A' ' 117' ' ' VAL . 20.7 mt-10 -56.13 -47.43 78.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.445 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 62.8 t80 -48.79 -33.64 10.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.917 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.561 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.5 m-85 -94.41 -66.12 0.94 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.873 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.727 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.71 -30.43 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.15 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.472 ' N ' ' O ' ' A' ' 116' ' ' PHE . 20.2 ttpp -65.84 -59.37 3.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.941 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.604 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.6 p -67.13 -34.21 68.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.172 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.604 ' CD2' HG13 ' A' ' 119' ' ' VAL . 92.8 m-85 -130.06 112.01 17.1 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.662 0.744 . . . . 0.0 110.96 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 1.39 4.46 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.679 2.252 . . . . 0.0 112.352 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -99.05 19.9 14.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.828 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 38.8 t -82.01 132.8 35.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.875 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.693 ' HG3' HG23 ' A' ' 145' ' ' THR . 46.1 mtt-85 -89.52 -41.92 11.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.868 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.417 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 168.94 150.35 6.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.468 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -103.18 142.34 15.48 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.517 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.635 ' N ' HD23 ' A' ' 112' ' ' LEU . 12.1 tptm -136.95 132.71 34.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.869 0.366 . . . . 0.0 110.868 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 3.0 p -120.72 129.26 75.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.849 HG22 ' O ' ' A' ' 139' ' ' TYR . 23.5 m -72.41 142.88 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.107 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.49 HD23 ' HA ' ' A' ' 136' ' ' SER . 11.5 mt -127.7 163.97 23.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.936 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.444 ' OD1' ' C ' ' A' ' 131' ' ' ASP . 0.6 OUTLIER -97.89 -175.08 3.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.839 179.865 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 44.5 tt0 -49.09 -48.67 44.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 21.5 p -65.91 -23.2 66.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.147 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.46 22.57 18.72 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 30.1 m -102.93 131.27 51.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.8 0.334 . . . . 0.0 111.138 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.49 ' HA ' HD23 ' A' ' 130' ' ' LEU . 5.4 t -39.45 116.83 0.65 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.864 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.1 mtmt -63.17 -28.17 69.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.914 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 123.98 14.34 3.8 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.506 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.849 ' O ' HG22 ' A' ' 129' ' ' VAL . 17.9 p90 -162.2 170.82 18.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.939 0.399 . . . . 0.0 110.921 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.42 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -172.71 -160.79 21.98 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.507 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -153.85 143.72 21.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.867 0.365 . . . . 0.0 110.861 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.561 HG11 ' CD2' ' A' ' 116' ' ' PHE . 14.7 m -115.39 -176.68 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.123 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 13.8 mttp -141.55 153.02 44.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.418 ' CE2' HD12 ' A' ' 98' ' ' LEU . 88.7 m-85 -146.48 128.82 15.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.88 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' THR . . . . . 0.693 HG23 ' HG3' ' A' ' 124' ' ' ARG . 36.7 p -66.5 -12.7 58.8 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.162 -179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -126.54 135.21 51.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.868 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.437 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 29.7 tt0 -79.08 -34.17 43.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.887 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 38.9 mt -53.98 -60.2 3.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.911 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -65.09 -38.45 90.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.58 ' CD ' HD21 ' A' ' 98' ' ' LEU . 1.4 tm0? -48.06 -42.55 28.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.888 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.573 ' HA ' HD12 ' A' ' 154' ' ' LEU . 34.7 mmtm -77.85 -26.94 49.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 27.1 mtt180 -65.09 -37.48 87.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.855 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.454 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -66.12 -36.04 82.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.104 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.573 HD12 ' HA ' ' A' ' 151' ' ' LYS . 28.1 mt -52.49 -41.49 63.43 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.934 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 8.8 t -91.86 -36.42 13.51 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.176 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 16.0 mm-40 -76.24 -62.54 1.58 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.877 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.574 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 10.5 m -71.79 0.54 8.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' GLN . . . . . 0.466 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.0 tp-100 -43.17 136.14 3.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.9 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 45.93 30.16 3.59 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.475 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.574 ' HB2' ' O ' ' A' ' 157' ' ' CYS . . . -49.79 112.31 0.64 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.828 0.347 . . . . 0.0 111.115 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 18.8 t -87.18 -33.84 7.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.84 -31.13 1.09 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.463 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.445 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 28.4 tp -90.17 109.43 20.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.882 0.372 . . . . 0.0 110.919 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 71.53 168.05 9.02 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.471 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' SER . . . . . 0.44 ' HB2' HG21 ' A' ' 104' ' ' THR . 39.5 m -66.24 -23.1 66.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.918 0.39 . . . . 0.0 110.863 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 166' ' ' LYS . . . . . 0.466 ' HB2' HG23 ' A' ' 104' ' ' THR . 58.9 mttm -110.29 155.81 41.29 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.632 0.73 . . . . 0.0 110.873 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.85 -176.85 1.65 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.676 2.25 . . . . 0.0 112.325 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.543 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 28.6 m -135.04 128.28 49.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.131 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 12.5 ttp180 -91.99 94.16 9.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.835 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.541 ' HB3' HD23 ' A' ' 154' ' ' LEU . 10.6 mt -72.14 152.64 42.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.484 ' O ' HD21 ' A' ' 154' ' ' LEU . 0.9 OUTLIER -167.01 178.32 5.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.891 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 45.5 t -103.79 99.45 8.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -78.74 137.92 37.99 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.086 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 72.4 mt -142.93 124.98 8.68 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.611 0.72 . . . . 0.0 111.12 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 -166.56 0.19 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.667 2.245 . . . . 0.0 112.37 179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.439 ' CD ' ' O ' ' A' ' 176' ' ' LYS . 0.4 OUTLIER -53.15 120.77 6.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.909 179.893 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -103.47 -45.71 4.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.124 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 87.9 p -154.8 166.19 34.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.864 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 17.8 mmm180 45.53 39.4 4.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.894 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 180' ' ' VAL . . . . . 0.476 HG13 ' HG3' ' A' ' 181' ' ' LYS . 12.7 p -49.89 -22.72 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.101 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.476 ' HG3' HG13 ' A' ' 180' ' ' VAL . 0.7 OUTLIER -173.13 143.87 1.12 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.566 0.698 . . . . 0.0 110.89 179.953 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 140.54 42.69 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.659 2.24 . . . . 0.0 112.341 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.557 HG13 ' O ' ' A' ' 183' ' ' VAL . 7.5 p -148.16 109.28 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.138 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -134.82 122.05 21.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.895 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 67.1 m -133.64 132.35 40.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.889 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 118.81 151.55 9.03 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.527 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 139.88 41.59 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.672 2.248 . . . . 0.0 112.373 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 188' ' ' SER . . . . . 0.434 ' O ' ' C ' ' A' ' 189' ' ' SER . 6.9 t -75.11 -47.49 28.39 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.842 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 189' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 188' ' ' SER . 17.4 p 35.41 44.82 0.19 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.841 -179.877 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.286 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.513 -179.96 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.456 -0.257 . . . . 0.0 112.456 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 72.8 p -114.01 41.52 2.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.85 0.357 . . . . 0.0 110.844 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 77.7 p 40.21 41.61 1.02 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.846 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -84.28 -51.45 3.93 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.494 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 4.4 m -101.32 102.79 13.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.905 0.383 . . . . 0.0 110.821 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 22.7 t -49.87 162.23 0.2 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.83 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -123.18 -156.62 9.62 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.522 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 157.86 58.87 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.638 2.225 . . . . 0.0 112.366 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -65.61 166.32 10.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.93 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 19.5 m-85 -124.72 100.37 6.59 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.928 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 45.9 m -118.69 146.55 44.62 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.86 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.717 HD22 HD21 ' A' ' 154' ' ' LEU . 68.3 mt -113.53 153.36 28.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.921 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -100.77 123.05 44.41 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.848 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 23.1 m -114.38 145.8 19.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.114 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.11 -176.75 14.51 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.513 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 48.78 52.06 14.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.827 0.346 . . . . 0.0 110.879 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.424 HD12 ' C ' ' A' ' 139' ' ' TYR . 28.7 mt -98.24 105.89 18.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.879 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.459 HG23 ' HB2' ' A' ' 166' ' ' LYS . 25.1 p -50.6 150.63 4.73 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.582 0.705 . . . . 0.0 111.158 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 3.16 2.95 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.665 2.243 . . . . 0.0 112.316 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -98.38 -13.33 20.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.881 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.471 HG13 ' HE2' ' A' ' 111' ' ' MET . 41.4 t -98.21 134.46 36.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.151 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.25 175.88 5.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.828 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -53.37 -44.79 68.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.858 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.96 -29.07 7.98 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.499 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.471 ' HE2' HG13 ' A' ' 107' ' ' VAL . 22.3 mtp -86.88 -59.47 2.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.788 0.328 . . . . 0.0 110.873 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 15.8 tp -40.18 -41.06 1.22 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.898 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.423 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 12.9 t80 -62.65 -67.17 0.44 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.966 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.77 ' HA ' HG12 ' A' ' 117' ' ' VAL . 30.3 mt-10 -52.52 -55.52 21.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.927 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 57.2 t80 -41.49 -32.28 0.33 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.896 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.498 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.0 m-85 -95.14 -67.53 0.85 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.883 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.77 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -37.65 -27.58 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.103 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.498 ' N ' ' O ' ' A' ' 116' ' ' PHE . 20.1 tptt -67.57 -57.87 5.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.885 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.655 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.3 p -71.56 -32.73 46.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.175 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.655 ' CD2' HG13 ' A' ' 119' ' ' VAL . 97.0 m-85 -126.3 108.04 24.09 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.622 0.725 . . . . 0.0 110.954 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.8 Cg_endo -69.76 2.44 3.53 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.667 2.245 . . . . 0.0 112.339 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 47.6 p -95.0 -10.33 31.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 10.0 t -57.09 142.65 41.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.887 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 61.7 mtp180 -104.46 -34.1 8.36 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.88 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.423 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 166.72 145.99 4.68 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.453 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.43 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -96.35 139.25 14.39 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.477 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 46.6 tptt -125.28 127.73 47.15 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.87 0.366 . . . . 0.0 110.866 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.1 p -117.72 141.28 37.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.958 HG22 ' O ' ' A' ' 139' ' ' TYR . 33.2 m -92.73 145.33 7.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.096 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.582 HD23 ' HA ' ' A' ' 136' ' ' SER . 23.4 mt -123.8 179.09 4.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.888 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 11.1 t0 -108.96 -178.96 3.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.875 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -53.57 -18.9 3.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.917 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 43.6 p -93.61 -27.27 16.69 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.163 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 107.52 17.29 11.47 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.476 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 19.1 m -100.05 139.27 21.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 0.0 111.112 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.582 ' HA ' HD23 ' A' ' 130' ' ' LEU . 7.5 t -49.76 100.34 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.507 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.4 mtmt -42.97 -36.09 1.44 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.877 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 128.35 16.97 2.03 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.548 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.958 ' O ' HG22 ' A' ' 129' ' ' VAL . 28.1 p90 -161.07 172.07 17.47 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.901 0.381 . . . . 0.0 110.96 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -174.94 -163.23 27.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.475 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -153.76 145.58 23.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.861 0.363 . . . . 0.0 110.863 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.487 HG11 ' CD2' ' A' ' 116' ' ' PHE . 29.3 m -119.6 -177.74 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.087 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 32.8 mttm -142.16 156.73 45.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -145.87 163.43 35.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 29.2 p -101.1 -19.88 15.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.129 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -117.02 120.47 38.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.825 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -65.45 -33.55 76.21 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.948 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 44.6 mt -57.71 -40.57 79.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.931 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.464 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 38.6 mt-10 -76.28 -38.53 56.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.829 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.684 ' HG2' HD21 ' A' ' 98' ' ' LEU . 22.0 tt0 -44.95 -48.43 11.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.869 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 5.1 mmmm -73.57 -37.37 65.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.407 ' O ' ' CG ' ' A' ' 156' ' ' GLU . 9.1 mtt-85 -56.25 -34.23 66.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.892 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.439 ' O ' HD12 ' A' ' 170' ' ' LEU . . . -72.0 -46.2 58.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.784 HD23 ' HB3' ' A' ' 170' ' ' LEU . 48.6 mt -44.36 -40.98 5.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.47 HG23 ' N ' ' A' ' 156' ' ' GLU . 14.9 t -92.33 -42.54 9.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.165 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.47 ' N ' HG23 ' A' ' 155' ' ' THR . 25.6 mm-40 -68.96 -64.87 0.79 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.611 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 10.4 m -70.11 -1.68 10.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.893 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 158' ' ' GLN . . . . . 0.487 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.8 tp-100 -42.48 141.95 0.9 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.891 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 158' ' ' GLN . . . 35.51 34.29 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.502 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.611 ' HB2' ' O ' ' A' ' 157' ' ' CYS . . . -58.49 110.65 1.02 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.769 0.319 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.41 ' O ' ' C ' ' A' ' 162' ' ' GLY . 22.9 t -79.27 -34.27 16.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.121 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 162' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.65 -36.23 0.15 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.464 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.441 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 25.2 tp -92.72 115.17 27.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.85 0.357 . . . . 0.0 110.885 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.77 146.85 0.13 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.495 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 m -50.81 -21.09 1.5 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.966 0.413 . . . . 0.0 110.855 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' LYS . . . . . 0.459 ' HB2' HG23 ' A' ' 104' ' ' THR . 36.5 mttm -109.08 156.05 39.86 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.595 0.712 . . . . 0.0 110.903 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 171.84 13.74 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.699 2.266 . . . . 0.0 112.295 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 168' ' ' VAL . 35.4 m -125.34 127.6 72.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.185 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 17.7 ttt180 -91.54 107.82 19.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.784 ' HB3' HD23 ' A' ' 154' ' ' LEU . 14.4 mt -84.4 143.39 29.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.932 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 15.2 m -154.6 171.41 19.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.881 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.673 HG22 HD11 ' A' ' 154' ' ' LEU . 3.0 t -101.0 100.6 10.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.112 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -82.37 140.12 33.68 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.136 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 174' ' ' ILE . . . . . 0.766 HG22 ' H ' ' A' ' 176' ' ' LYS . 41.5 mt -119.18 120.98 30.62 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.668 0.747 . . . . 0.0 111.131 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 1.4 4.5 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.704 2.269 . . . . 0.0 112.312 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.766 ' H ' HG22 ' A' ' 174' ' ' ILE . 17.7 mmmt -102.83 -42.09 5.97 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.883 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -47.31 134.24 11.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.117 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 68.7 m -96.26 90.5 5.49 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.884 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 3.5 tmm_? -95.42 74.44 3.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.852 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 71.4 t -115.39 107.09 21.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.119 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 34.9 mmtt -66.11 142.25 97.84 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.561 0.696 . . . . 0.0 110.93 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 162.64 41.29 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.678 2.252 . . . . 0.0 112.395 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 92.9 t -134.95 109.99 12.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.142 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -136.73 120.34 17.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 11.6 m -58.49 -54.26 49.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.849 -179.746 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 49.92 73.01 0.4 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.478 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 117.85 5.33 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.682 2.255 . . . . 0.0 112.329 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 5.2 m -90.34 169.79 10.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.831 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 36.4 m -156.49 152.83 27.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.889 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.482 -179.954 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.2 t -116.62 140.16 49.71 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.842 0.353 . . . . 0.0 110.903 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 57.8 m -98.4 -49.38 4.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.851 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 148.2 -93.11 0.15 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.474 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 20.3 t -115.1 86.06 2.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.857 0.36 . . . . 0.0 110.876 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 33.3 p -172.37 136.61 0.81 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.847 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 147.68 168.0 13.77 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.469 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 147.81 63.68 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.68 2.254 . . . . 0.0 112.333 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 26.3 mp0 -83.41 162.11 21.12 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.9 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -131.79 93.74 3.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.934 -179.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.8 m -112.33 147.19 36.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.839 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.817 HD22 HD21 ' A' ' 154' ' ' LEU . 92.2 mt -115.75 155.99 26.79 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.412 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 8.6 t80 -104.6 127.49 52.35 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.856 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.438 HG22 ' C ' ' A' ' 140' ' ' GLY . 28.4 m -116.55 155.28 18.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -142.59 178.12 21.26 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.485 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 52.87 50.28 18.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.874 0.369 . . . . 0.0 110.898 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 29.1 mt -96.9 103.44 15.37 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.899 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.426 HG21 ' HB2' ' A' ' 165' ' ' SER . 17.4 p -47.94 150.16 2.1 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 121.617 0.723 . . . . 0.0 111.152 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 2.98 3.03 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.623 2.215 . . . . 0.0 112.375 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.34 16.34 26.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.721 HG22 ' HE3' ' A' ' 111' ' ' MET . 59.5 t -129.62 142.17 44.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.109 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -128.95 -177.6 4.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.817 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -58.18 -47.98 81.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.848 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -42.26 -35.1 1.72 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.48 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.721 ' HE3' HG22 ' A' ' 107' ' ' VAL . 26.0 mtm -86.03 -45.72 11.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.823 0.344 . . . . 0.0 110.884 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.532 HD23 ' N ' ' A' ' 127' ' ' LYS . 16.0 tp -53.5 -33.45 54.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.503 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 9.8 t80 -68.71 -61.62 1.74 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.755 ' HA ' HG12 ' A' ' 117' ' ' VAL . 22.2 mt-10 -57.76 -51.78 68.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.901 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.545 ' CE1' ' HB2' ' A' ' 163' ' ' LEU . 66.5 t80 -44.1 -32.34 1.17 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.876 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.619 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.7 m-85 -95.25 -67.52 0.85 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.755 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.83 -29.35 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.158 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.483 ' N ' ' O ' ' A' ' 116' ' ' PHE . 22.9 ttpp -66.31 -58.31 5.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.901 179.883 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.529 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.6 p -67.41 -33.0 59.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.124 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.686 ' CE2' ' HB2' ' A' ' 153' ' ' ALA . 89.4 m-85 -129.12 113.31 18.5 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.683 0.754 . . . . 0.0 110.944 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.8 Cg_endo -69.77 -0.05 6.35 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.722 2.281 . . . . 0.0 112.353 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 69.0 m -105.22 35.41 2.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.864 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 3.0 t -98.09 138.59 35.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.907 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.571 HH11 HG22 ' A' ' 145' ' ' THR . 44.8 mtp85 -93.6 -38.06 11.55 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.857 -179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.503 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 159.22 141.72 3.21 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.491 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.645 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -90.41 138.04 14.25 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.44 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.532 ' N ' HD23 ' A' ' 112' ' ' LEU . 20.2 tptm -122.05 128.28 51.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.81 0.338 . . . . 0.0 110.9 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.9 p -114.86 135.64 54.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.948 HG22 ' O ' ' A' ' 139' ' ' TYR . 32.9 m -84.71 145.98 7.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.092 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.562 HD23 ' HA ' ' A' ' 136' ' ' SER . 31.1 mt -126.69 -179.66 4.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.849 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.479 ' O ' ' N ' ' A' ' 134' ' ' GLY . 2.2 t70 -118.69 -176.0 3.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.891 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -38.35 -61.38 0.69 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.887 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.402 ' H ' HG22 ' A' ' 133' ' ' THR . 0.0 OUTLIER -60.92 -24.84 66.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.148 -179.898 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.485 ' O ' HD22 ' A' ' 130' ' ' LEU . . . 105.16 4.45 41.27 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.502 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 5.3 m -77.24 145.2 10.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.811 0.339 . . . . 0.0 111.168 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.562 ' HA ' HD23 ' A' ' 130' ' ' LEU . 5.1 t -56.93 113.9 1.87 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.502 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 30.0 mtmt -56.73 -31.65 64.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.885 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.21 17.71 2.95 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.484 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.948 ' O ' HG22 ' A' ' 129' ' ' VAL . 28.0 p90 -162.55 174.8 12.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.964 0.412 . . . . 0.0 110.889 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.438 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -178.29 -162.42 28.01 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.485 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.412 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 4.5 m-85 -153.98 146.18 23.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.953 0.406 . . . . 0.0 110.858 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.645 HG12 ' HA2' ' A' ' 126' ' ' GLY . 17.8 m -116.87 -176.51 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.139 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 25.7 mttm -143.75 157.83 44.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.891 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.421 ' CE1' HG23 ' A' ' 142' ' ' VAL . 50.0 m-85 -146.79 161.85 39.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.884 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' THR . . . . . 0.571 HG22 HH11 ' A' ' 124' ' ' ARG . 69.9 p -95.76 -29.73 14.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.152 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -112.9 133.9 54.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.799 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -74.64 -34.47 62.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.867 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 64.6 mt -53.39 -40.45 65.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.927 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.484 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 4.3 mm-40 -80.66 -40.53 25.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.877 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.591 ' HG2' HD21 ' A' ' 98' ' ' LEU . 13.4 tt0 -41.6 -48.08 3.97 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.9 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 154' ' ' LEU . 40.4 mttp -71.67 -57.2 4.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.902 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.4 ' C ' ' O ' ' A' ' 151' ' ' LYS . 21.0 mtt-85 -38.18 -33.55 0.1 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.897 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.686 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -74.66 -43.49 55.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.117 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.817 HD21 HD22 ' A' ' 98' ' ' LEU . 14.7 mt -48.32 -38.2 18.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.499 HG23 ' N ' ' A' ' 156' ' ' GLU . 10.1 t -92.14 -45.76 8.11 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.136 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.499 ' N ' HG23 ' A' ' 155' ' ' THR . 16.8 mm-40 -67.99 -62.35 1.44 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.851 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.544 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 33.0 m -68.24 -3.25 10.12 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.897 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 5.1 tp-100 -45.36 139.58 3.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.916 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 44.2 34.35 3.23 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.505 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.629 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -55.33 113.0 1.23 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.814 0.34 . . . . 0.0 111.077 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.8 t -88.02 -32.31 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.151 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.53 -37.0 2.46 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.482 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.545 ' HB2' ' CE1' ' A' ' 115' ' ' PHE . 26.4 tp -89.65 117.19 28.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.901 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 68.19 154.22 0.55 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.528 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 165' ' ' SER . . . . . 0.426 ' HB2' HG21 ' A' ' 104' ' ' THR . 19.3 m -55.98 -25.4 43.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.953 0.406 . . . . 0.0 110.871 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 59.8 mttt -108.0 154.71 40.97 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.615 0.721 . . . . 0.0 110.871 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 173.39 11.07 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.696 2.264 . . . . 0.0 112.304 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.629 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 33.0 m -126.33 127.02 70.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.153 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 34.6 ttt85 -92.77 102.44 14.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.856 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.58 ' HB3' HD23 ' A' ' 154' ' ' LEU . 11.2 mt -76.88 149.84 36.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.919 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.7 m -158.58 175.57 13.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.871 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.624 HG22 HD11 ' A' ' 154' ' ' LEU . 11.3 t -105.78 101.62 12.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.141 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -75.97 171.58 14.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.119 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 174' ' ' ILE . . . . . 0.48 HG22 ' H ' ' A' ' 177' ' ' ALA . 65.3 mt -133.76 123.13 17.02 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.639 0.733 . . . . 0.0 111.086 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.453 ' O ' ' C ' ' A' ' 176' ' ' LYS . 53.0 Cg_endo -69.79 79.93 0.92 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.663 2.242 . . . . 0.0 112.321 179.883 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.453 ' C ' ' O ' ' A' ' 175' ' ' PRO . 45.2 mttm 33.56 37.05 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.912 179.906 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 177' ' ' ALA . . . . . 0.48 ' H ' HG22 ' A' ' 174' ' ' ILE . . . -56.5 -59.83 4.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.087 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 63.6 p -82.66 123.17 29.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.869 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 45.3 mtm180 -95.99 155.8 16.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.873 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 7.2 p -123.57 144.38 33.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.126 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -122.1 87.58 47.67 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.587 0.708 . . . . 0.0 110.901 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 111.39 2.79 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.698 2.265 . . . . 0.0 112.368 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 91.4 t -60.83 104.27 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.107 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -75.06 143.02 43.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.9 p -140.54 155.36 46.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 169.75 146.29 5.02 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.461 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 126.26 13.1 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.646 2.23 . . . . 0.0 112.361 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 188' ' ' SER . . . . . 0.412 ' O ' ' C ' ' A' ' 189' ' ' SER . 31.7 t -151.03 124.03 8.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.864 -179.857 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 189' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 188' ' ' SER . 3.1 t -36.49 -43.3 0.39 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.852 -179.808 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.308 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.471 179.995 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.445 -0.262 . . . . 0.0 112.445 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 30.8 t -75.5 134.98 40.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.869 0.366 . . . . 0.0 110.872 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 33.6 m -67.15 -53.55 29.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.829 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 89.22 -119.85 5.57 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.496 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 35.8 m -74.8 -47.85 28.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.878 0.371 . . . . 0.0 110.852 -179.755 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 47.4 t -64.04 120.39 11.94 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.882 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -48.51 146.29 5.74 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.491 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 108.96 2.2 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.694 2.263 . . . . 0.0 112.339 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -144.98 144.48 31.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.895 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' TYR . . . . . 0.493 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 5.0 m-85 -140.39 107.02 5.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.923 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 58.2 p -116.22 142.52 46.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.849 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.791 HD22 HD21 ' A' ' 154' ' ' LEU . 37.3 mt -115.79 147.89 40.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.917 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -93.88 135.68 34.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 140' ' ' GLY . 15.5 m -128.6 139.56 51.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.158 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -132.39 171.23 21.6 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.508 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ASP . . . . . 0.403 ' N ' ' O ' ' A' ' 138' ' ' GLY . 29.4 m-20 61.74 51.72 3.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.864 0.364 . . . . 0.0 110.928 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 25.6 mt -99.29 103.31 15.13 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.94 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.558 HG23 ' HB2' ' A' ' 166' ' ' LYS . 16.9 p -48.4 150.19 2.43 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.609 0.718 . . . . 0.0 111.111 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 -0.27 6.73 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.668 2.246 . . . . 0.0 112.333 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -99.73 10.19 41.77 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.479 ' HA ' ' HE2' ' A' ' 111' ' ' MET . 21.7 t -123.76 133.9 67.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.101 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -118.9 176.3 5.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.879 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.5 p-10 -52.22 -50.55 61.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -39.41 -39.12 1.07 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.468 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.479 ' HE2' ' HA ' ' A' ' 107' ' ' VAL . 29.7 mtm -82.77 -41.33 19.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.743 0.306 . . . . 0.0 110.876 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.412 HD23 ' N ' ' A' ' 127' ' ' LYS . 18.6 tp -58.8 -24.39 61.81 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.927 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.418 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 16.7 t80 -84.45 -62.37 1.57 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.884 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.7 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.0 mt-10 -57.76 -34.74 69.87 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.931 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.504 ' CZ ' ' HB2' ' A' ' 163' ' ' LEU . 84.7 t80 -59.85 -34.03 72.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.51 ' CD2' HG11 ' A' ' 142' ' ' VAL . 9.5 m-85 -95.03 -62.13 1.36 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.863 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.7 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.3 p -39.03 -27.16 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.131 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.462 ' N ' ' O ' ' A' ' 116' ' ' PHE . 19.5 tptt -68.96 -60.52 2.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.898 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.668 HG13 ' CD2' ' A' ' 120' ' ' TYR . 4.2 p -67.58 -28.86 43.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.146 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.668 ' CD2' HG13 ' A' ' 119' ' ' VAL . 95.1 m-85 -132.72 110.55 13.38 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.667 0.746 . . . . 0.0 110.894 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.1 Cg_endo -69.8 -2.47 10.25 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.701 2.267 . . . . 0.0 112.294 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 23.4 p -90.3 -4.04 57.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.855 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' CYS . . . . . 0.475 ' HA ' ' CD1' ' A' ' 144' ' ' PHE . 14.1 t -57.35 146.46 28.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.931 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.439 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 1.6 mmm180 -109.01 -36.45 6.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.901 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.418 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.29 149.24 5.78 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.48 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.442 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -100.11 135.82 12.36 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.472 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.412 ' N ' HD23 ' A' ' 112' ' ' LEU . 1.7 tmtp? -127.91 110.9 13.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.848 0.356 . . . . 0.0 110.883 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.527 ' O ' HG13 ' A' ' 128' ' ' VAL . 14.2 p -103.25 119.91 52.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.128 179.856 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.847 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 18.2 m -66.36 143.33 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.113 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 43.5 mt -121.49 -176.6 3.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.911 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -113.77 -175.72 2.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' GLN . . . . . 0.751 ' OE1' HG22 ' A' ' 133' ' ' THR . 0.0 OUTLIER -48.39 -35.18 12.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.912 -179.928 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.751 HG22 ' OE1' ' A' ' 132' ' ' GLN . 9.6 p -86.65 -23.16 25.76 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.145 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.54 23.36 8.93 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.503 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 30.6 m -99.12 128.56 50.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.836 0.351 . . . . 0.0 111.12 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.6 t -39.37 109.75 0.12 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.861 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.3 mtmt -58.53 -28.45 65.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.403 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 123.74 16.07 3.44 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.479 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.847 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 16.2 p90 -162.76 173.19 14.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.941 0.4 . . . . 0.0 110.929 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.421 ' O ' HG22 ' A' ' 100' ' ' VAL . . . -176.73 -163.7 29.44 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.525 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -151.23 148.12 27.82 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.878 0.37 . . . . 0.0 110.934 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.51 HG11 ' CD2' ' A' ' 116' ' ' PHE . 15.4 m -120.85 176.06 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 143' ' ' LYS . . . . . 0.439 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -133.69 161.86 33.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 179.939 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.475 ' CD1' ' HA ' ' A' ' 123' ' ' CYS . 96.9 m-85 -149.61 167.88 25.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 25.8 p -108.79 -8.13 15.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.142 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -132.51 124.44 28.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.856 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.493 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 16.3 tt0 -69.88 -30.92 68.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.889 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 48.6 mt -58.16 -54.61 44.98 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.928 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 54.4 mt-10 -67.57 -39.54 84.91 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.526 ' HG2' HD21 ' A' ' 98' ' ' LEU . 17.6 tt0 -44.01 -45.57 7.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.905 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 74.1 mttt -73.11 -29.89 63.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.942 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 47.3 mtp180 -63.57 -39.84 95.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.873 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.635 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -68.52 -42.87 77.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.138 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.791 HD21 HD22 ' A' ' 98' ' ' LEU . 29.3 mt -45.85 -43.1 13.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.933 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.51 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.4 t -91.1 -46.66 7.99 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.168 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.51 ' N ' HG23 ' A' ' 155' ' ' THR . 47.4 mm-40 -63.32 -63.58 1.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.877 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.731 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 34.0 m -67.7 -9.43 43.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.917 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 158' ' ' GLN . . . . . 0.427 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.6 tp-100 -37.93 145.22 0.07 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.969 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.07 33.71 0.5 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.514 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.731 ' HB2' ' O ' ' A' ' 157' ' ' CYS . . . -58.71 115.86 3.34 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.826 0.346 . . . . 0.0 111.054 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 23.1 t -90.77 -35.33 7.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.136 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.12 -33.28 0.16 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.498 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.504 ' HB2' ' CZ ' ' A' ' 115' ' ' PHE . 25.7 tp -93.69 115.98 28.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.868 0.366 . . . . 0.0 110.871 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 69.1 156.69 1.15 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.475 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 65.8 m -59.83 -19.97 54.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.995 0.426 . . . . 0.0 110.878 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 166' ' ' LYS . . . . . 0.558 ' HB2' HG23 ' A' ' 104' ' ' THR . 49.2 mttt -111.83 156.67 41.28 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.527 0.68 . . . . 0.0 110.93 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 177.62 5.38 Favored 'Trans proline' 0 N--CA 1.465 -0.153 0 C-N-CA 122.681 2.254 . . . . 0.0 112.376 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.652 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 31.4 m -131.33 125.98 57.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.138 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 30.3 ttm180 -91.65 99.76 12.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.856 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.559 ' HB3' HD23 ' A' ' 154' ' ' LEU . 13.4 mt -77.73 151.5 34.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.916 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.7 m -162.83 171.47 16.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.86 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.571 HG22 ' CD1' ' A' ' 154' ' ' LEU . 2.8 t -97.93 105.02 16.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.145 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -102.85 170.2 8.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.092 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' ILE . . . . . 0.654 HG23 ' HD2' ' A' ' 175' ' ' PRO . 77.2 mt -123.54 138.2 29.83 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.622 0.725 . . . . 0.0 111.131 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.654 ' HD2' HG23 ' A' ' 174' ' ' ILE . 53.8 Cg_endo -69.77 -49.87 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.68 2.254 . . . . 0.0 112.351 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 25.8 ttpp -132.69 139.0 47.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.92 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -153.26 134.6 14.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.08 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 58.0 p -121.57 103.62 9.05 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.839 -179.787 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 60.4 mtm180 -74.92 166.03 24.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.875 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 180' ' ' VAL . . . . . 0.422 HG22 ' N ' ' A' ' 181' ' ' LYS . 8.2 p -119.01 157.11 20.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.16 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.422 ' N ' HG22 ' A' ' 180' ' ' VAL . 0.0 OUTLIER -141.2 140.9 21.82 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.605 0.716 . . . . 0.0 110.933 179.883 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.75 115.98 4.35 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.707 2.271 . . . . 0.0 112.347 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 84.7 t -90.01 108.43 19.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -112.86 139.27 48.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.911 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 59.6 p -127.12 169.64 13.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.855 -179.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 169.69 157.83 12.68 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.493 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 139.17 39.57 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.694 2.263 . . . . 0.0 112.379 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 49.7 m -73.57 -51.64 16.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.848 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 2.5 t -140.33 166.07 25.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.847 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.367 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.52 179.998 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 27.1 t -146.92 154.45 41.31 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.904 0.383 . . . . 0.0 110.853 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 67.1 m -116.23 46.67 1.53 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.871 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 87.07 161.87 36.94 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.5 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 47.5 t -165.65 150.65 8.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.902 0.382 . . . . 0.0 110.844 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 15.3 m -152.55 123.84 7.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.846 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 66.51 87.61 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.482 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 81.82 0.8 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.704 2.27 . . . . 0.0 112.357 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' GLU . . . . . 0.467 ' O ' ' CD1' ' A' ' 96' ' ' TYR . 34.1 tt0 -162.78 136.16 5.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.858 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' TYR . . . . . 0.467 ' CD1' ' O ' ' A' ' 95' ' ' GLU . 4.4 m-85 -147.23 119.8 8.52 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.88 -179.824 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.7 p -133.3 149.13 51.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.887 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.83 HD22 HD21 ' A' ' 154' ' ' LEU . 23.6 mt -118.86 149.62 41.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.934 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.483 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 8.9 t80 -96.1 131.37 42.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.906 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.475 HG22 ' C ' ' A' ' 140' ' ' GLY . 17.1 m -122.25 138.3 52.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -130.47 179.77 16.66 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.514 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 51.32 54.03 11.84 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.8 0.334 . . . . 0.0 110.865 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.404 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.0 mt -101.95 103.24 13.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 52.3 p -49.37 150.53 3.18 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.561 0.696 . . . . 0.0 111.145 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 3.0 3.02 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.748 2.299 . . . . 0.0 112.381 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -99.21 -4.32 32.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.662 HG22 ' HE3' ' A' ' 111' ' ' MET . 93.1 t -109.1 144.39 17.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.151 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -129.8 179.75 5.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.86 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.7 -35.27 74.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.862 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -53.5 -32.46 45.74 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.465 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.662 ' HE3' HG22 ' A' ' 107' ' ' VAL . 32.9 mtm -89.03 -42.64 11.63 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.855 0.359 . . . . 0.0 110.892 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.531 HD23 ' N ' ' A' ' 127' ' ' LYS . 17.0 tp -56.91 -28.84 62.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.912 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.474 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 9.5 t80 -74.96 -62.87 1.4 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.709 ' HA ' HG12 ' A' ' 117' ' ' VAL . 19.4 mt-10 -61.65 -26.77 68.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.89 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.64 ' HZ ' ' HB1' ' A' ' 160' ' ' ALA . 84.2 t80 -65.85 -34.62 78.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.893 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -94.63 -58.37 2.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.888 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.709 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.2 p -43.21 -25.55 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.147 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 5.1 ttpm? -69.5 -60.65 2.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.892 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.624 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.2 p -65.46 -27.67 42.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.624 ' CD2' HG13 ' A' ' 119' ' ' VAL . 97.1 m-85 -137.79 113.18 9.13 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.666 0.746 . . . . 0.0 110.94 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 0.05 6.18 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.68 2.253 . . . . 0.0 112.344 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 16.1 m -99.72 24.89 7.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.864 -179.818 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 14.9 t -85.87 140.51 30.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.879 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.588 ' HE ' HG22 ' A' ' 145' ' ' THR . 7.9 mmt85 -95.82 -32.5 12.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.857 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.474 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 151.84 140.78 3.2 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.785 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -90.22 137.24 13.89 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.479 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.531 ' N ' HD23 ' A' ' 112' ' ' LEU . 1.6 tppp? -125.96 129.72 49.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 110.898 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.11 128.28 73.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.096 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.926 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 22.3 m -74.31 147.21 9.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.13 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 11.6 mt -129.01 173.32 10.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.928 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -105.55 -179.15 3.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.883 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 32.9 tt0 -46.24 -39.79 10.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 52.2 p -74.84 -34.07 62.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.131 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.02 23.35 6.17 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.505 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 18.8 m -103.37 132.63 49.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.842 0.353 . . . . 0.0 111.083 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.0 t -42.12 114.06 0.51 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.849 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.438 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.1 mtmt -61.3 -24.7 66.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.831 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 119.71 15.96 5.16 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.484 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.926 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 25.1 p90 -162.13 177.81 9.35 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.933 0.397 . . . . 0.0 110.913 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.475 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -179.63 -163.45 30.4 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.492 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -153.01 147.97 26.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.857 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.785 HG12 ' HA2' ' A' ' 126' ' ' GLY . 14.7 m -120.94 -178.61 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.139 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' LYS . . . . . 0.47 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 21.9 mtmm -141.04 159.18 42.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.826 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -147.32 171.21 15.8 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.857 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' THR . . . . . 0.588 HG22 ' HE ' ' A' ' 124' ' ' ARG . 75.4 p -110.48 -25.61 9.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.152 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -111.7 117.25 32.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.829 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -68.01 -23.74 65.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.879 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 67.7 mt -64.34 -35.85 82.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.931 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.497 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 20.8 mt-10 -88.94 -35.89 16.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.444 ' O ' HD11 ' A' ' 98' ' ' LEU . 22.4 tt0 -42.99 -45.14 4.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.928 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 36.6 mttp -77.41 -35.16 54.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.444 ' O ' ' CG ' ' A' ' 156' ' ' GLU . 21.3 mtp85 -55.69 -34.0 64.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.842 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -74.19 -40.74 62.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.107 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.83 HD21 HD22 ' A' ' 98' ' ' LEU . 19.1 mt -47.5 -41.76 21.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.931 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.456 HG23 ' N ' ' A' ' 156' ' ' GLU . 11.9 t -92.51 -42.4 9.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.173 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.456 ' N ' HG23 ' A' ' 155' ' ' THR . 46.5 mm-40 -67.33 -66.32 0.57 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.909 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.477 ' CB ' HD11 ' A' ' 170' ' ' LEU . 3.7 m -64.26 -13.08 47.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.862 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' GLN . . . . . 0.411 ' C ' ' O ' ' A' ' 157' ' ' CYS . 3.3 tp-100 -35.6 129.62 0.57 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.926 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 59.0 33.25 73.28 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.525 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.829 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -56.1 112.95 1.34 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 111.102 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.2 t -91.6 -32.95 5.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.153 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -43.52 -31.38 1.63 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.509 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.51 ' HB2' ' CE1' ' A' ' 115' ' ' PHE . 26.7 tp -94.97 112.85 24.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.842 0.353 . . . . 0.0 110.886 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.421 ' CA ' HG21 ' A' ' 107' ' ' VAL . . . 70.82 148.45 0.49 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.498 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 49.0 m -50.92 -31.61 18.15 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.939 0.399 . . . . 0.0 110.841 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -99.92 155.52 36.36 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.534 0.683 . . . . 0.0 110.904 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.84 174.48 9.51 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.703 2.269 . . . . 0.0 112.302 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.829 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 30.7 m -130.32 135.42 60.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.165 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 169' ' ' ARG . . . . . 0.405 ' O ' ' HG2' ' A' ' 169' ' ' ARG . 5.7 ptm180 -95.93 128.04 42.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.862 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.762 ' HB3' HD23 ' A' ' 154' ' ' LEU . 31.9 mt -102.06 136.75 41.35 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.951 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.3 m -151.78 -176.9 5.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 10.7 t -107.48 94.3 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.158 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.483 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -70.98 160.38 33.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.08 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 83.7 mt -124.14 122.79 26.1 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.64 0.734 . . . . 0.0 111.12 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.488 ' O ' ' N ' ' A' ' 177' ' ' ALA . 53.8 Cg_endo -69.75 -176.65 1.55 Allowed 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.676 2.251 . . . . 0.0 112.376 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.406 ' CA ' ' HE3' ' A' ' 176' ' ' LYS . 0.1 OUTLIER -46.93 89.52 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.867 179.941 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 177' ' ' ALA . . . . . 0.488 ' N ' ' O ' ' A' ' 175' ' ' PRO . . . -104.36 76.42 1.32 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.107 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 58.2 m -132.4 175.54 9.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.842 -179.736 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 2.6 ttt85 -124.1 126.04 45.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.838 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 13.4 p -64.26 136.04 27.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.166 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.479 ' CG ' ' HD2' ' A' ' 182' ' ' PRO . 41.5 tttt -162.42 139.62 6.23 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.581 0.705 . . . . 0.0 110.921 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.479 ' HD2' ' CG ' ' A' ' 181' ' ' LYS . 53.8 Cg_endo -69.83 95.99 0.58 Allowed 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.658 2.239 . . . . 0.0 112.368 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 68.2 t -98.38 88.46 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.107 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -174.83 133.7 0.35 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.888 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 43.5 m -107.84 140.57 40.74 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.837 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -82.41 -94.04 0.55 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.514 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 148.43 64.92 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.727 2.285 . . . . 0.0 112.299 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 36.1 p -90.99 -57.9 2.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.862 -179.854 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 53.8 p -158.03 139.85 13.93 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.806 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.47 179.982 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 68.8 m -53.3 147.5 10.18 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.864 0.364 . . . . 0.0 110.863 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 t -123.97 41.64 3.44 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.811 -179.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 68.65 -179.63 21.53 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.471 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 25.4 m -117.57 118.6 32.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.827 0.346 . . . . 0.0 110.858 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 93.3 p -135.7 106.43 6.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.887 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 147.49 -83.83 0.18 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.508 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 148.98 66.15 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.684 2.256 . . . . 0.0 112.337 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -151.03 151.93 32.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' TYR . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 7.3 m-85 -123.18 105.47 9.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.909 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.1 p -126.23 155.09 42.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.784 HD22 HD21 ' A' ' 154' ' ' LEU . 85.7 mt -126.15 144.05 50.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.918 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.48 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 11.6 t80 -94.47 131.24 40.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.436 ' CG2' HD11 ' A' ' 103' ' ' LEU . 34.8 m -120.03 147.52 23.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.125 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -134.9 -177.9 15.28 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.482 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 50.24 48.39 22.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.803 0.335 . . . . 0.0 110.882 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.446 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.2 mt -93.86 103.09 15.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.889 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.666 ' OG1' HG23 ' A' ' 107' ' ' VAL . 71.1 p -48.2 149.49 2.59 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.588 0.709 . . . . 0.0 111.153 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 2.61 3.34 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.707 2.271 . . . . 0.0 112.38 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -99.11 -9.83 23.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.852 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.666 HG23 ' OG1' ' A' ' 104' ' ' THR . 15.7 t -98.12 144.05 11.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.134 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -130.24 174.46 9.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.844 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -51.66 -50.74 59.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.875 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -45.54 -33.99 4.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.506 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.432 ' HE2' HG13 ' A' ' 107' ' ' VAL . 50.4 mtp -80.92 -61.5 1.94 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.781 0.324 . . . . 0.0 110.855 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.452 HD12 ' CD2' ' A' ' 163' ' ' LEU . 18.3 tp -41.23 -40.2 1.54 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.919 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.497 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 17.6 t80 -63.01 -68.12 0.37 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.903 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.749 ' HA ' HG12 ' A' ' 117' ' ' VAL . 26.7 mt-10 -48.74 -55.51 11.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.88 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.55 ' CB ' HD13 ' A' ' 163' ' ' LEU . 76.4 t80 -42.75 -32.1 0.56 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.885 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.467 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.1 m-85 -95.0 -67.23 0.86 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.873 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.749 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.81 -30.31 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.14 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.2 tttp -65.41 -58.5 5.7 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.929 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.58 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.3 p -67.27 -29.81 47.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.132 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.58 ' CD2' HG13 ' A' ' 119' ' ' VAL . 96.3 m-85 -137.06 109.49 9.05 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.685 0.755 . . . . 0.0 110.924 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 2.43 3.53 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.671 2.247 . . . . 0.0 112.318 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 1.3 p -95.49 -0.18 52.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.833 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 19.1 t -66.4 138.07 57.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.931 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -91.59 -38.61 12.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.497 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 164.37 150.42 6.13 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.476 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.631 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -94.21 137.52 13.57 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.447 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 19.7 tptm -125.27 118.72 26.61 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.838 0.351 . . . . 0.0 110.903 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.518 ' O ' HG13 ' A' ' 128' ' ' VAL . 7.7 p -112.45 115.57 50.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.109 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.913 HG22 ' O ' ' A' ' 139' ' ' TYR . 32.6 m -61.66 151.27 7.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.161 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.583 HD23 ' HA ' ' A' ' 136' ' ' SER . 49.0 mt -133.16 164.48 26.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.924 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.452 ' O ' ' N ' ' A' ' 134' ' ' GLY . 13.7 t70 -96.96 175.84 6.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.866 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 2.0 tp-100 -42.66 -44.25 4.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.905 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 44.0 p -70.0 -28.51 65.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.118 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 103.81 23.73 8.1 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.505 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 136' ' ' SER . 28.4 m -105.12 131.43 54.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-O 120.824 0.345 . . . . 0.0 111.122 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.583 ' HA ' HD23 ' A' ' 130' ' ' LEU . 5.8 t -37.89 114.16 0.33 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.426 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.7 mtmt -62.66 -25.89 68.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.907 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 119.41 17.18 4.9 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.5 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.913 ' O ' HG22 ' A' ' 129' ' ' VAL . 20.3 p90 -163.54 172.05 14.96 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.916 0.389 . . . . 0.0 110.984 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -176.22 -164.11 29.84 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.501 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' PHE . . . . . 0.48 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 3.7 m-85 -152.05 149.15 28.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.906 0.384 . . . . 0.0 110.845 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.631 HG12 ' HA2' ' A' ' 126' ' ' GLY . 16.1 m -123.0 161.05 25.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.131 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -119.05 158.41 25.89 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.872 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.524 ' CE1' HG23 ' A' ' 142' ' ' VAL . 84.4 m-85 -145.6 169.36 18.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 43.3 p -115.0 -24.79 8.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.123 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -112.99 99.82 8.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 16.7 tt0 -46.94 -45.26 20.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.884 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 33.6 mt -48.1 -40.57 23.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.927 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.474 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 4.4 mm-40 -80.98 -33.98 33.41 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.825 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.48 ' HG2' HD21 ' A' ' 98' ' ' LEU . 15.4 tt0 -49.79 -63.89 0.97 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.944 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -57.92 -47.62 82.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.923 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 47.0 mtt180 -43.97 -30.89 0.78 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.855 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -73.76 -39.1 64.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.064 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.784 HD21 HD22 ' A' ' 98' ' ' LEU . 12.2 mt -51.01 -38.14 49.46 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.886 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.508 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.8 t -92.46 -46.35 7.69 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.508 ' N ' HG23 ' A' ' 155' ' ' THR . 10.7 mt-10 -68.45 -63.1 1.13 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.828 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.48 ' CB ' HD11 ' A' ' 170' ' ' LEU . 40.3 m -68.64 -2.61 9.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.873 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -43.5 136.69 3.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.876 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 42.61 43.85 5.15 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.45 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.571 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -61.33 110.89 1.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.784 0.326 . . . . 0.0 111.134 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.7 -35.95 10.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.137 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -40.68 -34.48 0.74 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.501 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.55 HD13 ' CB ' ' A' ' 115' ' ' PHE . 16.1 tp -91.07 118.77 30.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.835 0.35 . . . . 0.0 110.946 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 165' ' ' SER . . . 61.22 135.07 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.465 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 165' ' ' SER . . . . . 0.411 ' C ' ' O ' ' A' ' 164' ' ' GLY . 58.8 m -37.58 -33.58 0.08 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.924 0.392 . . . . 0.0 110.844 -179.692 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 31.7 mttp -95.61 153.5 39.43 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.574 0.702 . . . . 0.0 110.876 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -176.27 1.44 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.677 2.252 . . . . 0.0 112.313 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.571 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 33.2 m -140.84 126.59 19.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 18.3 mtt180 -90.26 116.68 28.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.847 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.562 ' HB3' HD23 ' A' ' 154' ' ' LEU . 17.4 mt -89.9 137.48 32.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.903 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 13.2 m -149.52 179.72 7.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.89 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 5.0 t -103.99 98.1 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.087 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.46 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -69.73 146.36 51.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.069 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 59.8 mt -102.21 120.63 52.97 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.602 0.715 . . . . 0.0 111.134 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 -49.46 0.55 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.665 2.243 . . . . 0.0 112.35 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 19.6 tptm -78.06 65.32 3.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.87 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -80.54 -62.22 1.74 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.088 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 26.9 t -72.01 109.86 6.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.862 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 53.5 mtt180 -100.91 119.26 38.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.889 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 33.7 m -105.61 145.03 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.128 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 32.7 tttp -116.73 136.7 23.26 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.576 0.703 . . . . 0.0 110.889 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.71 107.04 1.76 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.718 2.279 . . . . 0.0 112.311 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 35.5 m -82.18 155.03 4.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.118 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -121.34 112.1 18.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.891 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 58.5 p -151.07 138.57 19.55 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.821 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 125.6 157.92 9.79 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.493 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 127.92 15.26 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.708 2.272 . . . . 0.0 112.363 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 52.3 p -156.93 167.44 30.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.82 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 85.5 p -67.87 169.83 9.13 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.832 -179.776 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.52 -179.975 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.501 -0.239 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 23.9 m -105.55 94.57 5.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.858 0.361 . . . . 0.0 110.878 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 m -91.25 -60.39 1.91 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.891 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -137.23 -139.32 3.88 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.466 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 63.2 p -126.32 134.22 51.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.875 0.369 . . . . 0.0 110.836 -179.691 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 28.8 t -101.27 -38.36 8.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.856 -179.814 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -168.24 95.3 0.11 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.481 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 101.22 0.88 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.742 2.294 . . . . 0.0 112.325 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -168.54 117.78 0.72 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' TYR . . . . . 0.509 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 33.1 m-85 -114.88 87.69 2.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.895 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 64.6 m -105.18 156.38 18.15 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.892 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.959 HD22 HD21 ' A' ' 154' ' ' LEU . 21.8 mt -122.23 143.01 49.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.949 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.439 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 8.5 t80 -93.11 126.87 38.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.912 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.438 HG22 ' C ' ' A' ' 140' ' ' GLY . 30.2 m -119.17 148.6 22.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.142 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.61 176.33 20.9 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.522 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ASP . . . . . 0.468 ' N ' ' O ' ' A' ' 138' ' ' GLY . 22.7 m-20 56.57 50.74 12.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.837 0.351 . . . . 0.0 110.878 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.406 ' H ' ' C ' ' A' ' 138' ' ' GLY . 25.9 mt -98.6 100.34 11.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 75.0 p -42.69 149.38 0.48 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.602 0.715 . . . . 0.0 111.128 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 3.13 2.93 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.711 2.274 . . . . 0.0 112.368 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 65.5 m-20 -104.22 11.93 34.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.903 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 1.02 HG22 ' HE3' ' A' ' 111' ' ' MET . 75.3 t -128.42 134.98 63.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.125 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -120.69 -175.99 3.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.869 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -57.88 -37.01 73.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -46.59 -41.51 12.82 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.443 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' MET . . . . . 1.02 ' HE3' HG22 ' A' ' 107' ' ' VAL . 27.9 mtm -83.82 -44.8 13.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.787 0.327 . . . . 0.0 110.863 -179.952 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 21.2 tp -51.74 -22.82 3.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.901 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.414 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 14.8 t80 -83.74 -64.69 1.12 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.863 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.712 ' HA ' HG12 ' A' ' 117' ' ' VAL . 27.1 mt-10 -57.2 -26.45 60.68 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.889 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.561 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 60.5 t80 -66.7 -34.83 78.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.907 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 11.5 m-85 -95.22 -57.72 2.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.839 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.712 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -43.23 -28.69 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.119 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 3.6 tptm -68.9 -59.61 2.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.856 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.631 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.3 p -65.29 -28.75 45.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.137 179.841 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.631 ' CD2' HG13 ' A' ' 119' ' ' VAL . 91.5 m-85 -138.17 114.43 9.08 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.695 0.759 . . . . 0.0 110.922 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.67 -0.2 6.49 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.717 2.278 . . . . 0.0 112.335 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' SER . . . . . 0.474 ' O ' HG23 ' A' ' 145' ' ' THR . 17.2 p -88.85 -17.73 29.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.816 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' CYS . . . . . 0.433 ' HA ' ' CD1' ' A' ' 144' ' ' PHE . 7.7 t -48.08 139.36 8.25 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.895 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 25.2 mtp180 -100.71 -34.96 9.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.862 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.414 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 164.02 145.56 4.42 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.521 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.435 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -98.39 133.82 11.47 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.485 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 13.4 tptt -124.79 128.94 49.5 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.834 0.349 . . . . 0.0 110.867 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.1 p -114.43 138.05 45.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.176 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.873 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 24.4 m -83.76 143.25 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.12 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 17.1 mt -122.7 171.73 8.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.904 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -105.55 -179.88 4.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.815 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 15.8 pt20 -45.6 -39.86 8.19 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.925 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 44.2 p -74.88 -33.79 62.11 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.136 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 111.79 21.28 6.47 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.526 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 27.3 m -100.66 143.45 14.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.812 0.339 . . . . 0.0 111.16 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 3.7 t -54.55 107.26 0.27 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.859 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.49 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.5 mtmt -52.47 -29.95 27.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.885 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.468 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 122.53 19.23 3.16 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.49 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.873 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 27.3 p90 -163.8 167.77 20.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.921 0.391 . . . . 0.0 110.909 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.438 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -171.11 -159.91 18.34 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.498 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -153.58 151.52 29.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.9 0.381 . . . . 0.0 110.877 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.465 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 18.4 m -124.1 176.36 5.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.16 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 33.8 mtmt -136.83 158.23 44.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.433 ' CD1' ' HA ' ' A' ' 123' ' ' CYS . 91.5 m-85 -145.38 167.05 23.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.905 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' THR . . . . . 0.474 HG23 ' O ' ' A' ' 122' ' ' SER . 27.7 p -105.48 -25.41 12.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.147 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.413 ' OD2' HD12 ' A' ' 148' ' ' LEU . 6.4 t70 -119.5 111.15 17.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.509 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 2.9 tm-20 -51.43 -45.75 62.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.874 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 148' ' ' LEU . . . . . 0.413 HD12 ' OD2' ' A' ' 146' ' ' ASP . 24.0 mt -42.0 -42.2 2.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.915 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 57.0 mm-40 -76.23 -41.77 48.17 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.424 ' HG2' HD21 ' A' ' 98' ' ' LEU . 17.7 tt0 -40.84 -57.79 1.85 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.924 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 32.9 mmtm -62.53 -51.53 67.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.925 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 36.8 mtp180 -41.81 -40.97 2.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.452 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -67.88 -48.22 66.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.043 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.959 HD21 HD22 ' A' ' 98' ' ' LEU . 15.3 mt -42.61 -42.46 3.42 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.913 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.534 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.2 t -89.12 -48.13 7.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.13 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.534 ' N ' HG23 ' A' ' 155' ' ' THR . 18.2 mm-40 -63.56 -64.35 0.92 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.437 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 2.5 m -68.25 -8.09 36.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.926 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 158' ' ' GLN . . . . . 0.493 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 3.5 tp-100 -36.14 134.38 0.41 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 -179.871 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 46.57 41.32 12.52 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.474 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.683 ' HB3' HG22 ' A' ' 168' ' ' VAL . . . -57.39 117.44 4.12 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.848 0.356 . . . . 0.0 111.084 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.6 t -92.9 -33.5 5.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.163 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.94 -36.33 2.55 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.443 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 18.2 tp -87.94 114.83 24.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.829 0.347 . . . . 0.0 110.868 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 70.8 161.27 3.88 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.4 p -66.97 -3.83 8.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.946 0.403 . . . . 0.0 110.85 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -128.37 154.78 79.17 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.547 0.689 . . . . 0.0 110.917 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 171.6 14.16 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.696 2.264 . . . . 0.0 112.337 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.683 HG22 ' HB3' ' A' ' 160' ' ' ALA . 32.8 m -128.97 126.29 64.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.137 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -87.99 112.6 22.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.886 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.687 ' HB3' HD23 ' A' ' 154' ' ' LEU . 13.9 mt -85.94 146.07 26.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.913 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.2 m -157.57 169.04 25.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.43 HG22 HD11 ' A' ' 154' ' ' LEU . 40.9 t -94.45 102.41 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.121 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.439 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -95.69 117.56 30.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.094 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 174' ' ' ILE . . . . . 0.454 HG23 ' HD2' ' A' ' 175' ' ' PRO . 48.1 mt -54.17 133.2 60.23 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.565 0.697 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.454 ' HD2' HG23 ' A' ' 174' ' ' ILE . 53.6 Cg_endo -69.77 -41.37 4.32 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.665 2.243 . . . . 0.0 112.344 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 3.1 mmmp? -148.74 132.13 16.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.909 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -130.6 36.91 3.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.12 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 11.5 t 41.97 44.24 2.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.833 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -96.08 100.53 12.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.869 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 180' ' ' VAL . . . . . 0.769 HG22 ' HD3' ' A' ' 182' ' ' PRO . 3.1 p -137.23 132.16 46.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.161 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 8.1 ptmm? -116.75 77.99 8.76 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.6 0.714 . . . . 0.0 110.872 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.769 ' HD3' HG22 ' A' ' 180' ' ' VAL . 53.5 Cg_endo -69.76 80.23 0.89 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.664 2.242 . . . . 0.0 112.342 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 87.3 t -138.41 127.56 31.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.146 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -87.34 146.74 25.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.893 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.5 m -134.62 168.07 19.66 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.859 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -136.22 144.73 16.57 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.493 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.67 153.12 69.72 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.71 2.273 . . . . 0.0 112.344 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 73.5 p -145.41 158.1 43.9 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.885 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 66.4 m -102.64 156.53 17.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.854 -179.816 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.451 179.951 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.451 -0.26 . . . . 0.0 112.451 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 79.7 p -61.29 127.03 29.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.861 0.362 . . . . 0.0 110.875 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 41.5 p -148.67 132.82 17.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.853 -179.816 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -120.5 173.97 15.54 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.44 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.4 t -117.89 -54.36 2.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.926 0.393 . . . . 0.0 110.839 -179.705 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 1.1 t -158.56 153.77 25.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.868 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 51.67 79.01 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.503 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 104.24 1.29 Allowed 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.65 2.233 . . . . 0.0 112.342 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -123.39 142.64 50.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.886 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 10.0 m-85 -134.38 131.85 38.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.946 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 29.0 m -145.14 162.9 35.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.839 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.78 HD22 HD21 ' A' ' 154' ' ' LEU . 91.8 mt -131.35 135.39 47.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.933 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.6 t80 -86.83 131.43 34.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.896 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 30.8 m -127.09 150.57 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.176 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.43 -170.99 12.26 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.476 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 45.41 51.47 9.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.828 0.347 . . . . 0.0 110.861 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.487 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.0 mt -96.93 102.46 14.24 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.465 HG23 ' HB2' ' A' ' 166' ' ' LYS . 37.1 p -48.74 151.37 2.13 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.617 0.722 . . . . 0.0 111.125 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 2.95 3.09 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.699 2.266 . . . . 0.0 112.351 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -103.85 17.8 23.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.432 HG13 ' CE ' ' A' ' 111' ' ' MET . 2.8 t -125.57 134.34 66.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.167 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -124.04 170.79 10.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.849 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.46 ' CG ' ' N ' ' A' ' 110' ' ' GLY . 0.3 OUTLIER -47.06 -49.97 20.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.912 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.46 ' N ' ' CG ' ' A' ' 109' ' ' ASP . . . -47.61 -26.46 3.85 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.454 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.432 ' CE ' HG13 ' A' ' 107' ' ' VAL . 27.2 mtp -89.23 -57.6 2.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.766 0.317 . . . . 0.0 110.874 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.501 HD23 ' N ' ' A' ' 127' ' ' LYS . 15.3 tp -46.86 -28.43 1.57 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.977 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.408 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.3 t80 -76.5 -66.64 0.78 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.93 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.679 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.9 mt-10 -54.96 -25.98 33.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.891 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.455 ' CB ' HD13 ' A' ' 163' ' ' LEU . 72.2 t80 -68.27 -35.73 78.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.862 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.594 ' CD2' HG11 ' A' ' 142' ' ' VAL . 12.1 m-85 -95.09 -56.97 2.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.679 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -42.41 -27.89 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.16 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 15.2 ttmm -66.88 -60.71 2.42 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.946 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.573 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.0 p -63.32 -32.91 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.112 179.849 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.573 ' CD2' HG13 ' A' ' 119' ' ' VAL . 93.6 m-85 -134.75 115.41 12.32 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.749 0.785 . . . . 0.0 110.905 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -1.8 9.13 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.672 2.248 . . . . 0.0 112.321 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 3.1 m -86.41 -12.64 48.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.806 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' CYS . . . . . 0.448 ' CB ' ' HA ' ' A' ' 117' ' ' VAL . 13.5 t -50.27 135.19 21.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.587 ' HE ' HG22 ' A' ' 145' ' ' THR . 93.9 mtt180 -96.99 -37.67 10.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.408 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 166.54 143.44 3.75 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.472 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.42 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -96.9 134.54 11.81 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.516 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.501 ' N ' HD23 ' A' ' 112' ' ' LEU . 10.1 tptm -125.78 123.86 39.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.81 0.338 . . . . 0.0 110.886 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -113.5 123.35 69.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.083 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.98 HG22 ' O ' ' A' ' 139' ' ' TYR . 25.0 m -68.81 149.22 11.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.097 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.628 HD22 ' O ' ' A' ' 134' ' ' GLY . 40.9 mt -127.34 -177.02 3.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.482 ' O ' ' N ' ' A' ' 134' ' ' GLY . 13.2 t0 -116.94 176.09 5.28 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.799 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -39.86 -39.84 0.89 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.913 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -82.29 -29.57 31.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.14 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.628 ' O ' HD22 ' A' ' 130' ' ' LEU . . . 112.41 0.99 26.38 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.506 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.59 ' O ' HG23 ' A' ' 135' ' ' VAL . 9.6 m -76.21 118.99 23.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 111.155 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.507 ' HA ' HD23 ' A' ' 130' ' ' LEU . 6.9 t -35.01 108.27 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.473 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.4 mtmt -50.39 -35.63 29.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.883 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.62 19.07 2.11 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.473 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.98 ' O ' HG22 ' A' ' 129' ' ' VAL . 22.1 p90 -163.32 168.61 20.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.918 0.39 . . . . 0.0 110.911 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -173.65 -163.56 27.4 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.43 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -152.89 147.6 26.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.92 0.39 . . . . 0.0 110.87 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.594 HG11 ' CD2' ' A' ' 116' ' ' PHE . 16.4 m -119.08 171.08 7.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.145 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' LYS . . . . . 0.475 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 34.3 mtpt -127.63 161.76 28.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.555 ' CE2' HD12 ' A' ' 98' ' ' LEU . 93.8 m-85 -149.75 160.91 43.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.867 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' THR . . . . . 0.587 HG22 ' HE ' ' A' ' 124' ' ' ARG . 76.7 p -99.73 -20.03 16.46 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.169 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -119.09 126.32 51.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.843 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 14.5 tt0 -71.71 -25.98 62.31 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.919 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 23.9 mt -65.85 -47.95 73.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.437 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 24.4 mt-10 -73.56 -39.29 64.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.862 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.551 ' CD ' HD21 ' A' ' 98' ' ' LEU . 1.4 tm0? -46.09 -39.13 8.93 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.907 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.433 ' HD3' HD12 ' A' ' 154' ' ' LEU . 27.8 mmtp -79.99 -43.94 21.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.896 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 3.0 mtt-85 -48.04 -28.47 2.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.552 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -78.64 -34.51 46.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.08 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.78 HD21 HD22 ' A' ' 98' ' ' LEU . 22.9 mt -55.87 -36.94 68.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.3 t -92.28 -35.71 13.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.131 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -81.8 -66.88 0.83 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.873 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.467 ' C ' HD11 ' A' ' 170' ' ' LEU . 99.7 m -60.92 -10.26 5.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.861 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 158' ' ' GLN . . . . . 0.404 ' C ' ' O ' ' A' ' 157' ' ' CYS . 3.0 tp-100 -36.34 132.05 0.59 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.937 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 52.54 38.49 51.78 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.479 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.756 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -54.02 115.04 1.82 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.851 0.357 . . . . 0.0 111.086 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 40.2 t -93.98 -36.27 7.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.11 -35.51 1.73 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.545 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.474 ' CD2' HD12 ' A' ' 112' ' ' LEU . 27.6 tp -83.9 109.58 17.7 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.853 0.358 . . . . 0.0 110.915 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 74.91 174.71 34.16 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.501 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 38.4 m -84.56 28.09 0.68 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.897 0.379 . . . . 0.0 110.837 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 166' ' ' LYS . . . . . 0.465 ' HB2' HG23 ' A' ' 104' ' ' THR . 29.5 mttm -159.55 156.59 25.35 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.561 0.695 . . . . 0.0 110.909 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 170.19 17.15 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.685 2.257 . . . . 0.0 112.314 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.756 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 31.1 m -131.09 128.57 62.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.098 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 36.7 ttt180 -86.54 109.6 19.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.826 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.575 ' HB3' HD23 ' A' ' 154' ' ' LEU . 12.6 mt -85.42 145.9 27.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.94 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.9 m -162.16 177.76 9.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.827 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 8.8 t -100.68 103.22 14.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.163 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -77.86 157.95 29.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.07 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 57.7 mt -129.35 119.23 19.42 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.646 0.736 . . . . 0.0 111.121 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -41.75 3.93 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.685 2.257 . . . . 0.0 112.343 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 1.1 tppp? -113.88 97.83 6.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.878 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -39.61 -67.81 0.2 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.112 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 38.5 m -147.6 116.25 6.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.868 -179.801 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 8.3 tpt180 -67.05 82.99 0.12 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.886 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 82.0 t -128.36 125.34 63.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.117 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 17.9 mmtt -113.19 143.06 28.49 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.575 0.702 . . . . 0.0 110.884 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 156.99 61.91 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.68 2.253 . . . . 0.0 112.377 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 34.4 m -140.29 164.16 22.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.121 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -127.83 162.27 27.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.905 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 93.1 p -168.41 176.69 5.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.826 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 178.42 82.61 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.453 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 175.85 7.52 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.676 2.251 . . . . 0.0 112.385 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 1.8 m -145.34 172.72 12.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.847 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 59.8 p -109.7 170.14 8.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.908 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.482 -179.987 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.506 -0.237 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 1.8 t -81.48 107.61 14.38 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.841 0.353 . . . . 0.0 110.891 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 86.6 p -86.96 -44.54 11.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.841 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -118.17 -134.17 5.01 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.522 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 90.0 p -98.01 146.62 25.33 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.867 0.365 . . . . 0.0 110.87 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 33.5 t -109.96 36.17 3.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.852 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -50.65 149.46 6.63 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.459 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 82.0 0.77 Allowed 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.678 2.252 . . . . 0.0 112.308 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -151.34 114.67 4.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.93 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' TYR . . . . . 0.501 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 2.1 m-85 -135.35 118.69 16.72 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.889 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.7 m -135.56 139.42 43.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.88 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.593 HD21 ' CG ' ' A' ' 150' ' ' GLN . 98.4 mt -108.69 151.93 25.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.891 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.571 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 5.7 t80 -99.63 121.29 41.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.903 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.443 HG22 ' C ' ' A' ' 140' ' ' GLY . 23.6 m -110.0 137.12 43.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.121 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -126.91 176.58 17.67 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.472 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 53.37 52.45 13.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.826 0.346 . . . . 0.0 110.87 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.453 HD12 ' C ' ' A' ' 139' ' ' TYR . 24.8 mt -97.92 98.49 9.84 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.926 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.451 HG23 ' HB2' ' A' ' 166' ' ' LYS . 2.2 p -45.99 151.54 0.88 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.599 0.714 . . . . 0.0 111.162 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 0.0 6.32 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.665 2.243 . . . . 0.0 112.309 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -101.23 16.58 25.03 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.831 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.536 HG22 ' HE3' ' A' ' 111' ' ' MET . 61.5 t -129.41 131.93 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.095 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -118.69 171.54 8.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.869 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.4 ' CG ' ' N ' ' A' ' 110' ' ' GLY . 2.3 p30 -48.62 -49.48 36.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.799 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLY . . . . . 0.4 ' N ' ' CG ' ' A' ' 109' ' ' ASP . . . -38.36 -37.2 0.47 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.469 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.536 ' HE3' HG22 ' A' ' 107' ' ' VAL . 27.6 mtm -86.43 -45.46 11.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.779 0.323 . . . . 0.0 110.848 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 13.9 tp -54.12 -20.36 6.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.905 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.504 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 15.0 t80 -86.19 -60.67 1.94 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.925 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.76 ' HA ' HG12 ' A' ' 117' ' ' VAL . 33.7 mt-10 -59.38 -46.73 87.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.879 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.495 ' CG ' HD13 ' A' ' 163' ' ' LEU . 69.5 t80 -48.03 -33.81 8.51 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.896 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.495 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.2 m-85 -95.02 -66.61 0.9 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.881 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.76 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.59 -30.0 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.091 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.474 ' N ' ' O ' ' A' ' 116' ' ' PHE . 0.0 OUTLIER -65.08 -57.29 9.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.915 179.922 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.551 HG22 ' CE2' ' A' ' 120' ' ' TYR . 2.6 p -66.4 -34.8 72.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.144 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.551 ' CE2' HG22 ' A' ' 119' ' ' VAL . 91.8 m-85 -135.22 115.67 11.93 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-O 121.701 0.762 . . . . 0.0 110.954 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 2.9 3.14 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.69 2.26 . . . . 0.0 112.321 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.0 p -86.06 -18.94 31.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 29.2 t -53.06 135.96 36.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.882 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 18.3 mtt180 -98.88 -30.86 12.15 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.877 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.504 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 161.62 147.73 5.07 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.484 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -91.35 141.67 15.77 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.533 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.85 105.29 7.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.756 0.312 . . . . 0.0 110.874 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -98.23 149.14 5.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.155 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.992 HG21 ' CE1' ' A' ' 139' ' ' TYR . 19.5 m -95.86 142.57 13.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.102 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.639 HD23 ' HA ' ' A' ' 136' ' ' SER . 13.9 mt -130.0 173.4 10.76 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.898 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.421 ' O ' ' N ' ' A' ' 134' ' ' GLY . 26.3 t0 -107.34 171.97 7.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.865 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -44.54 -26.0 0.32 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.92 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 49.2 p -86.42 -33.94 20.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.124 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 109.14 20.62 7.81 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.502 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.582 ' O ' HG23 ' A' ' 135' ' ' VAL . 25.0 m -100.19 115.71 41.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.881 0.372 . . . . 0.0 111.101 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.639 ' HA ' HD23 ' A' ' 130' ' ' LEU . 8.4 t -37.65 103.64 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.837 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.8 mttm -43.59 -37.49 2.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.891 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 129.43 20.46 1.4 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.464 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.992 ' CE1' HG21 ' A' ' 129' ' ' VAL . 28.0 p90 -161.39 -179.31 7.27 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.922 0.391 . . . . 0.0 110.923 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.443 ' C ' HG22 ' A' ' 100' ' ' VAL . . . 177.17 -166.33 36.86 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.472 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 3.6 m-85 -153.37 139.37 18.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.86 0.362 . . . . 0.0 110.935 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.495 HG11 ' CD2' ' A' ' 116' ' ' PHE . 27.8 m -112.93 -178.23 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -140.36 163.8 31.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.923 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -149.83 167.12 27.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.89 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 58.6 p -102.33 -12.07 18.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.118 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -137.04 122.33 19.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.895 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.501 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 4.6 tt0 -60.11 -37.5 80.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.905 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 34.9 mt -52.39 -49.97 63.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.935 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -70.04 -33.29 71.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.878 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.593 ' CG ' HD21 ' A' ' 98' ' ' LEU . 28.6 tt0 -58.44 -57.05 14.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.957 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.572 ' HD3' HD12 ' A' ' 154' ' ' LEU . 30.2 mmtm -59.11 -42.28 90.16 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.899 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 40.6 mtt-85 -54.69 -30.62 56.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.902 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.487 ' O ' ' CD1' ' A' ' 170' ' ' LEU . . . -73.36 -34.53 65.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.06 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.796 HD23 ' HB3' ' A' ' 170' ' ' LEU . 43.9 mt -56.51 -40.36 74.9 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.905 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 15.1 t -92.43 -34.3 14.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.128 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 39.0 mm-40 -78.55 -58.3 3.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.864 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.587 ' C ' HD11 ' A' ' 170' ' ' LEU . 36.0 m -79.96 11.77 3.15 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 158' ' ' GLN . . . . . 0.477 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 3.5 tp-100 -52.92 137.81 31.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.955 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.62 33.46 0.59 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.469 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.472 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -53.17 116.73 2.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.815 0.34 . . . . 0.0 111.1 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' A' ' 162' ' ' GLY . 24.1 t -86.91 -35.41 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.137 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 162' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.18 -38.6 0.26 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.535 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.495 HD13 ' CG ' ' A' ' 115' ' ' PHE . 18.9 tp -87.42 115.36 24.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.871 0.367 . . . . 0.0 110.864 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.42 159.19 1.03 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.511 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 71.1 m -62.47 -16.62 56.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.936 0.398 . . . . 0.0 110.869 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 166' ' ' LYS . . . . . 0.451 ' HB2' HG23 ' A' ' 104' ' ' THR . 28.3 mttp -113.33 155.79 44.09 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.584 0.707 . . . . 0.0 110.905 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 173.51 10.86 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.757 2.304 . . . . 0.0 112.336 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.472 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 27.1 m -128.51 125.93 64.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.091 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 11.3 ttm180 -88.44 108.61 19.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.889 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.796 ' HB3' HD23 ' A' ' 154' ' ' LEU . 17.1 mt -84.23 147.27 27.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 4.5 m -163.95 177.42 8.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 39.7 t -103.55 101.7 12.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.571 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -93.33 147.84 22.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.116 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 57.7 mt -128.64 130.88 23.49 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.623 0.725 . . . . 0.0 111.148 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -39.22 6.76 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.645 2.23 . . . . 0.0 112.397 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 22.7 mmtt -110.02 78.38 1.12 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.908 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -134.85 -55.31 0.82 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.109 179.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 28.9 t -170.72 116.32 0.47 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.888 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 179' ' ' ARG . . . . . 0.547 ' HD3' HG22 ' A' ' 180' ' ' VAL . 0.0 OUTLIER -44.82 144.53 1.14 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.863 -179.948 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 180' ' ' VAL . . . . . 0.547 HG22 ' HD3' ' A' ' 179' ' ' ARG . 32.9 m -46.79 -20.0 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.15 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.407 ' HD3' ' C ' ' A' ' 181' ' ' LYS . 0.0 OUTLIER -170.6 131.15 0.88 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.566 0.698 . . . . 0.0 110.867 179.943 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.73 156.82 62.42 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.726 2.284 . . . . 0.0 112.333 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 183' ' ' VAL . . . . . 0.53 ' O ' HG23 ' A' ' 183' ' ' VAL . 35.1 m -58.88 118.02 2.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.132 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -147.99 161.71 40.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.919 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 2.0 t -139.34 144.14 38.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.85 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 126.72 84.29 0.5 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 187' ' ' PRO . . . . . 0.446 ' O ' ' C ' ' A' ' 188' ' ' SER . 53.8 Cg_endo -69.74 -32.87 17.79 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.73 2.287 . . . . 0.0 112.315 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 188' ' ' SER . . . . . 0.446 ' C ' ' O ' ' A' ' 187' ' ' PRO . 47.9 m 34.36 46.34 0.17 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.89 -179.784 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 2.8 m -149.34 161.61 41.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.854 -179.831 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.515 -179.983 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.433 -0.267 . . . . 0.0 112.433 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 74.4 m -62.49 109.77 1.48 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 0.0 110.845 -179.744 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 78.4 p -112.68 134.2 54.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.854 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -167.72 75.37 0.13 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.513 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 18.3 m -131.74 135.62 46.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.887 0.375 . . . . 0.0 110.847 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 31.2 t -58.06 141.44 50.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.852 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 75.24 87.81 0.26 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.497 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 98.01 0.66 Allowed 'Trans proline' 0 C--N 1.34 0.129 0 C-N-CA 122.679 2.253 . . . . 0.0 112.387 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -134.22 158.78 42.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.882 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 13.1 m-85 -125.61 89.18 2.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.934 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.7 p -110.07 138.01 47.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.83 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.65 HD12 ' CE2' ' A' ' 144' ' ' PHE . 97.5 mt -111.25 146.77 36.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.933 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -93.09 130.73 38.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.907 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.495 HG22 ' C ' ' A' ' 140' ' ' GLY . 17.9 m -123.55 149.27 27.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.15 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.99 -167.63 11.0 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 41.44 52.57 3.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.828 0.347 . . . . 0.0 110.861 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.416 HD12 ' C ' ' A' ' 139' ' ' TYR . 26.4 mt -101.04 101.63 12.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.561 ' OG1' HG23 ' A' ' 107' ' ' VAL . 75.9 p -47.01 150.2 1.41 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.556 0.693 . . . . 0.0 111.17 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 3.12 2.96 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.69 2.26 . . . . 0.0 112.359 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 -100.57 -0.74 37.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.561 HG23 ' OG1' ' A' ' 104' ' ' THR . 20.9 t -108.01 136.52 43.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.168 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -118.92 175.77 5.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.868 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -58.29 -36.2 72.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -53.65 -33.92 49.25 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.542 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.455 ' CE ' HG13 ' A' ' 107' ' ' VAL . 23.7 mtm -83.69 -55.01 4.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.806 0.336 . . . . 0.0 110.921 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.409 HD23 ' N ' ' A' ' 127' ' ' LYS . 29.4 tp -41.02 -37.37 0.81 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.943 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.435 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 17.6 t80 -70.19 -65.92 0.66 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.942 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.737 ' HA ' HG12 ' A' ' 117' ' ' VAL . 19.1 mt-10 -49.42 -53.19 24.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.897 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.602 ' CB ' HD13 ' A' ' 163' ' ' LEU . 58.2 t80 -44.58 -33.29 1.72 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.934 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.565 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.6 m-85 -93.99 -66.7 0.9 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.888 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.737 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.88 -31.09 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.108 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.456 ' N ' ' O ' ' A' ' 116' ' ' PHE . 0.5 OUTLIER -65.31 -61.28 2.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.949 179.884 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.631 HG22 ' CD2' ' A' ' 120' ' ' TYR . 1.6 p -64.65 -32.56 58.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.157 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.631 ' CD2' HG22 ' A' ' 119' ' ' VAL . 97.8 m-85 -131.23 113.82 15.94 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.657 0.741 . . . . 0.0 110.933 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 1.09 4.76 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.67 2.247 . . . . 0.0 112.331 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 1.4 p -104.14 31.95 4.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.804 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 41.9 t -91.12 124.9 35.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.472 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 22.5 mtp180 -79.18 -39.54 33.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.873 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.435 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 159.74 154.18 7.18 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.524 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -97.29 147.0 18.51 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.514 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.409 ' N ' HD23 ' A' ' 112' ' ' LEU . 2.7 tmtp? -137.66 112.58 9.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.839 0.352 . . . . 0.0 110.887 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' VAL . . . . . 0.526 ' O ' HG13 ' A' ' 128' ' ' VAL . 12.8 p -106.76 119.43 56.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.127 179.899 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.746 HG22 ' O ' ' A' ' 139' ' ' TYR . 20.1 m -63.75 155.5 5.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 20.8 mt -134.81 167.66 20.46 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.426 ' O ' ' N ' ' A' ' 134' ' ' GLY . 20.6 t70 -99.65 175.4 5.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' GLN . . . . . 0.452 ' HG3' ' N ' ' A' ' 133' ' ' THR . 20.2 pt20 -43.38 -43.33 5.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' THR . . . . . 0.452 ' N ' ' HG3' ' A' ' 132' ' ' GLN . 34.3 p -72.65 -28.47 62.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.166 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 106.48 24.59 6.69 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.523 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 31.3 m -103.45 137.18 32.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.821 0.344 . . . . 0.0 111.1 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 1.6 t -48.95 110.46 0.36 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.835 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.461 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.1 mtmt -57.16 -33.86 67.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.882 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 127.31 17.54 2.17 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.537 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.746 ' O ' HG22 ' A' ' 129' ' ' VAL . 24.7 p90 -162.2 174.16 13.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.943 0.402 . . . . 0.0 110.949 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.495 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -177.94 -161.29 25.86 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.471 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -153.09 148.19 26.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.85 0.357 . . . . 0.0 110.897 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.565 HG11 ' CD2' ' A' ' 116' ' ' PHE . 16.9 m -118.63 -177.16 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.175 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' LYS . . . . . 0.472 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 40.5 mtmt -144.17 157.21 44.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.878 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.65 ' CE2' HD12 ' A' ' 98' ' ' LEU . 76.3 m-85 -146.93 160.72 41.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 32.8 p -102.01 -16.08 16.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.191 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -120.28 110.72 16.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.836 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 11.9 tt0 -57.91 -41.59 82.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.887 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 75.4 mt -48.16 -47.96 34.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.935 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.557 ' N ' ' CD ' ' A' ' 149' ' ' GLU . 0.0 OUTLIER -72.22 -44.6 62.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.887 179.899 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.437 ' C ' ' O ' ' A' ' 149' ' ' GLU . 20.2 tt0 -34.84 -58.59 0.51 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.93 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 12.6 mmtp -63.49 -34.35 77.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.912 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' ARG . . . . . 0.577 ' HB3' ' CE1' ' A' ' 120' ' ' TYR . 4.0 tpt180 -51.61 -41.03 60.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.849 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -71.77 -44.77 63.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.091 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.764 HD23 ' HB3' ' A' ' 170' ' ' LEU . 29.7 mt -50.47 -38.34 43.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.472 HG23 ' HG2' ' A' ' 156' ' ' GLU . 14.6 t -92.57 -37.08 12.66 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.472 ' HG2' HG23 ' A' ' 155' ' ' THR . 6.7 mm-40 -83.05 -65.02 1.06 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.897 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.494 ' N ' ' O ' ' A' ' 153' ' ' ALA . 76.2 m -62.8 -8.22 6.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.921 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -37.71 128.96 1.14 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.858 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 50.36 38.89 34.99 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.464 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.517 ' O ' HG22 ' A' ' 168' ' ' VAL . . . -60.0 116.35 4.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.813 0.34 . . . . 0.0 111.141 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.42 ' O ' ' C ' ' A' ' 162' ' ' GLY . 23.9 t -85.28 -37.85 12.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.144 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 162' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.75 -37.2 0.21 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.514 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.602 HD13 ' CB ' ' A' ' 115' ' ' PHE . 17.0 tp -86.38 114.52 23.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.848 0.356 . . . . 0.0 110.926 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 64.54 151.78 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.487 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 9.4 t -51.3 -25.28 5.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.948 0.404 . . . . 0.0 110.835 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 166' ' ' LYS . . . . . 0.402 ' HB2' HG23 ' A' ' 104' ' ' THR . 53.5 mttt -106.45 156.18 37.46 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.568 0.699 . . . . 0.0 110.892 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -175.42 1.15 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.682 2.255 . . . . 0.0 112.323 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.517 HG22 ' O ' ' A' ' 160' ' ' ALA . 12.6 m -137.84 128.63 37.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.139 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 7.8 mtp85 -88.51 111.89 22.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.846 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.764 ' HB3' HD23 ' A' ' 154' ' ' LEU . 15.3 mt -91.83 140.47 29.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 13.9 m -155.83 -177.61 6.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.833 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 4.7 t -102.69 100.13 9.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.149 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -78.39 172.56 13.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.119 179.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 174' ' ' ILE . . . . . 0.527 HG22 ' H ' ' A' ' 176' ' ' LYS . 10.8 mt -141.35 129.13 12.01 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.594 0.711 . . . . 0.0 111.136 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.69 4.32 2.23 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.71 2.274 . . . . 0.0 112.304 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.527 ' H ' HG22 ' A' ' 174' ' ' ILE . 20.9 ttmt -119.98 -56.97 1.98 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.92 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . 37.75 38.83 0.18 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.143 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 92.9 p -171.4 143.68 1.85 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.85 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 17.2 tpp85 -112.03 80.93 1.38 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.859 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 84.1 t -88.7 148.41 4.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.114 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 59.2 tttp -149.04 136.53 11.08 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.607 0.717 . . . . 0.0 110.897 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 102.11 0.98 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.685 2.257 . . . . 0.0 112.345 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 89.8 t -53.81 117.62 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.123 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -106.47 136.14 46.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.887 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 5.9 m -137.51 112.31 8.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -118.58 74.22 0.3 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.446 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 171.95 13.58 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.678 2.252 . . . . 0.0 112.315 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 6.3 t -140.41 111.2 6.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.896 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 50.0 p -169.49 169.64 8.73 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.864 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.272 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.486 -179.972 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.447 -0.261 . . . . 0.0 112.447 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 1.1 t -140.17 147.72 40.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.88 0.371 . . . . 0.0 110.892 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.1 t -104.57 89.36 3.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' GLY . . . . . 0.446 ' O ' ' C ' ' A' ' 91' ' ' SER . . . 76.08 99.06 0.14 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.503 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' SER . . . . . 0.446 ' C ' ' O ' ' A' ' 90' ' ' GLY . 11.4 t -34.98 135.5 0.2 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.875 0.369 . . . . 0.0 110.843 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 60.7 m -117.1 -56.22 2.27 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.855 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.417 ' HA2' ' HD2' ' A' ' 94' ' ' PRO . . . -178.41 107.85 0.24 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.469 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.417 ' HD2' ' HA2' ' A' ' 93' ' ' GLY . 53.7 Cg_endo -69.82 84.07 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.624 2.216 . . . . 0.0 112.322 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -146.04 133.37 20.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.869 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' TYR . . . . . 0.495 ' CE2' ' HB2' ' A' ' 147' ' ' GLU . 47.5 m-85 -131.15 106.41 8.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.944 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 11.1 m -120.65 154.79 35.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.849 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.531 HD22 HD21 ' A' ' 154' ' ' LEU . 22.4 mt -120.37 144.48 47.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.927 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -94.96 123.06 38.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.9 m -114.88 149.05 17.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.44 -175.1 13.65 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.509 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 50.83 50.01 19.89 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.806 0.336 . . . . 0.0 110.897 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 30.9 mt -98.94 104.34 16.38 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.924 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.631 HG23 ' HB2' ' A' ' 166' ' ' LYS . 14.9 p -49.08 150.16 3.01 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.583 0.706 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 2.95 3.08 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.651 2.234 . . . . 0.0 112.342 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -99.69 -13.4 19.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.865 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.724 HG22 ' HE3' ' A' ' 111' ' ' MET . 73.1 t -96.2 138.95 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.153 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.94 -176.11 3.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.849 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -65.4 -41.74 93.33 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.88 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.47 -34.47 13.78 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.475 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.724 ' HE3' HG22 ' A' ' 107' ' ' VAL . 25.5 mtm -81.71 -49.61 10.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.816 0.341 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.9 tp -50.86 -34.42 27.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.925 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' TYR . . . . . . . . . . . . . 12.9 t80 -68.8 -61.45 1.8 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.946 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.769 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.1 mt-10 -57.28 -53.86 53.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.847 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.426 ' HB2' HD13 ' A' ' 163' ' ' LEU . 69.2 t80 -42.3 -32.46 0.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.526 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.6 m-85 -95.17 -67.97 0.83 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.769 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.7 -29.37 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.489 ' N ' ' O ' ' A' ' 116' ' ' PHE . 19.1 tptt -67.46 -60.67 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.68 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.1 p -65.18 -31.91 55.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.133 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.68 ' CD2' HG13 ' A' ' 119' ' ' VAL . 97.3 m-85 -134.11 114.3 12.7 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.647 0.737 . . . . 0.0 110.965 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.31 8.25 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.678 2.252 . . . . 0.0 112.377 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 87.2 p -85.9 -16.45 38.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.834 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.4 t -52.22 139.7 23.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.839 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 42.0 mtm180 -105.0 -33.57 8.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.875 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 166.66 145.62 4.54 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.451 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.454 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -95.25 137.54 13.49 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.475 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -125.87 122.43 36.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.783 0.325 . . . . 0.0 110.914 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.0 p -113.62 138.14 44.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.137 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.976 HG22 ' O ' ' A' ' 139' ' ' TYR . 33.7 m -86.17 152.08 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.131 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.572 HD23 ' HA ' ' A' ' 136' ' ' SER . 17.8 mt -130.84 176.37 8.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.486 ' O ' ' N ' ' A' ' 134' ' ' GLY . 25.6 t0 -107.52 174.27 5.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -39.6 -40.27 0.86 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.909 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 30.4 p -74.83 -33.75 62.22 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.158 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 112.83 17.78 7.75 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.498 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 34.0 m -97.88 133.47 39.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.872 0.368 . . . . 0.0 111.105 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.572 ' HA ' HD23 ' A' ' 130' ' ' LEU . 2.6 t -43.2 105.68 0.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.889 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.499 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 27.1 mtmt -50.64 -35.82 32.39 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.897 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 129.27 20.22 1.45 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.483 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.976 ' O ' HG22 ' A' ' 129' ' ' VAL . 27.4 p90 -163.81 169.06 18.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.909 0.385 . . . . 0.0 110.95 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -171.87 -163.29 25.54 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.446 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -153.58 148.67 26.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.89 0.376 . . . . 0.0 110.898 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.526 HG11 ' CD2' ' A' ' 116' ' ' PHE . 27.8 m -124.6 168.49 17.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 143' ' ' LYS . . . . . 0.448 ' N ' ' HD3' ' A' ' 143' ' ' LYS . 0.0 OUTLIER -125.97 159.19 33.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.936 179.896 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -145.37 157.5 44.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.915 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 76.4 p -96.73 -19.22 19.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.169 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -120.64 120.58 36.14 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.863 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.495 ' HB2' ' CE2' ' A' ' 96' ' ' TYR . 0.1 OUTLIER -67.31 -39.19 85.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 39.3 mt -52.62 -34.44 51.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.911 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -85.06 -37.07 20.76 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.876 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 -43.84 -57.28 3.35 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.537 ' HA ' HD12 ' A' ' 154' ' ' LEU . 73.2 mttt -65.07 -27.53 68.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 15.1 ttt180 -59.94 -40.88 90.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.849 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.464 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -69.33 -46.12 67.85 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.136 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.76 HD23 ' HB3' ' A' ' 170' ' ' LEU . 29.7 mt -43.62 -40.82 4.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.906 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.505 HG23 ' N ' ' A' ' 156' ' ' GLU . 10.9 t -92.52 -45.32 8.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.119 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.505 ' N ' HG23 ' A' ' 155' ' ' THR . 12.2 mm-40 -67.38 -60.08 2.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.894 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.464 ' N ' ' O ' ' A' ' 153' ' ' ALA . 4.8 m -78.21 9.59 3.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 158' ' ' GLN . . . . . 0.43 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.8 tp-100 -51.85 128.73 24.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.894 -179.871 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 51.37 35.23 35.25 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.491 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -57.94 121.94 11.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.794 0.33 . . . . 0.0 111.122 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 25.6 t -93.38 -34.72 6.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.65 -34.12 0.24 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.501 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.426 HD13 ' HB2' ' A' ' 115' ' ' PHE . 29.1 tp -91.57 115.69 28.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.822 0.344 . . . . 0.0 110.895 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 164' ' ' GLY . . . . . 0.449 ' HA3' HG21 ' A' ' 107' ' ' VAL . . . 65.17 146.14 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.531 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 165' ' ' SER . . . . . 0.445 ' HB3' HG21 ' A' ' 104' ' ' THR . 6.2 t -48.97 -20.45 0.52 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.912 0.387 . . . . 0.0 110.86 -179.753 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 166' ' ' LYS . . . . . 0.631 ' HB2' HG23 ' A' ' 104' ' ' THR . 16.2 mtmt -108.48 155.29 40.69 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.586 0.708 . . . . 0.0 110.916 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 -173.07 0.65 Allowed 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.672 2.248 . . . . 0.0 112.38 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.491 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 34.6 m -139.62 124.53 20.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.075 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 39.8 ttm-85 -91.4 99.99 12.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.868 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.76 ' HB3' HD23 ' A' ' 154' ' ' LEU . 14.0 mt -76.36 145.73 39.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.905 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.421 ' N ' ' CD2' ' A' ' 154' ' ' LEU . 4.3 m -160.74 178.32 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.847 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 36.9 t -105.61 104.17 16.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.143 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -93.37 131.05 38.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.115 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 174' ' ' ILE . . . . . 0.674 HG23 ' HD2' ' A' ' 175' ' ' PRO . 84.7 mt -128.36 138.52 33.21 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.59 0.709 . . . . 0.0 111.144 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.674 ' HD2' HG23 ' A' ' 174' ' ' ILE . 53.8 Cg_endo -69.75 152.29 69.35 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.699 2.266 . . . . 0.0 112.355 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 17.9 ttpt -41.91 108.85 0.1 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.907 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -40.45 -59.06 1.41 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.097 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 3.4 m -155.33 178.26 10.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.859 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 69.6 ttt180 -90.3 134.23 34.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.929 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 78.2 t -109.74 132.98 56.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.157 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -136.02 144.96 50.48 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.569 0.699 . . . . 0.0 110.898 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.84 101.29 0.9 Allowed 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.627 2.218 . . . . 0.0 112.33 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 79.7 t -101.21 111.23 30.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.147 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.9 tt0 -104.39 129.39 52.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.911 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 79.6 p -162.44 147.9 12.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.842 -179.748 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -163.52 146.25 11.41 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.498 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 172.13 13.18 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.698 2.265 . . . . 0.0 112.334 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 67.9 p -171.25 164.68 7.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.845 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 36.0 t -163.9 159.1 20.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.853 -179.784 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.497 179.995 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.288 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 79.5 p -58.76 155.01 13.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.884 0.374 . . . . 0.0 110.865 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 19.5 m -71.36 89.1 0.9 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.849 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -145.99 -119.9 1.25 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.506 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 30.0 t -55.05 150.3 10.65 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.928 0.395 . . . . 0.0 110.839 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 46.3 m -118.09 55.64 0.88 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.849 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 39.03 73.45 0.16 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.496 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' PRO . . . . . 0.403 ' HG2' ' CE1' ' A' ' 96' ' ' TYR . 53.6 Cg_endo -69.84 173.56 10.86 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.668 2.245 . . . . 0.0 112.312 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -85.76 143.27 28.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.876 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' TYR . . . . . 0.5 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 21.1 m-85 -124.22 127.49 47.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.902 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 12.3 p -137.48 145.45 43.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.864 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.753 HD22 HD21 ' A' ' 154' ' ' LEU . 47.1 mt -120.99 139.17 53.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.945 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.907 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 12.3 t80 -90.22 131.07 36.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.899 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.521 HG22 ' C ' ' A' ' 140' ' ' GLY . 25.2 m -121.99 155.77 26.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.142 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -142.92 178.17 21.4 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.449 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 52.93 53.87 11.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.817 0.341 . . . . 0.0 110.831 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.406 HD23 ' HA ' ' A' ' 103' ' ' LEU . 24.6 mt -100.35 100.17 10.92 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.905 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.532 ' OG1' HG23 ' A' ' 107' ' ' VAL . 58.5 p -46.71 150.0 1.35 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.552 0.691 . . . . 0.0 111.172 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 2.75 3.25 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -102.43 6.81 40.34 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.835 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 1.086 HG13 ' HE2' ' A' ' 111' ' ' MET . 12.9 t -119.6 129.93 74.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.124 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -116.95 177.03 4.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.86 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -51.05 -53.75 30.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.836 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -38.74 -35.61 0.37 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.44 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' MET . . . . . 1.086 ' HE2' HG13 ' A' ' 107' ' ' VAL . 48.7 mtp -81.93 -59.43 2.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.807 0.336 . . . . 0.0 110.901 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.486 HD23 ' N ' ' A' ' 127' ' ' LYS . 22.5 tp -42.08 -31.43 0.36 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.914 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.541 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 10.9 t80 -72.24 -66.59 0.63 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.942 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.738 ' HA ' HG12 ' A' ' 117' ' ' VAL . 46.8 mt-10 -52.43 -47.39 66.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.873 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.508 ' CZ ' ' HB2' ' A' ' 163' ' ' LEU . 60.4 t80 -48.11 -33.08 7.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.896 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.492 ' CD2' HG11 ' A' ' 142' ' ' VAL . 8.1 m-85 -94.99 -66.23 0.93 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.904 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.738 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.74 -31.45 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.122 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.451 ' N ' ' O ' ' A' ' 116' ' ' PHE . 30.3 tttp -64.66 -58.16 7.06 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.878 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.454 HG13 ' CD2' ' A' ' 120' ' ' TYR . 2.8 p -66.7 -33.97 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.148 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.559 ' CD1' ' HB3' ' A' ' 149' ' ' GLU . 90.2 m-85 -129.55 115.09 18.21 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.714 0.768 . . . . 0.0 110.935 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.7 Cg_endo -69.79 -2.72 10.67 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.678 2.252 . . . . 0.0 112.361 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 56.4 m -104.85 39.87 1.61 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 49.6 t -98.17 132.43 43.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.89 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.448 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 19.7 mmt180 -83.26 -35.26 25.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 -179.847 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.541 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 148.34 139.99 3.26 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.464 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.768 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -82.88 148.61 25.97 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.509 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.486 ' N ' HD23 ' A' ' 112' ' ' LEU . 12.5 tptp -139.47 117.25 11.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.84 0.352 . . . . 0.0 110.881 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -106.04 146.76 12.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.145 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.81 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 30.1 m -93.66 150.93 3.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.08 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 15.5 mt -129.57 165.43 21.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.864 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -95.7 -177.2 3.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.848 179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -50.08 -37.6 34.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.941 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 41.0 p -75.16 -33.67 61.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.172 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 114.64 18.46 6.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.472 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 34.9 m -98.06 144.57 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.844 0.354 . . . . 0.0 111.114 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.9 t -56.79 105.06 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.48 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.1 mtmt -47.84 -29.18 3.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.89 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 121.0 18.37 3.88 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.542 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.81 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 9.9 p90 -161.8 175.89 11.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.926 0.393 . . . . 0.0 110.926 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.521 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -178.88 -162.23 27.94 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.44 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -153.64 146.32 24.24 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.896 0.379 . . . . 0.0 110.895 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.768 HG12 ' HA2' ' A' ' 126' ' ' GLY . 15.8 m -121.2 -176.61 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 143' ' ' LYS . . . . . 0.448 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 39.8 mtmt -144.56 162.78 35.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.886 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -149.78 159.04 44.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 69.8 p -93.92 -33.27 13.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.129 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 21.2 t0 -108.53 115.89 30.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.871 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.5 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 7.6 tt0 -59.62 -36.25 75.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.924 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 62.9 mt -53.31 -40.11 64.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.91 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.559 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 61.7 mt-10 -85.79 -22.48 27.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.856 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.517 ' O ' HD11 ' A' ' 98' ' ' LEU . 18.3 tt0 -57.73 -53.67 55.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.91 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 3.2 mtpm? -69.24 -43.62 73.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.935 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 53.1 mtt-85 -45.54 -35.96 4.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.844 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.405 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -72.2 -43.43 64.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.753 HD21 HD22 ' A' ' 98' ' ' LEU . 17.6 mt -46.1 -41.79 12.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 156' ' ' GLU . 12.3 t -91.37 -48.96 6.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.572 ' N ' HG23 ' A' ' 155' ' ' THR . 43.2 mm-40 -62.07 -66.5 0.53 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.479 ' CB ' HD11 ' A' ' 170' ' ' LEU . 66.4 m -62.83 -13.01 28.47 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.89 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 4.2 tp-100 -37.68 131.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.926 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 59.9 30.24 69.35 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.485 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.838 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -52.94 111.35 0.65 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.834 0.35 . . . . 0.0 111.083 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.4 t -89.35 -38.82 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.141 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -41.1 -32.35 0.6 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.451 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.508 ' HB2' ' CZ ' ' A' ' 115' ' ' PHE . 24.1 tp -90.84 116.27 28.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.857 0.36 . . . . 0.0 110.95 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 62.08 143.03 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.45 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 50.2 m -42.08 -32.16 0.43 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.934 0.397 . . . . 0.0 110.868 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 24.5 mttm -100.76 154.38 37.2 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.535 0.684 . . . . 0.0 110.888 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -178.99 2.6 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.697 2.264 . . . . 0.0 112.368 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.838 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 34.1 m -131.48 125.35 56.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.099 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 35.0 ttm180 -88.57 104.96 17.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.868 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.522 ' HB3' HD23 ' A' ' 154' ' ' LEU . 9.1 mt -84.18 145.86 28.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.938 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 5.1 m -159.24 173.72 15.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.855 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 172' ' ' VAL . . . . . 0.404 HG22 ' CD1' ' A' ' 154' ' ' LEU . 5.4 t -95.25 90.79 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.163 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.907 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -78.77 167.01 21.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.095 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 63.2 mt -124.23 123.08 26.01 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.64 0.733 . . . . 0.0 111.126 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.4 ' O ' ' C ' ' A' ' 176' ' ' LYS . 53.9 Cg_endo -69.83 -179.92 3.28 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.682 2.254 . . . . 0.0 112.326 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.4 ' C ' ' O ' ' A' ' 175' ' ' PRO . 45.3 mtpt -37.37 114.62 0.34 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.906 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -122.9 103.78 8.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.096 179.814 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 28.5 t -64.89 140.45 58.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.876 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 21.0 ttt-85 -112.85 151.24 30.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.851 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 180' ' ' VAL . . . . . 0.435 ' O ' HG23 ' A' ' 180' ' ' VAL . 28.3 m -99.14 126.79 52.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.103 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 11.5 tptt -86.78 131.85 44.03 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.518 0.675 . . . . 0.0 110.906 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 161.99 43.8 Favored 'Trans proline' 0 N--CA 1.465 -0.149 0 C-N-CA 122.713 2.275 . . . . 0.0 112.344 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 35.6 m -109.05 129.97 62.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.077 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -120.52 151.56 39.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 3.3 t -160.96 113.62 1.94 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.871 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -60.02 145.02 46.47 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.453 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 149.63 67.03 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.684 2.256 . . . . 0.0 112.333 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 4.0 t -126.22 126.24 43.72 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.854 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 32.7 t -83.23 -48.24 10.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.835 -179.814 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 -179.975 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 89.2 p -136.28 155.16 50.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.859 0.362 . . . . 0.0 110.859 -179.721 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 82.0 p 42.53 41.95 2.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.854 -179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -67.25 -54.89 18.09 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.465 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 73.1 m -103.08 151.34 22.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.866 0.365 . . . . 0.0 110.894 -179.755 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 95.3 p -70.35 174.42 5.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.83 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 112.0 72.14 0.62 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.496 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 91.62 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.684 2.256 . . . . 0.0 112.394 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -154.87 135.41 13.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.89 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 -142.92 114.21 7.84 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.917 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 77.3 p -129.53 157.36 42.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.867 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.855 HD22 HD21 ' A' ' 154' ' ' LEU . 87.1 mt -127.47 148.65 50.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.904 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.433 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 8.4 t80 -95.78 130.49 42.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.882 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -122.72 139.35 49.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.147 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -126.9 178.98 16.57 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.484 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 53.34 51.47 15.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.85 0.357 . . . . 0.0 110.903 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' LEU . . . . . 0.501 HD12 ' C ' ' A' ' 139' ' ' TYR . 21.3 mt -95.48 101.05 12.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.694 ' OG1' HG23 ' A' ' 107' ' ' VAL . 63.3 p -48.49 150.11 2.54 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.588 0.709 . . . . 0.0 111.133 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 2.96 3.04 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.679 2.253 . . . . 0.0 112.334 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -102.75 2.5 35.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.843 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.694 HG23 ' OG1' ' A' ' 104' ' ' THR . 5.7 t -108.49 136.64 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.116 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -124.66 168.43 13.17 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.906 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -46.29 -45.9 17.62 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.833 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.97 -36.45 20.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.512 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.434 ' HE2' HG13 ' A' ' 107' ' ' VAL . 19.2 mtp -78.56 -58.4 3.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.772 0.32 . . . . 0.0 110.846 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.594 HD23 ' N ' ' A' ' 127' ' ' LYS . 19.4 tp -45.32 -36.27 4.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.935 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.529 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 7.4 t80 -67.24 -61.11 2.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.901 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.751 ' HA ' HG12 ' A' ' 117' ' ' VAL . 44.6 mt-10 -57.17 -54.58 45.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.872 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.489 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 69.5 t80 -42.08 -32.19 0.44 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.855 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.586 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.8 m-85 -95.19 -67.54 0.85 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.892 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.751 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.69 -29.17 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.081 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.496 ' N ' ' O ' ' A' ' 116' ' ' PHE . 46.3 tttp -67.88 -57.19 6.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.907 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.677 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.8 p -71.15 -25.1 24.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.114 179.856 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.677 ' CD2' HG13 ' A' ' 119' ' ' VAL . 95.9 m-85 -135.26 109.17 10.44 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.702 0.763 . . . . 0.0 110.926 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' PRO . . . . . 0.426 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.4 Cg_endo -69.81 2.96 3.09 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.716 2.278 . . . . 0.0 112.357 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 15.0 m -109.97 30.83 6.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.834 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 42.6 t -92.83 132.12 37.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.903 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.46 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 42.2 mtp180 -83.31 -29.13 28.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.909 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.529 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 147.0 139.24 3.25 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.488 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.68 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -93.24 135.9 12.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.512 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' LYS . . . . . 0.594 ' N ' HD23 ' A' ' 112' ' ' LEU . 0.1 OUTLIER -121.4 143.71 49.07 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.784 0.326 . . . . 0.0 110.95 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.97 127.16 72.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.13 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.816 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 7.0 m -76.32 138.19 21.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.149 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 136' ' ' SER . 26.1 mt -116.28 160.68 20.12 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -87.88 -176.58 5.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -52.85 -37.24 60.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.921 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 27.6 p -75.76 -21.81 57.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.091 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.99 22.36 10.12 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.456 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 24.0 m -106.3 140.83 23.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.797 0.332 . . . . 0.0 111.159 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' SER . . . . . 0.438 ' HA ' HD23 ' A' ' 130' ' ' LEU . 2.7 t -47.06 108.63 0.15 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.867 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.473 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 30.4 mtmt -54.64 -32.26 58.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.912 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.24 17.44 2.44 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.491 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.816 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 17.2 p90 -163.76 171.27 15.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.913 0.387 . . . . 0.0 110.937 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -172.75 -162.59 25.13 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.447 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -154.0 142.4 20.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.878 0.37 . . . . 0.0 110.896 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.68 HG12 ' HA2' ' A' ' 126' ' ' GLY . 29.0 m -117.24 170.9 6.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.126 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 143' ' ' LYS . . . . . 0.46 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -131.05 160.54 34.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.948 179.849 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.41 ' CE2' HG23 ' A' ' 142' ' ' VAL . 86.2 m-85 -148.81 162.53 39.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.903 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 33.7 p -98.41 -26.6 14.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.154 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' ASP . . . . . 0.431 ' CG ' ' OE1' ' A' ' 149' ' ' GLU . 4.9 t70 -112.1 119.73 39.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.864 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -67.29 -31.65 72.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.908 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 21.7 mt -56.81 -54.01 51.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.893 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 150' ' ' GLN . 1.9 mp0 -64.81 -45.87 84.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.905 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.449 ' C ' ' O ' ' A' ' 149' ' ' GLU . 21.7 tt0 -33.46 -46.86 0.2 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.949 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 151' ' ' LYS . . . . . 0.434 ' O ' ' N ' ' A' ' 154' ' ' LEU . 13.8 mmtp -66.98 -55.76 13.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -38.69 -35.12 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.599 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -72.72 -44.89 61.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.855 HD21 HD22 ' A' ' 98' ' ' LEU . 16.1 mt -47.16 -38.95 12.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.925 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.616 HG23 ' N ' ' A' ' 156' ' ' GLU . 12.1 t -92.47 -51.12 5.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.145 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.616 ' N ' HG23 ' A' ' 155' ' ' THR . 79.1 mm-40 -64.35 -57.79 8.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.632 ' C ' HD11 ' A' ' 170' ' ' LEU . 53.3 m -75.18 5.33 5.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.871 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 3.3 tp-100 -53.1 137.45 33.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.903 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 45.48 37.24 6.39 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.468 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.862 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -54.89 116.19 2.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.894 0.378 . . . . 0.0 111.104 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 32.7 t -94.74 -33.45 4.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.16 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -45.04 -33.55 3.77 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.51 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.489 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 56.4 tp -85.63 115.24 23.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.866 0.365 . . . . 0.0 110.915 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 69.88 175.21 14.81 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.51 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 11.7 m -84.19 25.87 0.81 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.92 0.391 . . . . 0.0 110.825 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' LYS . . . . . 0.468 ' HB2' HG23 ' A' ' 104' ' ' THR . 19.7 mttp -157.24 157.05 30.16 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.585 0.707 . . . . 0.0 110.909 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 170.24 17.02 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.654 2.236 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.862 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 30.1 m -132.37 125.98 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.129 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 36.3 ttt85 -88.89 117.12 27.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.665 ' HB3' HD23 ' A' ' 154' ' ' LEU . 11.7 mt -93.24 139.37 30.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.894 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 15.9 m -156.55 173.0 17.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.836 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 15.6 t -93.79 99.21 9.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.134 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 173' ' ' ALA . . . . . 0.433 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -82.23 128.36 34.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.06 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 174' ' ' ILE . . . . . 0.636 HG22 ' H ' ' A' ' 176' ' ' LYS . 25.8 mt -79.1 126.88 81.05 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.599 0.714 . . . . 0.0 111.136 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 4.63 2.09 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.723 2.282 . . . . 0.0 112.348 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.636 ' H ' HG22 ' A' ' 174' ' ' ILE . 34.4 tttt -144.03 148.83 35.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.944 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 177' ' ' ALA . . . . . 0.431 ' N ' ' HG2' ' A' ' 176' ' ' LYS . . . -166.14 151.41 8.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.069 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 95.5 p -135.38 130.74 35.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.907 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 15.7 ttt180 -150.56 123.14 8.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.898 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 94.2 t -111.51 88.31 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.158 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.428 ' CG ' ' HD2' ' A' ' 182' ' ' PRO . 45.3 tttp -81.31 138.63 48.46 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.609 0.719 . . . . 0.0 110.862 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.428 ' HD2' ' CG ' ' A' ' 181' ' ' LYS . 53.5 Cg_endo -69.82 178.83 4.2 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.662 2.242 . . . . 0.0 112.357 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 9.8 p -109.22 131.58 59.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.104 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.1 mp0 -80.62 128.97 34.22 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.919 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 78.4 p -128.96 107.87 9.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.872 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 174.86 143.62 4.55 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.488 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 -179.25 2.77 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.672 2.248 . . . . 0.0 112.33 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 17.4 m -145.53 157.54 43.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.836 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.9 t -51.14 156.05 1.17 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.828 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.479 179.983 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 55.7 p -146.05 142.03 28.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.826 0.346 . . . . 0.0 110.881 -179.731 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 32.3 m -74.89 -46.0 39.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.813 -179.772 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.68 89.81 2.01 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.504 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 76.8 p -131.91 139.21 48.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.891 0.377 . . . . 0.0 110.879 -179.768 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 3.5 t -59.08 153.98 16.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.818 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -83.75 149.09 25.31 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.501 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 150.67 68.48 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.667 2.245 . . . . 0.0 112.335 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -83.29 160.17 21.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' TYR . . . . . 0.466 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 4.3 m-85 -120.03 104.74 10.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.946 -179.881 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 35.4 p -126.72 155.02 43.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.836 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.611 HD21 ' CD ' ' A' ' 150' ' ' GLN . 85.9 mt -124.87 139.57 53.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -90.27 125.97 35.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.415 HG22 ' C ' ' A' ' 140' ' ' GLY . 15.9 m -120.8 141.43 41.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.131 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -129.78 -175.87 14.21 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.431 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 51.13 52.65 14.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.839 0.352 . . . . 0.0 110.88 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 22.3 mt -98.49 112.67 24.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.978 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.419 HG21 ' HB2' ' A' ' 165' ' ' SER . 10.2 p -58.55 150.82 54.29 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.591 0.71 . . . . 0.0 111.115 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 2.42 3.55 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.689 2.259 . . . . 0.0 112.342 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -99.42 -5.67 29.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.822 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' VAL . . . . . 0.486 HG13 ' HE2' ' A' ' 111' ' ' MET . 31.6 t -102.08 143.49 14.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.162 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -127.93 173.87 9.65 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -54.0 -45.25 71.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.862 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.99 -26.28 26.6 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.488 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' MET . . . . . 0.486 ' HE2' HG13 ' A' ' 107' ' ' VAL . 35.0 mtp -85.36 -58.52 2.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.825 0.345 . . . . 0.0 110.885 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 40.5 tp -42.86 -36.7 1.58 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.919 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' TYR . . . . . 0.455 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.6 t80 -66.3 -68.33 0.38 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.88 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.715 ' HA ' HG12 ' A' ' 117' ' ' VAL . 23.8 mt-10 -48.9 -41.72 34.48 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.91 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' PHE . . . . . 0.519 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 53.8 t80 -54.29 -34.1 60.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.849 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' PHE . . . . . 0.464 ' O ' ' N ' ' A' ' 118' ' ' LYS . 9.1 m-85 -95.19 -64.36 1.07 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.895 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.715 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.7 -30.91 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.105 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' LYS . . . . . 0.464 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.1 ttpt -65.01 -61.17 2.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.916 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.455 HG13 ' CD2' ' A' ' 120' ' ' TYR . 2.5 p -66.78 -34.35 69.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.097 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' TYR . . . . . 0.509 ' CE2' ' HB2' ' A' ' 153' ' ' ALA . 90.7 m-85 -126.05 109.02 24.65 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.673 0.749 . . . . 0.0 110.946 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 2.13 3.8 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.69 2.26 . . . . 0.0 112.328 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 10.6 m -108.32 34.4 3.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.2 t -90.32 135.43 33.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.855 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.46 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 63.1 mtt180 -85.14 -36.39 21.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.455 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 154.48 143.04 3.58 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.484 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.67 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -91.52 138.68 14.4 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.488 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.71 131.96 45.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.79 0.328 . . . . 0.0 110.914 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 8.7 p -117.3 137.19 52.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.143 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' VAL . . . . . 0.873 HG22 ' O ' ' A' ' 139' ' ' TYR . 18.7 m -81.03 148.44 5.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.118 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 16.3 mt -133.09 169.8 16.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.88 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -104.22 177.32 4.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -46.36 -36.47 6.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 41.5 p -77.75 -33.27 52.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.49 17.04 9.57 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.49 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' VAL . . . . . 0.442 ' O ' HG23 ' A' ' 135' ' ' VAL . 20.3 m -96.42 127.63 48.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.342 . . . . 0.0 111.104 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 9.3 t -43.79 108.86 0.12 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.869 -179.846 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' LYS . . . . . 0.511 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.5 mtmt -52.51 -31.36 34.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.932 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.36 19.77 2.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.524 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' TYR . . . . . 0.873 ' O ' HG22 ' A' ' 129' ' ' VAL . 26.5 p90 -163.62 169.67 18.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.389 . . . . 0.0 110.915 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 140' ' ' GLY . . . . . 0.415 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -169.14 -163.86 23.87 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.446 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -153.86 148.91 26.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.917 0.389 . . . . 0.0 110.871 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.67 HG12 ' HA2' ' A' ' 126' ' ' GLY . 16.6 m -124.33 179.29 2.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.091 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' LYS . . . . . 0.46 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 22.9 mtpt -142.57 161.52 37.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.929 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.403 ' HE1' HG23 ' A' ' 142' ' ' VAL . 37.7 m-85 -149.9 153.66 37.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.877 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 51.5 p -91.5 -19.14 23.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -113.92 110.29 19.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.863 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' GLU . . . . . 0.466 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 16.0 tt0 -60.29 -35.75 76.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 93.6 mt -57.88 -45.01 87.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.946 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -74.56 -43.57 55.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.864 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' GLN . . . . . 0.611 ' CD ' HD21 ' A' ' 98' ' ' LEU . 1.6 tm0? -44.18 -38.91 4.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.976 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 24.7 mmtt -76.51 -40.3 50.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.921 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 54.9 mtt85 -53.84 -31.58 49.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.906 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' ALA . . . . . 0.509 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -69.1 -54.06 17.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.101 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.576 HD23 ' CB ' ' A' ' 170' ' ' LEU . 21.8 mt -40.27 -36.33 0.51 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.907 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 155' ' ' THR . . . . . 0.422 HG23 ' N ' ' A' ' 156' ' ' GLU . 7.7 t -92.4 -42.36 9.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.122 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 156' ' ' GLU . . . . . 0.422 ' N ' HG23 ' A' ' 155' ' ' THR . 24.0 mm-40 -75.68 -62.93 1.42 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.903 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 157' ' ' CYS . . . . . 0.574 ' CB ' HD11 ' A' ' 170' ' ' LEU . 53.7 m -67.13 -3.82 8.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.7 tp-100 -41.8 131.11 3.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.91 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 47.4 41.18 16.7 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.539 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 160' ' ' ALA . . . . . 0.564 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -60.22 111.05 1.38 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.788 0.328 . . . . 0.0 111.109 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.7 t -84.97 -35.66 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.132 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.5 -35.53 0.33 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.473 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' LEU . . . . . 0.463 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 29.7 tp -88.7 122.12 31.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.861 0.362 . . . . 0.0 110.921 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 61.94 157.62 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.486 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 165' ' ' SER . . . . . 0.419 ' HB2' HG21 ' A' ' 104' ' ' THR . 72.0 m -60.62 -12.51 10.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.923 0.392 . . . . 0.0 110.864 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 61.8 mttt -118.44 156.8 50.74 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.571 0.701 . . . . 0.0 110.88 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -177.26 1.8 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.651 2.234 . . . . 0.0 112.374 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 168' ' ' VAL . . . . . 0.564 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 29.8 m -138.73 124.76 24.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.154 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 34.6 ttt180 -87.84 107.0 18.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 170' ' ' LEU . . . . . 0.576 ' CB ' HD23 ' A' ' 154' ' ' LEU . 10.3 mt -81.98 146.84 29.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.908 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 8.0 m -163.33 179.73 7.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.839 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 13.4 t -102.66 101.75 12.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.128 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -76.89 167.33 22.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.117 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 86.9 mt -113.24 124.03 32.26 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.633 0.73 . . . . 0.0 111.121 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -49.47 0.55 Allowed 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.636 2.224 . . . . 0.0 112.329 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 29.9 mtmt -147.08 123.49 10.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.891 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -93.29 -54.14 3.81 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.111 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 33.4 t -171.51 133.01 0.78 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.896 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 21.4 tpt180 -44.93 130.26 7.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.891 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 95.5 t -94.0 111.69 25.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.125 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 181' ' ' LYS . . . . . 0.426 ' HA ' ' HD2' ' A' ' 182' ' ' PRO . 1.4 ttmp? -115.8 93.5 37.85 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.649 0.738 . . . . 0.0 110.88 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 182' ' ' PRO . . . . . 0.426 ' HD2' ' HA ' ' A' ' 181' ' ' LYS . 53.3 Cg_endo -69.75 101.5 0.92 Allowed 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.666 2.244 . . . . 0.0 112.339 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 26.8 m -63.59 141.9 17.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.111 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -70.54 151.38 45.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.937 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 40.2 p -77.75 -48.34 16.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.866 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 83.87 143.18 5.47 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.452 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -178.22 2.23 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.693 2.262 . . . . 0.0 112.383 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 68.2 p -156.21 156.57 34.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.856 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 58.7 m -123.82 -49.76 1.85 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.845 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.467 -179.999 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . 0.523 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 67.3 m-85 . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.872 0.367 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.8 m -97.91 161.68 13.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.876 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.884 HD22 HD21 ' A' ' 154' ' ' LEU . 26.0 mt -125.78 143.57 51.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.899 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -93.47 115.78 28.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.523 HG22 ' C ' ' A' ' 140' ' ' GLY . 5.3 m -108.09 148.48 12.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.143 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.7 -177.41 15.14 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.505 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . 0.42 ' N ' ' O ' ' A' ' 138' ' ' GLY . 24.8 m-20 50.87 51.81 16.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.868 0.366 . . . . 0.0 110.887 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.412 HD11 ' CG2' ' A' ' 100' ' ' VAL . 31.1 mt -98.27 102.58 14.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.897 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.501 ' OG1' HG23 ' A' ' 107' ' ' VAL . 72.9 p -47.57 149.85 1.94 Allowed Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.583 0.706 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 2.99 3.07 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.675 2.25 . . . . 0.0 112.327 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -98.32 -16.47 19.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.905 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.596 HG22 ' HE3' ' A' ' 111' ' ' MET . 51.1 t -93.39 145.56 7.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.161 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -129.78 -179.72 5.36 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.862 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -57.77 -51.12 70.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -39.85 -36.18 0.75 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.596 ' HE3' HG22 ' A' ' 107' ' ' VAL . 18.5 mtm -82.79 -59.26 2.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.795 0.331 . . . . 0.0 110.916 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.436 HD23 ' N ' ' A' ' 127' ' ' LYS . 25.2 tp -36.05 -44.02 0.36 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.88 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.406 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 16.1 t80 -63.6 -61.16 2.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.907 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.755 ' HA ' HG12 ' A' ' 117' ' ' VAL . 18.3 mt-10 -54.17 -55.68 25.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.862 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.828 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 71.3 t80 -41.13 -32.29 0.25 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.873 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.48 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.5 m-85 -95.25 -68.16 0.82 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.841 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.755 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.7 -30.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.148 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.48 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.5 ttpt -68.78 -53.96 18.69 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.888 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.574 HG13 ' CD2' ' A' ' 120' ' ' TYR . 2.6 p -70.73 -31.47 45.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.109 179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.574 ' CD2' HG13 ' A' ' 119' ' ' VAL . 94.2 m-85 -135.84 114.47 11.04 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.679 0.752 . . . . 0.0 110.913 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.82 0.53 5.55 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.658 2.239 . . . . 0.0 112.361 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 26.0 m -98.2 21.01 11.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.885 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 7.7 t -84.72 134.78 34.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.888 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 9.0 mmt85 -91.87 -38.94 12.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.836 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.406 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.96 152.27 7.13 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.536 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.406 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -101.66 143.01 15.9 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.488 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.436 ' N ' HD23 ' A' ' 112' ' ' LEU . 21.7 tptm -132.78 127.38 34.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 110.865 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.5 p -116.8 127.18 74.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.145 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.959 HG22 ' O ' ' A' ' 139' ' ' TYR . 20.3 m -73.91 143.65 13.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.127 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.627 HD23 ' HA ' ' A' ' 136' ' ' SER . 25.5 mt -130.57 163.82 26.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.927 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 134' ' ' GLY . 23.8 t70 -94.68 176.17 6.38 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -44.34 -40.38 5.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.894 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 18.1 p -72.37 -28.58 63.11 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.179 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 104.98 20.36 9.92 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.487 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 26.1 m -99.64 134.75 37.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.831 0.348 . . . . 0.0 111.15 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.627 ' HA ' HD23 ' A' ' 130' ' ' LEU . 6.0 t -48.62 112.92 0.67 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.813 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.3 mtmt -58.69 -28.56 65.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.954 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 122.83 15.25 3.97 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.441 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.959 ' O ' HG22 ' A' ' 129' ' ' VAL . 29.8 p90 -161.88 167.99 23.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.896 0.379 . . . . 0.0 110.912 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.523 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -169.64 -160.02 16.85 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.467 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -153.7 148.64 26.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.9 0.381 . . . . 0.0 110.874 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.446 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 28.5 m -123.3 170.6 13.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.077 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 25.3 mttt -129.67 156.06 44.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -143.09 171.56 13.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.9 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 1.7 p -108.3 -28.79 9.23 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -113.1 128.4 56.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.881 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.523 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 12.9 tm-20 -69.37 -38.37 78.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.87 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 26.9 mt -51.0 -44.82 60.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -73.16 -42.88 62.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.852 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 19.8 tt0 -38.74 -57.94 1.14 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.928 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 9.2 mmmm -63.21 -49.32 74.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.91 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 34.4 mtt-85 -43.43 -41.06 4.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.832 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.98 -44.3 76.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.098 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.884 HD21 HD22 ' A' ' 98' ' ' LEU . 24.2 mt -48.46 -40.63 26.98 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.906 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.1 t -91.36 -34.7 14.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 17.4 mm-40 -79.58 -65.1 1.04 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.876 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.549 ' C ' HD11 ' A' ' 170' ' ' LEU . 11.2 m -65.14 -8.74 18.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.877 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . 0.444 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.5 tp-100 -35.6 137.9 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.923 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.48 42.81 2.72 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.521 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.828 ' HB1' ' CZ ' ' A' ' 115' ' ' PHE . . . -57.75 110.9 0.98 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.803 0.335 . . . . 0.0 111.068 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.403 ' O ' ' C ' ' A' ' 162' ' ' GLY . 20.1 t -82.72 -41.76 17.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.135 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -37.87 -34.84 0.2 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.459 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.572 HD13 ' HB2' ' A' ' 115' ' ' PHE . 26.5 tp -90.23 115.77 27.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.811 0.339 . . . . 0.0 110.938 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.415 ' O ' ' C ' ' A' ' 165' ' ' SER . . . 62.52 137.85 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.481 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . 0.415 ' C ' ' O ' ' A' ' 164' ' ' GLY . 1.2 t -37.4 -32.87 0.05 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.916 0.389 . . . . 0.0 110.866 -179.782 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 164' ' ' GLY . 58.0 mttt -100.46 153.6 37.65 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.519 0.676 . . . . 0.0 110.913 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -179.19 2.77 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.67 2.247 . . . . 0.0 112.311 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.787 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 13.8 m -130.59 129.68 64.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.1 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.6 ttt-85 -89.27 110.58 21.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.883 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.825 ' HB3' HD23 ' A' ' 154' ' ' LEU . 12.5 mt -87.24 144.59 26.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.927 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.2 m -160.89 175.06 12.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 2.6 t -102.66 104.43 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.136 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.074 179.874 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . 0.405 ' CD1' ' HG3' ' A' ' 147' ' ' GLU . 9.4 m-85 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.867 0.365 . . . . 0.0 110.98 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 51.6 m -124.92 154.12 41.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.872 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.72 HD21 ' HG2' ' A' ' 150' ' ' GLN . 96.1 mt -126.65 143.44 51.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.9 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.445 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 11.4 t80 -92.51 142.13 27.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.863 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 21.6 m -132.02 150.86 34.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.109 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.15 -174.32 13.27 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.489 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 46.55 54.74 8.37 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.797 0.332 . . . . 0.0 110.852 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.421 HD12 ' C ' ' A' ' 139' ' ' TYR . 29.6 mt -101.84 112.09 24.57 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.895 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.74 ' OG1' HG23 ' A' ' 107' ' ' VAL . 73.3 p -53.59 148.98 16.67 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.61 0.719 . . . . 0.0 111.126 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 2.14 3.78 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.71 2.273 . . . . 0.0 112.35 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -97.98 -17.52 19.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.868 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.74 HG23 ' OG1' ' A' ' 104' ' ' THR . 14.7 t -87.58 143.77 10.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.102 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -131.65 172.2 12.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.855 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -49.59 -46.31 48.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -49.25 -28.91 9.27 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.461 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.452 ' O ' ' N ' ' A' ' 113' ' ' TYR . 14.1 mtp -86.4 -66.54 0.89 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.814 0.34 . . . . 0.0 110.866 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.423 ' C ' ' O ' ' A' ' 111' ' ' MET . 24.6 tp -35.75 -32.88 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.887 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.452 ' N ' ' O ' ' A' ' 111' ' ' MET . 12.0 t80 -68.84 -65.01 0.76 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.927 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.725 ' HA ' HG12 ' A' ' 117' ' ' VAL . 18.4 mt-10 -55.59 -39.57 70.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.559 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 58.0 t80 -54.55 -33.88 60.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.886 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.46 ' O ' ' N ' ' A' ' 118' ' ' LYS . 10.0 m-85 -95.27 -64.92 1.01 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.818 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.725 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.78 -30.92 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.076 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.46 ' N ' ' O ' ' A' ' 116' ' ' PHE . 5.3 ttpm? -65.45 -58.79 4.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.874 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.612 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.5 p -64.56 -33.78 65.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.172 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.612 ' CD2' HG13 ' A' ' 119' ' ' VAL . 91.0 m-85 -135.44 116.53 11.97 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.664 0.745 . . . . 0.0 110.965 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 1.94 3.97 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.671 2.247 . . . . 0.0 112.365 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 86.4 p -87.85 -23.27 24.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.835 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 7.7 t -47.19 137.04 8.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.885 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 51.7 mtm180 -99.3 -36.53 9.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.874 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.42 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.53 143.2 3.65 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.493 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.512 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -87.16 145.24 19.69 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.492 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 21.5 tptm -131.49 110.65 11.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.855 0.359 . . . . 0.0 110.86 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.7 p -102.48 139.85 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.109 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.776 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 25.0 m -86.32 158.34 3.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.566 HD23 ' HA ' ' A' ' 136' ' ' SER . 24.2 mt -137.38 167.78 20.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.878 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.443 ' O ' ' N ' ' A' ' 134' ' ' GLY . 17.7 t0 -102.18 175.06 5.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.83 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -42.03 -42.07 2.75 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.948 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 65.2 p -72.82 -31.83 65.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.097 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 108.88 19.79 8.41 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.487 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 24.9 m -99.7 127.76 52.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.353 . . . . 0.0 111.114 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.566 ' HA ' HD23 ' A' ' 130' ' ' LEU . 3.0 t -40.21 106.76 0.06 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.831 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.551 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.7 mtmt -50.38 -37.16 35.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.944 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 128.81 18.7 1.71 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.459 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.776 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 16.3 p90 -160.81 173.41 15.41 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.953 0.406 . . . . 0.0 110.935 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -177.26 -163.85 29.95 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.484 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.445 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 2.5 m-85 -152.83 150.44 29.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.888 0.375 . . . . 0.0 110.9 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.512 HG12 ' HA2' ' A' ' 126' ' ' GLY . 28.1 m -123.83 174.54 7.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.174 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . 0.445 ' HD3' ' N ' ' A' ' 143' ' ' LYS . 0.5 OUTLIER -134.77 158.43 44.18 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 179.872 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.479 ' CE1' HD12 ' A' ' 98' ' ' LEU . 75.1 m-85 -143.03 160.98 39.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.89 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 75.3 p -95.38 -14.81 23.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.177 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -128.16 123.66 34.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.898 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.405 ' HG3' ' CD1' ' A' ' 96' ' ' TYR . 15.3 tt0 -64.45 -39.23 93.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.911 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 95.3 mt -47.7 -46.96 30.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.941 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 55.8 mm-40 -74.53 -33.46 62.77 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.847 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.72 ' HG2' HD21 ' A' ' 98' ' ' LEU . 33.0 tt0 -46.73 -40.93 14.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.919 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.0 mmtp -81.59 -46.83 13.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 46.0 mtt180 -44.27 -41.36 5.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.85 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.474 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.95 -42.97 80.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.848 HD23 ' HB3' ' A' ' 170' ' ' LEU . 29.9 mt -51.99 -38.14 55.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 14.3 t -92.35 -33.53 14.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.166 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 45.8 mm-40 -83.49 -66.07 0.94 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.898 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.623 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 87.7 m -59.66 -13.26 9.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.93 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . 0.476 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.3 tp-100 -39.0 140.33 0.39 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.893 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 50.43 36.42 30.46 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.497 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.7 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -67.55 110.94 3.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.863 0.364 . . . . 0.0 111.073 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.433 ' O ' ' C ' ' A' ' 162' ' ' GLY . 25.2 t -92.68 -35.91 7.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.132 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -35.12 -35.85 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.482 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.559 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 38.1 tp -86.21 117.45 25.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.843 0.354 . . . . 0.0 110.911 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 66.46 170.46 3.81 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.499 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . 0.58 ' H ' HG21 ' A' ' 104' ' ' THR . 35.9 m -82.09 40.35 0.62 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.891 0.377 . . . . 0.0 110.873 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . 0.493 ' CG ' ' O ' ' A' ' 165' ' ' SER . 36.0 mttt -169.23 157.22 6.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.527 0.679 . . . . 0.0 110.912 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 172.37 12.77 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.677 2.251 . . . . 0.0 112.317 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.7 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 32.2 m -135.69 126.9 44.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.136 179.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 44.7 ttt180 -89.95 117.51 28.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.866 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.848 ' HB3' HD23 ' A' ' 154' ' ' LEU . 17.1 mt -93.35 145.19 24.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.97 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 9.9 m -158.16 174.25 15.48 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 39.4 t -98.69 102.08 12.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.082 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.152 179.811 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.894 0.378 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.9 m -121.15 154.87 35.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.604 HD21 ' HG2' ' A' ' 150' ' ' GLN . 83.2 mt -124.06 145.82 48.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -95.4 124.11 39.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.431 HG22 ' C ' ' A' ' 140' ' ' GLY . 33.0 m -115.25 148.41 18.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.131 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -136.19 -177.86 15.32 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.47 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 49.77 54.09 11.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.873 0.368 . . . . 0.0 110.88 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.421 HD12 ' C ' ' A' ' 139' ' ' TYR . 30.1 mt -100.51 102.56 13.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.936 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.419 HG21 ' HB2' ' A' ' 165' ' ' SER . 2.8 p -47.52 151.26 1.47 Allowed Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.591 0.71 . . . . 0.0 111.136 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.79 -1.38 8.4 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.689 2.259 . . . . 0.0 112.343 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -102.04 25.52 8.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.857 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.47 HG22 ' HE3' ' A' ' 111' ' ' MET . 22.2 t -134.62 138.73 49.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.148 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 45.0 m-20 -123.22 169.35 11.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.875 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.493 ' CG ' HG12 ' A' ' 128' ' ' VAL . 0.5 OUTLIER -46.77 -46.23 20.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 -179.958 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -41.8 -44.47 4.45 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.508 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.47 ' HE3' HG22 ' A' ' 107' ' ' VAL . 32.3 mtm -77.97 -41.37 36.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.785 0.326 . . . . 0.0 110.887 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 16.8 tp -57.05 -25.13 58.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.974 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.49 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 8.5 t80 -84.23 -63.03 1.42 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.905 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.726 ' HA ' HG12 ' A' ' 117' ' ' VAL . 23.9 mt-10 -55.39 -43.24 75.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.579 ' HB2' HD13 ' A' ' 163' ' ' LEU . 85.2 t80 -51.14 -33.02 24.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.845 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.557 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.9 m-85 -95.25 -65.78 0.95 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.726 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -37.16 -28.42 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.106 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.492 ' N ' ' O ' ' A' ' 116' ' ' PHE . 3.1 tptm -65.6 -53.73 37.62 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.937 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.551 HG13 ' CD2' ' A' ' 120' ' ' TYR . 4.1 p -71.16 -38.25 70.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 179.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.599 ' CE2' ' HB2' ' A' ' 153' ' ' ALA . 93.1 m-85 -127.17 116.19 21.75 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.629 0.728 . . . . 0.0 110.934 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 2.94 3.06 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.668 2.246 . . . . 0.0 112.365 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . 0.684 ' O ' HG22 ' A' ' 145' ' ' THR . 18.5 p -89.96 -26.47 20.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.818 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . 0.549 ' HA ' ' CD2' ' A' ' 144' ' ' PHE . 9.5 t -45.25 128.39 7.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.936 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -90.08 -34.88 15.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.869 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.49 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 172.14 166.2 30.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.443 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -115.66 144.22 18.36 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.462 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 18.1 tptt -136.01 128.89 31.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.792 0.329 . . . . 0.0 110.916 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.493 HG12 ' CG ' ' A' ' 109' ' ' ASP . 6.5 p -119.02 127.32 75.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.165 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.885 HG22 ' O ' ' A' ' 139' ' ' TYR . 10.3 m -74.58 153.51 6.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.139 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.489 HD23 ' HA ' ' A' ' 136' ' ' SER . 13.4 mt -130.52 176.82 7.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 134' ' ' GLY . 18.3 t70 -108.23 174.41 5.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.875 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -40.98 -45.06 2.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.879 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 20.8 p -71.57 -34.26 69.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.111 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 113.53 20.92 5.98 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.485 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 136' ' ' SER . 27.3 m -100.44 122.85 52.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.855 0.36 . . . . 0.0 111.138 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.489 ' HA ' HD23 ' A' ' 130' ' ' LEU . 7.3 t -34.57 106.83 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.87 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.496 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 26.8 mtmt -50.45 -34.51 25.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.869 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.2 18.64 2.27 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.518 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.885 ' O ' HG22 ' A' ' 129' ' ' VAL . 19.1 p90 -163.08 165.89 24.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.966 0.412 . . . . 0.0 110.883 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.431 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -166.67 -161.35 15.59 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.512 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -154.03 145.51 23.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.915 0.388 . . . . 0.0 110.861 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.557 HG11 ' CD2' ' A' ' 116' ' ' PHE . 24.4 m -117.31 -176.09 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.133 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 20.2 mtmm -143.57 160.76 40.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.864 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.549 ' CD2' ' HA ' ' A' ' 123' ' ' CYS . 65.5 m-85 -149.85 179.32 8.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . 0.684 HG22 ' O ' ' A' ' 122' ' ' SER . 0.1 OUTLIER -125.08 -16.62 5.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.16 -179.983 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -122.17 97.33 5.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.876 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.6 tt0 -44.83 -48.95 11.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.917 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 63.5 mt -44.85 -33.0 1.77 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.926 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -89.79 -36.69 14.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.834 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.604 ' HG2' HD21 ' A' ' 98' ' ' LEU . 13.6 tt0 -52.4 -47.53 66.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 61.9 mttt -69.99 -41.9 73.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.907 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 69.8 mtt180 -49.7 -34.3 18.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.869 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.599 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -73.3 -45.63 54.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.103 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.708 HD23 ' HB3' ' A' ' 170' ' ' LEU . 26.6 mt -48.4 -36.49 14.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.411 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.4 t -91.35 -40.61 11.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.411 ' N ' HG23 ' A' ' 155' ' ' THR . 56.7 mm-40 -77.56 -66.45 0.83 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.863 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.605 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 63.3 m -60.59 -11.6 7.64 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.855 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 157' ' ' CYS . 2.8 tp-100 -34.99 139.86 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.892 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 43.5 35.8 3.01 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.519 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.792 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -55.71 120.14 6.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.82 0.343 . . . . 0.0 111.146 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.8 t -95.1 -33.26 4.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.101 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -41.47 -36.53 1.54 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.53 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.579 HD13 ' HB2' ' A' ' 115' ' ' PHE . 22.6 tp -89.06 116.48 27.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.895 0.378 . . . . 0.0 110.875 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 68.77 157.89 1.31 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.505 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . 0.419 ' HB2' HG21 ' A' ' 104' ' ' THR . 49.9 m -62.34 -11.47 15.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.961 0.41 . . . . 0.0 110.839 -179.682 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 51.1 mttt -120.02 156.79 54.19 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.59 0.71 . . . . 0.0 110.895 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 177.36 5.68 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.65 2.233 . . . . 0.0 112.382 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.792 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 15.7 m -131.96 125.13 54.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.144 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 21.4 ttm180 -86.82 102.31 14.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.854 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.708 ' HB3' HD23 ' A' ' 154' ' ' LEU . 12.8 mt -81.55 140.67 34.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 19.9 m -156.46 178.03 10.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.839 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 3.3 t -99.95 99.69 8.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.081 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.144 179.826 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 13.4 m-85 . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.908 0.385 . . . . 0.0 110.921 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.1 m -138.91 148.27 43.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.861 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.668 HD12 ' CE2' ' A' ' 144' ' ' PHE . 82.9 mt -117.41 151.63 36.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.915 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.69 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 7.6 t80 -98.31 123.29 42.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.907 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 29.8 m -117.45 144.09 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.125 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.11 178.5 18.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.483 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . 0.45 ' N ' ' O ' ' A' ' 138' ' ' GLY . 1.2 m-20 57.73 53.88 6.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.82 0.343 . . . . 0.0 110.859 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.417 HD23 ' HA ' ' A' ' 103' ' ' LEU . 23.0 mt -100.8 103.34 14.55 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.896 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.488 HG21 ' HB3' ' A' ' 165' ' ' SER . 39.9 p -48.31 150.1 2.41 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.578 0.704 . . . . 0.0 111.146 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -1.56 8.69 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.678 2.252 . . . . 0.0 112.352 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -99.33 12.08 37.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.858 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.614 HG22 ' HE3' ' A' ' 111' ' ' MET . 62.1 t -123.32 139.92 48.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.096 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -122.08 171.59 8.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.878 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.411 ' HB3' HG12 ' A' ' 128' ' ' VAL . 3.5 p30 -52.63 -43.91 65.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.893 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -43.87 -37.3 4.04 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.507 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.614 ' HE3' HG22 ' A' ' 107' ' ' VAL . 28.2 mtm -81.45 -44.72 17.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.833 0.349 . . . . 0.0 110.889 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.488 HD23 ' N ' ' A' ' 127' ' ' LYS . 22.1 tp -53.92 -28.52 37.37 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.873 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.56 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 13.9 t80 -76.36 -65.36 0.93 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.908 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.776 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.0 mt-10 -55.23 -48.25 74.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.918 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.406 ' CB ' HD13 ' A' ' 163' ' ' LEU . 69.0 t80 -46.31 -33.82 4.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.938 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.492 ' O ' ' N ' ' A' ' 118' ' ' LYS . 6.9 m-85 -95.3 -67.09 0.87 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.847 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.776 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.8 p -36.51 -29.41 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.079 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.492 ' N ' ' O ' ' A' ' 116' ' ' PHE . 18.8 ttpp -67.47 -55.56 13.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.914 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.507 HG13 ' HD2' ' A' ' 120' ' ' TYR . 2.3 p -70.98 -30.72 42.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.123 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.582 ' CE1' ' HB3' ' A' ' 152' ' ' ARG . 97.6 m-85 -132.26 112.36 14.32 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.602 0.715 . . . . 0.0 110.955 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.3 Cg_endo -69.75 2.39 3.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.671 2.247 . . . . 0.0 112.338 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 6.3 p -92.87 -20.27 20.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.862 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.0 t -50.05 134.28 22.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.883 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -94.85 -35.7 11.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.56 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 167.1 143.91 3.93 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.492 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.54 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -97.34 136.58 12.83 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.473 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.488 ' N ' HD23 ' A' ' 112' ' ' LEU . 19.3 tttp -124.83 139.2 54.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.77 0.319 . . . . 0.0 110.925 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.411 HG12 ' HB3' ' A' ' 109' ' ' ASP . 6.3 p -123.17 139.62 49.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.149 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.812 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 6.3 m -89.91 152.71 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 7.9 mt -128.68 160.92 30.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -87.59 172.72 9.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.848 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.56 -19.99 0.39 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 58.1 p -89.45 -29.76 18.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.131 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 111.8 10.77 18.19 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.489 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 33.8 m -98.92 136.49 29.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.79 0.329 . . . . 0.0 111.159 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.6 t -43.23 105.78 0.06 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.88 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.512 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 26.0 mtmt -50.58 -32.98 20.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.918 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 123.58 19.9 2.72 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.548 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.812 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 13.9 p90 -163.83 168.77 19.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.952 0.406 . . . . 0.0 110.914 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.53 -160.88 18.8 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.522 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.4 m-85 -153.97 144.16 22.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.848 0.356 . . . . 0.0 110.918 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.54 HG12 ' HA2' ' A' ' 126' ' ' GLY . 20.6 m -120.97 174.02 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.144 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -132.93 163.75 28.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.869 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.668 ' CE2' HD12 ' A' ' 98' ' ' LEU . 75.3 m-85 -149.79 159.78 44.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.923 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 14.0 p -90.34 -39.37 12.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -109.23 132.04 54.49 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.87 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -72.27 -38.3 68.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.923 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 30.2 mt -48.78 -34.06 11.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.923 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -87.83 -37.27 16.69 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.905 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.473 ' O ' HD11 ' A' ' 98' ' ' LEU . 22.4 tt0 -41.61 -48.39 4.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.947 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 47.2 mttt -71.7 -32.22 67.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.864 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.582 ' HB3' ' CE1' ' A' ' 120' ' ' TYR . 0.6 OUTLIER -52.67 -39.45 61.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.841 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.499 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.86 -46.57 71.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.129 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.601 HD23 ' HB3' ' A' ' 170' ' ' LEU . 17.0 mt -40.36 -43.68 1.81 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.614 HG23 ' N ' ' A' ' 156' ' ' GLU . 14.6 t -92.7 -50.63 5.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.124 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.614 ' N ' HG23 ' A' ' 155' ' ' THR . 76.9 mm-40 -62.51 -57.63 10.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.914 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.683 ' O ' HD11 ' A' ' 170' ' ' LEU . 24.7 m -83.2 20.53 1.25 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.824 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . 0.419 ' OE1' ' N ' ' A' ' 159' ' ' GLY . 2.0 tp-100 -64.71 131.89 48.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.9 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.419 ' N ' ' OE1' ' A' ' 158' ' ' GLN . . . 47.09 29.69 4.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.479 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.438 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -50.12 119.23 3.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.827 0.346 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.427 ' O ' ' C ' ' A' ' 162' ' ' GLY . 37.5 t -88.12 -36.75 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.134 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -35.97 -38.59 0.23 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.492 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.406 HD13 ' CB ' ' A' ' 115' ' ' PHE . 20.0 tp -89.08 118.84 29.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.866 0.365 . . . . 0.0 110.918 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.454 ' CA ' HG21 ' A' ' 107' ' ' VAL . . . 64.91 153.49 0.11 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.487 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . 0.488 ' HB3' HG21 ' A' ' 104' ' ' THR . 16.7 t -55.66 -23.8 30.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.962 0.41 . . . . 0.0 110.839 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 58.8 mttt -109.24 154.95 41.84 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.572 0.701 . . . . 0.0 110.908 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 171.23 14.89 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.7 2.267 . . . . 0.0 112.34 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.438 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 16.4 m -121.18 125.84 74.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.085 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 35.1 ttt-85 -88.71 103.27 15.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.683 HD11 ' O ' ' A' ' 157' ' ' CYS . 11.7 mt -80.64 148.61 30.17 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.857 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 3.2 m -160.75 177.61 10.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.917 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.49 HG22 HD11 ' A' ' 154' ' ' LEU . 21.2 t -99.36 96.83 5.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.116 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.69 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.288 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.082 179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . 0.528 ' CD1' ' HG3' ' A' ' 147' ' ' GLU . 63.5 m-85 . . . . . 0 C--O 1.231 0.115 0 CA-C-O 120.903 0.383 . . . . 0.0 110.924 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 66.3 p -112.81 154.58 26.04 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.855 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 33.5 mt -124.79 142.4 51.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.907 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -91.25 132.88 35.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.899 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 18.9 m -126.02 151.82 32.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.128 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -141.72 -179.62 18.97 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.5 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 57.76 38.84 27.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.841 0.353 . . . . 0.0 110.905 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.484 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.2 mt -86.51 108.83 18.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.672 ' OG1' HG23 ' A' ' 107' ' ' VAL . 81.9 p -53.82 150.25 14.62 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.612 0.72 . . . . 0.0 111.144 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 2.21 3.74 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.706 2.271 . . . . 0.0 112.337 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 19.0 t0 -102.02 -3.17 28.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.672 HG23 ' OG1' ' A' ' 104' ' ' THR . 41.3 t -103.68 145.08 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.141 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -129.18 179.68 5.63 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -60.34 -37.86 81.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.881 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.43 -33.23 39.51 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.47 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.528 ' HE3' HG22 ' A' ' 107' ' ' VAL . 27.3 mtm -86.85 -46.91 9.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.842 0.353 . . . . 0.0 110.886 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.463 HD23 ' N ' ' A' ' 127' ' ' LYS . 18.1 tp -53.34 -23.03 8.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.929 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.496 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 13.0 t80 -82.63 -61.75 1.8 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.926 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.758 ' HA ' HG12 ' A' ' 117' ' ' VAL . 22.4 mt-10 -57.23 -46.58 82.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.867 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.683 ' HZ ' ' HB1' ' A' ' 160' ' ' ALA . 75.6 t80 -47.68 -33.23 6.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.499 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.6 m-85 -95.28 -66.98 0.88 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.861 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.758 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.73 -30.97 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.132 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.463 ' N ' ' O ' ' A' ' 116' ' ' PHE . 59.2 tttt -67.31 -60.61 2.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.903 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.603 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.7 p -64.65 -27.15 41.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.114 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.603 ' CD2' HG13 ' A' ' 119' ' ' VAL . 92.6 m-85 -137.94 115.89 9.57 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.7 0.762 . . . . 0.0 110.906 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -2.77 10.7 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.751 2.301 . . . . 0.0 112.336 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 73.2 m -99.25 32.28 2.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.854 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . 0.461 ' HB3' HG23 ' A' ' 117' ' ' VAL . 19.6 t -94.51 135.2 36.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.881 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 16.8 mtp180 -93.17 -39.0 11.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.867 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.496 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 163.56 149.43 5.73 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.582 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -102.9 134.27 11.75 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.518 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.463 ' N ' HD23 ' A' ' 112' ' ' LEU . 4.3 tppp? -123.21 137.56 54.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.806 0.336 . . . . 0.0 110.925 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.4 p -124.69 129.4 73.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.126 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.97 HG22 ' O ' ' A' ' 139' ' ' TYR . 22.5 m -75.18 150.49 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.085 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.429 HD23 ' HA ' ' A' ' 136' ' ' SER . 14.9 mt -127.03 174.91 8.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.925 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -103.18 178.27 4.6 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.846 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 25.3 tt0 -45.28 -43.08 10.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.905 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 27.8 p -74.68 -25.04 58.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.167 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 107.88 17.67 10.8 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.475 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 28.8 m -95.9 134.31 33.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.872 0.368 . . . . 0.0 111.126 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.429 ' HA ' HD23 ' A' ' 130' ' ' LEU . 4.8 t -44.18 107.2 0.08 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.863 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.5 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.7 mtmt -52.75 -32.36 42.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.902 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.7 18.74 2.63 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.482 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.97 ' O ' HG22 ' A' ' 129' ' ' VAL . 23.4 p90 -163.14 168.25 21.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.981 0.42 . . . . 0.0 110.9 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -170.74 -165.18 27.68 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.478 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -150.88 146.99 26.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.869 0.366 . . . . 0.0 110.893 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.582 HG12 ' HA2' ' A' ' 126' ' ' GLY . 17.8 m -119.2 179.32 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.113 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 31.3 mttt -138.53 160.35 39.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.899 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -148.34 161.99 40.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.855 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 44.0 p -101.88 -12.34 18.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.099 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.443 ' CG ' ' OE1' ' A' ' 149' ' ' GLU . 14.3 t0 -129.61 130.04 45.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.857 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.528 ' HG3' ' CD1' ' A' ' 96' ' ' TYR . 20.0 tt0 -71.83 -43.23 65.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 37.2 mt -45.23 -49.21 12.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.954 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.443 ' OE1' ' CG ' ' A' ' 146' ' ' ASP . 3.6 mp0 -72.8 -44.05 61.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.855 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 149' ' ' GLU . 17.4 tt0 -36.97 -55.28 0.93 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.932 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 13.7 mttm -64.48 -52.59 57.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 28.4 mtt180 -39.41 -33.29 0.15 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.853 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.448 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -73.98 -49.93 22.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.133 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.756 HD23 ' HB3' ' A' ' 170' ' ' LEU . 33.9 mt -43.34 -38.36 2.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.912 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.539 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.8 t -91.03 -48.3 7.06 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.167 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.539 ' N ' HG23 ' A' ' 155' ' ' THR . 53.1 mt-10 -69.56 -64.58 0.85 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.9 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.546 ' CB ' HD11 ' A' ' 170' ' ' LEU . 54.1 m -62.82 -8.3 6.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.905 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -40.5 140.95 0.59 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 37.66 45.6 1.48 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.465 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.683 ' HB1' ' HZ ' ' A' ' 115' ' ' PHE . . . -64.18 115.09 4.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.802 0.334 . . . . 0.0 111.129 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.0 t -84.88 -35.57 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.143 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -43.06 -34.44 2.06 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.453 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.618 HD13 ' CB ' ' A' ' 115' ' ' PHE . 19.2 tp -91.81 115.82 28.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.866 0.365 . . . . 0.0 110.922 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 166' ' ' LYS . . . 64.55 138.48 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.497 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 t -41.05 -27.92 0.07 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.944 0.402 . . . . 0.0 110.838 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . 0.401 ' N ' ' O ' ' A' ' 164' ' ' GLY . 57.5 mttt -103.78 154.67 37.83 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.526 0.679 . . . . 0.0 110.924 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.69 173.15 11.33 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.7 2.266 . . . . 0.0 112.413 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.672 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 21.1 m -124.45 131.27 73.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.127 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 43.4 ttt180 -94.84 105.01 16.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.92 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.756 ' HB3' HD23 ' A' ' 154' ' ' LEU . 13.3 mt -82.66 148.87 27.69 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.933 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.535 ' O ' HD21 ' A' ' 154' ' ' LEU . 2.0 m -158.72 -177.87 6.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.9 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 4.4 t -108.83 102.15 13.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.145 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.07 179.895 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.896 0.379 . . . . 0.0 110.934 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.0 p -117.13 146.26 43.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.859 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.88 HD21 ' HG2' ' A' ' 150' ' ' GLN . 46.3 mt -110.43 150.4 28.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.906 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.661 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 4.9 t80 -96.34 127.23 42.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.852 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.8 m -119.42 146.05 24.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.15 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.84 -177.99 15.9 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.463 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 52.85 51.57 15.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.88 0.371 . . . . 0.0 110.877 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 30.1 mt -98.04 118.52 34.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.936 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p -61.97 151.54 79.9 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.587 0.708 . . . . 0.0 111.094 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -0.02 6.29 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.718 2.278 . . . . 0.0 112.333 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -99.46 -0.24 41.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.484 HG22 ' HE3' ' A' ' 111' ' ' MET . 26.5 t -111.09 147.68 14.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.096 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -131.83 -178.81 5.05 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.885 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.64 -37.78 85.28 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.78 -26.93 26.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.52 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.484 ' HE3' HG22 ' A' ' 107' ' ' VAL . 34.3 mtm -93.8 -39.29 10.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 0.0 110.919 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.403 HD23 ' N ' ' A' ' 127' ' ' LYS . 49.3 tp -55.86 -30.41 61.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.938 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.501 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 22.5 t80 -78.8 -63.86 1.31 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.947 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.704 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.0 mt-10 -53.54 -36.31 61.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.886 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.488 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 67.6 t80 -58.09 -34.2 69.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.88 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.501 ' O ' ' N ' ' A' ' 118' ' ' LYS . 10.2 m-85 -95.25 -62.74 1.25 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.875 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.704 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -38.44 -26.39 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.115 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.501 ' N ' ' O ' ' A' ' 116' ' ' PHE . 18.2 tttm -71.05 -60.73 2.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.911 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.659 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.7 p -67.62 -25.79 33.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.165 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.659 ' CD2' HG13 ' A' ' 119' ' ' VAL . 92.2 m-85 -136.09 112.26 10.31 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.633 0.73 . . . . 0.0 110.95 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 54.0 Cg_endo -69.73 2.81 3.18 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.672 2.248 . . . . 0.0 112.343 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 32.0 m -105.44 27.9 7.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.853 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 36.8 t -89.0 124.73 34.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.857 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.488 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 14.0 mtp180 -79.21 -42.8 25.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.862 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.501 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 168.52 159.56 14.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.507 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -114.7 134.87 11.95 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.497 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.403 ' N ' HD23 ' A' ' 112' ' ' LEU . 3.5 tppp? -130.13 132.69 46.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.838 0.352 . . . . 0.0 110.878 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.2 p -118.1 129.7 74.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.911 HG22 ' O ' ' A' ' 139' ' ' TYR . 23.8 m -73.76 144.98 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.083 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.616 HD22 ' O ' ' A' ' 134' ' ' GLY . 46.4 mt -123.9 162.3 23.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.903 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.42 ' CG ' ' HG2' ' A' ' 137' ' ' LYS . 3.0 m-20 -93.33 -178.25 4.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -40.75 -59.05 1.49 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.955 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.411 ' H ' HG22 ' A' ' 133' ' ' THR . 0.0 OUTLIER -62.36 -30.83 71.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.616 ' O ' HD22 ' A' ' 130' ' ' LEU . . . 116.65 0.54 20.01 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.498 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.406 HG13 HG23 ' A' ' 133' ' ' THR . 3.5 m -73.43 141.12 16.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.787 0.327 . . . . 0.0 111.126 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.435 ' HA ' HD23 ' A' ' 130' ' ' LEU . 8.2 t -50.27 113.83 0.97 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.487 ' HB2' HG23 ' A' ' 129' ' ' VAL . 22.1 mtmt -58.76 -30.72 67.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.916 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 120.13 17.26 4.56 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.512 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.911 ' O ' HG22 ' A' ' 129' ' ' VAL . 19.0 p90 -163.29 167.96 21.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.985 0.422 . . . . 0.0 110.864 -179.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -171.56 -162.48 23.91 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.51 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -153.3 139.9 18.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.893 0.378 . . . . 0.0 110.88 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.4 m -110.75 176.85 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . 0.488 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 47.8 mttt -133.35 156.72 47.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.878 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -148.57 152.57 37.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . 0.428 HG23 ' CG ' ' A' ' 124' ' ' ARG . 25.3 p -96.0 -24.96 16.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.147 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -115.06 103.55 11.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.837 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 15.2 tm-20 -48.51 -47.23 39.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.914 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 65.6 mt -39.68 -44.35 1.51 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.935 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -72.48 -40.65 66.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.918 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.88 ' HG2' HD21 ' A' ' 98' ' ' LEU . 24.9 tt0 -40.36 -60.6 1.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.897 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 14.4 mttm -62.51 -44.78 95.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 57.6 mtt180 -48.0 -42.64 28.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.904 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.459 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -69.15 -45.19 70.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.814 HD21 HD22 ' A' ' 98' ' ' LEU . 13.8 mt -43.52 -41.38 4.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.952 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.431 HG23 ' N ' ' A' ' 156' ' ' GLU . 6.0 t -92.46 -41.64 10.18 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.431 ' N ' HG23 ' A' ' 155' ' ' THR . 21.6 mm-40 -70.04 -63.59 1.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.868 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.484 ' CB ' HD11 ' A' ' 170' ' ' LEU . 20.9 m -70.82 -0.32 8.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -43.69 129.79 5.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 55.45 33.78 59.1 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.495 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.887 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -48.64 116.58 1.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.799 0.333 . . . . 0.0 111.062 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.7 t -93.85 -31.39 4.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.138 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -46.29 -31.64 4.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.517 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.407 HD13 ' HB2' ' A' ' 115' ' ' PHE . 20.4 tp -91.37 115.7 28.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.851 0.358 . . . . 0.0 110.923 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.0 159.92 0.97 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.493 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 m -61.95 -19.68 63.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.959 0.409 . . . . 0.0 110.883 -179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 35.0 mttm -111.13 153.53 43.9 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.559 0.695 . . . . 0.0 110.89 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 171.79 13.85 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.659 2.239 . . . . 0.0 112.371 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.887 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 22.2 m -127.22 125.06 65.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.119 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.5 ttt180 -86.42 111.68 20.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.851 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.566 ' HB3' HD23 ' A' ' 154' ' ' LEU . 14.7 mt -87.16 139.95 30.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.2 m -152.74 178.17 9.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.823 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.431 HG22 HD11 ' A' ' 154' ' ' LEU . 2.8 t -100.73 96.15 4.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.661 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.128 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . 0.437 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 32.4 m-85 . . . . . 0 N--CA 1.457 -0.084 0 CA-C-O 120.897 0.38 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 52.6 p -138.52 159.66 41.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.9 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.58 HD21 ' CD ' ' A' ' 150' ' ' GLN . 79.5 mt -124.84 147.73 48.61 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -94.03 120.6 34.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.902 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.42 HG22 ' C ' ' A' ' 140' ' ' GLY . 31.2 m -114.04 145.41 19.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -133.67 -174.02 13.41 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.494 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 46.91 50.88 13.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.841 0.353 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 103' ' ' LEU . 20.4 mt -96.05 99.07 10.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.954 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.466 HG23 ' HB2' ' A' ' 166' ' ' LYS . 23.9 p -48.79 151.57 2.08 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.597 0.713 . . . . 0.0 111.122 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 1.56 4.32 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.694 2.262 . . . . 0.0 112.326 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -100.99 10.38 41.17 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.851 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.521 HG13 ' CE ' ' A' ' 111' ' ' MET . 3.9 t -121.57 147.03 25.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.1 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -132.77 178.52 6.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.873 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -56.18 -40.07 73.39 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -49.28 -40.18 29.41 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.521 ' CE ' HG13 ' A' ' 107' ' ' VAL . 36.1 mtm -82.57 -39.73 21.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.835 0.35 . . . . 0.0 110.876 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.635 HD23 ' N ' ' A' ' 127' ' ' LYS . 28.3 tp -57.71 -28.11 63.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.417 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.2 t80 -81.77 -60.02 2.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.92 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.727 ' HA ' HG12 ' A' ' 117' ' ' VAL . 20.7 mt-10 -56.13 -47.43 78.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.445 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 62.8 t80 -48.79 -33.64 10.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.917 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.561 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.5 m-85 -94.41 -66.12 0.94 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.873 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.727 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.71 -30.43 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.15 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.472 ' N ' ' O ' ' A' ' 116' ' ' PHE . 20.2 ttpp -65.84 -59.37 3.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.941 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.604 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.6 p -67.13 -34.21 68.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.172 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.604 ' CD2' HG13 ' A' ' 119' ' ' VAL . 92.8 m-85 -130.06 112.01 17.1 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.662 0.744 . . . . 0.0 110.96 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 1.39 4.46 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.679 2.252 . . . . 0.0 112.352 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -99.05 19.9 14.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.828 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 38.8 t -82.01 132.8 35.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.875 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.693 ' HG3' HG23 ' A' ' 145' ' ' THR . 46.1 mtt-85 -89.52 -41.92 11.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.868 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.417 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 168.94 150.35 6.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.468 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -103.18 142.34 15.48 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.517 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.635 ' N ' HD23 ' A' ' 112' ' ' LEU . 12.1 tptm -136.95 132.71 34.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.869 0.366 . . . . 0.0 110.868 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 3.0 p -120.72 129.26 75.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.849 HG22 ' O ' ' A' ' 139' ' ' TYR . 23.5 m -72.41 142.88 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.107 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.49 HD23 ' HA ' ' A' ' 136' ' ' SER . 11.5 mt -127.7 163.97 23.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.936 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.444 ' C ' ' OD1' ' A' ' 131' ' ' ASP . 0.6 OUTLIER -97.89 -175.08 3.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.839 179.865 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 44.5 tt0 -49.09 -48.67 44.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 21.5 p -65.91 -23.2 66.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.147 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.46 22.57 18.72 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 30.1 m -102.93 131.27 51.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.8 0.334 . . . . 0.0 111.138 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.49 ' HA ' HD23 ' A' ' 130' ' ' LEU . 5.4 t -39.45 116.83 0.65 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.864 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.1 mtmt -63.17 -28.17 69.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.914 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 123.98 14.34 3.8 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.506 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.849 ' O ' HG22 ' A' ' 129' ' ' VAL . 17.9 p90 -162.2 170.82 18.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.939 0.399 . . . . 0.0 110.921 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.42 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -172.71 -160.79 21.98 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.507 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -153.85 143.72 21.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.867 0.365 . . . . 0.0 110.861 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.561 HG11 ' CD2' ' A' ' 116' ' ' PHE . 14.7 m -115.39 -176.68 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.123 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 13.8 mttp -141.55 153.02 44.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.418 ' CE2' HD12 ' A' ' 98' ' ' LEU . 88.7 m-85 -146.48 128.82 15.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.88 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . 0.693 HG23 ' HG3' ' A' ' 124' ' ' ARG . 36.7 p -66.5 -12.7 58.8 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.162 -179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -126.54 135.21 51.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.868 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.437 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 29.7 tt0 -79.08 -34.17 43.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.887 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 38.9 mt -53.98 -60.2 3.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.911 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -65.09 -38.45 90.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.58 ' CD ' HD21 ' A' ' 98' ' ' LEU . 1.4 tm0? -48.06 -42.55 28.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.888 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.573 ' HA ' HD12 ' A' ' 154' ' ' LEU . 34.7 mmtm -77.85 -26.94 49.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 27.1 mtt180 -65.09 -37.48 87.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.855 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.454 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -66.12 -36.04 82.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.104 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.573 HD12 ' HA ' ' A' ' 151' ' ' LYS . 28.1 mt -52.49 -41.49 63.43 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.934 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 8.8 t -91.86 -36.42 13.51 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.176 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 16.0 mm-40 -76.24 -62.54 1.58 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.877 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.574 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 10.5 m -71.79 0.54 8.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . 0.466 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.0 tp-100 -43.17 136.14 3.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.9 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 45.93 30.16 3.59 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.475 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.574 ' HB2' ' O ' ' A' ' 157' ' ' CYS . . . -49.79 112.31 0.64 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.828 0.347 . . . . 0.0 111.115 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 18.8 t -87.18 -33.84 7.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.84 -31.13 1.09 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.463 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.445 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 28.4 tp -90.17 109.43 20.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.882 0.372 . . . . 0.0 110.919 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 71.53 168.05 9.02 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.471 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . 0.44 ' HB2' HG21 ' A' ' 104' ' ' THR . 39.5 m -66.24 -23.1 66.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.918 0.39 . . . . 0.0 110.863 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . 0.466 ' HB2' HG23 ' A' ' 104' ' ' THR . 58.9 mttm -110.29 155.81 41.29 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.632 0.73 . . . . 0.0 110.873 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.85 -176.85 1.65 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.676 2.25 . . . . 0.0 112.325 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.543 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 28.6 m -135.04 128.28 49.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.131 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 12.5 ttp180 -91.99 94.16 9.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.835 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.541 ' HB3' HD23 ' A' ' 154' ' ' LEU . 10.6 mt -72.14 152.64 42.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.484 ' O ' HD21 ' A' ' 154' ' ' LEU . 0.9 OUTLIER -167.01 178.32 5.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.891 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 45.5 t -103.79 99.45 8.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.086 179.893 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 19.5 m-85 . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.851 0.358 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 45.9 m -118.69 146.55 44.62 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.86 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.717 HD22 HD21 ' A' ' 154' ' ' LEU . 68.3 mt -113.53 153.36 28.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.921 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -100.77 123.05 44.41 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.848 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 23.1 m -114.38 145.8 19.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.114 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.11 -176.75 14.51 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.513 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 48.78 52.06 14.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.827 0.346 . . . . 0.0 110.879 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.424 HD12 ' C ' ' A' ' 139' ' ' TYR . 28.7 mt -98.24 105.89 18.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.879 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.459 HG23 ' HB2' ' A' ' 166' ' ' LYS . 25.1 p -50.6 150.63 4.73 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.582 0.705 . . . . 0.0 111.158 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 3.16 2.95 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.665 2.243 . . . . 0.0 112.316 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -98.38 -13.33 20.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.881 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.471 HG13 ' HE2' ' A' ' 111' ' ' MET . 41.4 t -98.21 134.46 36.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.151 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.25 175.88 5.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.828 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -53.37 -44.79 68.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.858 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.96 -29.07 7.98 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.499 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.471 ' HE2' HG13 ' A' ' 107' ' ' VAL . 22.3 mtp -86.88 -59.47 2.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.788 0.328 . . . . 0.0 110.873 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 15.8 tp -40.18 -41.06 1.22 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.898 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.423 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 12.9 t80 -62.65 -67.17 0.44 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.966 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.77 ' HA ' HG12 ' A' ' 117' ' ' VAL . 30.3 mt-10 -52.52 -55.52 21.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.927 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 57.2 t80 -41.49 -32.28 0.33 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.896 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.498 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.0 m-85 -95.14 -67.53 0.85 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.883 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.77 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -37.65 -27.58 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.103 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.498 ' N ' ' O ' ' A' ' 116' ' ' PHE . 20.1 tptt -67.57 -57.87 5.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.885 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.655 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.3 p -71.56 -32.73 46.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.175 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.655 ' CD2' HG13 ' A' ' 119' ' ' VAL . 97.0 m-85 -126.3 108.04 24.09 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.622 0.725 . . . . 0.0 110.954 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.8 Cg_endo -69.76 2.44 3.53 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.667 2.245 . . . . 0.0 112.339 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 47.6 p -95.0 -10.33 31.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 10.0 t -57.09 142.65 41.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.887 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 61.7 mtp180 -104.46 -34.1 8.36 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.88 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.423 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 166.72 145.99 4.68 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.453 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.43 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -96.35 139.25 14.39 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.477 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 46.6 tptt -125.28 127.73 47.15 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.87 0.366 . . . . 0.0 110.866 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.1 p -117.72 141.28 37.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.958 HG22 ' O ' ' A' ' 139' ' ' TYR . 33.2 m -92.73 145.33 7.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.096 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.582 HD23 ' HA ' ' A' ' 136' ' ' SER . 23.4 mt -123.8 179.09 4.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.888 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 11.1 t0 -108.96 -178.96 3.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.875 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -53.57 -18.9 3.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.917 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 43.6 p -93.61 -27.27 16.69 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.163 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 107.52 17.29 11.47 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.476 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 19.1 m -100.05 139.27 21.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 0.0 111.112 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.582 ' HA ' HD23 ' A' ' 130' ' ' LEU . 7.5 t -49.76 100.34 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.507 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.4 mtmt -42.97 -36.09 1.44 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.877 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 128.35 16.97 2.03 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.548 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.958 ' O ' HG22 ' A' ' 129' ' ' VAL . 28.1 p90 -161.07 172.07 17.47 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.901 0.381 . . . . 0.0 110.96 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -174.94 -163.23 27.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.475 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -153.76 145.58 23.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.861 0.363 . . . . 0.0 110.863 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.487 HG11 ' CD2' ' A' ' 116' ' ' PHE . 29.3 m -119.6 -177.74 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.087 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 32.8 mttm -142.16 156.73 45.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -145.87 163.43 35.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 29.2 p -101.1 -19.88 15.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.129 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -117.02 120.47 38.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.825 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -65.45 -33.55 76.21 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.948 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 44.6 mt -57.71 -40.57 79.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.931 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.464 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 38.6 mt-10 -76.28 -38.53 56.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.829 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.684 ' HG2' HD21 ' A' ' 98' ' ' LEU . 22.0 tt0 -44.95 -48.43 11.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.869 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 5.1 mmmm -73.57 -37.37 65.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.407 ' O ' ' CG ' ' A' ' 156' ' ' GLU . 9.1 mtt-85 -56.25 -34.23 66.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.892 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.439 ' O ' HD12 ' A' ' 170' ' ' LEU . . . -72.0 -46.2 58.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.784 HD23 ' HB3' ' A' ' 170' ' ' LEU . 48.6 mt -44.36 -40.98 5.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.47 HG23 ' N ' ' A' ' 156' ' ' GLU . 14.9 t -92.33 -42.54 9.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.165 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.47 ' N ' HG23 ' A' ' 155' ' ' THR . 25.6 mm-40 -68.96 -64.87 0.79 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.611 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 10.4 m -70.11 -1.68 10.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.893 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . 0.487 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.8 tp-100 -42.48 141.95 0.9 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.891 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 158' ' ' GLN . . . 35.51 34.29 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.502 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.611 ' HB2' ' O ' ' A' ' 157' ' ' CYS . . . -58.49 110.65 1.02 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.769 0.319 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.41 ' O ' ' C ' ' A' ' 162' ' ' GLY . 22.9 t -79.27 -34.27 16.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.121 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.65 -36.23 0.15 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.464 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.441 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 25.2 tp -92.72 115.17 27.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.85 0.357 . . . . 0.0 110.885 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.77 146.85 0.13 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.495 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 m -50.81 -21.09 1.5 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.966 0.413 . . . . 0.0 110.855 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . 0.459 ' HB2' HG23 ' A' ' 104' ' ' THR . 36.5 mttm -109.08 156.05 39.86 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.595 0.712 . . . . 0.0 110.903 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 171.84 13.74 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.699 2.266 . . . . 0.0 112.295 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 168' ' ' VAL . 35.4 m -125.34 127.6 72.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.185 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 17.7 ttt180 -91.54 107.82 19.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.784 ' HB3' HD23 ' A' ' 154' ' ' LEU . 14.4 mt -84.4 143.39 29.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.932 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 15.2 m -154.6 171.41 19.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.881 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.673 HG22 HD11 ' A' ' 154' ' ' LEU . 3.0 t -101.0 100.6 10.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.112 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.136 179.838 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.918 0.39 . . . . 0.0 110.934 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.8 m -112.33 147.19 36.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.839 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.817 HD22 HD21 ' A' ' 154' ' ' LEU . 92.2 mt -115.75 155.99 26.79 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.412 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 8.6 t80 -104.6 127.49 52.35 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.856 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.438 HG22 ' C ' ' A' ' 140' ' ' GLY . 28.4 m -116.55 155.28 18.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -142.59 178.12 21.26 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.485 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 52.87 50.28 18.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.874 0.369 . . . . 0.0 110.898 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 29.1 mt -96.9 103.44 15.37 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.899 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.426 HG21 ' HB2' ' A' ' 165' ' ' SER . 17.4 p -47.94 150.16 2.1 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 121.617 0.723 . . . . 0.0 111.152 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 2.98 3.03 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.623 2.215 . . . . 0.0 112.375 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.34 16.34 26.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.721 HG22 ' HE3' ' A' ' 111' ' ' MET . 59.5 t -129.62 142.17 44.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.109 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -128.95 -177.6 4.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.817 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -58.18 -47.98 81.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.848 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -42.26 -35.1 1.72 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.48 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.721 ' HE3' HG22 ' A' ' 107' ' ' VAL . 26.0 mtm -86.03 -45.72 11.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.823 0.344 . . . . 0.0 110.884 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.532 HD23 ' N ' ' A' ' 127' ' ' LYS . 16.0 tp -53.5 -33.45 54.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.503 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 9.8 t80 -68.71 -61.62 1.74 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.755 ' HA ' HG12 ' A' ' 117' ' ' VAL . 22.2 mt-10 -57.76 -51.78 68.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.901 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.545 ' CE1' ' HB2' ' A' ' 163' ' ' LEU . 66.5 t80 -44.1 -32.34 1.17 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.876 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.619 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.7 m-85 -95.25 -67.52 0.85 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.755 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.83 -29.35 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.158 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.483 ' N ' ' O ' ' A' ' 116' ' ' PHE . 22.9 ttpp -66.31 -58.31 5.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.901 179.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.529 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.6 p -67.41 -33.0 59.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.124 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.686 ' CE2' ' HB2' ' A' ' 153' ' ' ALA . 89.4 m-85 -129.12 113.31 18.5 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.683 0.754 . . . . 0.0 110.944 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.8 Cg_endo -69.77 -0.05 6.35 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.722 2.281 . . . . 0.0 112.353 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 69.0 m -105.22 35.41 2.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.864 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 3.0 t -98.09 138.59 35.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.907 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.571 HH11 HG22 ' A' ' 145' ' ' THR . 44.8 mtp85 -93.6 -38.06 11.55 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.857 -179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.503 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 159.22 141.72 3.21 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.491 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.645 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -90.41 138.04 14.25 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.44 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.532 ' N ' HD23 ' A' ' 112' ' ' LEU . 20.2 tptm -122.05 128.28 51.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.81 0.338 . . . . 0.0 110.9 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.9 p -114.86 135.64 54.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.948 HG22 ' O ' ' A' ' 139' ' ' TYR . 32.9 m -84.71 145.98 7.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.092 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.562 HD23 ' HA ' ' A' ' 136' ' ' SER . 31.1 mt -126.69 -179.66 4.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.849 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.479 ' O ' ' N ' ' A' ' 134' ' ' GLY . 2.2 t70 -118.69 -176.0 3.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.891 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -38.35 -61.38 0.69 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.887 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.402 ' H ' HG22 ' A' ' 133' ' ' THR . 0.0 OUTLIER -60.92 -24.84 66.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.148 -179.898 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.485 ' O ' HD22 ' A' ' 130' ' ' LEU . . . 105.16 4.45 41.27 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.502 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 5.3 m -77.24 145.2 10.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.811 0.339 . . . . 0.0 111.168 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.562 ' HA ' HD23 ' A' ' 130' ' ' LEU . 5.1 t -56.93 113.9 1.87 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.502 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 30.0 mtmt -56.73 -31.65 64.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.885 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.21 17.71 2.95 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.484 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.948 ' O ' HG22 ' A' ' 129' ' ' VAL . 28.0 p90 -162.55 174.8 12.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.964 0.412 . . . . 0.0 110.889 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.438 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -178.29 -162.42 28.01 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.485 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.412 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 4.5 m-85 -153.98 146.18 23.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.953 0.406 . . . . 0.0 110.858 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.645 HG12 ' HA2' ' A' ' 126' ' ' GLY . 17.8 m -116.87 -176.51 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.139 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 25.7 mttm -143.75 157.83 44.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.891 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.421 ' CE1' HG23 ' A' ' 142' ' ' VAL . 50.0 m-85 -146.79 161.85 39.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.884 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . 0.571 HG22 HH11 ' A' ' 124' ' ' ARG . 69.9 p -95.76 -29.73 14.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.152 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -112.9 133.9 54.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.799 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -74.64 -34.47 62.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.867 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 64.6 mt -53.39 -40.45 65.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.927 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.484 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 4.3 mm-40 -80.66 -40.53 25.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.877 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.591 ' HG2' HD21 ' A' ' 98' ' ' LEU . 13.4 tt0 -41.6 -48.08 3.97 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.9 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 154' ' ' LEU . 40.4 mttp -71.67 -57.2 4.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.902 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.4 ' C ' ' O ' ' A' ' 151' ' ' LYS . 21.0 mtt-85 -38.18 -33.55 0.1 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.897 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.686 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -74.66 -43.49 55.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.117 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.817 HD21 HD22 ' A' ' 98' ' ' LEU . 14.7 mt -48.32 -38.2 18.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.499 HG23 ' N ' ' A' ' 156' ' ' GLU . 10.1 t -92.14 -45.76 8.11 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.136 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.499 ' N ' HG23 ' A' ' 155' ' ' THR . 16.8 mm-40 -67.99 -62.35 1.44 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.851 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.544 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 33.0 m -68.24 -3.25 10.12 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.897 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 5.1 tp-100 -45.36 139.58 3.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.916 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 44.2 34.35 3.23 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.505 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.629 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -55.33 113.0 1.23 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.814 0.34 . . . . 0.0 111.077 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.8 t -88.02 -32.31 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.151 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.53 -37.0 2.46 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.482 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.545 ' HB2' ' CE1' ' A' ' 115' ' ' PHE . 26.4 tp -89.65 117.19 28.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.901 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 68.19 154.22 0.55 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.528 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . 0.426 ' HB2' HG21 ' A' ' 104' ' ' THR . 19.3 m -55.98 -25.4 43.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.953 0.406 . . . . 0.0 110.871 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 59.8 mttt -108.0 154.71 40.97 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.615 0.721 . . . . 0.0 110.871 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 173.39 11.07 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.696 2.264 . . . . 0.0 112.304 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.629 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 33.0 m -126.33 127.02 70.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.153 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 34.6 ttt85 -92.77 102.44 14.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.856 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.58 ' HB3' HD23 ' A' ' 154' ' ' LEU . 11.2 mt -76.88 149.84 36.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.919 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.7 m -158.58 175.57 13.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.871 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.624 HG22 HD11 ' A' ' 154' ' ' LEU . 11.3 t -105.78 101.62 12.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.141 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.119 179.852 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . 0.493 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 5.0 m-85 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 120.904 0.383 . . . . 0.0 110.923 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 58.2 p -116.22 142.52 46.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.849 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.791 HD22 HD21 ' A' ' 154' ' ' LEU . 37.3 mt -115.79 147.89 40.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.917 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -93.88 135.68 34.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 140' ' ' GLY . 15.5 m -128.6 139.56 51.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.158 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -132.39 171.23 21.6 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.508 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . 0.403 ' N ' ' O ' ' A' ' 138' ' ' GLY . 29.4 m-20 61.74 51.72 3.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.864 0.364 . . . . 0.0 110.928 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 25.6 mt -99.29 103.31 15.13 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.94 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.558 HG23 ' HB2' ' A' ' 166' ' ' LYS . 16.9 p -48.4 150.19 2.43 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.609 0.718 . . . . 0.0 111.111 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 -0.27 6.73 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.668 2.246 . . . . 0.0 112.333 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -99.73 10.19 41.77 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.479 ' HA ' ' HE2' ' A' ' 111' ' ' MET . 21.7 t -123.76 133.9 67.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.101 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -118.9 176.3 5.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.879 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.5 p-10 -52.22 -50.55 61.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -39.41 -39.12 1.07 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.468 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.479 ' HE2' ' HA ' ' A' ' 107' ' ' VAL . 29.7 mtm -82.77 -41.33 19.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.743 0.306 . . . . 0.0 110.876 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.412 HD23 ' N ' ' A' ' 127' ' ' LYS . 18.6 tp -58.8 -24.39 61.81 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.927 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.418 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 16.7 t80 -84.45 -62.37 1.57 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.884 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.7 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.0 mt-10 -57.76 -34.74 69.87 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.931 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.504 ' CZ ' ' HB2' ' A' ' 163' ' ' LEU . 84.7 t80 -59.85 -34.03 72.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.51 ' CD2' HG11 ' A' ' 142' ' ' VAL . 9.5 m-85 -95.03 -62.13 1.36 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.863 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.7 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.3 p -39.03 -27.16 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.131 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.462 ' N ' ' O ' ' A' ' 116' ' ' PHE . 19.5 tptt -68.96 -60.52 2.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.898 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.668 HG13 ' CD2' ' A' ' 120' ' ' TYR . 4.2 p -67.58 -28.86 43.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.146 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.668 ' CD2' HG13 ' A' ' 119' ' ' VAL . 95.1 m-85 -132.72 110.55 13.38 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.667 0.746 . . . . 0.0 110.894 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.1 Cg_endo -69.8 -2.47 10.25 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.701 2.267 . . . . 0.0 112.294 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 23.4 p -90.3 -4.04 57.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.855 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . 0.475 ' HA ' ' CD1' ' A' ' 144' ' ' PHE . 14.1 t -57.35 146.46 28.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.931 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.439 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 1.6 mmm180 -109.01 -36.45 6.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.901 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.418 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.29 149.24 5.78 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.48 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.442 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -100.11 135.82 12.36 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.472 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.412 ' N ' HD23 ' A' ' 112' ' ' LEU . 1.7 tmtp? -127.91 110.9 13.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.848 0.356 . . . . 0.0 110.883 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.527 HG13 ' O ' ' A' ' 128' ' ' VAL . 14.2 p -103.25 119.91 52.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.128 179.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.847 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 18.2 m -66.36 143.33 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.113 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 43.5 mt -121.49 -176.6 3.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.911 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -113.77 -175.72 2.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . 0.751 ' OE1' HG22 ' A' ' 133' ' ' THR . 0.0 OUTLIER -48.39 -35.18 12.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.912 -179.928 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.751 HG22 ' OE1' ' A' ' 132' ' ' GLN . 9.6 p -86.65 -23.16 25.76 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.145 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.54 23.36 8.93 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.503 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 30.6 m -99.12 128.56 50.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.836 0.351 . . . . 0.0 111.12 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.6 t -39.37 109.75 0.12 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.861 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.3 mtmt -58.53 -28.45 65.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.403 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 123.74 16.07 3.44 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.479 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.847 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 16.2 p90 -162.76 173.19 14.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.941 0.4 . . . . 0.0 110.929 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.421 ' O ' HG22 ' A' ' 100' ' ' VAL . . . -176.73 -163.7 29.44 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.525 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -151.23 148.12 27.82 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.878 0.37 . . . . 0.0 110.934 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.51 HG11 ' CD2' ' A' ' 116' ' ' PHE . 15.4 m -120.85 176.06 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . 0.439 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -133.69 161.86 33.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 179.939 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.475 ' CD1' ' HA ' ' A' ' 123' ' ' CYS . 96.9 m-85 -149.61 167.88 25.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 25.8 p -108.79 -8.13 15.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.142 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -132.51 124.44 28.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.856 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.493 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 16.3 tt0 -69.88 -30.92 68.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.889 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 48.6 mt -58.16 -54.61 44.98 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.928 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 54.4 mt-10 -67.57 -39.54 84.91 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.526 ' HG2' HD21 ' A' ' 98' ' ' LEU . 17.6 tt0 -44.01 -45.57 7.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.905 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 74.1 mttt -73.11 -29.89 63.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.942 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 47.3 mtp180 -63.57 -39.84 95.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.873 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.635 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -68.52 -42.87 77.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.138 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.791 HD21 HD22 ' A' ' 98' ' ' LEU . 29.3 mt -45.85 -43.1 13.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.933 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.51 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.4 t -91.1 -46.66 7.99 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.168 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.51 ' N ' HG23 ' A' ' 155' ' ' THR . 47.4 mm-40 -63.32 -63.58 1.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.877 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.731 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 34.0 m -67.7 -9.43 43.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.917 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . 0.427 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.6 tp-100 -37.93 145.22 0.07 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.969 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.07 33.71 0.5 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.514 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.731 ' HB2' ' O ' ' A' ' 157' ' ' CYS . . . -58.71 115.86 3.34 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.826 0.346 . . . . 0.0 111.054 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 23.1 t -90.77 -35.33 7.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.136 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.12 -33.28 0.16 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.498 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.504 ' HB2' ' CZ ' ' A' ' 115' ' ' PHE . 25.7 tp -93.69 115.98 28.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.868 0.366 . . . . 0.0 110.871 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 69.1 156.69 1.15 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.475 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 65.8 m -59.83 -19.97 54.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.995 0.426 . . . . 0.0 110.878 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . 0.558 ' HB2' HG23 ' A' ' 104' ' ' THR . 49.2 mttt -111.83 156.67 41.28 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.527 0.68 . . . . 0.0 110.93 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 177.62 5.38 Favored 'Trans proline' 0 N--CA 1.465 -0.153 0 C-N-CA 122.681 2.254 . . . . 0.0 112.376 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.652 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 31.4 m -131.33 125.98 57.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.138 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 30.3 ttm180 -91.65 99.76 12.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.856 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.559 ' HB3' HD23 ' A' ' 154' ' ' LEU . 13.4 mt -77.73 151.5 34.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.916 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.7 m -162.83 171.47 16.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.86 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.571 HG22 ' CD1' ' A' ' 154' ' ' LEU . 2.8 t -97.93 105.02 16.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.145 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.092 179.883 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 4.4 m-85 . . . . . 0 C--O 1.23 0.077 0 CA-C-O 120.915 0.388 . . . . 0.0 110.88 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.7 p -133.3 149.13 51.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.887 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.83 HD22 HD21 ' A' ' 154' ' ' LEU . 23.6 mt -118.86 149.62 41.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.934 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.483 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 8.9 t80 -96.1 131.37 42.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.906 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.475 HG22 ' C ' ' A' ' 140' ' ' GLY . 17.1 m -122.25 138.3 52.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -130.47 179.77 16.66 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.514 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 51.32 54.03 11.84 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.8 0.334 . . . . 0.0 110.865 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.404 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.0 mt -101.95 103.24 13.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 52.3 p -49.37 150.53 3.18 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.561 0.696 . . . . 0.0 111.145 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 3.0 3.02 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.748 2.299 . . . . 0.0 112.381 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -99.21 -4.32 32.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.662 HG22 ' HE3' ' A' ' 111' ' ' MET . 93.1 t -109.1 144.39 17.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.151 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -129.8 179.75 5.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.86 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.7 -35.27 74.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.862 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -53.5 -32.46 45.74 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.465 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.662 ' HE3' HG22 ' A' ' 107' ' ' VAL . 32.9 mtm -89.03 -42.64 11.63 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.855 0.359 . . . . 0.0 110.892 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.531 HD23 ' N ' ' A' ' 127' ' ' LYS . 17.0 tp -56.91 -28.84 62.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.912 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.474 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 9.5 t80 -74.96 -62.87 1.4 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.709 ' HA ' HG12 ' A' ' 117' ' ' VAL . 19.4 mt-10 -61.65 -26.77 68.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.89 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.64 ' HZ ' ' HB1' ' A' ' 160' ' ' ALA . 84.2 t80 -65.85 -34.62 78.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.893 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -94.63 -58.37 2.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.888 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.709 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.2 p -43.21 -25.55 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.147 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 5.1 ttpm? -69.5 -60.65 2.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.892 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.624 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.2 p -65.46 -27.67 42.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.624 ' CD2' HG13 ' A' ' 119' ' ' VAL . 97.1 m-85 -137.79 113.18 9.13 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.666 0.746 . . . . 0.0 110.94 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 0.05 6.18 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.68 2.253 . . . . 0.0 112.344 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 16.1 m -99.72 24.89 7.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.864 -179.818 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 14.9 t -85.87 140.51 30.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.879 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.588 ' HE ' HG22 ' A' ' 145' ' ' THR . 7.9 mmt85 -95.82 -32.5 12.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.857 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.474 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 151.84 140.78 3.2 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.785 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -90.22 137.24 13.89 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.479 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.531 ' N ' HD23 ' A' ' 112' ' ' LEU . 1.6 tppp? -125.96 129.72 49.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 110.898 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.11 128.28 73.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.096 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.926 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 22.3 m -74.31 147.21 9.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.13 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 11.6 mt -129.01 173.32 10.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.928 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -105.55 -179.15 3.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.883 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 32.9 tt0 -46.24 -39.79 10.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 52.2 p -74.84 -34.07 62.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.131 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.02 23.35 6.17 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.505 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 18.8 m -103.37 132.63 49.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.842 0.353 . . . . 0.0 111.083 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.0 t -42.12 114.06 0.51 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.849 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.438 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.1 mtmt -61.3 -24.7 66.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.831 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 119.71 15.96 5.16 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.484 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.926 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 25.1 p90 -162.13 177.81 9.35 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.933 0.397 . . . . 0.0 110.913 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.475 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -179.63 -163.45 30.4 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.492 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -153.01 147.97 26.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.857 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.785 HG12 ' HA2' ' A' ' 126' ' ' GLY . 14.7 m -120.94 -178.61 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.139 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . 0.47 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 21.9 mtmm -141.04 159.18 42.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.826 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -147.32 171.21 15.8 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.857 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . 0.588 HG22 ' HE ' ' A' ' 124' ' ' ARG . 75.4 p -110.48 -25.61 9.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.152 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -111.7 117.25 32.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.829 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -68.01 -23.74 65.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.879 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 67.7 mt -64.34 -35.85 82.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.931 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.497 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 20.8 mt-10 -88.94 -35.89 16.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.444 ' O ' HD11 ' A' ' 98' ' ' LEU . 22.4 tt0 -42.99 -45.14 4.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.928 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 36.6 mttp -77.41 -35.16 54.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.444 ' O ' ' CG ' ' A' ' 156' ' ' GLU . 21.3 mtp85 -55.69 -34.0 64.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.842 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -74.19 -40.74 62.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.107 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.83 HD21 HD22 ' A' ' 98' ' ' LEU . 19.1 mt -47.5 -41.76 21.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.931 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.456 HG23 ' N ' ' A' ' 156' ' ' GLU . 11.9 t -92.51 -42.4 9.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.173 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.456 ' N ' HG23 ' A' ' 155' ' ' THR . 46.5 mm-40 -67.33 -66.32 0.57 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.909 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.477 ' CB ' HD11 ' A' ' 170' ' ' LEU . 3.7 m -64.26 -13.08 47.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.862 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . 0.411 ' C ' ' O ' ' A' ' 157' ' ' CYS . 3.3 tp-100 -35.6 129.62 0.57 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.926 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 59.0 33.25 73.28 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.525 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.829 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -56.1 112.95 1.34 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 111.102 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.2 t -91.6 -32.95 5.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.153 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -43.52 -31.38 1.63 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.509 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.51 ' HB2' ' CE1' ' A' ' 115' ' ' PHE . 26.7 tp -94.97 112.85 24.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.842 0.353 . . . . 0.0 110.886 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.421 ' CA ' HG21 ' A' ' 107' ' ' VAL . . . 70.82 148.45 0.49 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.498 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 49.0 m -50.92 -31.61 18.15 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.939 0.399 . . . . 0.0 110.841 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -99.92 155.52 36.36 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.534 0.683 . . . . 0.0 110.904 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.84 174.48 9.51 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.703 2.269 . . . . 0.0 112.302 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.829 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 30.7 m -130.32 135.42 60.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.165 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . 0.405 ' HG2' ' O ' ' A' ' 169' ' ' ARG . 5.7 ptm180 -95.93 128.04 42.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.862 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.762 ' HB3' HD23 ' A' ' 154' ' ' LEU . 31.9 mt -102.06 136.75 41.35 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.951 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.3 m -151.78 -176.9 5.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 10.7 t -107.48 94.3 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.158 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.483 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.08 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 7.3 m-85 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.888 0.375 . . . . 0.0 110.909 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.1 p -126.23 155.09 42.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.784 HD22 HD21 ' A' ' 154' ' ' LEU . 85.7 mt -126.15 144.05 50.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.918 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.48 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 11.6 t80 -94.47 131.24 40.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.436 ' CG2' HD11 ' A' ' 103' ' ' LEU . 34.8 m -120.03 147.52 23.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.125 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -134.9 -177.9 15.28 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.482 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 50.24 48.39 22.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.803 0.335 . . . . 0.0 110.882 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.446 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.2 mt -93.86 103.09 15.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.889 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.666 ' OG1' HG23 ' A' ' 107' ' ' VAL . 71.1 p -48.2 149.49 2.59 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.588 0.709 . . . . 0.0 111.153 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 2.61 3.34 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.707 2.271 . . . . 0.0 112.38 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -99.11 -9.83 23.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.852 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.666 HG23 ' OG1' ' A' ' 104' ' ' THR . 15.7 t -98.12 144.05 11.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.134 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -130.24 174.46 9.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.844 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -51.66 -50.74 59.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.875 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -45.54 -33.99 4.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.506 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.432 ' HE2' HG13 ' A' ' 107' ' ' VAL . 50.4 mtp -80.92 -61.5 1.94 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.781 0.324 . . . . 0.0 110.855 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.452 HD12 ' CD2' ' A' ' 163' ' ' LEU . 18.3 tp -41.23 -40.2 1.54 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.919 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.497 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 17.6 t80 -63.01 -68.12 0.37 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.903 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.749 ' HA ' HG12 ' A' ' 117' ' ' VAL . 26.7 mt-10 -48.74 -55.51 11.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.88 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.55 ' CB ' HD13 ' A' ' 163' ' ' LEU . 76.4 t80 -42.75 -32.1 0.56 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.885 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.467 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.1 m-85 -95.0 -67.23 0.86 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.873 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.749 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.81 -30.31 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.14 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.2 tttp -65.41 -58.5 5.7 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.929 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.58 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.3 p -67.27 -29.81 47.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.132 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.58 ' CD2' HG13 ' A' ' 119' ' ' VAL . 96.3 m-85 -137.06 109.49 9.05 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.685 0.755 . . . . 0.0 110.924 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 2.43 3.53 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.671 2.247 . . . . 0.0 112.318 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 1.3 p -95.49 -0.18 52.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.833 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 19.1 t -66.4 138.07 57.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.931 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -91.59 -38.61 12.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.497 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 164.37 150.42 6.13 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.476 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.631 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -94.21 137.52 13.57 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.447 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 19.7 tptm -125.27 118.72 26.61 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.838 0.351 . . . . 0.0 110.903 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.518 HG13 ' O ' ' A' ' 128' ' ' VAL . 7.7 p -112.45 115.57 50.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.109 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.913 HG22 ' O ' ' A' ' 139' ' ' TYR . 32.6 m -61.66 151.27 7.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.161 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.583 HD23 ' HA ' ' A' ' 136' ' ' SER . 49.0 mt -133.16 164.48 26.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.924 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.452 ' O ' ' N ' ' A' ' 134' ' ' GLY . 13.7 t70 -96.96 175.84 6.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.866 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 2.0 tp-100 -42.66 -44.25 4.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.905 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 44.0 p -70.0 -28.51 65.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.118 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 103.81 23.73 8.1 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.505 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 136' ' ' SER . 28.4 m -105.12 131.43 54.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-O 120.824 0.345 . . . . 0.0 111.122 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.583 ' HA ' HD23 ' A' ' 130' ' ' LEU . 5.8 t -37.89 114.16 0.33 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.426 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.7 mtmt -62.66 -25.89 68.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.907 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 119.41 17.18 4.9 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.5 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.913 ' O ' HG22 ' A' ' 129' ' ' VAL . 20.3 p90 -163.54 172.05 14.96 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.916 0.389 . . . . 0.0 110.984 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -176.22 -164.11 29.84 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.501 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . 0.48 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 3.7 m-85 -152.05 149.15 28.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.906 0.384 . . . . 0.0 110.845 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.631 HG12 ' HA2' ' A' ' 126' ' ' GLY . 16.1 m -123.0 161.05 25.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.131 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -119.05 158.41 25.89 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.872 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.524 ' CE1' HG23 ' A' ' 142' ' ' VAL . 84.4 m-85 -145.6 169.36 18.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 43.3 p -115.0 -24.79 8.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.123 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -112.99 99.82 8.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 16.7 tt0 -46.94 -45.26 20.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.884 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 33.6 mt -48.1 -40.57 23.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.927 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.474 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 4.4 mm-40 -80.98 -33.98 33.41 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.825 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.48 ' HG2' HD21 ' A' ' 98' ' ' LEU . 15.4 tt0 -49.79 -63.89 0.97 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.944 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -57.92 -47.62 82.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.923 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 47.0 mtt180 -43.97 -30.89 0.78 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.855 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -73.76 -39.1 64.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.064 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.784 HD21 HD22 ' A' ' 98' ' ' LEU . 12.2 mt -51.01 -38.14 49.46 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.886 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.508 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.8 t -92.46 -46.35 7.69 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.508 ' N ' HG23 ' A' ' 155' ' ' THR . 10.7 mt-10 -68.45 -63.1 1.13 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.828 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.48 ' CB ' HD11 ' A' ' 170' ' ' LEU . 40.3 m -68.64 -2.61 9.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.873 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -43.5 136.69 3.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.876 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 42.61 43.85 5.15 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.45 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.571 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -61.33 110.89 1.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.784 0.326 . . . . 0.0 111.134 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.7 -35.95 10.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.137 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -40.68 -34.48 0.74 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.501 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.55 HD13 ' CB ' ' A' ' 115' ' ' PHE . 16.1 tp -91.07 118.77 30.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.835 0.35 . . . . 0.0 110.946 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 165' ' ' SER . . . 61.22 135.07 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.465 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . 0.411 ' C ' ' O ' ' A' ' 164' ' ' GLY . 58.8 m -37.58 -33.58 0.08 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.924 0.392 . . . . 0.0 110.844 -179.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 31.7 mttp -95.61 153.5 39.43 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.574 0.702 . . . . 0.0 110.876 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -176.27 1.44 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.677 2.252 . . . . 0.0 112.313 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.571 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 33.2 m -140.84 126.59 19.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 18.3 mtt180 -90.26 116.68 28.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.847 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.562 ' HB3' HD23 ' A' ' 154' ' ' LEU . 17.4 mt -89.9 137.48 32.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.903 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 13.2 m -149.52 179.72 7.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.89 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 5.0 t -103.99 98.1 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.087 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.46 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.33 -0.282 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.069 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . 0.509 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 33.1 m-85 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.924 0.392 . . . . 0.0 110.895 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 64.6 m -105.18 156.38 18.15 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.892 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.959 HD22 HD21 ' A' ' 154' ' ' LEU . 21.8 mt -122.23 143.01 49.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.949 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.439 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 8.5 t80 -93.11 126.87 38.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.912 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.438 HG22 ' C ' ' A' ' 140' ' ' GLY . 30.2 m -119.17 148.6 22.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.142 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.61 176.33 20.9 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.522 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . 0.468 ' N ' ' O ' ' A' ' 138' ' ' GLY . 22.7 m-20 56.57 50.74 12.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.837 0.351 . . . . 0.0 110.878 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.406 ' H ' ' C ' ' A' ' 138' ' ' GLY . 25.9 mt -98.6 100.34 11.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 75.0 p -42.69 149.38 0.48 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.602 0.715 . . . . 0.0 111.128 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 3.13 2.93 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.711 2.274 . . . . 0.0 112.368 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 65.5 m-20 -104.22 11.93 34.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.903 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 1.02 HG22 ' HE3' ' A' ' 111' ' ' MET . 75.3 t -128.42 134.98 63.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.125 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -120.69 -175.99 3.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.869 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -57.88 -37.01 73.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -46.59 -41.51 12.82 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.443 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 1.02 ' HE3' HG22 ' A' ' 107' ' ' VAL . 27.9 mtm -83.82 -44.8 13.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.787 0.327 . . . . 0.0 110.863 -179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 21.2 tp -51.74 -22.82 3.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.901 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.414 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 14.8 t80 -83.74 -64.69 1.12 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.863 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.712 ' HA ' HG12 ' A' ' 117' ' ' VAL . 27.1 mt-10 -57.2 -26.45 60.68 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.889 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.561 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 60.5 t80 -66.7 -34.83 78.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.907 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 11.5 m-85 -95.22 -57.72 2.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.839 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.712 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -43.23 -28.69 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.119 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 3.6 tptm -68.9 -59.61 2.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.856 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.631 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.3 p -65.29 -28.75 45.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.137 179.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.631 ' CD2' HG13 ' A' ' 119' ' ' VAL . 91.5 m-85 -138.17 114.43 9.08 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.695 0.759 . . . . 0.0 110.922 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.67 -0.2 6.49 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.717 2.278 . . . . 0.0 112.335 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . 0.474 ' O ' HG23 ' A' ' 145' ' ' THR . 17.2 p -88.85 -17.73 29.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.816 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . 0.433 ' HA ' ' CD1' ' A' ' 144' ' ' PHE . 7.7 t -48.08 139.36 8.25 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.895 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 25.2 mtp180 -100.71 -34.96 9.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.862 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.414 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 164.02 145.56 4.42 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.521 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.435 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -98.39 133.82 11.47 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.485 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 13.4 tptt -124.79 128.94 49.5 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.834 0.349 . . . . 0.0 110.867 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.1 p -114.43 138.05 45.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.176 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.873 HG22 ' O ' ' A' ' 139' ' ' TYR . 24.4 m -83.76 143.25 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.12 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 17.1 mt -122.7 171.73 8.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.904 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -105.55 -179.88 4.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.815 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 15.8 pt20 -45.6 -39.86 8.19 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.925 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 44.2 p -74.88 -33.79 62.11 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.136 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 111.79 21.28 6.47 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.526 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 27.3 m -100.66 143.45 14.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.812 0.339 . . . . 0.0 111.16 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 3.7 t -54.55 107.26 0.27 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.859 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.49 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.5 mtmt -52.47 -29.95 27.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.885 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.468 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 122.53 19.23 3.16 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.49 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.873 ' O ' HG22 ' A' ' 129' ' ' VAL . 27.3 p90 -163.8 167.77 20.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.921 0.391 . . . . 0.0 110.909 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.438 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -171.11 -159.91 18.34 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.498 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -153.58 151.52 29.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.9 0.381 . . . . 0.0 110.877 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.465 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 18.4 m -124.1 176.36 5.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.16 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 33.8 mtmt -136.83 158.23 44.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.433 ' CD1' ' HA ' ' A' ' 123' ' ' CYS . 91.5 m-85 -145.38 167.05 23.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.905 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . 0.474 HG23 ' O ' ' A' ' 122' ' ' SER . 27.7 p -105.48 -25.41 12.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.147 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.413 ' OD2' HD12 ' A' ' 148' ' ' LEU . 6.4 t70 -119.5 111.15 17.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.509 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 2.9 tm-20 -51.43 -45.75 62.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.874 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . 0.413 HD12 ' OD2' ' A' ' 146' ' ' ASP . 24.0 mt -42.0 -42.2 2.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.915 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 57.0 mm-40 -76.23 -41.77 48.17 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.424 ' HG2' HD21 ' A' ' 98' ' ' LEU . 17.7 tt0 -40.84 -57.79 1.85 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.924 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 32.9 mmtm -62.53 -51.53 67.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.925 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 36.8 mtp180 -41.81 -40.97 2.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.452 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -67.88 -48.22 66.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.043 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.959 HD21 HD22 ' A' ' 98' ' ' LEU . 15.3 mt -42.61 -42.46 3.42 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.913 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.534 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.2 t -89.12 -48.13 7.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.13 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.534 ' N ' HG23 ' A' ' 155' ' ' THR . 18.2 mm-40 -63.56 -64.35 0.92 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.437 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 2.5 m -68.25 -8.09 36.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.926 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . 0.493 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 3.5 tp-100 -36.14 134.38 0.41 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 -179.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 46.57 41.32 12.52 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.474 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.683 ' HB3' HG22 ' A' ' 168' ' ' VAL . . . -57.39 117.44 4.12 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.848 0.356 . . . . 0.0 111.084 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.6 t -92.9 -33.5 5.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.163 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.94 -36.33 2.55 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.443 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 18.2 tp -87.94 114.83 24.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.829 0.347 . . . . 0.0 110.868 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 70.8 161.27 3.88 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.4 p -66.97 -3.83 8.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.946 0.403 . . . . 0.0 110.85 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -128.37 154.78 79.17 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.547 0.689 . . . . 0.0 110.917 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 171.6 14.16 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.696 2.264 . . . . 0.0 112.337 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.683 HG22 ' HB3' ' A' ' 160' ' ' ALA . 32.8 m -128.97 126.29 64.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.137 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -87.99 112.6 22.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.886 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.687 ' HB3' HD23 ' A' ' 154' ' ' LEU . 13.9 mt -85.94 146.07 26.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.913 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.2 m -157.57 169.04 25.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.43 HG22 HD11 ' A' ' 154' ' ' LEU . 40.9 t -94.45 102.41 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.121 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.439 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.094 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 10.0 m-85 . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.92 0.39 . . . . 0.0 110.946 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 29.0 m -145.14 162.9 35.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.839 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.78 HD22 HD21 ' A' ' 154' ' ' LEU . 91.8 mt -131.35 135.39 47.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.933 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.6 t80 -86.83 131.43 34.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.896 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 30.8 m -127.09 150.57 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.176 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.43 -170.99 12.26 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.476 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 45.41 51.47 9.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.828 0.347 . . . . 0.0 110.861 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.487 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.0 mt -96.93 102.46 14.24 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.465 HG23 ' HB2' ' A' ' 166' ' ' LYS . 37.1 p -48.74 151.37 2.13 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.617 0.722 . . . . 0.0 111.125 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 2.95 3.09 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.699 2.266 . . . . 0.0 112.351 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -103.85 17.8 23.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.432 HG13 ' CE ' ' A' ' 111' ' ' MET . 2.8 t -125.57 134.34 66.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.167 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -124.04 170.79 10.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.849 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.46 ' CG ' ' N ' ' A' ' 110' ' ' GLY . 0.3 OUTLIER -47.06 -49.97 20.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.912 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.46 ' N ' ' CG ' ' A' ' 109' ' ' ASP . . . -47.61 -26.46 3.85 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.454 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.432 ' CE ' HG13 ' A' ' 107' ' ' VAL . 27.2 mtp -89.23 -57.6 2.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.766 0.317 . . . . 0.0 110.874 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.501 HD23 ' N ' ' A' ' 127' ' ' LYS . 15.3 tp -46.86 -28.43 1.57 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.977 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.408 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.3 t80 -76.5 -66.64 0.78 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.93 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.679 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.9 mt-10 -54.96 -25.98 33.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.891 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.455 ' CB ' HD13 ' A' ' 163' ' ' LEU . 72.2 t80 -68.27 -35.73 78.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.862 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.594 ' CD2' HG11 ' A' ' 142' ' ' VAL . 12.1 m-85 -95.09 -56.97 2.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.679 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -42.41 -27.89 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.16 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 15.2 ttmm -66.88 -60.71 2.42 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.946 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.573 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.0 p -63.32 -32.91 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.112 179.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.573 ' CD2' HG13 ' A' ' 119' ' ' VAL . 93.6 m-85 -134.75 115.41 12.32 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.749 0.785 . . . . 0.0 110.905 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -1.8 9.13 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.672 2.248 . . . . 0.0 112.321 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 3.1 m -86.41 -12.64 48.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.806 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . 0.448 ' CB ' ' HA ' ' A' ' 117' ' ' VAL . 13.5 t -50.27 135.19 21.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.587 ' HE ' HG22 ' A' ' 145' ' ' THR . 93.9 mtt180 -96.99 -37.67 10.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.408 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 166.54 143.44 3.75 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.472 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.42 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -96.9 134.54 11.81 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.516 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.501 ' N ' HD23 ' A' ' 112' ' ' LEU . 10.1 tptm -125.78 123.86 39.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.81 0.338 . . . . 0.0 110.886 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -113.5 123.35 69.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.083 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.98 HG22 ' O ' ' A' ' 139' ' ' TYR . 25.0 m -68.81 149.22 11.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.097 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.628 HD22 ' O ' ' A' ' 134' ' ' GLY . 40.9 mt -127.34 -177.02 3.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.482 ' O ' ' N ' ' A' ' 134' ' ' GLY . 13.2 t0 -116.94 176.09 5.28 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.799 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -39.86 -39.84 0.89 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.913 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -82.29 -29.57 31.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.14 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.628 ' O ' HD22 ' A' ' 130' ' ' LEU . . . 112.41 0.99 26.38 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.506 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.59 HG23 ' O ' ' A' ' 135' ' ' VAL . 9.6 m -76.21 118.99 23.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 111.155 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.507 ' HA ' HD23 ' A' ' 130' ' ' LEU . 6.9 t -35.01 108.27 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.473 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.4 mtmt -50.39 -35.63 29.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.883 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.62 19.07 2.11 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.473 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.98 ' O ' HG22 ' A' ' 129' ' ' VAL . 22.1 p90 -163.32 168.61 20.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.918 0.39 . . . . 0.0 110.911 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -173.65 -163.56 27.4 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.43 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -152.89 147.6 26.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.92 0.39 . . . . 0.0 110.87 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.594 HG11 ' CD2' ' A' ' 116' ' ' PHE . 16.4 m -119.08 171.08 7.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.145 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . 0.475 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 34.3 mtpt -127.63 161.76 28.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.555 ' CE2' HD12 ' A' ' 98' ' ' LEU . 93.8 m-85 -149.75 160.91 43.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.867 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . 0.587 HG22 ' HE ' ' A' ' 124' ' ' ARG . 76.7 p -99.73 -20.03 16.46 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.169 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -119.09 126.32 51.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.843 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 14.5 tt0 -71.71 -25.98 62.31 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.919 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 23.9 mt -65.85 -47.95 73.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.437 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 24.4 mt-10 -73.56 -39.29 64.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.862 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.551 ' CD ' HD21 ' A' ' 98' ' ' LEU . 1.4 tm0? -46.09 -39.13 8.93 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.907 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.433 ' HD3' HD12 ' A' ' 154' ' ' LEU . 27.8 mmtp -79.99 -43.94 21.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.896 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 3.0 mtt-85 -48.04 -28.47 2.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.552 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -78.64 -34.51 46.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.08 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.78 HD21 HD22 ' A' ' 98' ' ' LEU . 22.9 mt -55.87 -36.94 68.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.3 t -92.28 -35.71 13.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.131 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -81.8 -66.88 0.83 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.873 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.467 ' C ' HD11 ' A' ' 170' ' ' LEU . 99.7 m -60.92 -10.26 5.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.861 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . 0.404 ' C ' ' O ' ' A' ' 157' ' ' CYS . 3.0 tp-100 -36.34 132.05 0.59 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.937 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 52.54 38.49 51.78 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.479 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.756 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -54.02 115.04 1.82 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.851 0.357 . . . . 0.0 111.086 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 40.2 t -93.98 -36.27 7.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.11 -35.51 1.73 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.545 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.474 ' CD2' HD12 ' A' ' 112' ' ' LEU . 27.6 tp -83.9 109.58 17.7 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.853 0.358 . . . . 0.0 110.915 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 74.91 174.71 34.16 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.501 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 38.4 m -84.56 28.09 0.68 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.897 0.379 . . . . 0.0 110.837 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . 0.465 ' HB2' HG23 ' A' ' 104' ' ' THR . 29.5 mttm -159.55 156.59 25.35 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.561 0.695 . . . . 0.0 110.909 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 170.19 17.15 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.685 2.257 . . . . 0.0 112.314 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.756 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 31.1 m -131.09 128.57 62.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.098 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 36.7 ttt180 -86.54 109.6 19.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.826 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.575 ' HB3' HD23 ' A' ' 154' ' ' LEU . 12.6 mt -85.42 145.9 27.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.94 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.9 m -162.16 177.76 9.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.827 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 8.8 t -100.68 103.22 14.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.163 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.07 179.905 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . 0.501 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 2.1 m-85 . . . . . 0 C--O 1.231 0.079 0 CA-C-O 120.916 0.389 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.7 m -135.56 139.42 43.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.88 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.593 HD21 ' CG ' ' A' ' 150' ' ' GLN . 98.4 mt -108.69 151.93 25.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.891 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.571 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 5.7 t80 -99.63 121.29 41.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.903 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.443 HG22 ' C ' ' A' ' 140' ' ' GLY . 23.6 m -110.0 137.12 43.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.121 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -126.91 176.58 17.67 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.472 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 53.37 52.45 13.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.826 0.346 . . . . 0.0 110.87 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.453 HD12 ' C ' ' A' ' 139' ' ' TYR . 24.8 mt -97.92 98.49 9.84 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.926 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.451 HG23 ' HB2' ' A' ' 166' ' ' LYS . 2.2 p -45.99 151.54 0.88 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.599 0.714 . . . . 0.0 111.162 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 0.0 6.32 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.665 2.243 . . . . 0.0 112.309 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -101.23 16.58 25.03 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.831 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.536 HG22 ' HE3' ' A' ' 111' ' ' MET . 61.5 t -129.41 131.93 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.095 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -118.69 171.54 8.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.869 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.4 ' CG ' ' N ' ' A' ' 110' ' ' GLY . 2.3 p30 -48.62 -49.48 36.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.799 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . 0.4 ' N ' ' CG ' ' A' ' 109' ' ' ASP . . . -38.36 -37.2 0.47 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.469 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.536 ' HE3' HG22 ' A' ' 107' ' ' VAL . 27.6 mtm -86.43 -45.46 11.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.779 0.323 . . . . 0.0 110.848 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 13.9 tp -54.12 -20.36 6.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.905 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.504 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 15.0 t80 -86.19 -60.67 1.94 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.925 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.76 ' HA ' HG12 ' A' ' 117' ' ' VAL . 33.7 mt-10 -59.38 -46.73 87.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.879 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.495 ' CG ' HD13 ' A' ' 163' ' ' LEU . 69.5 t80 -48.03 -33.81 8.51 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.896 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.495 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.2 m-85 -95.02 -66.61 0.9 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.881 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.76 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.59 -30.0 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.091 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.474 ' N ' ' O ' ' A' ' 116' ' ' PHE . 0.0 OUTLIER -65.08 -57.29 9.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.915 179.922 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.551 HG22 ' CE2' ' A' ' 120' ' ' TYR . 2.6 p -66.4 -34.8 72.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.144 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.551 ' CE2' HG22 ' A' ' 119' ' ' VAL . 91.8 m-85 -135.22 115.67 11.93 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-O 121.701 0.762 . . . . 0.0 110.954 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 2.9 3.14 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.69 2.26 . . . . 0.0 112.321 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.0 p -86.06 -18.94 31.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 29.2 t -53.06 135.96 36.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.882 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 18.3 mtt180 -98.88 -30.86 12.15 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.877 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.504 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 161.62 147.73 5.07 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.484 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -91.35 141.67 15.77 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.533 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.85 105.29 7.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.756 0.312 . . . . 0.0 110.874 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -98.23 149.14 5.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.155 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.992 HG21 ' CE1' ' A' ' 139' ' ' TYR . 19.5 m -95.86 142.57 13.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.102 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.639 HD23 ' HA ' ' A' ' 136' ' ' SER . 13.9 mt -130.0 173.4 10.76 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.898 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.421 ' O ' ' N ' ' A' ' 134' ' ' GLY . 26.3 t0 -107.34 171.97 7.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.865 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -44.54 -26.0 0.32 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.92 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 49.2 p -86.42 -33.94 20.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.124 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 109.14 20.62 7.81 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.502 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.582 HG23 ' O ' ' A' ' 135' ' ' VAL . 25.0 m -100.19 115.71 41.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.881 0.372 . . . . 0.0 111.101 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.639 ' HA ' HD23 ' A' ' 130' ' ' LEU . 8.4 t -37.65 103.64 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.837 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.8 mttm -43.59 -37.49 2.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.891 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 129.43 20.46 1.4 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.464 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.992 ' CE1' HG21 ' A' ' 129' ' ' VAL . 28.0 p90 -161.39 -179.31 7.27 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.922 0.391 . . . . 0.0 110.923 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.443 ' C ' HG22 ' A' ' 100' ' ' VAL . . . 177.17 -166.33 36.86 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.472 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 3.6 m-85 -153.37 139.37 18.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.86 0.362 . . . . 0.0 110.935 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.495 HG11 ' CD2' ' A' ' 116' ' ' PHE . 27.8 m -112.93 -178.23 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -140.36 163.8 31.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.923 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -149.83 167.12 27.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.89 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 58.6 p -102.33 -12.07 18.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.118 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -137.04 122.33 19.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.895 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.501 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 4.6 tt0 -60.11 -37.5 80.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.905 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 34.9 mt -52.39 -49.97 63.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.935 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -70.04 -33.29 71.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.878 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.593 ' CG ' HD21 ' A' ' 98' ' ' LEU . 28.6 tt0 -58.44 -57.05 14.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.957 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.572 ' HD3' HD12 ' A' ' 154' ' ' LEU . 30.2 mmtm -59.11 -42.28 90.16 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.899 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 40.6 mtt-85 -54.69 -30.62 56.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.902 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.487 ' O ' ' CD1' ' A' ' 170' ' ' LEU . . . -73.36 -34.53 65.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.06 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.796 HD23 ' HB3' ' A' ' 170' ' ' LEU . 43.9 mt -56.51 -40.36 74.9 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.905 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 15.1 t -92.43 -34.3 14.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.128 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 39.0 mm-40 -78.55 -58.3 3.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.864 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.587 ' C ' HD11 ' A' ' 170' ' ' LEU . 36.0 m -79.96 11.77 3.15 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . 0.477 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 3.5 tp-100 -52.92 137.81 31.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.955 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.62 33.46 0.59 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.469 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.472 ' O ' HG22 ' A' ' 168' ' ' VAL . . . -53.17 116.73 2.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.815 0.34 . . . . 0.0 111.1 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' A' ' 162' ' ' GLY . 24.1 t -86.91 -35.41 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.137 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.18 -38.6 0.26 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.535 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.495 HD13 ' CG ' ' A' ' 115' ' ' PHE . 18.9 tp -87.42 115.36 24.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.871 0.367 . . . . 0.0 110.864 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.42 159.19 1.03 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.511 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 71.1 m -62.47 -16.62 56.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.936 0.398 . . . . 0.0 110.869 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . 0.451 ' HB2' HG23 ' A' ' 104' ' ' THR . 28.3 mttp -113.33 155.79 44.09 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.584 0.707 . . . . 0.0 110.905 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 173.51 10.86 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.757 2.304 . . . . 0.0 112.336 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.472 HG22 ' O ' ' A' ' 160' ' ' ALA . 27.1 m -128.51 125.93 64.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.091 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 11.3 ttm180 -88.44 108.61 19.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.889 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.796 ' HB3' HD23 ' A' ' 154' ' ' LEU . 17.1 mt -84.23 147.27 27.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 4.5 m -163.95 177.42 8.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 39.7 t -103.55 101.7 12.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.571 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.116 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 13.1 m-85 . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.851 0.358 . . . . 0.0 110.934 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.7 p -110.07 138.01 47.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.83 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.65 HD12 ' CE2' ' A' ' 144' ' ' PHE . 97.5 mt -111.25 146.77 36.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.933 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -93.09 130.73 38.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.907 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.495 HG22 ' C ' ' A' ' 140' ' ' GLY . 17.9 m -123.55 149.27 27.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.15 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.99 -167.63 11.0 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 41.44 52.57 3.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.828 0.347 . . . . 0.0 110.861 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.416 HD12 ' C ' ' A' ' 139' ' ' TYR . 26.4 mt -101.04 101.63 12.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.561 ' OG1' HG23 ' A' ' 107' ' ' VAL . 75.9 p -47.01 150.2 1.41 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.556 0.693 . . . . 0.0 111.17 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 3.12 2.96 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.69 2.26 . . . . 0.0 112.359 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 -100.57 -0.74 37.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.561 HG23 ' OG1' ' A' ' 104' ' ' THR . 20.9 t -108.01 136.52 43.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.168 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -118.92 175.77 5.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.868 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -58.29 -36.2 72.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -53.65 -33.92 49.25 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.542 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.455 ' CE ' HG13 ' A' ' 107' ' ' VAL . 23.7 mtm -83.69 -55.01 4.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.806 0.336 . . . . 0.0 110.921 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.409 HD23 ' N ' ' A' ' 127' ' ' LYS . 29.4 tp -41.02 -37.37 0.81 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.943 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.435 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 17.6 t80 -70.19 -65.92 0.66 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.942 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.737 ' HA ' HG12 ' A' ' 117' ' ' VAL . 19.1 mt-10 -49.42 -53.19 24.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.897 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.602 ' CB ' HD13 ' A' ' 163' ' ' LEU . 58.2 t80 -44.58 -33.29 1.72 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.934 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.565 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.6 m-85 -93.99 -66.7 0.9 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.888 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.737 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.88 -31.09 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.108 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.456 ' N ' ' O ' ' A' ' 116' ' ' PHE . 0.5 OUTLIER -65.31 -61.28 2.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.949 179.884 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.631 HG22 ' CD2' ' A' ' 120' ' ' TYR . 1.6 p -64.65 -32.56 58.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.157 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.631 ' CD2' HG22 ' A' ' 119' ' ' VAL . 97.8 m-85 -131.23 113.82 15.94 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.657 0.741 . . . . 0.0 110.933 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 1.09 4.76 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.67 2.247 . . . . 0.0 112.331 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 1.4 p -104.14 31.95 4.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.804 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 41.9 t -91.12 124.9 35.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.472 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 22.5 mtp180 -79.18 -39.54 33.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.873 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.435 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 159.74 154.18 7.18 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.524 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -97.29 147.0 18.51 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.514 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.409 ' N ' HD23 ' A' ' 112' ' ' LEU . 2.7 tmtp? -137.66 112.58 9.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.839 0.352 . . . . 0.0 110.887 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . 0.526 HG13 ' O ' ' A' ' 128' ' ' VAL . 12.8 p -106.76 119.43 56.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.127 179.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.746 HG22 ' O ' ' A' ' 139' ' ' TYR . 20.1 m -63.75 155.5 5.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 20.8 mt -134.81 167.66 20.46 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.426 ' O ' ' N ' ' A' ' 134' ' ' GLY . 20.6 t70 -99.65 175.4 5.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . 0.452 ' HG3' ' N ' ' A' ' 133' ' ' THR . 20.2 pt20 -43.38 -43.33 5.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . 0.452 ' N ' ' HG3' ' A' ' 132' ' ' GLN . 34.3 p -72.65 -28.47 62.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.166 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 106.48 24.59 6.69 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.523 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 31.3 m -103.45 137.18 32.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.821 0.344 . . . . 0.0 111.1 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 1.6 t -48.95 110.46 0.36 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.835 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.461 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.1 mtmt -57.16 -33.86 67.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.882 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 127.31 17.54 2.17 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.537 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.746 ' O ' HG22 ' A' ' 129' ' ' VAL . 24.7 p90 -162.2 174.16 13.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.943 0.402 . . . . 0.0 110.949 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.495 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -177.94 -161.29 25.86 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.471 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -153.09 148.19 26.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.85 0.357 . . . . 0.0 110.897 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.565 HG11 ' CD2' ' A' ' 116' ' ' PHE . 16.9 m -118.63 -177.16 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.175 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . 0.472 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 40.5 mtmt -144.17 157.21 44.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.878 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.65 ' CE2' HD12 ' A' ' 98' ' ' LEU . 76.3 m-85 -146.93 160.72 41.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 32.8 p -102.01 -16.08 16.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.191 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -120.28 110.72 16.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.836 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 11.9 tt0 -57.91 -41.59 82.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.887 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 75.4 mt -48.16 -47.96 34.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.935 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.557 ' N ' ' CD ' ' A' ' 149' ' ' GLU . 0.0 OUTLIER -72.22 -44.6 62.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.887 179.899 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.437 ' C ' ' O ' ' A' ' 149' ' ' GLU . 20.2 tt0 -34.84 -58.59 0.51 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.93 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 12.6 mmtp -63.49 -34.35 77.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.912 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . 0.577 ' HB3' ' CE1' ' A' ' 120' ' ' TYR . 4.0 tpt180 -51.61 -41.03 60.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.849 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -71.77 -44.77 63.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.091 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.764 HD23 ' HB3' ' A' ' 170' ' ' LEU . 29.7 mt -50.47 -38.34 43.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.472 HG23 ' HG2' ' A' ' 156' ' ' GLU . 14.6 t -92.57 -37.08 12.66 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.472 ' HG2' HG23 ' A' ' 155' ' ' THR . 6.7 mm-40 -83.05 -65.02 1.06 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.897 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.494 ' N ' ' O ' ' A' ' 153' ' ' ALA . 76.2 m -62.8 -8.22 6.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.921 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -37.71 128.96 1.14 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.858 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 50.36 38.89 34.99 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.464 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.517 ' O ' HG22 ' A' ' 168' ' ' VAL . . . -60.0 116.35 4.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.813 0.34 . . . . 0.0 111.141 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.42 ' O ' ' C ' ' A' ' 162' ' ' GLY . 23.9 t -85.28 -37.85 12.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.144 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.75 -37.2 0.21 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.514 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.602 HD13 ' CB ' ' A' ' 115' ' ' PHE . 17.0 tp -86.38 114.52 23.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.848 0.356 . . . . 0.0 110.926 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 64.54 151.78 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.487 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 9.4 t -51.3 -25.28 5.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.948 0.404 . . . . 0.0 110.835 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . 0.402 ' HB2' HG23 ' A' ' 104' ' ' THR . 53.5 mttt -106.45 156.18 37.46 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.568 0.699 . . . . 0.0 110.892 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -175.42 1.15 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.682 2.255 . . . . 0.0 112.323 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.517 HG22 ' O ' ' A' ' 160' ' ' ALA . 12.6 m -137.84 128.63 37.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.139 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 7.8 mtp85 -88.51 111.89 22.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.846 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.764 ' HB3' HD23 ' A' ' 154' ' ' LEU . 15.3 mt -91.83 140.47 29.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 13.9 m -155.83 -177.61 6.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.833 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 4.7 t -102.69 100.13 9.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.149 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.119 179.892 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . 0.495 ' CE2' ' HB2' ' A' ' 147' ' ' GLU . 47.5 m-85 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.855 0.36 . . . . 0.0 110.944 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 11.1 m -120.65 154.79 35.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.849 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.531 HD22 HD21 ' A' ' 154' ' ' LEU . 22.4 mt -120.37 144.48 47.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.927 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -94.96 123.06 38.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.9 m -114.88 149.05 17.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.44 -175.1 13.65 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.509 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 50.83 50.01 19.89 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.806 0.336 . . . . 0.0 110.897 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 30.9 mt -98.94 104.34 16.38 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.924 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.631 HG23 ' HB2' ' A' ' 166' ' ' LYS . 14.9 p -49.08 150.16 3.01 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.583 0.706 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 2.95 3.08 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.651 2.234 . . . . 0.0 112.342 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -99.69 -13.4 19.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.865 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.724 HG22 ' HE3' ' A' ' 111' ' ' MET . 73.1 t -96.2 138.95 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.153 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.94 -176.11 3.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.849 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -65.4 -41.74 93.33 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.88 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.47 -34.47 13.78 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.475 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.724 ' HE3' HG22 ' A' ' 107' ' ' VAL . 25.5 mtm -81.71 -49.61 10.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.816 0.341 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.9 tp -50.86 -34.42 27.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.925 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . . . . . . . . . 12.9 t80 -68.8 -61.45 1.8 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.946 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.769 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.1 mt-10 -57.28 -53.86 53.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.847 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.426 ' HB2' HD13 ' A' ' 163' ' ' LEU . 69.2 t80 -42.3 -32.46 0.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.526 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.6 m-85 -95.17 -67.97 0.83 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.769 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.7 -29.37 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.489 ' N ' ' O ' ' A' ' 116' ' ' PHE . 19.1 tptt -67.46 -60.67 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.68 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.1 p -65.18 -31.91 55.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.133 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.68 ' CD2' HG13 ' A' ' 119' ' ' VAL . 97.3 m-85 -134.11 114.3 12.7 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.647 0.737 . . . . 0.0 110.965 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.31 8.25 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.678 2.252 . . . . 0.0 112.377 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 87.2 p -85.9 -16.45 38.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.834 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.4 t -52.22 139.7 23.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.839 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 42.0 mtm180 -105.0 -33.57 8.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.875 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 166.66 145.62 4.54 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.451 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.454 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -95.25 137.54 13.49 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.475 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -125.87 122.43 36.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.783 0.325 . . . . 0.0 110.914 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.0 p -113.62 138.14 44.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.137 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.976 HG22 ' O ' ' A' ' 139' ' ' TYR . 33.7 m -86.17 152.08 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.131 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.572 HD23 ' HA ' ' A' ' 136' ' ' SER . 17.8 mt -130.84 176.37 8.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.486 ' O ' ' N ' ' A' ' 134' ' ' GLY . 25.6 t0 -107.52 174.27 5.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -39.6 -40.27 0.86 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.909 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 30.4 p -74.83 -33.75 62.22 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.158 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 112.83 17.78 7.75 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.498 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 34.0 m -97.88 133.47 39.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.872 0.368 . . . . 0.0 111.105 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.572 ' HA ' HD23 ' A' ' 130' ' ' LEU . 2.6 t -43.2 105.68 0.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.889 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.499 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 27.1 mtmt -50.64 -35.82 32.39 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.897 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 129.27 20.22 1.45 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.483 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.976 ' O ' HG22 ' A' ' 129' ' ' VAL . 27.4 p90 -163.81 169.06 18.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.909 0.385 . . . . 0.0 110.95 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -171.87 -163.29 25.54 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.446 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -153.58 148.67 26.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.89 0.376 . . . . 0.0 110.898 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.526 HG11 ' CD2' ' A' ' 116' ' ' PHE . 27.8 m -124.6 168.49 17.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . 0.448 ' HD3' ' N ' ' A' ' 143' ' ' LYS . 0.0 OUTLIER -125.97 159.19 33.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.936 179.896 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -145.37 157.5 44.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.915 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 76.4 p -96.73 -19.22 19.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.169 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -120.64 120.58 36.14 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.863 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.495 ' HB2' ' CE2' ' A' ' 96' ' ' TYR . 0.1 OUTLIER -67.31 -39.19 85.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 39.3 mt -52.62 -34.44 51.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.911 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -85.06 -37.07 20.76 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.876 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 -43.84 -57.28 3.35 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.537 ' HA ' HD12 ' A' ' 154' ' ' LEU . 73.2 mttt -65.07 -27.53 68.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 15.1 ttt180 -59.94 -40.88 90.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.849 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.464 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -69.33 -46.12 67.85 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.136 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.76 HD23 ' HB3' ' A' ' 170' ' ' LEU . 29.7 mt -43.62 -40.82 4.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.906 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.505 HG23 ' N ' ' A' ' 156' ' ' GLU . 10.9 t -92.52 -45.32 8.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.119 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.505 ' N ' HG23 ' A' ' 155' ' ' THR . 12.2 mm-40 -67.38 -60.08 2.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.894 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.464 ' N ' ' O ' ' A' ' 153' ' ' ALA . 4.8 m -78.21 9.59 3.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . 0.43 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.8 tp-100 -51.85 128.73 24.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.894 -179.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 51.37 35.23 35.25 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.491 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -57.94 121.94 11.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.794 0.33 . . . . 0.0 111.122 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 25.6 t -93.38 -34.72 6.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.65 -34.12 0.24 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.501 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.426 HD13 ' HB2' ' A' ' 115' ' ' PHE . 29.1 tp -91.57 115.69 28.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.822 0.344 . . . . 0.0 110.895 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . 0.449 ' HA3' HG21 ' A' ' 107' ' ' VAL . . . 65.17 146.14 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.531 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . 0.445 ' HB3' HG21 ' A' ' 104' ' ' THR . 6.2 t -48.97 -20.45 0.52 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.912 0.387 . . . . 0.0 110.86 -179.753 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . 0.631 ' HB2' HG23 ' A' ' 104' ' ' THR . 16.2 mtmt -108.48 155.29 40.69 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.586 0.708 . . . . 0.0 110.916 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 -173.07 0.65 Allowed 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.672 2.248 . . . . 0.0 112.38 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.491 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 34.6 m -139.62 124.53 20.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.075 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 39.8 ttm-85 -91.4 99.99 12.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.868 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.76 ' HB3' HD23 ' A' ' 154' ' ' LEU . 14.0 mt -76.36 145.73 39.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.905 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.421 ' N ' ' CD2' ' A' ' 154' ' ' LEU . 4.3 m -160.74 178.32 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.847 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 36.9 t -105.61 104.17 16.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.143 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.115 179.904 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . 0.5 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 21.1 m-85 . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.934 0.397 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 12.3 p -137.48 145.45 43.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.864 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.753 HD22 HD21 ' A' ' 154' ' ' LEU . 47.1 mt -120.99 139.17 53.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.945 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.907 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 12.3 t80 -90.22 131.07 36.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.899 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.521 HG22 ' C ' ' A' ' 140' ' ' GLY . 25.2 m -121.99 155.77 26.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.142 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -142.92 178.17 21.4 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.449 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 52.93 53.87 11.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.817 0.341 . . . . 0.0 110.831 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.406 HD23 ' HA ' ' A' ' 103' ' ' LEU . 24.6 mt -100.35 100.17 10.92 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.905 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.532 ' OG1' HG23 ' A' ' 107' ' ' VAL . 58.5 p -46.71 150.0 1.35 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.552 0.691 . . . . 0.0 111.172 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 2.75 3.25 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -102.43 6.81 40.34 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.835 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 1.086 HG13 ' HE2' ' A' ' 111' ' ' MET . 12.9 t -119.6 129.93 74.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.124 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -116.95 177.03 4.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.86 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -51.05 -53.75 30.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.836 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -38.74 -35.61 0.37 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.44 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 1.086 ' HE2' HG13 ' A' ' 107' ' ' VAL . 48.7 mtp -81.93 -59.43 2.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.807 0.336 . . . . 0.0 110.901 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.486 HD23 ' N ' ' A' ' 127' ' ' LYS . 22.5 tp -42.08 -31.43 0.36 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.914 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.541 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 10.9 t80 -72.24 -66.59 0.63 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.942 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.738 ' HA ' HG12 ' A' ' 117' ' ' VAL . 46.8 mt-10 -52.43 -47.39 66.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.873 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.508 ' CZ ' ' HB2' ' A' ' 163' ' ' LEU . 60.4 t80 -48.11 -33.08 7.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.896 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.492 ' CD2' HG11 ' A' ' 142' ' ' VAL . 8.1 m-85 -94.99 -66.23 0.93 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.904 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.738 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.74 -31.45 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.122 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.451 ' N ' ' O ' ' A' ' 116' ' ' PHE . 30.3 tttp -64.66 -58.16 7.06 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.878 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.454 HG13 ' CD2' ' A' ' 120' ' ' TYR . 2.8 p -66.7 -33.97 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.148 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.559 ' CD1' ' HB3' ' A' ' 149' ' ' GLU . 90.2 m-85 -129.55 115.09 18.21 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.714 0.768 . . . . 0.0 110.935 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.7 Cg_endo -69.79 -2.72 10.67 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.678 2.252 . . . . 0.0 112.361 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 56.4 m -104.85 39.87 1.61 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 49.6 t -98.17 132.43 43.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.89 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.448 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 19.7 mmt180 -83.26 -35.26 25.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 -179.847 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.541 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 148.34 139.99 3.26 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.464 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.768 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -82.88 148.61 25.97 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.509 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.486 ' N ' HD23 ' A' ' 112' ' ' LEU . 12.5 tptp -139.47 117.25 11.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.84 0.352 . . . . 0.0 110.881 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -106.04 146.76 12.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.145 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.81 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 30.1 m -93.66 150.93 3.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.08 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 15.5 mt -129.57 165.43 21.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.864 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -95.7 -177.2 3.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.848 179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -50.08 -37.6 34.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.941 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 41.0 p -75.16 -33.67 61.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.172 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 114.64 18.46 6.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.472 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 34.9 m -98.06 144.57 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.844 0.354 . . . . 0.0 111.114 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.9 t -56.79 105.06 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.48 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.1 mtmt -47.84 -29.18 3.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.89 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 121.0 18.37 3.88 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.542 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.81 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 9.9 p90 -161.8 175.89 11.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.926 0.393 . . . . 0.0 110.926 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.521 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -178.88 -162.23 27.94 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.44 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -153.64 146.32 24.24 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.896 0.379 . . . . 0.0 110.895 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.768 HG12 ' HA2' ' A' ' 126' ' ' GLY . 15.8 m -121.2 -176.61 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . 0.448 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 39.8 mtmt -144.56 162.78 35.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.886 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -149.78 159.04 44.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 69.8 p -93.92 -33.27 13.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.129 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 21.2 t0 -108.53 115.89 30.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.871 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.5 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 7.6 tt0 -59.62 -36.25 75.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.924 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 62.9 mt -53.31 -40.11 64.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.91 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.559 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 61.7 mt-10 -85.79 -22.48 27.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.856 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.517 ' O ' HD11 ' A' ' 98' ' ' LEU . 18.3 tt0 -57.73 -53.67 55.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.91 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 3.2 mtpm? -69.24 -43.62 73.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.935 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 53.1 mtt-85 -45.54 -35.96 4.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.844 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.405 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -72.2 -43.43 64.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.753 HD21 HD22 ' A' ' 98' ' ' LEU . 17.6 mt -46.1 -41.79 12.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 156' ' ' GLU . 12.3 t -91.37 -48.96 6.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.572 ' N ' HG23 ' A' ' 155' ' ' THR . 43.2 mm-40 -62.07 -66.5 0.53 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.479 ' CB ' HD11 ' A' ' 170' ' ' LEU . 66.4 m -62.83 -13.01 28.47 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.89 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 4.2 tp-100 -37.68 131.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.926 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 59.9 30.24 69.35 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.485 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.838 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -52.94 111.35 0.65 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.834 0.35 . . . . 0.0 111.083 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.4 t -89.35 -38.82 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.141 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -41.1 -32.35 0.6 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.451 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.508 ' HB2' ' CZ ' ' A' ' 115' ' ' PHE . 24.1 tp -90.84 116.27 28.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.857 0.36 . . . . 0.0 110.95 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 62.08 143.03 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.45 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 50.2 m -42.08 -32.16 0.43 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.934 0.397 . . . . 0.0 110.868 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 24.5 mttm -100.76 154.38 37.2 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.535 0.684 . . . . 0.0 110.888 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -178.99 2.6 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.697 2.264 . . . . 0.0 112.368 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.838 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 34.1 m -131.48 125.35 56.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.099 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 35.0 ttm180 -88.57 104.96 17.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.868 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.522 ' HB3' HD23 ' A' ' 154' ' ' LEU . 9.1 mt -84.18 145.86 28.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.938 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 5.1 m -159.24 173.72 15.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.855 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . 0.404 HG22 ' CD1' ' A' ' 154' ' ' LEU . 5.4 t -95.25 90.79 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.163 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.907 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.095 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.918 0.389 . . . . 0.0 110.917 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 77.3 p -129.53 157.36 42.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.867 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.855 HD22 HD21 ' A' ' 154' ' ' LEU . 87.1 mt -127.47 148.65 50.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.904 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.433 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 8.4 t80 -95.78 130.49 42.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.882 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -122.72 139.35 49.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.147 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -126.9 178.98 16.57 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.484 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 53.34 51.47 15.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.85 0.357 . . . . 0.0 110.903 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . 0.501 HD12 ' C ' ' A' ' 139' ' ' TYR . 21.3 mt -95.48 101.05 12.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.694 ' OG1' HG23 ' A' ' 107' ' ' VAL . 63.3 p -48.49 150.11 2.54 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.588 0.709 . . . . 0.0 111.133 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 2.96 3.04 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.679 2.253 . . . . 0.0 112.334 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -102.75 2.5 35.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.843 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.694 HG23 ' OG1' ' A' ' 104' ' ' THR . 5.7 t -108.49 136.64 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.116 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -124.66 168.43 13.17 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.906 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -46.29 -45.9 17.62 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.833 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.97 -36.45 20.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.512 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.434 ' HE2' HG13 ' A' ' 107' ' ' VAL . 19.2 mtp -78.56 -58.4 3.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.772 0.32 . . . . 0.0 110.846 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.594 HD23 ' N ' ' A' ' 127' ' ' LYS . 19.4 tp -45.32 -36.27 4.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.935 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.529 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 7.4 t80 -67.24 -61.11 2.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.901 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.751 ' HA ' HG12 ' A' ' 117' ' ' VAL . 44.6 mt-10 -57.17 -54.58 45.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.872 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.489 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 69.5 t80 -42.08 -32.19 0.44 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.855 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.586 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.8 m-85 -95.19 -67.54 0.85 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.892 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.751 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.69 -29.17 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.081 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.496 ' N ' ' O ' ' A' ' 116' ' ' PHE . 46.3 tttp -67.88 -57.19 6.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.907 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.677 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.8 p -71.15 -25.1 24.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.114 179.856 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.677 ' CD2' HG13 ' A' ' 119' ' ' VAL . 95.9 m-85 -135.26 109.17 10.44 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.702 0.763 . . . . 0.0 110.926 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . 0.426 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.4 Cg_endo -69.81 2.96 3.09 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.716 2.278 . . . . 0.0 112.357 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 15.0 m -109.97 30.83 6.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.834 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 42.6 t -92.83 132.12 37.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.903 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.46 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 42.2 mtp180 -83.31 -29.13 28.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.909 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.529 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 147.0 139.24 3.25 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.488 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.68 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -93.24 135.9 12.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.512 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . 0.594 ' N ' HD23 ' A' ' 112' ' ' LEU . 0.1 OUTLIER -121.4 143.71 49.07 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.784 0.326 . . . . 0.0 110.95 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.97 127.16 72.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.13 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.816 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 7.0 m -76.32 138.19 21.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.149 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 136' ' ' SER . 26.1 mt -116.28 160.68 20.12 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -87.88 -176.58 5.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -52.85 -37.24 60.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.921 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 27.6 p -75.76 -21.81 57.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.091 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.99 22.36 10.12 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.456 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 24.0 m -106.3 140.83 23.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.797 0.332 . . . . 0.0 111.159 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . 0.438 ' HA ' HD23 ' A' ' 130' ' ' LEU . 2.7 t -47.06 108.63 0.15 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.867 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.473 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 30.4 mtmt -54.64 -32.26 58.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.912 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.24 17.44 2.44 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.491 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.816 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 17.2 p90 -163.76 171.27 15.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.913 0.387 . . . . 0.0 110.937 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -172.75 -162.59 25.13 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.447 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -154.0 142.4 20.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.878 0.37 . . . . 0.0 110.896 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.68 HG12 ' HA2' ' A' ' 126' ' ' GLY . 29.0 m -117.24 170.9 6.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.126 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . 0.46 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -131.05 160.54 34.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.948 179.849 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.41 ' CE2' HG23 ' A' ' 142' ' ' VAL . 86.2 m-85 -148.81 162.53 39.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.903 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 33.7 p -98.41 -26.6 14.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.154 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . 0.431 ' CG ' ' OE1' ' A' ' 149' ' ' GLU . 4.9 t70 -112.1 119.73 39.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.864 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -67.29 -31.65 72.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.908 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 21.7 mt -56.81 -54.01 51.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.893 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 150' ' ' GLN . 1.9 mp0 -64.81 -45.87 84.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.905 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.449 ' C ' ' O ' ' A' ' 149' ' ' GLU . 21.7 tt0 -33.46 -46.86 0.2 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.949 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . 0.434 ' O ' ' N ' ' A' ' 154' ' ' LEU . 13.8 mmtp -66.98 -55.76 13.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -38.69 -35.12 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.599 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -72.72 -44.89 61.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.855 HD21 HD22 ' A' ' 98' ' ' LEU . 16.1 mt -47.16 -38.95 12.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.925 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.616 HG23 ' N ' ' A' ' 156' ' ' GLU . 12.1 t -92.47 -51.12 5.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.145 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.616 ' N ' HG23 ' A' ' 155' ' ' THR . 79.1 mm-40 -64.35 -57.79 8.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.632 ' C ' HD11 ' A' ' 170' ' ' LEU . 53.3 m -75.18 5.33 5.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.871 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 3.3 tp-100 -53.1 137.45 33.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.903 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 45.48 37.24 6.39 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.468 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.862 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -54.89 116.19 2.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.894 0.378 . . . . 0.0 111.104 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 32.7 t -94.74 -33.45 4.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.16 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -45.04 -33.55 3.77 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.51 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.489 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 56.4 tp -85.63 115.24 23.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.866 0.365 . . . . 0.0 110.915 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 69.88 175.21 14.81 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.51 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 11.7 m -84.19 25.87 0.81 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.92 0.391 . . . . 0.0 110.825 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . 0.468 ' HB2' HG23 ' A' ' 104' ' ' THR . 19.7 mttp -157.24 157.05 30.16 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.585 0.707 . . . . 0.0 110.909 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 170.24 17.02 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.654 2.236 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.862 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 30.1 m -132.37 125.98 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.129 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 36.3 ttt85 -88.89 117.12 27.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.665 ' HB3' HD23 ' A' ' 154' ' ' LEU . 11.7 mt -93.24 139.37 30.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.894 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 15.9 m -156.55 173.0 17.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.836 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 15.6 t -93.79 99.21 9.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.134 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . 0.433 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . . . . . . 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.06 179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' TYR . . . . . 0.466 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 4.3 m-85 . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.89 0.376 . . . . 0.0 110.946 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 35.4 p -126.72 155.02 43.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.836 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' LEU . . . . . 0.611 HD21 ' CD ' ' A' ' 150' ' ' GLN . 85.9 mt -124.87 139.57 53.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -90.27 125.97 35.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.415 HG22 ' C ' ' A' ' 140' ' ' GLY . 15.9 m -120.8 141.43 41.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.131 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -129.78 -175.87 14.21 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.431 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 51.13 52.65 14.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.839 0.352 . . . . 0.0 110.88 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 22.3 mt -98.49 112.67 24.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.978 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.419 HG21 ' HB2' ' A' ' 165' ' ' SER . 10.2 p -58.55 150.82 54.29 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.591 0.71 . . . . 0.0 111.115 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 2.42 3.55 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.689 2.259 . . . . 0.0 112.342 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -99.42 -5.67 29.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.822 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' VAL . . . . . 0.486 HG13 ' HE2' ' A' ' 111' ' ' MET . 31.6 t -102.08 143.49 14.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.162 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -127.93 173.87 9.65 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -54.0 -45.25 71.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.862 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.99 -26.28 26.6 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.488 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' MET . . . . . 0.486 ' HE2' HG13 ' A' ' 107' ' ' VAL . 35.0 mtp -85.36 -58.52 2.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.825 0.345 . . . . 0.0 110.885 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 40.5 tp -42.86 -36.7 1.58 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.919 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' TYR . . . . . 0.455 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.6 t80 -66.3 -68.33 0.38 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.88 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.715 ' HA ' HG12 ' A' ' 117' ' ' VAL . 23.8 mt-10 -48.9 -41.72 34.48 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.91 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' PHE . . . . . 0.519 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 53.8 t80 -54.29 -34.1 60.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.849 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' PHE . . . . . 0.464 ' O ' ' N ' ' A' ' 118' ' ' LYS . 9.1 m-85 -95.19 -64.36 1.07 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.895 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' VAL . . . . . 0.715 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.7 -30.91 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.105 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' LYS . . . . . 0.464 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.1 ttpt -65.01 -61.17 2.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.916 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.455 HG13 ' CD2' ' A' ' 120' ' ' TYR . 2.5 p -66.78 -34.35 69.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.097 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' TYR . . . . . 0.509 ' CE2' ' HB2' ' A' ' 153' ' ' ALA . 90.7 m-85 -126.05 109.02 24.65 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.673 0.749 . . . . 0.0 110.946 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 2.13 3.8 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.69 2.26 . . . . 0.0 112.328 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 10.6 m -108.32 34.4 3.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.2 t -90.32 135.43 33.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.855 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.46 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 63.1 mtt180 -85.14 -36.39 21.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.455 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 154.48 143.04 3.58 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.484 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.67 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -91.52 138.68 14.4 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.488 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.71 131.96 45.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.79 0.328 . . . . 0.0 110.914 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 8.7 p -117.3 137.19 52.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.143 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' VAL . . . . . 0.873 HG22 ' O ' ' A' ' 139' ' ' TYR . 18.7 m -81.03 148.44 5.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.118 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 16.3 mt -133.09 169.8 16.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.88 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -104.22 177.32 4.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -46.36 -36.47 6.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 41.5 p -77.75 -33.27 52.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.49 17.04 9.57 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.49 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 135' ' ' VAL . 20.3 m -96.42 127.63 48.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.342 . . . . 0.0 111.104 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 9.3 t -43.79 108.86 0.12 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.869 -179.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' LYS . . . . . 0.511 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.5 mtmt -52.51 -31.36 34.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.932 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.36 19.77 2.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.524 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' TYR . . . . . 0.873 ' O ' HG22 ' A' ' 129' ' ' VAL . 26.5 p90 -163.62 169.67 18.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.389 . . . . 0.0 110.915 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' GLY . . . . . 0.415 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -169.14 -163.86 23.87 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.446 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -153.86 148.91 26.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.917 0.389 . . . . 0.0 110.871 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.67 HG12 ' HA2' ' A' ' 126' ' ' GLY . 16.6 m -124.33 179.29 2.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.091 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' LYS . . . . . 0.46 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 22.9 mtpt -142.57 161.52 37.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.929 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.403 ' HE1' HG23 ' A' ' 142' ' ' VAL . 37.7 m-85 -149.9 153.66 37.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.877 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 51.5 p -91.5 -19.14 23.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -113.92 110.29 19.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.863 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' GLU . . . . . 0.466 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 16.0 tt0 -60.29 -35.75 76.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 93.6 mt -57.88 -45.01 87.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.946 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -74.56 -43.57 55.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.864 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' GLN . . . . . 0.611 ' CD ' HD21 ' A' ' 98' ' ' LEU . 1.6 tm0? -44.18 -38.91 4.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.976 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 24.7 mmtt -76.51 -40.3 50.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.921 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 54.9 mtt85 -53.84 -31.58 49.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.906 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' ALA . . . . . 0.509 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -69.1 -54.06 17.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.101 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.576 HD23 ' CB ' ' A' ' 170' ' ' LEU . 21.8 mt -40.27 -36.33 0.51 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.907 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' THR . . . . . 0.422 HG23 ' N ' ' A' ' 156' ' ' GLU . 7.7 t -92.4 -42.36 9.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.122 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' GLU . . . . . 0.422 ' N ' HG23 ' A' ' 155' ' ' THR . 24.0 mm-40 -75.68 -62.93 1.42 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.903 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' CYS . . . . . 0.574 ' CB ' HD11 ' A' ' 170' ' ' LEU . 53.7 m -67.13 -3.82 8.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.7 tp-100 -41.8 131.11 3.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.91 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 47.4 41.18 16.7 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.539 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' ALA . . . . . 0.564 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -60.22 111.05 1.38 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.788 0.328 . . . . 0.0 111.109 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.7 t -84.97 -35.66 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.132 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.5 -35.53 0.33 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.473 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' LEU . . . . . 0.463 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 29.7 tp -88.7 122.12 31.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.861 0.362 . . . . 0.0 110.921 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 61.94 157.62 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.486 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' SER . . . . . 0.419 ' HB2' HG21 ' A' ' 104' ' ' THR . 72.0 m -60.62 -12.51 10.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.923 0.392 . . . . 0.0 110.864 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 61.8 mttt -118.44 156.8 50.74 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.571 0.701 . . . . 0.0 110.88 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -177.26 1.8 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.651 2.234 . . . . 0.0 112.374 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' VAL . . . . . 0.564 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 29.8 m -138.73 124.76 24.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.154 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 34.6 ttt180 -87.84 107.0 18.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' LEU . . . . . 0.576 ' CB ' HD23 ' A' ' 154' ' ' LEU . 10.3 mt -81.98 146.84 29.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.908 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 8.0 m -163.33 179.73 7.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.839 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 13.4 t -102.66 101.75 12.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.128 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.117 179.88 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 N-CA-C 112.533 -0.227 . . . . 0.0 112.533 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 79.8 p -89.19 42.0 1.06 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.911 0.386 . . . . 0.0 110.852 -179.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 88.1 p -58.41 123.47 16.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.856 -179.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 149.17 49.14 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.486 -179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 2.9 m -155.26 111.02 3.1 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.866 0.365 . . . . 0.0 110.853 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 27.4 t -86.31 82.02 8.16 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.887 -179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 80.09 69.1 1.42 Allowed Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.529 -179.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -173.27 0.68 Allowed 'Trans proline' 0 C--N 1.341 0.15 0 C-N-CA 122.695 2.263 . . . . 0.0 112.372 -179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -126.07 143.69 51.01 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.9 -179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . 0.523 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 67.3 m-85 -128.08 86.79 2.51 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.924 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 28.8 m -97.91 161.68 13.62 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.876 -179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.884 HD22 HD21 ' A' ' 154' ' ' LEU . 26.0 mt -125.78 143.57 51.0 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.899 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 6.9 t80 -93.47 115.78 28.31 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.523 HG22 ' C ' ' A' ' 140' ' ' GLY . 5.3 m -108.09 148.48 12.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.143 179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.7 -177.41 15.14 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.505 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . 0.42 ' N ' ' O ' ' A' ' 138' ' ' GLY . 24.8 m-20 50.87 51.81 16.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.868 0.366 . . . . 0.0 110.887 -179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.412 HD11 ' CG2' ' A' ' 100' ' ' VAL . 31.1 mt -98.27 102.58 14.37 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.897 -179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.501 ' OG1' HG23 ' A' ' 107' ' ' VAL . 72.9 p -47.57 149.85 1.94 Allowed Pre-proline 0 C--N 1.33 -0.268 0 CA-C-O 121.583 0.706 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.82 2.99 3.07 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.675 2.25 . . . . 0.0 112.327 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -98.32 -16.47 19.33 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.905 179.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.596 HG22 ' HE3' ' A' ' 111' ' ' MET . 51.1 t -93.39 145.56 7.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.161 179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -129.78 -179.72 5.36 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.862 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.2 p-10 -57.77 -51.12 70.89 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -39.85 -36.18 0.75 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.464 -179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.596 ' HE3' HG22 ' A' ' 107' ' ' VAL . 18.5 mtm -82.79 -59.26 2.56 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.795 0.331 . . . . 0.0 110.916 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.436 HD23 ' N ' ' A' ' 127' ' ' LYS . 25.2 tp -36.05 -44.02 0.36 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.88 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.406 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 16.1 t80 -63.6 -61.16 2.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.907 -179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.755 ' HA ' HG12 ' A' ' 117' ' ' VAL . 18.3 mt-10 -54.17 -55.68 25.48 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.862 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.828 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 71.3 t80 -41.13 -32.29 0.25 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.873 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.48 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.5 m-85 -95.25 -68.16 0.82 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.841 -179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.755 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.7 -30.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.148 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.48 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.5 ttpt -68.78 -53.96 18.69 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.888 179.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.574 HG13 ' CD2' ' A' ' 120' ' ' TYR . 2.6 p -70.73 -31.47 45.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.245 -0.434 . . . . 0.0 111.109 179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.574 ' CD2' HG13 ' A' ' 119' ' ' VAL . 94.2 m-85 -135.84 114.47 11.04 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.679 0.752 . . . . 0.0 110.913 -179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.82 0.53 5.55 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.658 2.239 . . . . 0.0 112.361 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 26.0 m -98.2 21.01 11.48 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.885 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 7.7 t -84.72 134.78 34.33 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.888 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 9.0 mmt85 -91.87 -38.94 12.01 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.836 -179.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.406 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.96 152.27 7.13 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.536 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.406 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -101.66 143.01 15.9 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.488 -179.905 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.436 ' N ' HD23 ' A' ' 112' ' ' LEU . 21.7 tptm -132.78 127.38 34.49 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 110.865 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.5 p -116.8 127.18 74.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.145 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.959 HG22 ' O ' ' A' ' 139' ' ' TYR . 20.3 m -73.91 143.65 13.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.127 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.627 HD23 ' HA ' ' A' ' 136' ' ' SER . 25.5 mt -130.57 163.82 26.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.927 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.434 ' O ' ' N ' ' A' ' 134' ' ' GLY . 23.8 t70 -94.68 176.17 6.38 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.883 179.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 21.6 tt0 -44.34 -40.38 5.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.894 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 18.1 p -72.37 -28.58 63.11 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.179 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 104.98 20.36 9.92 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.487 179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 26.1 m -99.64 134.75 37.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.831 0.348 . . . . 0.0 111.15 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.627 ' HA ' HD23 ' A' ' 130' ' ' LEU . 6.0 t -48.62 112.92 0.67 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.813 -179.822 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 29.3 mtmt -58.69 -28.56 65.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.954 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 122.83 15.25 3.97 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.441 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.959 ' O ' HG22 ' A' ' 129' ' ' VAL . 29.8 p90 -161.88 167.99 23.78 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.896 0.379 . . . . 0.0 110.912 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.523 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -169.64 -160.02 16.85 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.467 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -153.7 148.64 26.64 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.9 0.381 . . . . 0.0 110.874 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.446 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 28.5 m -123.3 170.6 13.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.077 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 25.3 mttt -129.67 156.06 44.86 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.903 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 98.9 m-85 -143.09 171.56 13.9 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.9 179.921 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 1.7 p -108.3 -28.79 9.23 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 -179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.7 t70 -113.1 128.4 56.48 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.881 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.523 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 12.9 tm-20 -69.37 -38.37 78.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.87 -179.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 26.9 mt -51.0 -44.82 60.98 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 13.1 mm-40 -73.16 -42.88 62.32 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.852 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 19.8 tt0 -38.74 -57.94 1.14 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.928 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 9.2 mmmm -63.21 -49.32 74.67 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.91 179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 34.4 mtt-85 -43.43 -41.06 4.06 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.832 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.98 -44.3 76.95 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.098 179.958 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.884 HD21 HD22 ' A' ' 98' ' ' LEU . 24.2 mt -48.46 -40.63 26.98 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.906 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.1 t -91.36 -34.7 14.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 179.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 17.4 mm-40 -79.58 -65.1 1.04 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.876 -179.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.549 ' C ' HD11 ' A' ' 170' ' ' LEU . 11.2 m -65.14 -8.74 18.26 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.877 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . 0.444 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.5 tp-100 -35.6 137.9 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.923 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.48 42.81 2.72 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.521 -179.92 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.828 ' HB1' ' CZ ' ' A' ' 115' ' ' PHE . . . -57.75 110.9 0.98 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.803 0.335 . . . . 0.0 111.068 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.403 ' O ' ' C ' ' A' ' 162' ' ' GLY . 20.1 t -82.72 -41.76 17.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.135 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -37.87 -34.84 0.2 Allowed Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.459 179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.572 HD13 ' HB2' ' A' ' 115' ' ' PHE . 26.5 tp -90.23 115.77 27.7 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.811 0.339 . . . . 0.0 110.938 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.415 ' O ' ' C ' ' A' ' 165' ' ' SER . . . 62.52 137.85 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.481 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . 0.415 ' C ' ' O ' ' A' ' 164' ' ' GLY . 1.2 t -37.4 -32.87 0.05 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.916 0.389 . . . . 0.0 110.866 -179.782 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . 0.413 ' N ' ' O ' ' A' ' 164' ' ' GLY . 58.0 mttt -100.46 153.6 37.65 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.519 0.676 . . . . 0.0 110.913 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -179.19 2.77 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.67 2.247 . . . . 0.0 112.311 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.787 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 13.8 m -130.59 129.68 64.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.1 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.6 ttt-85 -89.27 110.58 21.33 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.883 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.825 ' HB3' HD23 ' A' ' 154' ' ' LEU . 12.5 mt -87.24 144.59 26.74 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.927 -179.987 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.2 m -160.89 175.06 12.94 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.891 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 2.6 t -102.66 104.43 16.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.136 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -85.81 161.81 18.95 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.074 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . 0.614 HG23 ' HD2' ' A' ' 175' ' ' PRO . 85.5 mt -131.74 137.46 30.37 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.635 0.731 . . . . 0.0 111.14 179.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.614 ' HD2' HG23 ' A' ' 174' ' ' ILE . 53.7 Cg_endo -69.76 -173.91 0.81 Allowed 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.668 2.245 . . . . 0.0 112.359 179.848 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 18.7 ttpp -54.81 94.61 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.873 179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -107.33 76.29 1.07 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.038 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 1.6 t -174.99 174.05 2.56 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.809 -179.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 15.1 mmm180 -120.1 110.72 16.98 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.872 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 28.7 m -73.6 135.69 27.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.133 179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -131.21 141.72 42.91 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.543 0.687 . . . . 0.0 110.892 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 139.67 40.62 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.723 2.282 . . . . 0.0 112.334 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 31.3 m -108.8 162.36 6.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.14 179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -160.17 149.83 17.9 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.877 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.4 m -145.28 144.72 30.93 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.865 -179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 168.35 69.59 0.03 OUTLIER Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.48 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.79 175.31 8.3 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.66 2.24 . . . . 0.0 112.324 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 36.0 p -165.48 145.87 6.91 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.886 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 1.2 t -126.83 156.62 41.03 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.831 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.304 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.486 -180.0 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.318 0 N-CA-C 112.482 -0.247 . . . . 0.0 112.482 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 36.1 m -157.46 168.51 27.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.86 0.362 . . . . 0.0 110.853 -179.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.2 t -105.56 80.28 1.55 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.874 -179.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 140.44 176.16 15.0 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.48 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 3.0 m -90.51 -50.87 5.69 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.858 0.361 . . . . 0.0 110.857 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 79.0 p -68.61 -50.69 49.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.843 -179.769 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 109.22 83.44 1.48 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.521 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 163.06 39.64 Favored 'Trans proline' 0 C--O 1.231 0.155 0 C-N-CA 122.701 2.267 . . . . 0.0 112.334 -179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 34.9 mp0 -73.23 178.0 4.76 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.855 -179.995 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . 0.405 ' CD1' ' HG3' ' A' ' 147' ' ' GLU . 9.4 m-85 -132.45 103.76 6.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.98 -179.88 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 51.6 m -124.92 154.12 41.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.872 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.72 HD21 ' HG2' ' A' ' 150' ' ' GLN . 96.1 mt -126.65 143.44 51.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.9 -179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.445 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 11.4 t80 -92.51 142.13 27.74 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.863 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 21.6 m -132.02 150.86 34.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.109 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.15 -174.32 13.27 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.489 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 46.55 54.74 8.37 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.797 0.332 . . . . 0.0 110.852 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.421 HD12 ' C ' ' A' ' 139' ' ' TYR . 29.6 mt -101.84 112.09 24.57 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.895 -179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.74 ' OG1' HG23 ' A' ' 107' ' ' VAL . 73.3 p -53.59 148.98 16.67 Favored Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.61 0.719 . . . . 0.0 111.126 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 2.14 3.78 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.71 2.273 . . . . 0.0 112.35 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -97.98 -17.52 19.14 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.868 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.74 HG23 ' OG1' ' A' ' 104' ' ' THR . 14.7 t -87.58 143.77 10.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.102 -179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -131.65 172.2 12.55 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.855 179.885 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 -49.59 -46.31 48.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.876 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -49.25 -28.91 9.27 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.461 -179.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.452 ' O ' ' N ' ' A' ' 113' ' ' TYR . 14.1 mtp -86.4 -66.54 0.89 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.814 0.34 . . . . 0.0 110.866 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.423 ' C ' ' O ' ' A' ' 111' ' ' MET . 24.6 tp -35.75 -32.88 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.887 -179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.452 ' N ' ' O ' ' A' ' 111' ' ' MET . 12.0 t80 -68.84 -65.01 0.76 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.927 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.725 ' HA ' HG12 ' A' ' 117' ' ' VAL . 18.4 mt-10 -55.59 -39.57 70.89 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.901 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.559 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 58.0 t80 -54.55 -33.88 60.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.886 -179.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.46 ' O ' ' N ' ' A' ' 118' ' ' LYS . 10.0 m-85 -95.27 -64.92 1.01 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.818 -179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.725 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.78 -30.92 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.076 -179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.46 ' N ' ' O ' ' A' ' 116' ' ' PHE . 5.3 ttpm? -65.45 -58.79 4.97 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.874 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.612 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.5 p -64.56 -33.78 65.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.172 179.859 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.612 ' CD2' HG13 ' A' ' 119' ' ' VAL . 91.0 m-85 -135.44 116.53 11.97 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-O 121.664 0.745 . . . . 0.0 110.965 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.74 1.94 3.97 Favored 'Trans proline' 0 C--N 1.341 0.137 0 C-N-CA 122.671 2.247 . . . . 0.0 112.365 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 86.4 p -87.85 -23.27 24.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.835 -179.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 7.7 t -47.19 137.04 8.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.885 -179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 51.7 mtm180 -99.3 -36.53 9.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.874 -179.87 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.42 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.53 143.2 3.65 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.493 -179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.512 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -87.16 145.24 19.69 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.492 -179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 21.5 tptm -131.49 110.65 11.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.855 0.359 . . . . 0.0 110.86 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.7 p -102.48 139.85 22.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.109 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.776 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 25.0 m -86.32 158.34 3.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.096 179.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.566 HD23 ' HA ' ' A' ' 136' ' ' SER . 24.2 mt -137.38 167.78 20.93 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.878 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.443 ' O ' ' N ' ' A' ' 134' ' ' GLY . 17.7 t0 -102.18 175.06 5.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.83 179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 39.6 tt0 -42.03 -42.07 2.75 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.948 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 65.2 p -72.82 -31.83 65.09 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.097 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.443 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 108.88 19.79 8.41 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.487 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 24.9 m -99.7 127.76 52.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.353 . . . . 0.0 111.114 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.566 ' HA ' HD23 ' A' ' 130' ' ' LEU . 3.0 t -40.21 106.76 0.06 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.831 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.551 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.7 mtmt -50.38 -37.16 35.92 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.944 179.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 128.81 18.7 1.71 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.459 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.776 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 16.3 p90 -160.81 173.41 15.41 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.953 0.406 . . . . 0.0 110.935 -179.778 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -177.26 -163.85 29.95 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.484 179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.445 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 2.5 m-85 -152.83 150.44 29.34 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.888 0.375 . . . . 0.0 110.9 -179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.512 HG12 ' HA2' ' A' ' 126' ' ' GLY . 28.1 m -123.83 174.54 7.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.174 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . 0.445 ' HD3' ' N ' ' A' ' 143' ' ' LYS . 0.5 OUTLIER -134.77 158.43 44.18 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.909 179.872 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.479 ' CE1' HD12 ' A' ' 98' ' ' LEU . 75.1 m-85 -143.03 160.98 39.33 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.89 179.948 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 75.3 p -95.38 -14.81 23.52 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.177 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -128.16 123.66 34.93 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.898 179.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.405 ' HG3' ' CD1' ' A' ' 96' ' ' TYR . 15.3 tt0 -64.45 -39.23 93.43 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.911 -179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 95.3 mt -47.7 -46.96 30.02 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.941 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 55.8 mm-40 -74.53 -33.46 62.77 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.847 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.72 ' HG2' HD21 ' A' ' 98' ' ' LEU . 33.0 tt0 -46.73 -40.93 14.31 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.919 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 18.0 mmtp -81.59 -46.83 13.85 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.908 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 46.0 mtt180 -44.27 -41.36 5.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.85 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.474 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.95 -42.97 80.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.258 -0.428 . . . . 0.0 111.106 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.848 HD23 ' HB3' ' A' ' 170' ' ' LEU . 29.9 mt -51.99 -38.14 55.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.883 -179.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 14.3 t -92.35 -33.53 14.55 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.166 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 45.8 mm-40 -83.49 -66.07 0.94 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.898 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.623 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 87.7 m -59.66 -13.26 9.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.93 -179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . 0.476 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.3 tp-100 -39.0 140.33 0.39 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.893 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 50.43 36.42 30.46 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.497 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.7 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -67.55 110.94 3.88 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.863 0.364 . . . . 0.0 111.073 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.433 ' O ' ' C ' ' A' ' 162' ' ' GLY . 25.2 t -92.68 -35.91 7.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.132 179.958 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . 0.433 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -35.12 -35.85 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.482 179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.559 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 38.1 tp -86.21 117.45 25.03 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.843 0.354 . . . . 0.0 110.911 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 66.46 170.46 3.81 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.499 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . 0.58 ' H ' HG21 ' A' ' 104' ' ' THR . 35.9 m -82.09 40.35 0.62 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.891 0.377 . . . . 0.0 110.873 -179.783 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . 0.493 ' CG ' ' O ' ' A' ' 165' ' ' SER . 36.0 mttt -169.23 157.22 6.98 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.527 0.679 . . . . 0.0 110.912 179.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 172.37 12.77 Favored 'Trans proline' 0 C--O 1.231 0.162 0 C-N-CA 122.677 2.251 . . . . 0.0 112.317 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.7 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 32.2 m -135.69 126.9 44.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.136 179.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 44.7 ttt180 -89.95 117.51 28.82 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.866 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.848 ' HB3' HD23 ' A' ' 154' ' ' LEU . 17.1 mt -93.35 145.19 24.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.97 179.996 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 9.9 m -158.16 174.25 15.48 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.864 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 39.4 t -98.69 102.08 12.95 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.082 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -93.17 131.28 38.38 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.152 179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 53.6 mt -69.0 130.25 91.62 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.565 0.698 . . . . 0.0 111.165 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.77 -42.25 3.56 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.648 2.232 . . . . 0.0 112.37 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 49.1 tttt -129.39 110.16 11.67 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.891 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -133.97 169.16 17.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.074 179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 73.6 m 42.58 38.62 1.32 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.888 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . 0.547 ' NE ' ' H ' ' A' ' 179' ' ' ARG . 0.0 OUTLIER -77.5 164.11 25.71 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.885 -179.938 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 91.1 t -115.36 138.68 44.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.162 179.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 1.3 mptp? -99.82 143.92 27.37 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.567 0.698 . . . . 0.0 110.861 179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.83 105.84 1.57 Allowed 'Trans proline' 0 C--N 1.342 0.199 0 C-N-CA 122.626 2.217 . . . . 0.0 112.357 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 25.8 m -117.4 127.23 74.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.134 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.6 tm-20 -119.41 136.54 54.24 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.896 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 75.0 p -83.46 110.59 18.31 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.867 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -71.7 -157.92 3.18 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.468 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 96.61 0.6 Allowed 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.666 2.244 . . . . 0.0 112.346 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 31.1 t -79.06 149.08 32.24 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.891 -179.846 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 58.9 m -80.1 172.14 14.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.836 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.307 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.53 -179.968 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.313 0 N-CA-C 112.436 -0.266 . . . . 0.0 112.436 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.8 m -51.06 175.97 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.87 0.367 . . . . 0.0 110.888 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 30.1 t -82.61 114.48 21.03 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.877 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -111.49 79.03 0.25 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.467 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 10.3 t 56.2 42.63 27.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.927 0.394 . . . . 0.0 110.898 -179.715 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.0 t -57.86 -61.13 2.76 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.845 -179.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.85 83.88 0.31 Allowed Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.49 -179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 120.47 7.25 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.713 2.275 . . . . 0.0 112.32 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 2.0 pp20? -117.16 151.8 36.11 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.846 -179.971 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 24.2 m-85 -134.92 102.95 5.41 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.935 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.9 m -121.15 154.87 35.64 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.882 -179.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.604 HD21 ' HG2' ' A' ' 150' ' ' GLN . 83.2 mt -124.06 145.82 48.98 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.905 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -95.4 124.11 39.26 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.431 HG22 ' C ' ' A' ' 140' ' ' GLY . 33.0 m -115.25 148.41 18.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.131 179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -136.19 -177.86 15.32 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.47 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 49.77 54.09 11.64 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.873 0.368 . . . . 0.0 110.88 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.421 HD12 ' C ' ' A' ' 139' ' ' TYR . 30.1 mt -100.51 102.56 13.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.936 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.419 HG21 ' HB2' ' A' ' 165' ' ' SER . 2.8 p -47.52 151.26 1.47 Allowed Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.591 0.71 . . . . 0.0 111.136 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.79 -1.38 8.4 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.689 2.259 . . . . 0.0 112.343 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -102.04 25.52 8.66 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.857 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.47 HG22 ' HE3' ' A' ' 111' ' ' MET . 22.2 t -134.62 138.73 49.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.148 -179.984 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 45.0 m-20 -123.22 169.35 11.36 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.875 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.493 ' CG ' HG12 ' A' ' 128' ' ' VAL . 0.5 OUTLIER -46.77 -46.23 20.36 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.85 -179.958 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -41.8 -44.47 4.45 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.508 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.47 ' HE3' HG22 ' A' ' 107' ' ' VAL . 32.3 mtm -77.97 -41.37 36.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.785 0.326 . . . . 0.0 110.887 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 16.8 tp -57.05 -25.13 58.14 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.974 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.49 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 8.5 t80 -84.23 -63.03 1.42 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.905 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.726 ' HA ' HG12 ' A' ' 117' ' ' VAL . 23.9 mt-10 -55.39 -43.24 75.0 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.893 179.994 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.579 ' HB2' HD13 ' A' ' 163' ' ' LEU . 85.2 t80 -51.14 -33.02 24.92 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.845 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.557 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.9 m-85 -95.25 -65.78 0.95 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.883 -179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.726 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -37.16 -28.42 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.106 179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.492 ' N ' ' O ' ' A' ' 116' ' ' PHE . 3.1 tptm -65.6 -53.73 37.62 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.937 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.551 HG13 ' CD2' ' A' ' 120' ' ' TYR . 4.1 p -71.16 -38.25 70.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.142 179.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.599 ' CE2' ' HB2' ' A' ' 153' ' ' ALA . 93.1 m-85 -127.17 116.19 21.75 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.629 0.728 . . . . 0.0 110.934 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.72 2.94 3.06 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.668 2.246 . . . . 0.0 112.365 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . 0.684 ' O ' HG22 ' A' ' 145' ' ' THR . 18.5 p -89.96 -26.47 20.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.818 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . 0.549 ' HA ' ' CD2' ' A' ' 144' ' ' PHE . 9.5 t -45.25 128.39 7.59 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.936 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 3.4 mmp_? -90.08 -34.88 15.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.869 -179.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.49 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 172.14 166.2 30.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.443 -179.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -115.66 144.22 18.36 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.462 -179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 18.1 tptt -136.01 128.89 31.16 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.792 0.329 . . . . 0.0 110.916 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.493 HG12 ' CG ' ' A' ' 109' ' ' ASP . 6.5 p -119.02 127.32 75.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.165 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.885 HG22 ' O ' ' A' ' 139' ' ' TYR . 10.3 m -74.58 153.51 6.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.139 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.489 HD23 ' HA ' ' A' ' 136' ' ' SER . 13.4 mt -130.52 176.82 7.84 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 -179.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.415 ' O ' ' N ' ' A' ' 134' ' ' GLY . 18.3 t70 -108.23 174.41 5.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.875 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 3.2 tp-100 -40.98 -45.06 2.5 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.879 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 20.8 p -71.57 -34.26 69.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.111 -179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.415 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 113.53 20.92 5.98 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.485 179.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 136' ' ' SER . 27.3 m -100.44 122.85 52.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.855 0.36 . . . . 0.0 111.138 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.489 ' HA ' HD23 ' A' ' 130' ' ' LEU . 7.3 t -34.57 106.83 0.04 OUTLIER 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.87 -179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.496 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 26.8 mtmt -50.45 -34.51 25.01 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.869 179.944 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.2 18.64 2.27 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.518 179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.885 ' O ' HG22 ' A' ' 129' ' ' VAL . 19.1 p90 -163.08 165.89 24.19 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.966 0.412 . . . . 0.0 110.883 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.431 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -166.67 -161.35 15.59 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.512 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -154.03 145.51 23.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.915 0.388 . . . . 0.0 110.861 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.557 HG11 ' CD2' ' A' ' 116' ' ' PHE . 24.4 m -117.31 -176.09 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.133 179.998 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 20.2 mtmm -143.57 160.76 40.06 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.864 179.88 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.549 ' CD2' ' HA ' ' A' ' 123' ' ' CYS . 65.5 m-85 -149.85 179.32 8.13 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.839 -179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . 0.684 HG22 ' O ' ' A' ' 122' ' ' SER . 0.1 OUTLIER -125.08 -16.62 5.98 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.16 -179.983 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -122.17 97.33 5.43 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.876 179.888 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.6 tt0 -44.83 -48.95 11.04 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.917 -179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 63.5 mt -44.85 -33.0 1.77 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.926 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -89.79 -36.69 14.99 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.834 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.604 ' HG2' HD21 ' A' ' 98' ' ' LEU . 13.6 tt0 -52.4 -47.53 66.22 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.923 -179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 61.9 mttt -69.99 -41.9 73.78 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.907 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 69.8 mtt180 -49.7 -34.3 18.32 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.869 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.599 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -73.3 -45.63 54.41 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.103 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.708 HD23 ' HB3' ' A' ' 170' ' ' LEU . 26.6 mt -48.4 -36.49 14.8 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.411 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.4 t -91.35 -40.61 11.37 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 179.958 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.411 ' N ' HG23 ' A' ' 155' ' ' THR . 56.7 mm-40 -77.56 -66.45 0.83 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.863 -179.963 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.605 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 63.3 m -60.59 -11.6 7.64 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.855 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . 0.425 ' C ' ' O ' ' A' ' 157' ' ' CYS . 2.8 tp-100 -34.99 139.86 0.09 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.892 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 43.5 35.8 3.01 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.519 -179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.792 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -55.71 120.14 6.82 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.82 0.343 . . . . 0.0 111.146 179.978 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.8 t -95.1 -33.26 4.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.101 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -41.47 -36.53 1.54 Allowed Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.53 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.579 HD13 ' HB2' ' A' ' 115' ' ' PHE . 22.6 tp -89.06 116.48 27.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.895 0.378 . . . . 0.0 110.875 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 68.77 157.89 1.31 Allowed Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.505 179.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . 0.419 ' HB2' HG21 ' A' ' 104' ' ' THR . 49.9 m -62.34 -11.47 15.54 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.961 0.41 . . . . 0.0 110.839 -179.682 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 51.1 mttt -120.02 156.79 54.19 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.59 0.71 . . . . 0.0 110.895 179.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 177.36 5.68 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.65 2.233 . . . . 0.0 112.382 179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.792 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 15.7 m -131.96 125.13 54.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.144 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 21.4 ttm180 -86.82 102.31 14.17 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.854 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.708 ' HB3' HD23 ' A' ' 154' ' ' LEU . 12.8 mt -81.55 140.67 34.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.921 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 19.9 m -156.46 178.03 10.79 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.839 -179.925 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 3.3 t -99.95 99.69 8.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.081 179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -71.53 162.04 30.08 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.144 179.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 70.9 mt -118.83 125.07 27.94 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.669 0.747 . . . . 0.0 111.105 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -49.45 0.55 Allowed 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.644 2.229 . . . . 0.0 112.357 179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.461 ' HD3' ' NE ' ' A' ' 179' ' ' ARG . 3.1 ttmm -141.11 108.33 5.5 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.908 179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -61.21 -72.54 0.11 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.074 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 5.7 t -146.09 158.17 43.87 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.868 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . 0.461 ' NE ' ' HD3' ' A' ' 176' ' ' LYS . 24.5 mmt180 -95.31 149.08 21.74 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.917 -179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 9.0 p -114.16 138.71 43.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.138 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 11.5 mtpp -151.36 146.58 19.13 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.593 0.711 . . . . 0.0 110.868 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.76 128.35 15.9 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.66 2.24 . . . . 0.0 112.366 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 82.4 t -91.49 95.78 5.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.137 179.931 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -85.92 165.48 16.73 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.875 -179.963 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -137.47 124.27 21.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.882 -179.812 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -139.94 72.89 0.41 Allowed Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.505 180.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 112.46 3.09 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.693 2.262 . . . . 0.0 112.339 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 25.9 p -95.99 83.44 3.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.861 -179.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 68.7 m 40.79 41.99 1.32 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.895 -179.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.298 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.524 -179.949 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 N-CA-C 112.509 -0.236 . . . . 0.0 112.509 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 1.9 m -113.44 -44.95 3.17 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.874 0.368 . . . . 0.0 110.808 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 77.5 p -89.36 134.14 34.2 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.886 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 150.82 -91.81 0.14 Allowed Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.454 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 14.0 t -69.02 137.69 53.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.917 0.389 . . . . 0.0 110.808 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 89.2 p -71.35 88.65 0.88 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.823 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -48.24 150.34 3.23 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.472 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.553 ' O ' ' CE1' ' A' ' 96' ' ' TYR . 53.8 Cg_endo -69.75 158.4 57.09 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.675 2.25 . . . . 0.0 112.362 -179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 4.5 mp0 -50.98 174.94 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.884 -179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . 0.553 ' CE1' ' O ' ' A' ' 94' ' ' PRO . 13.4 m-85 -143.62 119.3 10.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.921 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.1 m -138.91 148.27 43.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.861 -179.847 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.668 HD12 ' CE2' ' A' ' 144' ' ' PHE . 82.9 mt -117.41 151.63 36.65 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.915 179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.69 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 7.6 t80 -98.31 123.29 42.33 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.907 179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 29.8 m -117.45 144.09 26.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.125 179.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.11 178.5 18.51 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.483 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . 0.45 ' N ' ' O ' ' A' ' 138' ' ' GLY . 1.2 m-20 57.73 53.88 6.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.82 0.343 . . . . 0.0 110.859 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.417 HD23 ' HA ' ' A' ' 103' ' ' LEU . 23.0 mt -100.8 103.34 14.55 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.896 -179.95 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.488 HG21 ' HB3' ' A' ' 165' ' ' SER . 39.9 p -48.31 150.1 2.41 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.578 0.704 . . . . 0.0 111.146 179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 -1.56 8.69 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.678 2.252 . . . . 0.0 112.352 179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 69.5 m-20 -99.33 12.08 37.28 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.858 179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.614 HG22 ' HE3' ' A' ' 111' ' ' MET . 62.1 t -123.32 139.92 48.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.096 -179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -122.08 171.59 8.86 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.878 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.411 ' HB3' HG12 ' A' ' 128' ' ' VAL . 3.5 p30 -52.63 -43.91 65.72 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.893 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -43.87 -37.3 4.04 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.507 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.614 ' HE3' HG22 ' A' ' 107' ' ' VAL . 28.2 mtm -81.45 -44.72 17.06 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.833 0.349 . . . . 0.0 110.889 -179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.488 HD23 ' N ' ' A' ' 127' ' ' LYS . 22.1 tp -53.92 -28.52 37.37 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.873 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.56 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 13.9 t80 -76.36 -65.36 0.93 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.908 -179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.776 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.0 mt-10 -55.23 -48.25 74.17 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.918 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.406 ' CB ' HD13 ' A' ' 163' ' ' LEU . 69.0 t80 -46.31 -33.82 4.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.938 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.492 ' O ' ' N ' ' A' ' 118' ' ' LYS . 6.9 m-85 -95.3 -67.09 0.87 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.847 -179.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.776 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.8 p -36.51 -29.41 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.079 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.492 ' N ' ' O ' ' A' ' 116' ' ' PHE . 18.8 ttpp -67.47 -55.56 13.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.914 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.507 HG13 ' HD2' ' A' ' 120' ' ' TYR . 2.3 p -70.98 -30.72 42.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.198 -0.456 . . . . 0.0 111.123 179.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.582 ' CE1' ' HB3' ' A' ' 152' ' ' ARG . 97.6 m-85 -132.26 112.36 14.32 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.602 0.715 . . . . 0.0 110.955 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.425 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.3 Cg_endo -69.75 2.39 3.57 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.671 2.247 . . . . 0.0 112.338 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 6.3 p -92.87 -20.27 20.84 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.862 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.0 t -50.05 134.28 22.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.883 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 85.1 mtt180 -94.85 -35.7 11.95 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.874 -179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.56 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 167.1 143.91 3.93 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.492 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.54 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -97.34 136.58 12.83 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.473 -179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.488 ' N ' HD23 ' A' ' 112' ' ' LEU . 19.3 tttp -124.83 139.2 54.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.77 0.319 . . . . 0.0 110.925 179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.411 HG12 ' HB3' ' A' ' 109' ' ' ASP . 6.3 p -123.17 139.62 49.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.149 179.898 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.812 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 6.3 m -89.91 152.71 3.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.121 179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 7.9 mt -128.68 160.92 30.95 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.907 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -87.59 172.72 9.53 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.848 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -48.56 -19.99 0.39 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.891 -179.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 58.1 p -89.45 -29.76 18.79 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.131 -179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 111.8 10.77 18.19 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.489 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 33.8 m -98.92 136.49 29.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.79 0.329 . . . . 0.0 111.159 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 8.6 t -43.23 105.78 0.06 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.88 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.512 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 26.0 mtmt -50.58 -32.98 20.25 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.918 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.45 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 123.58 19.9 2.72 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.548 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.812 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 13.9 p90 -163.83 168.77 19.15 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.952 0.406 . . . . 0.0 110.914 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -169.53 -160.88 18.8 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.522 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.4 m-85 -153.97 144.16 22.1 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.848 0.356 . . . . 0.0 110.918 -179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.54 HG12 ' HA2' ' A' ' 126' ' ' GLY . 20.6 m -120.97 174.02 6.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.144 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 44.7 mtmt -132.93 163.75 28.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.869 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.668 ' CE2' HD12 ' A' ' 98' ' ' LEU . 75.3 m-85 -149.79 159.78 44.08 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.923 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 14.0 p -90.34 -39.37 12.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.16 -179.943 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -109.23 132.04 54.49 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.87 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 10.2 tt0 -72.27 -38.3 68.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.923 -179.954 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 30.2 mt -48.78 -34.06 11.55 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.923 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -87.83 -37.27 16.69 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.905 179.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.473 ' O ' HD11 ' A' ' 98' ' ' LEU . 22.4 tt0 -41.61 -48.39 4.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.947 -179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 47.2 mttt -71.7 -32.22 67.58 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.864 -179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.582 ' HB3' ' CE1' ' A' ' 120' ' ' TYR . 0.6 OUTLIER -52.67 -39.45 61.91 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.841 179.982 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.499 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -67.86 -46.57 71.37 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.129 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.601 HD23 ' HB3' ' A' ' 170' ' ' LEU . 17.0 mt -40.36 -43.68 1.81 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.911 -179.991 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.614 HG23 ' N ' ' A' ' 156' ' ' GLU . 14.6 t -92.7 -50.63 5.49 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.124 179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.614 ' N ' HG23 ' A' ' 155' ' ' THR . 76.9 mm-40 -62.51 -57.63 10.49 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.914 179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.683 ' O ' HD11 ' A' ' 170' ' ' LEU . 24.7 m -83.2 20.53 1.25 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.824 -179.907 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . 0.419 ' OE1' ' N ' ' A' ' 159' ' ' GLY . 2.0 tp-100 -64.71 131.89 48.13 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.9 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.419 ' N ' ' OE1' ' A' ' 158' ' ' GLN . . . 47.09 29.69 4.87 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.479 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.438 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -50.12 119.23 3.46 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.827 0.346 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.427 ' O ' ' C ' ' A' ' 162' ' ' GLY . 37.5 t -88.12 -36.75 9.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.134 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . 0.427 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -35.97 -38.59 0.23 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.492 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.406 HD13 ' CB ' ' A' ' 115' ' ' PHE . 20.0 tp -89.08 118.84 29.09 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.866 0.365 . . . . 0.0 110.918 -179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.454 ' CA ' HG21 ' A' ' 107' ' ' VAL . . . 64.91 153.49 0.11 Allowed Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.487 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . 0.488 ' HB3' HG21 ' A' ' 104' ' ' THR . 16.7 t -55.66 -23.8 30.25 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.962 0.41 . . . . 0.0 110.839 -179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 58.8 mttt -109.24 154.95 41.84 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.572 0.701 . . . . 0.0 110.908 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 171.23 14.89 Favored 'Trans proline' 0 C--N 1.341 0.145 0 C-N-CA 122.7 2.267 . . . . 0.0 112.34 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.438 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 16.4 m -121.18 125.84 74.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.085 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 35.1 ttt-85 -88.71 103.27 15.79 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.683 HD11 ' O ' ' A' ' 157' ' ' CYS . 11.7 mt -80.64 148.61 30.17 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.857 -179.914 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 3.2 m -160.75 177.61 10.28 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.917 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.49 HG22 HD11 ' A' ' 154' ' ' LEU . 21.2 t -99.36 96.83 5.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.116 179.963 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.69 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -93.09 172.47 8.29 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.082 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . 0.645 HG23 ' HD2' ' A' ' 175' ' ' PRO . 83.4 mt -125.68 137.71 30.51 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.604 0.716 . . . . 0.0 111.135 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.645 ' HD2' HG23 ' A' ' 174' ' ' ILE . 54.0 Cg_endo -69.7 174.86 8.83 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.665 2.243 . . . . 0.0 112.377 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 38.9 tptt -45.82 118.54 1.87 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.868 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -68.56 145.98 53.5 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.077 179.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 50.6 m -105.68 -50.32 3.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.864 -179.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 6.6 tpm_? 40.78 50.26 2.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.884 -179.932 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . 0.461 HG22 ' N ' ' A' ' 181' ' ' LYS . 7.2 p -117.22 155.19 18.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.122 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.461 ' N ' HG22 ' A' ' 180' ' ' VAL . 9.1 tppt? -143.08 134.65 12.88 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.623 0.725 . . . . 0.0 110.843 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.78 85.56 0.61 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.684 2.256 . . . . 0.0 112.325 179.911 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 67.1 t -134.14 107.89 10.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.094 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 6.6 tp10 -130.68 133.9 46.49 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.927 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.6 m -115.74 157.84 23.71 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.84 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 120.96 86.64 0.91 Allowed Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.503 -179.979 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 138.29 37.5 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.643 2.229 . . . . 0.0 112.363 -179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 31.1 t -95.64 -49.4 5.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.864 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 44.7 t -98.54 150.68 21.44 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.88 -179.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.332 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.527 -179.96 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.328 0 N-CA-C 112.48 -0.248 . . . . 0.0 112.48 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 47.9 t -123.54 103.07 8.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.93 0.395 . . . . 0.0 110.884 -179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.4 t -166.43 146.01 5.87 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.889 -179.827 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -90.06 113.33 4.19 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.512 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 47.4 p -170.37 141.34 1.98 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.886 0.374 . . . . 0.0 110.88 -179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 70.1 p -135.59 118.47 16.24 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.84 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -118.57 -161.31 11.77 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.517 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 125.21 11.89 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.722 2.282 . . . . 0.0 112.36 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 25.0 pm0 -65.28 154.28 38.66 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.853 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . 0.528 ' CD1' ' HG3' ' A' ' 147' ' ' GLU . 63.5 m-85 -127.76 104.04 7.62 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.924 -179.849 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 66.3 p -112.81 154.58 26.04 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.855 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 33.5 mt -124.79 142.4 51.45 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.907 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 6.1 t80 -91.25 132.88 35.84 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.899 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 18.9 m -126.02 151.82 32.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.128 -179.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -141.72 -179.62 18.97 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.5 179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.9 m-20 57.76 38.84 27.48 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.841 0.353 . . . . 0.0 110.905 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.484 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.2 mt -86.51 108.83 18.72 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.938 -179.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.672 ' OG1' HG23 ' A' ' 107' ' ' VAL . 81.9 p -53.82 150.25 14.62 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-O 121.612 0.72 . . . . 0.0 111.144 179.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.76 2.21 3.74 Favored 'Trans proline' 0 C--O 1.232 0.176 0 C-N-CA 122.706 2.271 . . . . 0.0 112.337 179.946 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 19.0 t0 -102.02 -3.17 28.11 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.884 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.672 HG23 ' OG1' ' A' ' 104' ' ' THR . 41.3 t -103.68 145.08 13.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.141 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.0 m-20 -129.18 179.68 5.63 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.883 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -60.34 -37.86 81.97 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.881 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.43 -33.23 39.51 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.47 -179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.528 ' HE3' HG22 ' A' ' 107' ' ' VAL . 27.3 mtm -86.85 -46.91 9.49 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.842 0.353 . . . . 0.0 110.886 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.463 HD23 ' N ' ' A' ' 127' ' ' LYS . 18.1 tp -53.34 -23.03 8.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.929 -179.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.496 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 13.0 t80 -82.63 -61.75 1.8 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.926 179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.758 ' HA ' HG12 ' A' ' 117' ' ' VAL . 22.4 mt-10 -57.23 -46.58 82.83 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.867 -179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.683 ' HZ ' ' HB1' ' A' ' 160' ' ' ALA . 75.6 t80 -47.68 -33.23 6.59 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.855 -179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.499 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.6 m-85 -95.28 -66.98 0.88 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.861 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.758 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.73 -30.97 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.132 179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.463 ' N ' ' O ' ' A' ' 116' ' ' PHE . 59.2 tttt -67.31 -60.61 2.44 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.903 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.603 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.7 p -64.65 -27.15 41.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.114 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.603 ' CD2' HG13 ' A' ' 119' ' ' VAL . 92.6 m-85 -137.94 115.89 9.57 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.7 0.762 . . . . 0.0 110.906 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 -2.77 10.7 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.751 2.301 . . . . 0.0 112.336 179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 73.2 m -99.25 32.28 2.79 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.854 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . 0.461 ' HB3' HG23 ' A' ' 117' ' ' VAL . 19.6 t -94.51 135.2 36.23 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.881 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 16.8 mtp180 -93.17 -39.0 11.27 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.867 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.496 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 163.56 149.43 5.73 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.509 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.582 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -102.9 134.27 11.75 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.518 -179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.463 ' N ' HD23 ' A' ' 112' ' ' LEU . 4.3 tppp? -123.21 137.56 54.85 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.806 0.336 . . . . 0.0 110.925 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.4 p -124.69 129.4 73.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.126 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.97 HG22 ' O ' ' A' ' 139' ' ' TYR . 22.5 m -75.18 150.49 6.82 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.085 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.429 HD23 ' HA ' ' A' ' 136' ' ' SER . 14.9 mt -127.03 174.91 8.5 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.925 179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -103.18 178.27 4.6 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.846 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 25.3 tt0 -45.28 -43.08 10.29 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.905 -179.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 27.8 p -74.68 -25.04 58.9 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.167 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 107.88 17.67 10.8 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.743 -0.742 . . . . 0.0 112.475 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 28.8 m -95.9 134.31 33.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.872 0.368 . . . . 0.0 111.126 -179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.429 ' HA ' HD23 ' A' ' 130' ' ' LEU . 4.8 t -44.18 107.2 0.08 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.863 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.5 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.7 mtmt -52.75 -32.36 42.87 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.902 179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.7 18.74 2.63 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.796 -0.716 . . . . 0.0 112.482 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.97 ' O ' HG22 ' A' ' 129' ' ' VAL . 23.4 p90 -163.14 168.25 21.08 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.981 0.42 . . . . 0.0 110.9 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -170.74 -165.18 27.68 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.478 179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.0 m-85 -150.88 146.99 26.68 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.869 0.366 . . . . 0.0 110.893 -179.854 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.582 HG12 ' HA2' ' A' ' 126' ' ' GLY . 17.8 m -119.2 179.32 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.113 179.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 31.3 mttt -138.53 160.35 39.8 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.899 179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -148.34 161.99 40.43 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.855 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 44.0 p -101.88 -12.34 18.33 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.099 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.443 ' CG ' ' OE1' ' A' ' 149' ' ' GLU . 14.3 t0 -129.61 130.04 45.14 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.857 179.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.528 ' HG3' ' CD1' ' A' ' 96' ' ' TYR . 20.0 tt0 -71.83 -43.23 65.92 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.904 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 37.2 mt -45.23 -49.21 12.52 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.954 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.443 ' OE1' ' CG ' ' A' ' 146' ' ' ASP . 3.6 mp0 -72.8 -44.05 61.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.855 179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.414 ' C ' ' O ' ' A' ' 149' ' ' GLU . 17.4 tt0 -36.97 -55.28 0.93 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.932 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 13.7 mttm -64.48 -52.59 57.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.916 179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 28.4 mtt180 -39.41 -33.29 0.15 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.853 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.448 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -73.98 -49.93 22.23 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.133 179.918 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.756 HD23 ' HB3' ' A' ' 170' ' ' LEU . 33.9 mt -43.34 -38.36 2.65 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.912 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.539 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.8 t -91.03 -48.3 7.06 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.167 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.539 ' N ' HG23 ' A' ' 155' ' ' THR . 53.1 mt-10 -69.56 -64.58 0.85 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.9 -179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.546 ' CB ' HD11 ' A' ' 170' ' ' LEU . 54.1 m -62.82 -8.3 6.64 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.905 -179.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -40.5 140.95 0.59 Allowed 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.883 -179.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 37.66 45.6 1.48 Allowed Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.465 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.683 ' HB1' ' HZ ' ' A' ' 115' ' ' PHE . . . -64.18 115.09 4.66 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.802 0.334 . . . . 0.0 111.129 179.928 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.0 t -84.88 -35.57 10.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.143 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -43.06 -34.44 2.06 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.453 179.983 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.618 HD13 ' CB ' ' A' ' 115' ' ' PHE . 19.2 tp -91.81 115.82 28.38 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.866 0.365 . . . . 0.0 110.922 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.401 ' O ' ' N ' ' A' ' 166' ' ' LYS . . . 64.55 138.48 0.02 OUTLIER Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.497 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 t -41.05 -27.92 0.07 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.944 0.402 . . . . 0.0 110.838 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . 0.401 ' N ' ' O ' ' A' ' 164' ' ' GLY . 57.5 mttt -103.78 154.67 37.83 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.526 0.679 . . . . 0.0 110.924 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -69.69 173.15 11.33 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.7 2.266 . . . . 0.0 112.413 179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.672 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 21.1 m -124.45 131.27 73.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.127 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 43.4 ttt180 -94.84 105.01 16.91 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.92 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.756 ' HB3' HD23 ' A' ' 154' ' ' LEU . 13.3 mt -82.66 148.87 27.69 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.933 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.535 ' O ' HD21 ' A' ' 154' ' ' LEU . 2.0 m -158.72 -177.87 6.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.9 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 4.4 t -108.83 102.15 13.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.145 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -86.55 138.34 31.79 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.07 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 74.6 mt -88.11 122.96 69.58 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.597 0.713 . . . . 0.0 111.131 179.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 -34.67 14.06 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.648 2.232 . . . . 0.0 112.341 179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 10.6 tmtt? -123.68 109.55 13.85 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.894 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -124.94 127.08 46.49 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.105 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 4.2 t -78.96 83.57 5.05 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.84 -179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . 0.495 ' O ' ' CD ' ' A' ' 179' ' ' ARG . 0.0 OUTLIER -66.66 114.64 5.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.882 -179.965 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 81.3 t -132.07 135.27 58.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.132 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.403 ' C ' ' HD3' ' A' ' 181' ' ' LYS . 0.0 OUTLIER -116.83 142.86 30.42 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.542 0.687 . . . . 0.0 110.904 179.916 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 144.48 54.17 Favored 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.662 2.241 . . . . 0.0 112.369 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 97.0 t -117.63 135.92 56.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.116 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -150.25 121.98 8.08 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.882 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 2.8 m -149.19 161.92 41.03 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.857 -179.801 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -176.61 69.27 0.08 OUTLIER Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.47 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.79 -24.25 29.75 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.641 2.227 . . . . 0.0 112.307 -179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 89.2 p -53.12 146.54 11.26 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.797 -179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.9 m -165.03 152.85 11.43 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.842 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.316 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.49 -179.956 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.515 -0.234 . . . . 0.0 112.515 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 4.8 t 67.76 42.05 2.07 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.868 0.366 . . . . 0.0 110.87 -179.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 57.1 m -81.55 -60.63 2.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.837 -179.809 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 95.11 54.55 1.47 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.488 -179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 91.1 p -38.76 129.23 1.52 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.937 0.399 . . . . 0.0 110.814 -179.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 36.4 p -123.38 163.2 21.26 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.867 -179.842 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -132.0 -77.98 0.15 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.471 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.76 157.88 58.86 Favored 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.685 2.257 . . . . 0.0 112.363 -179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -84.57 161.99 19.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.884 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 14.3 m-85 -127.93 99.73 5.63 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.934 -179.865 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 4.0 p -117.13 146.26 43.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.859 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.88 HD21 ' HG2' ' A' ' 150' ' ' GLN . 46.3 mt -110.43 150.4 28.9 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.906 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.661 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 4.9 t80 -96.34 127.23 42.14 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.852 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.8 m -119.42 146.05 24.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.15 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.84 -177.99 15.9 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.463 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 52.85 51.57 15.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.88 0.371 . . . . 0.0 110.877 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 30.1 mt -98.04 118.52 34.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.936 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p -61.97 151.54 79.9 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.587 0.708 . . . . 0.0 111.094 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -0.02 6.29 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.718 2.278 . . . . 0.0 112.333 179.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -99.46 -0.24 41.18 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.872 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.484 HG22 ' HE3' ' A' ' 111' ' ' MET . 26.5 t -111.09 147.68 14.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.096 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -131.83 -178.81 5.05 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.885 179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.64 -37.78 85.28 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.84 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.78 -26.93 26.87 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.52 -179.957 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.484 ' HE3' HG22 ' A' ' 107' ' ' VAL . 34.3 mtm -93.8 -39.29 10.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 0.0 110.919 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.403 HD23 ' N ' ' A' ' 127' ' ' LYS . 49.3 tp -55.86 -30.41 61.44 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.938 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.501 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 22.5 t80 -78.8 -63.86 1.31 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.947 -179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.704 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.0 mt-10 -53.54 -36.31 61.68 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.886 179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.488 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 67.6 t80 -58.09 -34.2 69.92 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.88 -179.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.501 ' O ' ' N ' ' A' ' 118' ' ' LYS . 10.2 m-85 -95.25 -62.74 1.25 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.875 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.704 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -38.44 -26.39 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.115 179.987 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.501 ' N ' ' O ' ' A' ' 116' ' ' PHE . 18.2 tttm -71.05 -60.73 2.07 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.911 179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.659 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.7 p -67.62 -25.79 33.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.165 179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.659 ' CD2' HG13 ' A' ' 119' ' ' VAL . 92.2 m-85 -136.09 112.26 10.31 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.633 0.73 . . . . 0.0 110.95 -179.938 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 54.0 Cg_endo -69.73 2.81 3.18 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.672 2.248 . . . . 0.0 112.343 179.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 32.0 m -105.44 27.9 7.91 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.853 -179.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 36.8 t -89.0 124.73 34.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.857 -179.909 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.488 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 14.0 mtp180 -79.21 -42.8 25.16 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.862 -179.858 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.501 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 168.52 159.56 14.42 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.507 -179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -114.7 134.87 11.95 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.497 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.403 ' N ' HD23 ' A' ' 112' ' ' LEU . 3.5 tppp? -130.13 132.69 46.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.838 0.352 . . . . 0.0 110.878 -179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.2 p -118.1 129.7 74.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.105 179.927 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.911 HG22 ' O ' ' A' ' 139' ' ' TYR . 23.8 m -73.76 144.98 12.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.083 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.616 HD22 ' O ' ' A' ' 134' ' ' GLY . 46.4 mt -123.9 162.3 23.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.903 179.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.42 ' CG ' ' HG2' ' A' ' 137' ' ' LYS . 3.0 m-20 -93.33 -178.25 4.69 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 5.2 pt20 -40.75 -59.05 1.49 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.955 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.411 ' H ' HG22 ' A' ' 133' ' ' THR . 0.0 OUTLIER -62.36 -30.83 71.46 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.127 -179.937 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.616 ' O ' HD22 ' A' ' 130' ' ' LEU . . . 116.65 0.54 20.01 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.498 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.406 HG13 HG23 ' A' ' 133' ' ' THR . 3.5 m -73.43 141.12 16.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.787 0.327 . . . . 0.0 111.126 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.435 ' HA ' HD23 ' A' ' 130' ' ' LEU . 8.2 t -50.27 113.83 0.97 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.886 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.487 ' HB2' HG23 ' A' ' 129' ' ' VAL . 22.1 mtmt -58.76 -30.72 67.75 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.916 179.944 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 120.13 17.26 4.56 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.512 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.911 ' O ' HG22 ' A' ' 129' ' ' VAL . 19.0 p90 -163.29 167.96 21.18 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.985 0.422 . . . . 0.0 110.864 -179.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -171.56 -162.48 23.91 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.51 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.2 m-85 -153.3 139.9 18.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.893 0.378 . . . . 0.0 110.88 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 9.4 m -110.75 176.85 1.48 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.141 179.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . 0.488 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 47.8 mttt -133.35 156.72 47.12 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.878 179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 95.6 m-85 -148.57 152.57 37.02 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.929 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . 0.428 HG23 ' CG ' ' A' ' 124' ' ' ARG . 25.3 p -96.0 -24.96 16.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.147 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -115.06 103.55 11.01 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.837 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 15.2 tm-20 -48.51 -47.23 39.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.914 -179.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 65.6 mt -39.68 -44.35 1.51 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.935 179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 12.8 mm-40 -72.48 -40.65 66.77 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.918 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.88 ' HG2' HD21 ' A' ' 98' ' ' LEU . 24.9 tt0 -40.36 -60.6 1.06 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.897 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 14.4 mttm -62.51 -44.78 95.54 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 179.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 57.6 mtt180 -48.0 -42.64 28.49 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.904 179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.459 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -69.15 -45.19 70.7 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.122 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.814 HD21 HD22 ' A' ' 98' ' ' LEU . 13.8 mt -43.52 -41.38 4.4 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.952 179.982 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.431 HG23 ' N ' ' A' ' 156' ' ' GLU . 6.0 t -92.46 -41.64 10.18 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.431 ' N ' HG23 ' A' ' 155' ' ' THR . 21.6 mm-40 -70.04 -63.59 1.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.868 -179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.484 ' CB ' HD11 ' A' ' 170' ' ' LEU . 20.9 m -70.82 -0.32 8.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.905 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -43.69 129.79 5.45 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.919 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 55.45 33.78 59.1 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.495 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.887 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -48.64 116.58 1.66 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.799 0.333 . . . . 0.0 111.062 179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.7 t -93.85 -31.39 4.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.138 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -46.29 -31.64 4.78 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.517 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.407 HD13 ' HB2' ' A' ' 115' ' ' PHE . 20.4 tp -91.37 115.7 28.25 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.851 0.358 . . . . 0.0 110.923 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.0 159.92 0.97 Allowed Glycine 0 N--CA 1.45 -0.378 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.493 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 m -61.95 -19.68 63.01 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.959 0.409 . . . . 0.0 110.883 -179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 35.0 mttm -111.13 153.53 43.9 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.559 0.695 . . . . 0.0 110.89 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.78 171.79 13.85 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.659 2.239 . . . . 0.0 112.371 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.887 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 22.2 m -127.22 125.06 65.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.119 179.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 24.5 ttt180 -86.42 111.68 20.76 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.851 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.566 ' HB3' HD23 ' A' ' 154' ' ' LEU . 14.7 mt -87.16 139.95 30.05 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.9 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.2 m -152.74 178.17 9.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.823 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.431 HG22 HD11 ' A' ' 154' ' ' LEU . 2.8 t -100.73 96.15 4.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.128 179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.661 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -80.66 168.98 18.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.128 179.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 58.0 mt -143.14 120.86 7.0 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-O 121.582 0.706 . . . . 0.0 111.106 -179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 -41.02 4.63 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.687 2.258 . . . . 0.0 112.348 179.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 26.7 mmtm -109.36 71.29 0.76 Allowed 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.864 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -76.47 -33.98 58.69 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.092 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 83.1 p -98.4 56.64 1.16 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.853 -179.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 8.2 ttp85 -95.96 75.17 3.09 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.893 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 86.8 t -115.94 108.18 24.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.088 179.992 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 4.2 mmpt? -134.46 153.02 78.95 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.605 0.717 . . . . 0.0 110.905 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 134.99 29.28 Favored 'Trans proline' 0 C--O 1.231 0.167 0 C-N-CA 122.697 2.265 . . . . 0.0 112.358 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 98.5 t -69.38 87.68 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.125 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . 0.461 ' C ' ' CD ' ' A' ' 184' ' ' GLU . 0.6 OUTLIER -85.36 153.73 22.35 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.924 -179.993 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 76.3 p -147.31 164.46 33.17 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.85 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -97.75 146.05 18.07 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.525 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.84 139.68 40.55 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.714 2.276 . . . . 0.0 112.316 -179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 1.4 t -140.6 154.52 46.5 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.849 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 4.0 m -81.07 144.46 31.71 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.828 -179.808 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.355 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.529 179.953 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 N-CA-C 112.472 -0.251 . . . . 0.0 112.472 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 13.4 t -66.83 128.39 36.13 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.877 0.37 . . . . 0.0 110.864 -179.734 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 72.9 m -131.59 133.89 45.47 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.874 -179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -171.04 81.37 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.497 -179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 83.7 p -97.55 91.86 5.64 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.857 0.36 . . . . 0.0 110.853 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.8 m -158.74 142.54 15.26 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.886 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -117.82 72.67 0.29 Allowed Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.485 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 150.87 68.73 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.654 2.236 . . . . 0.0 112.319 -179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.2 mp0 -72.16 154.24 41.17 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.876 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . 0.437 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 32.4 m-85 -130.29 124.06 31.5 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.932 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 52.6 p -138.52 159.66 41.51 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.9 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.58 HD21 ' CD ' ' A' ' 150' ' ' GLN . 79.5 mt -124.84 147.73 48.61 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.915 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -94.03 120.6 34.5 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.902 179.9 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.42 HG22 ' C ' ' A' ' 140' ' ' GLY . 31.2 m -114.04 145.41 19.92 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.132 179.962 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -133.67 -174.02 13.41 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.745 -0.741 . . . . 0.0 112.494 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 46.91 50.88 13.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.841 0.353 . . . . 0.0 110.87 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 103' ' ' LEU . 20.4 mt -96.05 99.07 10.87 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.954 -179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.466 HG23 ' HB2' ' A' ' 166' ' ' LYS . 23.9 p -48.79 151.57 2.08 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.597 0.713 . . . . 0.0 111.122 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 1.56 4.32 Favored 'Trans proline' 0 C--O 1.231 0.166 0 C-N-CA 122.694 2.262 . . . . 0.0 112.326 179.953 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -100.99 10.38 41.17 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.851 179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.521 HG13 ' CE ' ' A' ' 111' ' ' MET . 3.9 t -121.57 147.03 25.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.1 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -132.77 178.52 6.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.873 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.9 p30 -56.18 -40.07 73.39 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.87 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -49.28 -40.18 29.41 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.493 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.521 ' CE ' HG13 ' A' ' 107' ' ' VAL . 36.1 mtm -82.57 -39.73 21.87 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.835 0.35 . . . . 0.0 110.876 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.635 HD23 ' N ' ' A' ' 127' ' ' LYS . 28.3 tp -57.71 -28.11 63.55 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.897 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.417 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.2 t80 -81.77 -60.02 2.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.92 179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.727 ' HA ' HG12 ' A' ' 117' ' ' VAL . 20.7 mt-10 -56.13 -47.43 78.17 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.861 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.445 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 62.8 t80 -48.79 -33.64 10.8 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.917 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.561 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.5 m-85 -94.41 -66.12 0.94 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.873 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.727 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.71 -30.43 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.15 179.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.472 ' N ' ' O ' ' A' ' 116' ' ' PHE . 20.2 ttpp -65.84 -59.37 3.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.941 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.604 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.6 p -67.13 -34.21 68.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.172 179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.604 ' CD2' HG13 ' A' ' 119' ' ' VAL . 92.8 m-85 -130.06 112.01 17.1 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.662 0.744 . . . . 0.0 110.96 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 1.39 4.46 Favored 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.679 2.252 . . . . 0.0 112.352 179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -99.05 19.9 14.32 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.828 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 38.8 t -82.01 132.8 35.26 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.875 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.693 ' HG3' HG23 ' A' ' 145' ' ' THR . 46.1 mtt-85 -89.52 -41.92 11.75 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.868 -179.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.417 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 168.94 150.35 6.66 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.468 -179.948 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -103.18 142.34 15.48 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.793 -0.718 . . . . 0.0 112.517 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.635 ' N ' HD23 ' A' ' 112' ' ' LEU . 12.1 tptm -136.95 132.71 34.76 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.869 0.366 . . . . 0.0 110.868 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 3.0 p -120.72 129.26 75.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.151 179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.849 HG22 ' O ' ' A' ' 139' ' ' TYR . 23.5 m -72.41 142.88 14.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.107 179.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.49 HD23 ' HA ' ' A' ' 136' ' ' SER . 11.5 mt -127.7 163.97 23.11 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.936 -179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.444 ' C ' ' OD1' ' A' ' 131' ' ' ASP . 0.6 OUTLIER -97.89 -175.08 3.05 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.839 179.865 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 44.5 tt0 -49.09 -48.67 44.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.871 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 21.5 p -65.91 -23.2 66.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.147 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 96.46 22.57 18.72 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.492 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 30.1 m -102.93 131.27 51.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.8 0.334 . . . . 0.0 111.138 -179.955 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.49 ' HA ' HD23 ' A' ' 130' ' ' LEU . 5.4 t -39.45 116.83 0.65 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.864 -179.813 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.1 mtmt -63.17 -28.17 69.87 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.914 179.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 123.98 14.34 3.8 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.506 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.849 ' O ' HG22 ' A' ' 129' ' ' VAL . 17.9 p90 -162.2 170.82 18.38 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.939 0.399 . . . . 0.0 110.921 -179.807 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.42 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -172.71 -160.79 21.98 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.507 179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -153.85 143.72 21.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.867 0.365 . . . . 0.0 110.861 -179.841 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.561 HG11 ' CD2' ' A' ' 116' ' ' PHE . 14.7 m -115.39 -176.68 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.123 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 13.8 mttp -141.55 153.02 44.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.896 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.418 ' CE2' HD12 ' A' ' 98' ' ' LEU . 88.7 m-85 -146.48 128.82 15.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.88 179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . 0.693 HG23 ' HG3' ' A' ' 124' ' ' ARG . 36.7 p -66.5 -12.7 58.8 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.162 -179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -126.54 135.21 51.0 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.868 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.437 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 29.7 tt0 -79.08 -34.17 43.83 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.887 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 38.9 mt -53.98 -60.2 3.64 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.911 179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 7.1 mm-40 -65.09 -38.45 90.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.891 179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.58 ' CD ' HD21 ' A' ' 98' ' ' LEU . 1.4 tm0? -48.06 -42.55 28.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.888 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.573 ' HA ' HD12 ' A' ' 154' ' ' LEU . 34.7 mmtm -77.85 -26.94 49.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.898 179.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 27.1 mtt180 -65.09 -37.48 87.66 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.855 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.454 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -66.12 -36.04 82.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.104 179.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.573 HD12 ' HA ' ' A' ' 151' ' ' LYS . 28.1 mt -52.49 -41.49 63.43 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.934 -179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 8.8 t -91.86 -36.42 13.51 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.176 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 16.0 mm-40 -76.24 -62.54 1.58 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.877 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.574 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 10.5 m -71.79 0.54 8.73 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.903 -179.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . 0.466 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.0 tp-100 -43.17 136.14 3.02 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.9 -179.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 45.93 30.16 3.59 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.475 -179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.574 ' HB2' ' O ' ' A' ' 157' ' ' CYS . . . -49.79 112.31 0.64 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.828 0.347 . . . . 0.0 111.115 -179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 18.8 t -87.18 -33.84 7.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.126 -179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.84 -31.13 1.09 Allowed Glycine 0 N--CA 1.452 -0.262 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.463 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.445 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 28.4 tp -90.17 109.43 20.5 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.882 0.372 . . . . 0.0 110.919 -179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 71.53 168.05 9.02 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.471 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . 0.44 ' HB2' HG21 ' A' ' 104' ' ' THR . 39.5 m -66.24 -23.1 66.36 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.918 0.39 . . . . 0.0 110.863 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . 0.466 ' HB2' HG23 ' A' ' 104' ' ' THR . 58.9 mttm -110.29 155.81 41.29 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.632 0.73 . . . . 0.0 110.873 179.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.85 -176.85 1.65 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.676 2.25 . . . . 0.0 112.325 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.543 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 28.6 m -135.04 128.28 49.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.131 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 12.5 ttp180 -91.99 94.16 9.13 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.835 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.541 ' HB3' HD23 ' A' ' 154' ' ' LEU . 10.6 mt -72.14 152.64 42.17 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.9 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.484 ' O ' HD21 ' A' ' 154' ' ' LEU . 0.9 OUTLIER -167.01 178.32 5.81 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.891 -179.933 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 45.5 t -103.79 99.45 8.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.982 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -78.74 137.92 37.99 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.086 179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 72.4 mt -142.93 124.98 8.68 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 121.611 0.72 . . . . 0.0 111.12 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 -166.56 0.19 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.667 2.245 . . . . 0.0 112.37 179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.439 ' CD ' ' O ' ' A' ' 176' ' ' LYS . 0.4 OUTLIER -53.15 120.77 6.33 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.909 179.893 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -103.47 -45.71 4.77 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.124 179.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 87.9 p -154.8 166.19 34.25 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.864 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 17.8 mmm180 45.53 39.4 4.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.894 -179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . 0.476 HG13 ' HG3' ' A' ' 181' ' ' LYS . 12.7 p -49.89 -22.72 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.101 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.476 ' HG3' HG13 ' A' ' 180' ' ' VAL . 0.7 OUTLIER -173.13 143.87 1.12 Allowed Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.566 0.698 . . . . 0.0 110.89 179.953 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 140.54 42.69 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 122.659 2.24 . . . . 0.0 112.341 179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.557 ' O ' HG13 ' A' ' 183' ' ' VAL . 7.5 p -148.16 109.28 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.138 179.965 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -134.82 122.05 21.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.895 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 67.1 m -133.64 132.35 40.65 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.889 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 118.81 151.55 9.03 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.527 -179.954 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.68 139.88 41.59 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.672 2.248 . . . . 0.0 112.373 -179.961 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . 0.434 ' O ' ' C ' ' A' ' 189' ' ' SER . 6.9 t -75.11 -47.49 28.39 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.842 -179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . 0.434 ' C ' ' O ' ' A' ' 188' ' ' SER . 17.4 p 35.41 44.82 0.19 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.841 -179.877 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.286 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.513 -179.96 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.295 0 N-CA-C 112.456 -0.257 . . . . 0.0 112.456 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 72.8 p -114.01 41.52 2.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.85 0.357 . . . . 0.0 110.844 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 77.7 p 40.21 41.61 1.02 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.846 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -84.28 -51.45 3.93 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.494 -179.987 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 4.4 m -101.32 102.79 13.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.905 0.383 . . . . 0.0 110.821 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 22.7 t -49.87 162.23 0.2 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.83 -179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -123.18 -156.62 9.62 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.522 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 157.86 58.87 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.638 2.225 . . . . 0.0 112.366 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -65.61 166.32 10.84 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.93 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 19.5 m-85 -124.72 100.37 6.59 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.928 -179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 45.9 m -118.69 146.55 44.62 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.86 -179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.717 HD22 HD21 ' A' ' 154' ' ' LEU . 68.3 mt -113.53 153.36 28.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.921 -179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 8.4 t80 -100.77 123.05 44.41 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.848 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 23.1 m -114.38 145.8 19.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.114 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.11 -176.75 14.51 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.513 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 48.78 52.06 14.71 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.827 0.346 . . . . 0.0 110.879 -179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.424 HD12 ' C ' ' A' ' 139' ' ' TYR . 28.7 mt -98.24 105.89 18.1 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.879 -179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.459 HG23 ' HB2' ' A' ' 166' ' ' LYS . 25.1 p -50.6 150.63 4.73 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-O 121.582 0.705 . . . . 0.0 111.158 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 3.16 2.95 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.665 2.243 . . . . 0.0 112.316 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -98.38 -13.33 20.69 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.881 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.471 HG13 ' HE2' ' A' ' 111' ' ' MET . 41.4 t -98.21 134.46 36.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.151 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -121.25 175.88 5.91 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.828 179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.3 p-10 -53.37 -44.79 68.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.858 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.96 -29.07 7.98 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.499 -179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.471 ' HE2' HG13 ' A' ' 107' ' ' VAL . 22.3 mtp -86.88 -59.47 2.25 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.788 0.328 . . . . 0.0 110.873 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 15.8 tp -40.18 -41.06 1.22 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.898 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.423 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 12.9 t80 -62.65 -67.17 0.44 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.966 -179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.77 ' HA ' HG12 ' A' ' 117' ' ' VAL . 30.3 mt-10 -52.52 -55.52 21.51 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.927 179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.441 ' CE2' ' HB2' ' A' ' 163' ' ' LEU . 57.2 t80 -41.49 -32.28 0.33 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.896 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.498 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.0 m-85 -95.14 -67.53 0.85 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.883 -179.895 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.77 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -37.65 -27.58 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.103 179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.498 ' N ' ' O ' ' A' ' 116' ' ' PHE . 20.1 tptt -67.57 -57.87 5.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.885 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.655 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.3 p -71.56 -32.73 46.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.175 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.655 ' CD2' HG13 ' A' ' 119' ' ' VAL . 97.0 m-85 -126.3 108.04 24.09 Favored Pre-proline 0 C--N 1.329 -0.301 0 CA-C-O 121.622 0.725 . . . . 0.0 110.954 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.8 Cg_endo -69.76 2.44 3.53 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.667 2.245 . . . . 0.0 112.339 179.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 47.6 p -95.0 -10.33 31.23 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.882 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 10.0 t -57.09 142.65 41.61 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.887 -179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 61.7 mtp180 -104.46 -34.1 8.36 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.88 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.423 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 166.72 145.99 4.68 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.453 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.43 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -96.35 139.25 14.39 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.477 -179.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 46.6 tptt -125.28 127.73 47.15 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.87 0.366 . . . . 0.0 110.866 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 4.1 p -117.72 141.28 37.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.172 179.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.958 HG22 ' O ' ' A' ' 139' ' ' TYR . 33.2 m -92.73 145.33 7.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.096 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.582 HD23 ' HA ' ' A' ' 136' ' ' SER . 23.4 mt -123.8 179.09 4.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.888 179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 11.1 t0 -108.96 -178.96 3.72 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.875 179.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -53.57 -18.9 3.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.917 -179.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 43.6 p -93.61 -27.27 16.69 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.163 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 107.52 17.29 11.47 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.476 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 19.1 m -100.05 139.27 21.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.853 0.359 . . . . 0.0 111.112 -179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.582 ' HA ' HD23 ' A' ' 130' ' ' LEU . 7.5 t -49.76 100.34 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.858 -179.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.507 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.4 mtmt -42.97 -36.09 1.44 Allowed 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.877 179.92 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 128.35 16.97 2.03 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.548 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.958 ' O ' HG22 ' A' ' 129' ' ' VAL . 28.1 p90 -161.07 172.07 17.47 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.901 0.381 . . . . 0.0 110.96 -179.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -174.94 -163.23 27.74 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.475 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -153.76 145.58 23.46 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.861 0.363 . . . . 0.0 110.863 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.487 HG11 ' CD2' ' A' ' 116' ' ' PHE . 29.3 m -119.6 -177.74 1.29 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.087 179.995 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 32.8 mttm -142.16 156.73 45.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.887 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -145.87 163.43 35.1 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 179.969 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 29.2 p -101.1 -19.88 15.58 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.129 -179.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -117.02 120.47 38.49 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.825 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 5.5 tt0 -65.45 -33.55 76.21 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.948 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 44.6 mt -57.71 -40.57 79.83 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.931 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.464 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 38.6 mt-10 -76.28 -38.53 56.02 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.829 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.684 ' HG2' HD21 ' A' ' 98' ' ' LEU . 22.0 tt0 -44.95 -48.43 11.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.869 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 5.1 mmmm -73.57 -37.37 65.54 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.881 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.407 ' O ' ' CG ' ' A' ' 156' ' ' GLU . 9.1 mtt-85 -56.25 -34.23 66.19 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.892 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.439 ' O ' HD12 ' A' ' 170' ' ' LEU . . . -72.0 -46.2 58.09 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.105 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.784 HD23 ' HB3' ' A' ' 170' ' ' LEU . 48.6 mt -44.36 -40.98 5.75 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 179.999 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.47 HG23 ' N ' ' A' ' 156' ' ' GLU . 14.9 t -92.33 -42.54 9.75 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.165 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.47 ' N ' HG23 ' A' ' 155' ' ' THR . 25.6 mm-40 -68.96 -64.87 0.79 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.869 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.611 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 10.4 m -70.11 -1.68 10.74 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.893 -179.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . 0.487 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.8 tp-100 -42.48 141.95 0.9 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.891 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 158' ' ' GLN . . . 35.51 34.29 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.502 -179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.611 ' HB2' ' O ' ' A' ' 157' ' ' CYS . . . -58.49 110.65 1.02 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.769 0.319 . . . . 0.0 111.121 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.41 ' O ' ' C ' ' A' ' 162' ' ' GLY . 22.9 t -79.27 -34.27 16.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.121 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.65 -36.23 0.15 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.464 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.441 ' HB2' ' CE2' ' A' ' 115' ' ' PHE . 25.2 tp -92.72 115.17 27.87 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.85 0.357 . . . . 0.0 110.885 -179.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.77 146.85 0.13 Allowed Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.495 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.8 m -50.81 -21.09 1.5 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.966 0.413 . . . . 0.0 110.855 -179.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . 0.459 ' HB2' HG23 ' A' ' 104' ' ' THR . 36.5 mttm -109.08 156.05 39.86 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 121.595 0.712 . . . . 0.0 110.903 179.919 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 171.84 13.74 Favored 'Trans proline' 0 C--N 1.342 0.186 0 C-N-CA 122.699 2.266 . . . . 0.0 112.295 179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 168' ' ' VAL . 35.4 m -125.34 127.6 72.06 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.185 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 17.7 ttt180 -91.54 107.82 19.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.872 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.784 ' HB3' HD23 ' A' ' 154' ' ' LEU . 14.4 mt -84.4 143.39 29.47 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.932 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 15.2 m -154.6 171.41 19.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.881 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.673 HG22 HD11 ' A' ' 154' ' ' LEU . 3.0 t -101.0 100.6 10.69 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.112 179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -82.37 140.12 33.68 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.136 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . 0.766 HG22 ' H ' ' A' ' 176' ' ' LYS . 41.5 mt -119.18 120.98 30.62 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.668 0.747 . . . . 0.0 111.131 179.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.8 1.4 4.5 Favored 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.704 2.269 . . . . 0.0 112.312 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.766 ' H ' HG22 ' A' ' 174' ' ' ILE . 17.7 mmmt -102.83 -42.09 5.97 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.883 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -47.31 134.24 11.62 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.117 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 68.7 m -96.26 90.5 5.49 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.884 -179.788 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 3.5 tmm_? -95.42 74.44 3.3 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.852 -179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 71.4 t -115.39 107.09 21.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.119 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 34.9 mmtt -66.11 142.25 97.84 Favored Pre-proline 0 C--N 1.33 -0.282 0 CA-C-O 121.561 0.696 . . . . 0.0 110.93 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.73 162.64 41.29 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.678 2.252 . . . . 0.0 112.395 179.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 92.9 t -134.95 109.99 12.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.142 179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 11.9 mt-10 -136.73 120.34 17.18 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.883 179.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 11.6 m -58.49 -54.26 49.0 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.849 -179.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 49.92 73.01 0.4 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.478 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 117.85 5.33 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.682 2.255 . . . . 0.0 112.329 -179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 5.2 m -90.34 169.79 10.8 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.831 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 36.4 m -156.49 152.83 27.86 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.889 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.293 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.482 -179.954 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.493 -0.243 . . . . 0.0 112.493 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.2 t -116.62 140.16 49.71 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.842 0.353 . . . . 0.0 110.903 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 57.8 m -98.4 -49.38 4.69 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.851 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 148.2 -93.11 0.15 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.474 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 20.3 t -115.1 86.06 2.38 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.857 0.36 . . . . 0.0 110.876 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 33.3 p -172.37 136.61 0.81 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.847 -179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 147.68 168.0 13.77 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.774 -0.727 . . . . 0.0 112.469 179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 147.81 63.68 Favored 'Trans proline' 0 C--N 1.342 0.195 0 C-N-CA 122.68 2.254 . . . . 0.0 112.333 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 26.3 mp0 -83.41 162.11 21.12 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.9 -179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 16.1 m-85 -131.79 93.74 3.37 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.934 -179.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 15.8 m -112.33 147.19 36.88 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.839 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.817 HD22 HD21 ' A' ' 154' ' ' LEU . 92.2 mt -115.75 155.99 26.79 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.911 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.412 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 8.6 t80 -104.6 127.49 52.35 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.856 179.955 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.438 HG22 ' C ' ' A' ' 140' ' ' GLY . 28.4 m -116.55 155.28 18.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.137 179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -142.59 178.12 21.26 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.485 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 52.87 50.28 18.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.874 0.369 . . . . 0.0 110.898 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 29.1 mt -96.9 103.44 15.37 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.899 -179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.426 HG21 ' HB2' ' A' ' 165' ' ' SER . 17.4 p -47.94 150.16 2.1 Favored Pre-proline 0 C--N 1.33 -0.252 0 CA-C-O 121.617 0.723 . . . . 0.0 111.152 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 2.98 3.03 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 122.623 2.215 . . . . 0.0 112.375 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -104.34 16.34 26.37 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.86 179.917 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.721 HG22 ' HE3' ' A' ' 111' ' ' MET . 59.5 t -129.62 142.17 44.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.109 -179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -128.95 -177.6 4.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.817 179.959 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.2 p30 -58.18 -47.98 81.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.848 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -42.26 -35.1 1.72 Allowed Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.48 -179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.721 ' HE3' HG22 ' A' ' 107' ' ' VAL . 26.0 mtm -86.03 -45.72 11.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.823 0.344 . . . . 0.0 110.884 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.532 HD23 ' N ' ' A' ' 127' ' ' LYS . 16.0 tp -53.5 -33.45 54.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.503 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 9.8 t80 -68.71 -61.62 1.74 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.884 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.755 ' HA ' HG12 ' A' ' 117' ' ' VAL . 22.2 mt-10 -57.76 -51.78 68.15 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.901 -179.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.545 ' CE1' ' HB2' ' A' ' 163' ' ' LEU . 66.5 t80 -44.1 -32.34 1.17 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.876 -179.947 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.619 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.7 m-85 -95.25 -67.52 0.85 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.871 -179.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.755 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.83 -29.35 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.158 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.483 ' N ' ' O ' ' A' ' 116' ' ' PHE . 22.9 ttpp -66.31 -58.31 5.62 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.901 179.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.529 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.6 p -67.41 -33.0 59.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.124 179.886 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.686 ' CE2' ' HB2' ' A' ' 153' ' ' ALA . 89.4 m-85 -129.12 113.31 18.5 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-O 121.683 0.754 . . . . 0.0 110.944 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.412 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.8 Cg_endo -69.77 -0.05 6.35 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.722 2.281 . . . . 0.0 112.353 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 69.0 m -105.22 35.41 2.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.864 -179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 3.0 t -98.09 138.59 35.17 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.907 -179.971 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.571 HH11 HG22 ' A' ' 145' ' ' THR . 44.8 mtp85 -93.6 -38.06 11.55 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.857 -179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.503 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 159.22 141.72 3.21 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.491 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.645 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -90.41 138.04 14.25 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.44 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.532 ' N ' HD23 ' A' ' 112' ' ' LEU . 20.2 tptm -122.05 128.28 51.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.81 0.338 . . . . 0.0 110.9 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.9 p -114.86 135.64 54.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.948 HG22 ' O ' ' A' ' 139' ' ' TYR . 32.9 m -84.71 145.98 7.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.092 179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.562 HD23 ' HA ' ' A' ' 136' ' ' SER . 31.1 mt -126.69 -179.66 4.91 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.849 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.479 ' O ' ' N ' ' A' ' 134' ' ' GLY . 2.2 t70 -118.69 -176.0 3.0 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.891 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 6.0 pt20 -38.35 -61.38 0.69 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.887 -179.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.402 ' H ' HG22 ' A' ' 133' ' ' THR . 0.0 OUTLIER -60.92 -24.84 66.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.148 -179.898 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.485 ' O ' HD22 ' A' ' 130' ' ' LEU . . . 105.16 4.45 41.27 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.502 179.989 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 5.3 m -77.24 145.2 10.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 120.811 0.339 . . . . 0.0 111.168 -179.994 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.562 ' HA ' HD23 ' A' ' 130' ' ' LEU . 5.1 t -56.93 113.9 1.87 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.892 -179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.502 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 30.0 mtmt -56.73 -31.65 64.76 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.885 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.21 17.71 2.95 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.484 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.948 ' O ' HG22 ' A' ' 129' ' ' VAL . 28.0 p90 -162.55 174.8 12.16 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.964 0.412 . . . . 0.0 110.889 -179.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.438 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -178.29 -162.42 28.01 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.485 -179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.412 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 4.5 m-85 -153.98 146.18 23.78 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.953 0.406 . . . . 0.0 110.858 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.645 HG12 ' HA2' ' A' ' 126' ' ' GLY . 17.8 m -116.87 -176.51 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.132 -0.486 . . . . 0.0 111.139 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 25.7 mttm -143.75 157.83 44.11 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.891 179.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.421 ' CE1' HG23 ' A' ' 142' ' ' VAL . 50.0 m-85 -146.79 161.85 39.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.884 179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . 0.571 HG22 HH11 ' A' ' 124' ' ' ARG . 69.9 p -95.76 -29.73 14.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.152 -179.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -112.9 133.9 54.66 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.799 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -74.64 -34.47 62.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.867 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 64.6 mt -53.39 -40.45 65.06 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.927 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.484 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 4.3 mm-40 -80.66 -40.53 25.34 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.877 179.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.591 ' HG2' HD21 ' A' ' 98' ' ' LEU . 13.4 tt0 -41.6 -48.08 3.97 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.9 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.47 ' O ' ' N ' ' A' ' 154' ' ' LEU . 40.4 mttp -71.67 -57.2 4.58 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.902 179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.4 ' C ' ' O ' ' A' ' 151' ' ' LYS . 21.0 mtt-85 -38.18 -33.55 0.1 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.897 -179.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.686 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -74.66 -43.49 55.04 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.117 179.881 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.817 HD21 HD22 ' A' ' 98' ' ' LEU . 14.7 mt -48.32 -38.2 18.42 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.893 -179.966 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.499 HG23 ' N ' ' A' ' 156' ' ' GLU . 10.1 t -92.14 -45.76 8.11 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.136 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.499 ' N ' HG23 ' A' ' 155' ' ' THR . 16.8 mm-40 -67.99 -62.35 1.44 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.851 -179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.544 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 33.0 m -68.24 -3.25 10.12 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.897 -179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 5.1 tp-100 -45.36 139.58 3.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.916 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 44.2 34.35 3.23 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.505 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.629 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -55.33 113.0 1.23 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.814 0.34 . . . . 0.0 111.077 -179.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.8 t -88.02 -32.31 6.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.151 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.53 -37.0 2.46 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.482 179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.545 ' HB2' ' CE1' ' A' ' 115' ' ' PHE . 26.4 tp -89.65 117.19 28.34 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.85 0.357 . . . . 0.0 110.901 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 68.19 154.22 0.55 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.528 179.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . 0.426 ' HB2' HG21 ' A' ' 104' ' ' THR . 19.3 m -55.98 -25.4 43.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.953 0.406 . . . . 0.0 110.871 -179.757 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 59.8 mttt -108.0 154.71 40.97 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.615 0.721 . . . . 0.0 110.871 179.975 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.79 173.39 11.07 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.696 2.264 . . . . 0.0 112.304 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.629 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 33.0 m -126.33 127.02 70.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.153 179.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 34.6 ttt85 -92.77 102.44 14.84 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.856 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.58 ' HB3' HD23 ' A' ' 154' ' ' LEU . 11.2 mt -76.88 149.84 36.07 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.919 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.7 m -158.58 175.57 13.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.871 -179.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.624 HG22 HD11 ' A' ' 154' ' ' LEU . 11.3 t -105.78 101.62 12.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.141 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -75.97 171.58 14.2 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.119 179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . 0.48 HG22 ' H ' ' A' ' 177' ' ' ALA . 65.3 mt -133.76 123.13 17.02 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.639 0.733 . . . . 0.0 111.086 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.453 ' O ' ' C ' ' A' ' 176' ' ' LYS . 53.0 Cg_endo -69.79 79.93 0.92 Allowed 'Trans proline' 0 C--N 1.341 0.168 0 C-N-CA 122.663 2.242 . . . . 0.0 112.321 179.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.453 ' C ' ' O ' ' A' ' 175' ' ' PRO . 45.2 mttm 33.56 37.05 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.912 179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . 0.48 ' H ' HG22 ' A' ' 174' ' ' ILE . . . -56.5 -59.83 4.41 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.087 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 63.6 p -82.66 123.17 29.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.869 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 45.3 mtm180 -95.99 155.8 16.6 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.873 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 7.2 p -123.57 144.38 33.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.126 179.977 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -122.1 87.58 47.67 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.587 0.708 . . . . 0.0 110.901 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.7 111.39 2.79 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.698 2.265 . . . . 0.0 112.368 179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 91.4 t -60.83 104.27 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.107 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 4.8 pt-20 -75.06 143.02 43.66 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.9 p -140.54 155.36 46.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.891 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 169.75 146.29 5.02 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.724 -0.751 . . . . 0.0 112.461 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 126.26 13.1 Favored 'Trans proline' 0 C--O 1.231 0.168 0 C-N-CA 122.646 2.23 . . . . 0.0 112.361 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . 0.412 ' O ' ' C ' ' A' ' 189' ' ' SER . 31.7 t -151.03 124.03 8.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.864 -179.857 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . 0.412 ' C ' ' O ' ' A' ' 188' ' ' SER . 3.1 t -36.49 -43.3 0.39 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.852 -179.808 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.308 0 C-N-CA 120.779 -0.724 . . . . 0.0 112.471 179.995 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.289 0 N-CA-C 112.445 -0.262 . . . . 0.0 112.445 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 30.8 t -75.5 134.98 40.66 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.869 0.366 . . . . 0.0 110.872 -179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 33.6 m -67.15 -53.55 29.53 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.829 -179.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 89.22 -119.85 5.57 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.496 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 35.8 m -74.8 -47.85 28.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.878 0.371 . . . . 0.0 110.852 -179.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 47.4 t -64.04 120.39 11.94 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.882 -179.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -48.51 146.29 5.74 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.491 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 108.96 2.2 Favored 'Trans proline' 0 C--N 1.342 0.203 0 C-N-CA 122.694 2.263 . . . . 0.0 112.339 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.8 pt-20 -144.98 144.48 31.06 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.895 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . 0.493 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 5.0 m-85 -140.39 107.02 5.33 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.923 -179.891 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 58.2 p -116.22 142.52 46.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.849 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.791 HD22 HD21 ' A' ' 154' ' ' LEU . 37.3 mt -115.79 147.89 40.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.917 179.985 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 7.8 t80 -93.88 135.68 34.95 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.873 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 140' ' ' GLY . 15.5 m -128.6 139.56 51.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.158 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -132.39 171.23 21.6 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.508 179.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . 0.403 ' N ' ' O ' ' A' ' 138' ' ' GLY . 29.4 m-20 61.74 51.72 3.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.864 0.364 . . . . 0.0 110.928 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 25.6 mt -99.29 103.31 15.13 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.94 -179.955 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.558 HG23 ' HB2' ' A' ' 166' ' ' LYS . 16.9 p -48.4 150.19 2.43 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.609 0.718 . . . . 0.0 111.111 179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.82 -0.27 6.73 Favored 'Trans proline' 0 C--N 1.342 0.213 0 C-N-CA 122.668 2.246 . . . . 0.0 112.333 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -99.73 10.19 41.77 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.899 179.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.479 ' HA ' ' HE2' ' A' ' 111' ' ' MET . 21.7 t -123.76 133.9 67.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.101 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -118.9 176.3 5.35 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.879 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 13.5 p-10 -52.22 -50.55 61.74 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.898 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -39.41 -39.12 1.07 Allowed Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.468 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.479 ' HE2' ' HA ' ' A' ' 107' ' ' VAL . 29.7 mtm -82.77 -41.33 19.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.743 0.306 . . . . 0.0 110.876 -179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.412 HD23 ' N ' ' A' ' 127' ' ' LYS . 18.6 tp -58.8 -24.39 61.81 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.927 179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.418 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 16.7 t80 -84.45 -62.37 1.57 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.884 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.7 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.0 mt-10 -57.76 -34.74 69.87 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.931 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.504 ' CZ ' ' HB2' ' A' ' 163' ' ' LEU . 84.7 t80 -59.85 -34.03 72.57 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.923 -179.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.51 ' CD2' HG11 ' A' ' 142' ' ' VAL . 9.5 m-85 -95.03 -62.13 1.36 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.863 -179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.7 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.3 p -39.03 -27.16 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.131 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.462 ' N ' ' O ' ' A' ' 116' ' ' PHE . 19.5 tptt -68.96 -60.52 2.31 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.898 179.899 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.668 HG13 ' CD2' ' A' ' 120' ' ' TYR . 4.2 p -67.58 -28.86 43.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.146 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.668 ' CD2' HG13 ' A' ' 119' ' ' VAL . 95.1 m-85 -132.72 110.55 13.38 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.667 0.746 . . . . 0.0 110.894 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.429 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.1 Cg_endo -69.8 -2.47 10.25 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.701 2.267 . . . . 0.0 112.294 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 23.4 p -90.3 -4.04 57.39 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.855 -179.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . 0.475 ' HA ' ' CD1' ' A' ' 144' ' ' PHE . 14.1 t -57.35 146.46 28.96 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.931 179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.439 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 1.6 mmm180 -109.01 -36.45 6.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.901 -179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.418 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 165.29 149.24 5.78 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.48 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.442 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -100.11 135.82 12.36 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.472 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.412 ' N ' HD23 ' A' ' 112' ' ' LEU . 1.7 tmtp? -127.91 110.9 13.0 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.848 0.356 . . . . 0.0 110.883 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.527 HG13 ' O ' ' A' ' 128' ' ' VAL . 14.2 p -103.25 119.91 52.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.128 179.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.847 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 18.2 m -66.36 143.33 15.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.113 179.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 43.5 mt -121.49 -176.6 3.34 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.911 179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.1 t70 -113.77 -175.72 2.74 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.876 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . 0.751 ' OE1' HG22 ' A' ' 133' ' ' THR . 0.0 OUTLIER -48.39 -35.18 12.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.912 -179.928 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.751 HG22 ' OE1' ' A' ' 132' ' ' GLN . 9.6 p -86.65 -23.16 25.76 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.145 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 102.54 23.36 8.93 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.503 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 30.6 m -99.12 128.56 50.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.836 0.351 . . . . 0.0 111.12 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 4.6 t -39.37 109.75 0.12 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.861 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 28.3 mtmt -58.53 -28.45 65.47 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.403 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 123.74 16.07 3.44 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.479 179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.847 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 16.2 p90 -162.76 173.19 14.13 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.941 0.4 . . . . 0.0 110.929 -179.81 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.421 ' O ' HG22 ' A' ' 100' ' ' VAL . . . -176.73 -163.7 29.44 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.525 179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -151.23 148.12 27.82 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.878 0.37 . . . . 0.0 110.934 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.51 HG11 ' CD2' ' A' ' 116' ' ' PHE . 15.4 m -120.85 176.06 4.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.164 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . 0.439 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -133.69 161.86 33.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.899 179.939 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.475 ' CD1' ' HA ' ' A' ' 123' ' ' CYS . 96.9 m-85 -149.61 167.88 25.13 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.85 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 25.8 p -108.79 -8.13 15.4 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.142 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -132.51 124.44 28.51 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.856 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.493 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 16.3 tt0 -69.88 -30.92 68.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.889 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 48.6 mt -58.16 -54.61 44.98 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.928 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 54.4 mt-10 -67.57 -39.54 84.91 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.911 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.526 ' HG2' HD21 ' A' ' 98' ' ' LEU . 17.6 tt0 -44.01 -45.57 7.93 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.905 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 74.1 mttt -73.11 -29.89 63.24 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.942 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 47.3 mtp180 -63.57 -39.84 95.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.873 179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.635 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -68.52 -42.87 77.91 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.138 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.791 HD21 HD22 ' A' ' 98' ' ' LEU . 29.3 mt -45.85 -43.1 13.24 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.933 179.978 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.51 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.4 t -91.1 -46.66 7.99 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.168 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.51 ' N ' HG23 ' A' ' 155' ' ' THR . 47.4 mm-40 -63.32 -63.58 1.15 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.877 -179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.731 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 34.0 m -67.7 -9.43 43.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.917 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . 0.427 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 4.6 tp-100 -37.93 145.22 0.07 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.969 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.07 33.71 0.5 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.514 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.731 ' HB2' ' O ' ' A' ' 157' ' ' CYS . . . -58.71 115.86 3.34 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.826 0.346 . . . . 0.0 111.054 -179.992 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 23.1 t -90.77 -35.33 7.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.136 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.12 -33.28 0.16 Allowed Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.498 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.504 ' HB2' ' CZ ' ' A' ' 115' ' ' PHE . 25.7 tp -93.69 115.98 28.45 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.868 0.366 . . . . 0.0 110.871 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 69.1 156.69 1.15 Allowed Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.475 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 65.8 m -59.83 -19.97 54.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.995 0.426 . . . . 0.0 110.878 -179.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . 0.558 ' HB2' HG23 ' A' ' 104' ' ' THR . 49.2 mttt -111.83 156.67 41.28 Favored Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.527 0.68 . . . . 0.0 110.93 179.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 177.62 5.38 Favored 'Trans proline' 0 N--CA 1.465 -0.153 0 C-N-CA 122.681 2.254 . . . . 0.0 112.376 179.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.652 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 31.4 m -131.33 125.98 57.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.138 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 30.3 ttm180 -91.65 99.76 12.61 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.856 -179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.559 ' HB3' HD23 ' A' ' 154' ' ' LEU . 13.4 mt -77.73 151.5 34.1 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.207 -0.452 . . . . 0.0 110.916 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.7 m -162.83 171.47 16.65 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.86 -179.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.571 HG22 ' CD1' ' A' ' 154' ' ' LEU . 2.8 t -97.93 105.02 16.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.145 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -102.85 170.2 8.13 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.092 179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . 0.654 HG23 ' HD2' ' A' ' 175' ' ' PRO . 77.2 mt -123.54 138.2 29.83 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.622 0.725 . . . . 0.0 111.131 -179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.654 ' HD2' HG23 ' A' ' 174' ' ' ILE . 53.8 Cg_endo -69.77 -49.87 0.52 Allowed 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.68 2.254 . . . . 0.0 112.351 179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 25.8 ttpp -132.69 139.0 47.46 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.92 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -153.26 134.6 14.23 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.08 179.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 58.0 p -121.57 103.62 9.05 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.839 -179.787 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 60.4 mtm180 -74.92 166.03 24.3 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.875 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . 0.422 HG22 ' N ' ' A' ' 181' ' ' LYS . 8.2 p -119.01 157.11 20.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.16 179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.422 ' N ' HG22 ' A' ' 180' ' ' VAL . 0.0 OUTLIER -141.2 140.9 21.82 Favored Pre-proline 0 C--N 1.328 -0.349 0 CA-C-O 121.605 0.716 . . . . 0.0 110.933 179.883 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.75 115.98 4.35 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.707 2.271 . . . . 0.0 112.347 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 84.7 t -90.01 108.43 19.42 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.122 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 37.2 tt0 -112.86 139.27 48.64 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.911 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 59.6 p -127.12 169.64 13.21 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.855 -179.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 169.69 157.83 12.68 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.493 -179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 139.17 39.57 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.694 2.263 . . . . 0.0 112.379 -179.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 49.7 m -73.57 -51.64 16.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.848 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 2.5 t -140.33 166.07 25.69 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.847 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.367 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.52 179.998 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.351 0 N-CA-C 112.477 -0.249 . . . . 0.0 112.477 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 27.1 t -146.92 154.45 41.31 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.904 0.383 . . . . 0.0 110.853 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 67.1 m -116.23 46.67 1.53 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.871 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 87.07 161.87 36.94 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.5 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 47.5 t -165.65 150.65 8.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.902 0.382 . . . . 0.0 110.844 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 15.3 m -152.55 123.84 7.65 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.846 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 66.51 87.61 0.07 OUTLIER Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.482 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.8 81.82 0.8 Allowed 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.704 2.27 . . . . 0.0 112.357 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . 0.467 ' O ' ' CD1' ' A' ' 96' ' ' TYR . 34.1 tt0 -162.78 136.16 5.94 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.858 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . 0.467 ' CD1' ' O ' ' A' ' 95' ' ' GLU . 4.4 m-85 -147.23 119.8 8.52 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.88 -179.824 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 19.7 p -133.3 149.13 51.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.887 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.83 HD22 HD21 ' A' ' 154' ' ' LEU . 23.6 mt -118.86 149.62 41.24 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.934 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.483 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 8.9 t80 -96.1 131.37 42.6 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.906 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.475 HG22 ' C ' ' A' ' 140' ' ' GLY . 17.1 m -122.25 138.3 52.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.123 179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -130.47 179.77 16.66 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.514 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 5.0 m-20 51.32 54.03 11.84 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.8 0.334 . . . . 0.0 110.865 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.404 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.0 mt -101.95 103.24 13.88 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.896 -179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 52.3 p -49.37 150.53 3.18 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 121.561 0.696 . . . . 0.0 111.145 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.74 3.0 3.02 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.748 2.299 . . . . 0.0 112.381 179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -99.21 -4.32 32.3 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.871 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.662 HG22 ' HE3' ' A' ' 111' ' ' MET . 93.1 t -109.1 144.39 17.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.151 -179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 3.5 t70 -129.8 179.75 5.66 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.86 179.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -59.7 -35.27 74.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.862 -179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -53.5 -32.46 45.74 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.465 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.662 ' HE3' HG22 ' A' ' 107' ' ' VAL . 32.9 mtm -89.03 -42.64 11.63 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.855 0.359 . . . . 0.0 110.892 -179.987 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.531 HD23 ' N ' ' A' ' 127' ' ' LYS . 17.0 tp -56.91 -28.84 62.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.912 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.474 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 9.5 t80 -74.96 -62.87 1.4 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.928 -179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.709 ' HA ' HG12 ' A' ' 117' ' ' VAL . 19.4 mt-10 -61.65 -26.77 68.21 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.89 -179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.64 ' HZ ' ' HB1' ' A' ' 160' ' ' ALA . 84.2 t80 -65.85 -34.62 78.58 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.893 -179.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -94.63 -58.37 2.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.888 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.709 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.2 p -43.21 -25.55 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.147 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 5.1 ttpm? -69.5 -60.65 2.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.892 179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.624 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.2 p -65.46 -27.67 42.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.137 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.624 ' CD2' HG13 ' A' ' 119' ' ' VAL . 97.1 m-85 -137.79 113.18 9.13 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.666 0.746 . . . . 0.0 110.94 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 0.05 6.18 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.68 2.253 . . . . 0.0 112.344 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 16.1 m -99.72 24.89 7.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.864 -179.818 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 14.9 t -85.87 140.51 30.33 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.879 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.588 ' HE ' HG22 ' A' ' 145' ' ' THR . 7.9 mmt85 -95.82 -32.5 12.65 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.857 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.474 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 151.84 140.78 3.2 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.495 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.785 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -90.22 137.24 13.89 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.479 -179.919 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.531 ' N ' HD23 ' A' ' 112' ' ' LEU . 1.6 tppp? -125.96 129.72 49.82 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.866 0.365 . . . . 0.0 110.898 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -116.11 128.28 73.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.096 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.926 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 22.3 m -74.31 147.21 9.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.13 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 11.6 mt -129.01 173.32 10.54 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.928 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -105.55 -179.15 3.86 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.883 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 32.9 tt0 -46.24 -39.79 10.44 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 52.2 p -74.84 -34.07 62.24 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.131 -179.886 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.02 23.35 6.17 Favored Glycine 0 N--CA 1.45 -0.368 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.505 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 18.8 m -103.37 132.63 49.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.842 0.353 . . . . 0.0 111.083 -179.943 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 7.0 t -42.12 114.06 0.51 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.849 -179.871 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.438 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.1 mtmt -61.3 -24.7 66.61 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.831 179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 119.71 15.96 5.16 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.484 179.949 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.926 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 25.1 p90 -162.13 177.81 9.35 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.933 0.397 . . . . 0.0 110.913 -179.78 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.475 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -179.63 -163.45 30.4 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.705 -0.759 . . . . 0.0 112.492 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.8 m-85 -153.01 147.97 26.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.897 0.379 . . . . 0.0 110.857 -179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.785 HG12 ' HA2' ' A' ' 126' ' ' GLY . 14.7 m -120.94 -178.61 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.139 179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . 0.47 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 21.9 mtmm -141.04 159.18 42.77 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.826 179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -147.32 171.21 15.8 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.857 179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . 0.588 HG22 ' HE ' ' A' ' 124' ' ' ARG . 75.4 p -110.48 -25.61 9.94 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.152 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 17.0 t0 -111.7 117.25 32.37 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.829 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.1 tt0 -68.01 -23.74 65.04 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.879 -179.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 67.7 mt -64.34 -35.85 82.2 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.931 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.497 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 20.8 mt-10 -88.94 -35.89 16.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.444 ' O ' HD11 ' A' ' 98' ' ' LEU . 22.4 tt0 -42.99 -45.14 4.96 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.928 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 36.6 mttp -77.41 -35.16 54.46 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.906 179.944 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.444 ' O ' ' CG ' ' A' ' 156' ' ' GLU . 21.3 mtp85 -55.69 -34.0 64.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.842 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -74.19 -40.74 62.3 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.107 179.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.83 HD21 HD22 ' A' ' 98' ' ' LEU . 19.1 mt -47.5 -41.76 21.53 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.931 -179.957 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.456 HG23 ' N ' ' A' ' 156' ' ' GLU . 11.9 t -92.51 -42.4 9.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.173 179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.456 ' N ' HG23 ' A' ' 155' ' ' THR . 46.5 mm-40 -67.33 -66.32 0.57 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.909 179.975 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.477 ' CB ' HD11 ' A' ' 170' ' ' LEU . 3.7 m -64.26 -13.08 47.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.862 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . 0.411 ' C ' ' O ' ' A' ' 157' ' ' CYS . 3.3 tp-100 -35.6 129.62 0.57 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.926 -179.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 59.0 33.25 73.28 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.525 -179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.829 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -56.1 112.95 1.34 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.843 0.354 . . . . 0.0 111.102 -179.99 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 20.2 t -91.6 -32.95 5.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.153 179.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -43.52 -31.38 1.63 Allowed Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.509 179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.51 ' HB2' ' CE1' ' A' ' 115' ' ' PHE . 26.7 tp -94.97 112.85 24.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.842 0.353 . . . . 0.0 110.886 -179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.421 ' CA ' HG21 ' A' ' 107' ' ' VAL . . . 70.82 148.45 0.49 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.498 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 49.0 m -50.92 -31.61 18.15 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.939 0.399 . . . . 0.0 110.841 -179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -99.92 155.52 36.36 Favored Pre-proline 0 C--N 1.329 -0.305 0 CA-C-O 121.534 0.683 . . . . 0.0 110.904 179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.84 174.48 9.51 Favored 'Trans proline' 0 C--O 1.231 0.152 0 C-N-CA 122.703 2.269 . . . . 0.0 112.302 179.894 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.829 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 30.7 m -130.32 135.42 60.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.165 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . 0.405 ' HG2' ' O ' ' A' ' 169' ' ' ARG . 5.7 ptm180 -95.93 128.04 42.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.862 -179.945 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.762 ' HB3' HD23 ' A' ' 154' ' ' LEU . 31.9 mt -102.06 136.75 41.35 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.951 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 1.3 m -151.78 -176.9 5.82 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.879 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 10.7 t -107.48 94.3 3.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.158 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.483 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -70.98 160.38 33.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.08 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 83.7 mt -124.14 122.79 26.1 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-O 121.64 0.734 . . . . 0.0 111.12 179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.488 ' O ' ' N ' ' A' ' 177' ' ' ALA . 53.8 Cg_endo -69.75 -176.65 1.55 Allowed 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.676 2.251 . . . . 0.0 112.376 179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.406 ' HE3' ' CA ' ' A' ' 176' ' ' LYS . 0.1 OUTLIER -46.93 89.52 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.867 179.941 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . 0.488 ' N ' ' O ' ' A' ' 175' ' ' PRO . . . -104.36 76.42 1.32 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.107 179.848 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 58.2 m -132.4 175.54 9.2 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.842 -179.736 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 2.6 ttt85 -124.1 126.04 45.53 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.838 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 13.4 p -64.26 136.04 27.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.166 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.479 ' CG ' ' HD2' ' A' ' 182' ' ' PRO . 41.5 tttt -162.42 139.62 6.23 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-O 121.581 0.705 . . . . 0.0 110.921 179.944 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.479 ' HD2' ' CG ' ' A' ' 181' ' ' LYS . 53.8 Cg_endo -69.83 95.99 0.58 Allowed 'Trans proline' 0 C--N 1.341 0.183 0 C-N-CA 122.658 2.239 . . . . 0.0 112.368 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 68.2 t -98.38 88.46 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.107 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 27.2 tt0 -174.83 133.7 0.35 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.888 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 43.5 m -107.84 140.57 40.74 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.837 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -82.41 -94.04 0.55 Allowed Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.514 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 148.43 64.92 Favored 'Trans proline' 0 C--N 1.341 0.17 0 C-N-CA 122.727 2.285 . . . . 0.0 112.299 -179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 36.1 p -90.99 -57.9 2.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.862 -179.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 53.8 p -158.03 139.85 13.93 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.806 -179.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.47 179.982 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.497 -0.241 . . . . 0.0 112.497 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 68.8 m -53.3 147.5 10.18 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.864 0.364 . . . . 0.0 110.863 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 3.2 t -123.97 41.64 3.44 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.811 -179.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 68.65 -179.63 21.53 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.471 179.941 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 25.4 m -117.57 118.6 32.58 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.827 0.346 . . . . 0.0 110.858 -179.742 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 93.3 p -135.7 106.43 6.56 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.887 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 147.49 -83.83 0.18 Allowed Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.508 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 148.98 66.15 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.684 2.256 . . . . 0.0 112.337 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 54.3 mt-10 -151.03 151.93 32.74 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.887 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 7.3 m-85 -123.18 105.47 9.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.909 -179.822 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 2.1 p -126.23 155.09 42.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.784 HD22 HD21 ' A' ' 154' ' ' LEU . 85.7 mt -126.15 144.05 50.9 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.918 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.48 ' CD1' ' CE2' ' A' ' 141' ' ' PHE . 11.6 t80 -94.47 131.24 40.38 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.915 179.876 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.436 ' CG2' HD11 ' A' ' 103' ' ' LEU . 34.8 m -120.03 147.52 23.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.125 179.995 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -134.9 -177.9 15.28 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.482 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 50.24 48.39 22.27 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.803 0.335 . . . . 0.0 110.882 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.446 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.2 mt -93.86 103.09 15.22 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.889 -179.949 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.666 ' OG1' HG23 ' A' ' 107' ' ' VAL . 71.1 p -48.2 149.49 2.59 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-O 121.588 0.709 . . . . 0.0 111.153 179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.69 2.61 3.34 Favored 'Trans proline' 0 C--O 1.232 0.183 0 C-N-CA 122.707 2.271 . . . . 0.0 112.38 179.902 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -99.11 -9.83 23.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.852 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.666 HG23 ' OG1' ' A' ' 104' ' ' THR . 15.7 t -98.12 144.05 11.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.134 -179.985 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 11.4 m-20 -130.24 174.46 9.8 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.844 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -51.66 -50.74 59.77 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.875 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -45.54 -33.99 4.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.506 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.432 ' HE2' HG13 ' A' ' 107' ' ' VAL . 50.4 mtp -80.92 -61.5 1.94 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.781 0.324 . . . . 0.0 110.855 -179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.452 HD12 ' CD2' ' A' ' 163' ' ' LEU . 18.3 tp -41.23 -40.2 1.54 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.919 -179.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.497 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 17.6 t80 -63.01 -68.12 0.37 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.903 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.749 ' HA ' HG12 ' A' ' 117' ' ' VAL . 26.7 mt-10 -48.74 -55.51 11.24 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.88 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.55 ' CB ' HD13 ' A' ' 163' ' ' LEU . 76.4 t80 -42.75 -32.1 0.56 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.885 -179.944 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.467 ' O ' ' N ' ' A' ' 118' ' ' LYS . 8.1 m-85 -95.0 -67.23 0.86 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.873 -179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.749 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.81 -30.31 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.14 -179.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.467 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.2 tttp -65.41 -58.5 5.7 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.929 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.58 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.3 p -67.27 -29.81 47.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.132 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.58 ' CD2' HG13 ' A' ' 119' ' ' VAL . 96.3 m-85 -137.06 109.49 9.05 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.685 0.755 . . . . 0.0 110.924 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 2.43 3.53 Favored 'Trans proline' 0 C--O 1.232 0.184 0 C-N-CA 122.671 2.247 . . . . 0.0 112.318 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 1.3 p -95.49 -0.18 52.51 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.833 -179.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 19.1 t -66.4 138.07 57.32 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.152 -0.477 . . . . 0.0 110.931 -179.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 38.4 mtp180 -91.59 -38.61 12.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.497 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 164.37 150.42 6.13 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.476 -179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.631 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -94.21 137.52 13.57 Favored Glycine 0 N--CA 1.451 -0.337 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.447 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 19.7 tptm -125.27 118.72 26.61 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.838 0.351 . . . . 0.0 110.903 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.518 HG13 ' O ' ' A' ' 128' ' ' VAL . 7.7 p -112.45 115.57 50.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.109 179.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.913 HG22 ' O ' ' A' ' 139' ' ' TYR . 32.6 m -61.66 151.27 7.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.161 179.899 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.583 HD23 ' HA ' ' A' ' 136' ' ' SER . 49.0 mt -133.16 164.48 26.95 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.924 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.452 ' O ' ' N ' ' A' ' 134' ' ' GLY . 13.7 t70 -96.96 175.84 6.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.866 179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 2.0 tp-100 -42.66 -44.25 4.19 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.905 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 44.0 p -70.0 -28.51 65.56 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.118 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.452 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 103.81 23.73 8.1 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.505 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 136' ' ' SER . 28.4 m -105.12 131.43 54.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-O 120.824 0.345 . . . . 0.0 111.122 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.583 ' HA ' HD23 ' A' ' 130' ' ' LEU . 5.8 t -37.89 114.16 0.33 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 -179.846 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.426 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 29.7 mtmt -62.66 -25.89 68.36 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.907 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 119.41 17.18 4.9 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.5 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.913 ' O ' HG22 ' A' ' 129' ' ' VAL . 20.3 p90 -163.54 172.05 14.96 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.916 0.389 . . . . 0.0 110.984 -179.839 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -176.22 -164.11 29.84 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.501 -179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . 0.48 ' CE2' ' CD1' ' A' ' 99' ' ' PHE . 3.7 m-85 -152.05 149.15 28.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.906 0.384 . . . . 0.0 110.845 -179.864 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.631 HG12 ' HA2' ' A' ' 126' ' ' GLY . 16.1 m -123.0 161.05 25.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.131 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 7.6 mtmp? -119.05 158.41 25.89 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.872 179.927 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.524 ' CE1' HG23 ' A' ' 142' ' ' VAL . 84.4 m-85 -145.6 169.36 18.58 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.893 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 43.3 p -115.0 -24.79 8.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.123 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -112.99 99.82 8.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.856 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 16.7 tt0 -46.94 -45.26 20.62 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.884 -179.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 33.6 mt -48.1 -40.57 23.8 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.927 179.989 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.474 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 4.4 mm-40 -80.98 -33.98 33.41 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.825 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.48 ' HG2' HD21 ' A' ' 98' ' ' LEU . 15.4 tt0 -49.79 -63.89 0.97 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.944 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -57.92 -47.62 82.32 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.923 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 47.0 mtt180 -43.97 -30.89 0.78 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.855 179.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . . . . . . . . . . . -73.76 -39.1 64.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.064 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.784 HD21 HD22 ' A' ' 98' ' ' LEU . 12.2 mt -51.01 -38.14 49.46 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.886 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.508 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.8 t -92.46 -46.35 7.69 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.116 179.932 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.508 ' N ' HG23 ' A' ' 155' ' ' THR . 10.7 mt-10 -68.45 -63.1 1.13 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.828 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.48 ' CB ' HD11 ' A' ' 170' ' ' LEU . 40.3 m -68.64 -2.61 9.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.873 -179.891 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 3.0 tp-100 -43.5 136.69 3.14 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.876 -179.88 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 42.61 43.85 5.15 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.45 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.571 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -61.33 110.89 1.55 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.784 0.326 . . . . 0.0 111.134 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 21.8 t -85.7 -35.95 10.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.137 179.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -40.68 -34.48 0.74 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.501 179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.55 HD13 ' CB ' ' A' ' 115' ' ' PHE . 16.1 tp -91.07 118.77 30.67 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.835 0.35 . . . . 0.0 110.946 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 165' ' ' SER . . . 61.22 135.07 0.01 OUTLIER Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.465 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . 0.411 ' C ' ' O ' ' A' ' 164' ' ' GLY . 58.8 m -37.58 -33.58 0.08 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.924 0.392 . . . . 0.0 110.844 -179.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 31.7 mttp -95.61 153.5 39.43 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-O 121.574 0.702 . . . . 0.0 110.876 179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.79 -176.27 1.44 Allowed 'Trans proline' 0 C--N 1.341 0.152 0 C-N-CA 122.677 2.252 . . . . 0.0 112.313 179.891 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.571 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 33.2 m -140.84 126.59 19.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.109 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 18.3 mtt180 -90.26 116.68 28.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.847 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.562 ' HB3' HD23 ' A' ' 154' ' ' LEU . 17.4 mt -89.9 137.48 32.3 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.903 -179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 13.2 m -149.52 179.72 7.75 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.89 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 5.0 t -103.99 98.1 6.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.087 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.46 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -69.73 146.36 51.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.069 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 59.8 mt -102.21 120.63 52.97 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 121.602 0.715 . . . . 0.0 111.134 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_endo -69.8 -49.46 0.55 Allowed 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.665 2.243 . . . . 0.0 112.35 179.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 19.6 tptm -78.06 65.32 3.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.87 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -80.54 -62.22 1.74 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.088 179.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 26.9 t -72.01 109.86 6.11 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.862 -179.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 53.5 mtt180 -100.91 119.26 38.43 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.889 -179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 33.7 m -105.61 145.03 14.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.128 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 32.7 tttp -116.73 136.7 23.26 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.576 0.703 . . . . 0.0 110.889 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.71 107.04 1.76 Allowed 'Trans proline' 0 C--N 1.342 0.19 0 C-N-CA 122.718 2.279 . . . . 0.0 112.311 179.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 35.5 m -82.18 155.03 4.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.118 179.931 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -121.34 112.1 18.16 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.891 -179.984 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 58.5 p -151.07 138.57 19.55 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.821 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 125.6 157.92 9.79 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.493 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.79 127.92 15.26 Favored 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.708 2.272 . . . . 0.0 112.363 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 52.3 p -156.93 167.44 30.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.82 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 85.5 p -67.87 169.83 9.13 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.832 -179.776 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.691 -0.766 . . . . 0.0 112.52 -179.975 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.309 0 N-CA-C 112.501 -0.239 . . . . 0.0 112.501 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 23.9 m -105.55 94.57 5.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.858 0.361 . . . . 0.0 110.878 -179.765 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.9 m -91.25 -60.39 1.91 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.891 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -137.23 -139.32 3.88 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.466 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 63.2 p -126.32 134.22 51.17 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.875 0.369 . . . . 0.0 110.836 -179.691 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 28.8 t -101.27 -38.36 8.11 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.856 -179.814 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -168.24 95.3 0.11 Allowed Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.481 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 101.22 0.88 Allowed 'Trans proline' 0 C--N 1.341 0.141 0 C-N-CA 122.742 2.294 . . . . 0.0 112.325 -179.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -168.54 117.78 0.72 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.893 -179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . 0.509 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 33.1 m-85 -114.88 87.69 2.71 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.895 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 64.6 m -105.18 156.38 18.15 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.892 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.959 HD22 HD21 ' A' ' 154' ' ' LEU . 21.8 mt -122.23 143.01 49.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.949 179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.439 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 8.5 t80 -93.11 126.87 38.43 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.912 179.923 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.438 HG22 ' C ' ' A' ' 140' ' ' GLY . 30.2 m -119.17 148.6 22.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.142 179.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.61 176.33 20.9 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.522 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . 0.468 ' N ' ' O ' ' A' ' 138' ' ' GLY . 22.7 m-20 56.57 50.74 12.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.837 0.351 . . . . 0.0 110.878 -179.948 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.406 ' H ' ' C ' ' A' ' 138' ' ' GLY . 25.9 mt -98.6 100.34 11.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.884 -179.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 75.0 p -42.69 149.38 0.48 Allowed Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.602 0.715 . . . . 0.0 111.128 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.72 3.13 2.93 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.711 2.274 . . . . 0.0 112.368 179.929 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 65.5 m-20 -104.22 11.93 34.35 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.903 179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 1.02 HG22 ' HE3' ' A' ' 111' ' ' MET . 75.3 t -128.42 134.98 63.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.125 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -120.69 -175.99 3.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.869 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.7 p30 -57.88 -37.01 73.19 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.897 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -46.59 -41.51 12.82 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.443 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 1.02 ' HE3' HG22 ' A' ' 107' ' ' VAL . 27.9 mtm -83.82 -44.8 13.97 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.787 0.327 . . . . 0.0 110.863 -179.952 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 21.2 tp -51.74 -22.82 3.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.901 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.414 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 14.8 t80 -83.74 -64.69 1.12 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.863 -179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.712 ' HA ' HG12 ' A' ' 117' ' ' VAL . 27.1 mt-10 -57.2 -26.45 60.68 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.889 -179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.561 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 60.5 t80 -66.7 -34.83 78.72 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.907 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . . . . . . . . . 11.5 m-85 -95.22 -57.72 2.34 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.839 -179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.712 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -43.23 -28.69 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.119 -179.976 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 3.6 tptm -68.9 -59.61 2.95 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.856 179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.631 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.3 p -65.29 -28.75 45.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.137 179.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.631 ' CD2' HG13 ' A' ' 119' ' ' VAL . 91.5 m-85 -138.17 114.43 9.08 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.695 0.759 . . . . 0.0 110.922 -179.918 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.67 -0.2 6.49 Favored 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.717 2.278 . . . . 0.0 112.335 179.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . 0.474 ' O ' HG23 ' A' ' 145' ' ' THR . 17.2 p -88.85 -17.73 29.08 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.816 -179.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . 0.433 ' HA ' ' CD1' ' A' ' 144' ' ' PHE . 7.7 t -48.08 139.36 8.25 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.895 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 25.2 mtp180 -100.71 -34.96 9.64 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.862 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.414 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 164.02 145.56 4.42 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.521 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.435 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -98.39 133.82 11.47 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.485 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 13.4 tptt -124.79 128.94 49.5 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.834 0.349 . . . . 0.0 110.867 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.1 p -114.43 138.05 45.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.176 179.873 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.873 HG22 ' O ' ' A' ' 139' ' ' TYR . 24.4 m -83.76 143.25 12.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.12 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 17.1 mt -122.7 171.73 8.94 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.904 179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -105.55 -179.88 4.07 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.815 179.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 15.8 pt20 -45.6 -39.86 8.19 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.925 -179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 44.2 p -74.88 -33.79 62.11 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.136 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 111.79 21.28 6.47 Favored Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.526 179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 27.3 m -100.66 143.45 14.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.812 0.339 . . . . 0.0 111.16 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 3.7 t -54.55 107.26 0.27 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.859 -179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.49 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.5 mtmt -52.47 -29.95 27.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.086 -0.507 . . . . 0.0 110.885 179.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.468 ' O ' ' N ' ' A' ' 102' ' ' ASP . . . 122.53 19.23 3.16 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.49 179.925 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.873 ' O ' HG22 ' A' ' 129' ' ' VAL . 27.3 p90 -163.8 167.77 20.45 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.921 0.391 . . . . 0.0 110.909 -179.803 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.438 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -171.11 -159.91 18.34 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.498 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 6.0 m-85 -153.58 151.52 29.85 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.9 0.381 . . . . 0.0 110.877 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.465 ' CG2' ' HB2' ' A' ' 98' ' ' LEU . 18.4 m -124.1 176.36 5.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.16 179.979 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 33.8 mtmt -136.83 158.23 44.94 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.904 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.433 ' CD1' ' HA ' ' A' ' 123' ' ' CYS . 91.5 m-85 -145.38 167.05 23.83 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.905 179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . 0.474 HG23 ' O ' ' A' ' 122' ' ' SER . 27.7 p -105.48 -25.41 12.34 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.147 -179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.413 ' OD2' HD12 ' A' ' 148' ' ' LEU . 6.4 t70 -119.5 111.15 17.75 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.854 179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.509 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 2.9 tm-20 -51.43 -45.75 62.74 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.874 -179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . 0.413 HD12 ' OD2' ' A' ' 146' ' ' ASP . 24.0 mt -42.0 -42.2 2.77 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.915 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 57.0 mm-40 -76.23 -41.77 48.17 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.871 179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.424 ' HG2' HD21 ' A' ' 98' ' ' LEU . 17.7 tt0 -40.84 -57.79 1.85 Allowed 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.924 -179.936 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 32.9 mmtm -62.53 -51.53 67.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.925 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 36.8 mtp180 -41.81 -40.97 2.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.896 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.452 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -67.88 -48.22 66.69 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.043 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.959 HD21 HD22 ' A' ' 98' ' ' LEU . 15.3 mt -42.61 -42.46 3.42 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.913 -179.906 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.534 HG23 ' N ' ' A' ' 156' ' ' GLU . 9.2 t -89.12 -48.13 7.61 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.13 179.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.534 ' N ' HG23 ' A' ' 155' ' ' THR . 18.2 mm-40 -63.56 -64.35 0.92 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.892 179.993 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.437 ' O ' ' HB2' ' A' ' 160' ' ' ALA . 2.5 m -68.25 -8.09 36.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.926 -179.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . 0.493 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 3.5 tp-100 -36.14 134.38 0.41 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.898 -179.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 46.57 41.32 12.52 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.474 -179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.683 ' HB3' HG22 ' A' ' 168' ' ' VAL . . . -57.39 117.44 4.12 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.848 0.356 . . . . 0.0 111.084 179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.6 t -92.9 -33.5 5.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.163 179.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.94 -36.33 2.55 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.443 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . . . . . . . . . 18.2 tp -87.94 114.83 24.93 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.829 0.347 . . . . 0.0 110.868 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 70.8 161.27 3.88 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.495 179.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 1.4 p -66.97 -3.83 8.07 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.946 0.403 . . . . 0.0 110.85 -179.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 38.5 mttm -128.37 154.78 79.17 Favored Pre-proline 0 C--N 1.329 -0.31 0 CA-C-O 121.547 0.689 . . . . 0.0 110.917 179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 171.6 14.16 Favored 'Trans proline' 0 C--N 1.341 0.164 0 C-N-CA 122.696 2.264 . . . . 0.0 112.337 179.937 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.683 HG22 ' HB3' ' A' ' 160' ' ' ALA . 32.8 m -128.97 126.29 64.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.137 179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 45.1 ttt180 -87.99 112.6 22.77 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.886 -179.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.687 ' HB3' HD23 ' A' ' 154' ' ' LEU . 13.9 mt -85.94 146.07 26.85 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.913 -179.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.2 m -157.57 169.04 25.57 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.883 -179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.43 HG22 HD11 ' A' ' 154' ' ' LEU . 40.9 t -94.45 102.41 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.121 179.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.439 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -95.69 117.56 30.73 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.094 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . 0.454 HG23 ' HD2' ' A' ' 175' ' ' PRO . 48.1 mt -54.17 133.2 60.23 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.565 0.697 . . . . 0.0 111.142 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.454 ' HD2' HG23 ' A' ' 174' ' ' ILE . 53.6 Cg_endo -69.77 -41.37 4.32 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.665 2.243 . . . . 0.0 112.344 179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 3.1 mmmp? -148.74 132.13 16.61 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.909 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -130.6 36.91 3.88 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.12 179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 11.5 t 41.97 44.24 2.93 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.833 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -96.08 100.53 12.18 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.869 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . 0.769 HG22 ' HD3' ' A' ' 182' ' ' PRO . 3.1 p -137.23 132.16 46.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.161 179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 8.1 ptmm? -116.75 77.99 8.76 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-O 121.6 0.714 . . . . 0.0 110.872 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.769 ' HD3' HG22 ' A' ' 180' ' ' VAL . 53.5 Cg_endo -69.76 80.23 0.89 Allowed 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.664 2.242 . . . . 0.0 112.342 179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 87.3 t -138.41 127.56 31.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.146 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 2.0 tp10 -87.34 146.74 25.79 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.893 -179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.5 m -134.62 168.07 19.66 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.859 -179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -136.22 144.73 16.57 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.764 -0.731 . . . . 0.0 112.493 -179.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.67 153.12 69.72 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.71 2.273 . . . . 0.0 112.344 -179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 73.5 p -145.41 158.1 43.9 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.885 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 66.4 m -102.64 156.53 17.56 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.854 -179.816 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.321 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.451 179.951 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.341 0 N-CA-C 112.451 -0.26 . . . . 0.0 112.451 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 79.7 p -61.29 127.03 29.51 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.861 0.362 . . . . 0.0 110.875 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 41.5 p -148.67 132.82 17.32 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.853 -179.816 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -120.5 173.97 15.54 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.44 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 1.4 t -117.89 -54.36 2.34 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.926 0.393 . . . . 0.0 110.839 -179.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 1.1 t -158.56 153.77 25.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.868 -179.804 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 51.67 79.01 0.08 OUTLIER Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.503 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 104.24 1.29 Allowed 'Trans proline' 0 C--N 1.341 0.14 0 C-N-CA 122.65 2.233 . . . . 0.0 112.342 -179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 16.5 pt-20 -123.39 142.64 50.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.886 -179.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 10.0 m-85 -134.38 131.85 38.73 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.946 -179.892 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 29.0 m -145.14 162.9 35.93 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.839 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.78 HD22 HD21 ' A' ' 154' ' ' LEU . 91.8 mt -131.35 135.39 47.21 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.933 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.6 t80 -86.83 131.43 34.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.896 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 30.8 m -127.09 150.57 33.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.176 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -135.43 -170.99 12.26 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.696 -0.764 . . . . 0.0 112.476 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 45.41 51.47 9.58 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.828 0.347 . . . . 0.0 110.861 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.487 HD12 ' C ' ' A' ' 139' ' ' TYR . 31.0 mt -96.93 102.46 14.24 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.937 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.465 HG23 ' HB2' ' A' ' 166' ' ' LYS . 37.1 p -48.74 151.37 2.13 Favored Pre-proline 0 C--N 1.33 -0.275 0 CA-C-O 121.617 0.722 . . . . 0.0 111.125 179.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 2.95 3.09 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.699 2.266 . . . . 0.0 112.351 179.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -103.85 17.8 23.33 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.846 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.432 HG13 ' CE ' ' A' ' 111' ' ' MET . 2.8 t -125.57 134.34 66.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.167 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -124.04 170.79 10.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.849 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.46 ' CG ' ' N ' ' A' ' 110' ' ' GLY . 0.3 OUTLIER -47.06 -49.97 20.53 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.912 179.937 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.46 ' N ' ' CG ' ' A' ' 109' ' ' ASP . . . -47.61 -26.46 3.85 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.454 -179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.432 ' CE ' HG13 ' A' ' 107' ' ' VAL . 27.2 mtp -89.23 -57.6 2.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.766 0.317 . . . . 0.0 110.874 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.501 HD23 ' N ' ' A' ' 127' ' ' LYS . 15.3 tp -46.86 -28.43 1.57 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.977 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.408 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.3 t80 -76.5 -66.64 0.78 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.93 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.679 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.9 mt-10 -54.96 -25.98 33.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.891 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.455 ' CB ' HD13 ' A' ' 163' ' ' LEU . 72.2 t80 -68.27 -35.73 78.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.862 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.594 ' CD2' HG11 ' A' ' 142' ' ' VAL . 12.1 m-85 -95.09 -56.97 2.56 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.884 -179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.679 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -42.41 -27.89 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.16 179.967 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . . . . . . . . . 15.2 ttmm -66.88 -60.71 2.42 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.946 179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.573 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.0 p -63.32 -32.91 58.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.112 179.849 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.573 ' CD2' HG13 ' A' ' 119' ' ' VAL . 93.6 m-85 -134.75 115.41 12.32 Favored Pre-proline 0 C--N 1.328 -0.355 0 CA-C-O 121.749 0.785 . . . . 0.0 110.905 -179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 -1.8 9.13 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.672 2.248 . . . . 0.0 112.321 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 3.1 m -86.41 -12.64 48.6 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.806 -179.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . 0.448 ' CB ' ' HA ' ' A' ' 117' ' ' VAL . 13.5 t -50.27 135.19 21.91 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.886 -179.968 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.587 ' HE ' HG22 ' A' ' 145' ' ' THR . 93.9 mtt180 -96.99 -37.67 10.09 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.408 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 166.54 143.44 3.75 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.472 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.42 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -96.9 134.54 11.81 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.516 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.501 ' N ' HD23 ' A' ' 112' ' ' LEU . 10.1 tptm -125.78 123.86 39.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.81 0.338 . . . . 0.0 110.886 -179.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -113.5 123.35 69.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.083 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.98 HG22 ' O ' ' A' ' 139' ' ' TYR . 25.0 m -68.81 149.22 11.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.097 179.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.628 HD22 ' O ' ' A' ' 134' ' ' GLY . 40.9 mt -127.34 -177.02 3.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.891 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.482 ' O ' ' N ' ' A' ' 134' ' ' GLY . 13.2 t0 -116.94 176.09 5.28 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.924 179.799 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 0.4 OUTLIER -39.86 -39.84 0.89 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.913 -179.871 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -82.29 -29.57 31.08 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.14 -179.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.628 ' O ' HD22 ' A' ' 130' ' ' LEU . . . 112.41 0.99 26.38 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.789 -0.72 . . . . 0.0 112.506 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.59 HG23 ' O ' ' A' ' 135' ' ' VAL . 9.6 m -76.21 118.99 23.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 111.155 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.507 ' HA ' HD23 ' A' ' 130' ' ' LEU . 6.9 t -35.01 108.27 0.06 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.905 -179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.473 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.4 mtmt -50.39 -35.63 29.05 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.883 -179.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.62 19.07 2.11 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.473 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.98 ' O ' HG22 ' A' ' 129' ' ' VAL . 22.1 p90 -163.32 168.61 20.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.918 0.39 . . . . 0.0 110.911 -179.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -173.65 -163.56 27.4 Favored Glycine 0 N--CA 1.452 -0.251 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.43 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -152.89 147.6 26.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.92 0.39 . . . . 0.0 110.87 -179.863 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.594 HG11 ' CD2' ' A' ' 116' ' ' PHE . 16.4 m -119.08 171.08 7.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.145 179.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . 0.475 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 34.3 mtpt -127.63 161.76 28.11 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.93 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.555 ' CE2' HD12 ' A' ' 98' ' ' LEU . 93.8 m-85 -149.75 160.91 43.16 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.867 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . 0.587 HG22 ' HE ' ' A' ' 124' ' ' ARG . 76.7 p -99.73 -20.03 16.46 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.169 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 13.3 t0 -119.09 126.32 51.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.843 179.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 14.5 tt0 -71.71 -25.98 62.31 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.919 -179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 23.9 mt -65.85 -47.95 73.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.875 -179.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.437 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 24.4 mt-10 -73.56 -39.29 64.8 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.862 179.971 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.551 ' CD ' HD21 ' A' ' 98' ' ' LEU . 1.4 tm0? -46.09 -39.13 8.93 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.907 -179.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.433 ' HD3' HD12 ' A' ' 154' ' ' LEU . 27.8 mmtp -79.99 -43.94 21.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.896 179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 3.0 mtt-85 -48.04 -28.47 2.84 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.83 179.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.552 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -78.64 -34.51 46.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.08 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.78 HD21 HD22 ' A' ' 98' ' ' LEU . 22.9 mt -55.87 -36.94 68.13 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 12.3 t -92.28 -35.71 13.61 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.131 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -81.8 -66.88 0.83 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.873 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.467 ' C ' HD11 ' A' ' 170' ' ' LEU . 99.7 m -60.92 -10.26 5.43 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.861 -179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . 0.404 ' C ' ' O ' ' A' ' 157' ' ' CYS . 3.0 tp-100 -36.34 132.05 0.59 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.937 -179.932 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 52.54 38.49 51.78 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.479 179.994 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.756 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -54.02 115.04 1.82 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.851 0.357 . . . . 0.0 111.086 179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 40.2 t -93.98 -36.27 7.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.066 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -42.11 -35.51 1.73 Allowed Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.545 179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.474 ' CD2' HD12 ' A' ' 112' ' ' LEU . 27.6 tp -83.9 109.58 17.7 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.853 0.358 . . . . 0.0 110.915 -179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 74.91 174.71 34.16 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.501 179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 38.4 m -84.56 28.09 0.68 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.897 0.379 . . . . 0.0 110.837 -179.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . 0.465 ' HB2' HG23 ' A' ' 104' ' ' THR . 29.5 mttm -159.55 156.59 25.35 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-O 121.561 0.695 . . . . 0.0 110.909 179.934 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.76 170.19 17.15 Favored 'Trans proline' 0 C--N 1.341 0.153 0 C-N-CA 122.685 2.257 . . . . 0.0 112.314 179.895 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.756 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 31.1 m -131.09 128.57 62.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.191 -0.458 . . . . 0.0 111.098 179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 36.7 ttt180 -86.54 109.6 19.22 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.826 -179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.575 ' HB3' HD23 ' A' ' 154' ' ' LEU . 12.6 mt -85.42 145.9 27.23 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.94 -180.0 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 2.9 m -162.16 177.76 9.38 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.827 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 8.8 t -100.68 103.22 14.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.089 -0.505 . . . . 0.0 111.163 179.884 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -77.86 157.95 29.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.07 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 57.7 mt -129.35 119.23 19.42 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.646 0.736 . . . . 0.0 111.121 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.82 -41.75 3.93 Favored 'Trans proline' 0 C--N 1.342 0.193 0 C-N-CA 122.685 2.257 . . . . 0.0 112.343 179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 1.1 tppp? -113.88 97.83 6.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.878 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -39.61 -67.81 0.2 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.112 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 38.5 m -147.6 116.25 6.71 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.868 -179.801 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 8.3 tpt180 -67.05 82.99 0.12 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.886 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 82.0 t -128.36 125.34 63.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.117 179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 17.9 mmtt -113.19 143.06 28.49 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.575 0.702 . . . . 0.0 110.884 179.923 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.77 156.99 61.91 Favored 'Trans proline' 0 C--N 1.342 0.208 0 C-N-CA 122.68 2.253 . . . . 0.0 112.377 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 34.4 m -140.29 164.16 22.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.121 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -127.83 162.27 27.06 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.905 179.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 93.1 p -168.41 176.69 5.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.826 -179.778 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 178.42 82.61 0.06 OUTLIER Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.453 -179.979 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.71 175.85 7.52 Favored 'Trans proline' 0 C--N 1.341 0.163 0 C-N-CA 122.676 2.251 . . . . 0.0 112.385 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 1.8 m -145.34 172.72 12.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.847 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 59.8 p -109.7 170.14 8.26 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.908 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.333 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.482 -179.987 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.314 0 N-CA-C 112.506 -0.237 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 1.8 t -81.48 107.61 14.38 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.841 0.353 . . . . 0.0 110.891 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 86.6 p -86.96 -44.54 11.55 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.841 -179.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -118.17 -134.17 5.01 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.522 179.998 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 90.0 p -98.01 146.62 25.33 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.867 0.365 . . . . 0.0 110.87 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 33.5 t -109.96 36.17 3.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.13 -0.487 . . . . 0.0 110.852 -179.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -50.65 149.46 6.63 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.459 -179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 82.0 0.77 Allowed 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.678 2.252 . . . . 0.0 112.308 -179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -151.34 114.67 4.81 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.93 179.962 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . 0.501 ' CE1' ' HB2' ' A' ' 147' ' ' GLU . 2.1 m-85 -135.35 118.69 16.72 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.889 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 23.7 m -135.56 139.42 43.89 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.88 -179.886 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.593 HD21 ' CG ' ' A' ' 150' ' ' GLN . 98.4 mt -108.69 151.93 25.5 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.891 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.571 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 5.7 t80 -99.63 121.29 41.0 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.903 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.443 HG22 ' C ' ' A' ' 140' ' ' GLY . 23.6 m -110.0 137.12 43.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.121 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -126.91 176.58 17.67 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.472 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 53.37 52.45 13.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.826 0.346 . . . . 0.0 110.87 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.453 HD12 ' C ' ' A' ' 139' ' ' TYR . 24.8 mt -97.92 98.49 9.84 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.926 -179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.451 HG23 ' HB2' ' A' ' 166' ' ' LYS . 2.2 p -45.99 151.54 0.88 Allowed Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 121.599 0.714 . . . . 0.0 111.162 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.82 0.0 6.32 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.665 2.243 . . . . 0.0 112.309 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -101.23 16.58 25.03 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.831 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.536 HG22 ' HE3' ' A' ' 111' ' ' MET . 61.5 t -129.41 131.93 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.095 180.0 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -118.69 171.54 8.12 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.869 179.909 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.4 ' CG ' ' N ' ' A' ' 110' ' ' GLY . 2.3 p30 -48.62 -49.48 36.93 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.799 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . 0.4 ' N ' ' CG ' ' A' ' 109' ' ' ASP . . . -38.36 -37.2 0.47 Allowed Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.469 -179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.536 ' HE3' HG22 ' A' ' 107' ' ' VAL . 27.6 mtm -86.43 -45.46 11.13 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.779 0.323 . . . . 0.0 110.848 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 13.9 tp -54.12 -20.36 6.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.288 -0.415 . . . . 0.0 110.905 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.504 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 15.0 t80 -86.19 -60.67 1.94 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.925 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.76 ' HA ' HG12 ' A' ' 117' ' ' VAL . 33.7 mt-10 -59.38 -46.73 87.86 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.879 -179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.495 ' CG ' HD13 ' A' ' 163' ' ' LEU . 69.5 t80 -48.03 -33.81 8.51 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.896 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.495 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.2 m-85 -95.02 -66.61 0.9 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.881 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.76 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.59 -30.0 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.091 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.474 ' N ' ' O ' ' A' ' 116' ' ' PHE . 0.0 OUTLIER -65.08 -57.29 9.02 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.915 179.922 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.551 HG22 ' CE2' ' A' ' 120' ' ' TYR . 2.6 p -66.4 -34.8 72.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.144 179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.551 ' CE2' HG22 ' A' ' 119' ' ' VAL . 91.8 m-85 -135.22 115.67 11.93 Favored Pre-proline 0 C--N 1.328 -0.359 0 CA-C-O 121.701 0.762 . . . . 0.0 110.954 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.82 2.9 3.14 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.69 2.26 . . . . 0.0 112.321 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 80.0 p -86.06 -18.94 31.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.873 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 29.2 t -53.06 135.96 36.3 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.882 -179.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 18.3 mtt180 -98.88 -30.86 12.15 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.877 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.504 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 161.62 147.73 5.07 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.484 -179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -91.35 141.67 15.77 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.533 -179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.85 105.29 7.04 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.756 0.312 . . . . 0.0 110.874 -179.957 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.5 p -98.23 149.14 5.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.155 179.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.992 HG21 ' CE1' ' A' ' 139' ' ' TYR . 19.5 m -95.86 142.57 13.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.102 179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.639 HD23 ' HA ' ' A' ' 136' ' ' SER . 13.9 mt -130.0 173.4 10.76 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.898 179.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.421 ' O ' ' N ' ' A' ' 134' ' ' GLY . 26.3 t0 -107.34 171.97 7.09 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.865 179.862 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 9.3 pt20 -44.54 -26.0 0.32 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.92 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 49.2 p -86.42 -33.94 20.29 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.124 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 109.14 20.62 7.81 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.502 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.582 HG23 ' O ' ' A' ' 135' ' ' VAL . 25.0 m -100.19 115.71 41.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-O 120.881 0.372 . . . . 0.0 111.101 -179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.639 ' HA ' HD23 ' A' ' 130' ' ' LEU . 8.4 t -37.65 103.64 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.837 -179.845 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . . . . . . . . . 16.8 mttm -43.59 -37.49 2.56 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.891 179.947 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 129.43 20.46 1.4 Allowed Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.768 -0.729 . . . . 0.0 112.464 179.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.992 ' CE1' HG21 ' A' ' 129' ' ' VAL . 28.0 p90 -161.39 -179.31 7.27 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.922 0.391 . . . . 0.0 110.923 -179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.443 ' C ' HG22 ' A' ' 100' ' ' VAL . . . 177.17 -166.33 36.86 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.472 179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 3.6 m-85 -153.37 139.37 18.21 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.86 0.362 . . . . 0.0 110.935 -179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.495 HG11 ' CD2' ' A' ' 116' ' ' PHE . 27.8 m -112.93 -178.23 0.95 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.103 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -140.36 163.8 31.83 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.923 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -149.83 167.12 27.45 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.89 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 58.6 p -102.33 -12.07 18.2 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.121 -0.49 . . . . 0.0 111.118 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -137.04 122.33 19.33 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.895 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.501 ' HB2' ' CE1' ' A' ' 96' ' ' TYR . 4.6 tt0 -60.11 -37.5 80.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.905 -179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 34.9 mt -52.39 -49.97 63.37 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.935 179.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 6.7 mm-40 -70.04 -33.29 71.78 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.878 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.593 ' CG ' HD21 ' A' ' 98' ' ' LEU . 28.6 tt0 -58.44 -57.05 14.64 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.957 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.572 ' HD3' HD12 ' A' ' 154' ' ' LEU . 30.2 mmtm -59.11 -42.28 90.16 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.899 179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 40.6 mtt-85 -54.69 -30.62 56.18 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.902 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.487 ' O ' ' CD1' ' A' ' 170' ' ' LEU . . . -73.36 -34.53 65.65 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.06 179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.796 HD23 ' HB3' ' A' ' 170' ' ' LEU . 43.9 mt -56.51 -40.36 74.9 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.905 -179.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . . . . . . . . . 15.1 t -92.43 -34.3 14.19 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.128 179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . . . . . . . . . 39.0 mm-40 -78.55 -58.3 3.32 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.864 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.587 ' C ' HD11 ' A' ' 170' ' ' LEU . 36.0 m -79.96 11.77 3.15 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.878 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . 0.477 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 3.5 tp-100 -52.92 137.81 31.54 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.955 -179.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 40.62 33.46 0.59 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.469 -179.96 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.472 ' O ' HG22 ' A' ' 168' ' ' VAL . . . -53.17 116.73 2.55 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.815 0.34 . . . . 0.0 111.1 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.426 ' O ' ' C ' ' A' ' 162' ' ' GLY . 24.1 t -86.91 -35.41 8.62 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.137 179.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . 0.426 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.18 -38.6 0.26 Allowed Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.535 179.938 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.495 HD13 ' CG ' ' A' ' 115' ' ' PHE . 18.9 tp -87.42 115.36 24.79 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.871 0.367 . . . . 0.0 110.864 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 67.42 159.19 1.03 Allowed Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.511 179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 71.1 m -62.47 -16.62 56.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.936 0.398 . . . . 0.0 110.869 -179.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . 0.451 ' HB2' HG23 ' A' ' 104' ' ' THR . 28.3 mttp -113.33 155.79 44.09 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 121.584 0.707 . . . . 0.0 110.905 179.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 173.51 10.86 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.757 2.304 . . . . 0.0 112.336 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.472 HG22 ' O ' ' A' ' 160' ' ' ALA . 27.1 m -128.51 125.93 64.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.091 179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 11.3 ttm180 -88.44 108.61 19.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.889 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.796 ' HB3' HD23 ' A' ' 154' ' ' LEU . 17.1 mt -84.23 147.27 27.35 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.922 -179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 4.5 m -163.95 177.42 8.54 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.851 -179.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 39.7 t -103.55 101.7 12.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.148 179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.571 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -93.33 147.84 22.57 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.116 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 57.7 mt -128.64 130.88 23.49 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.623 0.725 . . . . 0.0 111.148 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 -39.22 6.76 Favored 'Trans proline' 0 C--N 1.341 0.184 0 C-N-CA 122.645 2.23 . . . . 0.0 112.397 179.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 22.7 mmtt -110.02 78.38 1.12 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.908 179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -134.85 -55.31 0.82 Allowed 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.109 179.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 28.9 t -170.72 116.32 0.47 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.888 -179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . 0.547 ' HD3' HG22 ' A' ' 180' ' ' VAL . 0.0 OUTLIER -44.82 144.53 1.14 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.863 -179.948 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . 0.547 HG22 ' HD3' ' A' ' 179' ' ' ARG . 32.9 m -46.79 -20.0 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.15 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.407 ' HD3' ' C ' ' A' ' 181' ' ' LYS . 0.0 OUTLIER -170.6 131.15 0.88 Allowed Pre-proline 0 C--N 1.329 -0.293 0 CA-C-O 121.566 0.698 . . . . 0.0 110.867 179.943 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.73 156.82 62.42 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.726 2.284 . . . . 0.0 112.333 179.902 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . 0.53 HG23 ' O ' ' A' ' 183' ' ' VAL . 35.1 m -58.88 118.02 2.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.257 -0.428 . . . . 0.0 111.132 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -147.99 161.71 40.81 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.919 179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 2.0 t -139.34 144.14 38.1 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.85 -179.777 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 126.72 84.29 0.5 Allowed Glycine 0 N--CA 1.451 -0.328 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.501 -179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . 0.446 ' O ' ' C ' ' A' ' 188' ' ' SER . 53.8 Cg_endo -69.74 -32.87 17.79 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.73 2.287 . . . . 0.0 112.315 -179.925 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . 0.446 ' C ' ' O ' ' A' ' 187' ' ' PRO . 47.9 m 34.36 46.34 0.17 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.89 -179.784 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 2.8 m -149.34 161.61 41.72 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.854 -179.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.515 -179.983 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.266 0 N-CA-C 112.433 -0.267 . . . . 0.0 112.433 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 74.4 m -62.49 109.77 1.48 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.841 0.353 . . . . 0.0 110.845 -179.744 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 78.4 p -112.68 134.2 54.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.854 -179.774 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -167.72 75.37 0.13 Allowed Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.799 -0.715 . . . . 0.0 112.513 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 18.3 m -131.74 135.62 46.96 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.887 0.375 . . . . 0.0 110.847 -179.72 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 31.2 t -58.06 141.44 50.0 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.852 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 75.24 87.81 0.26 Allowed Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.497 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.74 98.01 0.66 Allowed 'Trans proline' 0 C--N 1.34 0.129 0 C-N-CA 122.679 2.253 . . . . 0.0 112.387 -179.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 8.0 tp10 -134.22 158.78 42.85 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.882 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 13.1 m-85 -125.61 89.18 2.99 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.934 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 50.7 p -110.07 138.01 47.04 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.83 -179.798 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.65 HD12 ' CE2' ' A' ' 144' ' ' PHE . 97.5 mt -111.25 146.77 36.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.933 -179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 5.9 t80 -93.09 130.73 38.61 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.907 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.495 HG22 ' C ' ' A' ' 140' ' ' GLY . 17.9 m -123.55 149.27 27.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.15 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -138.99 -167.63 11.0 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.499 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 41.44 52.57 3.75 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.828 0.347 . . . . 0.0 110.861 -179.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.416 HD12 ' C ' ' A' ' 139' ' ' TYR . 26.4 mt -101.04 101.63 12.44 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.888 -179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.561 ' OG1' HG23 ' A' ' 107' ' ' VAL . 75.9 p -47.01 150.2 1.41 Allowed Pre-proline 0 C--N 1.33 -0.279 0 CA-C-O 121.556 0.693 . . . . 0.0 111.17 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.77 3.12 2.96 Favored 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.69 2.26 . . . . 0.0 112.359 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 -100.57 -0.74 37.14 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.561 HG23 ' OG1' ' A' ' 104' ' ' THR . 20.9 t -108.01 136.52 43.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.168 179.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 2.5 p30 -118.92 175.77 5.6 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.868 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -58.29 -36.2 72.95 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.879 179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -53.65 -33.92 49.25 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.704 -0.76 . . . . 0.0 112.542 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.455 ' CE ' HG13 ' A' ' 107' ' ' VAL . 23.7 mtm -83.69 -55.01 4.51 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.806 0.336 . . . . 0.0 110.921 179.966 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.409 HD23 ' N ' ' A' ' 127' ' ' LYS . 29.4 tp -41.02 -37.37 0.81 Allowed 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.943 -179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.435 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 17.6 t80 -70.19 -65.92 0.66 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.942 179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.737 ' HA ' HG12 ' A' ' 117' ' ' VAL . 19.1 mt-10 -49.42 -53.19 24.05 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.897 -179.984 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.602 ' CB ' HD13 ' A' ' 163' ' ' LEU . 58.2 t80 -44.58 -33.29 1.72 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.934 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.565 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.6 m-85 -93.99 -66.7 0.9 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.888 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.737 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.1 p -36.88 -31.09 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.108 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.456 ' N ' ' O ' ' A' ' 116' ' ' PHE . 0.5 OUTLIER -65.31 -61.28 2.21 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.949 179.884 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.631 HG22 ' CD2' ' A' ' 120' ' ' TYR . 1.6 p -64.65 -32.56 58.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.229 -0.442 . . . . 0.0 111.157 179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.631 ' CD2' HG22 ' A' ' 119' ' ' VAL . 97.8 m-85 -131.23 113.82 15.94 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.657 0.741 . . . . 0.0 110.933 -179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.77 1.09 4.76 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.67 2.247 . . . . 0.0 112.331 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 1.4 p -104.14 31.95 4.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.804 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 41.9 t -91.12 124.9 35.7 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.868 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.472 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 22.5 mtp180 -79.18 -39.54 33.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.873 -179.843 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.435 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 159.74 154.18 7.18 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.784 -0.722 . . . . 0.0 112.524 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -97.29 147.0 18.51 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.514 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.409 ' N ' HD23 ' A' ' 112' ' ' LEU . 2.7 tmtp? -137.66 112.58 9.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.839 0.352 . . . . 0.0 110.887 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . 0.526 HG13 ' O ' ' A' ' 128' ' ' VAL . 12.8 p -106.76 119.43 56.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.127 179.899 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.746 HG22 ' O ' ' A' ' 139' ' ' TYR . 20.1 m -63.75 155.5 5.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.116 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 20.8 mt -134.81 167.66 20.46 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.915 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.426 ' O ' ' N ' ' A' ' 134' ' ' GLY . 20.6 t70 -99.65 175.4 5.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.861 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . 0.452 ' HG3' ' N ' ' A' ' 133' ' ' THR . 20.2 pt20 -43.38 -43.33 5.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.909 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . 0.452 ' N ' ' HG3' ' A' ' 132' ' ' GLN . 34.3 p -72.65 -28.47 62.75 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.166 -179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.426 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 106.48 24.59 6.69 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.523 179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 31.3 m -103.45 137.18 32.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-O 120.821 0.344 . . . . 0.0 111.1 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 1.6 t -48.95 110.46 0.36 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.835 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.461 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.1 mtmt -57.16 -33.86 67.85 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.882 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 127.31 17.54 2.17 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.537 179.983 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.746 ' O ' HG22 ' A' ' 129' ' ' VAL . 24.7 p90 -162.2 174.16 13.28 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.943 0.402 . . . . 0.0 110.949 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.495 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -177.94 -161.29 25.86 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.741 -0.743 . . . . 0.0 112.471 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -153.09 148.19 26.71 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.85 0.357 . . . . 0.0 110.897 -179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.565 HG11 ' CD2' ' A' ' 116' ' ' PHE . 16.9 m -118.63 -177.16 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.175 179.944 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . 0.472 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 40.5 mtmt -144.17 157.21 44.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.174 -0.467 . . . . 0.0 110.878 179.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.65 ' CE2' HD12 ' A' ' 98' ' ' LEU . 76.3 m-85 -146.93 160.72 41.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.909 179.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 32.8 p -102.01 -16.08 16.58 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.191 -179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -120.28 110.72 16.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.836 179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 11.9 tt0 -57.91 -41.59 82.96 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.887 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 75.4 mt -48.16 -47.96 34.69 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.935 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.557 ' N ' ' CD ' ' A' ' 149' ' ' GLU . 0.0 OUTLIER -72.22 -44.6 62.68 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.887 179.899 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.437 ' C ' ' O ' ' A' ' 149' ' ' GLU . 20.2 tt0 -34.84 -58.59 0.51 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.93 -179.926 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 12.6 mmtp -63.49 -34.35 77.57 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.912 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . 0.577 ' HB3' ' CE1' ' A' ' 120' ' ' TYR . 4.0 tpt180 -51.61 -41.03 60.96 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.849 179.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.494 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -71.77 -44.77 63.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.091 179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.764 HD23 ' HB3' ' A' ' 170' ' ' LEU . 29.7 mt -50.47 -38.34 43.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.945 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.472 HG23 ' HG2' ' A' ' 156' ' ' GLU . 14.6 t -92.57 -37.08 12.66 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.12 179.939 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.472 ' HG2' HG23 ' A' ' 155' ' ' THR . 6.7 mm-40 -83.05 -65.02 1.06 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.897 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.494 ' N ' ' O ' ' A' ' 153' ' ' ALA . 76.2 m -62.8 -8.22 6.46 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.921 -179.959 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -37.71 128.96 1.14 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.858 -179.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 50.36 38.89 34.99 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.464 179.964 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.517 ' O ' HG22 ' A' ' 168' ' ' VAL . . . -60.0 116.35 4.09 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.813 0.34 . . . . 0.0 111.141 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.42 ' O ' ' C ' ' A' ' 162' ' ' GLY . 23.9 t -85.28 -37.85 12.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.144 179.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' A' ' 161' ' ' VAL . . . -36.75 -37.2 0.21 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.514 -179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.602 HD13 ' CB ' ' A' ' 115' ' ' PHE . 17.0 tp -86.38 114.52 23.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.848 0.356 . . . . 0.0 110.926 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 64.54 151.78 0.07 OUTLIER Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.487 179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 9.4 t -51.3 -25.28 5.59 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.948 0.404 . . . . 0.0 110.835 -179.708 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . 0.402 ' HB2' HG23 ' A' ' 104' ' ' THR . 53.5 mttt -106.45 156.18 37.46 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.568 0.699 . . . . 0.0 110.892 179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -175.42 1.15 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.682 2.255 . . . . 0.0 112.323 179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.517 HG22 ' O ' ' A' ' 160' ' ' ALA . 12.6 m -137.84 128.63 37.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.139 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 7.8 mtp85 -88.51 111.89 22.35 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.846 -179.939 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.764 ' HB3' HD23 ' A' ' 154' ' ' LEU . 15.3 mt -91.83 140.47 29.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.918 -179.967 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 13.9 m -155.83 -177.61 6.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.833 -179.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 4.7 t -102.69 100.13 9.78 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.149 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -78.39 172.56 13.44 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.119 179.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . 0.527 HG22 ' H ' ' A' ' 176' ' ' LYS . 10.8 mt -141.35 129.13 12.01 Favored Pre-proline 0 C--N 1.328 -0.335 0 CA-C-O 121.594 0.711 . . . . 0.0 111.136 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.69 4.32 2.23 Favored 'Trans proline' 0 C--O 1.232 0.18 0 C-N-CA 122.71 2.274 . . . . 0.0 112.304 179.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.527 ' H ' HG22 ' A' ' 174' ' ' ILE . 20.9 ttmt -119.98 -56.97 1.98 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.92 179.921 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . 37.75 38.83 0.18 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.211 -0.449 . . . . 0.0 111.143 179.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 92.9 p -171.4 143.68 1.85 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.85 -179.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 17.2 tpp85 -112.03 80.93 1.38 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.859 -179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 84.1 t -88.7 148.41 4.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.114 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 59.2 tttp -149.04 136.53 11.08 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 121.607 0.717 . . . . 0.0 110.897 179.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.73 102.11 0.98 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.685 2.257 . . . . 0.0 112.345 179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 89.8 t -53.81 117.62 0.96 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.123 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -106.47 136.14 46.76 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.887 -179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 5.9 m -137.51 112.31 8.91 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -118.58 74.22 0.3 Allowed Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.446 -179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.81 171.95 13.58 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.678 2.252 . . . . 0.0 112.315 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 6.3 t -140.41 111.2 6.9 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.896 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 50.0 p -169.49 169.64 8.73 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.112 -0.494 . . . . 0.0 110.864 -179.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.272 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.486 -179.972 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.296 0 N-CA-C 112.447 -0.261 . . . . 0.0 112.447 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 1.1 t -140.17 147.72 40.54 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.88 0.371 . . . . 0.0 110.892 -179.725 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 1.1 t -104.57 89.36 3.18 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.91 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . 0.446 ' O ' ' C ' ' A' ' 91' ' ' SER . . . 76.08 99.06 0.14 Allowed Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.503 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . 0.446 ' C ' ' O ' ' A' ' 90' ' ' GLY . 11.4 t -34.98 135.5 0.2 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.875 0.369 . . . . 0.0 110.843 -179.737 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 60.7 m -117.1 -56.22 2.27 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.855 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.417 ' HA2' ' HD2' ' A' ' 94' ' ' PRO . . . -178.41 107.85 0.24 Allowed Glycine 0 N--CA 1.452 -0.268 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.469 -179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.417 ' HD2' ' HA2' ' A' ' 93' ' ' GLY . 53.7 Cg_endo -69.82 84.07 0.68 Allowed 'Trans proline' 0 C--N 1.342 0.187 0 C-N-CA 122.624 2.216 . . . . 0.0 112.322 -179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -146.04 133.37 20.64 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.869 -179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . 0.495 ' CE2' ' HB2' ' A' ' 147' ' ' GLU . 47.5 m-85 -131.15 106.41 8.32 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.944 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 11.1 m -120.65 154.79 35.03 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.849 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.531 HD22 HD21 ' A' ' 154' ' ' LEU . 22.4 mt -120.37 144.48 47.86 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.927 -179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 3.6 t80 -94.96 123.06 38.23 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.905 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.9 m -114.88 149.05 17.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.14 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -137.44 -175.1 13.65 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.509 179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 50.83 50.01 19.89 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.806 0.336 . . . . 0.0 110.897 -179.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 30.9 mt -98.94 104.34 16.38 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.924 -179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.631 HG23 ' HB2' ' A' ' 166' ' ' LYS . 14.9 p -49.08 150.16 3.01 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 121.583 0.706 . . . . 0.0 111.112 179.989 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 2.95 3.08 Favored 'Trans proline' 0 C--N 1.341 0.172 0 C-N-CA 122.651 2.234 . . . . 0.0 112.342 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -99.69 -13.4 19.35 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.865 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.724 HG22 ' HE3' ' A' ' 111' ' ' MET . 73.1 t -96.2 138.95 20.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.153 -179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -118.94 -176.11 3.04 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.849 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -65.4 -41.74 93.33 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.88 -179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.47 -34.47 13.78 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.475 -179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.724 ' HE3' HG22 ' A' ' 107' ' ' VAL . 25.5 mtm -81.71 -49.61 10.25 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.816 0.341 . . . . 0.0 110.88 -179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 18.9 tp -50.86 -34.42 27.99 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.925 179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . . . . . . . . . 12.9 t80 -68.8 -61.45 1.8 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.946 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.769 ' HA ' HG12 ' A' ' 117' ' ' VAL . 17.1 mt-10 -57.28 -53.86 53.29 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.847 -179.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.426 ' HB2' HD13 ' A' ' 163' ' ' LEU . 69.2 t80 -42.3 -32.46 0.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.526 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.6 m-85 -95.17 -67.97 0.83 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.894 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.769 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.7 -29.37 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.117 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.489 ' N ' ' O ' ' A' ' 116' ' ' PHE . 19.1 tptt -67.46 -60.67 2.38 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.891 179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.68 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.1 p -65.18 -31.91 55.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.133 179.849 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.68 ' CD2' HG13 ' A' ' 119' ' ' VAL . 97.3 m-85 -134.11 114.3 12.7 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-O 121.647 0.737 . . . . 0.0 110.965 -179.961 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.75 -1.31 8.25 Favored 'Trans proline' 0 C--N 1.341 0.165 0 C-N-CA 122.678 2.252 . . . . 0.0 112.377 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 87.2 p -85.9 -16.45 38.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.834 -179.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.4 t -52.22 139.7 23.16 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.839 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 42.0 mtm180 -105.0 -33.57 8.28 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.875 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 166.66 145.62 4.54 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.451 -179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.454 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -95.25 137.54 13.49 Favored Glycine 0 N--CA 1.452 -0.281 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.475 -179.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -125.87 122.43 36.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.783 0.325 . . . . 0.0 110.914 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 6.0 p -113.62 138.14 44.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.137 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.976 HG22 ' O ' ' A' ' 139' ' ' TYR . 33.7 m -86.17 152.08 3.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.131 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.572 HD23 ' HA ' ' A' ' 136' ' ' SER . 17.8 mt -130.84 176.37 8.27 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.893 179.98 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.486 ' O ' ' N ' ' A' ' 134' ' ' GLY . 25.6 t0 -107.52 174.27 5.96 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.902 179.848 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 14.1 pt20 -39.6 -40.27 0.86 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.909 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 30.4 p -74.83 -33.75 62.22 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.158 -179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 131' ' ' ASP . . . 112.83 17.78 7.75 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.766 -0.73 . . . . 0.0 112.498 179.952 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 34.0 m -97.88 133.47 39.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.872 0.368 . . . . 0.0 111.105 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.572 ' HA ' HD23 ' A' ' 130' ' ' LEU . 2.6 t -43.2 105.68 0.05 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.889 -179.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.499 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 27.1 mtmt -50.64 -35.82 32.39 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.897 179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 129.27 20.22 1.45 Allowed Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.483 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.976 ' O ' HG22 ' A' ' 129' ' ' VAL . 27.4 p90 -163.81 169.06 18.81 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.909 0.385 . . . . 0.0 110.95 -179.823 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -171.87 -163.29 25.54 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.446 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -153.58 148.67 26.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.89 0.376 . . . . 0.0 110.898 -179.89 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.526 HG11 ' CD2' ' A' ' 116' ' ' PHE . 27.8 m -124.6 168.49 17.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.14 -0.482 . . . . 0.0 111.109 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . 0.448 ' HD3' ' N ' ' A' ' 143' ' ' LYS . 0.0 OUTLIER -125.97 159.19 33.31 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.936 179.896 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 95.2 m-85 -145.37 157.5 44.02 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.915 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 76.4 p -96.73 -19.22 19.11 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.169 -179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 14.1 t0 -120.64 120.58 36.14 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.863 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.495 ' HB2' ' CE2' ' A' ' 96' ' ' TYR . 0.1 OUTLIER -67.31 -39.19 85.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.894 -179.953 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 39.3 mt -52.62 -34.44 51.15 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.911 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -85.06 -37.07 20.76 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.876 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 -43.84 -57.28 3.35 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.881 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.537 ' HA ' HD12 ' A' ' 154' ' ' LEU . 73.2 mttt -65.07 -27.53 68.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.895 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 15.1 ttt180 -59.94 -40.88 90.48 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.849 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.464 ' O ' ' N ' ' A' ' 157' ' ' CYS . . . -69.33 -46.12 67.85 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.136 179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.76 HD23 ' HB3' ' A' ' 170' ' ' LEU . 29.7 mt -43.62 -40.82 4.29 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.906 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.505 HG23 ' N ' ' A' ' 156' ' ' GLU . 10.9 t -92.52 -45.32 8.18 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.119 179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.505 ' N ' HG23 ' A' ' 155' ' ' THR . 12.2 mm-40 -67.38 -60.08 2.87 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.894 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.464 ' N ' ' O ' ' A' ' 153' ' ' ALA . 4.8 m -78.21 9.59 3.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.886 -179.936 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . 0.43 ' NE2' ' O ' ' A' ' 154' ' ' LEU . 2.8 tp-100 -51.85 128.73 24.81 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.894 -179.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 51.37 35.23 35.25 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.478 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.491 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -57.94 121.94 11.77 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 120.794 0.33 . . . . 0.0 111.122 179.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 25.6 t -93.38 -34.72 6.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.136 -179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.65 -34.12 0.24 Allowed Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.501 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.426 HD13 ' HB2' ' A' ' 115' ' ' PHE . 29.1 tp -91.57 115.69 28.25 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.822 0.344 . . . . 0.0 110.895 -179.896 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . 0.449 ' HA3' HG21 ' A' ' 107' ' ' VAL . . . 65.17 146.14 0.04 OUTLIER Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.68 -0.771 . . . . 0.0 112.531 179.906 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . 0.445 ' HB3' HG21 ' A' ' 104' ' ' THR . 6.2 t -48.97 -20.45 0.52 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.912 0.387 . . . . 0.0 110.86 -179.753 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . 0.631 ' HB2' HG23 ' A' ' 104' ' ' THR . 16.2 mtmt -108.48 155.29 40.69 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 121.586 0.708 . . . . 0.0 110.916 179.9 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.8 -173.07 0.65 Allowed 'Trans proline' 0 C--O 1.232 0.192 0 C-N-CA 122.672 2.248 . . . . 0.0 112.38 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.491 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 34.6 m -139.62 124.53 20.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.075 179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 39.8 ttm-85 -91.4 99.99 12.84 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.868 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.76 ' HB3' HD23 ' A' ' 154' ' ' LEU . 14.0 mt -76.36 145.73 39.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.905 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.421 ' N ' ' CD2' ' A' ' 154' ' ' LEU . 4.3 m -160.74 178.32 9.58 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.847 -179.967 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 36.9 t -105.61 104.17 16.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.143 179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -93.37 131.05 38.91 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.115 179.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . 0.674 HG23 ' HD2' ' A' ' 175' ' ' PRO . 84.7 mt -128.36 138.52 33.21 Favored Pre-proline 0 C--N 1.328 -0.358 0 CA-C-O 121.59 0.709 . . . . 0.0 111.144 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.674 ' HD2' HG23 ' A' ' 174' ' ' ILE . 53.8 Cg_endo -69.75 152.29 69.35 Favored 'Trans proline' 0 C--N 1.342 0.189 0 C-N-CA 122.699 2.266 . . . . 0.0 112.355 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 17.9 ttpt -41.91 108.85 0.1 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.907 179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -40.45 -59.06 1.41 Allowed 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.097 179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 3.4 m -155.33 178.26 10.42 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.859 -179.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 69.6 ttt180 -90.3 134.23 34.45 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.929 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 78.2 t -109.74 132.98 56.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.157 -179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 17.4 pttp -136.02 144.96 50.48 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-O 121.569 0.699 . . . . 0.0 110.898 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.84 101.29 0.9 Allowed 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.627 2.218 . . . . 0.0 112.33 179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 79.7 t -101.21 111.23 30.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.147 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 7.9 tt0 -104.39 129.39 52.33 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.911 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 79.6 p -162.44 147.9 12.57 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.842 -179.748 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -163.52 146.25 11.41 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.498 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 172.13 13.18 Favored 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.698 2.265 . . . . 0.0 112.334 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 67.9 p -171.25 164.68 7.24 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.845 -179.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 36.0 t -163.9 159.1 20.6 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.853 -179.784 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.749 -0.738 . . . . 0.0 112.497 179.995 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.288 0 N-CA-C 112.492 -0.243 . . . . 0.0 112.492 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 79.5 p -58.76 155.01 13.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.884 0.374 . . . . 0.0 110.865 -179.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 19.5 m -71.36 89.1 0.9 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.849 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -145.99 -119.9 1.25 Allowed Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.506 -179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 30.0 t -55.05 150.3 10.65 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.928 0.395 . . . . 0.0 110.839 -179.773 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 46.3 m -118.09 55.64 0.88 Allowed 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.849 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 39.03 73.45 0.16 Allowed Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.496 -180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . 0.403 ' HG2' ' CE1' ' A' ' 96' ' ' TYR . 53.6 Cg_endo -69.84 173.56 10.86 Favored 'Trans proline' 0 C--N 1.341 0.177 0 C-N-CA 122.668 2.245 . . . . 0.0 112.312 -179.897 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -85.76 143.27 28.42 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.876 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . 0.5 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 21.1 m-85 -124.22 127.49 47.78 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.902 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 12.3 p -137.48 145.45 43.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.864 -179.888 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.753 HD22 HD21 ' A' ' 154' ' ' LEU . 47.1 mt -120.99 139.17 53.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.945 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.907 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 12.3 t80 -90.22 131.07 36.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.899 179.96 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.521 HG22 ' C ' ' A' ' 140' ' ' GLY . 25.2 m -121.99 155.77 26.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.142 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -142.92 178.17 21.4 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.449 179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 52.93 53.87 11.38 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.817 0.341 . . . . 0.0 110.831 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.406 HD23 ' HA ' ' A' ' 103' ' ' LEU . 24.6 mt -100.35 100.17 10.92 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.905 -179.988 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.532 ' OG1' HG23 ' A' ' 107' ' ' VAL . 58.5 p -46.71 150.0 1.35 Allowed Pre-proline 0 C--N 1.329 -0.284 0 CA-C-O 121.552 0.691 . . . . 0.0 111.172 179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.75 2.75 3.25 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.64 2.227 . . . . 0.0 112.363 179.962 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -102.43 6.81 40.34 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.835 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 1.086 HG13 ' HE2' ' A' ' 111' ' ' MET . 12.9 t -119.6 129.93 74.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.124 179.989 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -116.95 177.03 4.85 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.86 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -51.05 -53.75 30.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.836 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -38.74 -35.61 0.37 Allowed Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.44 -179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 1.086 ' HE2' HG13 ' A' ' 107' ' ' VAL . 48.7 mtp -81.93 -59.43 2.58 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.807 0.336 . . . . 0.0 110.901 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.486 HD23 ' N ' ' A' ' 127' ' ' LYS . 22.5 tp -42.08 -31.43 0.36 Allowed 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.251 -0.432 . . . . 0.0 110.914 -179.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.541 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 10.9 t80 -72.24 -66.59 0.63 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.942 179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.738 ' HA ' HG12 ' A' ' 117' ' ' VAL . 46.8 mt-10 -52.43 -47.39 66.39 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.873 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.508 ' CZ ' ' HB2' ' A' ' 163' ' ' LEU . 60.4 t80 -48.11 -33.08 7.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.896 -179.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.492 ' CD2' HG11 ' A' ' 142' ' ' VAL . 8.1 m-85 -94.99 -66.23 0.93 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.904 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.738 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.74 -31.45 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.122 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.451 ' N ' ' O ' ' A' ' 116' ' ' PHE . 30.3 tttp -64.66 -58.16 7.06 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.878 179.941 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.454 HG13 ' CD2' ' A' ' 120' ' ' TYR . 2.8 p -66.7 -33.97 66.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.148 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.559 ' CD1' ' HB3' ' A' ' 149' ' ' GLU . 90.2 m-85 -129.55 115.09 18.21 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 121.714 0.768 . . . . 0.0 110.935 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.7 Cg_endo -69.79 -2.72 10.67 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.678 2.252 . . . . 0.0 112.361 179.926 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 56.4 m -104.85 39.87 1.61 Allowed 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.863 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 49.6 t -98.17 132.43 43.69 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.89 -179.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.448 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 19.7 mmt180 -83.26 -35.26 25.48 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.899 -179.847 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.541 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 148.34 139.99 3.26 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.464 179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.768 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -82.88 148.61 25.97 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.509 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.486 ' N ' HD23 ' A' ' 112' ' ' LEU . 12.5 tptp -139.47 117.25 11.59 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.84 0.352 . . . . 0.0 110.881 -179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 7.6 p -106.04 146.76 12.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.145 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.81 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 30.1 m -93.66 150.93 3.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.08 179.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 15.5 mt -129.57 165.43 21.73 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.864 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 10.7 t70 -95.7 -177.2 3.97 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.848 179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 16.3 pt20 -50.08 -37.6 34.41 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.941 -179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 41.0 p -75.16 -33.67 61.51 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.172 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 114.64 18.46 6.52 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.472 179.942 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 34.9 m -98.06 144.57 11.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.844 0.354 . . . . 0.0 111.114 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 5.9 t -56.79 105.06 0.18 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.897 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.48 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.1 mtmt -47.84 -29.18 3.02 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.89 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 121.0 18.37 3.88 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.542 179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.81 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 9.9 p90 -161.8 175.89 11.46 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.926 0.393 . . . . 0.0 110.926 -179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.521 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -178.88 -162.23 27.94 Favored Glycine 0 N--CA 1.452 -0.257 0 C-N-CA 120.69 -0.767 . . . . 0.0 112.44 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -153.64 146.32 24.24 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.896 0.379 . . . . 0.0 110.895 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.768 HG12 ' HA2' ' A' ' 126' ' ' GLY . 15.8 m -121.2 -176.61 1.17 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.136 179.953 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . 0.448 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 39.8 mtmt -144.56 162.78 35.74 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.886 179.94 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -149.78 159.04 44.67 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.893 180.0 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 69.8 p -93.92 -33.27 13.55 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.178 -0.465 . . . . 0.0 111.129 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 21.2 t0 -108.53 115.89 30.94 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.871 179.885 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.5 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 7.6 tt0 -59.62 -36.25 75.95 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.924 -179.931 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 62.9 mt -53.31 -40.11 64.53 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.91 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.559 ' HB3' ' CD1' ' A' ' 120' ' ' TYR . 61.7 mt-10 -85.79 -22.48 27.65 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.856 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.517 ' O ' HD11 ' A' ' 98' ' ' LEU . 18.3 tt0 -57.73 -53.67 55.53 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.91 -179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 3.2 mtpm? -69.24 -43.62 73.65 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.935 179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 53.1 mtt-85 -45.54 -35.96 4.27 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.844 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.405 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -72.2 -43.43 64.5 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.112 179.951 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.753 HD21 HD22 ' A' ' 98' ' ' LEU . 17.6 mt -46.1 -41.79 12.77 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.892 179.997 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.572 HG23 ' N ' ' A' ' 156' ' ' GLU . 12.3 t -91.37 -48.96 6.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.099 179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.572 ' N ' HG23 ' A' ' 155' ' ' THR . 43.2 mm-40 -62.07 -66.5 0.53 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.895 -179.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.479 ' CB ' HD11 ' A' ' 170' ' ' LEU . 66.4 m -62.83 -13.01 28.47 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.89 -179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 4.2 tp-100 -37.68 131.35 0.98 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.926 -179.847 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 59.9 30.24 69.35 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.485 -179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.838 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -52.94 111.35 0.65 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.834 0.35 . . . . 0.0 111.083 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.4 t -89.35 -38.82 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.141 179.955 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -41.1 -32.35 0.6 Allowed Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.451 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.508 ' HB2' ' CZ ' ' A' ' 115' ' ' PHE . 24.1 tp -90.84 116.27 28.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.857 0.36 . . . . 0.0 110.95 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 62.08 143.03 0.01 OUTLIER Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.45 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 50.2 m -42.08 -32.16 0.43 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.934 0.397 . . . . 0.0 110.868 -179.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 24.5 mttm -100.76 154.38 37.2 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.535 0.684 . . . . 0.0 110.888 179.979 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -178.99 2.6 Favored 'Trans proline' 0 C--O 1.231 0.17 0 C-N-CA 122.697 2.264 . . . . 0.0 112.368 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.838 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 34.1 m -131.48 125.35 56.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.099 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 35.0 ttm180 -88.57 104.96 17.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.868 -179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.522 ' HB3' HD23 ' A' ' 154' ' ' LEU . 9.1 mt -84.18 145.86 28.15 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.938 179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 5.1 m -159.24 173.72 15.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.855 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . 0.404 HG22 ' CD1' ' A' ' 154' ' ' LEU . 5.4 t -95.25 90.79 2.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.163 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.907 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -78.77 167.01 21.81 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.095 179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 63.2 mt -124.23 123.08 26.01 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.64 0.733 . . . . 0.0 111.126 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.4 ' O ' ' C ' ' A' ' 176' ' ' LYS . 53.9 Cg_endo -69.83 -179.92 3.28 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 122.682 2.254 . . . . 0.0 112.326 179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.4 ' C ' ' O ' ' A' ' 175' ' ' PRO . 45.3 mtpt -37.37 114.62 0.34 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.906 179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -122.9 103.78 8.84 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.096 179.814 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 28.5 t -64.89 140.45 58.87 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.876 -179.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 21.0 ttt-85 -112.85 151.24 30.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.851 -179.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . 0.435 HG23 ' O ' ' A' ' 180' ' ' VAL . 28.3 m -99.14 126.79 52.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.103 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . . . . . . . . . 11.5 tptt -86.78 131.85 44.03 Favored Pre-proline 0 C--N 1.329 -0.313 0 CA-C-O 121.518 0.675 . . . . 0.0 110.906 179.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.75 161.99 43.8 Favored 'Trans proline' 0 N--CA 1.465 -0.149 0 C-N-CA 122.713 2.275 . . . . 0.0 112.344 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 35.6 m -109.05 129.97 62.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.077 179.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 22.9 tt0 -120.52 151.56 39.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.914 179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 3.3 t -160.96 113.62 1.94 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.158 -0.473 . . . . 0.0 110.871 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -60.02 145.02 46.47 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.453 179.993 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.78 149.63 67.03 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.684 2.256 . . . . 0.0 112.333 -179.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 4.0 t -126.22 126.24 43.72 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.854 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 32.7 t -83.23 -48.24 10.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.835 -179.814 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.489 -179.975 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 N-CA-C 112.47 -0.252 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 89.2 p -136.28 155.16 50.48 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.859 0.362 . . . . 0.0 110.859 -179.721 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 82.0 p 42.53 41.95 2.55 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.854 -179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . -67.25 -54.89 18.09 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.465 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 73.1 m -103.08 151.34 22.65 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.866 0.365 . . . . 0.0 110.894 -179.755 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 95.3 p -70.35 174.42 5.69 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.83 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 112.0 72.14 0.62 Allowed Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.496 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.69 91.62 0.51 Allowed 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.684 2.256 . . . . 0.0 112.394 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -154.87 135.41 13.43 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.89 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . . . . . . . . . 5.4 m-85 -142.92 114.21 7.84 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.917 -179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 77.3 p -129.53 157.36 42.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.867 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.855 HD22 HD21 ' A' ' 154' ' ' LEU . 87.1 mt -127.47 148.65 50.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.904 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.433 ' HB2' ' HB2' ' A' ' 173' ' ' ALA . 8.4 t80 -95.78 130.49 42.69 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.882 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -122.72 139.35 49.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.147 179.951 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -126.9 178.98 16.57 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.484 179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 53.34 51.47 15.37 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.85 0.357 . . . . 0.0 110.903 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . 0.501 HD12 ' C ' ' A' ' 139' ' ' TYR . 21.3 mt -95.48 101.05 12.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 -179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.694 ' OG1' HG23 ' A' ' 107' ' ' VAL . 63.3 p -48.49 150.11 2.54 Favored Pre-proline 0 C--N 1.33 -0.27 0 CA-C-O 121.588 0.709 . . . . 0.0 111.133 179.957 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.71 2.96 3.04 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.679 2.253 . . . . 0.0 112.334 179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -102.75 2.5 35.74 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.843 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.694 HG23 ' OG1' ' A' ' 104' ' ' THR . 5.7 t -108.49 136.64 43.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.116 -179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -124.66 168.43 13.17 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.906 179.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -46.29 -45.9 17.62 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.833 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -48.97 -36.45 20.42 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.512 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.434 ' HE2' HG13 ' A' ' 107' ' ' VAL . 19.2 mtp -78.56 -58.4 3.27 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 120.772 0.32 . . . . 0.0 110.846 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.594 HD23 ' N ' ' A' ' 127' ' ' LYS . 19.4 tp -45.32 -36.27 4.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.935 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.529 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 7.4 t80 -67.24 -61.11 2.08 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.901 -179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.751 ' HA ' HG12 ' A' ' 117' ' ' VAL . 44.6 mt-10 -57.17 -54.58 45.12 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.872 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.489 ' CD1' ' HB2' ' A' ' 163' ' ' LEU . 69.5 t80 -42.08 -32.19 0.44 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.855 -179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.586 ' CD2' HG11 ' A' ' 142' ' ' VAL . 7.8 m-85 -95.19 -67.54 0.85 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.892 -179.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.751 HG12 ' HA ' ' A' ' 114' ' ' GLU . 3.0 p -36.69 -29.17 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.081 179.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.496 ' N ' ' O ' ' A' ' 116' ' ' PHE . 46.3 tttp -67.88 -57.19 6.66 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.907 179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.677 HG13 ' CD2' ' A' ' 120' ' ' TYR . 3.8 p -71.15 -25.1 24.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.114 179.856 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.677 ' CD2' HG13 ' A' ' 119' ' ' VAL . 95.9 m-85 -135.26 109.17 10.44 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 121.702 0.763 . . . . 0.0 110.926 -179.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . 0.426 ' HD2' ' HA ' ' A' ' 120' ' ' TYR . 53.4 Cg_endo -69.81 2.96 3.09 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.716 2.278 . . . . 0.0 112.357 179.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 15.0 m -109.97 30.83 6.35 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.834 -179.87 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 42.6 t -92.83 132.12 37.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.903 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.46 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 42.2 mtp180 -83.31 -29.13 28.57 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.909 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.529 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 147.0 139.24 3.25 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.488 -179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.68 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -93.24 135.9 12.85 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.512 -179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . 0.594 ' N ' HD23 ' A' ' 112' ' ' LEU . 0.1 OUTLIER -121.4 143.71 49.07 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.784 0.326 . . . . 0.0 110.95 -179.988 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 5.2 p -124.97 127.16 72.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.13 179.883 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.816 HG21 ' CZ ' ' A' ' 139' ' ' TYR . 7.0 m -76.32 138.19 21.19 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.149 179.914 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . 0.438 HD23 ' HA ' ' A' ' 136' ' ' SER . 26.1 mt -116.28 160.68 20.12 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.883 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -87.88 -176.58 5.53 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.896 179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -52.85 -37.24 60.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.921 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 27.6 p -75.76 -21.81 57.07 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.091 -179.898 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 101.99 22.36 10.12 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.456 179.953 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . . . . . . . . . 24.0 m -106.3 140.83 23.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.797 0.332 . . . . 0.0 111.159 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . 0.438 ' HA ' HD23 ' A' ' 130' ' ' LEU . 2.7 t -47.06 108.63 0.15 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.867 -179.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.473 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 30.4 mtmt -54.64 -32.26 58.75 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.912 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 126.24 17.44 2.44 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.491 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.816 ' CZ ' HG21 ' A' ' 129' ' ' VAL . 17.2 p90 -163.76 171.27 15.78 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.913 0.387 . . . . 0.0 110.937 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . . . . . . . . . . . -172.75 -162.59 25.13 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.718 -0.754 . . . . 0.0 112.447 -179.991 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.4 m-85 -154.0 142.4 20.63 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.878 0.37 . . . . 0.0 110.896 -179.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.68 HG12 ' HA2' ' A' ' 126' ' ' GLY . 29.0 m -117.24 170.9 6.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.126 179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . 0.46 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 0.0 OUTLIER -131.05 160.54 34.33 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.948 179.849 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.41 ' CE2' HG23 ' A' ' 142' ' ' VAL . 86.2 m-85 -148.81 162.53 39.61 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.903 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 33.7 p -98.41 -26.6 14.41 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.154 -179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . 0.431 ' CG ' ' OE1' ' A' ' 149' ' ' GLU . 4.9 t70 -112.1 119.73 39.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.864 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . . . . . . . . . 9.2 tt0 -67.29 -31.65 72.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.908 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 21.7 mt -56.81 -54.01 51.29 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.893 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 150' ' ' GLN . 1.9 mp0 -64.81 -45.87 84.41 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.905 179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.449 ' C ' ' O ' ' A' ' 149' ' ' GLU . 21.7 tt0 -33.46 -46.86 0.2 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.949 -179.935 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . 0.434 ' O ' ' N ' ' A' ' 154' ' ' LEU . 13.8 mmtp -66.98 -55.76 13.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.911 179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -38.69 -35.12 0.17 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.869 179.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.599 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -72.72 -44.89 61.13 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.092 179.951 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.855 HD21 HD22 ' A' ' 98' ' ' LEU . 16.1 mt -47.16 -38.95 12.69 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.925 -179.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.616 HG23 ' N ' ' A' ' 156' ' ' GLU . 12.1 t -92.47 -51.12 5.28 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.145 179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.616 ' N ' HG23 ' A' ' 155' ' ' THR . 79.1 mm-40 -64.35 -57.79 8.36 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.632 ' C ' HD11 ' A' ' 170' ' ' LEU . 53.3 m -75.18 5.33 5.57 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.871 -179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 3.3 tp-100 -53.1 137.45 33.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.903 -179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 45.48 37.24 6.39 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.468 -179.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.862 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -54.89 116.19 2.6 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.894 0.378 . . . . 0.0 111.104 -179.999 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 32.7 t -94.74 -33.45 4.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.16 179.99 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -45.04 -33.55 3.77 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.51 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.489 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 56.4 tp -85.63 115.24 23.19 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.866 0.365 . . . . 0.0 110.915 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 69.88 175.21 14.81 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.51 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . . . . . . . . . 11.7 m -84.19 25.87 0.81 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.92 0.391 . . . . 0.0 110.825 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . 0.468 ' HB2' HG23 ' A' ' 104' ' ' THR . 19.7 mttp -157.24 157.05 30.16 Favored Pre-proline 0 C--N 1.328 -0.338 0 CA-C-O 121.585 0.707 . . . . 0.0 110.909 179.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 170.24 17.02 Favored 'Trans proline' 0 C--N 1.341 0.162 0 C-N-CA 122.654 2.236 . . . . 0.0 112.363 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.862 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 30.1 m -132.37 125.98 54.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.129 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 36.3 ttt85 -88.89 117.12 27.67 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.86 -179.975 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.665 ' HB3' HD23 ' A' ' 154' ' ' LEU . 11.7 mt -93.24 139.37 30.7 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.894 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 15.9 m -156.55 173.0 17.57 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.836 -179.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 15.6 t -93.79 99.21 9.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.134 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . 0.433 ' HB2' ' HB2' ' A' ' 99' ' ' PHE . . . -82.23 128.36 34.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.06 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . 0.636 HG22 ' H ' ' A' ' 176' ' ' LYS . 25.8 mt -79.1 126.88 81.05 Favored Pre-proline 0 C--N 1.329 -0.306 0 CA-C-O 121.599 0.714 . . . . 0.0 111.136 179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.78 4.63 2.09 Favored 'Trans proline' 0 C--O 1.231 0.161 0 C-N-CA 122.723 2.282 . . . . 0.0 112.348 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.636 ' H ' HG22 ' A' ' 174' ' ' ILE . 34.4 tttt -144.03 148.83 35.75 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.944 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . 0.431 ' N ' ' HG2' ' A' ' 176' ' ' LYS . . . -166.14 151.41 8.46 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.264 -0.425 . . . . 0.0 111.069 179.865 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 95.5 p -135.38 130.74 35.38 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.907 -179.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 15.7 ttt180 -150.56 123.14 8.52 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.898 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 94.2 t -111.51 88.31 1.1 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.158 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.428 ' CG ' ' HD2' ' A' ' 182' ' ' PRO . 45.3 tttp -81.31 138.63 48.46 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.609 0.719 . . . . 0.0 110.862 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.428 ' HD2' ' CG ' ' A' ' 181' ' ' LYS . 53.5 Cg_endo -69.82 178.83 4.2 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.662 2.242 . . . . 0.0 112.357 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 9.8 p -109.22 131.58 59.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.104 179.944 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 10.1 mp0 -80.62 128.97 34.22 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.919 179.971 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 78.4 p -128.96 107.87 9.96 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.872 -179.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 174.86 143.62 4.55 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.732 -0.746 . . . . 0.0 112.488 -179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.74 -179.25 2.77 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.672 2.248 . . . . 0.0 112.33 -179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 17.4 m -145.53 157.54 43.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.836 -179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 7.9 t -51.14 156.05 1.17 Allowed 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.828 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.275 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.479 179.983 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 N-CA-C 112.486 -0.246 . . . . 0.0 112.486 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 55.7 p -146.05 142.03 28.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.826 0.346 . . . . 0.0 110.881 -179.731 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 32.3 m -74.89 -46.0 39.07 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.813 -179.772 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 99.68 89.81 2.01 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.504 -179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' SER . . . . . . . . . . . . . 76.8 p -131.91 139.21 48.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.891 0.377 . . . . 0.0 110.879 -179.768 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 3.5 t -59.08 153.98 16.76 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.818 -179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -83.75 149.09 25.31 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.501 179.989 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.77 150.67 68.48 Favored 'Trans proline' 0 C--N 1.342 0.207 0 C-N-CA 122.667 2.245 . . . . 0.0 112.335 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -83.29 160.17 21.76 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.894 179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' TYR . . . . . 0.466 ' CZ ' ' HB2' ' A' ' 147' ' ' GLU . 4.3 m-85 -120.03 104.74 10.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.946 -179.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' SER . . . . . . . . . . . . . 35.4 p -126.72 155.02 43.36 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.836 -179.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.611 HD21 ' CD ' ' A' ' 150' ' ' GLN . 85.9 mt -124.87 139.57 53.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.896 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 10.1 t80 -90.27 125.97 35.68 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.871 179.9 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.415 HG22 ' C ' ' A' ' 140' ' ' GLY . 15.9 m -120.8 141.43 41.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.131 179.92 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -129.78 -175.87 14.21 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.715 -0.755 . . . . 0.0 112.431 -179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ASP . . . . . . . . . . . . . 26.0 m-20 51.13 52.65 14.5 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.839 0.352 . . . . 0.0 110.88 -179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' LEU . . . . . . . . . . . . . 22.3 mt -98.49 112.67 24.62 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.978 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.419 HG21 ' HB2' ' A' ' 165' ' ' SER . 10.2 p -58.55 150.82 54.29 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-O 121.591 0.71 . . . . 0.0 111.115 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 2.42 3.55 Favored 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.689 2.259 . . . . 0.0 112.342 179.964 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -99.42 -5.67 29.05 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.822 179.933 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' VAL . . . . . 0.486 HG13 ' HE2' ' A' ' 111' ' ' MET . 31.6 t -102.08 143.49 14.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.162 -179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -127.93 173.87 9.65 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.876 179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -54.0 -45.25 71.43 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.862 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLY . . . . . . . . . . . . . . . -52.99 -26.28 26.6 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.721 -0.752 . . . . 0.0 112.488 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' MET . . . . . 0.486 ' HE2' HG13 ' A' ' 107' ' ' VAL . 35.0 mtp -85.36 -58.52 2.64 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.825 0.345 . . . . 0.0 110.885 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 40.5 tp -42.86 -36.7 1.58 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.919 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' TYR . . . . . 0.455 ' CD1' ' HA2' ' A' ' 125' ' ' GLY . 25.6 t80 -66.3 -68.33 0.38 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.209 -0.451 . . . . 0.0 110.88 -179.96 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.715 ' HA ' HG12 ' A' ' 117' ' ' VAL . 23.8 mt-10 -48.9 -41.72 34.48 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.91 -179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' PHE . . . . . 0.519 ' CZ ' ' HB1' ' A' ' 160' ' ' ALA . 53.8 t80 -54.29 -34.1 60.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.849 -179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' PHE . . . . . 0.464 ' O ' ' N ' ' A' ' 118' ' ' LYS . 9.1 m-85 -95.19 -64.36 1.07 Allowed 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.895 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.715 HG12 ' HA ' ' A' ' 114' ' ' GLU . 2.9 p -36.7 -30.91 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.105 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' LYS . . . . . 0.464 ' N ' ' O ' ' A' ' 116' ' ' PHE . 33.1 ttpt -65.01 -61.17 2.31 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.916 179.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.455 HG13 ' CD2' ' A' ' 120' ' ' TYR . 2.5 p -66.78 -34.35 69.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.097 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' TYR . . . . . 0.509 ' CE2' ' HB2' ' A' ' 153' ' ' ALA . 90.7 m-85 -126.05 109.02 24.65 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-O 121.673 0.749 . . . . 0.0 110.946 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 2.13 3.8 Favored 'Trans proline' 0 C--N 1.341 0.161 0 C-N-CA 122.69 2.26 . . . . 0.0 112.328 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' SER . . . . . . . . . . . . . 10.6 m -108.32 34.4 3.64 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.873 -179.849 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 4.2 t -90.32 135.43 33.68 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.855 -179.949 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.46 ' HB2' ' CB ' ' A' ' 143' ' ' LYS . 63.1 mtt180 -85.14 -36.39 21.12 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.908 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.455 ' HA2' ' CD1' ' A' ' 113' ' ' TYR . . . 154.48 143.04 3.58 Favored Glycine 0 N--CA 1.45 -0.37 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.484 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.67 ' HA2' HG12 ' A' ' 142' ' ' VAL . . . -91.52 138.68 14.4 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.488 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.71 131.96 45.1 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.79 0.328 . . . . 0.0 110.914 179.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' VAL . . . . . . . . . . . . . 8.7 p -117.3 137.19 52.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.143 179.86 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' VAL . . . . . 0.873 HG22 ' O ' ' A' ' 139' ' ' TYR . 18.7 m -81.03 148.44 5.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.118 179.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' LEU . . . . . . . . . . . . . 16.3 mt -133.09 169.8 16.32 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.169 -0.468 . . . . 0.0 110.88 179.997 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -104.22 177.32 4.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' GLN . . . . . . . . . . . . . 10.7 pt20 -46.36 -36.47 6.43 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.878 -179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' THR . . . . . . . . . . . . . 41.5 p -77.75 -33.27 52.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.14 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 110.49 17.04 9.57 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.49 179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' VAL . . . . . 0.442 HG23 ' O ' ' A' ' 135' ' ' VAL . 20.3 m -96.42 127.63 48.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-O 120.819 0.342 . . . . 0.0 111.104 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' SER . . . . . . . . . . . . . 9.3 t -43.79 108.86 0.12 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.869 -179.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' LYS . . . . . 0.511 ' HE3' ' CE2' ' A' ' 139' ' ' TYR . 28.5 mtmt -52.51 -31.36 34.96 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.932 179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 124.36 19.77 2.54 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.524 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' TYR . . . . . 0.873 ' O ' HG22 ' A' ' 129' ' ' VAL . 26.5 p90 -163.62 169.67 18.26 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.389 . . . . 0.0 110.915 -179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' GLY . . . . . 0.415 ' C ' HG22 ' A' ' 100' ' ' VAL . . . -169.14 -163.86 23.87 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.446 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -153.86 148.91 26.8 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.917 0.389 . . . . 0.0 110.871 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.67 HG12 ' HA2' ' A' ' 126' ' ' GLY . 16.6 m -124.33 179.29 2.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.091 179.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' LYS . . . . . 0.46 ' CB ' ' HB2' ' A' ' 124' ' ' ARG . 22.9 mtpt -142.57 161.52 37.84 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.929 179.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.403 ' HE1' HG23 ' A' ' 142' ' ' VAL . 37.7 m-85 -149.9 153.66 37.04 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.877 179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' THR . . . . . . . . . . . . . 51.5 p -91.5 -19.14 23.13 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.147 -179.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -113.92 110.29 19.86 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.863 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' GLU . . . . . 0.466 ' HB2' ' CZ ' ' A' ' 96' ' ' TYR . 16.0 tt0 -60.29 -35.75 76.27 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.874 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' LEU . . . . . . . . . . . . . 93.6 mt -57.88 -45.01 87.03 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.946 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' GLU . . . . . . . . . . . . . 21.4 mt-10 -74.56 -43.57 55.09 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.864 179.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' GLN . . . . . 0.611 ' CD ' HD21 ' A' ' 98' ' ' LEU . 1.6 tm0? -44.18 -38.91 4.01 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.976 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' LYS . . . . . . . . . . . . . 24.7 mmtt -76.51 -40.3 50.51 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.921 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 54.9 mtt85 -53.84 -31.58 49.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.906 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' ALA . . . . . 0.509 ' HB2' ' CE2' ' A' ' 120' ' ' TYR . . . -69.1 -54.06 17.01 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.101 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.576 HD23 ' CB ' ' A' ' 170' ' ' LEU . 21.8 mt -40.27 -36.33 0.51 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.907 -179.971 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' THR . . . . . 0.422 HG23 ' N ' ' A' ' 156' ' ' GLU . 7.7 t -92.4 -42.36 9.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.122 179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' GLU . . . . . 0.422 ' N ' HG23 ' A' ' 155' ' ' THR . 24.0 mm-40 -75.68 -62.93 1.42 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.903 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' CYS . . . . . 0.574 ' CB ' HD11 ' A' ' 170' ' ' LEU . 53.7 m -67.13 -3.82 8.54 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.879 -179.952 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' GLN . . . . . . . . . . . . . 2.7 tp-100 -41.8 131.11 3.28 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.91 -179.896 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 47.4 41.18 16.7 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.539 -179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' ALA . . . . . 0.564 ' HB3' ' CG2' ' A' ' 168' ' ' VAL . . . -60.22 111.05 1.38 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.788 0.328 . . . . 0.0 111.109 -179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.7 t -84.97 -35.66 10.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.132 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . -38.5 -35.53 0.33 Allowed Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.787 -0.72 . . . . 0.0 112.473 179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' LEU . . . . . 0.463 ' HB2' ' CD1' ' A' ' 115' ' ' PHE . 29.7 tp -88.7 122.12 31.79 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.861 0.362 . . . . 0.0 110.921 -179.904 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' GLY . . . . . . . . . . . . . . . 61.94 157.62 0.09 OUTLIER Glycine 0 N--CA 1.451 -0.317 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.486 179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' SER . . . . . 0.419 ' HB2' HG21 ' A' ' 104' ' ' THR . 72.0 m -60.62 -12.51 10.37 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.923 0.392 . . . . 0.0 110.864 -179.763 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' LYS . . . . . . . . . . . . . 61.8 mttt -118.44 156.8 50.74 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-O 121.571 0.701 . . . . 0.0 110.88 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.77 -177.26 1.8 Allowed 'Trans proline' 0 C--N 1.341 0.175 0 C-N-CA 122.651 2.234 . . . . 0.0 112.374 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' VAL . . . . . 0.564 ' CG2' ' HB3' ' A' ' 160' ' ' ALA . 29.8 m -138.73 124.76 24.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.154 179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' ARG . . . . . . . . . . . . . 34.6 ttt180 -87.84 107.0 18.46 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' LEU . . . . . 0.576 ' CB ' HD23 ' A' ' 154' ' ' LEU . 10.3 mt -81.98 146.84 29.53 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.908 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 8.0 m -163.33 179.73 7.16 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.839 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' VAL . . . . . . . . . . . . . 13.4 t -102.66 101.75 12.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.128 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' ALA . . . . . . . . . . . . . . . -76.89 167.33 22.01 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.117 179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' ILE . . . . . . . . . . . . . 86.9 mt -113.24 124.03 32.26 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-O 121.633 0.73 . . . . 0.0 111.121 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -49.47 0.55 Allowed 'Trans proline' 0 C--O 1.232 0.191 0 C-N-CA 122.636 2.224 . . . . 0.0 112.329 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 29.9 mtmt -147.08 123.49 10.99 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.891 179.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' ALA . . . . . . . . . . . . . . . -93.29 -54.14 3.81 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.111 179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' SER . . . . . . . . . . . . . 33.4 t -171.51 133.01 0.78 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.896 -179.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' ARG . . . . . . . . . . . . . 21.4 tpt180 -44.93 130.26 7.35 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.891 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' VAL . . . . . . . . . . . . . 95.5 t -94.0 111.69 25.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.125 179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' LYS . . . . . 0.426 ' HA ' ' HD2' ' A' ' 182' ' ' PRO . 1.4 ttmp? -115.8 93.5 37.85 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-O 121.649 0.738 . . . . 0.0 110.88 179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' PRO . . . . . 0.426 ' HD2' ' HA ' ' A' ' 181' ' ' LYS . 53.3 Cg_endo -69.75 101.5 0.92 Allowed 'Trans proline' 0 C--N 1.342 0.212 0 C-N-CA 122.666 2.244 . . . . 0.0 112.339 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' VAL . . . . . . . . . . . . . 26.8 m -63.59 141.9 17.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.111 179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 184' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -70.54 151.38 45.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.937 179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 40.2 p -77.75 -48.34 16.85 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.866 -179.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 83.87 143.18 5.47 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.452 179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.73 -178.22 2.23 Favored 'Trans proline' 0 C--O 1.231 0.169 0 C-N-CA 122.693 2.262 . . . . 0.0 112.383 -179.998 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 188' ' ' SER . . . . . . . . . . . . . 68.2 p -156.21 156.57 34.37 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.856 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 189' ' ' SER . . . . . . . . . . . . . 58.7 m -123.82 -49.76 1.85 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.845 -179.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 190' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.31 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.467 -179.999 . . . . . . . . 0 0 . 1 stop_ save_